

Index

Note: Page numbers in *italics* refer to figures, those in **bold** refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58.

A

- A fibres 85.1, 85.2
 α -adrenoceptor agonists 106.8
 abacavir
 drug eruptions 31.18
 HLA allele association 12.5
 hypersensitivity 119.6
 pharmacological hypersensitivity 31.10–11
ABCA12 gene mutations 65.7
ABCC6 gene mutations 72.27, 72.30
ABCC11 gene mutations 94.16
 abdominal wall, lymphoedema 105.20–1
ABHD5 gene mutations 65.32
 abrasions, sports injuries 123.16
 Abrikossoff tumour 137.52
 abscesses 3.38
 anal 113.24, 113.25–6
 aseptic abscess syndrome 49.17
 breast 116.24
 filler adverse reaction 157.9
 glanders 26.53, 26.54
 hidradenitis suppurativa 92.4, 92.5
 differential diagnosis 92.7
 HIV infection 31.20
 immunodeficiency association 148.15
 intraoral 110.58
 krokodil abuse 121.3
 subungual 95.37–8
 acantholysis 3.33–4, 66.1, 66.2, 66.4
 pemphigus 50.3
 acantholytic dermatoses
 Hailey–Hailey disease variants 66.12
 see also transient acantholytic dermatosis
 acantholytic disorders, inherited 66.1–13
 see also Darier disease; Hailey–Hailey disease
 acantholytic dyskeratosis 71.24
 focal 110.19
 acanthoma fissuratum 123.13–14
 acanthosis 3.34
 Bowen disease 142.17
 peristomal papules 114.111
 acanthosis nigricans 64.3, 87.2–5, 147.14–15
 acquired generalized
 lipodystrophy 100.3
 acral 87.4–5
 associated disorders 87.3
 benign 147.14
 clinical features 87.4–5
 confluent and reticulated papillomatosis
 differential diagnosis 87.7
 congenital generalized lipodystrophies
 74.1
 Darier disease differential
 diagnosis 66.4
 definition 87.2
 dermatomyositis association 88.21
 differential diagnosis 87.5
 disease course 87.5
 drug-induced 87.4
 endocrine disorder skin signs **149.10**,
 149.11
 epidemiology 87.3
 familial 87.4
 familial partial lipodystrophy
 association 74.2
 generalized 87.4
 genital 111.27
 HIV infection 31.12
 investigations 87.5
 malignant 87.3, 87.5, 147.14–15
 management 87.5
 oral lesions 110.10
 paraneoplastic 87.5, 147.15–16, 152.1
 pathophysiology 87.3–4
 predisposing factors 87.4
 prognosis 87.5
 unilateral 87.5
 variants 87.4–5
 vulval 112.21
 acanthosis palmaris 147.15–16
 Acari 34.35, 34.36, 34.37–9
 Acaridae 34.48
 accelerated rheumatoid nodulosis 99.15
 acetone 95.63
 acetyl hexapeptide 3 156.5
 acetylcholine 2.8, 8.52
 atopic eczema 41.15
 itching in skin disease 83.6
 acetylcholine receptor antibodies 50.3
 Achenbach syndrome 101.6, 123.13
 achondroplasia, osteogenesis imperfecta
 differential diagnosis 72.10
 aciclovir 19.44
 erythema multiforme 47.6
 herpes simplex virus
 in HIV 31.23
 neonatal 116.22
 post-herpetic neuralgia 84.4–5
 resistance 31.23
 topical 18.13
 varicella-zoster virus 25.30, 31.23
 acid glycosaminoglycans 59.1
 acid lipase 65.10
 acid orcein–Giemsa stain **3.8**, 3.9
 acid phosphatase 2.43, 8.41
 lysosomal 8.44
 acids, chemical burns 129.12
Acinetobacter 26.50
Acinetobacter baumannii 34.18
 acitretin 19.37, 31.16
 congenital ichthyoses 65.38–9
 discoid lupus erythematosus
 treatment 89.41
 hand eczema treatment 39.18
 hidradenitis suppurativa management
 92.10
 keratitis–ichthyosis–deafness syndrome
 treatment 65.32
 keratoacanthoma treatment 142.36
 neutral lipid storage disease with
 ichthyosis treatment 65.33
 pityriasis rubra pilaris treatment 36.5,
 36.6
 psoriasis
 generalized pustular 35.37
 plaque **35.26**, 35.28
 squamous cell carcinoma secondary
 prevention 142.32
 subcorneal pustular dermatosis
 49.15
 Vohwinkel syndrome treatment 65.57
 Ackerman tumour *see* verrucous
 carcinoma
 acne
 agminate 90.28
 antibiotic therapy 19.43
 ocular side effects 109.46
 arthritis association 154.10
 comedonal 90.1, 90.2–3, 90.21
 management 90.38, 90.39–40
 mid-facial 90.62
 treatment algorithm 90.38
 cosmetica 90.17
 defensin activity 8.14
 detergent 90.17
 ectopic 92.1
 endocrine disorder skin signs **149.10**
 environmental, differential
 diagnosis **90.57**
 environmental pollution 90.56–7
 excoriée 90.23
 granulomatous 90.24
 hidradenitis suppurativa 92.2
 hirsutism association 89.65
 hyperandrogenism 145.18
 infantile 90.59, 90.61–2, 90.63, 117.5
 differential diagnosis 90.62
 inversa 92.1
 isotretinoin treatment 11.4
 joint symptom association 154.10
 keloid-like 96.46, 96.47
 mechanical 90.24
 mid-childhood 90.59, 90.60, 90.62
 differential diagnosis 90.63
 necrotica 90.32
 neonatal 90.59, 90.61, 90.63
 differential diagnosis **90.62**
 occupational 90.56–9
 chemical origin 130.10–12
 clinical features 90.58
 definition 90.56
 differential diagnosis **90.57**
 epidemiology 90.58
 investigations 90.58–9
 management 90.59
 papular elastorrhexis differential
 diagnosis 96.30
 penile 111.19
 photodynamic therapy 22.7
 pomade 90.17
 prepubertal 90.59–64
 clinical features 90.61–3
 complications/co-morbidities 90.63
 definition 90.59
 differential diagnosis 90.62–3
 disease course 90.63
 epidemiology 90.59–60
 investigations 90.63
 management 90.63–4
 pathophysiology 90.60–1
 prognosis 90.63
 scarring 90.63
 severity 90.63
 variants 90.62
 Propionibacterium acnes 26.43
 psychological impact 11.4
 pyogenic sterile arthritis, pyoderma
 gangrenosum and acne
 syndrome **45.3**, 45.8
 quality of life measurement 16.6
 surgery 20.47
 acne aestivalis 93.6
 acne conglobata 90.50–1, 90.54–6, 92.2,
 154.10
 acne fulminans differential
 diagnosis 90.52, 90.56
 assessment 90.56
 associated diseases 90.54
 clinical features 90.55–6
 complications 90.56
 definition 90.54
 differential diagnosis 90.55
 dissecting cellulitis of scalp
 association 107.8
 epidemiology 90.54
 genetics 90.54
 hidradenitis suppurativa differential
 diagnosis 113.21
 infants 90.62
 management 90.56, **90.57**
 pathophysiology 90.54
 acné excoriée 86.15–16, 90.23

- acne fulminans 90.50–3, 154.10
acne conglobata differential diagnosis 90.52, 90.56
assessment 90.52–3
associated disorders 90.50–1
clinical features 90.51–2
complications 90.53
definition 90.50
differential diagnosis 90.52
disease course 90.53
epidemiology 90.50–1
genetics 90.51
infections 90.51
investigations 90.52–3
isotretinoin-induced flare 90.51
management 90.53
pathophysiology 90.51
prognosis 90.53
variants 90.52
- acne inversa *see* hidradenitis suppurativa
acne keloidalis
nuchae 93.3–4, 123.16
scarring 90.32
- acne mechanica 123.15, 123.16
- acne of chemical origin
clinical features 130.11–12
differential diagnosis 130.11
hidradenitis suppurativa differential diagnosis 113.21
management 130.12
occupational disorders 130.10–12
- Acne Quality of Life Scale (AQOL) 16.6
Acne Symptom and Impact Scale (ASIS) 16.6
- acne vulgaris 90.1–3, **90.3–4**, 90.5–6, 90.7, 90.8–13, **90.14–16**, 90.16–50
acneform drug eruption differential diagnosis 118.17
adolescence 11.6
alcohol consumption 90.16
anxiety 90.34–5
assessment 90.32–4
associated diseases 90.3, **90.3–4**, 90.5–6, 90.7, 90.8–12
azelaic acid treatment 18.29
body mass index association 90.13, **90.15–16**, 90.16
causative organisms 90.19–20
chemical peels 159.5, 159.6, 159.8, 159.9
skin of colour 159.13
clinical features 90.20–36
complications/co-morbidities 90.34–6
cosmetics association 90.17
definition 90.1
depression 90.34–5
diet 90.13, **90.14–15**
differential diagnosis 90.24–32
disease course 90.36
drug-induced 90.10–12
eating disorder association 90.24
environmental factors 90.13, **90.14–16**, 90.16–18
epidemiology 90.2–3, **90.3–4**, 90.5–6, 90.7, 90.8–12
ethnicity 90.3
genetic factors 90.12–13
hormonal investigations **90.34**
hyperpigmentation 90.35, 90.36
immune response 90.35
inflammation 90.18–19
inflammatory 90.1
treatment algorithm 90.38
inflammatory lesions 90.21–2
inflammatory macules 90.22, 90.23
investigations 90.33–4
itching 90.22
lifestyle factors 90.13, **90.14–16**, 90.16–18
management 18.22, 90.37–50
first line therapy 90.37–8, 90.39
menstrual cycle 90.16
neurophysiology 90.19
nodular 90.22, 90.23
occupational acne differential diagnosis 130.11
papulopustular 90.40–4
systemic therapy 90.41–4
topical therapy 90.40–1
papulopustular rosacea differential diagnosis 91.10
pathophysiology 90.18–20
periorificial dermatitis differential diagnosis **91.18**
photoaggravated, actinic folliculitis differential diagnosis 93.6
predisposing factors 90.12–13, **90.14–16**, 90.16–18
pregnancy 90.17, 115.8–9
prognosis 90.36
Pseudomonas aeruginosa infection 26.52
psychological problem association 90.23
psychosocial effects 90.34–5
pyogenic granuloma 90.36
quality of life impact **90.33**, 90.34, **90.34**
rosacea conglobata differential diagnosis 91.16
scarring 90.22, 90.23, 90.24, 90.35
mimics 90.32
seborrhoea 90.36
severe
treatment 90.44–8
treatment algorithm 90.39
severity rating 90.32–3, **90.36**, **90.37**
sinus tracts 90.22, 90.23
sleep deprivation 90.16–17
smoking 90.16
stress factors 90.16–17
suicide risk 90.34–5
tuberous sclerosis complex differential diagnosis 80.12
UV radiation 90.17
variants 90.22–4
- acneform eruptions 120.3
chemical peels 159.12
drug-induced 118.16–17
- Acne-specific Quality of Life Questionnaire (Acne-QoL) 16.6
- acquired angio-oedema (AAE) 43.1
- acquired autoinflammatory disorders 154.10
- acquired digital fibrokeratoma 137.4
- acquired elastotic haemangioma 137.30
- acquired generalized lipodystrophy (AGL) 100.1–3
acquired partial lipodystrophy differential diagnosis 100.6
associated diseases 100.2
clinical features 100.2–3
differential diagnosis 100.3
epidemiology 100.1–2
investigations 100.3
management 100.3
pathophysiology 100.2
variants 100.3
- acquired immune deficiency syndrome *see* AIDS
- acquired immunodeficiency *see* immunodeficiency, acquired
- acquired lipodystrophy 100.1–4, 100.5, 100.6–12
congenital 100.3
generalized 100.1–3
HIV-associated 100.6–8
juvenile dermatomyositis 53.9
localized 100.8–12
- acquired partial lipodystrophy (APL) 100.4, 100.5, 100.6, 153.2
clinical features 100.4, 100.5, 100.6
differential diagnosis 100.6
epidemiology 100.4
investigations 100.6
management 100.6
pathophysiology 100.4
- acquired progressive lymphangioma 137.39–40
- acquired seed-like keratoses of palms and soles 147.17
- acquired ungual fibrokeratoma 95.26–7
acral fibromyxoma 137.61–2
superficial 95.30
- acral keratosis, mosaic 65.53
- acral peeling skin syndrome (APSS) 65.27, **71.6**, 71.7
keratolysis exfoliativa differential diagnosis 87.24
- acral persistent papular mucinosis 59.6, 59.7
- acral self-healing collodion baby 116.19
- acroangiokeratosis 101.5
Kaposi sarcoma, differential diagnosis 139.4
- acrocyanosis 81.10, 125.5–6
neonates 116.3
proximal nail fold capillaroscopy 95.52
- Raynaud phenomenon differential diagnosis 125.9
- Sneddon syndrome 101.21
- acrodermatitis chronica atrophicans 96.13–14, 96.19
Lyme disease 140.38
sclerosing panniculitis differential diagnosis 99.29
- acrodermatitis chronica migrans 26.70
- acrodermatitis continua of Hallopeau 35.40–2
clinical features 35.41–2
definition 35.40
differential diagnosis 35.42
epidemiology 35.41
investigations 35.42
management 35.42
pathophysiology 35.41
psoriasis 95.41
radiotherapy 24.6
- acrodermatitis dysmetabolica 63.26, 71.24
- acrodermatitis enteropathica 63.26, 81.17–18
breastfed infants 63.25–6
perineal candidosis of infancy differential diagnosis 32.66
perineum/perianal region 113.8
perioral involvement 110.16
telogen effluvium 89.25
zinc deficiency association 63.25, 110.16
- acro-dermato-ungual-lacrimal-tooth (ADULT) syndrome 67.9
ectrodactyly-ectodermal dysplasia-cleft lip/palate syndrome differential diagnosis 67.18
- acrodynia, mercury toxicity 122.5
- acrogeria 72.23–4
clinical features **72.21**
mandibuloacral dysplasia differential diagnosis 72.25
- acrokeratoelastoidosis 65.53–4, 96.28, 96.29
- punctate palmoplantar keratoderma differential diagnosis 65.52
- acrokeratosis paraneoplastica 147.19, 152.1
- psoriasis differential diagnosis 95.41
see also Bazex syndrome
- acrokeratosis verruciformis 66.1, 66.3, 66.5
Darier disease differential diagnosis 66.4
epidermodysplasia verruciformis differential diagnosis 25.60
longitudinal erythronychia 95.15
plantar wart differential diagnosis 25.50
- acromegaly 149.16–17
acne association 90.6
endocrine disorder skin signs 149.11, 149.14
facial changes 149.11
hyperpigmentation 88.18
macroglossia 110.60
- acromelalgia *see* erythromelalgia
- acronecrosis 95.47
- acro-osteolysis 95.47
with keratoderma 65.64
- acroparasthesiae, Fabry disease 81.7, 81.8
- acropustulosis
infantile 116.7–8
psoriasis 95.41
- acrospiroma, malignant 138.36
- acrylates, allergic contact dermatitis 128.12, 128.50
- acrylic resins, self-curing 95.62
- actin 3.21
- actinic cheilitis 110.78–9
carbon dioxide laser ablation 23.18
photodynamic therapy 22.5
- actinic comedonal plaque 96.3
- actinic dermatitis *see* chronic actinic dermatitis
- actinic elastosis *see* solar elastosis
- actinic folliculitis 93.6
- actinic granuloma 96.25–7
solar elastosis association 96.3
- actinic keratoses 142.1–7, **142.8**, 142.9–11
basal cell carcinoma association 125.13, 141.2
benign lichenoid keratosis differential diagnosis 133.7
- Bowen disease differential diagnosis 142.19
- bowenoid 142.3
- causative organisms 142.3
- chondrodermatitis nodularis differential diagnosis 108.9
- clinical features 142.3–6
immunocompromised patients 146.10–11
- complications/co-morbidity 142.6
- cutaneous horn differential diagnosis 142.12
- definition 142.1
- differential diagnosis 142.4–5
- disease course 142.6
- disseminated superficial actinic porokeratosis differential diagnosis 142.16
- epidemiology 142.2
- eyelid 109.46
- Flegel disease differential diagnosis 87.17
- histological sections 3.39
- HIV infection 31.30
- hyperplastic, squamous cell carcinoma differential diagnosis 108.25
- imiquimod therapy 18.27
- immunocompromised patients 146.10–11
- investigations 142.7
- keratoacanthoma differential diagnosis 142.35
- lichenoid 142.4
- lower leg eczema differential diagnosis 39.20
- management 142.7, **142.8**, 142.9–11, 146.15–16
ingenol mebutate therapy 18.27
topical diclofenac therapy 18.26
topical 5-fluorouracil 18.26
- pathophysiology 142.2–3
- photodynamic therapy 22.3, 22.4–5, 22.8
daylight regimen 22.11
pain 22.14
- porokeratosis differential diagnosis 87.21
- post-ionizing radiation keratosis differential diagnosis 142.14
- pre-malignant neoplasm of ear 108.23, 108.24
- prognosis 142.6
- progression prevention 146.15–16
- seborrhoeic keratosis differential diagnosis 133.3
- severity classification 142.5–6
- skin cancer risk 142.5, 146.9
- squamous cell carcinoma association 142.26
development risk 142.5, 146.9
differential diagnosis 108.25, 142.28
- sunscreen protection 9.12
- transplant recipients 25.63
- UV treatment-related 153.4
- variants 142.4
- venous lake association 103.14
- actinic lentiginos
chemical peel 159.5
laser treatment 23.12–13
sun exposure 132.6

- actinic prurigo 110.79, 127.3, 127.9–13
 clinical features 127.10–11
 definition 127.9
 differential diagnosis 127.11
 epidemiology 127.9–10
 ethnic groups 127.9, 127.10, 127.11
 genetics 127.10
 investigations 127.11–12, 127.35
 management 127.13
 pathophysiology 127.10
 polymorphic light eruption
 association 127.2
 differential diagnosis 127.4
 variants 127.11
- actinic purpura 101.5
- actinic reticuloid 127.13
- Actinobacillus actinomycetemcomitans* 26.63
- Actinomyces bovis* 26.80
- Actinomyces israelii* 26.79–80, 26.80, 26.81
- actinomycetoma 32.73
- actinomycosis 26.79–81
 abdominal 26.81
 botryomycosis differential
 diagnosis 26.73
 cervico-facial 26.80
 clinical features 26.80–1
 definition 26.79–80
 epidemiology 26.80
 hidradenitis suppurativa differential
 diagnosis 92.7
 investigations 26.81
 management 26.81
 pathophysiology 26.80
 pelvic 26.81
 primary cutaneous 26.81
 thoracic 26.80
 variants 26.80–1
 vulval 112.25
- activated leukocyte cell adhesion molecule
 (ALCAM) 8.12
- active pharmaceutical ingredient (API) of
 drugs 13.6
- acupuncture 86.40
- acute abdomen, IgA vasculitis differential
 diagnosis 102.15
- acute adenolymphangitis (ADL) 105.44
- acute cutaneous lupus erythematosus
 (ACLE) 51.21
- acute disseminated epidermal necrosis
 (ADEN) 47.2
- acute epidermal distension 87.27–9
- acute generalized exanthematous
 pustulosis (AGEP) 12.3, 119.1–4
- acute haemorrhagic oedema in
 infancy 117.9–10
 causes 119.2, **119.4**
 clinical features 119.2–4
 definition 119.1
 diagnostic criteria 119.3
 differential diagnosis 119.4
 DRESS differential diagnosis 119.10
 epidemiology 119.1
 investigations 119.4
 management 119.4
 pathophysiology 119.1–2
 postpustular desquamation 119.3
 severity classification 119.4
 subcorneal pustular dermatosis
 differential diagnosis 49.15
 symmetrical drug-related intertriginous
 and flexural exanthem differential
 diagnosis 118.6
- acute haemorrhagic oedema of
 childhood 111.20
- acute intermittent porphyria 60.4, 60.6
- acute limb ischaemia, treatment **103.4**
- acute myeloid leukaemia (AML)
 leukaemia cutis 148.2, **148.3**
 neutrophilic eccrine hidradenitis
 association 148.7
- acute necrotizing (ulcerative)
 gingivitis 110.52–3
- acute oedema blisters 87.27–9
- acute papular onychodermatitis (APOD) 33.3
- acute scrotum 111.20
- acute syndrome of apoptotic
 panepidermolysis 51.22
- acute-phase proteins (APPs) 8.31–2
- ACVRL1* gene mutations 110.14
- adalimumab
 acne conglobata treatment 90.56
 dosage **19.30**
 psoriasis treatment 19.29
 psoriatic arthritis treatment 35.46
 pyoderma gangrenosum
 treatment 49.5–6
 TNF- α neutralization 8.35
- ADAMs 8.43
- ADAM10* gene mutations 70.14
- Adamantiades–Behçet disease *see* Behçet
 disease
- Adams–Oliver syndrome
 amniotic band syndrome differential
 diagnosis 105.38
- aplasia cutis congenita 75.20
- congenital disorders of
 glycosylation 81.10
- ADAMTS 2.33
- adapalene 18.23
- adaptive immune system 8.26–31
 acne vulgaris 90.35
 antigen presentation 8.28–31
 immunological memory 8.54
 late-phase response 8.58–9
 mast cell roles 2.17
 MHC complex 8.26–8
 TGF- β role 8.36
- ADARI* gene mutation 70.16
- Addison disease 149.18
 acanthosis nigricans differential
 diagnosis 87.5
 chemotherapy-induced
 hyperpigmentation differential
 diagnosis 120.9
 chronic mucocutaneous
 candidosis 32.58
 dermatitis herpetiformis
 association 50.53
 endocrine disorder skin signs 149.14
 hyperpigmentation 88.7, 88.10, 88.17–18
 melanocortins 88.7
 melanocyte-stimulating hormone 70.1
 oral hyperpigmentation 110.66
 sweat sodium levels 94.3
- addisonian pigmentation 149.18
- adenoid cystic carcinoma 138.39–40
- adenoma sebaceum *see* angiofibromas
- adenomatous polyposis coli (APC) 80.13
see also Gardner syndrome
- adenopathy and extensive skin patch
 overlying a plasmacytoma (AESOP)
 syndrome 148.11–12
- adenosine deaminase deficiency 82.8
- adenosine triphosphate (ATP) 99.4
- adermatoglyphia 72.32
- adherence to treatment 11.7, 14.1, 14.8
 improvement 14.8
 technological solutions 11.7
see also non-adherence to treatment
- adherens junctions 2.19
- adhesins 26.5
- adhesion molecules
 on activated keratinocytes 8.12
 endothelial 8.8
 metastatic spread role 147.5
- adipocytes 2.43
 anatomy 99.3
 brown fat 99.3
 energy metabolism 99.4
 ghost 99.40, 99.41
 infectious panniculitis 99.44
 immune system interaction 99.7
 lobules 99.3
 mature 99.6–7
 necrosis 99.8
 oedema 105.31
 perivascular 99.7
 vascular supply 99.6
 white fat 99.3
- adipocytic tumours 100.17
- adipogenesis 99.5
- adipokines 99.5–6
- adiponectin 99.5
- adipophilin 3.20
- adipose tissue 2.43
 ablation 160.12
 abnormal deposition 105.31
 brown 2.43, 74.1, 99.1, 99.3
 energy homeostasis 99.4–5
 genetic disorders 74.1–6, 74.7, **74.8**,
 74.9–10
 pain in Dercum disease 100.15, 100.16
 physiology 99.4–6
 white 2.43, 74.1, 99.3, 99.4
see also lipodystrophy; obesity
- adiposis dolorosa **74.8**
- adiposis oedematosa 100.23
- adnexal polyp, neonates 116.18
- adnexal tumours, eyelid 109.47
- adolescence
 acne vulgaris 11.6
 annular lichenoid dermatitis of
 youth 37.9
 cholinergic urticaria 42.12, 47.12
 impact of skin conditions 11.6
 skin disease impact measurement 16.7
- adrenal carcinoma, hirsutism 89.65
- adrenal hyperfunction 149.17–18
- adrenal insufficiency 149.18
- adrenal steroid genesis pathway 90.5, 90.7
- adrenocortical disease, acquired 89.65
- adrenocorticotrophic hormone (ACTH) 74.3
 Cushing syndrome 88.18
 ectopic ACTH syndrome 88.20
 ectopic production causing oral
 hyperpigmentation 110.66
 solid malignant tumours 88.19, 88.20
 therapy causing oral
 hyperpigmentation 110.66
 tumour in Cushing disease 149.17
- adult myofibromatosis 137.42
- adult T-cell leukaemia–lymphoma
 (ATLL) 25.67–8, 140.34–6
 clinical features 140.35–6
 definition 140.34
 epidemiology 140.34
 investigations 140.36
 management 140.36
 pathophysiology 140.34–5
 variants 140.35–6
- adulthood, impact of skin conditions 11.6
- adult-onset Still disease 45.1, 45.10–11,
 55.4–5
 drug-induced serum sickness-like
 reaction differential diagnosis 118.9
 polyarteritis nodosa differential
 diagnosis 102.30
 Schnitzler syndrome differential
 diagnosis 45.10
- adverse events
 case–control studies 17.17
 clinical trials 17.16–18
 cohort studies 17.16
 photodynamic therapy 22.12–14
see also drug eruptions/reactions
- aeroallergens 41.32
- Aeromonas* 26.63
- Aeromonas hydrophila* 26.63, 26.64
- AESOP syndrome (adenopathy and
 extensive skin patch overlying a
 plasmacytoma) 148.11–12
- afamelanotide, skin cancer
 treatment 146.16–17
- α -fetoprotein 85.10
- African tick bite fever 34.38
- agammaglobulinaemia
 autosomal recessive 82.13
see also X-linked agammaglobulinaemia
- age
 wound healing 10.2, 10.9–10
see also adolescence; children; infant(s);
 neonates; older people
- ageing of skin 2.46–8, 2.46–8, 155.1–9
 anatomical site 155.5
 asymmetrical 155.1
- atrophic photoageing 155.1–2
 barrier dysfunction 155.8–9
 Bateman purpura 155.3–4
 clinical features 155.1–4
 collagen fibrils
 fragmentation 96.2, 155.6–8
 synthesis decrease 96.2, 155.8
 collagenous and elastotic marginal
 plaques of hands 96.4–5
 colour 155.4, 155.9
 cosmetic implications 155.9
 dermal connective tissue changes 96.1–6
 dermatoporosis 96.1, 155.9
 drug therapeutic outcome effects 14.7
 dyspigmentation 155.1, 155.9
 neck 155.3
 erythema 155.9
 external ear changes 108.6
- extrinsic 155.1
 colour 155.4
 neck 155.3
 pathophysiology 155.6
 variants 155.1–2
- fibroblasts 155.7–8
 filler use 157.1–2
 gene expression 2.47
 genetics 155.4
 grading 155.4–5
 hydration changes 155.9
 hyperpigmentation 155.1
 hypertrophic photoageing 155.2
 hypopigmentation 155.1, 155.3
 idiopathic guttate hypomelanosis 155.3
 implications 155.8–9
 intrinsic 155.1, 155.2
 pathophysiology 155.6
 photonumerical scale 155.5
 laxity 155.9
 lipid synthesis 2.47
 measurement 155.4–5
 menopausal 155.4
 natural 155.8
 neck 155.3
 pathophysiology 155.5–8
 photonumerical scale 155.5
 premature 79.1, **79.2**, 79.3–7
 reactive oxygen species 8.44, 155.4,
 155.6, 155.7–8, 155.9
 SCINEXA score 155.5
 smoking 155.2–3, 155.9
 social implications 155.9
 solar elastosis 96.2–4
 telangiectases 155.9
 topical retinoid therapy 155.9
 ultraviolet irradiation 155.6, 155.9
 venous lake association 103.14
see also photoageing; wrinkling
- AGE amyloidosis 110.59
- Agent Orange 90.58
- aggrecan 2.39
- agonists, inverse/partial 14.4
- agranulocytosis
 aphthous ulceration 110.39
 dapsone-induced 19.14
- α -hydroxy acids (AHA)
 antiageing products 156.3
 chemical peels 159.1–2, 159.13
- Aicardi syndrome 51.22, **74.8**
 MIDAS syndrome differential
 diagnosis 67.25
- AIDS 31.1–2
 case definition 31.5–6
 epidemiology 31.2
 progression to 31.6, 31.8
 predictors 31.8
see also HIV infection
- AIDS wasting syndrome 100.7
- AIDS-defining illnesses
 histoplasmosis 31.26–7
 HPV-associated cancers 31.24
 oesophageal candidosis 31.26
 opportunistic infections 31.5
 penicilliosis 31.27
 strongyloidosis 31.29
- ainhum 96.43–5

- AKT/PIK3/mTOR pathway 105.35, 105.37
 Alagille syndrome 152.5
 albendazole
 ancylostomiasis treatment 33.15
 cutaneous larva migrans treatment 33.19
 cysticercosis treatment 33.31
 enterobiasis treatment 33.14
 gnathostomiasis treatment 33.22
 loiasis treatment 33.11
 lymphatic filariasis management 105.45
 strongyloidosis treatment 33.17
 visceral larva migrans treatment 33.20
 albinism 2.17
 oculocutaneous 70.6–8
 prenatal diagnosis 7.9
 rufous 70.7
 albinism–deafness syndrome 70.9, 70.10
 Albright hereditary osteodystrophy 74.4, 74.6
 Alcian blue staining 3.8–9
 alcohol abuse/misuse
 α_1 -antitrypsin deficiency
 panniculitis 99.43
 benign symmetrical lipomatosis association 100.14
 dermatitis passivata 86.29
 hyperhidrosis 94.5
 pancreatic panniculitis 99.38, 99.39
 psoriasis 35.4
 psoriatic arthritis association 35.43, 35.44
 skin disease 86.32
 toxic shock syndrome association 26.30
 alcohol consumption
 acne vulgaris 90.16
 erythroplasia 110.72
 isotretinoin efficacy 90.47–8
 oral cancer risk 110.34
 porphyria cutanea tarda risk 60.13, 96.43
 alcohol sensitivity, flushing 106.7, 106.8
 alcoholic cirrhosis, palmar fascial fibromatosis 96.31
 alcohols, topical medication 18.7, 18.9
Alcyonidium diaphanum (sea chervil) 131.3
 aldehydes
 inhalation injury with burns 126.4
 topical therapy 18.9
 alexandrite laser 23.6
 hair removal 23.15
 Alezzandrini syndrome 88.43
 hair pigmentary defect 89.71
 algal infection 32.95–6
 alginate fillers 157.6
 algodystrophy 154.2
 algoneurodystrophy 85.13
 Alibert, Jean-Louis 1.4–5
 alitretinoin 19.37
 atopic eczema treatment 41.33
 congenital ichthyosis treatment 65.39
 topical 18.23
 alkali tests, occupational disorders 130.5
 alkaline phosphatase 2.43
 alkalis, chemical burns 129.12
 alkaptonuria 81.11, 81.13–14, 154.9
 ochronosis 88.51
 pinna 108.12, 108.14
 all or none clinical observations 17.3
 alleles 7.2
 dominant 7.2, 7.4
 recessive 7.3, 7.4
 allergenicity, theoretical 128.9
 allergens 8.56, 128.2
 airborne 109.17, 128.18
 baseline series 128.69–70
 binding to skin components 128.7
 clothing 128.45
 exposure reduction regulations 128.2
 nail abnormalities 95.43–4
 nail varnish 128.15
 occupational disorders 128.5, 130.6, 130.7–10
 plant 128.11, 128.14, 128.15, 128.17, 128.51–4
 airborne 128.18
 pollution effects 8.57
 solubility 8.56
 allergic contact dermatitis 41.23
 acrylates 128.12
 active treatment 128.75
 age 128.5–6
 allergen containment/
 replacement 128.76
 allergy sources 128.12–13
 ano-genital 111.10–11, 128.17
 antimicrobial agents 128.32–40
 arms 128.14
 atopic eczema relationship 41.13
 atopy 128.10–11
 avoidance advice 128.75
 axillae 128.16, 128.45
 behaviours 128.11–12
 bryozoan 131.3
 case definition 128.4
 causative organisms 128.10
 chemical burns differential diagnosis 129.12
 chemical factors 128.8
 chemical peels 159.12
 children 128.5–6
 chronic 128.13, 128.63–4
 climate 128.11
 clinical features 128.11–18
 clothing 128.13, 128.45–7
 complications/co-morbidities 128.62–3
 compound allergy 128.69
 corporate responsibility 128.76
 corticosteroid-induced 18.16
 cosmetic vehicles 128.40–2
 cosmetics 128.13, 128.15
 cultural factors 128.11
 data collection 128.3
 definition 128.2
 delayed reaction time 128.7–8
 depigmentation 128.60
 diagnosis 128.2
 differential diagnosis 128.61–2
 discoid 128.14
 disease course 128.63–4
 distribution 128.13
 domestic risks 128.77
 drug influences 128.6
 drug-induced eczema differential diagnosis 118.5
 duration 128.11–12
 ears 128.16
 eczema complication 39.20
 eczema development model 39.3
 education of community/
 workforce 128.77
 elicitation 128.6–8
 environmental factors 128.11
 epidemiology 128.3–6
 erythema multiforme-like reactions 128.59–60
 ethnicity 128.6
 exposed sites 128.17–18
 eyelids 109.5, 128.15
 face 128.14–15
 feet 128.17
 generalized erythroderma 128.17
 genetics 128.10–11
 granulomatous reactions 128.61
 haemodialysis complication 153.4
 hair dyes 89.73
 hand 128.14
 hand eczema 39.13
 historical aspects 128.1–2
 hobbies 128.12
 hormone effects 128.6
 hyperpigmentation 128.60
 hyposensitization 128.75
 incidence 129.2
 investigations 128.64–75
 intradermal tests 128.73–4
 open tests 128.73
 patch testing 128.64–73
 repeat open application tests 128.73
 spot tests 128.74–5
 usage tests 128.73
in vitro tests 128.74
 irritant contact dermatitis differential diagnosis 129.6
 jewellery 128.13, 128.16
 leg 128.17
 lower 39.20
 legal measures 128.76
 lichen planus 128.60
 lichenification 39.29
 lichenoid reactions 128.60
 lips 128.15–16
 lymphomatoid eruptions 128.60
 management 128.75–7
 medicament vehicles/
 excipients 128.40–2
 mercury toxicity 122.6
 metals 128.19–24
 systemically reactivated 128.59
 mucous membranes 128.18
 nail varnish 95.61
 neck 128.16
 non-eczematous responses 128.59–61
 occupational 128.12, 130.5–10
 occupational irritant contact dermatitis differential diagnosis 130.3
 onycholysis 128.61
 pathology 128.10
 pathophysiology 128.6–11
 pattern of spread 128.63
 perineum/perianal region 113.7
 perioral region 128.15–16
 periorificial dermatitis differential diagnosis 91.18
 photocontact 128.18
 plastics 128.48–51
 population studies 128.4–6
 predisposing factors 128.8
 presentation 128.13–18
 preservatives 128.32–40
 prevention 128.75–7
 previous history 128.12
 primary patterns 128.13–14
 primary site 128.11
 prognosis 128.63–4
 purpuric reactions 128.60
 regulatory measures 128.76
 relapse 128.63–4
 resins 128.48–51
 rubber allergy 128.5, 128.43–5
 scalp 107.4, 128.16
 seborrhoeic dermatitis differential diagnosis 40.4
 seborrhoeic dermatitis-like pattern 128.13
 sensitivity levels 128.63
 sensitization 128.6–7
 severity 128.13
 sex 128.6
 shoe allergy 128.47–8
 socioeconomic factors 128.11
 standardization 128.4
 stoma complication 114.1–3
 streaky 128.14
 systemic reactions 128.61
 drug-induced 118.4–5
 systemically reactivated 128.58–9
 thighs 128.17
 topical drugs 128.27–9, 128.30, 128.31
 transient acantholytic dermatosis association 87.22
 T_{reg} cells 128.7
 trunk 128.16–17
 ultraviolet filters 128.43
 ultraviolet light exposure 128.11
 variants 128.58–61
 vulval 112.14–15
 see also patch testing; photoallergic contact dermatitis; plant allergens
 allergic contact urticaria 128.81–5
 anaphylaxis 42.12, 128.83
 clinical features 128.82–4
 cross-reactivity 128.83
 differential diagnosis 128.84
 epidemiology 128.82
 foodstuffs 128.82–3, 128.84
 investigations 128.84–5
 latex allergy 128.83
 management 128.85
 pathophysiology 128.82
 severity classification 128.84
 vulval 112.15
 allergic drug reactions 14.5
 allergic eczema, infection relationship 41.13–14
 allergic rhinitis, atopic eczema association 41.11
 allergic rhinoconjunctivitis 151.1–2
 allergy 8.54–60
 alleviation of development 8.56
 atopic eczema role 41.11–12
 basophil role 8.19
 CCR3 role 8.39
 compound 128.69
 contact 41.32
 corticosteroid 128.18
 early-phase response 8.57–8
 effector phase 8.57–9
 eosinophil association 8.19
 food additives 128.15
 hand eczema 39.13
 historical aspects 1.8
 inflammatory response 8.55
 late-phase response 8.58–9
 phases 8.55–60
 photocontact 128.18
 photodynamic therapy 22.13
 prevalence 6.1
 primary immunodeficiency 82.2
 prostanoid secretion 8.48
 respiratory system disorders 151.1–2
 sensitization phase 8.55–6
 systemic 2.7
 Th2 cells 8.56–7
 see also named conditions and allergens
 Alliaceae 128.53
 allopurinol
 adverse drug reactions 154.14
 DRESS association 119.5, 119.8, 154.10
 exanthem induction 118.1
 gout treatment 154.10
 hypersensitivity reactions 119.6–7
 all-*trans*-retinoic acid 2.31
 allylamines 18.11–12, 19.43, 19.44
 aloe, anti-inflammatory products 156.9, 156.11
 alopecia
 acquired cicatricial 89.34–6
 causes 89.35–6
 definition 89.34
 disease course 89.35
 epidemiology 89.36
 investigations 89.36
 management 89.36
 symptoms 89.35
 androgenetic 89.14–24
 associated diseases 89.15–16
 clinical features 89.20–1
 diagnosis 89.28
 differential diagnosis 89.21
 follicle miniaturization 89.18
 genetics 89.18–20
 hair cycle dynamics 89.18
 hormonal influences 89.17–18
 investigations 89.21
 management 89.21–4
 papulopustular rosacea association 91.8
 pathophysiology 89.17–20
 pattern 89.17
 psychological consequences 89.20
 sex 89.15–16
 telogen effluvium differential diagnosis 89.28
 aplasia cutis 89.49
 arsenic toxicity 122.2, 122.3
 artefactual 89.44–5
 camouflage 89.21–2
 chemotherapy-induced 89.48–9, 120.5–6
 cicatricial

- central centrifugal 89.36, 89.42–3
 discoid lupus erythematosus 89.40, 89.41
 follicular lichen planus 89.37–40
 folliculitis decalvans 89.43–4
 non-specific 89.37
 primary **89.35**
 pseudopelade of Brocq 89.41–2
 secondary **89.35**, 107.5–9
 tufted folliculitis 89.44
 circumscribed of congenital origin 89.49
 cosmetic 89.44
 discoid lupus erythematosus 51.4, 51.5
 eating disorders 89.63
 frontal fibrosing 37.7, 37.17, 89.39
 hidrotic ectodermal dysplasia 67.22
 HIV infection 107.10
 Hodgkin disease 140.49
 junctional epidermolysis bullosa 71.12
 lichen planus 37.11
 lipodematosus 100.22–3, 107.9
 mucinosa 140.15
 neonatal occipital 116.3
 non-scarring 89.11, 89.13
 non-specific cicatricial 89.37
 organoid naevi 89.49
 permanent with chemotherapy 89.49
 psoriatic 107.2
 recessive generalized severe dystrophic epidermolysis bullosa 71.16
 scalp biopsy 89.11, 89.13
 scalp metastases 147.6
 scarring 89.34
 discoid lupus erythematosus differential diagnosis 51.9
 sarcoidosis 98.14
 scalp biopsy 89.11, 89.13
 syphilitic gumma 107.10
 traction alopecia 89.44
 sutural 89.49
 syphilitic 29.13, 29.15
 systemic lupus erythematosus 51.23
 thallium poisoning 122.8
 tick bites 34.38
 traction 89.44–5
 traumatic, tinea capitis differential diagnosis 32.40
 triangular 89.11, 89.49
 trichothiodystrophy differential diagnosis 78.11
 vitamin D deficiency 63.10
 wigs 89.21–2
 alopecia areata 89.28–34
 addisonian pigmentation 145.18
 atopy association 41.24
 camouflage 89.34
 clinical features 89.31–3
 definition 89.28
 differential diagnosis 89.32
 disease course/prognosis 89.32–3
 Down syndrome 76.2
 environmental factors 89.30–1
 epidemiology 89.28–9
 exclamation mark hairs 89.31
 genetics 89.30
 hair cycle disturbance 89.29–30
 hair pigmentary defect 89.71
 hair regrowth induction 18.30
 hairpiece wearing 89.34
 histological sections 3.40
 historical descriptions 89.28
 HIV infection 107.10
 immune privilege 89.29
 infants 117.14
 investigations 89.33
 lichen planus association 37.13
 loose anagen syndrome differential diagnosis 89.58
 management 89.33–4
 pathophysiology 89.29–31
 pili annulati association 89.56
 psychological factors 86.3
 rapid-onset hair greying 89.70
 severity classification 89.32
 tinea capitis differential diagnosis 32.40
 and totalis 18.28
 trichotillomania differential diagnosis 89.46
 Turner syndrome 76.3
 white hair sparing 89.30, 89.31, 89.32
 wig wearing 89.34
 alopecia universalis congenita
 atrichia with papular lesions differential diagnosis 68.13
 Olmsted syndrome 65.62
 ALOXE3 mutations 65.10, 65.12
 ALOX12B mutations 65.10, 65.12
 α -lipoic acid (ALA) 156.1–2, **156.10**
 alphaviruses 154.3
 Alport syndrome, collagen type IV 2.29
 al-Razi, Muhammed ibn Zakariyya 1.3
 Alstromeriaceae 128.53
 alternative splicing 7.1
 alternative therapies *see* complementary therapies; herbal products/medications
 aluminium 128.24
 factitious panniculitis 99.47
 aluminium acetate 18.9
 aluminium chloride hexahydrate 20.43, 85.16
 aluminium chloride, hyperhidrosis treatment 94.8
 aluminium hydrochloride hexahydrate 18.33
 amalgam fillings 128.18
 amalgam tattoos 110.65
 AMD3100, wound healing 10.11
 American Indians, actinic prurigo 127.9, 127.10, 127.11
 American Rheumatism Association, systemic lupus erythematosus diagnostic criteria 4.2
 amicrobial pustulosis of the skin folds 49.16–17
 amineptine, acne association 90.11
 amino acid disorders 81.11–16
 5-aminolaevulinic acid (ALA) 22.2, 22.3, 60.6
 acne conglobata treatment 90.56
 acne treatment 90.50
 actinic keratosis treatment 22.4–5
 application 22.9–10
 aminopenicillins 119.2, **119.4**
 aminopeptidase N (APN) 8.42
 amiodarone
 drug-induced hyperpigmentation 88.25, 88.26, 88.28
 laser treatment 23.14
 phototoxicity 127.29, 127.30, 129.10
 amniocentesis 7.9–10
 amniotic band syndrome 96.43–5
 lymphoedema 105.37–9
 raised linear bands of infancy differential diagnosis 116.18
see also constricting bands of the extremities
 amniotic band theory 105.38
 amniotic membrane, burn coverage 126.6
 amoebiasis **33.33**, 33.34–5
 genital 111.24
 perineum/perianal region 113.12
 amorolfine 18.12
 amphotericin
 blastomycosis treatment 32.87
 candidosis treatment 32.61
 cryptococcosis treatment 32.93
Talaromyces marneffei treatment 32.91
 amphotericin B, liposomal 33.51
 amputation stump neuroma 137.45
 Amsterdam dwarf *see* Cornelia de Lange syndrome
 amyloid
 disease-causing 58.2
 functional 58.2
 high-power microscopy 3.33
 purpura 58.10
 ultrastructure 58.1
 amyloid A amyloidosis 153.2
 amyloid deposits
 histological sections 3.39
 staining 3.9–10
 amyloid K 58.7
 amyloid light-chain amyloidosis 148.5
 amyloidogenesis 58.1–2
 amyloidoses 58.1–13
 A β 110.59
 amyloid light-chain 148.5
 cardiac involvement 150.4–5
 classification 58.2
 clinical presentation 58.2–3, **58.5**, **58.9**
 diagnosis 123.3
 electron microscopy 3.27, 58.4
 gelsolin 58.12
 hereditary 110.59
 histology 58.3
 hyperpigmentation 88.22–3
 immunohistochemistry 58.4
 investigations 58.3–4
 leprosy differential diagnosis 28.12
 lipid proteinosis differential diagnosis 72.33
 localized cutaneous 58.4–8
 associated diseases 58.5–6
 clinical features 58.8
 complications 58.8
 definition 58.4
 differential diagnosis 58.8
 disease course 58.8
 epidemiology 58.5–6
 ethnicity 58.5, 58.6
 familial 58.5–8, 58.8
 incidence 58.5
 lichenoid 58.5, 58.6, 58.8
 macular 58.5–6, 58.7, 58.8
 mixed 58.8
 nodular 58.6, 58.7–8, 58.8
 pathophysiology 58.7–8
 prevalence 58.5
 primary 58.2, 58.2.58.3, 58.4–8
 secondary 58.2, 58.2. 58.4, 58.5
 sex 58.5
 variants 58.8
 macroglossia 110.60
 macular 88.23
 malignancy association **147.22**
 management 58.12–13
 mevalonate kinase deficiency complication 45.6
 oral 110.58–9
 penile 111.20
 pressure ulcer association 124.5
 primary 110.58–9
 systemic 148.5
 respiratory disorder association 151.6
 secondary
 cutaneous 58.2
 oral 110.59
 solitary intraoral 110.59
 systemic lupus erythematosus association 51.31
 systemic with cutaneous involvement 58.2, 58.8–12
 definition 58.8–9
 epidemiology 58.9–10
 hereditary subtypes 58.11–12
 immunoglobulin production 58.10
 oral mucosa 58.10, 58.11
 pathophysiology 58.10–11
 variant 58.11
 topical treatment 58.12–13
 anabolic steroid use
 acne vulgaris association 90.10–11
 linear keloids 96.47
 α -N-acetyl-galactosaminidase deficiency 81.5
 anaemia 63.23–4, 148.16
 acquired pernicious
 systemic lupus erythematosus association 51.31
 vitamin B₁₂ deficiency association 63.19
 aplastic 77.4–5
 congenital 96.28
 generalized severe recessive dystrophic epidermolysis bullosa 71.26
 haemolytic
 congenital 88.49
 dapsone-induced 19.14
 iron deficiency 148.16
 megaloblastic 148.16
 renal failure 153.3
 severe 101.3
 anaesthesia
 nail surgery 95.53
 skin resurfacing 160.8–9
see also local anaesthesia
 anaesthetic agents, anaphylactic reactions 118.7
 anagen 89.3, 89.7
 androgenetic alopecia 89.18
 anagen release
 delayed 89.24, 89.25
 immediate 89.24
 anagrelide 101.12
 anakinra 19.32
 anal abscess 113.25–6
 fistula formation 113.26
 pilonidal sinus differential diagnosis 113.24
 anal agenesis 113.4
 anal canal 113.2
 anal duplication 113.4
 anal fissure 113.28–9
 Crohn disease differential diagnosis 113.25
 sexual abuse 113.32
 anal fistula 113.26–8
 clinical features 113.27–8
 Crohn disease differential diagnosis 113.25
 definition 113.26
 differential diagnosis 113.27
 epidemiology 113.26–7
 investigations 113.28
 management 113.28
 pathophysiology 113.27
 severity classification 113.27
 anal glands 113.2
 anal intraepithelial neoplasia 113.15–17, 142.25
 clinical features 113.16–17
 definition 113.15
 epidemiology 113.15–16
 human papillomavirus infection 31.24
 investigations 113.17
 management 113.17
 pathophysiology 113.16
 severity classification 113.17
 variants 113.16–17
 anal orifice 113.2
 anal rhagades 113.29
 anal sphincter, internal 113.2
 anal stenosis 113.4, 113.31
 anal tags 113.30–1
 analgesia
 hidradenitis suppurativa management 92.9
 Stevens–Johnson syndrome 119.21
 toxic epidermal necrolysis 119.21
 analgesics, anaphylactic reactions 118.7
 anaphylactoid purpura, allergic genital 111.20
 anaphylactoid reactions 118.6
 anaphylatoxins 8.32
 anaphylaxis
 allergic urticaria 42.13, 128.83
 analgesics 118.7
 arthropod bites/stings 34.4, 34.16
 definition 42.1
 drug-induced 118.6–8
 exercise-induced 42.12, 47.12
 wheat-dependent 42.5
 flushing **106.7**
 histamine mediation 8.46
 Hymenoptera stings 34.16
 IgA-mediated with IVIG therapy 19.36
 mastocytosis 46.3, 46.5, 46.9, 46.10, 117.16

- anaphylaxis (*continued*)
 platinum toxicity 122.9
 pseudoallergic reactions 118.6
 spina bifida 85.10
 tick bites 34.38
 wheat-dependent exercise-induced 42.5
- anaplasia 3.34
- anaplastic lymphoma kinase (ALK) 3.24
- cutaneous lymphomas 140.1–2
- anatomists' warts *see* tuberculosis, cutaneous, warty
- anchoring fibrils 2.21, 2.26–7
 function 2.27
- anchoring filaments 2.21, 2.26
- Ancient Egypt 1.1–2
- Ancient Greece 1.2
- Ancient India 1.2
- Ancylostoma brasiliense* 33.18
- Ancylostoma caninum* 33.18
- Ancylostoma ceylonicum* 33.18
- Ancylostoma duodenale* 33.15
- Ancylostoma*, urticaria weals 42.6
- ancylostomiasis 33.15
- androgen(s) 145.18
 deficiency 145.19
 female pattern hair loss 89.17–18
 fetal 111.5
 hair growth 89.8–10
 hirsutism 89.64
 male balding 89.17–18
 mechanism of action of hair follicles 89.9–10
 metabolism 89.9
 abnormalities in acne 90.3
 synthesis 89.9
 testicular 111.5
- androgen receptor(s) 89.9
 polymorphisms 145.19
 sweat coils 94.3
- androgen receptor blockers, papulopustular acne treatment 90.43
- androstenedione 145.18
- anetoderma 96.19, 96.20–2
 clinical features 96.22
 epidemiology 96.21
 investigations 96.22
 Jadassohn–Pellizzari type 96.21
 management 96.22
 pathophysiology 96.21–2
 of prematurity 116.9
 primary 96.21, 96.22
 Schwenger–Buzzi type 96.21
 secondary 96.21, 96.22
 variants 96.22
- aneuploidy 7.2, 7.5
- aneurysmal bone cysts, radiography 95.48
- angina bullosa haemorrhagica 110.68
 immunostaining 110.46
- angioblastoma of Nakagawa 137.25
- angioendothelioma, papillary intralymphatic 137.34–5
- angioendotheliomatosis, reactive 137.24–5
- angiofibromas
 acne vulgaris differential diagnosis 90.26
 cellular 137.9–10
 carbon dioxide laser ablation 23.18
 laser therapy 23.10
 penile ectopic lesions 111.5
 tuberous sclerosis complex 80.10, 80.11
- angiogenesis 103.1
 chemokines role 8.40
 metastatic spread role 147.5
 wound healing 10.6
 diabetic wounds 10.9
- angioimmunoblastic T-cell lymphoma 140.45
- angiokeratomas 103.9, 103.10, 103.13–14
 cherry angioma differential diagnosis 103.12
 circumscriptum 103.13–14
 corporis diffusum
 Fabry disease 81.7, 81.8, 81.9, 150.3
 lysosomal disorders 81.7
- Fabry disease 81.7, 81.8, 81.9, 103.9, 150.3
 of Fordyce 103.9, 103.13, 111.6
 fucosidosis 81.5
 glycoprotein degradation disorders 81.4, 81.5
 Kanzaki disease 81.5
 labia majora 112.3
 laser therapy 23.10, 23.11
 lysosomal storage diseases 81.7
 of Mibelli 103.13
 multiple 103.13
 purpura differential diagnosis 101.2
 solitary 103.13
 tuberous sclerosis complex 147.8
 venous lake differential diagnosis 103.14
- angioliomyoma 137.55, 137.56
- angioliopoma 137.58
- angiolymphoid hyperplasia with eosinophilia
 follicular mucinosis association 107.7
 pinna 108.12, 108.14
- angioma(s)
 cavernous 73.9–11, 103.21–3
 cherry 103.9, 103.12–13, 103.14
 laser therapy 23.10
 macroglossia 110.60
 senile 103.12–13
 spider 103.8, 103.10–12
 tufted 137.25–6
 venous 73.9–11, 103.21–3
- angioma serpiginosum 73.4, 103.15–16
- Fabry disease differential diagnosis 81.8
- livedo reticularis differential diagnosis 125.8
- angiomatoid fibrous histiocytoma 137.64–5
- angiomyofibroblastoma 137.9
- angiomyxoma
 cutaneous focal mucinosis differential diagnosis 59.15
 deep 137.64
 superficial 137.62
- angio-oedema
 ACE inhibitor-induced 43.1, 43.2
 allergic contact dermatitis differential diagnosis 128.61
 bradykinin-induced 43.1, 43.6
 caterpillar reactions 34.31
 cholinergic 42.12, 47.12
 definition 42.1
 drug-induced 118.6–8
 episodic with eosinophilia 43.4
 recurrent cutaneous necrotizing eosinophilic vasculitis differential diagnosis 102.11
- erythema marginatum association 47.12
- granulomatous cheilitis differential diagnosis 110.86
- loiasis 33.11
- macroglossia 110.60
- oral 110.59
- pseudoallergic reactions 118.6
- recurrent without weals 43.1–6
 clinical features 43.4–5
 epidemiology 43.2
 investigations 43.5
 laboratory profiles 43.5
 management 43.5–6
 pathophysiology 43.3–4
 solar 127.20
- systemic capillary leak syndrome 43.4
- urticaria 42.4, 42.14, 47.7, 151.2, 151.3
- vibratory 42.9, 42.10, 47.10, 123.25
- see also* acquired angio-oedema (AAE); angiotensin-converting enzyme (ACE) inhibitor-induced angio-oedema; hereditary angio-oedema (HAE); mast cell mediator-induced angio-oedema
- angiosarcoma 137.36–8, 146.12
 clinical features 137.37–8
 definition 137.36
 epithelioid 137.39
 eyelid oedema 105.15
- facial lymphoedema 105.16
 management 137.38
 pathophysiology 137.37
 post-irradiation 120.13, 137.36, 137.37
 radiotherapy-induced 120.13
 Stewart–Treves syndrome 105.53
- angiotensin-converting enzyme (ACE) 2.43
- angiotensin-converting enzyme (ACE) inhibitor(s)
 Marfan syndrome treatment 72.17
 pruritus induction 83.12
- angiotensin-converting enzyme (ACE) inhibitor-induced angio-oedema 43.1, 43.2, 149.15
 clinical features 43.4–5
 disease course/prognosis 43.4–5
 epidemiology 43.2
 management 43.6
 pathophysiology 43.3–4
- angiotrophic lymphoma 140.43–4
- angular cheilitis 110.79–80, 128.16
- candidosis 32.63
- folate deficiency association 63.19
- riboflavin deficiency differential diagnosis 63.15
- vitamin B₁₂ deficiency association 63.20
- zinc deficiency 71.24
- angular stomatitis, deficiency glossitis 110.64
- anhidrosis 94.10–12
 acquired idiopathic generalized 94.12
- Fabry disease 81.8
- Horner syndrome 85.15
- neurological causes 94.11
- Ross syndrome 94.11
- animal dander, atopic eczema 41.28
- animals, exposure to 41.8
- atopic eczema 41.28
- ankle–brachial Doppler pressure index 103.3
- arterial leg ulceration 104.8
- lower leg eczema 39.20
- ankyloblepharon–ectodermal defect–cleft lip/palate syndrome 67.15–17
 clinical features 67.15, 67.16
 clinical variants 67.16
 complications/co-morbidities 67.16
 definition 67.15
 epidemiology 67.15
 management 67.17
 nomenclature 67.15
 pathophysiology 67.15–16
 prognosis 67.16
- ankyloblepharon filiforme adnatum 67.15, 67.17
- ankyloglossia 110.20
 recessive generalized severe dystrophic epidermolysis bullosa 71.17
 superior syndrome 110.20
- ankylosing spondylitis, psoriatic arthritis differential diagnosis 35.44
- annular elastolytic giant cell granuloma 96.25–7, 97.10
- annular erythema of infancy 47.6–8
 causative organisms 47.6
 clinical features 47.7
 definition 47.6
 differential diagnosis 47.7
 epidemiology 47.6–7
 investigations 47.7–8
 lesions 47.6, 47.7
 management 47.8
 pathology 46.8, 47.6
 treatment ladder 47.8
- annular lichenoid dermatitis of youth 37.9
- annular erythema of infancy differential diagnosis 47.7
- ano-genital intraepithelial neoplasia 25.58–9, 142.25
 genital wart differential diagnosis 25.56
 transplant recipients 25.63
- ano-genital region 113.1
 allergic contact dermatitis 128.17
 congenital abnormalities 113.4
- developmental abnormalities 113.4
- eczema 111.10–12
- embryogenesis 113.3–4
- extramammary Paget disease 147.6–7
 function 113.1–3
 haemangiomas 111.7
- hidradenitis suppurativa 92.1, 92.5, 92.6, 92.8
 male 111.5, 111.7
- pilonidal sinus 123.22–3
- pruritus 128.17
- psoriasis 111.9–10
 structure 113.1–3
see also genital dermatoses
- ano-genital ulceration, HIV infection 113.13
- ano-genital warts 25.45, 25.55–8, 111.25, 112.28–9
 causative organisms 25.56
 clinical features 25.56–8
 common 25.47
 complications/co-morbidities 25.57
 differential diagnosis 25.57
 external 113.13–15
 HIV infection 31.24
 human papillomavirus 25.45
 imiquimod therapy 18.27
 infectivity 25.53
 management 18.27, 25.58
 men who have sex with men 31.24
 pathophysiology 25.55–6
 perianal 25.56, 25.57
 prognosis 25.58
 transmission 25.55
 treatment ladder 25.58
 variants 25.56–7
- anonychia 95.8
 hereditary 69.16
- ano-rectal abscess 113.25–6
 anal fistula 113.26
- ano-rectal adenocarcinoma, extramammary Paget disease association 112.36
- ano-rectal fistula 113.26–8
- ano-rectal pain 113.32
- anorexia nervosa 86.20–1, 89.63
- antennal procedures, complications 116.10
- Anthozoa 131.2
- anthrax 26.43–5
 carbuncle differential diagnosis 26.26
 clinical features 26.44
 epidemiology 26.43–4
 investigations 26.44
 management 26.44–5
 pathophysiology 26.44
 vaccination 26.45
 variants 26.44
- anthrax toxin receptor 2 (*ANTXR2*) gene mutations 72.17, 72.18
- Anthrenus* 34.30
- antiageing products 156.3–5
- antioxidants 156.1–2
 carnosine 156.7, 156.11
 phytochemicals 156.7–9
- antiandrogens
 female pattern hair loss management 89.23
 hirsutism treatment 89.67
- antiangiogenic agents, port-wine stains 23.9
- antibiotics 19.41–3
 acne conglobata treatment 90.56
 acne treatment
 comedonal 90.39–40
 ocular side effects 109.45–6
 severe 90.44
- acrodermatitis chronica atrophicans 96.14
- anaphylactic reactions 118.7, 118.8
- anti-inflammatory effects 19.43
- anti-p200 pemphigoid treatment 50.40, 50.41
- atopic eczema relationship 41.9
- bowel-associated dermatosis–arthritis syndrome treatment 49.13

- cellulitis treatment 105.14
confluent and reticulated papillomatosis treatment 87.7
DRESS association 119.5
drug-induced serum sickness-like reaction 118.8, 118.9
eczema induction 118.4
eosinophilic pustular folliculitis treatment 93.9
exanthem induction 118.1, 118.2
fixed drug eruption 118.12
hidradenitis suppurativa management 92.9–10
ocular side effects 109.45–6
oral contraceptive interactions 90.42
papulopustular acne treatment 90.40, 90.41–2
periorificial dermatitis management 91.18
prepubertal acne 90.64
recurrent cellulitis management 105.12
rosacea treatment 91.13, 91.14
side effects 90.42
topical 18.10–11
antibody deficiencies 82.12–13
antibody-dependent cellular toxicity (ADCC) 8.59
anticentromere antibodies (ACA), morphea 57.7
anticholinergics hyperhidrosis treatment 94.8
topical 18.33
anticoagulants antiphospholipid syndrome treatment 52.3
surgical bleeding complications 20.8, 20.11
anticonvulsants DRESS association 119.5
exanthem induction 118.1
anticytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) 143.30, 143.31
antidepressants 86.35–7
prescribing 86.35–6
scalp dysaesthesia treatment 107.14
switching drugs 86.37
antidiabetic drugs, pruritus induction 83.12
antiepileptic drugs, acne association 90.12
antifungal agents 19.43–4
confluent and reticulated papillomatosis treatment 87.7
topical 18.11–12
antigen presentation 8.27–31
antigen presenting cells (APC) 8.21, 8.28, 8.29, 136.1, 136.2
B7 family proteins 8.58
late-phase allergic response 8.59
sensitization 8.55
antiglomerular basement membrane vasculitis disease 102.19–20
antihistamines 19.3–5
adverse effects 19.4
cautions 19.4–5
children 42.17
contraindications 19.4
dermatological uses 19.4
dose 19.5
drug–drug interactions 19.5
first-generation 19.4
itch in atopic eczema 41.30
lichen simplex treatment 39.30
mastocytosis management 46.9
pharmacological properties 19.4
pregnancy 42.17
recurrent angio-oedema without weals 43.5
regimens 19.5
second-generation 19.4
solar urticaria 127.23
topical 18.33
urticaria management 42.16–18
urticarial vasculitis treatment 44.5
anti-infective agents, topical 18.9–11
anti-inflammatory products hidradenitis suppurativa management 92.10
phytochemicals 156.9–10
anti-105 kDa antigen pemphigoid 50.52
anti-laminin γ 1 pemphigoid *see* anti-p200 pemphigoid
antimalarials 19.5–7
adverse effects 19.6–7, 154.15
cardiotoxicity 19.7
cautions 19.7
contraindications 19.7
cutaneous toxicity 19.6
dermatological uses 19.5
discoid lupus erythematosus treatment 51.10–11
dosage 19.7
drug combinations 19.7
drug–drug interactions 19.6
gastrointestinal toxicity 19.7
hyperpigmentation 88.25, 88.28
oral 110.66
monitoring 19.7
myelotoxicity 19.6
nail coloration 95.14
neuromuscular toxicity 19.7
ocular side effects 109.43, 109.45
oculotoxicity 19.6–7
pharmacological properties 19.5–6
pre-treatment screening 19.7
regimens 19.7
reticular erythematous mucinosis treatment 59.9
sarcoidosis treatment 98.16
side effects 51.11, 51.22
subacute cutaneous lupus erythematosus 51.14
systemic lupus erythematosus 51.35, 88.21
antimicrobial agents 19.41–4
allergic contact dermatitis 128.32–40
Darier disease 66.9
topical corticosteroid formulations 18.18
antimicrobial peptides 2.12
immunity against ringworm 32.21
innate immunity 8.13–14
role in immunity/inflammation 8.14
antimicrobial resistance gonococcus 30.7, 30.8
syphilis 29.5
antimony, reactions to 122.1–2
antineoplastic agents, topical 18.26–8
antinuclear antibodies (ANA) 127.35
discoid lupus erythematosus 89.41
morphea 57.1, 57.6–7
scleroderma 57.1
Sjögren syndrome 55.7
Sneddon syndrome 101.21
systemic lupus erythematosus 51.27, 51.32–3
systemic sclerosis 56.2, 56.8
antioestrogen drugs, alopecia 89.49
antioxidants ageing skin 2.47
antiageing effects 156.1–2
cosmeceuticals 156.1–3
photoageing prevention 96.4
phytochemicals 156.6–8, 156.11
preservatives in topic medications 18.8
anti-p200 pemphigoid 50.18, 50.38–41
autoantibody specificity 50.10
bullous systemic lupus erythematosus differential diagnosis 50.48
clinical features 50.10, 50.39, 50.40
definition 50.38
differential diagnosis 50.39
epidemiology 50.38
investigations 50.39–40
management 50.40–1
nomenclature 50.38
pathophysiology 50.38–9
antiparasitic agents, topical 18.13
antiperspirants 18.33
antiphospholipid antibodies primary anetoderma association 96.21
Sneddon syndrome 101.21
antiphospholipid syndrome 52.1–3, 101.17, 101.19–20
cardiac involvement 150.4
catastrophic 51.24, 52.2
clinical features 52.2, 101.20
definition 52.1
diagnostic criteria 101.19
epidemiology 52.1–2, 101.19
investigations 52.2, 101.20
livedoid vasculopathy 101.22
management 52.2–3, 101.20
pathophysiology 52.2, 101.19–20
primary anetoderma association 96.21, 96.22
respiratory disease association 151.2
systemic lupus erythematosus 51.24
antiplatelet drugs, surgical bleeding complications 20.8, 20.10
anti-programmed-death 1 (anti-PD-1) antibodies 143.30
antipsychotic medication 86.37–8
body dysmorphic disorder 86.13
hyperprolactinaemia induction 149.15
antiretroviral drugs 31.8, 31.9–11
cutaneous morbidity reduction 31.12
cutaneous side effects 31.18, 31.19
hair loss association 89.47, 107.10
Kaposi sarcoma 31.30
lipodystrophy 31.10, 31.19–20
timing of initiation 31.9–10
antirheumatic therapies, cutaneous adverse reactions 154.14–15
anti-Ro antibody 51.34
antiseptics 18.9–10
antisynthetase syndrome 53.3, 53.4, 53.7, 53.8, 53.9
respiratory disease association 151.2–3
anti-TNF- α non-tuberculous mycobacterial infections 27.32
tuberculosis treatment 27.12
 α ₁-antitrypsin deficiency 74.9
respiratory disorder association 151.5
severe 99.41
 α ₁-antitrypsin deficiency panniculitis 99.8, 99.41–3
clinical features 99.42
complications/co-morbidities 99.42
definition 99.41
differential diagnosis 99.42
genetics 99.41
investigations 99.42–3
management 99.43
pancreatic panniculitis differential diagnosis 99.40
pathophysiology 99.41–2
antituberculous chemotherapy drug eruptions 31.17
see also ethambutol; isoniazid; rifampicin; thioacetazone
anti-type IV collagen pemphigoid 50.51
antiviral agents 19.44
erythema multiforme 47.6
herpes zoster treatment 109.38
topical 18.12–13
ants 34.14–16
bites clinical features 34.16
management 34.16
pathophysiology 34.15
venom 34.15
anus imperforate 113.4
pigmented lesion 143.14
see also anal entries
anxiety 11.1, 11.2, 11.3–4, 11.4
acne vulgaris 90.34–5
integrated management 11.8
peno-scrotodynia association 84.8
seborrheic dermatitis association 40.4
social 11.4
solar urticaria association 127.23
vulvodynia association 84.8
xeroderma pigmentosum 78.6
antiolytics 86.38
AP-1, ageing of skin 155.6, 155.7–8
APECED (autoimmune polyendocrinopathy, candidosis and ectodermal dystrophy) syndrome 32.68, 148.17, 148.18
Apert syndrome 67.7
acne 90.9–10
cutis laxa differential diagnosis 72.14
microtia 108.4
aphthous stomatitis Behçet syndrome 110.30–2
clinical features 110.28
definition 110.27
differential diagnosis 110.29
epidemiology 110.27
fixed drug eruption differential diagnosis 118.12
haematological disease 110.39–41
infections 110.48–54
investigations 110.29–30
low-power laser therapy 23.20
management 110.30
pathophysiology 110.28
recurrent 110.27–30
major 110.29
minor 110.28, 110.29
Sweet syndrome 110.32
systemic diseases association 110.39–56
variants 110.28
aphthous ulcers Behçet disease 48.7
oral and inflammatory bowel disease association 152.3
penile 111.17
scrotal 111.17
vulval 112.18
aphthovirus 25.80
Apis mellifera 34.14
aplasia cutis 89.11
alopecia 89.49
congenita 75.19–20
congenital erosive and vesicular dermatosis with reticulated scarring differential diagnosis 96.12
epidermolysis bullosa differential diagnosis 71.23
aplastic anaemia 77.4–5
definition 77.4–5
apocrine glands 2.2, 2.8, 2.9, 2.43, 138.1, 138.2
anatomy 94.15
carcinoma 138.23
cutaneous myoepithelioma 138.33–4
cylindroma 107.10, 138.30–1
malignant 138.35–6
disorders 94.15–18
hair-bearing sites 2.44
hidradenocarcinoma 138.36
hidradenoma 138.29–30
hidrocystoma 138.19–20
microcystic adnexal carcinoma 138.37–8
miliaria 94.17–18
mixed tumour of the skin 138.32–3
mucinous carcinoma 138.38–9
physiology 94.15
pregnancy 115.2
spiradenocarcinoma 138.36–7
spiradenoma 138.31–2
tubular adenoma 138.22
tumours 138.19–23
carcinomas 138.34–40
follicular 138.29–34
follicular carcinoma 138.35–40
apocrine glands 2.9
Apoidea 34.14
apolipoprotein E 62.8
apoptolysis, pemphigus 50.3
apoptosis 3.34
defects 82.14
diabetic wounds 10.9
inflammation 8.53–4
keratinocyte-induced 12.3
protease role 8.40

- apoptosis (*continued*)
 regulation 8.53, 8.54
 Stevens-Johnson syndrome 119.13
 toxic epidermal necrolysis 119.13
 UVR-regulated 9.6–7
- appearance role in society 11.1–2
- appliances causing coslissities 123.8
- apremilast
 plaque psoriasis treatment 35.29
 psoriatic arthritis treatment 35.45
- aquaporin(s) (AQPs) 94.2
 gene, ageing skin 155.9
- aqueous cream 18.9
- arachidonic acid 8.23, 8.49
- arachis oil 18.5–6
- Arachnida 34.32–5, 34.36, 34.37–9
 Acari 34.35–9
 Araneae 34.32–4
 Hexathelidae 34.33
 Lycosidae 34.34
 Scorpiones 34.34–5
 Sicariidae 34.33–4
 Theridiidae 34.32–3
- arachnidism 34.32
- Araneae 34.32–4
- arbutin 156.8–9, 156.11
- Arcanobacterium haemolyticum* 26.43
- Areca* nut 110.56
- arecoline 110.57
- arenavirus infections 25.69–72
- Argasidae 34.35–6
- Argentinian haemorrhagic fever 25.71
- arginine catabolic mobile element 26.9
- argininosuccinic aciduria 81.11, 81.15
 trichorhexis nodosa 89.54
- Argyll Robertson pupils 29.20
- argyria 88.52, 122.7–8
 ear piercing complications 108.8
 earrings 122.7
 generalized 122.7
- arm, swollen 105.12–14
 causes 105.12–13
 clinical features 105.13
 differential diagnosis 105.13
 epidemiology 105.13
 genetics 105.13
 investigations 105.14
 lymphoedema 105.51–2
 management 105.14
 overgrowth 105.12, 105.13
 pathophysiology 105.13
 predisposing factors 105.13
 psychosocial impact 105.53
see also digit(s); fingers; hand(s)
- armadillo family of proteins 2.18
- armchair legs 105.8, 105.50
- aromatase inhibitors, alopecia 89.49
- array chromosomal genomic hybridization (array CGH) 76.1
 chromosomal mosaicism detection 76.5
- arrector pili hamartoma 137.55
- arsenic keratosis 122.2, 122.3, 142.12–13
 clinical features 142.13
 definition 142.12
 epidemiology 142.12–13
 Flegel disease differential diagnosis 87.17
 investigations 142.13
 management 142.13
 multiple minute digitate keratoses differential diagnosis 87.18
 pathophysiology 142.13
 spiny keratoderma differential diagnosis 65.52
- arsenic, reactions to 122.2–3
 basal cell carcinoma risk 141.3
 pigmentation 88.52–3
- artefacts 3.27–8
 male genital dermatoses 111.7–9
 penile 111.8
 perianal/perineal 113.31–2
- arterial disease 103.2, 103.3, 103.4
- arterial occlusion
 acrocyanosis differential diagnosis 125.5
 filler adverse reaction 157.9–10
- arterial thrombosis
 antiphospholipid syndrome association 52.2
 HIV infection 31.13
- arterial tortuosity syndrome 72.12
- arterial/arteriolar disorders 103.2–18
 arterial disease 103.2, 103.3, 103.4
 cherry angiomas 103.12–13
 neurovascular disorders 103.6–8
 thromboangiitis obliterans 103.4–6, 121.2
see also angiokeratomas; erythromelalgia; telangiectasia
- arteriogenesis 103.1
- arterioles 2.42
- arteriovenous disorders 73.7–9
- arteriovenous fistula (AVF) 73.3, 73.4
- arteriovenous malformations (AVM) 73.3, 73.4, 73.7–8, 103.19–20, 103.21
 associated conditions 103.19, 103.20
 clinical features 103.21
 definition 103.19
 epidemiology 103.19
 infants 103.21
 investigations 103.20
 management 103.20
 pathophysiology 103.19–20
 peripheral 103.19–20, 103.21
- arthritis, cannabis 121.2
- arthritis
 acne association 154.10
 acne conglobata association 90.54
 adult-onset Still disease 45.10
 Behçet disease 48.5, 48.7, 48.9–10
 bowel-associated dermatosis–arthritis syndrome 49.13
 cervical 108.28
 dermatomyositis 53.9
 distal interphalangeal joint 95.41
 mutilans 35.43
 pyogenic, hidradenitis suppurativa association 92.2
 pyogenic sterile arthritis, pyoderma gangrenosum and acne syndrome 45.3, 45.8
 septic 154.3–4
 seronegative 154.5
 systemic lupus erythematosus 51.27–8
see also juvenile rheumatoid arthritis; mixed connective tissue disease; psoriatic arthritis; reactive arthritis; rheumatoid arthritis
- arthrochalasia multiplex congenita 72.5
- arthrogryposis renal dysfunction cholestasis (ARC) 65.27, 65.28
- arthropods, skin disease 34.1–5
 allergen injection 34.2
 anaphylaxis 34.4
 bite reactions 34.3, 34.3–4
 clinical features 34.3–4
 contact reactions 34.2
 definition 34.1
 disease transmission 34.2
 environmental factors 34.2–3
 injection of irritant/cytotoxic/pharmacologically active substances 34.2
 investigations 34.4–5
 management 34.5
 mechanical trauma 34.1
 mechanisms of action 34.1–3
 pathophysiology 34.1–3
 pet animals 34.4–5
 prevention 34.5
 retained mouthparts reactions 34.2
 secondary infection 34.2, 34.4
see also named arthropods and conditions
- aryl sulphatase, lysosomal 8.44
- asbestos, occupational acne 130.11
- Ascher syndrome 96.24–5
- Asclepius (Ancient Greek physician) 1.2
- Ascomycota* 28.3, 28.4, 32.3, 32.4
- ascorbic acid 63.22
 malaria treatment 94.13
- aseptic abscess syndrome 49.17
- ash-leaf macules, tuberous sclerosis complex 80.10, 80.11, 80.12
- ashy dermatosis 88.32–3
 pinta differential diagnosis 26.68
- aspartylglucosaminuria 81.5
- aspergillosis
 oral lesions 110.54
 panniculitis 99.58
 rhinocerebral 110.54
- Aspergillus niger*, otomycosis 32.17, 32.18
- Aspergillus*, systemic mycosis 32.94–5
- Aspergillus terreus* 32.55
- aspirin
 Kawasaki disease treatment 102.33
 stabilization 46.9
 thrombocytosis treatment 101.12
 urticarial eruptions 42.16, 47.7, 118.7
- assassin bugs 34.27–8
- Assessments of the Psychological and Social Effects of Acne (APSEA) questionnaire 16.6
- asteatosis 87.25–7
 skin barrier function effects 155.9
see also eczema, asteatotic
- asthma
 atopic 2.7, 151.2
 atopic eczema association 41.11, 41.23
 eosinophil association 8.19
 platelet activating factor dysregulation 8.47
 platinum toxicity 122.9
- astroglioma 18.9
- astrocytoma
 melanoma–astrocytoma syndrome 147.7
 neurofibromatosis association 80.3, 147.8
- asymmetric periflexural exanthem of childhood 25.89
- ataxia telangiectasia 78.11, 82.11
 respiratory disorder association 151.5
- ataxia with vitamin E deficiency (AVED) 63.11
- atazanavir 31.10
- atherosclerosis 103.2–4
- athletes *see* sports injuries
- athlete's foot *see* tinea pedis
- athlete's nodule 123.16
- athyroidal hypothyroidism with spiky hair and cleft palate syndrome 68.23
- ATM gene mutations 147.13
- atopic blepharoconjunctivitis 109.15, 109.17
 clinical characteristics 109.22, 109.23
- atopic dermatitis *see* atopic eczema (dermatitis)
- atopic dirty neck 41.16, 41.18
- atopic eczema (dermatitis) 2.7, 41.1–34, 117.2–3
 actinic prurigo differential diagnosis 127.11
 β-adrenergic signalling defect 149.9
 adult phase 41.19, 41.20
 allergic contact dermatitis differential diagnosis 128.61, 128.62
 relationship 41.13
 allergic rhinitis association 41.23
 allergy management 41.31–2
 ano-genital 111.11
 antimicrobial peptides 2.12
 assessment 41.26, 41.27
 assessment tools 16.3
 asthma association 41.11, 41.23
 autoantigens 41.14
 autoimmunity 41.14
 bathing 41.28–30
 breastfeeding impact 41.7, 41.25, 41.32
 childhood phase 41.16, 41.17–19, 41.19, 41.20
 children with HIV infection 31.35
 chronic actinic dermatitis association 127.14
 cigarette smoke association 41.7–8
 climate factors 41.6–7
 clinical features 41.15–16, 41.17–19, 41.19, 41.20, 41.21–5
- collagen type XXIX 2.29
- complications/co-morbidities 41.21–3
- Compositae allergy 128.52
- defensin activity 8.14
- definition 41.1
- dermatophyte-induced onychomycosis differential diagnosis 32.49
- desensitization 41.32
- diagnosis 41.21
- diagnostic criteria 41.1, 41.2
- diet 41.7
- differential diagnosis 41.21
- disease course 41.24–5
- disease flares 41.13–14
- dry skin association 41.23
- eczema herpeticum 25.39
- eczematous cheilitis 110.84
- educational underachievement 11.5
- emollients 41.28–30
- endocrine factors 41.15
- environmental factors 41.6–8
- eosinophil granule proteins 8.19
- epidemiology 41.3–4
- filaggrin mutations 8.56
- filaggrin status 41.2
- genetics 41.5–6
- growth delay 41.22
- hand 39.17, 41.20, 41.21
- hand eczema association 39.3, 39.12
- history 41.15–16
- HIV infection 31.14
 children 31.35
- hygiene hypothesis 41.8–9
- hyperpigmentation 41.16, 41.18
- hypopigmentation 41.16, 41.17
- IFN-γ treatment 8.34
- IgE 41.11–12, 41.14
- immune dysregulation 41.9–10
- immunological abnormalities 26.13
- incidence 129.2
- infantile phase 41.16
- infantile seborrhoeic dermatitis differential diagnosis 117.2
- infections 41.30
- inflammation suppression 41.30
- innate immune cells 41.11
- innate immunity 41.11, 41.13
- investigations 41.25–6
- irritant contact dermatitis differential diagnosis 129.6
- itch management 41.30
- keratosis pilaris association 87.9
 differential diagnosis 87.10
- lichenification 39.4
- lipids 41.6
- lip-lick cheilitis 41.24, 41.29
- lower leg 39.20
- lymphoma association 41.23
- macrophage inhibitory factor role 8.22
- management 19.10, 41.25, 41.26–34
 first line treatment 41.25, 41.27–31
 second line treatment 41.31–2
 third line treatment 41.32–4
 topical tacrolimus 18.20
- mast cell role 2.17
- MHC role 8.27
- mucous membrane pemphigoid differential diagnosis 50.29
- nomenclature 41.1, 41.2
- non-adherence to treatment 11.4
- occupational advice 41.25
- occupational allergic contact dermatitis differential diagnosis 130.6
- occupational irritant contact dermatitis differential diagnosis 130.3
- ocular abnormalities 41.22–3
- oral therapy 41.30–1
- pathogenesis 41.2
- pathophysiology 41.4–6
- patient education 15.3
- pharmacological abnormalities 41.14
- photoaggravated, chronic actinic dermatitis differential diagnosis 127.16

- phototherapy 41.32
 pollution association 41.7–8
 prevalence 5.9, 6.1, 41.3, 41.4
 prevention 41.25
 prognosis 41.24–5
 protein–energy malnutrition differential diagnosis 63.4
 pruritus 41.14–15, 83.9
 psoriasis differential diagnosis 31.15
 psychological factors 41.15, 41.21–2, 86.2
 psychological impact 11.4
 PUVA 21.4
 quality of life 41.21
 measures 16.6
 recurrent herpes simplex 25.16
 severity 41.3–4
 classification 41.21
 sex steroid influence 41.15
 skin barrier function 41.5
 social class trend 5.10
 social stigma 11.5
 staphylococcal infections 2.13
 Staphylococcus aureus infection 26.13, 41.13, 41.30
 disease flares 41.13–14
 streptococcal infections 26.12–13
 stress role 8.50–1
 subtypes 5.4
 sweating 41.15
 topical therapy 41.28–30, 41.31
 tacrolimus 18.20
 treatment 5.3
 T-reg cells 41.10–11
 trigger factor reduction 41.28–9
 urban versus rural living 41.7
 UVA-1 phototherapy 21.6
 UVB phototherapy 21.4, 21.5
 vascular abnormalities 41.14
 weaning age 41.7
 wet wrap technique 41.31
 white dermographism 41.14
 xerosis cutis differential diagnosis 87.26
 atopic eruption of pregnancy 83.12, 115.15, 115.16
 atopic eye disease 109.15–17, 109.18–19, 109.19, 109.20–2, 109.22–4, 109.24, 109.24
 classification 109.15
 clinical features 109.17, 109.18–19, 109.19, 109.20–2, 109.22, 109.23
 clinical variants 109.17, 109.19, 109.22
 complications/co-morbidities 109.22
 diagnosis 109.23
 differential diagnosis 109.22
 epidemiology 109.15
 investigations 109.22
 management 109.22–4, 109.24
 algorithm 109.24
 pathophysiology 109.15–17
 severity classification 109.22
 treatment ladder 109.22–4
 atopic keratoconjunctivitis 109.15, 109.16–17, 109.22
 clinical characteristics 109.19, 109.20–1, 109.22, 109.23
 severity classification 109.22
 atopic march 41.11–12
 atopy
 allergic contact dermatitis 128.10–11
 Comèl–Netherton syndrome 65.25
 lichen striatus association 37.18
 patch test 41.13
 ATP7A gene mutations 81.18
 atranol 128.53
 atrial myxoma 101.16, 101.17
 atrachia 68.3–4, 68.12–15
 with papular lesions 68.3, 68.12–15
 atrophia maculosa varioliformis, pachydermodactyly association 96.36
 atrophie blanche 101.22–3
 chronic venous insufficiency 103.38, 103.39
 Klinefelter syndrome 76.4
 malignant atrophic papulosis differential diagnosis 101.24
 systemic lupus erythematosus 51.24–5
 atrophoderma
 follicular 96.14–15
 linear 96.15
 of Pasini–Pierini 57.11, 57.13, 96.15–16
 vermiculatum 87.10
 atrophy of skin 96.6–19
 atrophic scars 96.11–12
 corticosteroid-induced 96.7–9
 clinical features 96.8
 investigations 96.8
 management 96.9
 pathophysiology 96.7–8
 facial hemiatrophy 96.17–18
 follicular atrophoderma 96.14–15
 linear atrophoderma 96.15
 onchocerciasis 33.3, 33.4
 panatrophy 96.7, 96.17
 paroxysmal finger haematoma 96.16–17, 101.6
 see also acrodermatitis chronica atrophicans; ageing of skin; photodamage; poikiloderma, acquired; striae
 atropine-like drugs, hyperhidrosis treatment 94.9
 atypical cutaneous lymphoproliferative disorder (ACLD) 31.31–2
 atypical fibroxanthoma 137.22–3
 radiation-induced 24.19, 137.22
 atypical intradermal smooth muscle neoplasm 137.57
 atypical lipomatous tumour 137.60–1
 atypical vascular proliferation after radiotherapy (AVPR) 137.40, 137.41
 auramine–rhodamine staining 3.10
 Auspitz's sign 35.9–10
 autism, trichothiodystrophy association 89.55
 autoantibodies
 systemic sclerosis 56.2, 56.8
 transplacental transfer of maternal 116.11–14
 autoantigens, atopic eczema 41.14
 auto-eczematization 34.38
 autoimmune disorders
 acquired generalized lipodystrophy association 100.3
 adrenalitis 145.18
 blistering 3.11
 erythema multiforme differential diagnosis 47.6
 immunofluorescence studies 3.17–18
 immunopathology techniques 3.17
 bullous pemphigoid association 50.11
 complement defects 82.18
 delayed-type hypersensitivity 8.60
 diabetes 64.4
 interstitial granulomatous dermatitis association 154.14
 mixed cryoglobulinaemia 125.10
 morphoea association 57.5
 nitric oxide role 8.46
 pityriasis rubra pilaris association 36.1
 pregnancy 115.5–6
 primary immunodeficiency 82.2
 proximal nail fold
 capillaroscopy 95.52–3
 reactive oxygen species production 8.44
 respiratory system disorder association 151.2–3
 sarcoidosis association 98.2
 systemic sclerosis association 56.7
 systemic with renal involvement 153.6
 TNF- α role 8.35
 vitiligo 88.35
 see also dermatomyositis; systemic sclerosis
 autoimmune gastritis, vitamin B₁₂ deficiency association 63.19
 autoimmune lymphoproliferative syndrome 74.9, 82.14–15
 autoimmune polyendocrine syndrome
 diabetes associations 64.4
 type 1 82.17
 autoimmune polyendocrinopathy, candidosis and ectodermal dystrophy (APECED) syndrome 32.68, 148.17, 148.18
 autoimmune thyroid disease 145.20
 dermatitis herpetiformis
 association 50.53
 DRESS association 119.10
 granuloma annulare association 97.2
 palmoplantar pustulosis association 35.38
 pityriasis rubra pilaris association 36.1
 sarcoidosis association 98.2
 systemic sclerosis association 56.7
 urticaria association 42.3
 autoimmunity
 atopic eczema 41.14
 morphoea 57.6–7
 autoinflammatory disorders 19.32, 45.1–12
 acquired 154.10
 classification 45.2
 complex and polygenic presenting with urticarial/maculopapular rash 45.9–11
 hereditary 154.10
 management 45.12
 monogenic 45.1–2, 45.3, 45.4–8, 154.10
 definition 45.1–2
 musculoskeletal 154.10–11
 pyoderma gangrenosum association 49.3
 autoinflammatory granulomatosis of childhood 45.3, 45.7, 96.37, 154.8
 autoinflammatory syndromes with pustulosis 45.7–8
 autonomic nervous system 85.3
 dysfunction and benign symmetrical lipomatosis association 100.14
 autosomal dominant familial partial lipodystrophy 100.3
 autosomal dominant periodic fever see tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS)
 autosomal dominant punctate porokeratosis 65.52
 autosomal recessive congenital ichthyosis (ARCI) 65.3, 65.6–13
 bathing 65.38
 collodion baby association 116.19
 Comèl–Netherton syndrome differential diagnosis 65.25
 hyperparathyroidism 145.21
 management 65.38–9
 palmoplantar hyperkeratosis 65.42
 pathophysiology 65.6
 autosomal recessive hypotrichosis 2.19
 localized 68.5, 68.15
 syndromic 68.17–18
 autosomal recessive ichthyosis with hypotrichosis 65.36, 68.6, 68.17–18
 pili torti 68.20–1
 avalvulosis 103.36
 avidin 63.23
 avidin–biotin–peroxidase complex (ABC) method 3.16
 axilla
 allergic contact dermatitis 128.16, 128.45
 bacterial flora 26.5
 extramammary Paget disease 147.6
 hidradenitis suppurativa 92.1, 92.5, 92.6, 92.8
 axillary vault excision 94.10
 axillary web syndrome 103.33
 axon reflex response 8.51
 azathioprine 19.7–10
 adverse effects 19.8–9
 anti-p200 pemphigoid treatment 50.40, 50.41
 atopic eczema treatment 41.33
 breastfeeding mothers 51.30
 bullous systemic lupus erythematosus treatment 50.48, 50.49
 carcinogenesis 19.9
 cautions 19.9
 chronic actinic dermatitis management 127.20
 contraindications 19.9
 dermatological uses 19.8
 dose 19.9
 hypersensitivity syndrome 19.9
 infection risk 19.9
 irritant contact dermatitis 129.8
 monitoring 19.10
 myelosuppression 19.8–9
 pemphigus treatment 50.8
 pharmacological properties 19.8
 polymorphic light eruption management 127.8
 pre-treatment screening 19.9
 regimens 19.9
 skin cancer association 146.6, 146.7
 systemic lupus erythematosus treatment 51.30, 51.36
 azelaic acid 18.12, 18.29, 159.2
 comedonal acne treatment 90.40
 papulopustular acne treatment 90.40–1
 rosacea treatment 91.13
 azoles 19.43
 azone, penetration enhancer 18.7
B
 B cell(s) 8.31
 biological therapies against 19.32–4
 histamine regulation of function 8.47
 IgE-committed 8.56
 immunogenotyping 3.27
 see also B-cell lymphoma; cutaneous B-cell lymphoma
 B-cell receptor 8.31
 β -blockers, flushing treatment 106.8–9
 β -catenin 2.4
 β -defensins 2.12
 babesiosis 34.38
 bacillary angiomatosis 26.61–2, 34.12
 cherry angioma differential diagnosis 103.12
 differential diagnosis 26.62
 Fournier 31.20–1
 Kaposi sarcoma differential diagnosis 31.29, 111.24, 139.4
 oral lesions 110.53
 bacille Calmette–Guérin (BCG) disseminated infection 31.35
 infection 82.8
 polyclonal antibody 3.10
 see also BCG vaccination
Bacillus anthracis 26.43–5
Bacillus oleronius, rosacea association 91.5
 bacitracin 18.10
 back, upper, surgery 20.46
 bacteria, skin 2.13, 26.2–6
 adherence 26.5
 Staphylococcus aureus 26.7
 age effects 26.4
 ethnic differences 26.4
 hydration effects 26.4
 microbial ecology 26.2–4
 modifying factors 26.4
 normal flora 26.3–4
 quantitative cultural studies 26.4
 sampling methods 26.2–3
 sex differences 26.4
 skin defences 26.5–6
 specialized areas 26.4–5
 temporary resident 26.3
 bacterial antigens
 delayed sensitivity testing 4.24–5
 delayed-type tests 4.25
 infective eczema 39.23–4
 bacterial endocarditis, hyperhidrosis 94.5
 bacterial furuncle, tinea capitis differential diagnosis 32.40

- bacterial infections 26.1–85
 abnormal sweat odour 94.16
 anaerobic 26.64–6
 aphthous ulceration 110.40
 arthropathies 154.3–5
 atopic eczema 41.22
 children with HIV 31.35
 chronic otitis externa 108.18
 confluent and reticulated
 papillomatosis 87.6
 dysgonic fermenters 26.63–4
 ear piercing complications 108.7
 erythema annulare centrifugum 47.9
 erythema multiforme 47.3
 erythema nodosum 19.18, **99.19**
 eugonic fermenters 26.64
 eyes 109.41–2
 gastrointestinal in rosacea 91.4
 Gram-negative bacteria 26.48–64
 anaerobic 26.64–6
 Gram-positive bacteria 26.6–48
 HIV infection 31.20–2
 children 31.35
 host defence 26.2
 immunodeficiency association 148.15
 infectious panniculitis 99.43, 99.44
 infective cheilitis 110.87
 lymphatic malformations 73.16
 mucous membrane pemphigoid
 differential diagnosis 50.29
 neonates 116.23–7
 oral lesions 110.52–3
 perineum/perianal region 113.9–11
 pinna 108.11
 pityriasis lichenoides 135.4
 polyarteritis nodosa induction 102.30
 reactive arthritis 112.17
 secondary with varicella
 infection 25.25–6
 systemic lupus erythematosus
 association 51.19
 umbilicus 116.25
 vulval 112.23–5
 X-linked hypohidrotic ectodermal
 dysplasia with
 immunodeficiency 67.10, 67.11
see also named organisms and conditions
 bacterial interference 26.5–6
 bactericidal respiratory burst 8.18
Bacteroides 26.64
 balanitis 111.3–4
 candidal 32.65
 circinate and reactive arthritis 154.2,
 154.3
 penile cancer risk 111.30
 pseudoepitheliomatous micaceous and
 keratotic 111.29
 xerotica obliterans 111.14
 Zoon plasma cell 110.88
 balanoposthitis **111.3**, **111.4**
 lichen sclerosus differential
 diagnosis 111.14
 non-specific 111.16–17
 non-syphilitic spirochaetal
 ulceration 111.23
 balding, common 89.14
 associated diseases 89.15–16
see also hair loss, pattern
 balicitib, morphoea association 57.11
 ballooning degeneration 3.35
 balsam(s) 128.25–7
 balsam of Peru 128.25, 128.26, 128.27
 delayed-type hypersensitivity 8.60
 bamboo hair, Netherton syndrome 89.53–4
 Bamforth–Lazarus syndrome 68.23
 Bannayan–Riley–Ruvalcaba
 syndrome 74.8, 80.13
 benign symmetrical lipomatosis
 differential diagnosis 100.15
 infiltrating lipomatosis of the face
 differential diagnosis 100.18
 BAPomas 132.35
 barber's hair sinus 123.22
 barley itch 34.49
 Barmah Forest virus 25.77
 Barraquer–Simons syndrome 100.4, 153.2
 barrier cream, hand eczema protection
 39.17
 Bartholin's abscess 30.4, 30.5, 30.11
 vulval 112.23, 112.24
 Bartholin's cyst, vulval 112.31
 Bartholin's gland
 malakoplakia involvement 112.25
 obstruction 112.31
Bartonella 26.59–63
Bartonella alsatica 34.12
Bartonella bacilliformis 26.62, 31.21
Bartonella henselae
 bacillary angiomatosis 26.61–2, 31.21
 cat scratch disease 26.60–1, 34.12
Bartonella quintana 34.12
 bacillary angiomatosis 26.61–2
 head louse association 34.18
 trench fever 26.60, 34.21
 Bart–Pumphrey syndrome 65.57
 knuckle pad association 96.34
 basal cell carcinoma (BCC) 141.1–21
 actinic keratosis association 125.13, 142.2
 advanced 141.10
 allergic contact dermatitis differential
 diagnosis 128.62
 ano-genital 113.20
 basosquamous 141.6
 benign lichenoid keratosis differential
 diagnosis 133.7
 Bowen disease association 142.17
 chondrodermatitis nodularis differential
 diagnosis 108.9, 141.11
 cicatricial pemphigoid differential
 diagnosis 50.51
 clinical features 141.8–11
 immunocompromised patients 146.11
 cytodagnosis 3.26
 definition 141.1
 differential diagnosis 141.10–11
 with eccrine differentiation 138.38
 environmental factors 141.2–3
 epidemiology 141.2
 external ear 108.24
 eyelid 109.49–50
 fibroepithelial 141.10, 141.17
 genetic syndromes **141.4**, **141.5**
 genetics 141.3, 141.5
 genital 111.33
 high-risk **141.16**
 histological patterns 141.6, 141.7, 141.8
 HIV infection 31.30
 imiquimod therapy 18.27
 immunocompromised patients 146.11
 management 146.13–14
 incidence 6.1
 infiltrative 141.6, 141.7
 investigations 141.11–12, 141.14
 keloid differential diagnosis 96.48
 lip 110.81
 lupus vulgaris co-morbidity 27.24
 management 18.27, 31.31, 141.12–16
 Mohs micrographic surgery 20.36,
 20.37, 20.38, 20.39
 photodynamic therapy 22.5, 22.6, 22.7
 radiotherapy 24.19, 140.7–12, 140.9,
 146.14
 surgical treatment 140.7, 140.8, **140.9**,
 141.16–17
 topical 5-fluorouracil therapy 18.26
 metastatic 141.10
 metatypical 141.6
 micronodular 141.6, 141.7
 Mohs micrographic surgery 20.36, 20.37,
 20.38, 20.39
 high-risk facial tumour 20.39
 morphoeic (sclerosing) 22.7, 141.6,
 141.9–10
 naevoid syndrome 141.2
 epidermoid cysts 134.1
 nail apparatus 95.33
 nodular 141.6, 141.8, 141.12, 141.13
 nomenclature 141.1
 Paget disease of the nipple differential
 diagnosis 138.42
 pathology 141.4, 141.6
 pathophysiology 141.2–4, **141.5**, 141.6,
 141.7–8
 photocarcinogenesis 127.29
 photodynamic therapy 22.5, 22.6, 22.7
 phymatous rosacea differential
 diagnosis 91.11
 pigmented 20.46, 141.8, 141.9
 post-organ transplantation 24.14
 radiation-induced 24.19
 radiodermatitis presentation 107.4
 radiotherapy 140.7–12, 146.14
 adjuvant 140.9
 recurrence 24.19
 rosacea obscuring 91.12
 seborrhoeic keratosis differential
 diagnosis 133.3
 skin wrinkling 155.2
 squamous cell carcinoma differential
 diagnosis 108.25
 superficial 141.6, 141.9, 141.12
 actinic keratosis differential
 diagnosis 142.5
 Bowen disease differential
 diagnosis 142.19, 142.20
 carbon dioxide laser ablation 23.18
 disseminated superficial actinic
 porokeratosis differential
 diagnosis 142.16
 surgical treatment 140.7, 140.8, **140.9**,
 141.16–17
 topical 5-fluorouracil therapy 18.26
 ulcerated 141.10
 UV radiation as risk factor 141.2
 UVR role 9.9–10
 variants 141.8–10
 vulval 112.37
see also naevoid basal cell carcinoma
 (BCC) syndrome
 basal cell naevus syndrome 67.7
 basal cell papilloma *see* seborrhoeic
 keratosis
 basal lamina 3.34
 lymphatic system 2.43
 basaloid follicular hamartoma 138.13
 base excision repair (BER) 9.6
 basement membrane 2.1, 2.2, 2.20–1, 2.22
 adhesion to dermis 2.27
 barrier 129.3
 collagen 2.22, 2.23
 mechanical function 123.5
 vascular 2.42–3
 wound healing 10.6
 basement membrane zone (BMZ) 2.20–1
 attachment structures 2.21
 biochemical components 2.20–1
 laminins 2.23–5
 molecular components **2.21**
 ultrastructure 2.20, 2.21
 basic fibroblast growth factor (bFGF) 8.5
Basidiobolus ranarum 32.80–1
Basidiomycota 28.3, 28.4–5, 32.3, 32.4–5
 basiloa *see* basal cell carcinoma (BCC)
 basophils 8.17, 8.19
 Bateman purpura 101.5, 155.3–4
 Bateman, Thomas 1.4
 bath itch 83.11
 bath oils 18.9
 Bazex syndrome **68.6**, 68.20, 96.14, 147.19,
 152.1
 atrichia with papular lesions differential
 diagnosis 68.14
 basal cell carcinoma **141.4**, 141.21
 milia association 134.5
 pili torti **68.6**
 differential diagnosis 68.20
see also acrokeratosis paraneoplastica
 Bazin disease *see* erythema induratum of
 Bazin
 B-cell lymphoma
 age-related Epstein–Barr virus-
 associated 25.34
 diffuse large B-cell lymphoma 140.37,
 140.41–3
see also cutaneous B-cell lymphoma
 B-cell lymphoproliferative disorders,
 Schnitzler syndrome association 45.10
 BCG vaccination 27.11–12
 complications 27.11, 27.21
 leprosy 28.17
 lupus vulgaris 27.21
 complications 27.24
 primary inoculation tuberculosis 27.13
 bcl-2 3.25
 bcl-6 3.24–5
 beard
 growth 89.8
 ringworm 32.41
see also pseudofolliculitis barbae
 Beare–Stevenson syndrome 67.7, 87.3
 Beau's lines 95.11
 becapermin 10.11, 18.34
 neuropathic ulcers 85.6
 Becker melanosis 75.19
 laser treatment 23.13–14
 speckled lentiginous naevi differential
 diagnosis 132.17
 Beckwith–Wiedemann syndrome
 macroglossia 110.60
 pinna creases 108.6
 bedbugs 34.24–5, 34.26, 34.27
 clinical features 34.25, 34.26
 epidemiology 34.24
 infestation prevention 34.27
 management 34.25, 34.27
 papular urticaria 117.11
 pathophysiology 34.24–5
 bees 34.14–16
 stings
 clinical features 34.15–16
 management 34.16
 pathophysiology 34.15
 venom 34.15
 beeswax 18.7
 beetles 34.28–30
 allergenic species 34.30
 vesicating species 34.29
 Behçet disease 48.1–7, **48.8–10**, 48.10,
 110.30–2
 aetiology 110.30–1
 anal fissure differential diagnosis 113.29
 aphthous stomatitis differential
 diagnosis 110.29
 autoimmune mechanisms 48.3
 bowel-associated dermatosis–
 arthritis syndrome differential
 diagnosis 49.13
 causative organisms 48.2
 classification 48.1
 clinical features 48.3–7, 110.31, 151.5
 complications/co-morbidities 48.6
 cytokine mediators 48.3
 definition 48.1
 diagnosis 110.31–2, 123.3
 differential diagnosis **48.6**
 disease course 48.6–7
 endothelial cells 48.3
 epidemiology 48.1–2
 erythema nodosum differential
 diagnosis 99.22
 genetics 48.2–3
 genital ulceration 111.17, 111.18
 heat shock proteins 48.3
 IL-1 antagonist therapy 19.32
 investigations 48.7
 management 110.32
 mucocutaneous lesions 48.2, 48.4, 48.5,
 48.7, **48.9**
 mucous membrane pemphigoid
 differential diagnosis 50.29
 ocular disease 48.4–5, 48.7, **48.9**
 pathophysiology 48.2–3
 perineum/perianal region 113.8
 presentation 48.3–4
 prevention 48.10
 respiratory disorder association 151.4
 severity 48.6
 subcutaneous Sweet syndrome
 differential diagnosis 99.49–50
 systemic lesions 48.4–6

- systemic lupus erythematosus
differential diagnosis 51.27
- thrombophlebitis migrans
association 103.32
treatment ladder 48.9–10
variants 48.4–6
vulval ulcers 112.19
- bejel 26.66–7
- beliefs, role in distress 11.2–3
- belimumab 19.32
discoid lupus erythematosus
treatment 51.11
systemic lupus erythematosus
treatment 51.36
- Bell palsy, HSV infection 25.19
- benign cephalic histiocytosis 136.14, 136.15
infants 117.15
see also juvenile xanthogranuloma
- benign hypergammaglobulinaemic purpura 101.7–8
- benign lichenoid keratosis 37.15, 133.6–7
- benign lymphoendothelioma 105.39
- benign migratory glossitis 110.13–14
- benign symmetrical lipomatosis 100.13–15
clinical features 100.14–15
differential diagnosis 100.15
epidemiology 100.14
investigations 100.15
management 100.15
pathophysiology 100.14
variants 100.15
- benzalkonium chloride 18.9, 128.28
- benzimidazole, dracunculiasis
treatment 33.12
- 1,2-benzisothiazolin-3-one 128.14, 128.36–7
- benznidazole, trypanosomiasis
treatment 33.40
- benzocaine, topical 128.29
- benzodiazepines, restless legs syndrome
management 85.17
- benzoic acid 129.8, 129.9
Whitfield's ointment 18.12
- benzoyl peroxide 18.12
comedonal acne treatment 90.39, 90.40
papulopustular acne treatment 90.40
- benzyl benzoate, scabies treatment 18.13, 34.44
- Berardinelli-Seip syndrome 74.1
hypertrichosis 89.61
- beriberi 63.14
- Berloque dermatitis 88.29, 88.30
- beryllium, reactions to 122.8
sarcoidosis 98.4
- Bet v1 allergen 128.82–3
- β-blockers
anaphylactic reactions 118.7
drug eruptions 118.3
Marfan syndrome treatment 72.17
- β-hydroxyl acids (BHA), antiageing
products 156.3
- betel nut
argyria 122.7–8
erythroplasia 110.72
lichen planus 37.3
oral cancer risk 110.34
oral hyperpigmentation 110.66
oral submucous fibrosis 110.56, 110.57
- Bethyloidea 34.15
- bexarotene 18.23, 19.37
- bias 5.8, 5.13
language 17.8
publication 17.8, 17.11
- Bible, the 1.2
- Biett, Laurent 1.5
- bilharziasis *see* schistosomiasis
- biliary tract disease 152.5
- bilirubin 88.50
- biliverdin 88.50
- bimatoprost 18.34
hypertrichosis 89.63
- biocides
formaldehyde-releasing 128.34–5
isothiazolinones 128.35–7
- biofeedback therapies 86.40
- biofilms, bacterial 26.5
- biological therapies 14.1, 19.28–35
acne fulminans treatment 90.53
adverse effects 19.28, 19.30
anaphylactic reactions 118.7
atopic eczema treatment 41.33–4
B-cell directed 19.32–4
cautions 19.31
contraindications 19.31
directed against cytokines 19.29–32
disadvantages 19.28–9
dose 19.30
drug immunogenicity 19.30
drug–drug interactions 19.31
erythema nodosum treatment 99.24
hidradenitis suppurativa
management 92.10
monitoring 19.31
nomenclature 19.29
ocular side effects 109.46
palmoplantar pustulosis 35.40
pharmacological properties 19.30
plaque psoriasis 35.29–31
pre-treatment screening 19.31
psoriatic arthritis treatment 35.45–6
pyoderma gangrenosum
treatment 49.5–6
regimens 19.30
side effects 11.6–7
skin cancer association 146.5
systemic lupus erythematosus
treatment 51.36–7
TNF antagonists 19.29–31
urticarial vasculitis treatment 44.5
- biomarkers, atopic eczema treatment 41.34
- biomaterials, wound healing 10.12–13
- biopsy
fetal 7.9
nail 95.54, 95.55–7, 95.57
penis 111.4
sentinel lymph node 143.23, 143.25–7, 145.7
- biopsy of skin 3.2–5
artefacts 3.27–8
care of specimen 3.5
contraindications 3.3
curettage 3.3, 3.4
elliptical surgical 3.3, 20.12–14
excision 3.3
fixatives 3.5
artefacts 3.28
immunofluorescence technique 3.12–13
incision 3.3
incisional 20.12–14
panniculitis 3.2
indications 3.2
information provided with specimen 3.4
informed consent 3.2
instruments 3.3
investigative techniques 3.2
laboratory methods 3.5–10
lesion type 3.2
local anaesthesia 3.2–3
multiple 3.2
needle 3.4
punch 3.3–4, 20.14
panniculitis 3.2
shave 3.3, 3.4, 20.14
site
histological variation 3.29–30
selection 3.2
skin surface 4.22
snap freezing 3.12–13
snip 3.3
surgical planning 20.14–15
techniques 3.2, 3.3–4, 20.12–14
transport media 3.5
type 3.2
ultrastructural studies 3.5
- bioterrorism, anthrax 26.44
- biotin deficiency 63.22–3
acrodermatitis enteropathica differential
diagnosis 63.26
- biotin metabolism disorders 81.17
- biotinidase deficiency 63.23, 81.17
trichorrhexis nodosa 89.54
- bipolar disorder 86.33
- Bipolaris* 32.78, 32.79
- Birbeck granules 2.15
- birch pollen allergy 128.82–3
- Birt–Hogg–Dubé syndrome
acne vulgaris differential
diagnosis 90.25
fibrofolliculoma 138.16
perifollicular fibroma 138.16
renal involvement 153.2
respiratory disorder association 151.5
trichodiscoma 138.15
- birthweight, acne vulgaris
association 90.17
- bismuth 88.53
- bisphenols 18.10
- bisphosphonates, osteogenesis imperfecta
treatment 72.111
- bite injuries 131.4–6
infants 117.13, 117.14
penile 111.9, 111.26
rodent 131.4–5
see also insect bites
- bitumen, occupational skin cancers
130.14
- Björnstad syndrome, pili torti 68.9, 89.52
differential diagnosis 68.20
- Black Death 26.57
- black heel/palm 101.6–7, 123.10, 123.15
- black piedra 32.15–16
- black skin, biological significance 88.8
- blackflies 34.6–8, 34.8
vectors 33.1, 33.2
- blackfoot disease 122.3
- bladder carcinoma, stoma 114.2
- Blaschkitis 75.19
- Blaschko's lines 7.7–8
erythema multiforme 47.6
generalized skin disease 75.19
linear atrophoderma 96.15
linear morphoea 57.17, 57.18, 57.19
pigmentary mosaicism 76.5, 117.12, 117.13
porokeratosis 87.21
- blast crisis 125.4
- Blastomyces dermatitidis* 32.85, 32.86, 32.87
- blastomycosis 32.85–7
chromoblastomycosis differential
diagnosis 32.77
clinical features 32.86
differential diagnosis 32.86
disseminated 32.86
epidemiology 32.85–6
genital 111.24
HIV infection-associated 32.86
investigations 32.86–7
management 32.87
oral lesions 110.54
paracoccidioidomycosis differential
diagnosis 32.90
pathophysiology 32.86
perineum/perianal region 113.11
primary cutaneous 32.86
pulmonary 32.86
treatment ladder 32.87
- Blau syndrome *see* autoinflammatory
granulomatosis of childhood
- bleach 18.10
- bleomycin
cutaneous sclerosis induction 96.43
drug eruption 31.17–18
flagellate hyperpigmentation
induction 120.8, 120.9
HPV infections 18.13
intralesional therapy 20.44
warts 25.54
topical 18.26
- blepharitis
acute 109.13
chronic 109.12
clinical features 109.13
differential diagnosis 109.13
investigations 109.14
- management 109.14–15, 109.16
pathology 109.10
staphylococcal 109.10, 109.13
treatment ladder 109.15
- blepharochalasis 96.19, 96.24–5
- blepharoconjunctivitis
atopic 109.15, 109.17, 109.22, 109.23
herpes simplex virus 109.36–7, 109.39
- blepharophyma 91.8
- blindness
atopic keratoconjunctivitis 109.22
onchocerciasis 33.1, 33.5
vitamin A deficiency 63.7
vitamin E deficiency 63.11
- blister(s)
acute oedema 87.27–9
formation 123.6
friction 123.6, 123.8–10
sports injuries 123.15
sucking 116.3
- blister beetles 34.29
- blistering
buffalopox 25.9
calcium pump disorders 71.24
congenital erosive and vesicular
dermatosis healing with reticulated
supple scarring 116.8–9
desmosomal disorders 71.24
hereditary diseases 71.1–30
infants 71.24–5
juvenile spring eruption 127.8–9
metabolic disorders 71.24
monkeypox 25.8
neonates 71.24–5
oral mucosa 110.7, 110.8, 110.26
peeling skin syndromes 71.23–4
PUVA side effect 21.12
signalling disorders 71.24
treatment 71.24–30
vaccinia virus 25.7
see also epidermolysis bullosa;
keratoderma
- blistering distal dactylitis 26.34, 117.8
- Bloch, Bruno 128.1
- blocking, artefacts 3.28
- blood pressure, UVR role 9.9, 9.13
- blood transfusions, anaphylactic
reactions 118.7
- blood vessels
abnormal/decreased support 101.5–6
innervation 85.3
skin 2.41–3
vasculogenesis 103.1
vasodilatation/vasoconstriction 2.43
- Bloom syndrome 79.2, 79.3–4, 82.11, 148.13
- basal cell carcinoma 141.5
- Cockayne syndrome differential
diagnosis 78.9
- discoid lupus erythematosus differential
diagnosis 51.9
- malignancy association 147.12
- neonatal lupus erythematosus
differential diagnosis 51.38, 116.13
- Rothmund–Thomson syndrome
differential diagnosis 77.6
- blowflies 34.9–10
- blue rubber bleb naevus syndrome 73.12–13
cherry angioma differential
diagnosis 103.12
oral haemangiomas 110.15
- blue toe syndrome 101.15–16
- blueberry muffin baby 116.20, 148.5
- blushing 106.1–3, 106.4–7, 106.8–10
clinical presentation 106.3, 106.4–7, 106.8
complications 106.9
epidemiology 106.1, 106.2
investigations 106.8
management 106.8–9, 106.10
pathophysiology 106.2–3
physiology 106.1
prognosis 106.9–10
psychosocial aspects 106.3
- bocaparvovirus 25.67

- body art 110.65
 piercing 110.65
see also tattoos
- body contouring 160.11–12
- body dysmorphic disorder 86.10–13
 acne vulgaris association 90.23–4
 assessment **86.11**
 clinical features 86.12
 epidemiology 86.11
 investigations 86.12
 management 86.12–13, 86.39
 pathophysiology 86.11
- body mass index (BMI), acne vulgaris 90.13, **90.15–16**, 90.16
- body odour, olfactory reference syndrome differential diagnosis 86.9
- body temperature, core 125.1
- body washing, compulsive 86.20
- boils *see* furuncle
- Bolivian haemorrhagic fever 25.71
- Bombus* 34.14
- bone
 glucocorticoid adverse effects **19.19**, 19.20
 metabolic defect in NF1 80.3
 systemic lupus erythematosus effects 51.28
- bone marrow
 failure in dyskeratosis congenita 69.14, 69.15, 77.4
 mastocytosis 46.3, 46.4
- bone marrow transplantation
 Chédiak–Higashi syndrome 70.9
 Griscelli–Prunieras syndrome 70.9
 oral lesions 110.55
 oral ulceration 110.40
 permanent alopecia 89.49
 wound healing 10.11
- bone morphogenetic proteins (BMPs) 2.3
 hair follicle stem cell activity regulation 89.8
 inhibitory factors 2.4
 signalling 2.4
- Book syndrome, premature hair greying 89.70
- Bordeaux mixture 110.56
- borderline personality disorder, dermatitis artefacta 86.27
- Borrelia* 26.68–71
 morphoea association 57.9
 tick vector 34.35
- Borrelia afzelii* 96.13
- Borrelia burgdorferi* 26.69–71
 acrodermatitis chronica atrophicans 96.13
 atrophoderma of Pasini–Pierini 96.15, 96.16
 infectious panniculitis 99.44
 lichen sclerosus 26.70
 lymphocytoma cutis 135.8, 135.9, 135.10
 morphoea 26.70
 primary cutaneous marginal zone lymphoma 140.38, 140.39
- Borrelia recurrentis* 26.68–9, 34.21
- bosentan, Raynaud phenomenon treatment 125.10
- botflies 34.10
- botryomycosis 26.72–3
 HIV infection 31.20
- botulinum toxin
 acquired resistance 158.8
 aesthetic uses 158.1–9
 antiageing products 156.4
 characteristics **158.3**
 combination treatment 158.8
 early research 158.1–2
 gustatory sweating 85.16
 historical aspects 158.1–2
 manufacture 158.3
 ocular side effects 109.46
 potency 158.3
 rosacea treatment 91.14
 topical application 158.9
- botulinum toxin A injection
 adverse events 158.8
 aesthetic uses 158.1–9
 brow elevation 158.5
 clinical applications 158.3–7
 history 158.2
 contraindications 158.8
 crow's feet 158.5, 158.6
 developments 158.9
 early research 158.1–2
 facial muscles 158.3, 158.7
 forehead 158.4–5
 glabella 158.4
 historical aspects 158.1–2
 hyperhidrosis treatment 94.9, 94.12
 lateral periocular lines 158.5, 158.6
 lower face 158.6–7
 mentalis muscle 158.6, 158.7
 mid face 158.5–6
 neck muscles 158.7
 orbicularis oris muscle 158.6, 158.7
 pharmacology 158.2–3
 upper face 158.3–4
- botulinum toxin B 158.2–3
- botulism, wound from injecting drug abuse 121.4
- Bouchard nodes 154.8
- Bourneville disease *see* tuberous sclerosis complex
- boutonneuse fever 34.38
- bovine collagen fillers 157.6
- bowel disease, dermatosis association 114.7–8, 114.9, 114.10
- bowel-associated dermatosis–arthritis syndrome (BADAS) 49.12–14, 99.50, 152.3–4
 clinical features 49.13
 definition 49.12
 differential diagnosis 49.13
 epidemiology 49.12
 investigations 49.13
 management 49.13–14
 pathergy 49.13
 pyoderma gangrenosum differential diagnosis 49.4
- Bowen disease 124.25, 142.16–23, 142.24
 actinic keratosis differential diagnosis 142.3, 142.4–5, 142.5
 anal intraepithelial neoplasia 113.15
 anogenital 142.18, 142.19
 associated diseases 142.17
 basal cell carcinoma differential diagnosis 141.11
 benign lichenoid keratosis differential diagnosis 133.7
 clinical features 142.18–19, 142.20
 immunocompromised patients 146.10–11
 carbon dioxide laser ablation 23.18
 complications/co-morbidities 142.19
 Crohn disease association 112.22
 definition 142.16
 differential diagnosis 14.20, 142.19, **142.20**
 disease course 142.19
 disseminated superficial actinic porokeratosis differential diagnosis 142.16
 epidemiology 142.17
 extramammary Paget disease differential diagnosis 138.43
 genital HPV association 25.59
 human papillomavirus 31.24
 immunocompromised patients 146.10–11
 investigations 142.19
 lupus vulgaris differential diagnosis 27.24
 malignant transformation risk 142.23
 management 142.19, 142.21–3, 142.24
 algorithm 142.23
 Paget disease of the nipple differential diagnosis 138.42
 pagetoid 112.32
 pathophysiology 142.17–18
 penile 111.27–8
- perianal 113.16–17, 142.19
 photodynamic therapy 22.5, 22.6, 22.8, 22.9
 pigmented 142.19
 pre-malignant neoplasm of ear 108.23
 prognosis 142.19
 progression prevention 146.15
 radiotherapy 24.13
 squamous cell carcinoma association 142.26
 topical 5-fluorouracil 18.26
 transplant recipients 25.63
 variants 142.18, 142.19
 vulval intraepithelial neoplasia 112.32–4
- Bowenoid papulosis 113.17, 142.18, 142.21
 Bowen disease differential diagnosis 142.19
 human papillomavirus 31.24
 penile 111.27–8
 vulval intraepithelial neoplasia 112.32–4
- BP180 autoantibody 50.12, 50.15, 50.34
- brachioradial pruritus 83.13
- Braden scale for pressure ulcers 124.5
- Bradford–Hill criteria of causality 5.8
- bradykinin formation/breakdown 43.3
- BRAF inhibitors 143.32–3, 143.34
- BRAF mutated melanoma 143.31–3, 143.34
- BRAF–MEK inhibitor combination therapy, melanoma 143.33
- brain surgery, medical trauma hair loss 89.45
- brain–skin axis 149.8
- branchial arch/branchial cleft syndrome
 microtia 108.4
 peri-auricular anomalies 108.5
 syndromic cleft lip/palate 110.23
- branchio-otic syndrome 117.12
- branchio-oto-renal syndrome 108.3, 108.4
- periauricular cysts/sinusitis 117.12
- Brazilian haemorrhagic fever 25.71
- breast
 abscess 116.24
 masses in traumatic panniculitis 99.51
 sebaceous glands of areola 93.12
 swollen 105.23–4
- breast cancer
 carcinoma en cuirasse 147.2, 147.3
 carcinoma erysipeloides 105.51, 147.2, 147.3
 Cowden syndrome association 80.14
 cutaneous sarcoidosis differential diagnosis 98.13
 inflammatory 105.23
 metastases 147.2, 147.3
 post-irradiation angiosarcoma 137.36
 subcutaneous sarcoidosis differential diagnosis 98.12
 telangiectatic metastatic carcinoma 147.2
- breast cancer-related
 lymphoedema 105.12–14, 105.19, 105.22, 105.23–4
 breast reconstruction 105.49
- breast reconstruction, lymphoedema 105.49
- breast surgery, Mondor disease 103.33, 103.34
- breastfeeding
 atopic eczema prevention 41.7, 41.25, 41.32
 azathioprine for SLE treatment 51.30
 scabies management 34.44
 zinc deficiency 63.25–6
- breathing exercises, lymphoedema 105.57
- BRESEK syndrome 65.23
- BRESHECK syndrome 65.23, 68.15
- Brevibacterium* 26.4
- brilliant green 18.33
- Brill–Zinsser disease 26.77
- brimonidol 18.34, 91.13
- British Association of Dermatologists: Dermatological Diagnostic Index System 4.2
- brittle bone disease *see* osteogenesis imperfecta
- brittle cornea syndrome 72.7
- brodalumab, plaque psoriasis treatment 35.31
- bromhidrosis 94.15–16
- bromides, acne association 90.12
- bromidrosiphobia 86.8
- 2-bromo-2-nitropropane-1,3-diol (bronopol) 128.35
- bromoderma 116.14
- bromodomains, systemic sclerosis 56.12
- bronze baby syndrome 88.49–50
- Brooke–Spiegler syndrome 138.9–10
- spiradenoma 138.31
- brown adipose tissue 74.1, 99.1, 99.3
 adipocyte mitochondria 99.3
- Brucella* 26.58–9
 brucellosis 26.58–9
 contact 26.59
 hyperhidrosis 94.5
Brugia malayi 33.7, 105.42, 105.44
Brugia timori 33.7, 105.42, 105.44
 bruising *see* ecchymosis
- Brunsting–Perry pemphigoid 50.45, 50.49–51
 mucous membrane pemphigoid differential diagnosis 50.24
- Bryant's sign 152.6
- Bryozoa 131.3
- B-type natriuretic peptide (BNP) 105.3, 105.6
- bubble hair 89.60, 89.61
- bubo 30.18, 30.19
 chancreoid 30.21, 30.22
 plague 26.58
- Bubostomum phlebotomum* 33.18
- buccal fat-pad herniation 110.59
- buccal mucosa 110.6
- Buddhism, early 1.2
- Buerger disease *see* thromboangiitis obliterans
- buffalo hump 31.20
 HIV-associated lipodystrophy 100.7
- buffalopox 25.9
- bugs 34.23–5, 34.26, 34.27–8
 Anthocoridae 34.28
 Belostomatidae 34.28
 Cimicidae 34.24–5, 34.26, 34.27
 classification 34.23–4
 Pentatomidae 34.28
 Reduviidae 34.27–8
- bulimia 86.20–1, 89.63
- bullae 3.34–5
 blistering distal dactylitis 26.34
 diabetic 64.7, 87.28, 87.29
 neonatal differential diagnosis **116.23**
 systemic lupus erythematosus 51.26
- bullous cicatricial pemphigoid **50.10**
- bullous congenital ichthyosiform erythroderma 71.23
- bullous dermatosis of childhood, chronic 117.10–11
 oral ulceration 110.42
- bullous diseases
 arthropod bites/stings 34.4
 autoimmune, erythema multiforme differential diagnosis 47.6
 cytodagnosis 3.25–6
 diagnosis 3.11
 digestive system 152.6
 electron microscopy 3.26
 HSV infection 25.16
 immunofluorescence studies 3.17–18
 infants 117.7–8
 internal malignancy association 147.21–2
 renal failure 153.4
 skin picking disorder differential diagnosis 86.15
 vulval 112.18–20
- bullous impetigo 2.19, 26.13, 26.14, 26.15, 117.7
 blistering distal dactylitis differential diagnosis 26.34

- chronic bullous dermatosis of childhood
differential diagnosis 117.10
- cytodiagnosis 3.26
- epidermolysis bullosa differential
diagnosis 71.23
- HIV infection 31.20
- linear IgA disease differential
diagnosis 50.36
- neonatal 116.23
- bullous lichen planus 37.9–10, 37.14, 37.18
- bullous lichen planus pemphigoides **50.10**
- bullous pemphigoid 50.10–18, 50.19,
50.20–2, **50.23**
acute epidermal distention differential
diagnosis 87.28
- anti-p200 pemphigoid differential
diagnosis 50.39
- autoantibodies 50.12
screening 50.15
serum 50.13–14
specificity **50.10**
tissue-bound 50.13
- autoimmune disorder association 50.11
- blister formation 50.11
- bullous systemic lupus erythematosus
differential diagnosis 50.48
- cellular immune response 50.12
- chemokines 50.12
- childhood 50.18, 50.20
- clinical features **50.10**, 50.16–18, 50.19,
50.20
- collagen type XVII 2.29
- complement deposition 3.18
- complications/co-morbidities 50.18, 50.20
- cytodiagnosis 3.26
- cytokines 50.12
- definition 50.10
- dermal–epidermal basement membrane
changes 2.22
- diagnostic pathway 50.21
- differential diagnosis 50.18, 50.21
- disease course 50.20
- epidemiology 50.10–11
- epidermolysis bullosa acquisita
differential diagnosis 50.43, 50.45
- genetics 50.15–16
- histopathology 50.13
- immunoglobulins 3.18
- immunostaining **110.46**
- investigations 50.20
- linear IgA disease differential
diagnosis 50.36
- localized 50.17–18, 50.19
- malignancy association 147.21–2
- management 50.20–2, **50.23**, **50.24**
- mucous membrane pemphigoid
differential diagnosis 50.24
- papular 50.17
- pathogenic mechanisms 50.12–13
- pathophysiology 50.11–16
- predisposing factors 50.13
- prognosis 50.20
- prurigo nodularis 83.18–19
- prurigo-like 50.17
- radiodermatitis differential
diagnosis 120.13
- refractory 50.22
- renal disease 153.6
- severity classification 50.18
- stoma complication 114.5–6, 114.7
- treatment guidelines 50.22
- variants 50.17–18
- vulvar, clinical features **112.19**
- bullous pemphigoid (BP) antigen 50.3,
71.9
- bullous systemic lupus erythematosus
50.46–8, 50.49
autoantibodies 50.48, 50.49
specificity **50.10**
- clinical features 50.47–8
- clinical signs **50.10**
definition 50.46
diagnosis 50.47, 50.48
differential diagnosis 50.48
disease course 50.48
- epidemiology 50.47
investigations 50.48
management 50.48, **50.49**
nomenclature 50.46
pathophysiology 50.47
prognosis 50.48
- bullying 11.2
- bumblebees 34.14
- Bunyamwera virus 25.72
- bunyavirus infections **25.69**, 25.72
- burden of skin disease 5.5–8
economic 6.1, 6.5–9
- Bureau–Barrière syndrome 65.64
- Burkholderia* 26.52–4
Burkholderia mallei 26.52, 26.53–4
Burkholderia pseudomallei 26.52–3
- Burkitt lymphoma 25.34
- burning feet syndrome 85.16–17
- burning mouth syndrome 84.1–3, 128.18
causes **110.63**
clinical features 84.2, 110.63–4
differential diagnosis **84.2**
epidemiology 84.1–2, 110.63
investigations 84.2, 110.64
management 84.2, 84.3, 110.64
oral soreness 110.63–4
pathophysiology 84.2, 110.63
primary 110.63
secondary 110.63
treatment ladder **84.3**
- burns 126.1–11
bioengineered products 126.6–7
biological membranes 126.6
biosynthetic membranes 126.5–6
cause of death 126.1
chemical 129.11–13, 159.11
oral cavity 110.73
children 126.3
depth 126.2, 126.3
evaluation 126.5–7
dermal 126.5
dermal substitutes 126.6–7
escharotomy 126.7
full-thickness 126.6–7
hypermetabolism 126.9–11
infections
central line-associated 126.8
control 126.7–9
inhalation injuries 126.5
systemic 126.8
topical 126.8
inhalation injury 126.1, 126.4–5
initial assessment 126.1, 126.2–4
management 126.1, 126.5–7, 126.10–11
skin grafting 10.12
nutrition in hypermetabolic response
management 126.10
oral cavity 110.73
overresuscitation 126.4
partial-thickness 126.5–6, 126.7
pharmacological therapies 126.10–11
physical therapy 126.10
pre-hospital care 126.1, 126.2
Pseudomonas aeruginosa infection 26.52
resuscitation 126.1, 126.2–4
resuscitation formula 126.3–4
second-degree 126.5
sepsis 126.9
Acinetobacter 26.50
shock 126.2–3
size 126.1, 126.2, 126.3
skin grafting 10.12
stem cell use 126.7
surgical management 126.7
synthetic membranes 126.5–6
thermal injury complications 126.1
topical dressing 126.7
underresuscitation 126.4
ventilator-associated pneumonia 126.8
wound excision and closure 126.10
- Burrow's solution 18.9
- Burton's lead line 122.5
- Buruli ulcer 27.36, 27.37–9
genital 111.24
giant water bug carrier 34.28
- Bury disease 102.8
- Buschke–Löwenstein tumour 111.32, 113.19
- Buschke–Ollendorff syndrome 96.40
- congenital elastoma 75.18
- papular elastorrhexis differential
diagnosis 96.30
- pseudoxanthoma elasticum differential
diagnosis 72.30
- busulphan
alopecia induction 120.5
hyperpigmentation 88.26
oral hyperpigmentation 110.66
- butenafine 18.11
- butterflies 34.30–2
clinical features of reactions 34.31–2
epidemiology of reactions 34.30–1
pathophysiology of reactions 34.31
- butyl nitrite, drug eruptions 31.18
- Bwamba fever virus 25.72
- C**
- C chemokines 8.36, **8.37**
- C fibres 85.1, 85.2
- eccrine glands 94.3
- erythromelalgia 103.7
- C1-esterase inhibitor (C1INH) 8.41
hereditary angio-oedema
treatment 43.5–6, 110.9
- C1-esterase inhibitor (C1INH)
deficiency 43.1, 43.2
acquired 43.6
disease course/prognosis 43.4
epidemiology 43.5
investigations 43.5
management 43.5, **43.6**
oral 110.59
pathophysiology 43.3–4
replacement therapy 19.34–5
see also hereditary angio-oedema (HAE)
- C1q deficiency 82.18
- C2 deficiency 82.18
- C3 deficiency 82.17, 82.18
- cabergoline, restless legs syndrome
management 85.17
- cacosmia 86.8
- CACP (camptodactyly, arthropathy,
coxa vara and pericarditis)
syndrome 96.37, 96.38
- cadherins 2.19
desmosomal 2.18
- caeruloplasmin 81.19
- café-au-lait macules 80.1, **132.2**, 148.12
laser treatment 23.13, 160.5
- McCune–Albright syndrome 80.4, **80.5**
NF1 80.1, 80.3, 80.4
and pulmonary stenosis 80.5, 80.7
speckled lentiginous naevi differential
diagnosis 132.17
- caffeine 18.34, 156.10, **156.11**
- CAG1* gene mutations 72.27
- Calabar swelling 33.10
- calamine lotion, malaria treatment 94.13
- calamine powder 18.8
- calcaneal petechiae 101.6–7
- calcific uraemic arteriopathy 99.31–3,
101.24–5
definition 99.31
differential diagnosis 99.33
investigations 99.32–3
pathophysiology 99.31–2
see also calciphylaxis
- calcification 61.1–10
acne scarring 90.35
dystrophic
ghost adipocytes 99.40
malignancy association **147.22**
secondary to trauma/injection/
infusion of calcium-containing
materials 61.3
secondary to tumours/genetic
disease 61.3–4
traumatic panniculitis 99.52
- dystrophic secondary to inflammatory
disease/infections 61.1–3
causative organisms 61.1
- clinical features 61.2
definition 61.1
epidemiology 61.1
investigations 61.2
management 61.2
nomenclature 61.1
pathophysiology 61.1
treatment ladder **61.2**
- ectopic disorders 72.26–32
familial tumoral calcinosis 81.19–20
idiopathic of skin and subcutaneous
tissues 61.4–5
metastatic 61.5–6, 145.21
malignancy association **147.22**
sarcoïd granulomas 99.51
- calcified cutaneous nodules of the
heels 117.14
- calcifying aponeurotic fibroma 137.7–8
- calcifying chondrodysplasia 96.14
- calcifying fibrous tumour/
pseudotumour 137.7
- calcifying lupus panniculitis, subacute
cutaneous lupus erythematosus
association 51.12
- calcifying nodule, pinna **108.12**, 108.14
- calcineurin inhibitors, topical 18.19–21
- atopic eczema treatment 41.31
drug eruption treatment 118.3
hand eczema treatment 39.17
plaque psoriasis treatment 35.25
- calcinosis cutis 61.4–5, 61.6
dermatomyositis association 53.8,
53.12
dystrophic
lupus panniculitis association 51.25
subacute cutaneous lupus
erythematosus association 51.12
familial tumoral calcinosis 81.19–20
malignancy association 147.23
miliary 61.4, 61.5, 61.6
sarcoidosis association 98.14
systemic sclerosis 56.4, 56.13
see also scrotal calcinosis
- calcinosis, Raynaud phenomenon,
oesophageal dysfunction,
sclerodactyly and telangiectasia
(CREST) syndrome 56.1, 61.2
- calcinosis, scrotal 61.4, 61.5, 111.26
- calciphylaxis 61.6–9, 99.31–3, 145.21
associated disorders **99.33**
clinical features 61.7–8, **61.8**
cutaneous 101.24–5
definition 61.6, 99.31
diabetes association 64.7
differential diagnosis 61.7, **61.8**, 99.33
epidemiology 61.6–7
genital ulceration 111.18
investigations 61.8, 99.32–3
management 61.8–9
nomenclature 61.6
pathophysiology 61.7, 99.31–2
renal disease 153.2, 153.3
systemic lupus erythematosus 51.25
- calcipotriol 18.25–6
structure 18.24
topical corticosteroid formulations
18.18–19
- calcitonin gene-related peptide
(CGRP) 85.2, 85.3
atopic eczema 8.50, 8.51
- calcitriol 18.25
plaque psoriasis 35.23
structure 18.24
- calcium channel blockers
anal fissure management 113.29
lower limb oedema 105.8
phototoxicity 127.28
Raynaud phenomenon treatment
125.9–10
- calcium hydroxylapatite fillers 157.5–6
- calcium pump disorders 71.24
- calcium-channel deficiencies 82.8
- calf muscle pump 103.28, 103.37
ambulatory venous pressure 39.19
- Calliphoridae 34.9–10

- callosities 123.6–8
 clinical features 123.7–8
 definition 123.6
 epidemiology 123.6–7
 fingers 123.11–12
 hereditary 123.7
 management 123.8
 musical instruments 123.11
 pathophysiology 123.7
- calluses 123.6–8
 clinical features 123.7–8
 definition 123.6
 epidemiology 123.6–7
 management 123.8
 pathophysiology 123.7
 sports injuries 123.16
- calponin 3.21
- Calymmatobacterium granulomatis* 26.66, 30.23, 30.24
 HIV infection 31.22
- Camisa syndrome 65.49
 collodion baby 116.19
- Campbell de Morgan spots 103.12–13
 male genital 111.6
- camphor 18.34
- campptodactyly 96.37–8
- campptodactyly, arthropathy, coxa vara and pericarditis (CACP) syndrome 96.37, 96.38
- campptodactyly, tall stature and hearing loss (CATSHL) syndrome 96.37, 96.38
- canakinumab 19.32
- Canale–Smith syndrome 74.9
- cancer 86.20
 drug induced 154.15
 phobias 86.20
see also malignancy; metastases; *named tumours, diseases and conditions*; skin cancer
- cancer-associated coagulopathy 147.24
- cancer-related lymphoedema 105.22–3
 abdominal wall lymphoedema 105.21
 genital lymphoedema 105.18
see also breast cancer-related lymphoedema
- cancrem oris 116.26
 infective cheilitis 110.87
- Candida* 32.56
 acute generalized exanthematous pustulosis differential diagnosis 119.4
 adherence 32.57
 allergy 32.67–8
 antigen test 4.24
 chronic paronychia 95.37
 classification 32.56
 cutaneous infection in infants 117.8
 diabetic infections 64.3
 diagnosis 32.9
 ecology 32.56–7
 genetic typing methods 32.57
 hyphae 32.57
 identification 32.59–60
 mycelium formation 32.58
 onychomycosis 31.32
 otomycosis 32.17, 32.18
 papillary hyperplasia 110.61
 primary immunodeficiency 82.2
 stoma infection 114.3, 114.4
 syndrome 32.68
 virulence 32.57
 yellow nail syndrome 95.14
- Candida albicans* 32.56–7
 annular erythema of infancy 47.6
 cutaneous carriage 32.57
 HIV infection 31.26, 110.70
 identification 32.59–60
 melanin production 32.58
 oral carriage 32.56–7
 vaginal carriage 32.57
- Candida glabrata* 32.60
 fluconazole resistance 32.61
 HIV infection 110.70
- Candida krusei* 32.59, 32.60
 fluconazole resistance 32.61
 HIV infection 110.70
- Candida parapsilosis*, HIV infection 110.70
- Candida tropicalis* 32.59
 HIV infection 110.70
- candidiasis
 acrodermatitis continua of Hallopeau differential diagnosis 35.42
 chronic mucocutaneous 82.17, 116.23
 congenital 116.27
 neonatal 116.27
 perineum/perianal region 113.11
 psoriasis differential diagnosis 35.19
 severe combined immunodeficiency 82.7
 vulvo-vaginal 112.25–6
- candidosis 32.56–70
 acute erythematous 32.62
 acute pseudomembranous 32.62
 angular cheilitis 32.63, 110.80
 aphthous ulceration 110.40
 balanitis 32.65
 chronic
 erythematous 32.62
 nodular 32.63
 oral 110.73–4
 plaque-like 32.63
 pseudomembranous 32.62
 chronic mucocutaneous 32.58, 32.61, 32.68–70
 APECED syndrome 148.17, 148.18
 autosomal recessive/dominant 32.68
 classification 32.68
 clinical features 32.69
 definition 32.68
 endocrinopathy associated 32.68
 hypothyroidism association 32.58, 32.68, 32.69
 idiopathic 32.68
 immunodeficiency association 148.14–15
 immunological abnormalities 32.69
 investigations 32.69
 late-onset 32.68–9
 management 32.61, 32.69–70
 oral lesions 110.17
 pathophysiology 32.68–9
- congenital 32.67
 cutaneous 32.69
 definition 32.56
 endocrine factors 32.58
 first line treatment 32.61
 genital mucous membranes 32.64–6, 111.23
 histology 32.60
- HIV infection
 association 31.26, 32.59, 32.61, 110.70–1
 children 31.35
 infants 116.23
 management 32.61
 oral 31.33, 31.35, 110.70–1, 110.73
- host factors 32.58
 immunological factors 32.58–9
 intertrigo 32.63–4, 32.69
 management 18.12, 32.61
 median rhomboid glossitis 32.63, 110.71
 nail area 32.66–7, 32.69
 nodular/granulomatous of the napkin area 32.66
 oesophageal 31.26
 onychomycosis 32.61, 32.67
 oral 32.60, 110.68–71, 110.73–4
 acute 110.69
 children with HIV 31.35
 denture-related stomatitis 110.69–70
 diagnosis 110.74
 HIV-associated 31.33, 31.35, 110.70–1, 110.73
 iron deficiency anaemia 148.16
 management 110.74
 oral mucosa 32.61–3, 110.9, 110.73
 paronychia 32.66–7, 32.69
 pathophysiology 32.57–9
- perianal 32.65
 perineal of infancy 32.65–6
 pseudomembranous disease 31.26
 scrotal 32.65
 systemic 32.94
 therapeutic agents 31.26, 32.61
 thrush 110.73
 tinea cruris differential diagnosis 32.46
 vaginal 31.26
 vulvo-vaginal 32.64–5
- CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) syndrome 45.4, 45.8, 74.9
- canicola fever 26.71
- cannabis 121.1–2
- Cannon disease *see* white sponge naevus
- canthus, inner, radiotherapy for skin cancer 24.10
- Cantu syndrome 68.2, 68.11
- capecitabine, skin cancer treatment in immunocompromised patients 146.16
- capillaries 2.42
- capillaritis 88.49, 101.8
- capillaroscopy, proximal nail fold 95.50–3
- capillary aneurysm–venous lakes 103.8
- capillary disorders 73.1–7
- capillary haemangioma
 lobular 137.26–8
 progressive 137.25
see also infantile haemangiomas; pyogenic granuloma
- capillary malformation–arteriovenous malformation 73.3–4, 80.8, 80.9
- arteriovenous malformations 73.7
- capillary malformations 73.1–2
 in localized overgrowth syndromes 73.5–6
 phakomatosis
 pigmentovascularis 75.22–3
 progressive patchy 73.4
 Sturge–Weber syndrome 73.2–3
see also port-wine stains
- capillary naevi, livedo reticularis differential diagnosis 125.8
- Capnocytophaga canimorsus* 26.63–4, 131.5
- capsaicin 8.52–3, 18.34–5, 85.2
- carbamazepine, hypersensitivity reactions 12.5–6, 119.6, 119.7
- carbaryl 18.13
- carbidopa, cutaneous sclerosis induction 96.43
- carbon dioxide laser
 basal cell carcinoma treatment 141.16
 hair removal 23.17–18, 23.19
 incisional surgery 23.17–18
 NF1 treatment 80.4
 photothermal ablation 23.16–17
 port-wine stains 23.9
 skin resurfacing 160.6–8
 tuberous sclerosis complex treatment 80.12
- carbon monoxide toxicity, inhalation injury with burns 126.4, 126.5
- carboxylase deficiency, hereditary multiple 63.23
- carboxypeptidase 8.21
- carbuncle 26.25–6
- carcinoembryonic antigen (CEA) 3.20
- carcinogenesis
 azathioprine 19.9
 field 146.10
 infrared radiation-induced 125.11
 oxygen-dependent cytotoxicity 8.44
 photocarcinogenesis 127.29
 radiation 24.3, 24.6, 24.7
 reduced immune surveillance 146.5–6
 UV radiation 9.9–10
 UVB phototherapy 21.12
 viral infections 25.4
- carcinoid syndrome 88.19
 flushing 88.20, 106.3, 106.8, 147.24, 147.25
 niacin deficiency association 63.16
- pigmentation 88.20
 scleroderma-like skin changes 147.21
- carcinoid tumour 145.19
 endocrine disorder skin signs 149.11
- carcinoma en cuirasse 147.2, 147.3
- carcinoma erysipelloides 105.23, 105.51, 147.2, 147.3
 perineal 113.20
- carcinoma *in situ* 142.16–26
 ano-genital psoriasis differential diagnosis 111.9
 penis 111.27–8
 vulval intraepithelial neoplasia 112.32–4
see also Bowen disease
- carcinoma simplex, vulval intraepithelial neoplasia 112.32–4
- CARD14 gene mutations 36.2, 36.6
- CARD14-mediated pustular psoriasis (CAMPS) 45.11
- CARD15 gene mutations 45.7
- cardiac disorders 150.1–6
 dermatoses with skin features 150.4–6
 hereditary syndromes 150.1, 150.2, 150.3–4
 infections 150.5
 inflammatory disorders 150.4–5
 sarcoidosis 98.6
 skin signs 150.1
 systemic diseases with skin features 150.4–6
 tuberous sclerosis complex 80.12
- cardiac embolus 101.16–17
- cardiac pacemakers, skin problems 150.6
- Cardiff Acne Disability Index (CADI) 16.6
- cardio-facio-cutaneous syndrome 80.8, 80.9, 150.3
- cardiomyopathy
 dermatomyositis 53.10
 iron deficiency association 63.24
 selenium deficiency 63.29
- cardiovascular disease
 dermatomyositis 53.10
 DRESS association 119.9
 neonatal lupus erythematosus 51.37, 51.38–9
 oral manifestations 110.90
 pseudoxanthoma elasticum 72.28–9
 psoriasis association 35.21
 systemic lupus erythematosus 51.28, 51.32
 UVR role 9.9
 Williams–Beuren syndrome 72.15
- caring attitudes 15.2
- carmustine, topical 140.23
- Carney complex 74.5, 132.3, 147.10–11, 150.4
 diagnostic criteria 147.11
 lentigines 132.5, 147.17
 malignancy association 147.11
 oral mucosa 110.12
- carosine 156.6–7, 156.11
- carotenaemia 63.8–9, 88.50–1
- β-carotene 63.8
 polymorphic light eruption management 127.8
- carotenoderma *see* carotenaemia
- carotenoids 70.1
 skin colour 88.1, 88.2
- carpal tunnel syndrome, pachydermodactyly association 96.36
- carpet beetle 34.30
- Carpoglyphidae 34.48
- carrier peptides 156.5, 156.10
- cartilage hair hypoplasia 82.12
 basal cell carcinoma 141.5
- Carvajal–Huerta syndrome 65.50, 65.56
 woolly hair 89.57
 differential diagnosis 68.20
- carvermoma 73.9–11
- case–control studies about adverse events 17.17
- caspases 8.53, 8.54
- Castellani's paint 18.33

- Castleman disease
 paraneoplastic pemphigus association 50.6
 see also multicentric Castleman disease
 castor oil 18.6
 cat bites 131.5–6
 cat fleas 117.11
 cat scratch disease 26.60–1, 31.21, 34.12
 anthrax differential diagnosis 26.44
 cataract 109.22
 atopic eczema association 41.23
 polar bear rug 109.20–1, 109.22
 PUVA side effects 21.14
 catastrophic antiphospholipid syndrome 51.24, 52.2
 catecholamines 8.52
 β -catenin gene mutations 138.14
 caterpillar dermatitis 34.30
 cathelicidins 2.12, 2.43, 8.13, 8.14, 26.5
 cathepsin B 8.41
 cathepsin C 8.41, 65.61
 cathepsin D 8.22, 8.41
 cathepsin G 8.21, 8.22
 cathepsin K 57.11
 cathepsin S 40.2
 catheter-related infections (CRI), burns 126.8
 CATSHL (camptodactyly, tall stature and hearing loss) syndrome 96.37, 96.38
 cauda equina 85.9
 cauliflower ear 108.6, 108.7
 causalgia 85.13
 causation 5.8–9, 5.13
 caustics 20.43–4
 wart treatment 25.52
 cavernous angioma 73.9–11, 103.21–3
 cavernous haemangiomas *see* infantile haemangiomas
 CC chemokines 8.36, 8.37, 8.38
 CCBE1 gene mutations 73.19
 CCL18 8.38
 CCL27 8.38
 CCM1, CCM2 and CCM3 gene mutations 73.4
 CCR1 8.39
 CCR2 8.39
 CCR3 8.39
 CCR4 8.39
 CCR5 8.39–40, 31.3
 CCR5 co-receptor antagonists 31.10
 CCR5 gene 31.8
 CCR6 8.40
 CCR7 8.40
 CCR8 8.40
 CCR9 8.40
 CCR10 8.40
 CCR11 8.40
 CD nomenclature 3.24
 CD1a 3.23
 CD2 3.24
 CD3 3.24, 8.30
 CD4 8.30
 CD4 receptor 31.3
 CD4+ T cells 3.24, 8.27, 8.31
 drug hypersensitivity reactions 12.3
 oral candidosis in AIDS patients 32.59
 CD4 T-helper cells 31.5
 CD5 3.24
 CD7 3.24
 CD8 8.30
 CD8+ T cells 3.24, 8.27
 drug hypersensitivity reactions 12.3
 HIV infection 31.5
 lichen planus 37.2
 CD10 3.22–3, 3.24–5
 CD20 3.24, 19.33
 CD23 8.57, 8.58
 CD28 8.28
 CD30 3.24, 3.25
 CD30+ lymphoproliferative disorders *see* cutaneous CD30+ lymphoproliferative disorders
 CD31 3.23
 CD34 3.21–2
 CD40 deficiency 82.10
 CD40 ligand 82.10
 CD44 8.5
 CD45 3.24
 CD56 3.24
 CD68 3.23
 CD80 8.28
 CD86 8.28
 CD99 8.12
 CD123 3.24
 CD151 71.5–6
 CD163 3.23
 CDAGS (craniostenosis, delayed closure of the fontanelles, cranial defects or deafness, anal anomalies, genitourinary anomalies and skin eruption) syndrome 87.21
 CDKN2A gene mutations 143.4, 143.6, 147.7
 CEACAM1 8.12
 CECR1 gene mutations 102.30
 CEDNIK (cerebral dysgenesis–neuropathy–ichthyosis–palmoplantar keratoderma) 65.27, 65.28
 celiprolol 72.8
 cell adhesion, keratinocytes 8.5–6
 cell adhesion molecules (CAMs) 8.7, 8.8, 8.11–12
 cell death *see* apoptosis; necrosis
 cell therapy 14.1
 cell–cell adhesion in epidermis/dermis during inflammation 8.9–13
 cellist's chest 123.12
 cell-mediated immune response 25.4
 cellular angiofibroma 137.9–10
 cellular neurothekeoma 137.50–1
 cellular retinoic acid binding proteins (CRABP) 18.21
 cellular retinol binding proteins (CRBP) 18.21
 cellulite 100.23–5
 cellulitis 26.10, 26.17–21
 abdominal wall lymphoedema cause 105.21
 Aeromonas-induced 26.63
 allergic contact dermatitis differential diagnosis 128.62
 ano-genital 26.33–4, 111.21, 113.10
 differential diagnosis 113.11
 associated diseases 26.18
 bullous 26.19, 26.20
 causative organisms 26.18–19, 26.63
 clinical features 26.19–20, 105.11–12
 clostridial 26.74
 cutaneous vasculitis differential diagnosis 102.4
 definition 26.17–18
 differential diagnosis 26.20
 dissecting of scalp 90.31, 92.2, 107.8–9
 epidemiology 26.18
 gangrenous 26.74
 glanders 26.53
 HIV infection 31.20
 ingrowing toenail 95.21
 investigations 26.20–1, 105.12
 lipodermatosclerosis differential diagnosis 105.10
 Lyme disease differential diagnosis 26.70
 lymphoedema
 association 105.11–12
 complication 105.13, 105.52
 genital 105.18
 obesity-related 105.20
 management 26.21, 105.12, 105.14
 necrotizing 26.74
 necrotizing subcutaneous infection differential diagnosis 26.74
 neonatal 116.25
 orbital 116.25
 pathophysiology 26.18–19
 perianal streptococcal 26.33–4, 111.21, 113.10
 periobital 26.18
 preorbital 116.25
 recurrent 105.10–12
 sclerosing panniculitis differential diagnosis 99.29
 staphylococcal genital 111.21
 stoma infection 114.3, 114.4
 tongue 26.18
 toxic shock syndrome association 26.30
 vulval 112.24
 see also erysipelas; lipodermatosclerosis
 centipedes 34.54
 central nervous system (CNS), DRESS involvement 119.9
 centrifugal lipodystrophy (CLD) 100.11–12
 centrofacial lentiginosis syndrome 110.12
 Cephalopoda 131.4
 cephalosporins 19.42
 ceramide A 8.4
 ceramide B 8.4
 ceramide synthase 3 65.10
 Ceratophyllidae 34.12
 Ceratopogonidae 34.7, 34.8
 cercarial dermatitis 33.24, 33.27–8
 cerebellar ataxia, Refsum disease 65.29
 cerebral cavernous malformation 73.4–5
 cerebral dysgenesis–neuropathy–ichthyosis–palmoplantar keratoderma (CEDNIK) 65.27, 65.28
 cerebro-oculo-facio-skeletal syndrome 78.8
 Cockayne syndrome differential diagnosis 78.9
 xeroderma pigmentosum differential diagnosis 78.6
 cerebrotendinous xanthomatosis 62.10
 tendon xanthomas 62.3
 certolizumab, psoriatic arthritis treatment 19.29, 35.46
 cerumen 108.2–3
 ceruminous gland tumours 108.22–3
 cervical arthritis 108.28
 cervical carcinoma
 human papillomavirus 25.45
 invasive 25.58–9
 cervical intraepithelial neoplasia (CIN) 25.58–9
 cervical lymph nodes 110.4–5
 cervical lymphadenitis, *Mycobacterium scrofulaceum* 27.41
 cervical spine disease, scalp dysaesthesia 107.14
 cervicitis, gonococcal 30.3, 30.4
 cestode infections 33.29–33
 cetearyl alcohol 128.40
 cetomacrogols 18.7
 cetrimide 18.9
 CFTR gene mutations 94.4
 carriers, transient aquagenic keratoderma differential diagnosis 65.55
 chloride transport 94.4
 CGCX gene mutations 72.27
 Chagas disease *see* trypanosomiasis
 chalazion 109.15
 eyelid 109.48
 Merkel cell carcinoma differential diagnosis 109.50–1
 sebaceous gland carcinoma of eyelid differential diagnosis 109.50–1, 138.18
 chamomile
 anti-inflammatory products 156.9–10, 156.11
 antioxidant products 156.11
 antioxidant properties 156.9–10
 hair dye 89.73
 Chanarin–Dorfman *see* neutral lipid storage disease with ichthyosis
 chancre 29.8–9
 extragenital 29.10
 primary syphilitic on finger 95.37
 trypanosomiasis 33.39
 chancroid 26.82–3
 chancroid 30.20–3
 classification 30.20
 clinical features 30.21
 complications/co-morbidities 30.21
 definition 30.20
 epidemiology 30.20
 investigations 30.22–3
 nomenclature 30.20
 pathophysiology 30.20–1
 perineum/perianal region 113.12–13
 treatment ladder 30.23
 CHAND syndrome 67.16
 tricho-dento-osseous syndrome differential diagnosis 67.19
 chapping of lips 110.82
 Charcot joints 29.19, 29.20
 Charcot–Marie–Tooth disease *see* peroneal muscular atrophy
 CHARGE (coloboma, heart defects, atresia of the nasal choanae, retardation of growth/development, genital/urinary abnormalities and ear abnormalities and deafness) syndrome 82.8, 108.3
 Chédiak–Higashi syndrome 2.17, 70.2, 70.8–9, 82.13–14, 147.13, 148.15, 148.17
 clinical features 147.13
 genetics 147.13
 neoplasia incidence 147.13
 neutrophil defects 8.18
 oculocutaneous albinism differential diagnosis 70.7
 primary immunodeficiency 82.2
 cheek
 biting 110.74
 see also buccal mucosa
 cheilitis 110.82–8
 allergic contact 128.15
 causes 110.82
 clarinettist's 123.11, 123.12
 clinical features 110.83
 contact 110.82–3
 diagnosis 110.83
 drug-induced 110.83–4
 eczematous 110.84
 exfoliative 110.84
 factitious 86.25–6, 110.84
 flavouring agents 128.26
 foreign body 110.85
 glandular 110.85
 infective 110.87
 irritant contact dermatitis 129.5
 lip-lick 41.24, 41.29
 lipsticks/lipsalves 110.82, 110.83, 128.32
 management 110.83
 nail varnish 128.16
 nickel 128.16
 plasma cell 110.87–8
 retinoid 90.46, 90.48
 systemic lupus erythematosus association 51.27
 see also actinic cheilitis; angular cheilitis; granulomatous cheilitis
 cheiroarthropathy, diabetes association 64.6
 chemical burns 129.11–13
 acids 129.12
 acronecrosis 95.47
 alkalis 129.12
 ano-genital 111.11
 clinical features 129.12
 definition 129.12
 epidemiology 129.11–12
 management 129.12–13
 occupational 129.12
 oral cavity 110.73
 selenium toxicity 122.6
 severity classification 129.12
 chemical cautery, ingrowing toenail 95.58–60
 chemical depigmentation 88.45–6
 chemical exposure
 exogenous photosensitizers 127.27
 nail colour changes 95.14
 photosensitivity 127.26–30
 scleroderma induction 56.13–14

- chemical peels 159.1–13
 acne treatment 90.50
 acneform eruptions 159.12
 actinic keratosis treatment 142.11
 allergic contact dermatitis 159.12
 Bowen disease treatment 142.23
 caustic 159.2–3
 chemical burns 159.11
 chemistry 159.1–3
 complications 159.9–13
 consent 159.7
 contraindications 159.5–6
 counselling 159.6–7
 deep 159.4
 depth 159.3–4
 indications 159.4–5
 infection 159.10–11
 medium depth 159.4
 metabolic action 159.1–2
 milia 159.12
 photo documentation 159.7
 pigmentary disorder treatment 88.34
 postinflammatory hyper-/hypo-pigmentation 159.12
 post-peel care 159.9
 premature peeling 159.11–12
 pre-peel procedure 159.6–7
 procedure 159.7–9
 side effects 159.9–13
 skin of colour 159.13
 skin priming 159.7
 superficial 159.3, 159.4
 systemic toxicity 159.12
 technique 159.7–8
 toxic action 159.3
- chemokine receptors 8.38, 8.39–40
 chemokines
 expression by NK cells 8.16
 functions 8.38
 inflammation role 8.36, 8.37, 8.38–9, 8.40
 keratinocyte function regulation 8.4–5
 Langerhans cell migration 8.29
 lichen planus 37.2
 morphoea 57.7–8
 neutrophil adhesion role 8.18
 wound healing 10.3
- chemotherapy
 alopecia 89.48–9
 dermatoses 120.1–12
 dyspigmentation 120.8–10
 hair changes 120.5–6
 hyperpigmentation 88.26, 88.28, 120.8–9
 hypertrichosis 120.6
 hypopigmentation 120.9–10
 intertriginous eruption associated with 120.1, 120.2
 Kaposi sarcoma 31.30
 lymphatic filariasis treatment 33.9
 melanoma 143.34–5
 Merkel cell carcinoma 145.8–9
 mycosis fungoides 140.23, 140.25–6
 nail changes 120.6–8
 oral ulceration 110.40
 papulopustular reactions 120.3–4
 photosensitivity induction 120.10–11
 recall reaction 120.11–12
 scalp cooling 89.49
 scalp pustules 107.12
 Sézary syndrome 140.23, 140.25–6
 skin cancer association 146.6
 subcutaneous extravasation 99.47
 topical 18.26–8
 toxic erythema 120.1–3
 symmetrical drug-related intertriginous and flexural exanthem differential diagnosis 118.6
 uncombable hair syndrome 89.57
- cherry angioma 103.9, 103.12–13, 103.14
Cheyletiella mites 34.50–1
 Chiari malformation type 1, syringomyelia association 85.7
 chickenpox *see* varicella infection
 chigoes 34.13
 Chikungunya fever 25.75–6, 154.3
 genital ulceration 111.19, 111.24
 oral ulceration 110.48
 chilblain(s) 99.35, 125.4–5
 discoid lupus erythematosus differential diagnosis 51.9
 proximal nail fold capillaroscopy 95.52
 chilblain lupus 51.7, 51.22, 125.4
 chilblain-like lesions 147.24
 child abuse
 anal trauma 113.32
 genital wart transmission 25.55
 lichen sclerosus differential diagnosis 112.8
 male ano-genital signs 111.8–9
 Menkes disease differential diagnosis 63.28
 osteogenesis imperfecta differential diagnosis 72.10
 perianal trauma 113.32
 traumatic ecchymoses 101.2
see also non-accidental injury
- CHILD (congenital hemidysplasia with ichthyosiform erythroderma and limb defects) syndrome 65.21–3
 congenital epidermal naevi 75.3–4, 75.7
 management 75.9
 spinal dysraphism association 85.8–9
- childbirth
 perineal trauma 113.32
 telogen gravidarum 89.25
- Childhood Atopic Dermatitis Impact Scale (CADIS) 16.6
- children
 acne 90.59–64, 117.5
 acute haemorrhagic oedema 111.20
 age effects on drug therapeutic outcomes 14.7
 AIDS case definition 31.6
 annular erythema of infancy 47.6–8
 annular lichenoid dermatitis of youth 37.9
 antihistamines 42.17
 asymmetric periflexural exanthem 25.89
 atopic eczema 41.16, 41.17–19, 41.19
 atrichia with papular lesions 68.12
 autoinflammatory granulomatosis of childhood 45.7
 bites 117.13
 blistering distal dactylitis 26.34
 bronze baby syndrome 88.49–50
 bullous pemphigoid 50.18, 50.20
 burns 126.3
 cat scratch disease 26.60
 chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome 45.8
 chronic mucocutaneous candidosis 32.69
 cold panniculitis 99.33–4, 99.35
 contact dermatitis 128.5–6
 cutis laxa 79.6
 diffuse neurofibroma 137.49
 disseminated superficial porokeratosis 65.67–8
 early childhood impact of skin conditions 11.5
 Epstein-Barr virus 25.31
 flushing 106.8
 generalized pustular psoriasis 35.35–6
 genital wart transmission 25.55
 granuloma annulare 97.1
 granulomatous periorificial dermatitis 91.18, 91.19
 hair loss 89.11
 hair pulling 86.17, 86.18
 hair-pulling tic 89.46
 HIV immunorestitution 31.8
 HIV infection 31.34–5
 papular pruritic eruption 116.23
 Hutchinson-Gilford progeria syndrome 79.4, 79.5
 hypertrichosis in hypothyroidism 89.62
 idiopathic facial aseptic granuloma 91.15
 immunosuppression 31.34–5
 inclusion body fibromatosis 137.10–11
 juvenile hyaline fibromatosis 72.17–18
 juvenile plantar dermatosis 39.21–2
 Kaposi sarcoma 31.35, 139.4
 Kawasaki disease 26.84, 102.32
 keratitis-ichthyosis-deafness syndrome 65.31–2
 keratolytic winter erythema 65.66
 leukaemia cutis 148.2
 lichen nitidus 37.10
 linear IgA disease 50.33, 50.35
 lipoatrophic panniculitis of the ankles 99.52–3
 lipoblastoma 137.59–60
 lipofibromatosis 137.14
 lorincrin keratoderma 65.49
 malnutrition 63.6
 severity classification 63.4, 63.5
 meningococcal infection 26.49
 Menkes disease 63.27–8
 molluscum contagiosum 25.12
 morphoea 57.22–3
 disease course 57.23
 pansclerotic 57.16–17
 multiple sulphatase deficiency 65.29
 Münchausen syndrome by proxy 86.30
 nails 95.46
 neutrophilic eccrine hidradenitis 94.14
 non-accidental injury
 chemical burns differential diagnosis 129.12
 irritant contact dermatitis differential diagnosis 129.6
 organ transplantation 146.4
 pansclerotic morphoea 57.16–17
 papular pruritic eruption of HIV 116.23
 patch testing 128.6
 pigmented neuroectodermal tumour 137.53–4
 pityriasis alba 117.5
 polyomavirus 25.41–2
 porokeratosis 65.67–8, 87.19
 prepubertal acne 90.59–64
 primary herpetic gingivostomatitis 25.17
 psoriasis 35.17–18
 Refsum disease 65.28–9
 roseola infantum 25.34–5
 scabies 34.44
 scarlet fever 26.35
 seborrheic dermatitis differential diagnosis 40.4
 Sjögren-Larsson syndrome 65.29–30
 skin disease impact measurement 16.6–7
 staphylococcal scalded skin syndrome 26.27, 26.28
 streptococcal dermatitis/perianal cellulitis 26.33–4, 113.10
 streptococcal vulvovaginitis 26.33
 sun exposure 143.5–6
 systemic lupus erythematosus 51.30
 tropical ulcer 26.65
 urticaria 42.15
 UV radiation exposure 9.12
 varicella infection 25.24
 vernal keratoconjunctivitis 109.19
 vitamin D deficiency management 63.11
 waxy keratoses 65.71
 Werner syndrome 79.1, 79.3
 wound healing 10.2
 yaws 26.67
 zinc deficiency 63.26
see also infant(s); neonates; syphilis, congenital
- Children's Dermatology Life Quality Index (CDLQI) 16.6–7
 Chilopoda 34.54
 CHIME (coloboma heart defect-ichthyosiform dermatosis-mental retardation-ear anomalies) syndrome 65.34
 China, history of medicine 1.2
 Chironomidae 34.8
 Chi-square test 17.21
Chlamydia infection 26.75–6
 clinical features 30.10–13, 30.14
 complications/co-morbidities 30.11–12
 definition 30.8
 differential diagnosis 30.10–11
 disease course 30.13
 environmental factors 30.10
 epidemiology 30.9
 genital 30.8–13, 30.14, 30.15
 investigations 30.13, 30.15
 management 30.15
 nomenclature 30.8
 pathophysiology 30.9–11
 prognosis 30.13
 treatment ladder 30.15
- Chlamydia pneumoniae* 26.75–6
Chlamydia psittaci 26.76
Chlamydia trachomatis 26.75, 30.8, 30.9
 diagnosis 30.19
 elementary body 30.10
 inclusion bodies 30.13, 30.15
 life cycle 30.10, 30.11
 lymphogranuloma venereum 30.17
 perineum/perianal region 113.12
 reticulate body 30.10
- Chlamydophila pneumoniae*, rosacea association 91.5
 chloasma 32.12
 chloracne 90.12, 90.56–7, 130.10–12
 chemicals causing 90.57
 clinical features 90.58, 130.11–12
 comedones 90.12
 definition 130.10
 differential diagnosis 130.11
 dioxins 90.58
 epidemiology 90.58, 130.11
 hidradenitis suppurativa differential diagnosis 113.21
 investigations 90.58–9
 management 90.59, 130.12
 treatment 90.49
- chloramphenicol, grey baby syndrome 88.50
 chlorhexidine 18.9–10, 128.28
 chloride, sweat composition 94.4
 chloride transport, *CFTF* gene mutations 94.4
 chlorine-releasing agents 18.10
 chloroatranol 128.53
 chlorocresol 18.8
 chloroform 129.3
 chloroma, HIV infection 31.31
 Chloropidae 34.7
 chloroquine 19.5
 acute generalized exanthematous pustulosis predisposition 119.2, 119.4
 discoid lupus erythematosus treatment 51.10, 89.41
 dosage 19.7
 drug eruptions 118.3
 hair pigmentary changes 89.71
 nail colouration 95.14
 porphyria cutanea tarda treatment 60.14
 pruritus induction 83.12
 subacute cutaneous lupus erythematosus treatment 51.14
 systemic lupus erythematosus treatment 51.35
- chloroxyleneol 18.10, 128.38–9
 chlorphenamine 19.4
 chlorpromazine
 hyperpigmentation 88.27
 phototoxicity 127.29
 chlorpropamide, eczema induction 118.4
 choanal atresia and lymphoedema 73.20
 cholera 5.8–9
 cholesterol 62.10
 cholestasis, chronic 62.11
 xanthelasma 62.4, 62.11
 cholesteatoma, external auditory canal 108.27–8
 cholesterol emboli 101.15–16
 systemic lupus erythematosus 51.25
 cholesterol embolization syndrome (CES) 101.15–16

- cholesterol synthesis disorders **81.2**, 81.16
see also congenital hemidysplasia with ichthyosiform erythroderma and limb defects (CHILD) syndrome; Conradi–Hünemann–Happle syndrome
- cholesterol, X-linked syndromes concerning distal biosynthesis 65.20–3
- chondrocytes, hamartomatous proliferations 73.15
- chondrodermatitis nodularis 108.8–10
 basal cell carcinoma differential diagnosis 108.9, 141.11
 clinical features 108.9
 definition 108.8
 epidemiology 108.8
 investigations 108.9
 management 108.9
 pathophysiology 108.8–9
- chondroid syringoma, malignant 138.32, 138.33
- chordomas 113.4
- choriocarcinoma
 pemphigoid gestationis 115.13
 transplacental transfer of maternal disease 116.14
- chorionic villus sampling (CVS) 7.9–10
- choroidoretinitis, congenital syphilis 29.31, 29.32
- Christ–Siemens–Touraine syndrome 67.1–2
 hypohidrotic ectodermal dysplasia differential diagnosis 67.14
- chromhidrosis 94.17
- chromium
 allergic contact dermatitis 128.2, 128.3, 128.5, 128.14
 clinical features 128.22
 prognosis 128.22–3
 avoidance 128.23
 chemistry 128.22
 patch tests 128.23
 regulatory measures 128.76
 systemically reactivated allergic contact dermatitis 128.59
- chromoblastomycosis 32.76–8
 causative organisms 32.77, 32.78
 clinical features 32.77
 definition 32.76
 epidemiology 32.76
 investigations 32.77–8
 management 32.78
 pathophysiology 32.76–7
 treatment ladder **32.78**
- chromogranin A 3.20
- chromophores 23.3, 23.4, 23.6
 cellular epidermis 9.5
 UVR effects 9.4
- chromosomal disorders 76.1–5
 autosomal 76.1–3
 genetic tools 76.1
 mosaicism 76.5
 sex chromosome defects 76.3–5
- chromosomal microarray analysis (CMA) 76.1
- chromosome(s)
 abnormalities 7.2, 7.5
 external ear anomaly association 108.3
 complex rearrangements 7.2
 crossing-over 7.8
 deletions 7.5
 insertions 7.5
 microdeletions 7.2
 pseudo-autosomal region 7.4
 structural rearrangements 7.5
 substitutions 7.5
 translocations 7.2
- chromosome 4, short-arm deletion syndrome 76.2, 76.3
- chromosome 5, short-arm deletion syndrome 76.3
- chromosome 5p syndrome *see* cri du chat syndrome
- chromosome 18, long-arm deletion syndrome 76.3
- chronic actinic dermatitis 127.13–20
 associated diseases 127.13–14
 chemical-induced photosensitivity differential diagnosis 127.29, 127.30
 clinical features 127.14–17, 127.18
 definition 127.13
 differential diagnosis 127.16
 disease course 127.16–17
 drug-induced photosensitivity differential diagnosis 127.29, 127.30
 epidemiology 127.13–14
 investigations 127.17–20
 management 127.20
 nodular prurigo-like morphology 127.15, 127.17
 pathophysiology 127.14, 127.15
 polymorphic light eruption differential diagnosis 127.4
 prognosis 127.16–17
 severity classification 127.15
 variants 127.15
- chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome **45.4**, 45.8, **74.9**
- chronic bullous dermatosis of childhood 110.42, 117.10–11
see also immunobullous disease
- chronic cutaneous lupus erythematosus (CCLE) 51.21–2
- chronic granulomatous disease **148.17**
 bacterial infections 148.15
 functional phagocyte deficiency 82.15
 primary immunodeficiency 82.2
- chronic infantile neurological, cutaneous and articular (CINCA) syndrome 45.2, **45.3**, 45.5
 infantile urticaria 117.6
- chronic lymphocytic leukaemia (CLL)
 basal cell carcinoma incidence 141.3
 leukaemia cutis 148.2, **148.3**
 necrobiotic xanthogranuloma association 136.22
 paraneoplastic pemphigus association 50.6, 148.8
 skin cancers 146.3
- chronic myelomonocytic leukaemia (CMML)
 leukaemia cutis 148.2, **148.3**
 pemphigus 125.4
- chronic obstructive pulmonary disease
 benign symmetrical lipomatosis association 100.14
 psoriasis association 35.21
 urticarial vasculitis complication 44.4
- chronic pain syndromes, genital 111.36
- chronic papillomatous dermatitis *114.13*, 114.112
 management 114.113
- chronic papular onychodermatitis (CPOD) 33.3, 33.4
- chronic recurrent multifocal osteomyelitis (CRMO) 45.8
- chronic renal disease 101.3
 pruritus 83.10–11
- chronic venous disease, oedema 105.7
- chronic venous insufficiency 103.36–7, **103.38**, 103.39, 103.40
 clinical features **103.38**
 definition 103.36
 epidemiology 103.36–7
 investigations 103.40
 lipodema differential diagnosis 100.20, **100.21**
 lymphoedema **103.38**, 105.7
 management 103.40
 nomenclature 103.36
 pathophysiology 103.37, 103.40
 severity classification 103.40
- chrysoarobin, hair pigmentary changes 89.71
- chrysiasis 88.53, 122.3, 122.4
 chrysochroma 88.53
- Churg–Strauss syndrome *see* eosinophilic granulomatosis with polyangiitis
- chylous reflux 105.41
- chyluria, lymphatic filariasis 105.44
- chymase 2.17, 8.21, 8.41
- cicatrical pemphigoid 50.49–51, **110.31**
 bullous **50.10**
 electron microscopy 3.26
 genital 111.19–20
 mucous membrane pemphigoid differential diagnosis 50.24
 oral mucosa 110.7, 110.8
 perineum/perianal region 113.8
 scalp 107.7–8
- ciclopirox olamine 18.12
- ciclosporin 19.10–12
 acne association 90.11
 acne conglobata treatment 90.56
 adverse effects 19.10–11
 atopic eczema treatment 19.10, 41.33
 cautions 19.11
 contraindications 19.11
 CYP3A4 interactions 19.11
 dermatological uses 19.10
 dose 19.12
 DRESS treatment 119.11
 drug–drug interactions 19.11
 dyslipidaemia induction 62.11
 generalized pustular psoriasis treatment 35.37
 HIV infection complications 31.16
 hyperlipidaemia 19.11
 hypertrichosis 89.62, **89.63**, 149.15
 irritant contact dermatitis 129.8
 male genital lichen planus 111.16
 malignancy association 19.11
 monitoring 19.12
 nephrotoxicity 19.11
 pemphigus treatment 50.9
 pharmacological properties 19.10
 plaque psoriasis treatment **35.26**, 35.27–8
 polymorphic light eruption management 127.8
 pre-treatment screening 19.11–12
 psoriasis treatment 19.10
 regimens 19.12
 skin cancer association 146.6, **146.7**
 solar urticaria 127.23
 squamous cell carcinoma secondary prevention 142.33
 Stevens–Johnson syndrome/toxic epidermal necrolysis 119.22
 topical therapy 18.21
- cidofovir
 human papillomavirus treatment 31.24
 topical therapy 18.13
 wart treatment 25.54
- Cimex lectularius* 34.24, 34.25
- Cimicidae 34.24–5, 34.26, 34.27
- CINCA (chronic infantile neurological, cutaneous and articular) syndrome 45.2, **45.3**, 45.5
 infantile urticaria 117.6
 cinnamal 129.8, 129.9
 cinnamic acid 129.8, **129.9**
- circumcision 111.6–7
 genital lymphoedema 105.19
 lichen sclerosis management 111.15
 penile carcinoma protection 111.29
- circumscribed neurodermatitis 39.28–30
 cirroid aneurysm 137.28
- citric acid, antiageing products 156.3
- citruillinaemia, pili torti differential diagnosis 68.20
- citruillinated peptides 154.6
- Cladophialophora carrionii* 32.77, 32.78
- clarinettist's cheilitis 123.11, 123.12
- Clarkson syndrome 43.4
- claudication, treatment **103.4**
- claudins 2.20, 129.3
 gene mutations 2.20, 65.36
CLDN1 gene mutations 65.36
- clear cell acanthoma 133.5–6
- clear cell sarcoma 137.66
- cleft lip/palate 110.21–3
 amniotic band association 105.38
 clinical features 110.22–3
 definition 110.21
 epidemiology 110.21–2
 genetics 110.22
 investigations 110.23
 management 110.23
 pathophysiology 110.22
 syndromes including **110.22**
 syndromic 110.23
 van der Woude syndrome 110.26
 variants 110.23
- clegs 34.7
- climate, allergic contact dermatitis 128.11
- clindamycin 18.10, 19.43
 comedonal acne treatment 90.39–40
 hidradenitis suppurativa management 92.9
 papulopustular acne treatment 90.40
- clinical trials
 about adverse events 17.16–18
 application of results to specific patient 17.15
 clinical outcome measures 17.13–14
 company sponsored 17.3, 17.9
 concealment of treatment allocation 17.13
 core outcome measures 17.14
 critical appraisal 17.12–18
 diagnostic tests 17.15–16
 ethics 14.12
 evidence-based medicine 17.2–3
 identification of adverse events 14.6
 importance of results 17.14–15
 indices 17.14
 intention to treat analysis 17.13
 likelihood ratio 17.15–16
 masking 17.13
 negative results 17.3, 17.9
 outcome variables 17.14
 phase I studies 14.12
 power 17.23
 pre-/post-test probability 17.15–16
 random assignment of patients 17.12–13
 registration 14.12
 reporting guidelines 14.12, 17.13
 sample size 17.23
 substitute/surrogate end points 17.14
 validity 17.12–13
 strengthening 17.13–14
see also randomized controlled trials (RCT)
- clioquinol, topical 18.18, 128.29
- clitoris 112.2–3
 melanoma 112.38
 variations 112.3
- clofazimine
 acne fulminans treatment 90.53
 erythema nodosum leprosum treatment 28.16
 hyperpigmentation 88.25
 leprosy treatment 28.15
- clomipramine, trichotillomania treatment 89.47
- clonidine, hyperhidrosis treatment 94.9
- clostridial myonecrosis 26.47–8
- Clostridium* 26.47–8
 cellulitis 26.74
- Clostridium botulinum* 121.4
- Clostridium perfringens* 26.47–8
- Clostridium sordelli* 121.4
 heroin users 26.48
 toxic shock syndrome association 26.31
- Clostridium tetani* 121.4
- clothing
 allergic contact dermatitis 128.13, 128.45–7
 callosities 123.8
 dyes 128.46–7
 formaldehyde 128.45, 128.46
 photoprotection 9.12
- clotrimazole, candidosis treatment 32.61

- Clouston syndrome 65.58, 65.61, 67.21–2, 68.6, 68.17
 malignancy association 65.58
 oral lesions 110.17
- CLOVES (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal/spinal anomalies) syndrome 74.6, 105.27, 105.28
 capillary malformations 73.5–6
 lymphatic malformations 73.16, 105.35
 naevi 75.7
- club foot, amniotic band association 105.38
 clubbing 95.6–7
 HIV infection 31.32
 paraneoplastic 147.17
 sarcoidosis association 98.14
 with tripe palms 147.16
- cluster of jewels sign 50.35–6, 50.37
- Clutton's joints, congenital syphilis 29.31, 29.32
- Cnidaria 131.1–2
- coagulation disorders 101.2
 ecchymoses 101.1
 liver disease 152.8
- coagulation, protease role 8.40
- coagulopathy
 cancer-associated 147.24
 erythema multiforme differential diagnosis 47.5
 HIV infection 31.13
 systemic 101.17–20
- coal tar 18.32–3
- coal-tar distillates 130.11
 actinic keratosis 142.2
 eczema treatment 39.7
 hand 39.17
 plaque psoriasis 35.24–5
- cobalamin deficiency 63.19–20
- cobalt allergy 128.21–2
 avoidance 128.21
 chemistry 128.21
 clinical features 128.21
 occurrence 128.21
 patch tests 128.22, 128.67–8
 prognosis 128.22
 systemically reactivated allergic contact dermatitis 128.59
- Cobb syndrome 103.20
- cocaine 121.2–3
- Coccidioides immitis* 32.87, 32.88–9
- Coccidioides posadasii* 32.87, 32.88–9
- coccidioidin test 4.24–5
- coccidioidomycosis 32.87–9
 clinical features 32.88
 endemic 31.27
 epidemiology 32.87–8
 investigations 32.88–9
 management 32.89
- coccygeal dimple 85.9
- coccygodynia, idiopathic 113.32
- Cochrane Collaboration 17.6, 17.9
- Cochrane Library 17.6–7
- Cockayne syndrome 78.7–9
 classification 78.7
 clinical features 78.7–9
 definition 78.7
 epidemiology 78.7
 investigations 78.9
 management 78.9
- Mulvihill–Smith syndrome differential diagnosis 72.26
- neonatal lupus erythematosus differential diagnosis 51.38
- pathophysiology 78.7
- premature ageing 79.2
- progeria differential diagnosis 72.22
- Rothmund–Thomson syndrome differential diagnosis 77.6
- severity 78.9
- skin ageing 2.47
- trichothiodystrophy differential diagnosis 78.11
 type A 79.2
 type B 79.2
- variants 78.8–9
- xeroderma pigmentosum differential diagnosis 78.6
- xeroderma pigmentosum/Cockayne syndrome complex 78.6
- Cockayne syndrome proteins A and B 78.2
- cockroaches 34.30
- cocoa butter 18.6
- coeliac disease 152.3
 aphthous stomatitis differential diagnosis 110.29
 urticaria association 42.3
- coenzyme Q10 156.2, 156.11
- Coffin–Lowry syndrome 74.5
- Cogan syndrome, urticarial vasculitis association 44.2
- cognitive behavioural therapy (CBT) 86.39
 body dysmorphic disorder 86.12–13, 86.39
- cohort studies 17.5
 about adverse events 17.16
- colchicine 19.12–13
 acne conglobata treatment 90.56
 adverse effects 19.13
 Behçet syndrome management 48.7, 48.8, 48.9–10, 110.32
 contraindications 19.13
 cutaneous small-vessel vasculitis treatment 102.8
 dermatological uses 19.12
 dose 19.13
 drug–drug interactions 19.13
 epidermolysis bullosa acquisita treatment 50.46
 erythema nodosum treatment 99.24
 monitoring 19.13
 pharmacological properties 19.12–13
 regimens 19.13
 Sweet syndrome treatment 49.12
 urticarial vasculitis treatment 44.5
- cold
 diseases caused/aggravated by 125.1–11
 paronychia 95.37
 physiological reactions 125.1
- cold agglutinin(s) 25.32, 101.12, 101.13, 101.15, 125.11
 monoclonal 101.13
- cold agglutinin disease 125.11
- cold agglutinin-related cutaneous occlusion 101.13–14
 management 101.15
- cold injury
 neonatal 99.33–4, 116.14
 subcutaneous fat necrosis of the newborn 116.15
 sports enthusiasts 123.15
- cold panniculitis 99.33–5, 116.14
 adults 99.34
 definition 99.33
 differential diagnosis 99.35
 equestrian 99.34, 99.35, 125.4
 infants 99.33–4
 investigations 99.34–5
 management 99.35
 neonates 99.33–4
 pathophysiology 99.33–4
- cold-induced sweating syndrome 94.7
- cold-induced vasodilation 85.4
- Cole disease 65.54
- Coleoptera 34.28–30
- colicpictorum 122.4–5
- colitis
 collagenous 152.3
see also ulcerative colitis
- collagen 2.2
 biology 2.31
 biosynthesis 2.30–1
 cross-linking 2.31–2
 degradation 2.32–3, 9.10–11
 extracellular matrix 2.27–8
 fibrils
 fragmentation in ageing 96.2, 155.6–8
 synthesis decrease 96.2, 155.8
 gene expression regulation 2.31
 genetic heterogeneity 2.28
 hydroxylation reactions 2.30–1
- inherited disorders 72.1–11
 light absorption 23.3–4
 mechanical function 123.5
 scar tissue 10.8
 selective photothermolysis 23.4
 subunits 2.28
 synthesis
 by fibroblasts 2.40–1
 in hypopituitarism 149.16
- transepidermal elimination 96.49–50, 96.51
- type(s) 2.28–9
 type I 2.28
 ageing of skin 155.6–7
 type III 2.28
 type IV 2.20, 2.28–9
 anti-type IV collagen pemphigoid 50.51
 basement membrane 2.22, 2.23
 bullous systemic lupus erythematosus 50.47
 diagnosis of epidermolysis bullosa 71.21
 wound healing 10.13
 type V 2.29
 type VI 2.29
 type VII 2.26–7, 2.29, 71.5
 diagnosis of epidermolysis bullosa 71.22
 dominant generalized dystrophic epidermolysis bullosa 71.14
 dominant/recessive dystrophic bullous dermolysis of the newborn 71.16
 dystrophic epidermolysis bullosa 71.18
 type XVII 2.29, 71.4
 type XXIX 2.29
 wound healing 10.7
- collagen fillers 157.6
 with polymethylmethacrylate 157.7
- collagen vascular disease
 oral lesions 110.48, 110.91
 primary immunodeficiency 82.2
 urticaria differential diagnosis 42.14
- collagenase 2.32
- collagenoma 96.40
 congenital 75.18, 96.40
 verrucous perforating 96.51
- collagenosis
 nuchae 137.12
 reactive perforating 64.4, 65.69
 familial 96.50–1, 96.53
 lip 110.88
- collagenous and elastotic marginal plaques of hands 96.4–5
- collagenous colitis 152.3
- collier's stripes 88.53
- collodion baby 65.7, 65.9, 65.11, 116.19
 clinical features 116.19–20
 definition 116.19
 epidemiology 116.19
 investigations 116.20
 loricrin keratoderma 65.49
 management 65.37–8, 116.20
 pathophysiology 116.19
 restrictive dermopathy differential diagnosis 72.20
 trichothiodystrophy 65.33
- collodions 18.2
- colloid body 3.35
- colloid degeneration 3.35, 96.5–6
 nodular 96.6
 penile 111.27
- colloid milia 96.5–6
 clinical features 96.6
 differential diagnosis 96.5, 96.6
 electron microscopy 3.27
 management 96.6
 pathophysiology 96.5–6
 solar elastosis differential diagnosis 96.4
- colloid osmotic pressure 105.3
- coloboma heart defect–ichthyosiform dermatosis–mental retardation–ear anomalies (CHIME) syndrome 65.34
- coloboma, heart defects, atresia of the nasal choanae, retardation of growth/development, genital/urinary abnormalities and ear abnormalities and deafness (CHARGE) syndrome 82.8, 108.3
- colonic adenocarcinoma 147.12
- colony-stimulating growth factors 8.5
- colophonium 128.15, 128.58
- colophony allergy 128.54–5, 128.58
- Colorado tick fever 34.38
- colour Doppler scanning 4.22
- colour of skin 88.1–2, 155.4
 ageing 155.4, 155.9
 black skin biological significance 88.8
 chemical peels 159.13
- combined immunodeficiencies 82.7–12
 with associated features 82.11–12
 cartilage hair hypoplasia 82.12
 common variable
 immunodeficiency 82.13
 DOCK8 deficiency 82.9–10
 MHC class I deficiency 82.10
 P13kδ deficiency 82.13
 syndromic 82.11–12
 Wiskott–Aldrich syndrome 82.9
 X-linked lymphoproliferative diseases 82.10–11
see also dyskeratosis congenita; Fanconi anaemia; severe combined immunodeficiency (SCID)
- comedo naevus 90.25, 138.4–5
- comedones 130.11
 acne 90.1
 amineptine-induced 90.11
 closed 90.21, 90.24
 familial 90.25
 mechanical acne 90.24
 open 90.21
 removal 90.48, 90.49
 retinoic acid therapy 18.22
 secondary 92.5
 senile 90.26
 solar 90.26
 subtypes 90.21
 surgery 20.47
see also chloracne
- Comel–Netherton syndrome 65.24–5, 82.11
- common variable
 immunodeficiency 82.13, 148.17
 epidemiology 146.2
- communication, medication errors 14.9
- community diagnosis 5.2
- co-morbidities 11.6
- comparative genomic hybridization (CGH), melanoma diagnosis 143.19
- complement 136.2
 activation
 primary anetoderma 96.21
 regulation defects 82.18
 bullous disorders 3.18
 macrophage role 8.22
 pathway 8.31–2
 systemic lupus erythematosus 51.34
- complement 1q (C1q) 10.6
- complement diseases 82.17–18
- complementary therapies 15.2, 86.40
 acne therapy 90.49
see also herbal products/medications
- complex regional pain syndrome (CRPS) 85.12–14
 clinical features 85.13–14
 definition 85.12
 dermatological manifestations 85.13
 epidemiology 85.13
 investigations 85.14
 management 85.14
 pathophysiology 85.13
 stages 85.13
- Compositae 128.52, 128.53, 128.54
- composite haemangi endothelioma 137.35
- compression therapy
 immobility-induced lymphoedema 105.51
 lipodermatosclerosis 105.10

- lymphatic malformations 105.37
 lymphoedema 105.56, 105.57, 105.57
 obesity-related lymphoedema 105.20
 phlebolympoedema 105.9
 conception, effects on drug therapeutic outcome 14.7
 conditioners (hair) 89.72
 condoms, rubber accelerators 128.17
 condyloma, giant of penis 111.32
 condylomata acuminata 25.53, 25.56, 112.29, 113.13–15
 giant 113.19
 HIV infection 31.24
 oral 110.62
 see also ano-genital warts
 condylomata lata
 genital wart differential diagnosis 25.57, 111.25
 perineum/perianal region 113.12
 secondary syphilis 29.12, 29.14
 cone-nosed bugs 34.27–8
 confidence intervals 5.13, 17.18, 17.21–2
 confluent and reticulated papillomatosis (CARP) 32.14, 87.5–7
 clinical features 87.6–7
 definition 87.5
 differential diagnosis 87.7
 epidemiology 87.5–6
 management 87.7
 pathophysiology 87.6
 confocal microscopy *see* reflectance confocal microscopy
 confounding 5.8, 5.13
 congenital acquired lipodystrophy 100.3
 congenital adrenal hyperplasia 149.18
 clinical features 90.8
 hirsutism 89.65, 90.8
 late-onset, acne association 90.5, 90.8
 non-classical 90.5, 90.8
 congenital candidosis 32.67
 congenital cutis laxa 96.20
 congenital cystic median raphe anomalies 111.26
 congenital dermal sinuses 85.8
 congenital disorders of glycosylation 81.2, 81.10–11
 congenital epidermal naevi *see* naevi, congenital epidermal
 congenital erosive and vesicular dermatosis with reticulated scarring 96.12, 116.8–9
 congenital erythropoietic porphyria 60.4, 60.7, 60.9–11
 bone marrow transplantation 60.10–11
 clinical features 60.9–10
 definition 60.9
 differential diagnosis 60.10
 disease course 60.10
 genetic counselling 60.11
 hypertransfusion 60.10
 investigations 60.10
 management 60.10–11
 nomenclature 60.9
 prognosis 60.10
 congenital fascial dystrophy 72.18
 congenital generalized
 lipodystrophies 74.1, 74.2
 congenital generalized multiple fibromatosis 72.18
 congenital haemangiomas 117.23
 congenital heart block 51.37
 neonatal lupus erythematosus 51.38–9
 congenital hemidysplasia with ichthyosiform erythroderma and limb defects (CHILD) syndrome 65.21–3
 congenital epidermal naevi 75.3–4, 75.7
 management 75.9
 spinal dysraphism association 85.8–9
 congenital hypertrichosis 113.4
 generalized 89.61
 lanuginosa 89.61
 localized 68.11, 89.61–2
 congenital ichthyosiform erythroderma 65.9–13, 65.10, 116.19
 clinical features 65.11–12
 definition 65.9–10
 investigations 65.12–13
 management 65.39
 pathophysiology 65.10
 congenital ichthyosis–follicular atrophoderma–hypotrichosis–hypohidrosis (IFAH) 65.36
 congenital lipodystrophy 74.1–3
 acquired 100.3
 generalized 74.1, 74.2
 congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal/spinal anomalies (CLOVES) syndrome 74.6, 105.27, 105.28
 capillary malformations 73.5–6
 lymphatic malformations 73.16, 105.35
 naevi 75.7
 congenital localized hypertrichosis 68.11
 congenital malformations 7.5
 ano-genital region 113.4
 prenatal diagnosis 7.9–10
 superficial capillary (*see* port-wine stains)
 vulval 112.4
 congenital melanocytic naevi *see* naevi, congenital melanocytic
 congenital melanocytic naevus syndrome 75.13
 congenital muscle hamartoma 75.20
 congenital pseudo-ainhum 96.44–5, 116.18
 raised linear bands of infancy
 differential diagnosis 116.18
 congenital rubella syndrome 25.79, 116.22–3
 neonatal lupus erythematosus
 differential diagnosis 116.13
 congenital self-healing reticulohistiocytosis (CSHRH) 136.5
 congenital syphilis *see* syphilis, congenital
 congenital tuberculosis 116.26–7
Candidobolus coronatus 32.80–1
 conjunctiva
 chancere 109.42
 irritation 41.22
 Kaposi sarcoma 109.51
 local anaesthesia 20.12
 melanoma 109.50, 143.13
 naevi 132.24
 papillomas 25.57
 ulceration 87.14
 xerosis 87.14
 conjunctivitis
 chronic allergic 50.29
 cicatricial associated with
 immunobullous disorders 109.25–7, 109.28–9, 109.29–34, 109.35, 109.36
 see also Stevens–Johnson syndrome; toxic epidermal necrolysis (TEN)
 clinical features 109.27, 109.28–9, 109.29–30
 definition 109.25
 differential diagnosis 109.26, 109.30–1
 epidemiology 109.26
 erythema multiforme major 109.34, 109.36
 graft-versus-host disease 109.36
 investigations 109.30–1
 management 109.31–4, 109.35, 109.36
 mucous membrane
 pemphigoid 109.25–7, 109.28–9, 109.29–34, 109.35, 109.36
 pathophysiology 109.26–7
 gonococcal 30.3, 30.4, 30.8
 herpes simplex virus 109.36–8, 109.39
 Lyme disease 109.42
 psoriatic arthritis association 35.43
 connective tissue, ageing/photodamage changes 96.1–6
 connective tissue diseases
 acquired 96.1–53
 ageing 96.1–6
 elastic fibre degradation 96.19–28, 96.29
 elastic tissue deposition 96.29–30
 excessive response to injury 96.45–9
 fibromatoses 96.30–40
 fibrous cutaneous nodules 96.40–5
 perforating dermatoses 96.49–53
 photodamage 96.1–6
 skin atrophy 96.6–19
 hand–arm vibration syndrome
 differential diagnosis 123.24
 histological sections 3.39
 immunological tests 125.9
 immunopathology techniques 3.17
 inherited 72.1–33
 collagen disorders 72.1–11
 ectopic calcification disorders 72.26–32
 elastic fibre disorders 72.11–17
 infantile stiff skin syndromes 72.17–20
 mineralization abnormalities 72.26–32
 premature ageing syndromes 72.20–6
 malignancy association 147.19–21
 overlap 53.9
 papular/nodular mucinosis 59.13–14
 radiography 95.47
 renal involvement 153.6
 Sjögren syndrome association 55.6, 55.7
 subcorneal pustular dermatosis
 association 49.14
 systemic lupus erythematosus
 differential diagnosis 51.27
 systemic sclerosis overlap 56.7–8
 undifferentiated 54.1
 urticarial vasculitis co-morbidity 44.2, 44.4
 see also mixed connective tissue disease
 connective tissue growth factor (CTGF) 10.3, 10.7
 connexin(s) 2.19, 2.20
 scarring 10.8
 connexin disorders 67.7, 68.16–17
 keratitis–ichthyosis–deafness syndrome 65.30–2
 palmoplantar keratoderma and hearing impairment 65.56
 connexin-26, associated disorders 65.30, 65.56
 connexons 2.19, 2.20
 Conradi–Hünemann–Happle syndrome 65.20–2, 96.14
 clinical features 65.21
 management 65.21–2
 pathophysiology 65.20–1
 constricting bands of the extremities 96.43–5
 clinical features 96.44–5
 definition 96.43
 differential diagnosis 96.44–5
 epidemiology 96.43–4
 management 96.45
 pathophysiology 96.44
 variants 96.44
 see also amniotic band syndrome
 constriction artefact 86.27
 construct validity 16.2
 contact dermatitis
 airborne, chronic actinic dermatitis
 differential diagnosis 127.16
 arsenic toxicity 122.2
 cellulitis differential diagnosis 26.20
 children 128.5–6
 chronic otitis externa 108.18
 delayed-type hypersensitivity 8.60
 discoid lupus erythematosus differential diagnosis 51.9
 ear piercing complications 108.7
 erysipelas differential diagnosis 26.20
 erythematolangleiectatic rosacea
 differential diagnosis 91.9
 eyelids 109.5
 gold reactions 122.4
 hand eczema 39.17
 historical aspects 1.8
 lichen planus-like 37.3
 mast cell role 2.17
 mercury toxicity 122.6
 musical instruments 123.11
 non-immune 129.9
 perianal 113.8
 phototoxic 129.9–10
 purpura 101.9
 scalp disorders 107.4
 symmetrical drug-related intertriginous and flexural exanthem differential diagnosis 118.6
 transient acantholytic dermatosis association 87.22
 urticaria differential diagnosis 42.14
 vesicular palmar 128.14
 see also allergic contact dermatitis; irritant contact dermatitis
 contact hypersensitivity (CHS) 8.15
 acquired immunity model 9.8–9
 macrophage inhibitory factor role 8.15
 pathophysiology 8.28
 contact urticaria syndrome 41.32
 see also allergic contact urticaria
 contingency tables 17.21
 contrast agents, gadolinium causing nephrogenic systemic fibrosis 96.41
 Control of Substances Hazardous to Health (COSHH) legislation 128.76
 contusion, external ear 108.6–7
Conus (cone shell) 131.3–4
 convertase 8.41
 coolants, occupational dermatitis 130.1
 Copenhagen Psoriasis Severity Index 16.2
 coping strategies 86.3–4
 copper
 accumulation in Wilson disease 81.19
 contact allergy 128.24
 copper deficiency 2.36, 63.27–8
 hair colour changes 89.71
 Menkes disease 81.18
 copra itch 34.48
 coral bead sign 147.23
 coral strings 131.1–2
 cord tethering 85.9
 corneal argyrosis 122.7
 corneal opacity, recessive X-linked ichthyosis 65.6
 corneal scarring, atopic keratoconjunctivitis 109.22
 Cornelia de Lange syndrome
 facial features 75.14
 hypertrichosis 89.61
 oral lesions 110.24
 corneocytes 2.1, 2.6
 structure 2.7
 corneodesmosin 71.5
 cornification, inherited disorders 65.2
 exfoliative disorders 65.24–7
 see also ichthyoses
 corns 123.6–8
 clinical features 123.7–8
 definition 123.6
 epidemiology 123.6–7
 management 123.8
 pathophysiology 123.7
 sports injuries 123.16
 corona phlebectatica paraplantaris 103.38
 chronic venous insufficiency 103.39
 coronary artery disease 150.5–6
 HIV-associated lipodystrophy association 100.7
 hyperlipoproteinaemia type III 62.8
 systemic lupus erythematosus 51.28
 corticosteroid-induced rosacea-like dermatosis 91.16–17
 corticosteroids
 acne therapy 90.49
 acneform reactions 90.10–11
 acute graft-versus-host disease treatment 38.5–6
 adverse reactions 154.15
 allergy 128.18
 alopecia areata treatment 89.33
 anti-p200 pemphigoid treatment 50.40–1
 atopic eczema treatment 41.30
 atrophy of skin 96.7–9

- corticosteroids (*continued*)
 Behçet syndrome management 48.7, 48.8, 48.9, 110.32
 blanching effect on skin 13.7
 bowel-associated dermatosis–arthritis syndrome treatment 49.13–14
 bullous systemic lupus erythematosus treatment 50.48, 50.49
 candidosis effects 32.58
 chronic graft-versus-host disease treatment 38.9
 cutaneous small-vessel vasculitis treatment 102.8
 Darier disease treatment 66.9
 DRESS treatment 119.11
 dyslipidaemia induction 62.11
 eosinophilic granulomatosis with polyangiitis treatment 102.29
 eosinophilic pustular folliculitis treatment 93.9
 epidermolysis bullosa acquisita treatment 50.46
 erosive pustular dermatitis of scalp treatment 107.11
 erythema nodosum treatment 99.24
 fixed drug eruption treatment 118.14
 giant cell arteritis treatment 102.35
 granulomatosis with polyangiitis treatment 102.27
 granulomatous cheilitis treatment 110.87
 Hailey–Hailey disease treatment 66.13
 hypertrichosis treatment 89.63
 irritant contact dermatitis treatment 129.8
 itch in atopic eczema treatment 83.9
 lichen planus treatment 37.15, 37.16, 37.17, 37.18
 male genital 111.16
 lichen sclerosus management 112.9
 lichen striatus treatment 37.20
 localized lipatrophy induction 100.10–11
 melasma treatment 88.12
 mixed connective tissue disease treatment 54.3
 molecule structure 18.14
 morphea treatment 107.6
 mucous membrane pemphigoid treatment 109.33
 ocular side effects 109.43, 109.46
 pemphigus treatment 50.8
 phobias 86.20
 poststeroid panniculitis treatment 99.35, 99.55–6
 potency 18.14
 purpura treatment 101.5–6
 pyoderma gangrenosum treatment 49.5
 recurrent aphthous stomatitis treatment 110.30
 sarcoidosis treatment 98.15–17
 seborrhoeic dermatitis treatment 40.5, 40.6, 107.2
 subcorneal pustular dermatosis treatment 49.15
 subcutaneous Sweet syndrome treatment 99.49
 tinea modification 32.50
 transdermal 13.7
 zoster infection treatment 25.30
see also glucocorticoid(s)
- corticosteroids, intralesional 18.19, 20.44
 foreign-body reactions 123.20
 keloid 96.48
 skin atrophy 96.7
- corticosteroids, oral
 acne fulminans treatment 90.53
 discoid lupus erythematosus treatment 51.10
 mastocytosis treatment 46.10
 morphea treatment 57.27, 57.28
 psoriatic arthritis treatment 35.45
 subacute cutaneous lupus erythematosus treatment 51.14
 systemic lupus erythematosus treatment 51.35–6
 pregnancy 51.30
- corticosteroids, systemic
 dermatomyositis treatment 53.11–12
 erythema multiforme treatment 47.6
 hidradenitis suppurativa management 92.10
 safe treatments in pregnancy 115.17
 solar urticaria treatment 127.23
 Stevens–Johnson syndrome/toxic epidermal necrolysis 119.22
 transient acantholytic dermatosis treatment 87.24
- corticosteroids, topical 18.13–19
 allergic reactions 128.29, 128.31
 antimicrobial agent combination 18.18
 asteatotic eczema treatment 39.11, 87.27
 chronic actinic dermatitis treatment 127.20
 comedone formation 130.11
 cross-reactions 18.16–17
 discoid lupus erythematosus treatment 51.10, 89.41
 eczema treatment 39.6, 39.7
 endocrine impact 149.15
 eye drops 18.17
 formulations 18.18–19
 granuloma annulare treatment 97.7
 hand eczema treatment 39.17
 hydroa vacciniforme treatment 127.26
 indications 18.14, 18.15
 infantile acropustulosis treatment 116.8
 infection exacerbation 18.17
 lichen simplex treatment 39.30
 lower leg eczema treatment 39.21
 mastocytosis treatment 46.9
 mechanism of action 18.14–15
 mycosis fungoides treatment 140.23
 nail psoriasis treatment 95.42
 necrobiosis lipoidica treatment 97.11
 occlusion 18.19
 perineum/perianal region reactions 113.8
 peristomal skin disease treatment 114.9, 114.113
 pityriasis alba treatment 39.26
 pityriasis lichenoides management 135.5
 pityriasis rubra pilaris treatment 36.6
 plaque psoriasis treatment 35.22–3
 polymorphic light eruption management 127.7
 rebound phenomenon 18.18
 safe treatments in pregnancy 115.17
 side effects 18.15–18
 local 18.15–17
 systemic 18.15–18
 subacute cutaneous lupus erythematosus treatment 51.14
 systemic lupus erythematosus treatment 51.35
 tachyphylaxis 18.18
 transient acantholytic dermatosis treatment 87.24
 vascular effects 18.17
 vehicles 18.18–19
 vitiligo treatment 88.39
- corticotrophin *see* adrenocorticotrophic hormone (ACTH)
- cortisol, endocrine impact of therapy 149.15
- Corynebacterium* 26.3–4
 abnormal sweat odour 94.16
 pitted keratolysis 26.42
 trichomycosis pubis 111.23
- Corynebacterium acnes* *see* *Propionibacterium acnes*
- Corynebacterium diphtheriae* 26.38
- Corynebacterium minutissimum* 26.39, 31.22
- Corynebacterium pyogenes* *see* *Trueperella pyogenes*
- Corynebacterium tenuis*, trichomycosis axillaris 26.41
- coryneform bacteria 26.3–4, 26.37–43
 classification 26.37
 definition 26.37
 diseases caused by 26.37
- cosmeceuticals 156.1–10, 156.10–11, 156.11
 antiageing 156.3–5
 phytochemicals 156.7
 coenzyme Q10 156.2
 herbal products/phytochemicals 156.5–10, 156.11
see also antioxidants
- cosmetic fillers, panniculitis 99.48
 cosmetic units, facial surgery 20.2
- cosmetics
 acne vulgaris association 90.17
 allergic contact dermatitis 128.13, 128.15, 128.31–2
 avoidance 128.32
 clinical features 128.31–2
 incidence 128.31
 comedonal acne 130.11
 facial melanosis 88.10
 hair 89.71–5, 128.16, 128.32
 colouring 89.72–4
 irritant contact dermatitis 129.4
 nails 95.60–4
 patch testing 128.32
 plant allergens 128.31
 vehicles 128.40–2
- cost analysis study 6.3
 cost–benefit analysis (CBA) 6.4
 cost-effectiveness analysis (CEA) 6.4
 Costello syndrome 72.12, 80.8, 80.9, 150.3
 rhabdomyosarcoma risk 110.62
- cost-minimization studies 6.4
 cost-of-illness
 psoriasis 6.7–9
 skin cancer 6.5–6, 6.7
 studies 6.3–4
- cost-utility analysis (CUA) 6.4
- co-trimoxazole 19.43
 drug eruptions 31.17, 31.18
 cotton-seed dermatitis 34.49
- counselling, interpersonal 86.39
- cow hair sinus 123.22
- Cowden syndrome *see* PTEN hamartomatous tumour syndrome
- Cowden-like syndrome 80.13, 80.14
- cowpox 25.8–9
 vulval lesions 112.27
- Coxiella burnetii*, infectious panniculitis 99.44
- Coxsackie virus infections 25.79, 25.81–2
 hand, foot and mouth disease 117.7
 oral ulceration 110.48–9
- crab louse 34.17, 34.22–3
- crack cocaine 121.2–3
- cradle cap 117.1, 117.2
- Crandall syndrome, pili torti 89.52
- craniosynostosis, delayed closure of
 the fontanelles, cranial defects or deafness, anal anomalies, genitourinary anomalies and skin eruption (CDAGS) syndrome 87.21
- craniosynostosis
 cutis laxa differential diagnosis 72.14
 syndromic cleft lip/palate 110.23
- C-reactive protein (CRP) 8.31
- creams 18.2, 18.9
 creeping hair 123.22
- creosote 130.11
- CREST (calcinosis, Raynaud phenomenon, oesophageal dysfunction, sclerodactyly and telangiectasia) syndrome 56.1
 calcinosis 61.2
- Creutzfeldt–Jakob disease, new variant 20.7–8
- cri du chat syndrome 76.3
 premature hair greying 89.70
- Crimean Congo haemorrhagic fever 25.72
- crinkles 96.2
- Crisponi syndrome 96.37
- critical limb ischaemia 85.6
- Crohn disease 113.24–5, 152.1–3
 acne fulminans association 90.50
 anal abscess differential diagnosis 113.26
 anal fissure differential diagnosis 113.29
- anal fistula differential diagnosis 113.27
 ano-genital lesions 112.22–3
 aphthous stomatitis differential diagnosis 110.29
 aphthous ulceration 110.41–2
 clinical features 113.24–5
 cutaneous 97.11–13, 152.2
 definition 113.24
 differential diagnosis 113.25
 epidemiology 113.24
 erythema nodosum 99.21
 folliculitis differential diagnosis 113.10
 genital 111.20, 114.7
 genital erythema 111.19
 granulomatous cheilitis association 110.86
 differential diagnosis 110.86
 haemorrhoids differential diagnosis 113.31
 hidradenitis suppurativa association 92.2
 differential diagnosis 92.7, 113.21
 investigations 113.25
 lesions 152.2
 lips 97.12
 lupus vulgaris differential diagnosis 27.24
 malakoplakia differential diagnosis 113.25
 management 112.25
 metastatic 97.13, 113.24, 113.25
 mucocutaneous features 113.24, 113.25
 necrobiosis lipoidica association 97.8
 pathophysiology 113.24
 perianal 97.12, 113.24–5
 perineal 97.12, 114.7
 pilonidal sinus differential diagnosis 113.24
 psoriasis association 35.20
 reactive lesions 152.2–3
 sarcoidosis differential diagnosis 98.2
 vulval 98.14
 selenium toxicity 122.6
 skin cancer association 146.5, 146.10
 skin tags 111.5
 stoma complication 114.7–8, 114.9, 114.10
 subacute cutaneous lupus erythematosus association 51.12
 vulval lesions 112.22–3
see also oro-facial granulomatosis
- cromoglicate 18.35
 solar urticaria 127.23
- Cronkhite–Canada syndrome
 intestinal polyposis 152.4
 telogen effluvium 89.27
- Cross syndrome 70.9
- Crofti lymphoma 140.40–1
- croton oil 129.3
- Crouzon syndrome 67.7, 87.3
- Crowe’s sign 80.3
- crown of jewels sign 50.35–6
- crow’s feet, botulinum toxin injection 158.5, 158.6
- crush injuries, gas gangrene 26.47
- crust 3.35
- cryofibrinogen 101.12, 101.13
- cryofibrinogenaemia 101.13, 101.15
- cryogelling/cryoagglutination disorders 101.12–15
 clinical features 101.14–15
 complications/co-morbidities 101.14–15
 differential diagnosis 101.14
 epidemiology 101.13
 investigations 101.15
 management 101.15
 pathophysiology 101.13–14
 variants 101.14
- cryogen spray cooling 23.5
- cryoglobulinaemia 101.13–15, 125.10–11
 clinical features 125.10
 cold urticaria 42.11
 definition 125.10
 epidemiology 125.10

- investigations 125.11
 management 101.15, 125.11
 mixed 125.10, 125.11
 myeloma-linked 147.24
 pathophysiology 125.10
 Schnitzler syndrome differential
 diagnosis 45.10
 systemic lupus erythematosus
 association 51.25, 51.34
 type I 102.17, 148.6
 urticarial vasculitis association 44.2
see also vasculitis, cutaneous,
 cryoglobulinaemic
 cryoglobulins 101.12–13, 125.10
 cryoglobulinaemia type I
 diagnosis 148.6
 mechanism of action 101.14–15
 pathology 101.13
 systemic lupus erythematosus 51.34
 cryoprecipitation 160.11–12
 cryoproteins, urticaria 47.11
 cryopyrin-associated periodic
 syndrome 45.4–5
 cryosurgery 20.43
 basal cell carcinoma treatment 141.16
 cryotherapy
 actinic keratosis treatment 142.8, 142.9
 Bowen disease treatment 142.21, 142.22,
 142.24
 squamous cell carcinoma
 treatment 142.32
 wart treatment 25.52
 cryptococcal meningitis 31.27
 cryptococcosis 32.92–3
 genital 111.24
 HIV infection 31.27
 Kaposi sarcoma differential
 diagnosis 31.29
 oral lesions 110.54
Cryptococcus gattii 32.92, 32.93
Cryptococcus neoformans 32.92, 32.93
 HIV infection 31.27
 cryptogenic-organizing pneumonia 53.9
 cryptosporidiosis, HIV infection 31.28
 crystal globulin vasculopathy 101.17
 crystal methamphetamine abuse 121.2
 crystal violet 88.53
Ctenophalides canis 34.12
Ctenophalides felis 34.12, 34.13
 CTSC gene mutations 65.61
 C-type lectins 8.15
 Cubozoa 131.1
 Culicidae 34.6
 Cullen's sign 152.6
 cultural factors, diagnosis of skin
 disease 4.4
 cultured skin substitute (CSS) 126.6
 curettage 20.44–5, 20.45
 actinic keratosis treatment 142.8, 142.9
 Bowen disease treatment 142.21–2,
 142.22
 keratoacanthoma 142.35–6, 142.36
 squamous cell carcinoma
 treatment 142.33
 curlicue pattern 3.35
 Curth's angle 95.6
 Cushing disease
 acne association 90.5
 ACTH-producing tumour 149.17
 endocrine disorder skin signs 149.12
 facial changes 149.11
 Cushing syndrome
 candidosis susceptibility 32.58
 familial partial lipodystrophy
 differential diagnosis 74.2
 hirsutism 89.65
 hyperpigmentation 88.7, 88.18
 periocular oedema 105.16
 purpura 101.5–6
 striae 96.9, 96.10
 symptoms/signs 90.8
 cutaneous aggressive epidermotropic
 CD8+ T-cell lymphoma 140.32–3
 cutaneous anaplastic large-cell
 lymphoma 140.1–2, 140.29–31
 management 140.28, 140.31
 treatment algorithm 140.28
 cutaneous B-cell lymphoma 140.2
 biopsy 3.2
 classification 140.37–8
 diffuse large 140.37, 140.41–3
 follicle centre cell 140.37, 140.40–1
 immunopathology techniques 3.25
 intravascular large 140.43–4
 pathogenesis 140.38
 photodynamic therapy 22.7
 post-transplant lymphoproliferative
 disorder 140.48
 primary 140.37–43
 radiotherapy 24.16
 secondary 140.43–5
 treatment algorithm 140.38
 see also lymphomatoid granulomatosis
 cutaneous calcinosis *see* calcinosis cutis
 cutaneous calciphylaxis 101.24–5
 cutaneous CD4+ small/medium-
 sized pleomorphic T-cell
 lymphoma 140.34
 cutaneous CD30+ lymphoproliferative
 disorders 140.27–32
 anaplastic large-cell lymphoma 140.29–
 31
 Hodgkin disease differential
 diagnosis 140.49–50
 subcutaneous panniculitis-like T-cell
 lymphoma 140.31–2
 treatment algorithm 140.28
 see also lymphomatoid papulosis
 cutaneous endometriosis 112.31
 cutaneous epithelioid angiomatous
 nodule 137.29–30
 cutaneous graft-versus-host disease
 extracorporeal
 photochemotherapy 21.6–7
 UVA-1 phototherapy 21.6
 cutaneous horn 142.11–12
 keratoacanthoma differential
 diagnosis 142.35
 penile 111.29
 cutaneous larva migrans 33.18–19
 HIV infection 31.28
 oral 110.72
 perineum/perianal region 113.12
 cutaneous lupus mucinosis 59.13–14
 cutaneous lymphadenoma 138.12–13
 cutaneous lymphocyte antigen 140.2
 cutaneous lymphoid hyperplasia *see*
 pseudolymphoma
 cutaneous meningioma 137.52
 cutaneous microvascular occlusion
 in sepsis with disseminated
 intravascular coagulation
 (DIC) 101.18
 cutaneous mucinosis *see* mucinosis,
 cutaneous
 cutaneous myoepithelioma 138.33–4
 cutaneous myxoid cyst 137.62
 cutaneous neoplasms
 immunopathology 3.18–25
 metastatic 3.23
 cutaneous neuroendocrine carcinoma *see*
 Merkel cell carcinoma
 cutaneous peripheral T-cell
 lymphoma 140.32–7
 see also primary cutaneous peripheral
 T-cell lymphoma
 cutaneous phobias 86.19–20
 cutaneous rhabdomyosarcoma 137.58
 cutaneous small-vessel vasculitis
 (CSVV) 102.5–8, 102.7
 aetiological triggers 102.5
 clinical features 102.6–8
 cryoglobulinaemic vasculitis differential
 diagnosis 102.17
 definition 102.5
 differential diagnosis 102.7
 epidemiology 102.5
 erythema elevatum diutinum
 differential diagnosis 102.9
 investigations 102.8
 management 102.8
 nomenclature 102.5
 pathophysiology 102.5, 102.6
 severity classification 102.7
 variants 102.6
 cutaneous T-cell lymphoma (CTCL) 140.1
 acquired ichthyoses 65.40
 aggressive epidermotropic
 CD8+ 140.32–3
 angioimmunoblastic 140.45
 biopsy 3.2
 CD4+ small/medium-sized
 pleomorphic 140.34
 cell of origin 140.2, 140.3
 chronic actinic dermatitis differential
 diagnosis 127.16
 epidermotropism 140.2
 erythroderma 39.32
 extracorporeal photochemotherapy 21.6
 genital ulceration 111.19
 granulomatous slack skin disease 96.27–
 8, 140.17–18
 HIV infection 31.31
 hydroa vacciniforme differential
 diagnosis 127.24
 hypopigmentation 88.44
 immunopathology techniques 3.25
 management
 extracorporeal
 photochemotherapy 21.6
 mechlorethamine therapy 18.27
 novel therapies 140.3–4
 PUVA 21.4
 radiotherapy 24.16
 UVB phototherapy 21.4
 molecular abnormalities 140.3
 non-Hodgkin lymphoma
 association 140.5
 pagetoid reticulosis 140.16–17
 peripheral 140.32–7
 photodynamic therapy 22.7
 poikiloderma atrophicans
 vasculare 96.10
 post-transplant lymphoproliferative
 disorder 140.47–8, 140.48
 primary 140.2–27
 PUVA 21.4
 radiotherapy 24.16
 secondary 140.46–7
 skin cancer 146.12
 UVB phototherapy 21.4
 variants 140.2
 see also follicular mucinosis; mycosis
 fungoides; primary cutaneous
 peripheral T-cell lymphoma; Sézary
 syndrome
 cutaneous–intestinal syndrome with
 oro-pharyngeal ulceration 101.24
 cuticle removers 95.63
 cutis hyperelastica *see* Ehlers–Danlos
 syndrome
 cutis laxa 79.5–7
 acquired 72.13, 96.19–20
 anetoderma association 96.22
 autosomal dominant 72.11, 72.12, 72.13,
 79.6
 autosomal recessive 72.12, 72.13,
 79.6–7
 clinical features 72.11, 72.12, 72.13–14,
 96.19–20
 congenital 96.19
 congenital disorders of
 glycosylation 81.10
 definition 96.19
 differential diagnosis 72.13
 Ehlers–Danlos syndrome differential
 diagnosis 72.7, 72.14
 epidemiology 72.11, 96.19
 genetics 96.19
 inherited generalized 72.11, 72.12,
 72.13–14
 investigations 72.14
 management 72.14
 Menkes disease differential
 diagnosis 63.28
 Michelin tyre baby differential
 diagnosis 72.15
 pathophysiology 72.11, 96.19
 pseudoxanthoma elasticum differential
 diagnosis 72.30
 pseudoxanthoma elasticum-like
 phenotype 72.30
 variants 72.11, 72.12, 72.13
 X-linked 72.12, 72.13
 cutis marmorata 116.3
 cutis marmorata telangiectasia
 congenita 116.3
 cutis verticis gyrata
 endocrine disorder skin signs 149.10,
 149.11
 malignancy association 147.23
 scalp 100.23, 107.9
 cutting oils 130.11
 CX3C chemokines 8.36, 8.37
 CX3CR1 8.40
 CXC chemokines 8.36, 8.37, 8.38, 8.39
 CXCL8 *see* interleukin 8 (IL-8)
 CXCR2 8.40
 CXCR4 31.3
 mutations 146.2
 cyanide toxicity 126.4
 cyanoacrylates, nail eczema 95.43
 cyanosis
 peripheral (*see* acrocyanosis)
 platinum toxicity 122.9
 cyclic haematopoiesis 148.17
 bacterial infections 148.15
 cyclohexylamine 96.42
 cyclo-oxygenase (COX)
 acne vulgaris pathology 90.18–19
 prostanoid synthesis 8.48–9
 cyclo-oxygenase 2 (COX-2) inhibitors 8.49
 cyclophosphamide
 alopecia induction 120.5
 eosinophilic granulomatosis with
 polyangiitis 102.29
 granulomatosis with polyangiitis 102.27
 mucous membrane
 pemphigoid 109.33–4
 pemphigus treatment 50.8–9
 systemic lupus erythematosus
 treatment 51.36
CYLD gene mutations 138.30
 basal cell carcinoma 141.5
 cylindroadenocarcinoma 138.35–6
 cylindroma
 malignant 138.35–6
 scalp 138.30–1
CYP2D6 gene mutations 141.3
CYP3A4
 ciclosporin drug interactions 19.11
 colchicine drug interactions 19.13
CYP4F2 gene mutations 65.11, 65.12
CYP21A2 gene mutations 90.5
 cyproterone acetate
 female pattern hair loss
 management 89.23
 hirsutism treatment 89.67–8
 papulopustular acne treatment 90.43
 sebaceous gland hyperplasia
 treatment 93.13
 side effects 89.68
 cyst(s)
 cutaneous 134.1–5
 epidermoid 134.1–2
 mucinous vulval 112.29
 retention 109.47–8
 sebaceous 134.1
 see also epidermoid cysts; milia;
 steatocystoma multiplex;
 trichilemmal cysts
 cyst of Moll 109.47–8
 cyst of Zeiss 109.47, 109.48
 cysteine protease 8.56
 cysteinyl leukotrienes 8.49
 cystic fibrosis
 acrodermatitis enteropathica 63.25
 sweat electrolytes 94.4
 cystic hygroma, Turner syndrome 105.35
 cysticercosis 33.30–1

- cytochrome P450 (CYPs) 14.3
 drug interactions 14.8
 drugs as pro-haptens 12.4
 protease inhibitor effects 31.11
- cytodiagnosis 3.25–6
 cytokeratin(s) 58.7
 immunopathology 3.18–19
 cytokeratin 7 (CK-7), Paget disease
 diagnosis 3.19–20
 cytokeratin 20 (CK-20), Merkel cell
 carcinoma diagnosis 3.19
 cytokines 8.32
 antibodies causing
 immunodeficiency 148.16, **148.17**
 anti-inflammatory 8.32, 8.35–6
 biological therapies against 19.29–32
 cascades in bacterial infections 26.6
 expression by NK cells 8.16
 immune response role 8.32
 immunity against ringworm 32.21
 inducible NOS regulation 8.46
 inflammation 8.2, 8.32, **8.33–4**
 inhibitors 8.35–6
 keratinocyte function regulation 8.4–5
 mast cell 8.21
 mutations **148.18**
 pro-inflammatory 8.32, 8.58
 release by Langerhans cells 2.14
 signalling in macrophages in
 inflammatory dermatoses 8.23
 suppressors 8.35–6
 tissue repair and metastatic spread
 role 147.5
 wound healing 10.2, 10.3, **10.4**
- cytomegalovirus (CMV) 25.36–7
 complications/comorbidities 25.37
 congenital 25.36
 neonatal lupus erythematosus
 differential diagnosis 116.13
 disseminated infection 25.36
 epidemiology 25.36
 high-power microscopy 3.33
 HIV infection 31.23–4
 immune restoration disease 31.24, 31.36
 infectious panniculitis 99.44
 investigations 25.37
 management 25.37
 oral lesions 110.51, 110.52
 papular-pruritic gloves and socks
 syndrome 25.87
 perineum/perianal region 113.11
 primary mononucleosis 25.36
 systemic sclerosis 56.11
 vulval lesions 112.28
- cytophagic histiocytic panniculitis 99.58–9
 cytotoxic agents
 topical 18.26–8
see also chemotherapy
 cytotoxic T lymphocyte-associated protein
 4 (CTLA-4) 143.30
 cytotoxic T lymphocytes (CTLs) 8.27,
 8.31, 31.5
 erythema multiforme 47.4, 47.5
 melanocyte-specific 88.36
- D**
- dabrafenib 143.32
 dacarbazine, melanoma treatment 143.34
 dactylitis
 sarcoid 98.12
 chronic 154.8
 syphilitic 29.30, 29.31
- Dandy–Walker syndrome, facial
 haemangiomas 110.15
- dapsone 18.10, 19.13–15
 acne conglobata treatment 90.56
 acne fulminans treatment 90.53
 adverse effects 19.14–15
 anti-p200 pemphigoid treatment 50.40–1
 α_1 -antitrypsin deficiency panniculitis
 treatment 99.43
 bullous systemic lupus erythematosus
 treatment 50.48, **50.49**, 51.26
 cautions 19.15
 comedonal acne treatment 90.40
- contraindications 19.15
 dermatitis herpetiformis 50.54, **50.55**
 dermatological uses 19.13
 dose 19.15
 drug eruptions 31.17
 drug–drug interactions 19.15
 eosinophilic pustular folliculitis
 treatment 93.8
 epidermolysis bullosa acquisita
 treatment 50.46
 erythema elevatum diutinum
 treatment 102.10
 hypersensitivity syndrome 19.15
 leprosy treatment 28.14, 28.15
 linear IgA disease treatment 50.37, **50.38**
 monitoring 19.15
 mucous membrane pemphigoid
 treatment 109.33
 papulopustular acne treatment 90.40
 pemphigus treatment 50.9
 pharmacological properties 19.13–14
 pre-treatment screening 19.15
 regimens 19.15
 Sweet syndrome treatment 49.12
 urticarial vasculitis treatment 44.5
- daptomycin 19.43
 DARE database 17.6
 Darier disease 66.1–4, 66.5, 66.6–9
 blistering 71.24
 classification 66.1
 clinical features 66.3–4, 66.5, 66.6–9,
 112.5
 carbon dioxide laser ablation 23.18
 co-morbidities 66.7–9
 complications 66.7–9
 confluent and reticulated papillomatosis
 differential diagnosis 87.7
 cytodagnosis 3.26
 definition 66.1, 112.5
 differential diagnosis 66.4, 66.6, 112.5
 disease course 66.9
 dyskeratosis 66.2
 epidemiology 66.1, 112.5
 Flegel disease differential
 diagnosis 87.17
 genetic mutations 66.1–2
 genital papular acantholytic
 dyskeratosis differential
 diagnosis 112.43
 Hailey–Hailey disease differential
 diagnosis 66.12
 investigations 66.9
 keratosis pilaris differential
 diagnosis 87.10
 lichen striatus differential
 diagnosis 37.20
 longitudinal erythronychia 95.15
 management 66.9, 112.5
 carbon dioxide laser ablation 23.18
 radiotherapy 24.6
 mosaicism 66.4, 66.6
 nail lichen planus differential
 diagnosis 95.45
 nails 95.43
 neuropsychiatric features 66.8–9
 nomenclature 66.1
 oral lesions 110.17
 pathophysiology 66.1–3
 pemphigus vulgaris differential
 diagnosis 50.7
 presentation 66.3–4, 66.5, 66.6, 66.7
 prognosis 66.9
 radiotherapy 24.6
 scrotal squamous cell carcinoma 111.20
 seborrhoeic dermatitis differential
 diagnosis 40.4
 severity classification 66.6–7
 spiny keratoderma differential
 diagnosis 65.52
 tattoo association 123.21
 treatment ladder **66.9**
 variants 66.4, 66.7, 66.8
 vulval 112.5
- Darier sign 46.4, 46.5, 46.7
 pruritus 83.8
- Darier–Roussy sarcoid 99.50
 darkling beetles 34.29
 daunorubicin, hyperpigmentation
 induction 120.8
 day care 41.8
 D-dimer, venous malformation 73.11
 De Barsy syndrome 79.6
 De Lange syndrome *see* Cornelia de Lange
 syndrome
 deafness
 keratitis–ichthyosis–deafness
 syndrome 65.30–2
 periauricular cysts/sinuses 117.12
 systemic lupus erythematosus 51.29
 death fever *see* leishmaniasis, visceral
 decision making, economic burden of
 disease 6.9
 decongestive lymphatic therapy (DLT) 105.9
 abdominal wall lymphoedema 105.21
 genital lymphoedema 105.19
 trauma-induced lymphoedema 105.50
 decorsin 2.40
 deep ‘aggressive’ angiomyxoma 137.64
 deep vein insufficiency 103.36
 deep vein thrombosis (DVT) 103.28–30,
 147.26
 causes **103.28**, 103.29
 cellulitis differential diagnosis 26.20,
 26.21
 clinical features 103.29
 definition 103.28
 epidemiology 103.28
 immobility-induced
 lymphoedema 105.51
 investigations 103.29, **103.30**
 management 103.29–30
 pathophysiology 103.28–9
 recurrent cellulitis differential
 diagnosis 105.12
 risk factors **103.28**
 Wells scoring system 103.29, **103.30**
- deer flies 34.7
 defensins 2.12, 2.43, 8.13, 8.14, 26.5
 α -defensins 8.13, 8.14
 β -defensins 8.13
 θ -defensins 8.13
 defibrillators, implantable, skin
 problems 150.6
 deficiency of interleukin 1 receptor
 antagonist (DIRA) 45.7
 acne association 154.10
 deficiency of interleukin 36 receptor
 antagonist (DITRA) 45.8, 45.11
 Degos acanthoma *see* clear cell acanthoma
 Degos disease (malignant atrophic
 papulosis) 101.23–4, 111.18
 systemic lupus erythematosus 51.25
 dehydroepiandrosterone (DHEA) 145.18,
 149.18
 prepubertal acne 90.61
 delayed hypersensitivity 8.60
 drug reactions 41.32
 erythema induratum of Bazin 99.27
 erythema multiforme 47.2
see also erythema nodosum
 delayed tests 4.24, 4.25
 deliberate self-harm 86.30–1
 Dellemann syndrome 137.58
 deltanoids 18.23–6
 delusional beliefs 86.4–10
 infestations 86.4–7, 86.8
 Morgellons syndrome 86.9–10
 olfactory 86.8–9
- Demodex*
 HIV infection 31.28
 rosacea association 91.4, 91.5
Demodex folliculorum 34.52–4, 109.10,
 109.13
Demodicidae 34.52–4
 dendrite surveillance extension and
 retraction cycling habitude
 (dSEARCH) 2.14
 dendritic cell disorders 136.1, 136.2–8
 dendritic cells 2.15
 antigen presentation 8.28
- early-phase allergic response 8.58
 HIV infection 31.5
 IFN actions 8.34–5
 immature 8.29
 inflammation role 8.2
 maturation 8.35
 non-Langerhans cell 8.29
 plasmacytoid 8.29
 T-reg actions 8.35
- dendritiform keratopathy 109.40
 dendrocyte hamartoma, medallion-like
 dermal 116.10–11
 dendrolimiasis 34.31
 dengue fever 25.73–4
 gingival bleeding 110.48
 measles differential diagnosis 25.85
 mortality 5.8
 dengue haemorrhagic fever 25.74
 dengue shock syndrome 25.74
 denileukin diftitox 140.26–7
 Dennie–Morgan fold 41.22
 dental amalgam
 lichen planus 37.3
 mercury toxicity 128.18
 dentifrices, cheilitis 110.82–3
 dentition 110.3–4
 dento-gingival junction 110.4
 denture(s), allergic reactions 128.18
 denture-induced hyperplasia 110.59
 denture-related stomatitis 110.69–70
 angular cheilitis association 110.80
 depigmentation
 allergic contact dermatitis 128.60–1
 chemical 88.45–6
 onchocerciasis 33.4–5
 radiotherapy-induced 120.14
see also hypopigmentation
 depigmenting agents 18.28–9
 depilatories 18.29
 deposition disorders, malignancy
 association 147.22–3
 depression 11.1, 11.2, 11.3–4, 86.32–3
 acne vulgaris 90.34–5
 hidradenitis suppurativa 92.9
 integrated management 11.8
 isotretinoin association 86.34–5, 90.46–7
 lichen simplex association 39.30
 peno-scrotodynia association 84.8
 pyoderma gangrenosum
 association 49.2
 seborrhoeic dermatitis association 40.4
 solar urticaria association 127.23
 vulvodinia association 84.8
 xeroderma pigmentosum 78.6
- Dercum disease **74.8**, 100.15–17
 benign symmetrical lipomatosis
 differential diagnosis 100.15
 clinical features 100.16–17
 epidemiology 100.15–16
 investigations 100.17
 lipoedema differential
 diagnosis 105.31–2
 management 100.17
 obesity association 100.15, 100.26
 pathophysiology 100.16
 variants 100.16
- dermabrasion, actinic keratosis
 treatment 142.11
 dermal artefact 86.27
 dermal deposits, histological sections 3.39
 dermal erythropoiesis 116.20
 dermal mucinosis 59.2–15
 cutaneous focal mucinosis 59.14–15
 digital myxoid cyst 59.15, 59.16
 lichen myxoedematosus 59.2–8
 myxoedema in thyroid disease 59.11–13
 papular and nodular mucinosis in
 connective tissue disease 59.13–14
 reticular erythematosus
 mucinosis 59.8–9
 scleredema 59.9–11
 self-healing cutaneous mucinosis 59.14
 dermal nerve sheath myxoma 137.50
 dermal non-neural granular cell
 tumour 137.62–3

- dermal pigmentation, laser treatment 23.14
- dermal-epidermal junction 2.2, 2.21
- barrier 129.3
- hemidesmosomes 2.25
- Dermatophagoides 34.52
- dermatitis
- arsenic 122.2, 122.3
 - beryllium 122.8
 - caterpillar 34.30
 - chronic acral 39.14
 - chronic superficial scaly 39.26–7
 - development 128.9
 - exfoliative 39.30–5
 - in Hodgkin disease 140.49
 - malignancy association 147.23
 - eyelids 39.21
 - gangrenosa infantum 26.83–4
 - granulomatous periorificial of childhood 91.18, 91.19
 - periorificial dermatitis differential diagnosis 91.18
 - haemosiderosis 88.49
 - halo 39.27–8
 - infective 39.22–4
 - HTLV-1-associated of children 39.24
 - interdigital 39.17
 - lichenoid 37.14–15
 - localized, Compositae allergy 128.52
 - lower legs 39.18–21
 - nails 95.44
 - non-infectious 140.36
 - nummular 39.7–9, 39.14
 - chronic superficial scaly dermatitis differential diagnosis 39.27
 - clinical features 39.8–9
 - definition 39.7
 - differential diagnosis 39.8–9
 - epidemiology 39.7
 - infection 39.8
 - investigations 39.9
 - lower leg 39.20
 - management 39.9
 - pathophysiology 39.7–8
 - pityriasis alba differential diagnosis 39.25
 - variants 39.8
 - passivata 86.29
 - perioral 18.7, 90.29
 - perioral/periorificial facial 91.17–18
 - papulopustular rosacea differential diagnosis 91.11, 91.18
 - photodynamic therapy 22.13
 - photosensitivity 127.13
 - Pyometes mites 34.49
 - retinoid 90.46, 90.48
 - schistosomiasis 33.25
 - simulate 86.28
 - stasis 39.19
 - vegetans 26.83
 - see also allergic contact dermatitis; atopic eczema (dermatitis); contact dermatitis; eczema; hand eczema; irritant contact dermatitis; photoallergic contact dermatitis
- dermatitis artefacta 86.23–8
- acné excoriée differential diagnosis 86.16
- with artefact of patch tests 86.26
- cicatricial pemphigoid differential diagnosis 50.51
- clinical features 86.24–7
- complications/co-morbidities 86.27
- epidemiology 86.23
- of genitalia 111.8
- investigations 86.27
- management 86.28
- pathophysiology 86.23–4
- variants 86.25–7
- Dermatitis Family Impact (DFI) Questionnaire 16.7
- dermatitis herpetiformis 5.10, 50.52–4, 50.55
- bullous pemphigoid differential diagnosis 50.21
 - bullous systemic lupus erythematosus differential diagnosis 50.48
 - clinical features 50.53–4
 - complications/co-morbidities 50.54
 - cytodiagnosis 3.26
 - definition 50.52
 - diabetes associations 64.4
 - diagnosis 50.54
 - dietary gluten 50.53
 - disease course 50.54
 - epidemiology 50.52–3
 - gluten-sensitive enteropathy association 50.52–3
 - immunopathology 3.18
 - immunostaining 110.46
 - investigations 50.54
 - iodine exposure 50.53
 - lichen planopilaris association 37.12
 - linear IgA disease differential diagnosis 50.36
 - malignancy association 147.22
 - management 50.54, 50.55
 - nomenclature 50.52
 - oral ulceration 110.42
 - pathophysiology 50.53
 - prognosis 50.54
 - recurrent cutaneous necrotizing eosinophilic vasculitis differential diagnosis 102.11
 - subcorneal pustular dermatosis differential diagnosis 49.15
- Dermatobia hominis* 34.11–12
- dermatofibromas 137.19–21
- surgery 20.46
- dermatofibrosarcoma protruberans (DFSP) 3.21–2, 137.14–16
- clinical features 137.15
 - definition 137.14
 - epidemiology 137.14
 - fibrosarcomatous 137.15
 - keloid differential diagnosis 96.48
 - management 137.15–16
 - pathophysiology 137.14–15
 - radiotherapy 24.14
- dermatofibrosis lenticularis pseudoxanthoma elasticum differential diagnosis 72.30
- see also Buschke–Ollendorff syndrome
- dermatological health services
- research 5.10–12
 - available services 5.11–12
 - needs assessment 5.11
 - need/supply/demand relationship 5.12
- dermatological non-disease, genital 111.36
- dermatological pathomimicry 86.28–9
- Dermatology Life Quality Index (DLQI) 6.4, 16.4, 16.5, 16.6
- dermatomyofibroma 137.8
- dermatomyositis 53.1–12, 147.19–20
- acanthosis nigricans association 88.21
 - allergic contact dermatitis differential diagnosis 128.61
 - amyopathic 53.1, 147.20
 - systemic lupus erythematosus differential diagnosis 51.27
 - antisynthetase antibodies 151.3
 - autoantibody specificity 147.20
 - cardiac involvement 150.4
 - classification 53.1
 - clinical features 53.3–10
 - clinically amyopathic 53.1, 53.9
 - complications/co-morbidities 53.10
 - definition 53.1
 - differential diagnosis 53.10
 - disease course 53.10
 - drug-induced 53.9–10
 - epidemiology 53.2
 - eyelids 53.5
 - face 53.4–5
 - histopathology 53.3
 - hypertrichosis 89.63
 - hypomyopathic 53.1
 - inclusion body 53.1
 - investigations 53.10–11
 - lichen planus association 37.13
 - bulles
 - management 53.11–12
 - muscle
 - histopathology 53.3, 53.4
 - investigations 53.11
 - signs 53.8
 - nail fold 53.5–6
 - panniculitis association 53.8, 99.36, 99.38
 - pathophysiology 53.2–3
 - periocular oedema 105.16
 - pigmentation 88.21
 - presentation 53.3–9
 - prognosis 53.10
 - proximal nail fold capillaroscopy 95.52
 - respiratory disease association 151.2
 - respiratory features 53.8–9
 - severity classification 53.10
 - skin histopathology 53.3
 - skin signs 53.3–8
 - telogen effluvium 89.26
 - variants 53.9–10
 - see also juvenile dermatomyositis; mixed connective tissue disease
- dermatopathia pigmentosa
- reticularis 70.13–14
- dermatopathology 3.1
- artefacts 3.27–8
 - descriptive terms 3.33–9
 - histological sections revealing little/no abnormality 3.39–40
 - histopathology skin report 3.33
- Dermatophagoides pteronyssinus* 34.48
- dermato-pharmacokinetic (DPK) method for topical products 13.7
- dermatophytes
- adherence to keratinocytes 32.21
 - allergic response 32.50–1
 - anthropophilic 32.19–20
 - biology 32.20–2
 - classification 32.18
 - epidermis invasion 32.21
 - geophilic 32.19
 - immunity against 32.21–2
 - onychomycosis 32.47–9
 - parasitism 32.20–1
 - penetration 32.21
 - perineum/perianal region 113.11
 - remote reaction 39.27
 - superficial mycoses caused by 32.35–51
 - taxonomy 32.19
 - zoophilic 32.19, 32.20
- dermatophytide reactions 32.50–1, 39.27
- dermatophytosis 32.18–35
- co-morbidities 32.22
 - erythema annulare centrifugum 47.9
 - erythroderma 39.33
 - hand eczema 39.17
 - HIV infection 31.26
 - children 31.35
 - identification 32.23, 32.24–5, 32.25–8, 32.29–30, 32.30–2
 - immunity against 32.21–2
 - Kaposi sarcoma differential diagnosis 31.29
 - Langerhans cell histiocytosis differential diagnosis 136.6
 - leprosy differential diagnosis 28.11
 - lower leg eczema differential diagnosis 39.20
 - management 32.32–5
 - pathophysiology 32.22–3
 - physiological tests 32.23
 - prevention 32.32–3
 - pseudofolliculitis differential diagnosis 93.2
 - psoriasis differential diagnosis 31.15
 - therapeutic agents 32.33–4
 - topical therapy 32.33, 32.34
 - failures 32.34–5
- dermatoporosis, ageing of skin 96.1, 155.9
- dermatoses
- affecting nails 95.38–46
 - corticosteroid-induced rosacea-like 91.16–17
 - eye 109.1–5
 - flagellate 120.8
 - internal malignancy association 147.18–24
 - perforating 96.49–53
 - photoaggravated 127.1, 127.31
 - pigmented purpuric 101.8–10
 - prurigo nodularis 83.19
 - pruritus 83.8–9
 - rosacea relationship 91.15–19
 - dermatosis papulosa nigricans 133.3, 133.4, 133.5
 - eyelid 109.48
 - dermcidin 26.5
 - Dermestidae 34.30
 - dermis 2.2, 13.1
 - blood supply 2.2
 - cell–cell adhesion during inflammation 8.9–13
 - development 2.5
 - embryonic 2.3–4
 - extracellular matrix 2.27–8
 - immune surveillance 2.15
 - inflammation cellular components 8.6
 - mechanical function 123.5
 - resident T cells 2.15
 - dermographism 42.8–10
 - black 42.10
 - cholinergic 42.10
 - cold urticaria association 42.11
 - delayed 42.10
 - diagnosis 123.3
 - genital 111.36
 - symptomatic 42.8–10
 - urticaria 42.14, 47.9–10, 47.11
 - white 41.14, 42.10
 - dermoid cysts 110.10, 113.4, 117.12
 - genital 111.27
 - dermopanniculosis deformans 100.23
 - dermoscopy 4.20–1
 - melanoma 144.1, 144.2, 144.5, 144.6–7, 144.7, 144.8, 144.9, 144.10–12
 - naevi 144.1–2
 - scabies mite identification 4.22
 - short-term digital dermoscopic monitoring 144.5
 - deroofing, hidradenitis suppurativa management 92.10
 - descending perineum syndrome 113.32
 - desmin 3.21
 - desmocollin(s) 2.18
 - desmocollin 3 71.5
 - desmoglein(s) 2.18, 2.19
 - desmoglein compensation hypothesis 50.2
 - desmoglein 1 50.2, 50.3, 65.50, 71.5
 - desmoglein 3 50.2–3, 50.3
 - desmoplakin 71.3, 71.10, 71.24
 - Carvajal–Huerta syndrome 65.56
 - striate palmoplantar keratoderma 65.50
 - desmoplasia 3.35
 - desmoplastic fibroblastoma 137.12
 - desmoplastic trichoepitheliomas 138.10–11
 - desmosome 2.35
 - desmosomes 2.18–19
 - desquamation 2.7
 - en aires 39.15
 - neonates 116.3
 - detergent 128.17
 - barrier disruption 129.3
 - exposure reduction regulations 128.2
 - detergent acne 90.17
 - Dettol 128.38–9
 - Deuteromyces* 28.3, 28.5, 32.3, 32.5
 - developmental abnormalities 75.19–23, 117.12–13
 - ano-genital region 113.4
 - fistulae, hidradenitis suppurativa differential diagnosis 113.21
 - see also naevi, congenital; named congenital conditions
 - Devon colic 122.4–5
 - diabetes 64.1–7
 - actinic granuloma association 96.25
 - alopecia areata association 89.29
 - benign symmetrical lipomatosis association 100.14

- diabetes (*continued*)
 bullae 64.7, 87.28, 87.29
 calluses 123.7
 control 85.6
 cutaneous complications 149.14
 dermatopathy 64.2
 disease associations 64.4
 dyslipidaemia 62.11
 endocrine disorder skin signs 149.11, 149.11, 149.13, **149.14**
 erythrasma association 26.39
 familial partial lipodystrophy association 74.2
 fat hypertrophy 100.12
 Flegel disease association 87.17
 furunculosis 26.23–4
 genetic syndromes 64.4
 granulomatous disorders 64.5–6
 hyperlipidaemia-related skin disease 64.3
 infections 64.3
 insulin sensitivity 99.5
 interstitial granulomatous dermatitis association 154.14
 lichen planus 37.13
 multicentric reticulohistiocytosis association 136.24
 necrobiosis lipoidica association 64.5, 97.8
 neurological damage 64.2
 obesity 64.3
 palmar fascial fibromatosis 96.31
 palmoplantar pustulosis association 35.38
 perforating dermatitis 96.49, 96.50, 96.51
 pruritus 83.12
 pruritus ani differential diagnosis 113.5
 pseudoscars 96.12
 psoriasis association 35.21
 pyoderma gangrenosum association 49.2
 scleredema association 59.9, 59.10
 toxic shock syndrome association 26.30
 treatment-related skin manifestations 64.4
 type 1, dermatitis herpetiformis association 50.53
 vascular damage 64.1–2
 wound healing 10.9
see also neuropathic ulcer
- diabetes insipidus, Langerhans cell histiocytosis association 136.5
 diabetic dermopathy 96.12
 diabetic embryopathy syndrome 108.3
 diabetic foot 64.2
 wound healing 10.9
 diabetic thick skin 96.42
 diabetic ulcers 85.4–7
 healing 10.2
 diagnosis 4.1
 additional clinical examination 4.19–26
 simple 4.18–19
 cultural factors 4.4
 data collation 4.2
 dietary factors 4.3
 disease definition 4.1–2
 distribution of lesions 4.6
 duration of symptoms 4.3
 ethnicity 4.4
 evolution of symptoms 4.3
 examination of skin 4.5
 family history 4.4
 history taking 4.2
 imaging 4.20–2
 internet use 4.26
 leisure factors 4.4
 medications 4.3
 occupational factors 4.4
 presenting complaint 4.2–5
 psychological factors 4.4–5
 quality of life 4.5
 radiological examination 4.22
 skin lesion description 4.5–17
 skin palpation 4.17–18
 skin testing techniques 4.23–5
 social factors 4.4–5
 symptoms 4.2–3
 teledermatology 4.25–6
 travel history 4.4
 diagnostic criteria 4.1–2, 5.4–5
 diagnostic tests, clinical trials 17.15–16
 dialysis *see* haemodialysis
 diascopy 4.19
 diastematomyelia, lumbosacral hypertrichosis 89.62
 diazolidinyl urea 128.34
 diclofenac
 actinic keratosis treatment **142.8**, 142.9, 146.15
 Bowen disease treatment 142.23
 topical 18.26–7
 Dictyoptera 34.30
 didanosine, drug eruptions 31.18
 dietary factors 5.10
 acne vulgaris 90.13, **90.14–15**
 atopic eczema 41.7
 diagnosis of skin disease 4.3
see also food(s)
- diethylcarbamazine
 loiasis treatment 33.11
 lymphatic filariasis treatment 33.9, 105.45
 streptocerciasis treatment 33.6, **33.7**
 visceral larva migrans treatment **33.20**
- Dietzia papillomatosis* 87.6
 diffuse alveolar damage 53.9
 diffuse infiltrative lymphocytosis syndrome (DILS) 154.3
 diffuse large B-cell lymphoma 140.37, 140.41–3
 clinical features 140.42–3
 definition 140.41
 epidemiology 140.42
 immunophenotype 140.42
 investigations 140.43
 management **140.38**, 140.43
 pathophysiology 140.42
 systemic lupus erythematosus association 147.21
 diffuse lymphangiomatosis 137.41
 diffuse neurofibroma 137.49
 diffuse plane xanthomatosis 136.18, 136.19
 DiGeorge syndrome 82.8, **148.17**
 candidosis association 148.14
 digestive system disorders 152.1–9
 gastrointestinal bleeding **152.7**
 intestine 152.1–4
 oesophagus 152.1–4
 stomach 152.1–4
 systemic disease association 152.6–9
 digger's itch 131.2
 digit(s)
 acral fibromyxoma 137.62
 camptodactyly 96.37–8
 constricting bands of the extremities 96.43–5
 fibrous nodules 96.40
 fused
 in Kindler syndrome 71.19
 in recessive generalized severe dystrophic epidermolysis bullosa 71.17
 necrotic in herpes simplex virus (HSV) 31.22
 systemic sclerosis 56.13, 56.18, **56.21**
 ulceration in systemic sclerosis 56.4, 56.13, 56.18
see also fingers; toe(s)
- digital ischaemia
 malignancy association 147.24
 paraneoplastic 147.24
 digital mucous cyst 137.62
 digital myxoid cyst 59.15, 59.16
 digital myxoid pseudocyst 95.24–5, **95.26**
 dihydropyrimidine dehydrogenase 18.26
 dihydrotestosterone (DHT), male balding 89.17
 dihydroxyacetone 18.35
 dilated cardiomyopathy, neonatal lupus erythematosus 51.38
 diltiazem
 acute generalized exanthematous pustulosis predisposition 119.2, **119.4**
 cutaneous sclerosis induction 96.43
 dimethylfumarate 19.16
 dimethylsulfoxide (DMSO) 129.3, 129.4
 penetration enhancer 18.7, 18.8
 dimeticone 18.13
 dinitrochlorobenzene (DNCB) 128.5, 128.6, 128.7
 mucous membrane application 128.18
 sensitivity capacity 128.10
 sensitizing agent use 18.30
 Diogenes syndrome 86.29
 dioxins 130.11
 chloracne 90.58
 intoxication 90.58
 management 90.59
 dipeptidyl peptidase IV (DP IV) 8.42
 diphenacylprone, sensitizing agent use 18.30
 diphenhydramine 18.33
 diphtheria **26.37**, 26.38–9
 cutaneous 26.38, 26.39
 faucial 26.38
 toxins 26.38, 26.39
 umbilical infection 116.25
 diploid/triploid mosaicism **74.5**
 diploidy 7.5
 Diplopoda 34.54–5
 Diptera 34.6–12
 classification 34.6–7
 diseases **34.6**
 clinical features 34.7–8
 management 34.8
 pathology 34.7
see also myiasis
- Dipylidium caninum*, enterobiasis differential diagnosis 33.14
 direct immunofluorescence (DIF) technique 3.11, 3.12, 3.13
 dirofilariasis 33.22
 dirt phobias 86.20
 disability 86.4
 caused by skin disease 5.5
 years lost to 5.6–7
 disability adjusted life years (DALYs) 6.3, 6.4
 disabling pansclerotic morphea of children 99.13
 discoid dermatitis **142.20**
 discoid lupus erythematosus (DLE) 51.1–11, 89.40–1
 acquired catarrhal alopecia 89.36
 actinic keratosis differential diagnosis 142.4
 annular atrophic plaques 51.5
 associated diseases 51.2–3
 chronic blepharitis **109.12**
 cicatricial alopecia 89.40, 89.41
 classification 51.1–2
 clinical features 51.4–5, 51.4–10, 89.41
 definition 51.2
 differential diagnosis 51.9
 disease course 51.10
 disseminated 51.6–7
 epidemiology 51.2–3
 erythema multiforme differential diagnosis 47.5
 follicular mucinosis association **107.7**
 frontal fibrosing alopecia association 89.39
 genetic factors 51.4
 immunostaining **110.46**
 investigations 51.10
 lichen planus of nails 95.45
 lip manifestations 110.88
 localized disease 51.4–5
 lymphocytoma cutis differential diagnosis 135.9
 management 19.5, 51.10–11, 89.41
 mixed lichen planus pattern 37.9, 37.18
 otitis externa association 108.16
 pathophysiology 51.3, **51.4**, 89.40–1
 pinna **108.13**, **108.14**
 predisposing factors **51.3**
 primary immunodeficiency 82.3
 prognosis 51.10
 severity classification 51.9–10
 tattoo association 123.21
 tinea faciei differential diagnosis 32.42
 variants 51.7–9
 disfigurement, diagnosis 4.3
 dissecting cellulitis of scalp 92.2, 107.8–9
 disseminate and recurrent
 infundibulofolliculitis 93.6–7
 disseminated Calmette-Guérin infection 31.35
 disseminated gonococcal infection (DGI) 30.3, 30.4, 30.6
 prognosis 30.7
 disseminated intravascular coagulation (DIC)
 antiphospholipid syndrome differential diagnosis 52.2
 haemorrhage 101.18
 thrombophlebitis migrans 103.32
 disseminated lichenoid papular dermatosis of AIDS 95.45
 disseminated superficial actinic porokeratosis (DSAP) 65.67, 87.18, 87.19, 87.20, 87.21, 142.14–16
 clinical features 142.15–16
 definition 142.14
 differential diagnosis 142.16
 epidemiology 142.15
 genetics 142.15
 investigations 142.16
 management 142.16
 pathophysiology 142.15
 variants 142.16
 disseminated superficial porokeratosis of childhood 65.67–8
 of immunosuppression 65.67
 dissociation constant, irritants 129.3
 distress 11.2
 beliefs role 11.2–3
 emotional 11.3
 management 11.2
 psoriasis 11.6
 dithranol 18.35
 hair pigmentary changes 89.71
 plaque psoriasis 35.24
 side effects 18.35, **18.36**
 diuretics, pruritus induction 83.12
 DMDM hydantoin 128.35
 DNA 7.1, 7.2
 free fetal 7.10
 hypermethylation 7.6
 methylation 7.5, 7.6
 polymorphisms 7.6
 replication 7.5
 DNA damage
 basal cell carcinoma 141.3
 p53 induction 9.8
 repair 9.5–6
 failure in xeroderma pigmentosum 9.6
 tanning association 88.9
 UVR exposure 9.13
 DNA markers 7.8–9
 DNA repair disorders 78.1–12, 82.11
 ataxia telangiectasia 78.11
 Fanconi anaemia 78.11
see also Cockayne syndrome; trichothiodystrophy; xeroderma pigmentosum
 DNA viruses **25.2–3**, 25.4
 DOCK8 deficiency 82.9–10
 DOCK8 gene mutations 146.2
 dog bites 131.5–6
 dolutegravir 31.10
 dominant/recessive dystrophic bullous dermolysis of the newborn **71.14**, 71.15–16
 donkeys, glanders infection 26.53–4
 donor-derived cells, skin cancer 146.9

- Donovan bodies 30.25
 donovanosis
 HIV infection 31.22
 perineum/perianal region 113.12
 dopamine agonists, restless legs syndrome management 85.17
 dopamine, hair follicle effects 149.15
 Dowling–Degos disease 70.3, 70.14
 Darier disease differential diagnosis 66.4
 hidradenitis suppurativa association 92.2
 transient acantholytic dermatosis differential diagnosis 87.23
 vulval lesions 112.21–2
 Down syndrome 76.1–2, 108.3
 elastosis perforans serpiginosa association 96.52, 96.53
 fissured tongue 110.21
 lip fissures 110.88
 macroglossia 110.60
 microtia 108.4
 oral lesions 110.24
 doxepin 18.33
 solar urticaria 127.23
 doxorubicin
 drug eruptions 31.18
 nail colouration 95.14
 doxycycline
 α_1 -antitrypsin deficiency panniculitis treatment 99.43
 onchocerciasis treatment 33.6
 D-penicillamine
 adverse reactions 154.15
 copper deficiency 2.36
 dracunculiasis 33.11–13
 clinical features 33.11–12
 definition 33.11
 epidemiology 33.11
 investigations 33.12
 management 33.12–13
 nomenclature 33.11
 pathophysiology 33.11
Dracunculus medinensis 33.11, 33.13
 life cycle 33.12
 DRESS *see* drug reaction with eosinophilia and systemic symptoms (DRESS)
 drilling fluid, perforating dermatosis 96.51
 drug(s)
 absorption 14.2–3
 active pharmaceutical ingredient 13.6
 administration routes 14.2–3
 affinity for receptor binding 14.3
 age effects 14.7
 bioavailability 13.5–7
 bioequivalence 13.5–7
 biological activation 14.5
 choice 14.6–7
 clinical pharmacology 14.1–12
 conception effects on therapeutic outcome 14.7
 cream formulations 13.5
 development 14.11–12
 diagnosis of skin disease 4.3
 distribution 14.3
 dose relationship with outcome 14.6–7
 excipients 128.40–2
 excretion 14.3
 extracellular mechanisms 14.4
 factors affecting therapeutic outcome 14.6–11
 fertility effects 14.8
 fragrances in 128.26
 genetic variations in targets 14.10
 hydrocarbon-based formulations 13.5
 hydrophilic 14.4–5
 idiosyncratic reactions 14.5
 interactions 14.8, 19.2
 intracellular mechanisms 14.4, 14.5
 intrinsic activity 14.3–4
 lactation effects on therapeutic outcome 14.8
 licensing procedures 14.11, 14.12
 lipophilicity 13.3–4, 13.5
 mechanisms underlying actions 14.4–5
 medical decision making 14.6–7
 medication errors 14.8–10
 metabolism 14.3
 molecular weight 13.3–4, 13.5
 novel methods of delivery 14.2–3
 oral administration 14.2
 parenteral administration 14.2
 permeability coefficients 13.3
 personalized medicines 14.10
 pharmacodynamics 14.3–6
 clinical factors affecting 14.7–8
 pharmacogenetics 14.10–11
 pharmacokinetics 14.1–3
 clinical factors affecting 14.7–8
 pharmacovigilance registries 14.6
 phase I and II reactions 14.3
 polar gel formulations 13.5
 pre-clinical identification 14.11
 pregnancy effects on therapeutic outcome 14.7–8
 product labelling 14.10
 receptor binding 14.3–4
 regulatory approval 14.12
 skin colouration 4.13
 solubility 13.3–4, 13.5
 specificity of receptor binding 14.3
 spermatogenesis effects 14.8
 subcutaneous administration 14.2
 terminology 14.1, 14.2
 topical
 allergic contact dermatitis 128.27–9, 128.30, 128.31
 sensitization avoidance 128.29
 systemic reactions 128.28–9
 toxicity 14.5–6
 transmembrane mechanisms 14.4–5
 transporters
 gene polymorphisms 14.10
 interactions 14.8
 types 14.1
 vehicles 128.40–2
 volume of distribution 14.3
see also adherence to treatment; adverse events; clinical trials; topical drug delivery
 drug abuse
 cannabis 121.1–2
 cocaine 121.2–3
 heroin use 121.3
Clostridium sordelli association 26.48
see also injecting drug abuse
 drug eruptions/reactions 14.5–6
 abnormal platelet function 101.3
 acanthosis nigricans 87.4
 acne vulgaris 90.10–12
 acquired ichthyoses 65.41
 acute generalized exanthematous pustulosis 12.3, 119.1–4
 allergic 14.5
 allergic contact dermatitis 128.12, 128.13
 differential diagnosis 128.62
 anaphylaxis 118.6–8
 angio-oedema 118.6–8
 ano-genital region 128.17
 benign 118.1–18
 cheilitis 110.83–4
 complex regional pain syndrome association 85.13
 conjunctival cicatrization 109.27
 delayed hypersensitivity 41.32
 dermatomyositis 53.9–10
 eccrine glands 94.14
 eczema 118.4–5
 erythema multiforme 47.3, 47.4
 topical medications 47.4
 erythema nodosum 19.20, 99.18, 99.20, 118.15–16
 erythroderma 39.31, 39.33
 erythromelalgia 103.7
 exanthems 31.18, 118.1–3
 exogenous photosensitizers 127.27
 flushing induction 106.2
 generalized exfoliative dermatitis 118.17–18, 119.11–12
 granuloma annulare 97.2
 hair pigmentary changes 89.71
 HIV infection 31.17–20, 31.34
 children 31.35
 mechanisms 31.18
 hypermelanosis 88.25–30
 hypertrichosis 89.62, 89.63
 topical medications 89.63
 immunological 12.1–6 (*see also* drug hypersensitivity)
 clinical phenotype 12.5–6
 HLA allel association 12.5
 immunosuppressive drug therapy-induced skin cancer 146.3–4, 146.6–7
 lichen planus 37.3
 lichenoid 118.9–11
 lichen planus differential diagnosis 112.11
 liver disease association 152.9
 localized lipotrophy with injected drugs 100.9–11
 Lyme disease differential diagnosis 26.70
 maculopapular 118.1
 morbilliform 118.1
 morphea 57.11
 multiple minute digitate keratoses 87.17
 nail colour changes 95.14
 nail shedding 95.8
 neutrophilic eccrine hidradenitis 94.14, 148.7
 ocular 109.43, 109.45–7
 ocular mucous membrane pemphigoid 109.29
 older people 14.7
 onycholysis 95.10
 oral hyperpigmentation 110.66–7
 oral lesions 110.55–6
 oral manifestations 110.89
 paronychia 95.36
 pemphigus 50.4
 penile 111.19
 perineum/perianal region 113.8, 113.9
 photosensitivity 127.26–30
 phototoxic 120.10–11
 pityriasis lichenoides differential diagnosis 135.5
 pityriasis rosea 25.90, 118.14–15
 differential diagnosis 25.91–2
 pruritus 83.12, 118.3–4
 psoriasis 35.4
 differential diagnosis 31.15
 pustular 119.1–4
 scarlet fever differential diagnosis 26.36
 seborrhoeic dermatitis differential diagnosis 40.4
 secondary dyslipidaemia 62.11
 serum sickness-like reactions 118.8–9
 severe cutaneous adverse reaction (SCAR) syndromes 119.1, 119.4
 skin-test reactivity 128.6
 solar urticaria differential diagnosis 127.22
 spontaneous reporting 14.6
 Stevens–Johnson syndrome 47.3
 subacute cutaneous lupus erythematosus 51.12
 Sweet syndrome 49.6, 49.7, 49.9, 148.6
 symmetrical drug-related intertriginous and flexural exanthem 118.4, 118.5–6
 systemic lupus erythematosus 51.19
 systemically reactivated allergic contact dermatitis 128.58–9
 telogen effluvium 89.27
 topical medications in erythema multiforme 47.4
 urticarial 42.5, 42.14, 42.16, 47.7, 118.6–8
see also fixed drug eruptions (FDEs); Stevens–Johnson syndrome; toxic epidermal necrolysis (TEN)
 drug hypersensitivity
 hapten action 12.4
 IgE-mediated 12.1–2
 infection-related danger signalling 12.4
 non-hapten actions 12.4–5
 pharmacological interaction with immune receptors 12.5
 pro-hapten action 12.4
 T-cell-mediated 12.2–4
 toxic erythema of chemotherapy differential diagnosis 120.2
 drug(s), illicit 121.1–4
 injecting 121.3–4
see also heroin use; injecting drug abuse
 drug reaction with eosinophilia and systemic symptoms (DRESS) 12.3, 12.5, 12.6, 25.37, 119.4–11
 acute generalized exanthematous pustulosis differential diagnosis 119.4
 allopurinol 119.5, 119.8, 154.10
 antiretroviral therapy effect 31.10
 antirheumatic therapies 154.14–15
 autoantibodies 119.10
 classification 119.7–8
 clinical features 119.7–10
 complications/co-morbidities 119.10
 definition 119.4–5
 diagnostic criteria 119.9
 differential diagnosis 119.10
 disease course 119.10
 drug eruptions 31.17, 31.18, 31.18
 drug-induced exanthem differential diagnosis 118.2, 118.3
 epidemiology 119.5
 genetics 119.6–7
 haptenization theory 119.5
 head and neck oedema 119.8
 herpesvirus reactivation 119.6
 investigations 119.11
 management 119.5, 119.10–11
 overlap syndromes 119.9–10
 pathophysiology 119.5–7
 prognosis 119.10
 severity classification 119.10
 variants 119.9–10
 drug-induced baboon syndrome
see symmetrical drug-related intertriginous and flexural exanthem (SDRIFE)
 drug-induced hypersensitivity syndrome (DIHS) *see* drug reaction with eosinophilia and systemic symptoms (DRESS)
 drummer's digit 123.12
 dry skin, atopic eczema association 41.23
DSG1 gene mutations 65.50
DSP gene mutations 65.50, 65.56
 Duane retraction syndrome, microtia 108.4
 Dubowitz syndrome, keloid association 96.47
 dum-dum fever *see* leishmaniasis, visceral
 dumping syndrome flush 106.8
 Dupuytren contracture 96.31–3, 137.13
 camptodactyly differential diagnosis 96.38
 keloid association 96.47
 knuckle pad association 96.34
 dyes
 clothing 128.46–7
 disperse 128.46–7
see also hair cosmetics, dyes
 dynamic psychotherapies 86.39–40
 dynorphins 83.6
 dysaesthesia
 genital 111.36
 inflammation 8.1–2
 mood stabilizers 86.38
 scalp 107.14
 dysaesthetic syndromes 84.1
 dyschromatoses 70.1, 70.3, 70.15–16
 chemical peels 159.5, 159.8, 159.9, 159.13
 symmetrica hereditaria 70.3, 70.15–16
 universalis hereditaria 70.3, 70.16
see also pigmentary disorders
 dyskeratosis 3.35–6

- dyskeratosis congenita 69.12–15, 70.12–13, 77.1–4, 82.12, 147.13–14
 acquired poikiloderma 96.10
 associated allelic disorders 77.4
 classification 70.3, 77.1
 clinical features 69.13–15, 77.2, 77.3–4, 147.13
 definition 77.1
 diagnosis 77.4
 epidemiology 146.2
 gene mutations 69.13, 147.13–14
 genetics 77.1–3
 genital leukoplakia 111.7
 investigations 69.15, 77.4
 Kindler syndrome differential diagnosis 71.19
 malignancy association 147.14
 management 69.15, 77.4
 nail lichen planus differential diagnosis 95.45
 oral lesions 110.17–18
 pathophysiology 69.13, 77.1–3
 prognosis 77.4
 variants 69.15
- dyslipidaemias
 classification 62.1, 62.2
 combined 62.7–8
 cutaneous features 62.2–11
 diabetes 62.11
 drug eruptions 62.11
 insulin resistance 62.11
 primary 62.6–10
 secondary 62.10–11
 xanthomas 62.2–6
- dysphagia
 dermatomyositis 53.9, 53.10
 systemic sclerosis 56.13, 56.15
- dyspigmentation
 ageing of skin 155.1, 155.9
 neck 155.3
 chemotherapy-induced 120.8–10
 occupational 130.12–13
 systemic sclerosis 56.4
- dysplasia 3.36
 dysproteinaemic purpura 101.7–8
 dysthymia 86.33
 dystonin epidermal isoform 71.4
 dystrophic epidermolysis bullosa 71.2, 71.14–18
 dominant
 acral 71.14, 71.15
 generalized 71.14–15
 dominant/recessive
 nails only 71.14, 71.15
 pretibial 71.14, 71.15
 pruriginosa 71.14, 71.15
 epidermolysis bullosa acquisita
 differential diagnosis 50.45
 management 71.25–7
 molecular pathology 71.18
 neonatal 71.14, 71.15–16
 pain management 71.27
 recessive 110.16
 centripetalis 71.14, 71.18
 generalized intermediate 71.14, 71.17, 71.18
 generalized severe 71.14, 71.16–17, 71.25–7
 inversa 71.14, 71.17–18
 localized 71.14, 71.18
 prenatal diagnosis 7.9
 revertant mosaicism 7.8
 wound healing 10.11
 skin grafting 71.27
 squamous cell carcinoma
 association 142.27
- E**
 ear
 ageing changes 108.6
 allergic contact dermatitis 128.16
 anatomy 108.1–2
 cauliflower 108.6, 108.7
 cerumen 108.2–3
 chondrodermatitis nodularis 108.8–10
 chromosomal abnormality
 association 108.3
 congenital ichthyoses 65.39
 contusion 108.6–7
 developmental defects 108.3–6
 earlobe creases 108.6
 elastotic nodules 96.3–4
 examination 108.3
 granuloma fissuratum 123.13–14
 haematoma 108.6–7, 123.16
 hair developmental anomalies 108.6
 hypohidrotic ectodermal
 dysplasia 67.13, 67.14
 infections 108.11, 108.15–22
 juvenile spring eruption 127.9
 keloid on lobe 96.46
 length 108.6
 low-set 108.5
 malignancy 108.23–7
 malignant external otitis 26.52
 microbiology 108.2
 nerve supply 108.2
 periauricular anomalies 108.5
 periauricular cysts/sinuses 117.12
 petrified 108.27
 physiology 108.1–2
 piercing 108.7–8, 108.8, 128.16
 complication prevention 108.8
 complications 108.7–8
 pinna shape variation 108.5–6
 pre-malignant neoplasms 108.23
 pseudocyst 108.10–11
 radiotherapy for skin cancer 24.10–11
 referred pain 108.28
 sample collection for fungal
 infections 32.8
 skin disease manifestations 108.11, 108.12–13, 108.14–15
 systemic lupus erythematosus 51.29
 traumatic conditions 108.6–7
 tumours 108.22–7
 weathering nodule 108.13, 108.15
 chondrodermatitis nodularis
 differential diagnosis 108.9
 wedge excision 20.33
 see also external auditory canal; Frank's sign; otitis externa
- earrings
 argyria 122.7
 dermatitis 128.16
 embedded 108.7
- eating disorders 86.20–1
 acne vulgaris 90.24
 alopecia 89.63
 anorexia nervosa 86.20–1, 89.63
 bulimia 86.20–1, 89.63
 hypertrichosis 89.63
 psychodermatological
 co-morbidities 86.21
- Ebola haemorrhagic fever 25.72–3
 EC Cosmetic Directive 128.9
 E-cadherin 2.4
 ecchymosis 101.1
 Bateman purpura 155.3–4
 causes 101.2
 purpura artefact 86.27
 scurvy differential diagnosis 63.22
 traumatic 101.2
- eccrine duct-blocking agents,
 hyperhidrosis treatment 94.8
- eccrine glands 2.8–9, 2.43, 138.1, 138.2
 anatomy 94.1–2
 angiomatous naevus 138.24
 C fibres 94.3
 carcinoma 138.34–5
 digital papillary
 adenocarcinoma 138.35
 eyelid 109.51
 squamoid 138.35
 cutaneous myoeptithelioma 138.33–4
 cylindroma 107.10, 138.30–1
 malignant 138.35–6
 development 2.4, 94.1–2
 digital papillary adenocarcinoma 138.35
 disorders 94.4–14, 94.15
 anhidrosis 94.10–12
 drug reactions 94.14
 with eccrine gland inclusions 94.14, 94.15
 hyperhidrosis 94.4–10
 hypohidrosis 94.10–12
 milaria 94.12–13
 neutrophilic eccrine
 hidradenitis 94.13–14
 ducts 94.2
 dermal tumour 138.25
 hidroacanthoma simplex 138.25
 milaria 116.5
 poroma 138.25–6
 syringofibroadenoma 138.26–7
 syringoma 138.27–8
 epithelioma 138.38
 hair-bearing sites 2.44
 hamartomas 138.23–9
 hidradenocarcinoma 138.36
 hidradenoma 138.29–30
 hydrocystoma 138.24
 intraepidermal sweat unit 94.2
 microcystic adnexal carcinoma 138.37–8
 mixed tumour of the skin 138.32–3
 neonates 116.2
 papillary adenoma 138.28–9
 physiology 94.2–4
 pregnancy 115.2
 secretory coil 94.2, 94.3
 sodium pump 94.2
 spiradenocarcinoma 138.36–7
 spiradenoma 138.31–2
 sweating control 94.3–4
 central 94.3
 local 94.3–4
 neonates 116.2
 tubular papillary adenoma 138.28–9
 tumours 109.51, 138.23–9
 carcinomas 138.34–40
 follicular 138.29–34
 follicular carcinoma 138.35–40
- eccrine sweating, spinal cord injury 85.10
 eccrine syringosquamous metaplasia 94.14
 Echelle de Cotation des Lésions d'Acné (ECLA) 16.3
 Echelle d'évaluation Clinique des Catrices d'Acné (ECCA) 16.3
 echinocandin antifungals 19.44
 echinococcosis 33.29–30
 Echinococcus granulosis 33.29–30
 Echinococcus multilocularis 33.29–30
 Echinoidea 131.3
 echovirus infection 25.79, 25.81
 econazole, candidosis treatment 32.61
 economic burden of disease 6.1, 6.5–9
 decision making 6.9
 psoriasis 6.7–9
 skin cancer 6.5–6, 6.7, 6.9
- Ecstasy 121.2
 ecthyma 26.16–17
 diphtheria differential diagnosis 26.38
 HIV infection 31.20
 ecthyma gangrenosum 26.52
 ano-genital 111.22, 113.11
 anthrax differential diagnosis 26.44
 ecthyma differential diagnosis 26.17
 HIV infection 31.20
 necrotizing subcutaneous infection
 differential diagnosis 26.74
 neonatal 116.26
 varicella-zoster virus differential
 diagnosis 31.23
- ectodermal dysplasia–ectrodactyly–
 macular dystrophy (EEM)
 syndrome 2.19
- ectodermal dysplasias 67.1–26
 anhidrotic 67.14
 ectrodactyly–ectodermal dysplasia–
 cleft lip/palate syndrome
 differential diagnosis 67.18
 investigations 67.14
 management 67.14–15
 classification 67.1, 67.3, 67.3–5, 67.6
 molecular approaches 67.6
 definition 67.1, 67.2–3
 epidemiology 67.6
 focal facial dermal dysplasia 67.25–6
 genetics 67.6–7, 67.10
 hidrotic 67.21–2 (see also Clouston
 syndrome)
 plantar keratoderma differential
 diagnosis 69.12
 hypohidrotic 67.1, 67.7–8, 67.11–15
 ankyloblepharon–ectodermal
 defect–cleft lip/palate syndrome
 differential diagnosis 67.16
 clinical features 67.11, 67.12–13
 complications/co-morbidities 67.14
 definition 67.11
 differential diagnosis 67.14
 epidemiology 67.11–12
 nomenclature 67.11
 pathophysiology 67.12
 severity classification 67.14
 variants 67.13
 X-linked hypohidrotic ectodermal
 dysplasia with immunodeficiency
 differential diagnosis 67.11
 molecular pathways 67.6
 mutations in TNF-like/NF- κ B signalling
 pathways 67.7–8
 nomenclature 67.1
 palmoplantar keratoderma 65.61–3
 pathophysiology 67.6–10
 scrotal cribriform atrophy 111.7
 signalling pathways 67.6
 skin fragility syndrome 71.9–10
 syndromes 2.19
 TP63-related phenotypes 67.8–9
 X-linked anhidrotic 67.1
 X-linked hypohidrotic ectodermal
 dysplasia with immunodeficiency
 (EDA-ID) 67.10–11
 genetics 67.11
 pathogenesis 67.10
 see also ankyloblepharon–ectodermal
 defect–cleft lip/palate syndrome;
 ectrodactyly–ectodermal dysplasia–
 cleft lip/palate (EEC) syndrome;
 focal dermal hypoplasia; tricho-
 dento-osseous syndrome; tricho-
 rhino-phalangeal syndrome
- ectodysplasin A (EDA) gene 67.8
 ectodysplasin A (EDA) pathway 67.7, 67.8
 ectodysplasin A receptor (EDAR) 67.8
 ectopeptidases 8.42
 ectopic ACTH syndrome 88.20, 147.17
 ectopic calcification disorders 72.26–32
 ectrodactyly–ectodermal dysplasia–cleft
 lip/palate (EEC) syndrome 67.6,
 67.7, 67.17–19, 108.3
 clinical features 67.18
 definition 67.17
 diagnostic criteria 67.18
 differential diagnosis 67.18
 epidemiology 67.17–18
 investigations 67.18
 management 67.18–19
- ectropion, harlequin ichthyoses 65.7
 eczema 39.1–7
 acute phase 39.3, 39.4
 management 39.6
 ano-genital 111.10–12
 antimony reactions 122.2
 apron 39.13–14, 39.15
 asteatotic 39.10–11, 39.20, 87.26
 transient acantholytic dermatosis
 association 87.22
 basal cell carcinoma differential
 diagnosis 141.11
 chronic 39.3, 39.4
 management 39.7
 classification 39.1–2
 clinical features 39.4–5
 complications/co-morbidities 39.5
 conditioned hyperirritability 39.5
 definition 39.1
 dermatitis herpetiformis differential
 diagnosis 50.53

- discoid 39.7–9
 DRESS differential diagnosis 119.10
 drug-induced 118.4–5
 endogenous 39.1, **39.2**
 epidemiology 39.2–3
 erythroderma 39.32
 exogenous 39.1, **39.2**
 extramammary Paget disease
 differential diagnosis 112.37,
 138.43
 eyelids 39.21
 fingertip 39.14, 39.15
 genital 128.17
 gold-induced 122.3
 hyperkeratotic
 allergic contact dermatitis differential
 diagnosis 128.62
 palmar 39.11, 39.13, 39.14
 infantile 117.2–3
 infected 39.24
 secondary 39.4, 39.6
 infective 39.22–4
 in chronic otitis externa 108.18
 HTLV-1-associated of children 39.24
 lower leg 39.20
 investigations 39.5–6
 irritant vulval 112.13–14
 juvenile plantar dermatosis 39.21–2
 lichenification 39.4
 lower legs 39.18–21
 clinical features 39.19–20
 complications/co-morbidities 39.20
 definition 39.18
 differential diagnosis 39.20
 epidemiology 39.18
 management 39.20–1
 pathophysiology 39.19
 variants 39.20
 male ano-genital 111.10
 management 39.6–7
 microbial 39.22–4
 molluscum contagiosum
 association 25.13
 mouth 41.24
 nail involvement 95.43–4
 nipple 138.42
 nomenclature 39.1
 patch testing 39.5–6
 patchy vesiculosquamous 39.15
 pathophysiology 39.3–4
 phenylketonuria 81.12
 photosensitivity 127.13
 pityriasis rosea differential
 diagnosis 39.4
 pompholyx, blistering distal dactylitis
 differential diagnosis 26.34
 post-traumatic 39.24–5
 primary immunodeficiency 82.2
 recurrent vesicular, allergic
 contact dermatitis differential
 diagnosis 128.62
 ring 39.16
 seborrhoeic vulval 112.13
 psoriasis differential
 diagnosis 112.16
 secondary dissemination 39.5
 secondary infections 39.4, 39.6
 subacute 39.3, 39.4
 management 39.6–7
 systemically reactivated allergic contact
 dermatitis 128.58
 unclassified 39.2
 varicose 39.18
 allergic contact dermatitis differential
 diagnosis 128.62
 venous in chronic venous
 insufficiency **103.38**
 vulval
 irritant 112.13–14
 seborrhoeic 112.13, 112.16
 winter 39.10–11
 see also atopic eczema; hand eczema;
 pompholyx eczema
 Eczema Area and Severity Index
 (EASI) 16.3
 eczema herpeticum 25.19, 25.39–41, 41.13,
 110.50, 110.51
 clinical features 25.39–41
 definition 25.39
 investigations 25.41
 management 25.41
 nomenclature 25.39
 education, underachievement 11.5
 Edwards syndrome 76.2
 efavirenz, drug eruptions 31.18
 eflornithine topical medication 18.29
 hirsutism 89.67
 pseudofolliculitis treatment 93.2
 e-health 11.7
 Ehlers–Danlos syndrome 72.1–8
 arthrochalasia type 72.5
 atrophic scars 96.11
 blepharochalasis differential
 diagnosis 96.25
 calcification 61.4
 classical 72.3–4
 classification 72.1
 clinical features 72.3–7
 collagen type I 2.28
 collagen type III 2.28
 collagen type V 2.29
 cutis laxa differential diagnosis 72.7,
 72.14, 96.20
 dermatoparaxis type 72.5–6
 differential diagnosis 72.7
 elastosis perforans serpiginosa 96.53
 epidemiology 72.1–2
 fibronectin-deficient type 72.6
 genetics 72.2, 72.2–3
 hypermobility type 72.4
 investigations 72.7
 keloid association 96.47
 kyphoscoliosis types 72.5, 72.7
 management 72.7–8
 Marfan syndrome association 72.1,
 72.16
 mechanical properties of skin 123.5
 Menkes disease differential
 diagnosis 63.28
 musculocontractual 72.5
 occipital horn syndrome 72.6
 pathophysiology 72.2
 periodontitis type 72.6
 periventricular nodular
 heterotopia 72.7
 piezogenic pedal papules 123.26
 pregnancy 72.8, 115.6
 progeroid 72.6–7
 congenital disorders of
 glycosylation 81.10
 with progressive kyphoscoliosis,
 myopathy and hearing loss 72.5
 spondylocheiro dysplastic form 72.5
 subtypes 72.2–3
 tenascin-X deficient 72.7
 variants 72.3–7
 vascular type 72.4–5, 72.8
 X-linked type 72.5
Ehrlichia 26.63
 ehrlichiosis 26.63, 34.38
 toxic shock syndrome differential
 diagnosis 26.31
Eikenella corrodens 26.64
 Ekbom disease 86.4
 elastases 2.36, 10.2
 elastic fibres 2.2, 2.5, 2.33–4
 components 2.34
 degradation disorders 96.19–28, 96.29
 see also acrokeratoelastoidosis;
 anetoderma; cutis laxa; elastolysis;
 pseudoxanthoma elasticum
 actinic granuloma 96.3, 96.25–7
 annular elastolytic giant cell
 granuloma 96.25–7, 97.10
 blepharochalasis 96.24–5
 granuloma multiforme 96.27
 mid-dermal elastolysis 96.23
 fibrillinopathy 72.15–17
 inherited disorders 72.11, **72.12**,
 72.13–17
 elastinopathies 72.11, **72.12**, 72.13–15
 fibrillinopathy 72.15–17
 mechanical function 123.5
 metabolic turnover 2.36
 transepithelial elimination of altered
 fibres 96.28
 elastic tissue 2.2
 acquired deposition disorders 96.29–30
 elasticity
 biological 123.5
 measurement 16.4
 elastin 2.34–6, 123.5
 production 2.35–6
 wound healing 10.8
 elastin (*ELN*) gene 2.35
 mutations 2.36, 72.14, 72.15
 elastin-associated microfibrils 2.34, 2.36–7
 elastinopathies 72.11, **72.12**, 72.13–15
 elastoderma 96.30
 elastofibroma 137.10
 dorsi 96.30
 elastogenesis, growth hormone
 role 149.16
 elastolysis
 acquired 96.19
 congenital 96.19
 generalized 96.19
 localized 96.19
 mid-dermal 96.23
 perifollicular 96.23
 upper dermal 96.24
 elastoma, congenital 75.18
 elastophagocytosis 96.19
 elastosis
 late-onset focal dermal 96.30
 linear focal 96.29–30
 elastosis perforans serpiginosa 65.69,
 96.51–3, 153.3
 annular elastolytic giant cell granuloma
 differential diagnosis 96.27
 clinical features 96.52–3
 definition 96.51
 epidemiology 96.51–2
 pathophysiology 96.52
 elastotic degeneration 3.35
 elastotic haemangioma, acquired 137.30
 elastotic nodules of the ear 96.3–4
 elbows, nail–patella syndrome 69.16
 electrical burns, acronecrosis 95.47
 electrocautery 20.40
 electromagnetic spectrum 9.1
 electron beam radiotherapy 24.1–2
 keloid treatment 24.7
 mycosis fungoides 24.14–16, 140.24
 scleredema treatment 59.11
 Sézary syndrome 140.24
 electron microscopy 3.26–7
 viral disease techniques 3.27
 electrosurgery 20.40–3
 bipolar biterminal 20.41
 characteristics 20.40–1
 currents 20.41
 effects 20.41
 electrocoagulation 20.41
 electrodessication 20.41, 20.42
 electrosection 20.41
 fulguration 20.41, 20.42
 hazards 20.41–3
 rhinophyma 20.41, 20.42
 risks 20.41–3
 elephantiasis 105.6–9, 105.52
 neurofibromatosa 80.3
 nostra of ears 108.18
 nostras verrucosa 105.20–1, 105.24–5,
 105.52
 tropical see lymphatic filariasis
 elicitation, allergic contact
 dermatitis 128.6–8
 elkonxyis 95.11
 ellagic acid, antioxidant use 156.8
 Ellis–van Creveld syndrome 67.9
 ELOVL4 deficiency 65.27
 EMBASE 17.6, 17.7
 Emberger syndrome 73.20, 105.18, 105.27,
 105.30
 emboli, purpura 101.15–20
 emilins 2.37
 emissary veins 20.3
emm genes, streptococcal infections 26.11,
 26.12, 26.35
 emollients 18.8–9
 asteatotic eczema treatment 39.11
 atopic eczema 41.29–30
 eczema treatment 39.7
 erythroderma treatment 39.35
 hand eczema treatment 39.17, 39.18
 irritant contact dermatitis 129.7
 keratolysis exfoliativa
 treatment 87.25
 pityriasis alba treatment 39.26
 pityriasis rubra pilaris treatment 36.6
 radiotherapy protection 120.13
 xerosis cutis treatment 87.27
 emopamil binding protein (*EBP*) gene
 mutations 65.20–1
 emotional abuse 117.13
 emotions
 distress 11.2–3, 11.6
 embarrassment 11.4
 management 11.2
 reactions to skin conditions 11.3
 employment, underachievement 11.5
 emulsifiers, topical drug delivery 13.9,
 18.6, 18.7
 emulsifying wax 18.7
 en coup de sabre 107.6
 encephalitis
 herpes B virus infection 25.38
 HSV infection 25.16
 varicella infection 25.25
 encephalocraniocutaneous
 lipomatosis **74.8**, 100.18–19
 lipodema of scalp differential
 diagnosis 100.23
 naevus psiloliparus 75.18
 enchondroma 73.15
 radiography 95.48
 Encode Consortium 7.1, 7.2
 endocrine disorders 149.1–22, **149.6**
 adrenal hyperfunction 149.17–18
 adrenal insufficiency 149.18
 atopic eczema 41.15
 biological basis 149.1–2, **149.3**, 149.4,
 149.4–5, 149.6–10
 clinical aspects 149.10–11, 149.12, 149.13,
 149.14, 149.15–22
 hyperandrogenism 145.18–19
 hyperoestrogenism 145.19
 hyperpituitarism 149.16–17
 hypoandrogenism 145.19
 hypo-oestrogenism 145.19
 hypopituitarism 149.16
 obesity 100.25–6
 oral manifestations **110.89**
 patient evaluation 149.10–11, 149.12,
 149.13, 149.14
 polyendocrine disease 145.20
 skin signs **149.10**, 149.11–13, 149.13,
 149.13, 149.14
 skin therapy 149.15
 see also named conditions
 endocrine signalling 149.2, **149.3**, 149.6
 complexity 149.7–8
 endocrinology principles 149.1–2, **149.3**,
 149.4, **149.5**, 149.6–10
 neuro-endocrine organ role of
 skin 149.4, **149.4–5**, 149.6–7
 end-of-life skin changes 124.8
 endometriosis, cutaneous 112.31
 endorphin(s) 83.6
 β-endorphin 74.4
 endoscopic transthoracic sympathectomy,
 flushing 106.9
 endothelial adhesion molecules 8.9
 endothelial cells
 acute phase inflammation 8.2
 high-power microscopy 3.32
 inflammation role 8.7
 endothelial growth factor receptor
 (EGFR) 2.4

- endothelial growth factor receptor (EGFR) inhibitors
- hypertrichosis 120.6
 - nail changes 120.6, 120.7
 - papulopustular eruptions 120.3, 120.4
 - pustules 107.12
 - squamous cell carcinoma management 146.14
- endothelin(s) 88.7–8
- endothelin 1 88.7–8
- functions 8.12–13
 - itching in skin disease 83.7
 - keratinocyte production 88.20
 - scleroderma renal crisis 56.15
- endothelin 3 88.8
- endothelium
- antigens 2.43
 - skin vasculature 2.41–2
- endotoxins 41.8
- end-stage organ failure, skin cancer association 146.4
- energy fluence, selective thermolysis 23.5
- enfuvirtide 31.10
- ENG gene mutations 110.14
- enkephalins 83.6
- The Enlightenment 1.3–4
- Entamoeba histolytica* 33.34–5
- perineum/perianal region 113.12
- enterobiasis 33.13–14
- Enterobius vermicularis* 33.13, 33.14
- enteroviruses 25.79–84
- infection 25.80–1
- envenomation
- Cnidaria 131.1, 131.2
 - fish stings 131.4
 - sea urchins 131.3
 - snake bites 131.5
- environmental allergies, IgE 8.56
- environmental factors
- allergic contact dermatitis 128.11
 - atopic eczema 41.6–8
- environmental pollution
- acne 90.56–7
 - allergens 8.57
 - atopic eczema association 41.7–8
- enzymatic fat necrosis 99.38, 99.39
- enzyme-linked immunosorbent assay (ELISA) 3.11
- eosin 18.33
- eosinophil cationic protein (ECP) 8.19
- eosinophil peroxidase (EPO) 8.19
- eosinophil-derived neurotoxin (EDN) 8.19
- eosinophilia
- cholesterol embolization syndrome 101.16
 - DRESS syndrome 119.8
 - gold reaction 122.4
 - loiasis 33.11
 - eosinophilia–myalgia syndrome 96.43
 - eosinophilic angiocentric fibrosis 102.13
 - eosinophilic annular erythema 47.10
 - eosinophilic cellulitis 47.10, 47.17
 - eosinophilic fasciitis 57.17, 57.23, 99.13
 - systemic sclerosis differential diagnosis 56.15, **56.16**
- eosinophilic folliculitis, HIV infection 31.16
- eosinophilic globules 3.37
- eosinophilic granuloma *see* granuloma faciale
- eosinophilic granulomatosis with polyangiitis 102.27–9
- classification 102.28, 102.29
 - clinical features 102.28, 102.29
 - definition 102.27
 - epidemiology 102.27–8
 - genital 111.21
 - granulomatosis with polyangiitis differential diagnosis 102.25
 - investigations 102.29
 - management 102.29
 - pathophysiology 102.28
 - recurrent cutaneous necrotizing eosinophilic vasculitis differential diagnosis 102.10, 102.11
 - respiratory disorder association 151.3–4
- eosinophilic pustular folliculitis 93.7–8, **93.9**, 117.11–12
- classical adult 93.8
 - immunosuppression-associated 93.8
 - infantile 93.9–10
- eosinophilic ulcer of oral mucosa 110.27
- eosinophils 8.17, 8.19
- fibrosis role 8.6
 - high-power microscopy 3.31
 - membrane 8.19
- eotaxin (CCL11) 8.38, 8.39
- ephelides 88.15–16, 132.1–3
- clinical features 132.2–3
 - definition 132.1
 - differential diagnosis 132.2–3
 - epidemiology 132.1
 - investigations 132.3
 - laser treatment 23.12
 - management 132.3
 - pathophysiology 132.1
- epidemic typhus 26.76–7
- epidemiology of skin disease 5.1–14
- analytical 5.2–3
 - association 5.8–9, 5.10, 5.13
 - causation 5.8–9, 5.13
 - climate 5.10
 - comparisons 5.2–3
 - determination of skin disease frequency 5.8–10
 - diagnostic criteria 5.4–5
 - dietary factors 5.10
 - disability 5.5
 - disease definition 5.4–5
 - disease types 5.4
 - early environment 5.9
 - genetics 5.9
 - geographical factors 5.10
 - handicap 5.5
 - impairment 5.5
 - infective agents 5.10
 - inferences 5.2–3
 - later environment 5.9–10
 - macroclimate 5.10
 - microclimate 5.10
 - natural history 5.10
 - occupational factors 5.10
 - population level 5.2–4
 - prevention paradox 5.3–4
 - public health 5.4–8
 - risk factors 5.8–9, 5.13
 - study types 5.14
 - terminology 5.13–14
- epidemiology, pathophysiology 32.88
- epidermal barrier 8.4–5
- formation by keratinocytes 8.4
 - kallikrein role in dysfunction 8.42
 - neonates 41.25
- epidermal cyst, vulval **112.30**
- epidermal differentiation complex (EDC) 2.7
- epidermal growth factor (EGF), keratinocyte function effects 8.4, 8.5
- epidermal growth factor receptor (EGFR) inhibitors, acne association 90.12
- epidermal melanin unit 88.2–3
- epidermal naevi **75.2**
- confluent and reticulated papillomatosis differential diagnosis 87.7
- epidermal naevus syndrome 73.17
- encephalocraniocutaneous lipomatosis differential diagnosis 100.19
 - incontinentia pigmenti differential diagnosis 70.11
- epidermal necrosis 51.22
- epidermal pigmentation, laser treatment 23.12–14
- epidermal structures 2.5–7
- epidermal sunburn cells (SBC) 9.6
- epidermis 2.1, 2.2, 13.1
- adherence to dermis 2.21
 - barrier 129.2–3
 - cell–cell adhesion during inflammation 8.9–13
 - cooling 23.5
 - cornified cell envelope 2.6
 - differentiation of structures 2.4
 - embryonic 2.3
 - heat damage 23.5
 - inflammation cellular components 8.2, 8.3, 8.6
 - layers 2.5–7
 - macrofibres 2.7
 - Merkel cells 2.11–12
- epidermodysplasia verruciformis 25.59–61, 26.60, **146.2**
- acquired 25.62–3
 - basal cell carcinoma **141.5**
 - children with HIV 31.35
 - clinical features 25.60
 - epidemiology 25.59, 146.1
 - human papillomavirus 31.24, 31.25
 - investigations 25.60
 - malignant progression 25.63
 - management 25.60–1, 25.63
 - pathophysiology 25.59–60
 - spiny keratoderma differential diagnosis 65.52
- epidermoid carcinoma, anal/perianal 113.17–20
- epidermoid cysts 134.1–2
- ear piercing complications 108.7
 - hidradenitis suppurativa 92.5
 - malignant degeneration 134.2
 - plantar 25.50
 - surgery 20.45–6, 20.47
 - trichilemmal cyst differential diagnosis 134.3
- epidermoid implantation cyst 95.48
- epidermolysis bullosa 71.1–23
- acquisita, vulval **112.19**
 - allopapuloid 96.40
 - anchoring fibril role 2.27
 - antibody probes 71.21–2
 - antigen mapping 71.21–2
 - aplasia cutis congenita 75.20
 - bone marrow stem cell therapy 71.29
 - cell therapy
 - with intradermal allogeneic fibroblasts 71.28
 - with intradermal mesenchymal stromal cells 71.28–9
 - chromosomal mutations 5.9
 - classification 71.2
 - clinical features 112.4
 - clinical subtypes 71.6–19
 - Cole disease differential diagnosis 65.54
 - collagens type VII and XVII 2.29
 - definition 112.4
 - dental defects 110.16
 - dermal–epidermal basement membrane changes 2.21, 2.22
 - diagnosis 71.19–23
 - differential diagnosis 71.23
 - digestive system 152.6
 - electron microscopy 3.26–7
 - friction blisters 123.9
 - gene mutations 71.3–5
 - gene therapy 71.27–8
 - natural 71.29
 - genomic editing 71.28
 - hemidesmosome gene mutations 2.26
 - hereditary
 - epidermolysis bullosa acquisita differential diagnosis 50.43
 - linear IgA disease differential diagnosis 50.36
 - hypertrichosis 89.63
 - immunofluorescence studies 3.17
 - incidence 71.2
 - inducible pluripotent stem cells 71.29–30
 - infants 71.24–5
 - junctional 71.2, 71.11–14
 - generalized intermediate **71.11**, 71.12–13
 - generalized late-onset **71.11**, 71.13
 - generalized severe 71.11–12
 - localized **71.11**, 71.13
 - localized inversa **71.6**, 71.13–14
 - localized laryngo-onycho-cutaneous syndrome **71.6**, 71.14
 - molecular pathology 71.14
 - with pyloric atresia **71.11**, 71.13
 - with respiratory/renal involvement **71.11**, 71.13
 - keratolysis exfoliativa differential diagnosis 87.24
 - laminin 322 role 2.26
 - lethal acantholytic 65.56
 - nail lichen planus differential diagnosis 95.45
 - nail loss 95.8
 - neonates 71.24–5
 - next generation sequencing 71.23
 - nonsense read-through drugs 71.30
 - oral lesions 110.16, **110.17**
 - oral mucosa 110.7, **110.8**
 - pain management 71.27
 - prevalence 71.2
 - recombinant protein therapy 71.28
 - renal failure 153.6
 - revertant mosaicism 71.29
 - Sanger sequencing 71.22–3
 - skin biopsy 71.19
 - skin proteins 71.3–5
 - small molecule therapies 71.30
 - transmission electron microscopy 71.19–21
 - treatment 71.24–30
 - vulval 112.4
 - see also* dystrophic epidermolysis bullosa; Kindler syndrome
- epidermolysis bullosa acquisita 50.18, 50.41–3, **50.44**, 50.45–6, 71.23
- anti-p200 pemphigoid differential diagnosis 50.39
- autoantibodies 50.42
- specificity **50.10**
- autoantigen 50.42
- bullous pemphigoid differential diagnosis 50.21
- bullous systemic lupus erythematosus differential diagnosis 50.48
- classical mechanobullous variant 50.43, **50.44**, 50.45
- clinical features 50.43, **50.44**, 50.45
 - definition 50.41
 - diagnosis 50.45–6
 - differential diagnosis 50.45
 - disease course 50.45
 - epidemiology 50.41–2
 - genetics 50.43
 - IgA deposits 50.43
 - inflammatory bowel disease association 152.3
 - inflammatory variant 50.43, **50.44**, 50.45
 - investigations 50.45–6
 - linear IgA disease differential diagnosis 50.36
 - malignancy association 147.22
 - management 50.46
 - mucous membrane pemphigoid 109.27
 - differential diagnosis 50.24
 - oral ulceration 110.42
 - pathophysiology 50.42–3
 - predisposing factors 50.42
 - prognosis 50.45
 - variants 50.43, **50.44**, 50.45
- epidermolysis bullosa simplex 2.8, 71.2, 71.6–11, 123.9
- acral peeling skin syndrome **71.6**, 71.7
 - differential diagnosis 65.27
 - ankyloblepharon–ectodermal defect–cleft lip/palate syndrome differential diagnosis 67.16
 - autosomal recessive
 - BP230 **71.6**, 71.9
 - exophilin-5 **71.6**, 71.9
 - keratin 14 **71.6**, 71.8
 - desmoplakin deficiency **71.6**, 71.10
 - diagnosis 71.21
 - dyskeratosis congenita differential diagnosis 69.15
 - generalized

- intermediate 71.6, 71.7–8
severe 71.6, 71.7
localized 71.6–7
management 71.25
migratory circinate 71.6, 71.8
molecular pathology 71.10–11
with mottled pigmentation 71.6, 71.8
with muscular dystrophy 71.6, 71.8–9
Ogna 71.6, 71.8
plakoglobin deficiency 71.6, 71.10
plakophilin-1 deficiency 71.6, 71.9–10
with pyloric atresia 71.6, 71.9
superficialis 71.6, 71.10
epidermolytic hyperkeratosis 3.36
epidermolytic ichthyosis 65.13–15, 65.16, 65.18, 65.39
clinical features 65.14–15, 65.16
hyperparathyroidism 145.21
investigations 65.15
management 65.39
superficial 65.14, 65.15, 65.17
epidermolytic palmoplantar keratoderma 65.43–4
knuckle pad association 96.34
Epidermophyton 32.18, 32.19
identification 32.32
Epidermophyton floccosum 32.32
tinea corporis 32.35, 32.36
tinea cruris 32.46
tinea pedis 32.43, 32.44
epididymo-orchitis
Chlamydia infection 30.11, 30.15
gonococcal 30.7, 30.7
epigenetic phenomena 7.6
epigenetics 5.9
epigenomics 7.6
epilepsy
NF1 80.3, 80.4
palmar fascial fibromatosis 96.31
temporal lobe, olfactory reference syndrome differential diagnosis 86.9
tuberous sclerosis complex 80.10, 80.11–12
epiloia *see* tuberous sclerosis
epinephrine
with local anaesthesia 20.11, 20.12
systemic absorption 20.12
episodic angio-oedema with eosinophilia 43.4
epispadias 111.7
epistasis 7.2
epithelial cells, immune response 8.58
epithelial keratinization in male anogenital region 111.5
epithelial markers, immunopathology 3.18–19
epithelial membrane antigens (EMA) 3.19–20
epithelial neutrophil activating peptide 78 (CXCL5) 8.39
epithelial sheath neuroma 137.53
epithelial $\gamma\delta$ T cells, keratinocyte interactions 8.4
epithelioid angiomas, oral lesions 110.53
epithelioid angiosarcoma 137.39
epithelioid
haemangioendothelioma 137.38–9
epithelioid haemangioma 137.28–9
cutaneous epithelioid angiomatous nodule 137.29–30
epithelioid sarcoma 137.65–6
subcutaneous granuloma annulare differential diagnosis 99.14
epithelioma
amoebiasis differential diagnosis 33.35
cuniculatum 142.29
eyelid 109.50–1
superficial with sebaceous differentiation 138.18
eponychium 2.11
epoxy resins 128.18, 128.48–9
Epstein–Barr virus (EBV) 25.31–3, 146.7
annular erythema of infancy 47.6
biology 25.31
chronic active 25.31, 25.33
drug exanthem association 12.3
erythema annulare centrifugum 47.9
extranodal NK/T-cell lymphoma 140.36–7
haemophagocytic lymphohistiocytosis association 136.9
hairy leukoplakia 110.74
HIV infection
children 31.35
hairy leukoplakia 31.33
immunocompromised patients 110.52
infectious mononucleosis 25.31–3
lymphomas 25.33
lymphomatoid granulomatosis 151.6
lymphoproliferative disease 25.34, 140.47
myopericytoma association 137.42
oral hairy leukoplakia 25.32–3
oral lesions 110.51, 110.52
papular-pruritic gloves and socks syndrome 25.87
post-transplant lymphoproliferative disorder 140.47
primary 25.31
staining 3.10
systemic lupus erythematosus association 51.19
systemic sclerosis 56.11
X-linked lymphoproliferative diseases 82.10–11
Epstein's pearls 116.4
epulis fissuratum 110.59
Erdheim–Chester disease 136.19–20
erectile dysfunction, systemic sclerosis 56.21
erethism, mercury toxicity 122.5
ERG (Ets-related gene) 3.23
ergot intoxication, Raynaud phenomenon differential diagnosis 125.9
erisipela de la costa 33.3
Erysipelothrix rhusiopathiae 26.46–7
erlotinib, pustules 107.12
erosive adenomatosis of the nipple 138.22
erosive pustular dermatitis of scalp 107.11–12
amicrobial pustulosis of the skin folds differential diagnosis 49.17
cicatricial pemphigoid differential diagnosis 50.51
dissecting cellulitis of scalp differential diagnosis 107.8
eruptive vellus hair cyst 90.27, 90.28, 138.7–8
keratosis pilaris differential diagnosis 87.10
Er:YAG laser
hair removal 23.17
skin resurfacing 160.6–8
erysipelas 26.10, 26.17–21
allergic contact dermatitis differential diagnosis 128.62
associated diseases 26.18
causative organisms 26.18–19
clinical features 26.19–20
definition 26.17–18, 105.10
differential diagnosis 26.20
epidemiology 26.18, 105.10
eyelids 109.41
HIV infection 31.20
investigations 26.20–1
management 26.21
neutrophilic eccrine hidradenitis differential diagnosis 120.2
nomenclature 105.10
pathophysiology 26.18–19, 105.10–11
pinna 108.11
sclerosing panniculitis differential diagnosis 99.29
see also cellulitis
erysipeloid 26.46–7
erythema
action spectrum 9.5, 9.11
ageing of skin 155.9
annular of infancy 47.6–8
chemical peel complication 159.8, 159.10
definition 4.13
dermatomyositis 53.7, 53.8
eosinophilic annular 47.10
erysipelas-like 45.6, 64.2
flagellate in dermatomyositis 53.7
generalized exfoliative dermatitis 119.11–12
infrared radiation-induced 125.11
irritant contact dermatitis 129.6
keratolytic winter 65.66–7
migratory 147.19
necrolytic acral, HCV association 25.65
necrolytic migratory 47.13–15, 47.16
erythema multiforme differential diagnosis 47.5
oral mucosa 110.9
palmar 147.24, 152.9
endocrine disorder skin signs 149.10
PUVA side effect 21.12
reactive inflammatory 47.1–15, 47.16
recurrent toxin-mediated perineal 26.32
scarlatiniform 26.36
systemically reactivated allergic contact dermatitis 128.58
tumour necrosis factor receptor-associated periodic syndrome 45.5
UVB phototherapy side effect 21.11
UVR-induced 9.7
see also toxic erythema of chemotherapy
erythema ab igne 125.12, 125.13
livedo reticularis differential diagnosis 125.8
erythema annulare centrifugum (EAC) 47.6, 47.8–10, 147.19
classification 47.9
clinical features 47.10
definition 47.8
differential diagnosis 47.10
eosinophilic infiltrate 47.10
epidemiology 47.9
gold reactions 122.4
infection association 47.9
investigations 47.10
lesions 47.8
lymphohistiocytic infiltrate 47.9, 47.10
management 47.10
molluscum contagiosum association 25.13
nomenclature 47.8, 47.9
pathophysiology 47.9–10
treatment ladder 47.10
erythema chronicum migrans 26.71
acrodermatitis chronica atrophicans differential diagnosis 96.14
annular erythema of infancy differential diagnosis 47.7
Lyme disease 26.69–70
erythema dyschromicum perstans 88.32–3
pinta differential diagnosis 26.68
erythema elevatum diutinum 102.8–10
clinical features 102.9–10
epidemiology 102.8
investigations 102.10
knuckle pads differential diagnosis 96.35
management 102.10
pathophysiology 102.8–9
rheumatic fever 55.2
rheumatoid arthritis coexistence 55.2
systemic lupus erythematosus association 51.30
erythema gyratum atrophicans, annular erythema of infancy differential diagnosis 47.7
repens 47.10–11, 147.19
erythema induratum of Bazin 27.29–31, 99.8, 99.26–8, 151.4
clinical features 27.30–1, 99.26–7
definition 27.29
differential diagnosis 27.31
epidemiology 27.30
investigations 27.31, 99.27–8
management 27.31
pancreatic panniculitis differential diagnosis 99.40
pathophysiology 27.30, 99.28
vasculitis 99.27–8
erythema infectiosum 25.66–7
parvovirus B19 154.2, 154.3
erythema marginatum 47.11–13
clinical features 47.12–13
definition 47.11–12
epidemiology 47.12
investigations 47.13
pathophysiology 47.12
rheumatic fever 55.8, 154.4
treatment ladder 47.13
erythema migrans
lingual 110.13–14
oral mucosa 110.9
erythema multiforme 47.1–6, 110.31
aetiology 47.2–4, 110.42
allergic contact dermatitis 128.59–60
atypical cases 47.6
bullous 47.4, 47.5, 47.6
classification 47.2
clinical features 47.1–2, 47.5–6, 110.42
Compositae allergy 128.52
cutaneous lupus erythematosus 51.22
cytomegalovirus infection 25.37
definition 47.1–2
diagnosis 110.43
differential diagnosis 47.5, 47.6
drug-induced 31.17, 31.18, 47.3, 47.4
erythema marginatum differential diagnosis 47.12
genital ulceration 111.18
granuloma annulare differential diagnosis 97.6
haemorrhagic crusting of lips 110.83
Hailey–Hailey disease differential diagnosis 66.12
herpes-associated 25.19
herpes-induced 47.2–3, 47.6
hypocomplementaemic urticarial vasculitis differential diagnosis 102.19
immunology 47.2–3
immunostaining 110.46
Kawasaki disease differential diagnosis 102.33
lesions 47.1, 47.2
linear IgA disease differential diagnosis 50.36
localized vesiculobullous 47.5
Lyme disease differential diagnosis 26.70
major 47.6
ocular complications 109.34, 109.36
Stevens–Johnson syndrome differential diagnosis 119.17
management 47.6, 110.43
mercury toxicity 128.24
milker's nodule association 25.12
minor 47.5
molluscum contagiosum association 25.13
Mycoplasma pneumoniae infection 26.75
oral mucosa 110.7, 110.8
oral ulceration 110.42–3
orf infection 25.10, 25.11
papular form 47.5, 47.6
paronychia 95.36
pathology 47.4–5
pemphigus vulgaris differential diagnosis 50.7
photoaggravation 47.5
predisposing factors 110.42
recurrent herpes simplex 25.16
rheumatic fever 55.8
sarcoidosis association 98.14
secondary syphilis 31.21
simplex form 47.5
systemically reactivated allergic contact dermatitis 128.58
terminology 47.1–2
topical agent-induced 47.4
triggers 47.3

- erythema multiforme (*continued*)
 tuberculosis 151.4
 urticaria differential diagnosis 42.14
 viral infections 47.2–3, 47.6
- erythema neonatorum 116.3
- erythema nodosum 99.18, **99.19–20**, 99.20–4
 aetiology 99.18, **99.19–20**
 associated diseases 99.18
 complications 99.24
 differential diagnosis 99.22
 drug eruptions 118.15–16
 epidemiology 99.19
 idiopathic 98.2
 inflammatory bowel disease
 association 152.2
 investigations 99.22–4
 leprosum 28.3, 28.5, 28.6, 28.12, 28.13, 99.24–6
 dactylitis 154.4
 histopathology 99.25–6
 synovitis 154.4
 treatment 28.16
 management 99.24
 Miescher radial granulomas 99.22–3
 pathophysiology 99.18, 99.20–1
 pregnancy 115.9
 presentation 99.21
 radiotherapy-induced 120.14
 sarcoidosis 98.1, 98.6, 98.14, 98.15
 differential diagnosis 98.2, 98.12
 sclerosing panniculitis differential diagnosis 99.29
 streptococcal infection 26.11
 Sweet syndrome association 99.18
 tuberculous 27.31, 151.4
 variants 99.22
 vasculitis 99.24
- erythema toxicum neonatorum 116.4–5
 infantile eosinophilic pustular folliculitis differential diagnosis **93.10**
- erythropoietic protoporphyria, priming phenomenon 60.14–15
- erythrasma **26.37**, 26.39–41
 clinical features 26.39–40
 differential diagnosis 26.39–40
 investigations 26.40–1
 management 26.41
 pathophysiology 26.39
 pitted keratolysis differential diagnosis 26.42
 pityriasis rotunda differential diagnosis 87.8
 pityriasis versicolor differential diagnosis 32.12
 variants 26.39
- erythrocytosis 125.6
- erythroderma 39.30–5
 allergic contact dermatitis differential diagnosis 128.62
 bullous congenital ichthyosiform, epidermolysis bullosa differential diagnosis 71.23
 causes 39.31
 chronic actinic dermatitis 127.18
 clinical features 39.31–4
 complications/co-morbidities 39.34
 congenital ichthyosiform 65.9–13, 65.10, 116.19
 clinical features 65.11–12
 definition 65.9–10
 investigations 65.12–13
 management 65.39
 pathophysiology 65.10
 reticular **65.14**, 65.15–17
 definition 4.8, 39.30
 disease course 39.34
 eczema as cause 39.2
 epidemiology 39.30–1
 exfoliative, Compositae allergy 128.52
 generalized 128.17
 HIV infection 31.14
 ichthyosiform 39.33
 investigations 39.35
- leukaemia cutis differential diagnosis 140.49
 malignancy association 147.23
 management 39.35
 pathophysiology 39.31
 pityriasis rubra pilaris differential diagnosis 36.4
 primary immunodeficiency 82.3
 prognosis 39.34
 psoriasis 35.16–17, 107.3
 severe combined immunodeficiency 82.7–8
 of unknown origin 39.33
 variants 39.32–4
- erythrodermic sarcoidosis 98.13
- erythrokeratoderma 65.17–19
 progressive symmetrical 65.18–19
 variabilis 65.17–18, 65.39
 pityriasis rubra pilaris differential diagnosis 36.4
- erythrokeratolysis hiemalis 65.66–7
- erythromelalgia 84.10, 103.6–8
 clinical features 103.7, 103.8
 definition 103.6
 epidemiology 103.6
 investigations 103.8
 malignancy association 147.24
 management 103.8
 medication-induced 103.7
 mushroom-induced 103.7
 myeloproliferative disorders 101.12
 pathophysiology 103.6–7
 primary 103.6–7
 secondary 103.7
- erythromelanos follicularis et colli 87.9, 87.10
- erythromycin 18.10
 anti-inflammatory effects 19.43
- erythronychia, longitudinal 95.15–16
- erythroplasia of Queyrat 111.27–8
 human papillomavirus 31.24
- erythroplasia, oral mucosa 110.71–2
- erythropoietic porphyria
 congenital 60.4, 60.7, 60.9–11
 hypertrichosis 89.63
 xeroderma pigmentosum differential diagnosis 78.6
- erythropoietic protoporphyria 60.4, 60.5, 60.7, 60.14–16
 clinical features 60.14–15
 definition 60.14
 genetic counselling 60.16
 investigations 60.15
 juvenile spring eruption differential diagnosis 127.9
 lip lesions 110.24
 lipid proteinosis differential diagnosis 72.32–3
 liver disease 60.16
 management 60.6, 60.15–16
 perioral lesions 110.24
 priming phenomenon 60.14–15
 pseudoporphyria differential diagnosis 60.19
 solar urticaria differential diagnosis 127.22
- Escherichia coli*
 erythema annulare centrifugum 47.9
 HIV infection 31.20
 esdepallethrin, scabies treatment 34.44
 E-selectin 8.7–8
 essential fatty acid deficiency 63.23
 essential thrombocythaemia 101.11–12
- etanercept
 acne conglobata treatment 90.56
 acute graft-versus-host disease treatment 38.6
 cutaneous sclerosis induction 96.43
 dosage **19.30**
 palmoplantar pustulosis treatment 35.40
 psoriasis therapy 19.29, 31.16
 psoriatic arthritis treatment 35.46
 pyoderma gangrenosum treatment 49.6
 TNF- α neutralization 8.35
- transient acantholytic dermatosis treatment 87.24
- ethambutol 27.9, 27.10
 drug eruptions 31.17
- ethics, clinical trials 14.12
- ethnicity/ethnic groups 5.9
 ageing of skin 155.4
 allergic contact dermatitis 128.6
 diagnosis of skin disease 4.4
 systemic sclerosis 56.7
- ethosomes 18.8
- ethylenediamine dihydrochloride 128.40–1
 contact allergy 118.4
- ethylenediaminetetraacetate 18.8
- etidronate 99.55
- etretinate 31.16
 Vohwinkel syndrome treatment 65.57
- EU Cosmetics Directive 128.76
- EU Directives on Dangerous Substances and Dangerous Preparations 128.76
- eumelanin 88.5, 89.69
- European Enlightenment 1.3–4
EVER1 and *EVER2* gene mutations 146.1
- evidence-based medicine (EBM) 17.1–24
 aetiology and pathogenesis of disease 17.6
 all or none clinical observations 17.3
 application to specific patient 17.7, 17.8, 17.11–12
 best evidence 17.4–7
 finding 17.6–7
 clinical importance 17.7
 critical appraisal of evidence 17.7–18
 data evaluation 17.17–23
 statistical testing 17.19–20
 data reporting 17.18–19
 deductions from pathophysiology 17.6
 distinguishing effective from ineffective/harmful treatments 17.1–2
 expert opinion 17.5–6
 formulating questions 17.3–4
 hierarchy of evidence 17.4–5
 levels of evidence 17.4
 limitations 17.2–3
 literature evaluation 17.2
 meta-analysis 17.5
 need for 17.1–3
 physician recall/records 17.5
 practising 17.2
 search strategies 17.4
 shortcut method for appraising clinical research papers 17.23–4
 statistical methods 17.20–3
 systematic reviews 17.5
 threats to 17.3
 validity 17.7–9
 see also clinical trials; randomized controlled trials (RCT)
- Ewing sarcoma, extraosseous 137.54
 examination of skin, diagnosis 4.5
- exanthem(s)
 acute generalized exanthematous pustulosis 12.3, 119.1–4
 drug eruptions 31.18, 118.1–3, 119.1–4
 differential diagnosis 118.2
 gold reactions 122.4
 mercury toxicity 122.5, 128.24
 symmetrical drug-related intertriginous and flexural 118.4, 118.5–6
 exanthem infantum see fifth disease
 exanthem subitum see roseola infantum
- exercise
 anaphylaxis induction 42.12
 lymph drainage 105.50
 lymphoedema management 105.56
 obesity-related 105.20
 phlebotymphoedema treatment 105.9
- exercise-induced purpura 101.5, **101.9**
- exfoliative dermatitis 39.30–5
 malignancy association 147.23
 exfoliative dermatitis toxin 8.28
- exocytosis 3.36
- Exophiala dermatidis*, systemic mycosis 32.95
- Exophiala jeanselmei* **32.78**, 32.79
- exophilin-5 71.3–4, 71.9
- expert opinion 17.5–6
- extensibility of skin 123.5
- external auditory canal 108.2
 cholesteatoma 108.27–8
 hair in 108.28
 keratosis obturans 108.28
 squamous cell carcinoma 108.26–7
 tumours 108.22–4
- external auditory meatus, bacterial flora 26.5
- external jugular vein 20.3
- external root sheath tumours 138.5–7
- extracellular matrix (ECM) 2.27–8
 collagens 2.27–8
 molecules in wound healing 10.3
 photoageing 2.47
 proteoglycans 2.37, 2.40
 regulation by MMPs 8.43
- extracorporeal photochemotherapy (photopheresis) (ECP) 21.1, 21.6–7
 acute graft-versus-host disease treatment 38.6
 administration 21.10–11
 delivery 21.11
 historical aspects 1.8
 mycosis fungoides 140.26
 regimen variables 21.11
 scleredema treatment 59.11
 Sézary syndrome 140.26
 side effects 21.14
- extractable nuclear antigen (ENA) 54.2, 127.35
- extramedullary haematopoiesis 148.5
- extranodal NK/T-cell lymphoma 140.36–7
- extrinsic allergic alveolitis, acquired partial lipodystrophy association 100.4
- eye(s)
 Dennie–Morgan fold 41.22
 glucocorticoid adverse effects **19.19**
 PUVA side effects 21.14
- eye disease
 Adamantides–Behçet disease 48.4–5, 48.7, **48.9**
 atopic eczema 41.22–3
 bacterial infections 109.41–2
 congenital ichthyoses 65.39
 corticosteroid-induced 109.43
 dermatoses 109.1–5
 drug-induced 109.43, 109.45–7
 generalized severe recessive dystrophic epidermolysis bullosa 71.26
 infections 109.36–8, 109.39–40, 109.40–3
 inherited disorders 109.43, **109.44–5**
 iris hamartomas 80.1, 80.2, 80.3, 80.4
 leprosy 28.13
 differential diagnosis 28.12
 melanoma 143.14
 Menkes disease 63.27
 nail–patella syndrome 69.16
 phakomatosis pigmentovascularis 75.23
 pseudoxanthoma elasticum 72.29
 psoriasis 35.14
 psoriatic arthritis association 35.43
 retinoid-induced 19.38
 rosacea 91.1, **91.2**, 91.3, 91.4
 clinical features 91.8
 differential diagnosis 91.11
 disease course 91.12
 management 91.13, 91.14, **91.15**
 sarcoidosis 98.5
 Stevens–Johnson syndrome/toxic epidermal necrolysis 119.16, 119.18
 management 119.20
 systemic diseases 109.36, **109.37**
 systemic lupus erythematosus 51.29
 tuberous sclerosis complex 80.12
 viral infections 109.36–8, 109.39–40, 109.40
 vitamin A deficiency 63.7
 vitamin E deficiency 63.11
 xeroderma pigmentosum 78.4–5
 see also atopic eye disease; conjunctivitis

- eye drops, corticosteroid 18.17
 eye sign, trypanosomiasis 33.39
 eye worm 33.10
 eyebrows
 elevation with botulinum toxin injection 158.5
 hair pulling 86.17, 86.18
 eyelash follicle, hordeolum 109.41
 eyelashes
 hair pulling 86.17, 86.18
Phthirus pubis 109.42
 eyelids
 allergic contact dermatitis 109.5, 128.15
 benign cysts 109.47–8
 blepharochalasis 96.24–5
 contact dermatitis 109.5
 dermatitis 39.21
 dermatomyositis 53.5
 dermatoses 109.5–7, **109.8**, 109.9–10, 109.11–12, 109.13–15
 eczema 39.21
 erysipelas 109.41
 impetigo 109.41
 infections 109.36–7, 109.38
 leishmaniasis 109.12, 109.43
 lipoid proteinosis 72.32, 72.33
 molluscum contagiosum 109.36, 109.38
 necrotizing fasciitis 109.41
 oedema 105.15, 105.16
 periorbital oedema 109.5–6
 psoriasis 35.14, 109.5
 ptosis 109.5
 radiotherapy for skin cancer 24.10
 skin diseases 109.5
 surgery 20.5
 tumours 109.46–51
 benign 109.46–9
 malignant 109.49–51
 warts 109.36, 109.38
 wedge excision 20.33
 ezetimibe, familial hypercholesterolaemia management 62.7
- F**
 fabricated illness 86.30
 Fabry disease 81.7–9, 150.3
 angiokeratoma **103.9**
 circumscriptum 103.14
 corporis diffusum 81.7, 81.8, 81.9
 clinical features 81.7–8
 differential diagnosis 81.8
 genetics 81.7
 investigations 81.8–9
 management 81.9
 nephropathy 153.1
 pathophysiology 81.7
 variants 81.8
- face
 angiosarcoma 137.36
 botulinum toxin A injection 158.3–7
 congenital melanocytic naevi 75.13–14
 dermatomyositis 53.4–5
 disfigurement with infantile haemangiomas 117.21–2
 fibrous papule 137.2–3
 glial heterotopic nodules 137.52–3
 hair sinus 123.23
 Horner syndrome 85.14–15
 infiltrating lipomatosis 100.17–18
 mucopolysaccharidoses 81.2–3
 radiotherapy for skin cancer 24.11, 24.12
 venous malformation 73.10
see also surgery, facial
- face, head and neck, swollen 105.14–17
 clinical features 105.16
 definition 105.14
 epidemiology 105.15
 investigations 105.16
 management 105.16–17
 pathophysiology 105.15–16
 facial Afro-Caribbean childhood eruption 91.18, 91.19
 facial artery 20.3
 facial fillers, foreign-body cheilitis 110.85
 facial folliculitis *see* sycosis
- facial hemiatrophy 96.17–18
 facial melanosis 88.9–15
 erythromelanosis follicularis of the face and neck 88.14–15
 peribuccal pigmentation of Brocq 88.15
 photocontact 88.12–13
 poikiloderma of Civatte 88.13–14
see also melasma
- facial nerve, motor branches 20.4–5
 facial picking disorder 86.15
 acné excoriée differential diagnosis 86.16
 factitious cheilitis 86.25–6, 110.84
 factitious nail disease 86.26
 factitious skin disease 86.22–30
 dermatitis artefacta 86.23–8
 acné excoriée differential diagnosis 86.16
 dermatitis passivata 86.29
 dermatitis simulate 86.28
 dermatological pathomimicry 86.28–9
 fabricated illness 86.30
 induced illness 86.30
 lymphoedema 105.50
 malingering 86.23, 86.29
 medicolegal issues 86.30
 Münchhausen syndrome 86.23, 86.29–30
 by proxy 86.22, 86.23, 86.30
 nomenclature 86.22–3
 panniculitis 99.45–8
 pseudologica fantastica 86.29–30
 factor 1 deficiency 82.18
 factor XIIIa 3.22
 famciclovir 19.44
 post-herpetic neuralgia treatment 84.5
 familial adenomatous polyposis (FAP) **74.8**, 80.13
 Gardner syndrome **74.8**, 134.1, 142.39
 oral lesions 110.24
 Muir–Torre syndrome differential diagnosis 142.39
 familial amyloid polyneuropathy 58.11–12
 familial annular erythema 47.7
 familial benign chronic pemphigus, radiotherapy 24.6
 familial cold autoinflammatory syndrome *see* Muckle–Wells syndrome
 familial cold urticaria syndrome 45.5
 familial dysautonomia
 hyperhidrosis 94.5
 respiratory disorder association 151.5
 familial frontonasal dysplasia, type 1 **74.8**
 familial haemophagocytic lymphohistiocytosis 136.9
 malignant histiocytosis differential diagnosis 136.27
 familial hibernian fever *see* tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS)
 familial hypercholesterolaemia 62.6–7
 clinical features 62.6–7
 definition 62.6
 diagnostic criteria **62.7**
 epidemiology 62.6
 investigations 62.7
 lipid concentrations **62.7**
 management 62.7
 pathophysiology 62.6
 tendon xanthomas 62.2, 62.6
 xanthelasmas 62.4
 familial lipoedema 74.10
 familial lupus anticoagulant syndrome *see* antiphospholipid syndrome
 familial mandibuloacral dysplasia 72.24–5
 familial Mediterranean fever 45.1, 45.2, **45.2**, **45.3**, 45.5–6, 58.13
 amyloid A amyloidosis 153.2
 clinical features 45.6
 IgA vasculitis association 102.14
 pathophysiology 45.5–6
 scrotal inflammation 111.20
 systemic lupus erythematosus differential diagnosis 51.27
 familial melanoma syndrome 147.7
 familial multiple lipomatosis **74.8**, 74.9
- benign symmetrical lipomatosis differential diagnosis 100.15
 Dercum disease differential diagnosis 100.17
 familial partial lipodystrophy 74.1–3
 acquired generalized lipodystrophy differential diagnosis 100.3
 acquired partial lipodystrophy differential diagnosis 100.6
 autosomal dominant 100.3
 familial progressive hyperpigmentation **70.2**, 70.11
 familial reactive perforating collagenosis 96.50–1
 elastosis perforans serpiginosa differential diagnosis 96.53
 familial sea-blue histiocytosis 136.20–1
 familial trichoepithelioma, carbon dioxide laser ablation 23.18
 familial tumoral calcinosis 81.19–20
 Family Dermatology Life Quality Index (FDLQI) 16.7
 Family Reported Outcome Measure (FROM-16) 16.7
 family, skin disease impact measurement 16.7
 Fanconi anaemia 78.11, 82.12, 147.14, **148.13**
 dyskeratosis congenita differential diagnosis 70.13
 malignancy association 147.14
 Far East scarlet-like fever 26.36
 Farber disease 81.7
 hyaline fibromatosis syndrome differential diagnosis 72.18
 farm environment 41.8
 Fas ligand (FasL) 8.53–4
 fasciitis
 ischaemic 137.6
 malignancy association 147.21
 necrotizing 26.74
 nodular 110.61, 137.4–5
 systemic sclerosis differential diagnosis 56.15
 Fascin 136.3
 FasL, induction 12.3
 fat, acquired generalized lipodystrophy 100.2
 fat cell tumours 137.58–61
 fat hypertrophy 100.12–13
 insulin-induced localized 100.12–13
 fat necrosis 99.8
see also subcutaneous fat necrosis, of the newborn
 fat redistribution syndrome *see* HIV-associated lipodystrophy
 fat reduction 160.11–12
 cryolipolysis 160.11–12
 high-intensity focused ultrasound 160.11–12
 fat, subcutaneous 2.43
 anatomy 99.1, 99.2, 99.3
 cellular composition 99.2, 99.3
 functions 2.43
 inflammatory diseases 99.6–8
 necrosis in the newborn 116.14–16
 physiology 99.4–6
 psychosocial aspects 99.1
 T cells 99.7
 FAT4 gene mutations 73.19
 fatigue, systemic sclerosis 56.13
 FATP4 gene mutations 65.35
 fatty acids 99.4
 topical medication 18.7
 fauces, examination 110.7
 Favre–Chaix purpura 101.8
 Favre–Racouchot syndrome 90.26, 96.3
 FBN1 gene mutations 72.16, 72.18
 FcRn/Fc complex 8.58, 14.3
 FcεRI 8.57, 8.58
 FcεRII 8.57, 8.58
 Felty syndrome
 leg ulcers 55.3
 oral ulceration 110.16
 female genital mutilation 112.41
- female pattern hair loss (FPHL) 89.15
 androgen levels 89.17
 associated diseases 89.16
 clinical features 89.20–1
 differential diagnosis 89.21
 genetics 89.19–20
 pattern 89.17
 femoral veins, venous hypertension 39.19
 fenofibrate, burns treatment 126.11
 fermitin 8.5
 FERMT1 gene mutations 8.5
 ferric salts, tattoos 88.53
 ferroxidase deficiency 60.14
 ferrous sulphate supplementation 63.25
 fertility
 drug effects 14.8
 methotrexate effect 19.24
 fetal alcohol syndrome, hypertrichosis 89.61
 fetal *in utero* experience 5.9
 fetal programming 149.8
 fetal varicella syndrome 116.22
 fetus
 medical procedure complications 116.10
 skin biopsy 7.9
 wound healing 10.9–10
 FGFR3 gene mutations 87.4, 90.10, 133.2
 FH gene mutations 147.12
 fibreglass dermatitis 123.21, 130.1
 fibrillin(s) 2.36
 fibrillin-1
 actinic elastosis biomarker 96.4
 gene mutations 56.16, 96.9–10
 fibrillinopathies 72.15–17
 fibrin
 pericapillary 39.19
 wound healing 10.4–5
 fibrin plug, wound healing 10.2–3
 fibrinogen defects 101.3
 fibrinoid degeneration 3.35
 fibrinolysis, venous malformation 73.11
 fibroblast(s) 2.4, 2.40–2.41
 acute phase inflammation 8.2
 ageing of skin 155.7–8
 chromosomal mosaicism 76.5
 collagen fibril effects 155.7
 collagen synthesis 2.40–1
 collapse 155.7–8
 dermal 2.45
 high-power microscopy 3.32
 HOX gene expression 2.41
 inflammatory response 8.6
 keloid 10.9
 proteoglycan/glycosaminoglycan synthesis 2.40–1
 recruitment in wound healing 10.7–8
 wound healing 10.8
 mesenchymal precursors 10.10
 fibroblast growth factor (FGF) 2.3, 2.4
 wound healing 10.6, 10.11
 fibroblast growth factor 7 (FGF-7), wound healing 2.40
 fibroblast growth factor receptor(s) (FGFR)
 acanthosis nigricans 87.3
 Crouzon syndrome 67.7, 87.3
 fibroblast growth factor receptor 2 (FGFR2) 19.43
 signalling 90.3
 fibroblast growth factor receptor 3 (FGFR3)
 epidermal naevus syndrome 75.7
 fibroblastic rheumatism 55.4, 154.8
 fibrocytes 8.6
 fibrodysplasia ossificans progressiva 72.31
 fibroepithelial polyps, vulval **112.30**
 fibroepithelioma of Pinkus 138.12
 fibrofolliculoma 138.16
 acne vulgaris differential diagnosis 90.25
 fibrohistiocytic tumours 3.22, 137.19–23
 fibrokeratoma
 acquired digital 137.4
 acquired ungual 95.26–7
 surgical resection 95.58, 95.59

- fibroma
 calcifying aponeurotic 137.7–8
 desmoplastic fibroblastoma 137.12
 nuchal-type 137.12
 plaque-like CD34-positive
 dermal 137.8–9
 pleomorphic 137.3–4
 tendon sheath 137.11–12
 vulval 112.30
- fibromatoses 96.30–40
 camptodactyly 96.37–8
 infantile 96.33, 137.14
 knuckle pads 96.34–5
 pachydermodactyly 96.36
 palmar fascial 96.31–3
 camptodactyly differential diagnosis 96.38
 penile 96.33–4, 137.13–14
 plantar fascial 96.33
 white fibrous papulosis of the neck 96.36–7
see also juvenile fibromatoses
- fibromyalgia
 Dercum disease differential diagnosis 100.17
 psoriatic arthritis differential diagnosis 35.44
- fibromyxoid sarcoma, low-grade 137.18–19
- fibromyxoma, acral 137.61–2
 superficial 95.30
- fibronectins 2.2
 wound healing 10.4–5
- fibro-osseous pseudotumour of the digits 137.5–6
- fibrosarcoma
 keloid differential diagnosis 96.48
 palmar fascial fibromatosis differential diagnosis 96.32
 plantar fascial fibromatosis differential diagnosis 96.33
- fibrosis
 morphea 57.8
 mucous membrane pemphigoid 109.27
 management 109.34
 nephrogenic systemic 153.4–5
 oral submucous 110.56–7
- fibrous cutaneous nodules 96.40–5
- fibrous digital nodules 96.40
- fibrous hamartoma of infancy 137.6–7
- fibrous histiocytoma 137.19–21
 aneurysmal 137.19, 137.20, 137.21
 atypical 137.21
 cellular 137.19, 137.20, 137.21
 clinical features 137.21
 epidemiology 137.19–20
 epithelioid 137.21
 management 137.21
 pathophysiology 137.20–1
- fibrous papule of the face 137.2–3
- fibrous tumours 137.2–19
- fibroxanthoma, atypical 137.22–3
 radiation-induced 24.19, 137.22
- fibulins 2.2, 2.36–7
- fiddler's fingers 123.11
- fiddler's neck 90.24, 123.11
- field blocks 20.12
- field carcinogenesis, clinical features 146.10
- fifth disease 117.6
 human parvovirus B19 5.10
- filaggrin 2.1, 2.6–7, 39.3
 atopic eczema 41.2
 functions 8.4, 8.42
- filaggrin (*FLG*) gene mutations 8.56, 39.3, 39.4, 65.3–4, 129.3
 atopic eczema 41.5–6, 41.8, 41.11, 41.23
 hand eczema 39.13
- filariasis
 genital lymphoedema 105.18, 105.19
 immunity 33.8
 life cycle 105.43
 river blindness 109.42–3
see also lymphatic filariasis
- fillers 157.1–11
 abscesses 157.9
 adverse reactions 157.8–10
 alginates 157.6
 biodegradable 157.3–6
 bovine collagen 157.6
 calcium hydroxylapatite 157.5–6
 cannula techniques 157.2–3
 collagen 157.6
 collagen-stimulating 157.3–4
 combination 157.7
 depot technique 157.3
 fanning technique 157.3
 human collagen 157.6
 hyaluronic acid 157.4–5
 hydroxyethylmethacrylate and ethylmethacrylate microspheres suspended in hyaluronic acid 157.7
 hyperpigmentation response to inflammation 157.11
 indications 157.1–2
 inert 157.4–6
 injection errors 157.8
 needle techniques 157.2, 157.3
 non-biodegradable 157.6–7
 polyacrylamide 157.7
 polyalkylamide 157.7
 poly-L-lactic acid 157.2, 157.3–4
 polymethylmethacrylate and collagen 157.7
 porcine collagen 157.6
 risk assessment/reduction 157.8
 silicones 157.6–7
 skin types 157.10–11
 techniques 157.2–3
 types 157.3–7
- filovirus infections 25.69
- finasteride
 female pattern hair loss management 89.23
 hirsutism treatment 89.68
 male pattern baldness management 89.22–3
- fine-needle aspiration (FNA), lymph nodes 4.22
- finger pebbles, diabetes association 64.6
- fingers
 Achenbach syndrome 101.6, 123.13
 acquired digital fibrokeratoma 137.4
 callosities 123.11–12
 digital mucous cyst 137.62
 distal phalangeal erosive lesions 95.47
 fibro-osseous pseudotumour of the digits 137.5–6
 fiddler's 123.11
 fused
 in Kindler syndrome 71.19
 in recessive generalized severe dystrophic epidermolysis bullosa 71.17
 inclusion body fibromatosis 137.10–11
 paronychia 95.37
 paroxysmal haematoma 96.16–17
 primary syphilis 95.37
 silicone rubber prosthesis 95.63
see also clubbing
- finger tip
 painful dorsolateral fissure 95.37
 unit 18.3–4
- fish odour syndrome 94.16–17
 olfactory reference syndrome differential diagnosis 86.9
- fish, venomous 131.4
- Fishman syndrome 100.18
- fistulous tracts, schistosomiasis 33.25
- Fitz-Hugh–Curtis syndrome 30.12, 30.13
- Fitzpatrick classification of skin types 9.8
- fixatives, biopsy of skin 3.5
 artefacts 3.28
- fixed drug eruptions (FDEs) 12.3, 88.28, 88.29, 118.11–14
 causes 118.12
 clinical features 118.12–13
 complications/co-morbidities 118.13
 differential diagnosis 118.12–13
- disease course 118.13
- epidemiology 118.11
- erythema multiforme differential diagnosis 47.5
- generalized bullous 12.3, 118.12, 118.13
- investigations 118.13–14
- management 118.14
- pathophysiology 118.12
- perineum/perianal region 113.8
- prognosis 118.13
- fixed-effects models 17.9–10
- flaps, surgical 20.25–7, 20.28, 20.29–30, 20.30
 advancement 20.26–7, 20.29
 axial pattern 20.26
 complications 20.28, 20.30–1
 flap necrosis 20.28, 20.30
 pedicle 20.25, 20.26, 20.30
 random pattern 20.25–6
 rotation 20.26, 20.27, 20.29
 transposition 20.26, 20.26, 20.29–30, 20.30
 types 20.29–30
- flashlamps
 hair removal 23.6
 port-wine stains 23.9
 pulse rate 23.12
 telangiectases 23.10
 vascular lesion treatment 23.6
- flavivirus infections 25.69, 25.73–4
- flavouring agents 128.25–7
- flea bites 34.12–14
 bedbug bite differential diagnosis 34.25
 clinical features 34.13
 epidemiology 34.12–13
 investigations 34.13
 management 34.13
 murine typhus 26.77
 pet animals 34.12, 34.13
 plague 26.57, 26.58
 tungiasis 34.13–14
- Flegel disease 65.70, 87.16–17
- Fleming–Giovanni syndrome 89.59
- flesh flies 34.10
- FLG* gene mutations *see* filaggrin (*FLG*) gene mutations
- Fli-1 3.23
- florid cutaneous papillomatosis 147.16
- florid oral papillomatosis 110.38
- flower bugs 34.28
- fluconazole 19.44
 coccidioidomycosis treatment 32.89
 dermatophytosis treatment 32.34
 failure 32.35
- flucytosine 19.44
- fluorescence lifetime imaging microscopy (FLIM) 155.5
- fluorescence
 microlymphangiography 105.53, 105.54
- fluorescence microscopy, viral infections 25.5
- fluorescent *in situ* hybridization (FISH), melanoma diagnosis 143.19
- fluorescent tubes
 UVR exposure 9.13
 UVR source 9.3
- fluoroquinolones 19.42
- fluorouracil
 Flegel disease treatment 87.17
 HPV infection treatment 18.13
 hyperpigmentation induction 120.8
 multiple minute digitate keratoses treatment 87.18
- 5-fluorouracil 18.26
 actinic keratosis treatment 142.8, 142.9, 146.15
 anal intraepithelial neoplasia 113.17
 basal cell carcinoma treatment 141.14
 Bowen disease treatment 142.21, 142.22
 intralesional therapy 20.44
 keratoacanthoma treatment 142.36
 nail colouration 95.14
 wart treatment 25.52
- flushing 106.1–3, 106.4–7, 106.8–10
- associated disorders 106.3, 106.4–7, 106.8
 causes 106.2–3
 clinical presentation 106.3, 106.4–7, 106.8
 complications 106.9
 drug-induced 106.2
 endocrine disorder skin signs 149.10, 149.11
 epidemiology 106.1, 106.2
 food-induced 106.2
 investigations 106.8
 malignancy association 147.24–5
 management 106.8–9, 106.10
 paediatric 106.8
 pathophysiology 106.2–3
 physiology 106.1
 prognosis 106.9–10
 rosacea 91.12
 sweating association 106.3, 106.4–7
- flutamide
 female pattern hair loss management 89.23
 hirsutism treatment 89.68
- FMO3* gene 94.17
- foam cells, sphingolipidoses 81.7
- focal acantholytic dyskeratosis 110.19
- focal acral hyperkeratosis 65.53–4
- focal dermal hypoplasia 67.3, 67.3, 67.23–4
 anetoderma differential diagnosis 96.22
 clinical features 67.23–4
 congenital erosive and vesicular dermatosis with reticulated scarring differential diagnosis 96.12
 definition 67.23
 epidermolysis bullosa differential diagnosis 71.23
 Klinefelter syndrome 76.4
 lips 110.10
 management 67.24
 MIDAS syndrome differential diagnosis 67.25
 nomenclature 67.23
 oral mucosa 110.10
 pathophysiology 67.23
- focal epithelial hyperplasia 110.60
- focal facial dermal dysplasia 67.25–6
- focal mucinosis 59.14–15
 oral lesions 110.24
- folate
 metabolic pathway and methotrexate interaction 19.23
 supplementation in methotrexate therapy 19.24
- folate deficiency 63.18–19, 88.24
 aphthous ulceration 110.39
 deficiency glossitis 110.64
 iron deficiency differential diagnosis 63.24
 neural tube defects 85.9
 vitamin B₁₂ deficiency differential diagnosis 63.20
- folate synthesis inhibitors 19.43
- folds, filler use 157.1–2
- foliate papillitis 110.60
- folic acid, metabolic pathway 19.14
- folinic acid 19.24
- follicle centre cell lymphoma 140.37, 140.40–1
- follicle mites 34.52–4, 109.10, 109.13
 clinical features 34.53–4
 pathophysiology 34.53
- follicular atrophoderma 96.14–15
see also Bazex syndrome
- follicular hyperkeratosis 3.36
- follicular infundibulum
 comedo naevus 138.4–5
 tumour 138.3–4
- follicular keratoses *see* keratosis follicularis
- follicular lichen planus 37.6–7, 37.12, 89.37–40
- follicular mucinoses 59.15–17, 140.15–16
 acquired cicatricial alopecia 89.36
 clinical features 140.16
 definition 140.15
 management 140.16
 pathophysiology 140.15–16

- Pinkus 59.15–16, 59.17
scalp 107.7
trichodysplasia spinulosa differential diagnosis 87.15
urticaria-like 59.16–17
follicular naevus/naevus comedonicus syndrome 75.7
follicular occlusion triad 107.8
hidradenitis suppurativa 92.2
folliculitis 26.21–3, 90.29–30
actinic 93.6
bacterial 93.2
causative organisms 26.22
chronic 26.22
clinical features 26.22–3
decalvans 89.43–4, 90.30
acquired cicatricial alopecia 89.36
tufted folliculitis 89.44
defensin activity 8.14
definition 26.21
dermatophytosis 32.22
diabetes 64.4
disseminate and recurrent
infundibulofolliculitis 93.6–7
eosinophilic pustular 93.7–8, **93.9**, 117.11–12
infantile 93.9–10
epidemiology 26.22
Gram-negative
acneform drug eruption differential diagnosis 118.17
Pseudomonas aeruginosa infection 26.52
hair pulling 86.18
HIV infection 31.20, 89.47, 107.10
immunodeficiency association 148.15
investigations 26.23
keloidalis 90.30, 93.3–4
Malassezia 31.28, 32.13–14, 76.2, 90.30
management 26.23, 90.30
necrotizing infundibular crystalline 65.69
necrotizing lymphocytic of the scalp margin 93.4–5
occupational acne differential diagnosis 130.11
oil 130.14
pathophysiology 26.22
perforating 153.3
perineum/perianal region 113.9–10
Pityrosporum, acneform drug eruption differential diagnosis 118.17
scalp 90.30, 93.5–6
necrotizing lymphocytic folliculitis of the scalp margin differential diagnosis 93.5
staphylococcal 31.20
transient acantholytic dermatosis differential diagnosis 87.23
tufted 89.44
varicella-zoster virus 31.23
see also sycosis
Fonsecaea pedrosoi 32.77–8
food(s)
allergic contact urticaria 128.82–3, 128.84
cheilitis 110.83
flushing induction **106.2**
gustatory hyperhidrosis 94.7–8
oral hyperpigmentation 110.66–7
urticaria 42.5, 42.13, 47.7–8
food additives
allergy 128.15
flavouring agents 128.25–7
spices 128.25–7
food allergies 41.24
atopic eczema 41.12–13, 41.31–2
cross-reactivity 128.83
IgE 8.56
foot
acral fibromyxoma 137.62
allergic contact dermatitis 128.17
biomechanics 123.7
burning feet syndrome 85.16–17
calcified cutaneous nodules of the heels 117.14
callosities/corns/calluses 123.6–8
contact casting 85.6–7
diabetic 64.2
erythromelalgia 84.10
haemosiderotic fibrolipomatous tumour 137.63
hair sinus 123.22
immersion foot 125.3–4
ischaemic **103.2**
juvenile plantar dermatosis 39.21–2
mycetoma 32.74, 32.75
neuropathic 85.5
pedal papules of infancy 117.14
piezogenic pedal papules 123.25–6
pressure offloading 85.6–7
trench foot 125.3–4
ulceration prevention 85.6
verrucous carcinoma 142.28
wet gangrene in diabetes 64.1
see also toe(s)
foot and mouth disease 25.79–80
foot ulcer, diabetic 64.2
footprinting 160.2
footwear
calluses/corns/callosities 123.7, 123.8
deformities 123.6
insoles 123.9
nail trauma 95.18–21
Fordyce spots 93.10–12, 110.18, 111.5–6, 112.3
acne vulgaris differential diagnosis 90.25
foreign-body reactions
cheilitis 110.85
clinical features 123.17–18
definition 123.16
fibreglass dermatitis 123.21, 130.1
hair 123.22–3
hair-thread tourniquet syndrome 123.23
hypertrophic scars 96.46
intralesional corticosteroids 123.20
investigations 123.18, **123.19**
keloid 96.46
management 123.18
mechanical injury 123.16–18, **123.19**, 123.20–3
paraffinoma 99.47, 123.20
pathophysiology 123.16–17
penile 111.8
pentazocine ulcers 123.20
pseudofolliculitis 112.24
sarcoidosis 98.7, 98.9
differential diagnosis 98.2, 98.14
vulval 98.14
silicone reactions 123.20–1
tattoo complications 88.54–5, 123.21–2
vitamin injections 123.20
foreskin *see* prepuce
forest plot 17.10
formaldehyde
allergic contact dermatitis 128.33–4
clothing resins 128.45, 128.46
contact with 5.4
exposure **128.33**
hyperhidrosis treatment 94.8
regulatory measures 128.76
resins 128.50–1
topical therapy 18.9, 18.33
formaldehyde-releasing preservatives/biocides 128.34–5
formalin, wart treatment 25.51–2
formication, cocaine use 121.3
Formicidae 34.15
foscarnet
drug eruptions 31.18
herpes simplex virus treatment 31.23
Fournier gangrene 26.74, 111.22, **111.23**
HIV infection 31.20
FOXO2 gene mutations 103.34, 103.36, 103.37, 105.25, 105.30
genital lymphoedema 105.17, 105.18
lymphoedema–distichiasis syndrome 150.3
Fox–Fordyce disease 94.17–18
FOXP-1 3.25
Fox's sign 152.6
fractalkine, Dercum disease 100.16
fractional photothermolysis 160.7
ablative 160.7–8, 160.9, **160.9**, 160.10
non-ablative 160.8, 160.9
fragile X syndrome **74.5**, 76.4–5
macrotonia 108.5
fragrances 128.25–7
allergy
clinical features 128.25–6
prevalence 128.25
avoidance 128.26
delayed-type hypersensitivity 8.60
patch tests 128.26–7
photocontact facial melanosis 88.12
phototoxic 127.28
framycetin 18.11
Francisella tularensis 26.56–7
Franklin disease 110.60
Frank's sign 108.6
coronary artery disease 150.5
freckles *see* ephelides
freckling, axillary in NF1 80.1, **80.2**, 80.3
free fatty acids (FFAs) 90.20
free margins, facial surgery 20.2
friction 123.5–13
callosities/corns/calluses 123.6–8
coefficient 123.6
dynamic 123.6
sports injuries 123.15–16
static 123.6
friction blisters 123.6, 123.8–10
definition 123.8
epidemiology 123.9
management 123.9–10
pathophysiology 123.9
frontonasal dysplasia, hair follicle naevus association 138.7
frostbite 99.35, 125.2–3
acrocrosis 95.47
clinical features 125.2
definition 125.2
ear piercing complications 108.8
investigations 125.2
management 125.2–3
pathophysiology 125.2
prognosis 125.2
severity classification 125.2
fucosidosis 81.5
fuel oils, occupational skin cancers 130.14
fulguration 20.41, 20.42
fumarate hydratase (FH) 147.12
fumaric acid esters 19.15–17
adverse effects 19.16
contraindications 19.16
dermatological uses 19.16
dose 19.16, **19.17**
drug–drug interactions 19.16
monitoring 19.16–17
pharmacological esters 19.16
plaque psoriasis treatment 19.16, **35.26**, 35.28
regimens 19.16, **19.17**
fungal antigens, delayed sensitivity testing 4.24–5
fungal infections 32.1–6
aphthous ulceration 110.40
atrophic scars 96.11
classification **32.3**, 32.3–5
conidia 32.4
dimorphic **32.3**
disseminated
causing arthropathy 154.5
infectious panniculitis 99.44
erythema nodosum **99.19**
external ear 108.15
genital 111.24
heterosexual men 31.26
histological sections 3.39
HIV infection 31.26–8
infectious panniculitis 99.43–4
infective cheilitis 110.87
IRIS/IRD/IRAD **31.36**
irritant contact dermatitis differential diagnosis 129.4
lymphoedema 105.52
mal de Meleda 65.48
microscopy in diagnosis 4.22
moulds 32.3
nails, differential diagnosis **95.44**
neonatal 116.27
occupational irritant contact dermatitis differential diagnosis 130.3
oral lesions 110.53–4
panniculitis 99.58
perineum/perianal region 113.7, 113.11
Pneumocystis jiroveci cutaneous infection 32.95
pruritus ani differential diagnosis 113.5
reproduction 32.4
respiratory disorder association 151.4
spore formation 32.4
subcutaneous mycoses 32.70–81
Basidiobolus 32.80–1
chromoblastomycosis 32.76–8
classification 32.70
Conidiobolus coronatus 32.80–1
culture 32.70
histopathology 32.70
identification 32.70
lobomycosis 32.79
mycetoma 32.73–6
phaeohyphomycosis 32.78–9
rhinosporidiosis 32.79–80
sporotrichosis 32.71–3
superficial mycoses 32.6–23, 32.24, 32.25–8, 32.29, 32.30–70
black piedra 32.15–16
classification 32.6
collection of material 32.7–8
culture 32.8–9
dermatophyte-induced 32.35–51
dermatophytosis 32.18–35
direct examination 32.8
identification 32.6–10
isolate identification 32.10
molecular diagnostics 32.9–10
Neoscytalidium 32.51–3
otomycosis 32.17–18
saprophytic moulds 32.18
tinea nigra 32.14–15
white piedra 32.16–17
systemic mycoses 32.81–96
Aspergillus 32.94–5
blastomycosis 32.85–7
coccidioidomycosis 32.87–9
cryptococcosis 32.92–3
cultures 32.82
Exophiala dermatitidis 32.95
histoplasmosis 32.82–5
identification 32.81–2
mucormycosis 32.94
paracoccidioidomycosis 32.89–90
pathophysiology 32.81
Pythium insidiosum 32.95
serological tests 32.81–2
Talaromyces marneffeii 32.90–1
Trichosporon 32.94–5
taxonomy 32.3–5
vulval 112.25–7
Wood's light examination 32.6–7
yeasts **32.3**
yellow-nail syndrome differential diagnosis 105.34
see also candidosis; *named organisms and conditions*; onychomycosis; otomycosis
fungi
biology 32.2–6
classification 32.2, 32.3–5
conidia 32.5
dimorphic 32.2
erythromelalgia association 103.7
moulds 32.2
nomenclature 32.2–3, 32.5–6
polymorphism 32.5
reproduction 28.4, 32.2–3
spore (conidia) formation 32.4, 32.5
taxonomy 32.3–5
yeasts 32.2

- fungicides, oral submucous fibrosis association 110.56
- funnel web spiders 34.33
- furin 8.36
- furrows, linear 96.2
- furuncle 26.23–5
 - clinical features 26.24–5
 - definition 26.23
 - differential diagnosis 26.24–5
 - epidemiology 26.23
 - investigations 26.25
 - management 26.25
 - pathophysiology 26.23–4
 - PVL 26.24, 26.25
 - variants 26.24
- furunculosis
 - botryomycosis differential diagnosis 26.73
 - diabetes 26.23–4
 - hidradenitis suppurativa differential diagnosis 92.7
 - Mycobacterium fortuitum* infection 27.43
 - perineum/perianal region 113.9–10
 - staphylococcal of pinna 108.11
- Fusarium* spp. 32.55
- fusicidic acid 18.10–11
- fusion inhibitors 31.9
- Fusobacterium* 26.64
 - acute necrotizing (ulcerative) gingivitis 110.52
 - tropical ulcer 26.65–6
- Fusobacterium ulcerans* 26.65
- G**
- gabapentin 86.38
 - restless legs syndrome management 85.17
- gadolinium contrast agents, nephrogenic systemic fibrosis 96.41
- galactorrhoea, endocrine disorder skin signs 149.10
- galactosidosis 81.6
- Galen (Roman physician) 1.3
- gallates 18.8
- gallbladder disorders 152.4–5
- Galli–Galli disease 70.3, 70.14
 - transient acantholytic dermatosis differential diagnosis 87.23
- Gamasida 34.52
- gamma benzene hydrochloride 18.13
- ganglion cysts, digital myxoid cyst 59.15
- gangrene
 - blackfoot disease with arsenic toxicity 122.3
 - Fournier 26.74
 - HIV infection 31.20
 - mixed connective tissue disease 54.2, 54.3
 - noma neonatorum 116.26
 - oro-facial 116.26
 - peripheral 103.2
 - progressive bacterial synergistic 26.74
 - rheumatoid arthritis 55.3
 - synergic with stomas 114.3, 114.4
 - treatment 103.4
 - wet of foot 64.1
 - see also ecthyma gangrenosum; gas gangrene; pyoderma gangrenosum
- gangrenous cellulitis 26.74
- gangrenous pyoderma see pyoderma gangrenosum
- gap junctions 2.19, 2.20
 - function 2.19
 - scarring 10.8
- Gardner syndrome 74.8, 80.13
 - benign symmetrical lipomatosis differential diagnosis 100.15
 - clinical features 80.13
 - epidermoid cysts 134.1
 - investigations 80.13
 - management 80.13
 - Muir–Torre syndrome differential diagnosis 142.39
 - oral lesions 110.24
 - pathophysiology 80.13
- GARFIELD acronym 82.2
- garlic allergy 128.51–2, 128.53
- Garrod's pads 123.11
- gas gangrene 26.47–8
 - necrotizing subcutaneous infection differential diagnosis 26.74
- gastrointestinal cancer, acanthosis nigricans association 87.3, 147.14–15
- gastrointestinal diseases
 - aphthous ulceration 110.41–2
 - Candida albicans* 32.56–7
 - generalized severe recessive dystrophic epidermolysis bullosa 71.25–6
 - glucocorticoid adverse effects 19.19, 19.20
 - malabsorption 152.7
 - microflora and atopic eczema relationship 41.9
 - oral manifestations 110.89
 - retinoid adverse effects 19.38
 - rosacea association 91.4
 - Stevens–Johnson syndrome 119.18
 - systemic lupus erythematosus 51.29
 - systemic sclerosis 56.15
 - toxic epidermal necrolysis 119.18
- gastro-oesophageal reflux, systemic sclerosis 56.4, 56.13, 56.15
- gastrostomy, painful bleeding 114.113
- gastrulation 2.3
- GATA1 gene mutations 116.8
- GATA2 gene mutations 73.20, 105.17, 105.18, 105.30
- Gaucher cells, sphingolipidoses 81.7
- Gaucher disease
 - collodion baby 116.19
 - type 1 81.6, 81.7
 - type 2 65.27, 65.28, 81.6
 - type 3 81.6
- gel(s) 18.2
- gel nails 95.62–3
 - removal 95.63
- gel polish 95.63
- gelatinases 2.33
- gelsolin amyloidosis 110.59
- gemcitabine-associated
 - livedoid thrombotic microangiopathy 99.56–7
- gene therapy 14.1
- gene tracking 7.8
- generalized anxiety disorder (GAD) 86.4
- generalized bullous fixed drug eruption (GBFDE) 12.3, 118.12, 118.13
 - investigations 118.13–14
 - management 118.14
- generalized exfoliative dermatitis (GED) 119.11–12
 - drug-induced 118.17–18, 119.11–12
- generalized follicular basaloid hamartoma syndrome 141.4
- generalized hereditary hypotrichosis simplex 68.4, 68.16
- generalized lymphatic dysplasia 105.27, 105.28
 - swollen face, head and neck 105.15
- generalized skin disease, linear manifestations 75.19
- genes 7.2, 7.4
 - autosomal 7.4
 - copy number variation 7.4
 - features 7.5
 - mutations 7.5–7, 7.8
 - frameshift 7.6
 - gain-of-function 7.6
 - missense 7.5
 - nonsense 7.5
 - point 7.5
 - penetrance 7.4
- genetic counselling 7.9
- congenital erythropoietic porphyria 60.11
- erythropoietic protoporphyria 60.16
- melanoma 143.6
- porphyria cutanea tarda 60.14
- variegate porphyria 60.18
- genetic disorders, obesity 100.26
- genetic linkage 7.8
- genetics/genetic factors 5.9, 7.1–2, 7.2–3, 7.4–10
 - epigenetic phenomena 7.6
 - genetic linkage 7.6
 - historical aspects 1.8
 - infants 117.12–13
 - information websites 7.1–2
 - inheritance 7.2, 7.2–3, 7.4
 - linkage studies 7.8
 - medical 7.2, 7.2–3, 7.4
 - molecular mimicry 7.6
 - mosaicism 7.4, 7.7–8
 - prenatal diagnosis 7.9–10
 - receptor effects 7.6
 - respiratory disorder association 151.4–5
 - terminology 7.2
 - see also pharmacogenetics
- genital candidosis 32.64–6, 111.23
- genital dermatoses
 - allergic 128.18
 - anaphylactoid purpura 111.20
 - Bowen disease 142.18, 142.19
 - deep 'aggressive' angiomyxoma 137.64
 - historical aspects 1.8
 - intraepithelial neoplasia 142.25
 - investigations 111.4
 - lymphangiectasia 105.41
 - male 111.36
 - artefacts 111.7–9
 - benign tumours 111.26–7
 - carcinoma *in situ* 111.27–9
 - examination 111.2–4
 - extramammary Paget disease 147.7
 - history taking 111.2–4
 - inflammatory 111.9–21
 - malignancy 111.29–34
 - non-sexually transmitted infections 111.21–4
 - precancerous dermatoses 111.27–9
 - sexually transmitted infections 111.24–6
 - trauma 111.7–9
 - ulceration 111.4, 111.17–19
- mucous membrane pemphigoid 50.27
- peno-scrotodynia differential diagnosis 84.9
- sarcoidosis 98.14
- Stevens–Johnson syndrome 119.17, 119.18
 - management 119.20
 - management 119.20
 - vulvodynia differential diagnosis 84.9
 - see also vulva; vulval conditions
- genital dysaesthetic syndromes 84.1
- genital herpes 111.24
 - maternal 25.22, 25.23
 - primary 25.20–2
 - recurrent 25.21
- genital intraepithelial neoplasia 142.25
- genital lesions, lichen planus 37.6
- genital melanosis, laser treatment 23.13
- genital naevi, atypical 112.32
- genital oedema 105.5
- genital papular dyskeratosis acantholytic 112.43
- Darier disease differential diagnosis 112.5
- genital ulceration
 - HIV infection 113.13
 - primary herpes genitalis 25.20–2
- genital warts see ano-genital warts
- genitalia, male
 - congenital/developmental abnormalities 111.7
 - embryology 111.4–5
 - fasciitis lesions 99.47
 - function 111.4–5
 - structure 111.4–5
 - swollen 105.17–19
 - variants 111.5–7
- genito-ano-rectal syndrome 30.18
- genito-gingival syndrome 111.16
- genito-urinary tract, generalized severe recessive dystrophic epidermolysis bullosa 71.26
- genodermatoses 7.2
 - hidradenitis suppurativa association 92.2
 - inheritance patterns 7.2, 7.2–3
 - internal malignancy association 147.7–13
 - prenatal diagnosis 7.9–10
 - vulval 112.4–5
- genome 7.1, 7.4
 - sequence 7.8–9
- genome-wide association studies 7.9
- genomic imprinting 7.4–5
- genomics, functional 7.1
- genophotodermatoses 127.1
 - investigations 127.35
- gentamicin 18.11
- gentian violet 18.33, 88.53
- geographic tongue 110.9, 110.13–14, 110.21
 - oral soreness 110.63
 - psoriasis 35.14, 35.15
- geotrichosis, oral lesions 110.54
- geroderma osteodysplastica 72.12
- GGCX gene mutations 72.30
- Gianotti–Crosti syndrome 25.32, 25.37, 25.87–9, 117.11
 - associated infections 25.88
 - clinical features 25.88–9
 - epidemiology 25.88
 - hepatitis association 152.9
 - hepatitis B association 25.64
 - investigations 25.89
 - management 25.89
 - pathophysiology 25.88
 - pityriasis lichenoides differential diagnosis 135.5
- giant cell arteritis 102.33–5
 - clinical features 102.34
 - definition 102.33
 - epidemiology 102.33–4
 - investigations 102.35
 - management 102.35
 - oral lesions 110.54–5
 - pathophysiology 102.34
- giant cell(s), high-power microscopy 3.31–2
- giant cell tumour
 - angioblastoma 137.34
 - fibroblastoma 137.16
 - radiography 95.48
 - of tendon sheath 137.19
- giant condyloma of penis 111.32
- giant lichenification of Pautrier 39.29
- giant melanotrichoblastoma 138.11
- giant water bugs 34.28
- gigantism, macroglossia 110.60
- gingiva
 - argyria 122.7
 - pregnancy changes 115.2–3
- gingivitis
 - acute necrotizing (ulcerative) 110.52–3
 - bacterial, mucous membrane pemphigoid differential diagnosis 50.29
 - desquamative 32.63
 - oral soreness 110.63
 - scurvy association 63.21
- gingivostomatitis
 - mercury toxicity 122.5
 - primary herpetic 25.16–17, 25.18
 - white folded (see white sponge naevus)
- GJB2 gene mutations 65.30
- glanders 26.53–4
- glans penis, psoriasis 35.12
- glatiramer acetate injections
 - lupus panniculitis differential diagnosis 99.36
 - panniculitis 99.48
- glaucoma
 - atopic eye disease 109.22
 - phakomatosis pigmentovascularis 75.23
 - Sturge–Weber syndrome 75.22
 - Gleich syndrome 43.4

- gliadin 50.53
 glial heterotopic nodules 137.52–3
 glial proliferation, tuberosclerotic nodules 80.10
 gliomas 80.10
 Global Burden of Disease 2020 study 5.5–8
 global genome repair (GGR) 9.6
 glomangioma, multiple inherited 137.44
 glomangiomyoma 137.43, 137.44
Glomeromycota 28.3, 28.4, 32.3, 32.4
 glomeruloid haemangioma 137.25
glomulin gene 137.44
 glomus tumour 3.21, 3.22, 137.43–5
 clinical features 137.44–5
 definition 137.43
 epidemiology 137.43–4
 nail 95.22–3
 pathophysiology 137.44
 radiography 95.48
 glomuvenous malformations 73.13–14, 110.15, 137.44
 glossitis
 deficiency 110.64
 folate deficiency association 63.19
 median rhomboid 32.63, 110.71
 riboflavin deficiency differential diagnosis 63.15
 vitamin B₁₂ deficiency association 63.20
 glossodynia *see* burning mouth syndrome
 glossopyrosis *see* burning mouth syndrome
 gloves, hand eczema protection 39.17
 glucagon 145.19–20
 glucagon-like peptide-1 (GLP-1) 145.20
 burns treatment 126.11
 glucagonoma 47.13, 47.14, 47.15, 145.19–20
 oral ulceration 110.56
 glucagonoma syndrome 147.19
 erythema multiforme differential diagnosis 47.5
 necrolytic migratory erythema 47.13, 152.6
 vulval lesions 112.42–3
see also necrolytic migratory erythema
 glucan 31.17
 β-glucan synthase inhibitors 19.43
 glucocorticoid(s) 19.17
 acquired resistance 19.19–20
 adrenal suppression 19.19
 adverse effects 19.18–19
 bone effects 19.19, 19.20
 cautions 19.19–20
 collagen biosynthesis inhibition 2.31
 contraindications 19.20
 dermatological uses 19.17
 dose 19.20–1
 drug–drug interactions 19.20
 infection susceptibility 19.19, 19.20
 mineralocorticoid effects 19.18
 monitoring 19.21
 pharmacological properties 19.17–18
 pre-treatment screening 19.20
 regimens 19.20–1
 steroid withdrawal syndrome 19.18–19
 glucocorticoid receptor 18.14–15
 glucocorticoid receptor b (GRb) 18.15
 glucocorticoid response elements (GRE) 18.15
 gluconolactone 156.3–4
 glucose, sweat composition 94.4
 glucose transporter protein 1 (GLUT-1) 117.18, 117.21
 glucose transporter receptor 4 (GLUT-4) 99.4
 glucose-6-phosphate dehydrogenase (G6PD) deficiency
 antimalarial cautions 19.6, 19.7
 dapsone contraindication 19.14, 19.15
 glue sniffer's rash 121.2
 glutaraldehyde
 aqueous solution 18.33
 hyperhidrosis treatment 94.8
 topical therapy 18.9
 wart treatment 25.51
 gluten, dietary 50.53
 gluten-free diet 50.54, 50.55
 gluten-sensitive enteropathy (GSE)
 dermatitis herpetiformis 50.52–3
 subacute cutaneous lupus erythematosus association 51.12
 glyceryl trinitrate 18.37
 anal fissure management 113.29
 Raynaud phenomenon treatment 125.10
 glycine-glutamate-lysine-glycine (GEGK) 156.4
 glycolic acid
 acquired ichthyoses treatment 87.2
 chemical peel 88.34, 159.2, 159.4, 159.8, 159.9
 skin of colour 159.13
 glycopeptides 19.42–3
 glycoprotein degradation disorders 81.4–5
 classification 81.4
 glycopyrrolate
 gustatory sweating treatment 18.33
 hyperhidrosis treatment 94.9
 glycopyrronium 18.33
 glycosaminoglycans (GAGs) 2.37, 2.38, 2.39, 2.40
 deposition in pretibial myxoedema 105.48
 lysosomal storage disorders 81.2, 81.3
 mechanical function 123.5
 synthesis by fibroblasts 2.40–1
 glycosylation, congenital disorders 81.2, 81.10–12
 Glycyphagidae 34.48
 glycyrrhetic acid 18.35–6
 glypicans 2.37
 G_{M1} gangliosidosis 81.6
 GNAQ mutated melanoma 143.33–4
 gnathophyma 91.8
Gnathostoma hispidum 33.20, 33.21
Gnathostoma nipponicum 33.20
Gnathostoma spinigerum 33.20, 33.21
 gnathostomiasis 33.20–2
 gnats 34.6
 goitre, blepharochalasis association 96.25
 gold
 contact allergy 128.16, 128.23–4
 hyperpigmentation 88.53
 oral 110.66
 immune reactions 122.3
 oro-facial granulomatosis 128.61
 reactions to 122.3–4
 sensitization 122.3
 ear piercing complications 108.7
 Goldenhar syndrome
 microtia 108.4
 peri-auricular anomalies 108.5
 golimumab, psoriatic arthritis
 treatment 19.29, 35.46
 Goltz syndrome/Goltz–Gorlin syndrome
see focal dermal hypoplasia
 Gomm–Button disease *see* Sweet syndrome
 Gomori silver impregnation technique 3.8, 3.9
 gonococcal infections, complement cascade defects 82.17
 gonorrhoea 30.1–4, 30.5, 30.6–8
 causative organism 30.3
 clinical features 30.3–4, 30.5, 30.6–7
 co-morbidities 30.4
 complications 30.4, 30.5
 definition 30.1
 differential diagnosis 30.3–4
 disease course 30.6–7
 epidemiology 30.1–2
 investigations 30.7
 management 30.7, 30.7–8
 nomenclature 30.1
 oral lesions 110.53
 pathophysiology 30.2–3
 perineum/perianal region 113.12
 prognosis 30.6–7
 treatment ladder 30.7
 Good syndrome 148.16, 148.18
 Goodpasture syndrome
 collagen type IV 2.29
see also antiglomerular basement membrane vasculitis disease
 Gordon syndrome, camptodactyly 96.37
 Gorham–Stout syndrome 105.39
 diffuse lymphangiomatosis 137.41
 lymphatic malformations 73.16
 Gorlin naevoid basal cell carcinoma (BCC) syndrome *see* naevoid basal cell carcinoma (BCC) syndrome
 Gorlin's sign 72.4
 Gottron syndrome *see* acrogeria
 Gottron's papules, dermatomyositis 53.6
 Gougerot–Carteaud syndrome 87.5
 gout 154.9–10
 hyperhidrosis 94.5
 hyperlipoproteinaemia type III 62.8
 psoriatic arthritis differential diagnosis 35.44
 tophaceous 99.57, 154.9–10
 gouty panniculitis 99.57–8
 gouty tophi, pinna 108.13, 108.14
 G-protein(s), heterotrimeric 75.20–1
 G-protein-coupled receptors (GPCRs) 14.4, 14.5
 Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach 17.11
 graft-versus-host disease 38.1–11
 acute 38.1, 38.2–3, 38.3–6
 clinical features 38.3–5
 investigations 38.5
 management 38.5–6, 38.7
 severity 38.5
 treatment ladder 38.6
 chronic 32.10, 32.11, 38.1, 38.2, 38.3, 38.6–9
 autoimmune model 38.2
 chronic donor T-cell activation 38.2
 clinical features 32.10, 38.6–9
 clinical variants 38.8–9
 complications/comorbidities 38.9
 management 38.9, 38.11
 sclerotic disease 38.8, 38.9, 100.4
 severity 38.9, 38.10
 treatment ladder 38.11
 classification 38.1
 cutaneous
 extracorporeal photochemotherapy 21.6–7
 UVA-1 phototherapy 21.6
 definition 38.1
 dyskeratosis congenita differential diagnosis 69.15
 epidemiology 38.1–2
 erythema multiforme differential diagnosis 47.5
 lichen planus nail changes 95.45
 lichenoid 112.12
 macrophage inhibitory factor role 8.23
 mast cell role 2.17
 mucocele 110.61
 mucous membrane pemphigoid differential diagnosis 50.29
 ocular complications 109.36
 oral lesions 110.55
 pathophysiology 38.2–3
 skin cancer 146.9
 toxic erythema of chemotherapy differential diagnosis 120.2
 transfusion-associated 148.19
 verruciform xanthoma 110.62
 vulval erosions 112.42
 Graham–Little syndrome 89.39–40
 grain itch 34.49
 grain-shovellers' itch 34.49
 Gram stain 3.10
 Gram-positive bacteria
 coagulase-negative staphylococci 26.9
see also staphylococcal infections; *Staphylococcus aureus*; streptococcal infections
 granular cell tumours 137.51–2
 dermal non-neural 137.62–3
 myoblastoma 112.30
 oral 110.39
 primitive polypoid 137.62–3
 granulation tissue, wound healing 10.3, 10.7
 granulocyte colony-stimulating factor (G-CSF), Sweet syndrome 49.8, 49.9
 granulocyte–macrophage colony-stimulating factor (GM-CSF), atopic eczema 41.10
 granulocytic sarcoma, aphthous ulceration 110.40
 granuloma 3.36
 delayed-type hypersensitivity 8.60
 gravidarum 137.26
 idiopathic facial aseptic 91.15
 milium 116.25
 peristomal 114.11
 schistosomiasis 33.25
 severe combined immunodeficiency 82.8
 telangiectaticum 137.26
see also pyogenic granuloma; sarcoid granuloma
 granuloma annulare 97.1–8
 annular elastolytic giant cell granuloma differential diagnosis 96.27
 annular lichen planus differential diagnosis 37.8–9
 associated diseases 97.2
 clinical features 97.1, 97.3–7
 complications/co-morbidities 97.7
 definition 97.1
 diabetes association 64.5–6
 differential diagnosis 97.6–7
 disease course 97.4
 disseminated 97.4
 drug-induced 97.2
 elastosis perforans serpiginosa differential diagnosis 96.53
 endocrine disorder skin signs 149.10
 epidemiology 97.1–2
 generalized 97.4, 97.5
 hand 97.1
 histological sections 3.40
 HIV infection 31.17
 infections 97.2
 interstitial 97.2, 97.3
 investigations 97.7
 knuckle pads differential diagnosis 96.35
 localized 97.3, 97.4
 malignancy association 147.23
 management 97.7
 necrobiosis lipoidica association 97.2, 97.9
 pathophysiology 97.2–3
 perforating 97.3, 97.4–5, 97.7
 periosis differential diagnosis 125.5
 prognosis 97.7
 sarcoidal 97.3
 scalp 107.6
 subcutaneous 97.3, 97.5, 97.6, 99.13–15
 clinical features 99.13
 differential diagnosis 99.14
 investigations 99.14–15
 necrobiotic xanthogranuloma differential diagnosis 99.17
 pathophysiology 99.13–14
 sun exposure 97.2
 trauma 97.2
 tuberculoid 97.3
 variants 97.3–6
see also necrobiotic granuloma
 granuloma faciale 102.11–13
 clinical features 102.12–13
 epidemiology 102.11
 extrafacial 102.13
 investigations 102.13
 laser treatment 23.11, 23.18
 lymphocytoma cutis differential diagnosis 135.9
 management 102.13
 pathophysiology 102.11–12
 phymatous rosacea differential diagnosis 91.11

- granuloma inguinale 26.66, 30.23–5, **30.25**
 classification 30.23
 clinical features 30.23–5
 complications/co-morbidities 30.25
 definition 30.23
 differential diagnosis 30.24–5
 epidemiology 30.23
 investigations 30.25
 management 30.25
 nomenclature 30.23
 pathophysiology 30.23
 perineum/perianal region 113.12
 treatment ladder **30.25**
- granuloma multiforme 96.27
 leprosy differential diagnosis 28.11, 96.27
- granulomatosis
 autoinflammatory of childhood 45.7
 necrotizing sarcoid 151.5–6
see also lymphomatoid granulomatosis;
 oro-facial granulomatosis
- granulomatosis with polyangiitis 102.23–5, 102.26, 102.27, 110.40, 111.18
 clinical features 102.24–5, 102.26, 102.27
 definition 102.23
 epidemiology 102.23
 genital ulceration 111.18
 management 102.27
 pathophysiology 102.23–4
 respiratory disorder association 151.3
- granulomatous cheilitis 97.11, 110.85–7
 clinical features 110.86–7
 definition 110.85
 differential diagnosis 110.86–7
 epidemiology 110.85–6
 investigations 110.87
 lip fissures 110.88
 management 110.87
 pathophysiology 110.86
- granulomatous dermatosis,
 interstitial 154.8, 154.14
- granulomatous disorders 97.1–13
 beryllium nodules 122.8
 cutaneous Crohn disease 97.11–13
 diabetes 64.5–6
 ear piercing complications 108.7
 mercury toxicity 122.5
 perioral dermatitis **91.18**
see also granuloma annulare; necrobiosis
 lipoidica; sarcoidosis
- granulomatous reactions, allergic contact
 dermatitis 128.61
- granulomatous slack skin disease 96.19, 96.27–8, 140.17–18
- granulosis rubra nasi 94.10
- granzyme 3.24
- grape seed extract (GSE) 156.7, **156.11**
- Graves disease 145.20–1
 endocrine disorder skin signs 149.12
 hypertrichosis 89.63
 myxoedema 59.11, 59.12
 periocular oedema 105.16
 pretibial myxoedema 105.47, 105.48
- greases
 occupational skin cancers 130.14
 topical medication 18.6
- Greater Patient 16.7
- Greece, Hippocrates' era 1.2–3
- green tea 156.7–8, **156.11**
- Greither keratoderma 65.46–7
- grenz zone 3.36
- grey baby syndrome 88.50
- Grey Turner's sign 152.6
- Griselli syndrome **148.17**
 bacterial infections 148.15
 type 1 **70.2**, 70.9
 type 2 82.13–14
- Griselli–Pruniéras syndrome **70.2**, 70.9
- griseofulvin 19.44
 dermatophytosis 32.34
 tinea capitis treatment 32.40
- GRO-a (CXCL1) 8.39
- grocer's itch 34.48
- Grocott silver staining 3.10
- groin
 bacterial flora 26.5
 hidradenitis suppurativa 92.1, 92.5, 92.6, 92.8
 intertrigo 123.16
 ground itch *see* strongyloidosis
 Grover disease *see* transient acantholytic
 dermatosis
- growth factors
 angiogenic 103.1
 keratinocyte function regulation 8.5
 platelets 8.24–5
 wound healing 10.2, 10.3, **10.4**
 augmentation 10.11
- growth hormone *see* recombinant human
 growth hormone (rhGH)
- growth retardation
 atopic eczema 41.22
 Comèl–Netherton syndrome 65.25
- growth retardation, alopecia,
 pseudoanodontia, optic atrophy
 (GAPO) syndrome **68.4**, 68.14, 68.15
- Grzybowski–Torre syndrome 142.37–8
 keratoacanthoma differential
 diagnosis 142.35
 multiple self-healing squamous
 epithelioma differential
 diagnosis 142.37
- Guanieri bodies 25.6
- guanosine analogues 19.44
- Guillain–Barré syndrome, syringomyelia
 association 85.8
- guinea pig maximization test 128.9
- guinea worm *see* dracunculiasis
- guitar nipple 123.12
- gummata 29.6, 29.16, 29.16–17, 29.18
 late congenital syphilis 29.32
 scarring alopecia 107.10
- Gunther disease, epidermolysis bullosa
 differential diagnosis 71.23
- gustatory hyperhidrosis 85.15–16, 94.7–8
- gut microflora, atopic eczema
 relationship 41.9
- gynaecomastia
 endocrine disorder skin signs **149.10**,
 149.11
 secondary hypopituitarism 149.16
- H**
- H₂ receptor(s) 19.4
- H₂ receptor antagonists, wart
 treatment 25.53–4
- Haberland syndrome 100.18
- habit tic, nails 95.17, 95.18
- haem 60.1–2
 biosynthesis 60.2, 60.3
- haemangioendotheliomas
 composite 137.35
 epithelioid 137.38–9
 kaposiform 137.33
 malignant 137.36
 pseudomyogenic 137.35–6
 retiform 137.34
- haemangiomas
 acquired elastotic 137.30
 amniotic band association 105.38
 ano-genital 111.7
 capillary
 lobular 137.26–8
 progressive 137.25
 congenital 117.23
 epithelioid 137.28–9
 cutaneous epithelioid angiomatous
 nodule 137.29–30
 glomeruloid 137.25
 hobnail 137.30–1
 lips 110.15
 lobular capillary of nail
 apparatus 95.21–2
 microvenular 137.31
 oral mucosa 110.15
 papillary 137.26
 pregnancy 115.2
 radiography 95.48
 sinusoidal 137.31–2
 spindle cell 137.32
 symplastic 137.32–3
 verrucous 103.23–4
see also infantile haemangiomas
- haemangiopericytoma, infantile 137.42
- haemangiosarcoma 137.36
- haematological disease
 aphthous ulceration 110.39–41
 non-mast cell in mastocytosis 46.2, 46.3,
 46.6, 46.10
 oral manifestations **110.90**
 urticarial vasculitis co-morbidity 44.2, 44.4
- haematological malignancies
 HPV infections 25.62
 involving the skin 148.10–12
 paraneoplastic syndrome
 association 148.6–10
 pemphigus 125.4
 skin disorders caused by infiltration
 with neoplastic cells 148.2–5
 skin manifestations 148.1–2
- haematoma
 ear piercing complications 108.7
 external ear 108.6–7, 123.16
 paroxysmal of finger 96.16–17, 101.6
 penile 111.7
 subungual 95.16–17, 123.15
- haematopoiesis
 cyclic 148.15, **148.17**
 extramedullary 148.5
- haematopoietic stem cell transplantation
 (HSCT) 81.4
- haematopoietic tumours 147.2
- haematoxylin and eosin (H&E)
 staining 3.7, 3.8
- haemochromatosis 152.5, 154.9
 acanthosis nigricans differential
 diagnosis 87.5
 chemotherapy-induced
 hyperpigmentation differential
 diagnosis 120.9
 hyperpigmentation 88.22, 88.23
 haemosiderin 88.49
 porphyria cutanea tarda risk 60.12–13
- haemodialysis
 arteriovenous shunt complications 153.4
 malnutrition risk 63.6
 porphyria cutanea tarda risk 60.13
 pseudoporphyria induction 60.19
 scurvy association 63.21
- haemoglobin
 light absorption 23.3, 23.5
 selective photothermolysis 23.4
 skin colour 70.1, 88.1
- haemoglobinopathies 148.16
 pseudoxanthoma elasticum-like
 lesions 96.28
- haemolysis transfusion reactions, IVIG
 adverse reaction 19.36
- haemolytic anaemia
 congenital 88.49
 dapsone-induced 19.14
- haemophagocytic
 lymphohistiocytosis 25.32, 136.1,
 136.9–11
 clinical features 25.32, 136.10
 definition 136.9
 diagnostic criteria **136.10**
 epidemiology 136.9
 genetics 136.10, **136.11**
 investigations 136.10–11
 management 25.32, 136.11
 nomenclature 136.9
 pathophysiology 25.32, 136.9–10
 primary 136.9, 136.11
 secondary 136.9, 136.11
 treatment ladder **136.11**
- haemophilia
 HIV infection 31.35
 presentation 101.1
Haemophilus ducreyi 30.20, 30.21, 30.22
 perineum/perianal region 113.12–13
Haemophilus influenzae type b, cellulitis 26.18
- haemopoietic cell transplantation (HCT),
 skin cancer 146.4
- haemorrhagic fever
 with renal syndrome (HFRS) 25.72
see also viral haemorrhagic fevers
- haemorrhoids 113.29–31
 clinical features 113.30–1
 definition 113.29
 epidemiology 113.30
 external 113.30
 internal 113.30
 prolapsed 113.30, 113.31
 management 113.31
 pathophysiology 113.30
 severity classification **113.31**
 thrombosed external 113.30
 anal abscess differential
 diagnosis 113.26
 variants 113.30–1
- haemosiderin, venous stasis
 association 23.14
- haemosiderosis, cutaneous 88.48–9
- haemosiderotic fibrolipomatous
 tumour 137.63
- haemostasis 20.45
- Hailey–Hailey disease 66.1, 66.10–13
 blistering 71.24
 classification 66.10
 clinical features 66.11–13, 112.5
 carbon dioxide laser ablation 23.18
 co-morbidities 66.12–13
 complications 66.12–13
 course 66.13
 cytodiagnosis 3.25–6
 Darier disease differential
 diagnosis 66.4, 112.5
 definition 66.10, 112.5
 differential diagnosis 66.12, 112.5
 epidemiology 66.10
 genetic mutations 66.10–11
 genital papular acantholytic
 dyskeratosis differential
 diagnosis 112.43
 HSV infection 25.16
 investigations 66.13
 management 66.13, 112.5
 nails 95.43
 nomenclature 66.10
 pathophysiology 66.10–11, 112.5
 pemphigus vulgaris differential
 diagnosis 50.7
 perineum/perianal region 113.8
 seborrhoeic dermatitis differential
 diagnosis 40.4
 severity classification 66.12
 squamous cell carcinoma
 association 142.27
 symmetrical drug-related intertriginous
 and flexural exanthem differential
 diagnosis 118.6
 treatment ladder **66.13**, **112.5**
 variants 66.12
 vulval 112.5
- Haim–Munk syndrome 65.61
- hair
 bamboo in Netherton syndrome 89.53–4
 biology 89.2–10
 braiding 89.44–5, 89.60
 bubble 89.60, 89.61
 Chediak–Higashi syndrome 82.14
 chemotherapy effects 120.5–6
 colour
 cosmetic 89.72–4
 variation 89.69
 Comèl–Netherton syndrome 65.25, 82.11
 congenital ichthyoses 65.39
 corkscrew in scurvy 63.21
 cortex 89.5–6
 creeping 123.22
 cuticle 89.5, 89.6
 cuticular cells 2.9, 89.5
 depigmentation
 folate deficiency association 63.19
 induced by chemotherapy 120.6
 vitamin B₁₂ deficiency
 association 63.20
 ectrodactyly–ectodermal dysplasia–cleft
 lip/palate syndrome 67.18

- exclamation mark 89.31
 foreign body 123.22–3
 function 2.43
 greying 2.18, 89.69–70
 premature 89.70
 rapid-onset 89.70
 repigmentation 89.70
 hidrotic ectodermal dysplasia 67.21, 67.22
 HIV infection 31.32–3
 hypohidrotic ectodermal dysplasias 67.12–13
 implantation complications 123.23
 ingrowing 93.1–2, 112.24
 inherited disorders 2.9, 68.1, 68.2–10, 68.11–22
 atrichias 68.3–4, 68.12–15
 diagnosis 68.2–10, 68.23–4
 hair shaft structural abnormalities 68.18–23
 hypertrichoses 68.1, 68.2–3, 68.11
 hypotrichoses 68.4–10, 68.15–18
 inner root sheath 2.9
 iron deficiency 63.24
 junctional epidermolysis bullosa 71.12
 keratin(s) 2.9
 keratin filaments 89.6
 kinky 68.23
 knotting 89.60
 lanugo 116.4
 lichen planus complications 37.11–12
 liver disease 152.8
 medulla 89.6
 melanin 89.68
 melanocytes 89.68–9
 Menkes disease 81.18
 oral 110.21
 outer root sheath 2.9
 pigmentation 89.68–71
 accidental discoloration 89.71
 acquired defects 89.71
 biology 89.68–9
 colour variation 89.69
 loss 89.69–70
 nutritional deficiencies 89.71
 physical phenomena 89.71
 pregnancy changes 115.1, 115.2
 recessive generalized severe dystrophic epidermolysis bullosa 71.16
 red colour 89.69
 regrowth induction 18.36
 minoxidil 18.30, 120.6
 relaxing 89.75
 sample collection in fungal infection 32.7
 seasonal moulting 89.8
 shaft abnormalities 89.49–60
 shedding in infancy 116.3, 117.14
 sinus 123.22–3
 spiky 68.23
 split ends 89.60
 spun-glass 89.57
 straightening 89.75
 structural components 89.6
 sulphur content 89.55
 systemic lupus erythematosus 51.23
 terminal 89.9
 hirsutism 89.64
 thallium poisoning 122.8
 tissue assay for metal poisoning 122.1
 tricho-dento-osseous syndrome 67.19, 68.23
 tricho-rhino-phalangeal syndrome 67.20
 trichothiodystrophy 65.33, 78.9, 78.10
 twisted 89.51, 89.52
 types 89.2
 uncombable 89.57, 89.58
 woolly 68.19–20, 89.57
 palmoplantar keratoderma 65.55–6
 see also hirsutism; hypertrichosis; hypotrichoses
 hair artefact 86.26
 hair bulb 89.4
 melanocytes 89.69
 hair cosmetics 89.71–5, 128.16, 128.32
 bleaches 89.74
 colouring 89.72–4, 128.41–2
 dyes 89.72–4, 128.11, 128.41–2
 metallic 89.73
 synthetic organic 89.73
 permanent waving 89.74–5
 setting lotions 89.75
 vegetable dyes 89.72–3
 hair cycle 2.9, 2.10, 2.45, 89.6–8
 androgenetic alopecia 89.18
 asynchrony 89.8
 control 89.7–8
 disturbance in alopecia areata 89.29–30
 regulation 8.50
 hair discs *see* touch spots
 hair fibre, normal growth 2.9
 hair follicle unit, signalling mechanisms 8.50
 hair follicles 2.1–2, 2.44, 138.1
 alopecia areata 89.30
 anagen 89.3, 89.7
 anatomy 89.3–6
 androgen mechanism of action 89.9–10
 cycles 2.9, 2.10, 2.45, 89.6–8
 asynchrony 89.8
 control 89.7–8
 density 89.2–3
 dermal papilla 89.4–5
 dermal sheath 89.5
 development 2.4, 89.2–3
 dilated pore 138.3
 distribution 89.2–3
 exogen 89.7
 eyelash 109.41
 follicular units 89.3
 groups 89.3
 infundibulum 89.3
 inner root sheath 89.4, 89.5
 innervation 89.6
 isthmus 89.3
 kenogen 89.7
 keratinization 89.5
 melanogenic activity 89.69
 mesenchymal lesions 138.15–16
 miniaturization in balding 89.18
 multigeminate 89.59
 naevi 138.7
 outer root sheath 89.5
 pili multigemini 89.59
 scalp 149.4
 stem cells 2.45, 89.4
 activity regulation 89.8
 suprabulbar region 89.4
 telogen 89.7
 trichilemmal cysts 107.10
 tumours 138.2–5
 types 89.2
 see also follicle and follicular entries; hidradenitis suppurativa
 hair germ cell tumours/cysts 138.7–13
 hair growth 89.8–10
 hair loss
 acquired disorders
 excessive growth 89.61–8
 non-scarring 89.14–34
 scarring 89.34–47, 89.48
 alterations in HIV infection 89.47
 androgens 89.8–10
 axillary 89.9
 beard 89.8
 catagen 89.7, 89.8
 excessive 89.61–8
 facial 89.9
 hypoparathyroidism 145.21–2
 Klinefelter syndrome 76.4
 pubic 89.9
 racial variability 89.9
 rate 89.8
 scalp 89.8
 terminal 89.9
 vellus hair 89.8
 hair loss
 antiretroviral drugs 89.47
 approach to patient 89.10–11, 89.12, 89.13–14
 associated symptoms 89.10
 camouflage 89.21–2
 alopecia areata 89.34
 children 89.11
 clinical examination 89.10–11
 clinical photography 89.11
 family history 89.11
 history 89.10
 HIV infection 89.47, 107.10
 hyperandrogenism 145.18
 infancy 117.14
 infections 89.47
 leprosy 89.47
 male pattern 89.14–15
 medical trauma 89.45
 microscopy 89.11
 patches 89.11
 pattern 89.14–24
 clinical features 89.20–1
 differential diagnosis 89.21
 epidemiology 89.15–16, 89.17
 female 89.15
 follicle miniaturization 89.18
 genetics 89.18–20
 grading 89.15, 89.16
 hormonal influences 89.17–18
 investigations 89.21
 management 89.21–4
 pathophysiology 89.17–20
 sex 89.15–16
 surgical treatment 89.23–4
 scalp biopsy 89.11, 89.13–14
 scarring 86.18
 syphilis 89.47
 wigs 89.21–2
 alopecia areata 89.34
 see also alopecia
 hair matrix tumours 138.13–15
 hair pull test 89.10–11
 hair pulling disorder 86.17
 tic in children 89.46
 hair reduction, laser therapy 23.15–16
 hair removal
 hirsutism 89.66–8
 laser-assisted 23.15, 160.6
 complications 23.15–16
 physical methods 89.66–7
 hair shaft
 fractures 89.44
 pathology terminology 89.50
 structural abnormalities 68.18–23, 89.11, 89.49–60, 89.61
 defects with increased fragility 89.50–6
 defects without increased fragility 89.56–60, 89.61
 trauma 89.60
 weathering 89.54–5, 89.59–60
 colouration 89.71
 hair sinus 123.22–3
 hair styling, traction alopecia 89.44–5
 HAIR-AN (hyperandrogenaemia, insulin resistance and acanthosis nigricans) 87.4, 90.8–9
 hairball 89.46
 hair-thread tourniquet syndrome 123.23
 hairy cell leukaemia 147.24
 hairy ears, acquired 108.6
 hairy leukoplakia 31.33, 110.9, 110.74–5
 HIV infection 31.33, 110.74, 110.75
 half-and-half nails 95.14
 Hallermann–Streiff syndrome 79.2
 sutural alopecia 89.49
 halo sign, giant cell arteritis 102.35
 halogenated salicylanilides 128.78
 hamartomas 103.8
 basaloid follicular 138.13
 Cowden syndrome 80.13
 hair follicle naevus 138.7
 iris 80.1, 80.2, 80.3, 80.4
 pilomatricoma 138.13–14
 rhabdomyosarcomatous congenital 137.57–8
 sclerosing epithelial 138.10
 smooth muscle 137.55
 trichoblastoma 138.11–12
 trichoepitheliomas 138.9–10
 desmoplastic 138.10–11
 solitary giant 138.11
 trichofolliculoma 138.8–9
 tuberous sclerosis complex 80.9
 hand(s)
 acral fibromyxoma 137.62
 callosities 123.8, 123.16
 collagenous and elastotic marginal plaques 96.4–5
 dermatomyositis 53.6–7, 53.8
 gangrene in mixed connective tissue disease 54.2, 54.3
 interdigital sinus 123.22
 neutrophilic dermatosis 49.9, 49.10, 49.11, 148.6
 sensory innervation 20.5
 hand eczema 39.11–18, 129.2, 129.4
 acute 39.18
 advice to patients 129.7
 aetiology 39.12
 atopic 39.17, 41.20, 41.21
 atopic eczema association 39.3
 chronic 39.17–18
 classification 39.12
 clinical features 39.13–17
 complications/co-morbidities 39.16–17
 Compositae allergy 128.52
 definition 39.11
 differential diagnosis 39.16
 disease course 39.17
 epidemiology 39.12
 fingertip 39.14, 39.15
 gloves for protection 39.17
 investigations 39.17
 management 39.17–18
 nickel sensitivity 128.8, 128.20
 occupational 130.2
 patch testing 39.17
 pathophysiology 39.12–13
 prognosis 39.17
 severity classification 39.16
 variants 39.13–16
 vesicular 128.58, 128.59
 hand, foot and mouth disease 25.81–2, 117.6–7
 oral mucosa 110.7, 110.8
 oral ulceration 110.48–9
 hand hygiene, surgery 20.6–7
 hand washing, compulsive 86.20
 hand–arm vibration syndrome 123.23–5, 130.14–15
 clinical features 123.24–5
 definition 123.23
 differential diagnosis 123.24
 epidemiology 123.23–4
 hypothenar hammer syndrome
 differential diagnosis 123.12
 investigations 123.25
 management 123.25
 pathophysiology 123.24
 Raynaud phenomenon differential diagnosis 125.9
 severity assessment 123.24, 123.25
 handicap, caused by skin disease 5.5
 Hand–Schüller–Christian syndrome 136.5
 hangnails 95.38
 Hansemann cells 136.21
 hantavirus pulmonary syndrome 25.72
 haploidy 7.5
 Happle–Tinschert syndrome
 basal cell carcinoma 141.4
 naevi 75.7
 haptenization 119.5
 haptens 12.4, 128.8
 photoactivation 128.78
 harlequin colour change, neonates 116.3
 Hartnup disease 63.16, 81.11, 81.15–16
 Cockayne syndrome differential diagnosis 78.9
 hydroa vacciniforme differential diagnosis 127.24
 harvest mites 34.51–2

- Hashimoto thyroiditis 145.20, 145.21
 interstitial granulomatous dermatosis
 association 154.14
 myxoedema 59.11
 systemic lupus erythematosus
 association 51.31
- Hashimoto–Pritzker disease 136.5
- Haverhill fever 26.72, 131.4–5
- hay fever *see* allergic rhinitis
- Hay–Wells syndrome 67.6
- hazard ratio 5.13
- H-caldesmon 3.21
- head and neck cancers
 metastatic 147.4
 mucinous carcinoma 138.38–9
 risk factors **110.33**
 trichofolliculoma 138.9
- head and neck oedema, DRESS
 syndrome 119.8
- head and neck surgery 20.2–5
 motor nerves 20.4–5
- head, face and neck, swollen 105.14–17
- head lice 34.18–21
 clinical features 34.19
 epidemiology 34.18
 investigations 34.19–20
 management 34.20–1
 pathophysiology 34.18–19
 pesticide resistance 34.20
 therapeutic failure 34.21
- Heaf test 4.24
- health anxieties 86.20
- health economics 6.1–9
 approaches 6.1–5
 comparative studies 6.3, 6.4–5
 cost analysis study 6.3
 cost-of-illness study 6.3–4
 economic burden 6.1, 6.5–9
 evaluations 6.2–5
 implementation of findings 6.5
 indirect costs 6.3–4
 methods 6.1–5
 non-comparative studies 6.3
 quality of life 6.3, 6.4–5, 6.9
 types of evaluations 6.2–5
- health-related quality of life (HRQoL) 16.4
- hearing aids, dermatitis 128.16
- heat
 bubble hair 89.60, 89.61
 carcinomas 125.12–13
 diseases caused by 125.12–13
 physiological reactions 125.11
- heat-shock protein 90a, wound
 healing 10.11
- heat-shock protein(s), Behçet disease 48.3
- heavy metals
 oral hyperpigmentation 110.66–7
 toxicity
 protein–energy malnutrition
 differential diagnosis 63.4
 Raynaud phenomenon differential
 diagnosis 125.9
- heavy-chain disease 110.60
- Heberden nodes 154.8
 knuckle pads differential
 diagnosis 96.35
- Heck disease 110.60
- hedghog pathway inhibitors
 basal cell carcinoma treatment 141.15
 naevoid basal cell carcinoma syndrome
 treatment 141.20–1
- heel
 calcified cutaneous nodules 117.14
 piezogenic pedal papules 123.25–6
- Helicobacter pylori* 152.1
 hereditary angio-oedema
 association 43.3
 iron deficiency association 63.24
 urticaria association 42.3, 42.6, 42.7
- helminth infections
 atopic eczema protection 41.8–9
 perineum/perianal region 113.11–12
- heloma *see* corns
- hemidesmosomal–anchoring filament
 complexes 2.44
- hemidesmosomes 2.21, 2.25–6, 2.27
 components 2.25
 gene mutations 2.25–6
 ultrastructure 2.25, 2.26
- Hemiptera 34.23–5, 34.26, 34.27–8
 Anthoridae 34.28
 Belostomatidae 34.28
 Cimicidae 34.24–5, 34.26, 34.27
 classification 34.23–4
 Pentatomidae 34.28
 Reduviidae 34.27–8
- Hemiscorpius* 34.35
- henna 89.72–3
 nail plate pigmentation 95.12
 tattoos 88.54
- Hennekam lymphangiectasia–
 lymphoedema syndrome 73.19
- intestinal lymphangiectasia 105.42
- Henoch–Schönlein purpura
 genital 111.20
see also IgA vasculitis
- heparan sulphate proteoglycans
 (HSPGs) 2.25, 59.1
- heparin
 antiphospholipid syndrome
 treatment 52.3
 cutaneous sclerosis induction 96.43
- heparin necrosis
 clinical features 101.10–11
 management 101.10–11
 pathophysiology 101.10
 purpura 101.10–11
- heparin-induced thrombocytopenia
 (HIT) 101.10–11
- hepatic haemangioma 117.21
- hepatic porphyria, hypertrichosis 89.63
- hepatitis 25.63–5
 Gianotti–Crosti syndrome 152.9
 HSV infection 25.16
 pyoderma gangrenosum 152.9
- hepatitis A virus 25.79, 25.83–4, 152.4
- hepatitis B virus 25.63–5
 clinical features 25.64
 complications/co-morbidities 25.64
 dermatoses 152.4–5
 epidemiology 25.64
 human bites 131.6
 lichen planus 37.2, 37.13
 management 25.64–5
 pathophysiology 25.64
 polyarteritis nodosa 102.30
 polyarthritis 154.2–3
 urticarial vasculitis association 44.2
 variants 25.64
- hepatitis C virus 25.65
 antibodies with cryoglobulins 101.13
 chronic 25.65
 cryoglobulinaemic vasculitis 102.17
 dermatoses 152.5
 human bites 131.6
 lichen planus 37.2, 37.13
 management 25.65
 necrolytic acral erythema 25.65, 152.5
 polyarthritis 154.2–3
 porphyria cutanea tarda
 management 60.14
 risk 60.13
 urticaria association 42.7, 47.6
 urticarial vasculitis association 44.2
 variants 25.65
- hepatobiliary disease, pruritus 83.11
- hepatocellular carcinoma, pityriasis
 rotunda association 87.7
- hepatocyte growth factor activator
 inhibitor 1 (HAI-1) 8.42
- hepatoerythropoietic porphyria 60.12
- hepatolenticular degeneration 81.19
- hepatomegaly, neonatal lupus
 erythematosus 51.38
- hepatovirus 25.80, 25.83
- herbal products/medications 86.40
 acne therapy 90.49
 cosmeceutical use 156.5–10, **156.11**
- hereditary angio-oedema (HAE) 43.1,
 43.2, 110.9
 clinical features 43.4–5
 diagnosis 110.9
 disease course/prognosis 43.4
 emergency treatment 43.5
 epidemiology 43.2
 genetics 43.3–4
 long-term prophylaxis 43.6
 management 19.34, 43.5–6, 110.9
 oral reactions 110.9
 pathophysiology 43.3–4
 precipitating event 110.9
 protease inhibitor deficiency 8.41
 short-term prophylaxis 43.5–6
 subacute cutaneous lupus
 erythematosus association 51.12
- hereditary anonychia 69.16
- hereditary autoinflammatory
 disorders 154.10
 drug-induced serum sickness-like
 reaction differential diagnosis 118.9
- hereditary benign intraepithelial
 dyskeratosis
 oral lesions 110.18
see also Witkop–von Sallmann syndrome
- hereditary benign telangiectasia 103.18
- generalized essential telangiectasia
 differential diagnosis 103.17
- hereditary coproporphyrria 60.4, 60.6, 60.7,
 60.17
- hereditary disease *see* inherited disorders;
named hereditary disorders
- hereditary epidermal polycystic disease *see*
 steatocystoma multiplex
- hereditary gelsolin amyloidosis 110.59
- hereditary haemorrhagic telangiectasia
 (HHT) 73.8–9, **103.9**, 103.10
 arteriovenous malformations 73.7
 association 103.19, **103.20**
 generalized essential telangiectasia
 differential diagnosis 103.17
 lips 110.14–15
 liver disease association 152.8
 oral mucosa lesions 110.14–15
- hereditary leiomyomatosis and renal cell
 carcinoma syndrome 147.12, 153.2
- hereditary lipomatosis 74.6, **74.8**
- hereditary lymphoedema
 autosomal dominant primary 73.18
 type 1A 73.17–18
- hereditary mucoepithelial dysplasia
 (HMD) 110.15–16
 ichthyosis follicularis with atrichia and
 photophobia syndrome differential
 diagnosis 65.23
 perineal intertriginous plaques 113.4
- hereditary multiple carboxylase
 deficiency 63.23
- hereditary non-polyposis colon
 cancer (HNPCC), Muir–Torre
 syndrome 90.27, 138.16, 142.38,
 147.12
- hereditary panniculitis 74.9
- hereditary periodic fevers 45.4–7
- hereditary polymorphous light eruption of
 American Indians 127.9
- hereditary progressive mucinous
 histiocytosis 136.21
- hereditary sensory and autonomic
 neuropathies (HSANs) 85.10–12
 classification 85.11
 definition 85.10
 epidemiology 85.11–12
 self-mutilating behaviour 85.11–12
 types 85.11–12
- hereditary sensory motor neuropathy type
 III 28.12
- hereditary symmetrical dyschromatosis,
 freckles 88.16
- heredopathia atactica polyneuriformis *see*
 Refsum disease
- Hermansky–Pudlak syndrome 2.17, **70.2**,
70.8, **148.17**
 bacterial infections 148.15
 basal cell carcinoma **141.5**
 immune dysregulation 82.13–14
- oculocutaneous albinism differential
 diagnosis 70.7
 platelet function abnormalities 101.3
- heroin use 121.3
Clostridium sordelli association 26.48
- herpangina 25.82–3
 oral mucosa 110.7, 110.8
 oral ulceration 110.48
- herpes B virus infection 25.38
- herpes genitalis 111.15, 111.24
 maternal 25.22, 25.23
 primary 25.20–2
 recurrent 25.21
- herpes labialis 25.18–19
 reactivation 25.39
 recurrent 110.80–1
- herpes simplex virus (HSV) 25.15,
 25.16–23
 aciclovir resistance 31.23
 allergic contact dermatitis differential
 diagnosis 128.62
 aphthous ulceration 110.40
 atopic eczema risks 41.13, 41.30
 Bell palsy 25.19
 biology 25.16
 blepharoconjunctivitis 109.38, 109.39
 brucellosis differential diagnosis 26.59
 children with HIV infection 31.35
 conjunctivitis 109.38, 109.39
 cytodiagnostics 3.26
 eczema herpeticum 25.39–41
 erythema multiforme 25.19, 47.2–3, 47.6
 fixed drug eruption differential
 diagnosis 118.12
- hand, foot and mouth disease
 differential diagnosis 25.82
- heterotopic sebaceous glands differential
 diagnosis 93.12
- HIV infection 31.22–3
 children 31.35
 oral 31.33
 HIV replication activation 31.23
- hypertrophic 112.28
- immune restoration disease 31.22, 31.36
- infective cheilitis 110.87
- inoculation 25.23
- Langerhans cell histiocytosis differential
 diagnosis 136.6
- lymphocytoma cutis in scars 135.9
 management 19.44
- neonatal 25.22–3, 116.21–2
 epidermolysis bullosa differential
 diagnosis 71.23
- ocular manifestations 109.38, 109.39
- perineum/perianal region 113.11
- pinna 108.11
- pregnancy 115.3
- primary 25.15
 herpes genitalis 25.20–2
 primary herpetic
 gingivostomatitis 25.16–17, 25.18
- prophylaxis 160.9
 reactivation
 by PUVA 21.12
 by UVB phototherapy 21.11
- recurrent infection 25.16
 genital 25.21
 labial 110.50
 oral 110.50
 oro-facial and cutaneous 25.18–20
 secondary bacterial infection 31.22
- stomatitis 110.7, 110.8, 110.49–50
 causative organisms 110.49
 clinical features 110.49, 110.50
 disease course/prognosis 110.49
 investigations 110.49
 management 110.50
 pathology 110.49
- subclinical virus shedding 25.16
- vulval 112.28
see also herpes genitalis; herpes labialis
- herpes simplex virus type 1 (HSV-1),
 Behçet disease association 48.2
- herpes zoster
 clinical features 110.51

- complex regional pain syndrome
 association 85.13
 cytodiagnostics 3.26
 hair pigmentary defect 89.71
 Hodgkin disease 140.50
 infancy 116.22
 Langerhans cell histiocytosis differential
 diagnosis 136.6
 management 19.44, 110.51
 mouth ulcers 110.51
 neurogenic bladder dysfunction 153.6
 ocular manifestations 109.38, 109.40
 oticus 25.29
 pinna 108.11, 108.15
 post-herpetic neuralgia 84.3, 84.4
 reactivation 84.4
 vaccine for prevention 84.5
 transient acantholytic dermatosis
 differential diagnosis 87.23
see also zoster infection
- herpesvirus infections 25.15–41
 biology 25.15
 eczema herpeticum 25.39–41
 herpes B virus 25.38
 human bites 131.6
 oral ulceration 110.49–51
 reactivation in DRESS syndrome 119.6
see also cytomegalovirus (CMV);
 Epstein–Barr virus (EBV); herpes
 simplex virus (HSV); human herpes
 virus (HHV); varicella-zoster virus
 (VZV)
- herpetic gingivostomatitis, primary 25.16–
 17, 25.18
- herpetic whitlow 25.23, 95.35–6
 acrodermatitis continua of Hallopeau
 differential diagnosis 35.42
 blistering distal dactylitis differential
 diagnosis 26.34
- herpetiform ulceration 110.29
 12-HETE 8.48
 15-HETE 8.48
- heterochromia of iris, facial
 hemiatrophy 96.18
- heterosexual men, fungal infections 31.26
- heterotrimeric G-protein mosaic
 disorders 75.20–1
- heterozygous 7.2
 Heubner arteritis 29.6–7
 hexachlorobenzene, hypertrichosis 89.63
 hexachlorophene 18.10
cis-6-hexadecenoic acid 26.5
 HFE gene mutations 88.22
 hibernoma 137.59
- hidradenitis, neutrophilic eccrine 94.13–
 14, 120.1, 120.2
- hidradenitis suppurativa 90.31, 92.1–11
 acne conglobata association 90.54,
 154.10
 anal abscess differential
 diagnosis 113.26
 ano-genital 113.21–3
 clinical features 92.4–7, 92.8, 92.9,
 113.21–2
 carbon dioxide laser incisional
 surgery 23.18
 complications/co-morbidities 92.9,
 154.11
 definition 92.1, 113.21
 diagnostic criteria 92.4
 differential diagnosis 92.7, 113.21
 disease course 92.9
 dissecting cellulitis of scalp
 association 107.8
 epidemiology 92.1–2, 113.21
 folliculitis differential diagnosis 113.10
 furunculosis association 113.9
 genetics 92.4
 investigations 92.9, 113.22
 latent class analysis 5.4
 malakoplakia differential
 diagnosis 112.25
 management 92.9–11, 113.22–3
 obesity aggravation 100.26
 pathophysiology 92.2–4, 113.21
- perianal 113.21–3
 pilonidal sinus differential
 diagnosis 113.24
 predisposing factors 92.2–3
 presentation 92.4–7
 prognosis 92.9
 severity classification 92.7, 92.8, 92.9,
 113.21, 113.22
 squamous cell carcinoma
 association 142.27
 variants 92.7
- hidradenoma
 malignant 138.36
 papilliferum 112.31, 138.21–2
- hidrocantoma simplex 138.25
- hidrotic ectodermal dysplasia 67.21–2
 plantar keratoderma differential
 diagnosis 69.12
see also Clouston syndrome
- high density lipoprotein (HDL), acquired
 generalized lipodystrophy 100.1,
 100.2
- high-intensity focused ultrasound
 (HIFU) 160.12
- highly active antiretroviral therapy
 (HAART)
 HIV-associated lipodystrophy 100.6,
 100.7, 100.8
 immunosuppression-associated
 eosinophilic pustular folliculitis
 association 93.8
- Hippoboscidae 34.7
- Hippocrates (Greek physician) 1.2–3
- hirsutism 89.64–8
- clinical features 89.64–6
 hyperandrogenism 145.18
 hypertrichosis differential
 diagnosis 68.12
 idiopathic 89.64, 89.65–6
 investigations 89.66
 management 89.66–8
 PCOS 89.64, 89.65
 SAHA syndrome 89.65
 severity classification 89.66
 variants 89.65–6
- histamine 8.2, 8.46–7, 19.3–4
 basophils 8.19
 cellular source 8.47
 itching in skin disease 83.6
 mast cell mediator 8.20–1
 pruritus 41.14
 receptors 8.46
 regulation of formation/release 8.47
 seborrheic dermatitis association 40.2
 solar urticaria 127.21
 urticaria 42.4, 42.5, 42.12–13
- histamine receptors
 itching in skin disease 83.6
 urticaria 42.4
- histamine suppressor factor (HSF) 8.47
- histatins 8.13, 8.14
- histiocytes
 function 136.1–2
 high-power microscopy 3.31
 malignant proliferation 136.26–7
 ontogeny 136.1
 sea-blue 136.20
- histiocytic disorders, xanthomas 62.2
- histiocytic lymphoma, true 136.27–8
- histiocytic markers 3.23
- histiocytic sarcoma 136.28–9
- histiocytoma
 cutis 137.19
 dermatofibrosarcoma protuberans
 differential diagnosis 137.15
 Kaposi sarcoma differential
 diagnosis 31.29
 rheumatic fever 55.2
see also fibrous histiocytoma
- histiocytoses 136.1–29, 136.15–16
 aphthous ulceration 110.41
 benign cephalic 136.14, 136.15
 infants 117.15
 classification 136.2
- dendritic cell disorders 136.1, 136.2–8
 diffuse plane xanthomatosis 136.18,
 136.19
- Erdheim–Chester disease 136.19–20
- familial sea-blue 136.20–1
- generalized eruptive 136.14–15
- haemophagocytic
 lymphohistiocytosis 136.1, 136.9–11
- hereditary progressive mucinous 136.21
- histiocytic sarcoma 136.28–9
- intralymphatic 154.8, 154.14
- juvenile xanthogranuloma 136.12–14,
 136.20
- malakoplakia 136.21
- multicentric
 reticulohistiocytosis 136.22–4
- necrobiotic xanthogranuloma 136.21–2
- non-dendritic cell disorders 136.9–11
- non-Langerhans cell 117.15, 136.11–26
- progressive nodular 136.16
- reticulohistiocytoma 136.20–1
- sinus with massive
 lymphadenopathy 136.24–6
- true histiocytic lymphoma 136.27–8
- xanthoma disseminatum 136.17–18
see also Langerhans cell histiocytosis;
 malignant histiocytosis
- histiocytosis and lymphadenopathy
 syndrome 68.2, 68.11–12
- histiocytosis X *see* Langerhans cell
 histiocytosis
- histone deacetylase inhibitors 140.27
- histone H4 26.5
- histopathology of skin 3.1–40
 artefacts 3.27–8
 laboratory methods 3.5–27
 microscopic examination of tissue
 sections 3.29–40
 report 3.33
see also biopsy of skin
- Histoplasma capsulatum* 32.82–5
 identification 32.84–5
- histoplasmin test 4.24–5
- histoplasmosis 32.82–5
 acute disseminated 32.83–4
 acute pulmonary 32.84
 African 32.84, 32.85
 asymptomatic 32.83
 chronic pulmonary 32.84
 clinical features 32.83–5
 disseminated 31.27
 chronic 32.84
 epidemiology 32.82–3
 genital 111.24
 HIV infection 31.26–7
 HIV infection-associated 32.84, 32.85
 investigations 32.84–5
 Kaposi sarcoma differential
 diagnosis 31.29
 management 32.85
 oral lesions 110.54
 pathophysiology 32.83
 perineum/perianal region 113.11
 primary cutaneous 32.84
 treatment ladder 32.85
 variants 32.83–4
- history of dermatology 1.1–8
 after the fall of Rome 1.3–4
 ancient civilizations 1.1–2
 Britain in late 19th century 1.6
 French physicians 1.4–5
 German-speaking Europeans 1.6
 natural sciences 1.6
 rational medicine 1.2–3
 scientific dermatology 1.4–7
 speciality development in 20th
 century 1.7–8
 surgery 1.8
 United States 1.6–7
- HIV infection 31.1–35, 31.36
 acanthosis nigricans 31.12
 acquired hairy ears 108.6
 alopecia 107.10
 alopecia areata 107.10
 anal fissure differential diagnosis 113.29
- ano-genital *Malassezia* 111.12
 ano-genital ulceration 113.13
 antibody response 31.4–5
 antiretroviral drugs 31.9–11
 aphthous ulceration 110.39, 110.40,
 110.54
 arterial thrombosis 31.13
 arthropathy 154.2–3
 atopic eczema 31.14
 bacillary angiomatosis association 26.61
 bacterial infections 31.20–2
 children 31.35
 blastomycosis association 32.86
 botryomycosis 26.73
 candidosis 31.26, 32.59
 infants 116.23
 management 32.61
 oral 31.33, 110.70–1, 110.73
 CCR2 role 8.39
 CCR5 role 8.39–40
 CD4 count 31.7, 31.8
 drug hypersensitivity 31.19
 treatment initiation 31.10
 CD4 receptor 31.3
 CD4 T-cell responses 31.5
 CD8 count 31.7
 CD8 T lymphocytes 31.5
 cellular responses 31.5
 chancroid association 30.20, 30.21, 30.23
 children 31.34–5
 chronic actinic dermatitis
 association 127.14
 clinical features 31.5–8
 coagulopathy 31.13
 co-infections 31.8
 reactive arthritis 154.2
 tuberculosis 27.1, 27.3, 27.10
 complications/co-morbidities 31.7–8
 crusted scabies 34.45
 cryptococcosis 31.27
 association 32.92, 32.93
 cutaneous larva migrans 31.28
 CXCR4 expression 8.39
 cytomegalovirus 31.23–4
 definition 31.1
 Demodex 31.28
 dendritic cell role 31.5
 dermatological manifestations 31.11–35,
 31.36
 diagnosis 31.11–12
 investigations 31.12
 of seroconversion 31.7
 dermatophytosis 31.26
 children 31.35
 diagnosis 31.8, 31.9
 differential diagnosis 31.7
 diffuse infiltrative lymphocytosis
 syndrome 154.3
 disease course 31.8
 disseminated lichenoid papular
 dermatosis of AIDS 95.45
 DRESS association 119.5
 drug eruptions 31.17–20
 children 31.35
 mechanisms 31.18
 drug-induced conditions 31.34
 eosinophilic folliculitis 31.16
 eosinophilic pustular folliculitis
 immunosuppression-associated 93.8
 infantile 93.9
 epidemiology 31.2
 Epstein–Barr virus
 children 31.35
 hairy leukoplakia 31.33
 erythroderma 31.14
 association 39.31
 eyelid Kaposi sarcoma 109.51
 folliculitis 89.47, 107.10
 eosinophilic 31.16
 immunosuppression-associated
 eosinophilic pustular 93.8
 infantile eosinophilic pustular 93.9
 fungal infections 31.26–8
 genital ulceration 111.25
 granuloma annulare 31.17

- HIV infection (*continued*)
 granuloma inguinale association 30.23
 haemophilia 31.35
 hair abnormalities 31.32–3
 hair loss 89.47
 hairy leukoplakia 31.33, 110.74, 110.75
 herpes simplex virus 31.22–3
 children 31.35
 oral 31.33
 high-power microscopy 3.33
 histoplasmosis 31.26–7
 association 32.84, 32.85
 human papillomavirus 25.61–2, 31.24–5
 children 31.35
 oral 31.33–4
 humoral response 31.4–5
 hyperpigmentation 31.12–13
 hypertrichosis of eyelashes 89.47
 ichthyosis 31.12
 immunology 31.3–4
 immunosuppression 31.5
 immunosuppression-associated
 eosinophilic pustular
 folliculitis 93.8
 infections 31.20–9
 inflammatory dermatoses 31.13–17
 intravenous drug use 31.35
 intrinsic immunity 31.4
 investigations 31.8, 31.9
 lymphogranuloma venereum
 association 30.16, 30.17
 lymphoma 31.31–2
 macrophage target 8.23
 malakoplakia 31.29
 management 31.9–11
 mechanism of action 31.3, 31.4
 melanoma 31.30–1
 Merkel cell carcinoma 145.2
 microblasts 31.9
 molluscum contagiosum 31.25
 mouth ulceration 110.54
 mycobacterial infections
 non-tuberculous 27.32
 tuberculosis co-infection 27.1, 27.3,
 27.10
 myopericytoma 137.42
 nail colouration 95.14, 95.15
 nail disorders 31.32–3
 neonates 116.23
 neoplasms 31.29–32
 non-melanoma skin cancer 31.30–1
 onchocerciasis 31.28
 onychomycosis 31.26, 31.32
 oral hyperpigmentation 110.67
 oral lesions 110.51, 110.54
 mucosal white lesions 110.9
 warts 110.62
 oro-pharynx 31.29, 31.33–4
 papular pruritic eruption 116.23
 parvovirus B19 31.25
 pathophysiology 31.2–5
 perineum/perianal region 113.13
 periodontal disease 31.33
 pigmentary disorders 31.12–13
 pityriasis rubra pilaris association 36.1,
 36.2
Pneumocystis jiroveci cutaneous
 infection 32.95
 porphyria cutanea tarda 31.17
 risk 60.13
 pregnancy 31.34, 115.4
 presentation 31.6–7
 prevention 31.9
 primary infection 31.3–4
 symptomatic 31.6
 prognosis 31.7, 31.8
 progression to AIDS 31.6, 31.8
 predictors 31.8
 protozoal infections 31.28
 pruritic papular eruption 31.16–17
 pruritus 31.12
 psoriasis 31.15–16, 35.18
 psoriatic arthritis 35.44
 radiotherapy 31.34
 reactive arthritis co-infection 154.2
 replication and herpes simplex
 virus 31.23
 scabies 31.28
 scalp 107.10
 seborrhoeic dermatitis 31.14
 association 40.1, 40.4
 skin cancer 146.3
Staphylococcus aureus carriage 26.7
 strongyloidosis 31.29
 syphilis
 CSF examination 29.26
 differential diagnosis 29.19
 telogen effluvium association 89.47,
 107.10
 testing 31.11–12
 thrombocytopenic purpura 31.13
 toxic shock syndrome association 26.30
 transmission to infants 116.23
 treatment guidelines 31.9–10
 tuberculosis co-infection 27.1, 27.3, 27.10
 vaccination 31.9
 variants 31.7
 varicella-zoster virus 31.23
 venous thrombosis 31.13
 viral infections 31.22–5
 viral load 31.8
 viral replication suppression 31.9
 virology 31.2–3
 visceral leishmaniasis 33.50–1
 vitiligo 31.12, 31.13
 warts 25.61–2
 women 31.34
 xerosis 31.12
 yellow nails 95.15
see also immune reconstitution
 associated disease (IRAD); immune
 reconstitution inflammatory
 syndrome (IRIS); immune
 restoration disease (IRD); Kaposi
 sarcoma
 HIV-1 31.2–3
 HIV-associated lipodystrophy 100.6–8
 clinical features 100.7–8
 differential diagnosis 100.7
 epidemiology 100.6–7
 management 100.8
 pathophysiology 100.7
 severity classification 100.7–8
 HLA-B27 haplotype 154.5
 HMB-45, melanoma diagnosis 3.21
 hoarseness
 plantar keratoderma 69.12
 systemic disease 151.7
 hobnail haemangioma 137.30–1
 Hodgkin disease
 acquired ichthyoses 65.40
 cutaneous manifestations 140.49–50
 erythroderma 39.32
 granulomatous slack skin disease
 association 140.18
 HIV infection 31.31
 ichthyosis association 147.17
 Kaposi sarcoma association 139.5
 malignant histiocytosis differential
 diagnosis 136.27
 paraneoplastic pemphigus
 association 148.8
 pigmentation 88.19
 sarcoidosis association 98.2
 skin involvement 148.4
 urticarial vasculitis association 44.2
 warts 25.62
 hogweed, giant 129.10
 holistic management 15.1–4
 caring attitudes 15.2
 dermatological disease 15.2–3
 information websites 15.3–4
 patient empowerment 15.3–4
 scientific medicine tensions 15.2
 support organizations 15.4
 holocarboxylase synthetase
 deficiency 63.23, 81.17
 holster sign 53.6, 53.7
 homocystinuria, Marfan syndrome
 differential diagnosis 72.16–17
 homozygosity 7.2, 7.4
 honey, topical application 18.34
 honeybee 34.14
 hooking thumb 123.16
 hookworm 33.15
 hordeolum 109.41
 hormonal therapy
 papulopustular acne 90.42–4
 severe acne 90.44
 hormones
 active metabolites 149.7
 biological effects 149.7
 gender differences 149.7
 hidradenitis suppurativa
 association 92.2
 neuroendocrine 149.6–7
 skin as target 149.7–8
 hormone-sensitive lipase (HSL) 99.4, 99.5
 Horner syndrome 85.14–15
 facial hemiatrophy 96.18
 horns 34.15
 venom 34.15
 horse flies 34.7, 34.8
 horse(s), glanders infection 26.53–4
 horse rider's pernio 99.34, 99.35, 125.4
 horseradish peroxidase 3.15
 Horton disease *see* giant cell arteritis
 host defence, hidradenitis suppurativa
 association 92.2–3
 house flies 34.7
 house-dust mite 8.56
 atopic eczema 41.28, 41.32
 Howel-Evans syndrome 147.7, 152.1
 malignancy 65.59
 punctate palmoplantar keratoderma
 differential diagnosis 65.52
 striate palmoplantar keratoderma
 differential diagnosis 65.51
 HOX genes, expression by fibroblasts 2.41
 Hoyeraal–Hreidarrson syndrome 69.15,
 77.3
 HRAS gene mutations 75.2, 142.35
 mosaicism 75.6, 75.7–8
 Hughes syndrome *see* antiphospholipid
 syndrome
 human bites 131.6
 infants 117.13, 117.14
 human collagen fillers 157.6
 human β -defensin 1 (HBD-1) 8.14
 human genome, organization 7.4
 Human Genome Project 7.1
 human granulocytic anaplasmosis *see*
 ehrlichiosis
 human herpes virus (HHV)
 CXCR2 receptor expression 8.39
 drug exanthem association 12.3
 IRIS/IRD/IRAD 31.36
 roseola infantum 25.34–5
 human herpes virus 6 (HHV-6) 25.34–5
 lichen planus 37.2
 oral lesions 110.51, 110.52
 pityriasis rosea 25.90
 in pregnancy 115.9
 reactivation 25.35–6
 roseola infantum 117.6
 human herpes virus 7 (HHV-7) 25.34–5,
 25.35
 lichen planus 37.2
 oral lesions 110.52
 pityriasis rosea 25.90
 reactivation 25.35–6
 roseola infantum 117.6
 human herpes virus 8 (HHV-8) 25.37–8,
 31.29
 CXCR2 receptor expression 8.39
 immunohistochemical staining 139.4
 Kaposi sarcoma 139.1, 139.2–3, 146.7
 lymphoma 31.31
 oral lesions 110.52
 human leukocyte antigens (HLA) 3.24, 7.6
 class I alleles 14.10–11
 class II alleles in pemphigus 50.4
 disease associations 7.6, 7.7
 drug-induced adverse reactions 12.5
 lichen planus 37.3
 subacute cutaneous lupus
 erythematosus 51.13
 systemic sclerosis 56.11
 human papillomavirus (HPV) 25.43,
 25.44–5, 25.45–63
 actinic keratosis 142.3
 anal squamous cell carcinoma 113.19
 ano-genital 111.25
 associated intraepithelial and invasive
 neoplasias 25.58–9
 biology 25.45–6
 Bowen disease 142.18
 cervical carcinoma 25.45, 25.58–9
 cervical infection 25.45
 children with HIV 31.35
 clinical features 113.14
 clinical lesions 25.44–5
 definition 25.43, 113.13
 disease domain 25.43, 25.45
 epidemiology 113.13
 epidermodysplasia verruciformis 25.59–
 61, 26.60, 146.1
 genital infection 25.45
 genital intraepithelial neoplasia 142.25
 Hailey–Hailey disease 66.13
 heterotopic sebaceous glands differential
 diagnosis 93.12
 HIV infection 25.61–2, 31.24–5
 children 31.35
 oral 31.33–4
 iatrogenic immunosuppression 25.63
 immune compromise 25.61–3
 immunity 25.46
 infective cheilitis 110.87
 investigations 113.15
 keratinocyte effects 8.5
 latent infection 25.45–6
 lymphangiectasia differential
 diagnosis 105.41
 malignancy 25.45, 31.24
 management 113.15
 oral cavity cancer 110.34
 oral papilloma 110.61
 oro-pharyngeal carcinoma 31.34
 pathophysiology 113.14
 perineum/perianal region 113.11,
 113.12, 113.13–15
 persistent infections 148.15
 photodynamic therapy for
 neoplasia 22.7
 polymerase chain reaction 111.4
 pregnancy 115.3
 prophylactic vaccination 25.46
 squamous cell carcinoma 142.27–8
 of external auditory canal 108.26
 of nail apparatus association 95.31
 pathogenesis 146.7–8
 squamous intraepithelial lesions 142.25
 subclinical infection 25.45–6
 transplant recipients 25.63
 vaccination 25.59, 110.34, 113.15, 142.25,
 146.8
 anal intraepithelial neoplasia
 prevention 113.17
 variants 113.14
 verrucous carcinoma 142.28
 vulval lesions 112.28–9
see also ano-genital warts; warts,
 cutaneous
 human papillomavirus 6 (HPV-6), HIV
 infection 31.24
 human papillomavirus 11 (HPV-11), HIV
 infection 31.24
 human papillomavirus 13 (HPV-13) 110.60
 human papillomavirus 16 (HPV-16) 112.29,
 112.33
 Bowen disease 142.18
 bowenoid papulosis 142.19
 genital intraepithelial neoplasia 142.25
 human papillomavirus 18 (HPV-18) 112.29,
 112.33
 Bowen disease 142.18
 bowenoid papulosis 142.19
 genital intraepithelial neoplasia 142.25
 human papillomavirus 32 (HPV-32) 110.60

- human parvovirus B19 5.10
 drug-induced serum sickness-like
 reaction differential diagnosis 118.9
- human polyomavirus
 6 and 7 25.43
 13, 14, 15, 16 and 17 89.47
- human retroviruses 25.67–8, 25.69
- human β -defensin(s) 1–3 (hBD 1–3) 2.12
- human β -defensin 2 (hBD-2) 8.40
- human T cell lymphotropic virus 1
 (HTLV-1) 25.67–8, 25.69
- adult T-cell leukaemia–
 lymphoma 140.34–6
- atopic eczema differential
 diagnosis 41.21
- crusted scabies 34.45
- infected dermatitis 25.68, 25.69
- infective dermatitis, in children 39.24
- mycosis fungoides 140.4
- seborrhoeic dermatitis association 40.1
- humblebees 34.14
- humectants, topical drug delivery 18.6,
 18.7
- Hunter syndrome 81.2, 81.3
 hyaline fibromatosis syndrome
 differential diagnosis 72.18
- naevus mucinosus 75.18
- Hunter's glossitis
 folate deficiency association 63.19
- vitamin B₁₂ deficiency association 63.20
- hunting reaction of Lewis 125.1
- Huriez syndrome 65.59, 65.60
- Werner syndrome differential
 diagnosis 72.23
- Hurler syndrome 81.1, 81.2, 81.3, 81.4
- hypertrichosis 89.61
- Hurler–Scheie syndrome 81.1, 81.2, 81.3
- Hutchinson lupus 125.4
- Hutchinson sign 109.38
 nail fold 95.34
 subungual melanoma 143.13
- Hutchinson summer prurigo 127.9
- Hutchinson teeth, congenital
 syphilis 29.32, 29.33
- Hutchinson triad, congenital
 syphilis 29.33
- Hutchinson–Gilford progeria
 syndrome 79.2, 79.4–5
 clinical features 72.21
- restrictive dermopathy differential
 diagnosis 72.20
- skin ageing 2.47
- stiff skin syndrome differential
 diagnosis 72.18
- hyaline degeneration 3.35
- hyaline deposits, electron microscopy 3.27
- hyaline fibromatosis syndrome 72.17–18,
 96.39
see also juvenile hyaline fibromatosis
- hyaline ring granuloma 110.61–2
- hyaluronan 2.40
 wound healing 2.40, 10.5
- hyaluronan synthase 59.1
- hyaluronic acid 2.2, 2.40
 fillers 157.4–5
- hydantoin, hyperpigmentation 88.26–7,
 88.28
- hydatid disease 33.29–30
- hydatiform mole, pemphigoid
 gestationis 115.13
- hydradenitis suppurativa 136.6
- hydrargyria 122.5–6
- hydration
 bacterial population effects 26.4
- irritant contact dermatitis 129.6
- hydroa aestivale 127.9, 127.23
- hydroa vacciniforme 25.33, 127.23–6
 clinical features 127.24–5
 definition 127.23
- differential diagnosis 127.24
- epidemiology 127.24
- investigations 127.25, 127.26
- juvenile spring eruption differential
 diagnosis 127.9
- management 127.25–6
- pathophysiology 127.24
- scarring 90.32
- hydrocele 105.18, 105.44
 management 105.45
- hydrocephalus, congenital melanocytic
 naevi 75.15
- hydrocolloid barrier dressings 114.7
- hydrocortisone 18.14, 19.17, 19.18
- hydrofluoric acid, chemical burns 129.12
- hydrogen chloride, inhalation injury with
 burns 126.4
- hydrogen peroxide 8.44
 ageing skin 2.47
- hair bleaching 89.73, 89.74
- topical therapy 18.10
- hydrogenated aromatic
 hydrocarbons 130.10–11
- hydromyelia 85.7–8
- hydrophobicity, irritants 129.3
- hydropic degeneration 3.35
- hydrops
 non-immune 105.33
- Turner syndrome 105.35
- hydroquinone 156.3, 156.10
 arbutin 156.8–9
- depigmentation 88.45, 88.46
- hypermelanosis treatment 88.33
- melasma treatment 88.12
- monobenzyl ether 18.28
- ochronosis induction 88.51
- topical 18.28
- hydroxy acids 156.10
 antiageing products 156.3–4
- chemical peels 159.1–2, 159.13
- hydroxybenzoates 18.8
- hydroxycarbamide 19.21–2, 101.12
 adverse effects 19.21–2
- cautions 19.22
- contraindications 19.22
- dermatological uses 19.21
- dermatomyositis induction 53.9–10
- dose 19.22
- drug eruptions 31.18
- drug–drug interactions 19.22
- monitoring 19.22
- nail colouration 95.14
- oral hyperpigmentation 110.66
- pharmacological properties 19.21
- plaque psoriasis 35.26, 35.29
- pre-treatment screening 19.22
- regimens 19.22
- hydroxycarbamide dermopathy 53.10
- hydroxychloroquine
 acute generalized exanthematous
 pustulosis predisposition 119.2,
 119.4
- adverse effects 154.15
- discoid lupus erythematosus
 treatment 19.5, 51.10, 89.41
- dosage 19.7
- erythema nodosum treatment 99.24
- hair pigmentary changes 89.71
- reticular erythematosus mucinosis
 treatment 59.9
- retinal toxicity 19.6–7
- rheumatoid arthritis treatment 19.5
- sarcoidosis treatment 98.16, 98.17
- subacute cutaneous lupus
 erythematosus 51.14
- systemic lupus erythematosus
 treatment 19.5, 51.35
- urticarial vasculitis treatment 44.5
- uses 19.5
- 7-hydroxycholesterol 62.10
- hydroxyethyl starch, pruritus
 induction 83.12, 118.3
- hydroxyethylmethacrylate and
 ethylmethacrylate microspheres
 suspended in hyaluronic acid
 fillers 157.7
- 21-hydroxylase 90.5, 90.7, 90.8
- 21-hydroxylase deficiency 89.65
- hydroxyproline 2.32
- hydroxyurea *see* hydroxycarbamide
- Hydrozoa 131.1
- hygiene hypothesis, atopic eczema 41.8–9
- Hymenoptera 34.14–16
 classification 34.14–15
- hyperaldosteronism 149.18
- hyperalgesia, inflammation 8.1–2
- hyperandrogenaemia, insulin resistance
 and acanthosis nigricans
 (HAIR-AN) 87.4, 90.8–9
- hyperandrogenism 149.18–19
- hyperbaric oxygen, lymphoedema 105.57
- hypercalcaemia
 hyperparathyroidism 145.21
- management 99.55
- subcutaneous fat necrosis of the
 newborn 99.54, 99.55, 116.15, 116.16
- hypercarotenaemia 88.50–1
- hypercortisolism 149.17–18
- acne association 90.5
- see also* Cushing syndrome
- hyper eosinophilic syndrome
 aphthous ulceration 110.41
- genital ulceration 111.18
- lymphocytic variant 25.33
- malignancy association 147.24
- recurrent cutaneous necrotizing
 eosinophilic vasculitis differential
 diagnosis 102.11
- respiratory disorder association 151.5
- hypergammaglobulinaemia, Sjögren
 syndrome 55.6, 55.7
- hyperglycaemia, neuropathic ulcer 85.4
- hypergranulosis 3.36
- hyperhidrosis 94.4–10
 aluminium hydrochloride hexahydrate
 therapy 18.33
- asymmetrical 94.7
- axillary 94.5–6
 treatment 94.8, 94.10
- compensatory 94.7
- craniofacial 94.6
- definition 94.4
- epidemiology 94.4
- focal 94.5–6
- generalized 94.4–5, 147.18
- causes 94.4
- granulosis rubra nasi 94.10
- gustatory 85.15–16, 94.7–8
- idiopathic circumscribed 94.7
- local circumscribed 94.6–7
- localized 147.18
- malignancy association 147.18
- management 18.33, 94.8–10
- naevoid 94.7
- palmoplantar 94.5, 94.6, 96.14
- paroxysmal unilateral 147.18
- pathophysiology 94.4–5
- pitted keratolysis association 26.42,
 26.43
- Ross syndrome 94.11–12
- shoe dermatitis 128.48
- spinal cord injury 85.10
- surgical treatment 94.9–10
- sympathectomy 94.9–10
- syringomyelia association 85.8
- treatment 26.43
- hyper-IgD syndrome 45.2, 45.3
- hyper-IgE syndrome 148.17
 eczematous lesions 41.9
- primary immunodeficiency 82.2, 82.17
- hyperinsulinaemia, acquired generalized
 lipodystrophy 100.1, 100.2
- hyperkalaemia, potassium iodide
 toxicity 19.28
- hyperkeratosis 3.36–7
 actinic keratosis 142.2, 142.3
- keratinization disorders 65.2
- lenticularis perstans 87.16–17
- multiple minute digitate 65.69–70
- of the nipple 65.71
- oil 130.14
- palmoplantar 96.14
- peristomal papules 114.111
- retention 87.7
- hyperkeratotic plaque, Darier disease 66.3,
 66.4
- hyperlipidaemia
 ciclosporin-induced 19.11
- granuloma annulare association 97.2
- psoriasis association 35.21
- retinoid-induced 19.39
- hyperlipidaemia-related skin disease 64.3
- hyperlipoproteinaemia
 type I 62.8–9
- type III 62.7–8
 palmar xanthomas 62.5, 62.8
- tuberous xanthomas 62.3, 62.8
- xanthelasma 62.4
- type IV 62.10
- type V 62.9
- hypermelanosis 88.8
 acquired 88.9–34
- adrenal insufficiency 145.18
- chemotherapy-induced 120.8
- chemotherapy-induced
 hyperpigmentation differential
 diagnosis 120.9
- drug origin 88.25–30
- endocrine disorders 88.17–19
- facial 88.9
- linear and whorled naevoid 70.2, 70.10,
 70.11–12
- physiological 88.9
- pituitary oversecretion of
 ACTH 149.18
- post-inflammatory 88.31–2
- ashy dermatosis differential
 diagnosis 88.33
- systemic disorders 88.19–25
- treatment 88.33–4
- see also* hyperpigmentation; melasma;
 named disorders
- hypermetabolism, burns 126.9–11
- hyperoestrogenism 145.19
- hyperoxaluria 101.16–17
- hyperparathyroidism 145.21
 bone resorption 95.48
- calciophylaxis 61.9
- MEN type 2b 147.10
- miliary calcification 61.6
- radiography 95.48
- vitamin D deficiency differential
 diagnosis 63.10
- hyperphosphataemic familial tumoral
 calcinosis 81.19
- hyperpigmentation
 acne 90.35, 90.36
- acquired 88.9–15
 differential diagnosis 88.11
- acromegaly 88.18
- Addison disease 88.7, 88.10, 88.17–18
- ageing of skin 155.1
- allergic contact dermatitis 128.60
- amiodarone-induced 88.25, 88.26, 88.28
- amyloidoses 88.22–3
- antimalarials 88.25, 88.28
- oral 110.66
- atopic eczema 41.16, 41.18
- bleomycin-induced 120.9
- chemical peel 159.5
 contraindication 159.6
- skin of colour 159.13
- chemotherapy-induced 88.26, 88.28,
 120.8–9
- chlorpromazine-induced 88.27
- chronic venous insufficiency 103.38,
 103.39
- clofazimine-induced 88.25
- Cushing syndrome 88.7, 88.18
- dermatomyositis 88.21
- disorders 70.1, 70.2–3, 70.11–15
- drug-induced 88.25–8
- chemotherapy 88.26, 88.28, 120.8–9
- definition 88.25
- laser treatment 23.14
- minocycline 23.14, 88.27, 110.66
- dyskeratosis congenita 69.13
- electron microscopy 3.27
- endocrine disorder skin signs 149.10
- familial progressive 70.2, 70.11
- Fanconi anaemia 82.12

- hyperpigmentation (*continued*)
 filler-induced inflammation
 response 157.11
 fixed drug eruptions 88.28, 88.29
 folate deficiency association 63.19
 genital 111.34
 haemochromatosis 88.22, 88.23
 HIV infection 31.12–13
 hydantoin-induced 88.26–7, 88.28
 hyperthyroidism 88.19
 Klinefelter syndrome 76.4
 lupus erythematosus 88.21
 malabsorption 88.23–5
 mercury toxicity 122.5, 122.6
 minocycline-induced 23.14, 88.27, 110.66
 morphea 88.20–1
 multiple organ failure 88.21
 neonates 116.4
 neurological disease 88.21
 nutritional deficiencies 88.23–5
 oral in HIV 31.33
 paraneoplastic 147.17, **147.18**
 phenytoin-induced 88.26–7
 photodynamic reactions 88.29–30
 phototoxic reactions 88.29–30
 phytophotodermatitis 127.28
 pityriasis rotunda differential
 diagnosis 87.8
 POEMS syndrome 88.25
 post-inflammatory 88.7
 chemical peels 159.12
 chemical peels in skin of colour 159.13
 chemotherapy-induced
 hyperpigmentation differential
 diagnosis 120.9
 laser treatment 23.14
 primary biliary cirrhosis 88.22
 primary immunodeficiency 82.3
 psoriasis 35.9
 psychotropic drugs 88.27
 renal failure 88.22, 153.3
 retinoic acid therapy 18.22
 rheumatoid arthritis 88.20
 sports injuries 123.16
 systemic sclerosis 56.4, 88.20–1
 tattoo removal complication 160.4, 160.5
 tetracycline-induced 88.27, 88.28
 vitamin B₁₂ deficiency association 63.20
see also hypermelanosis
 hyperpituitarism 149.16–17
 hyperprolactinaemia 149.17
 hypersalivation, mercury toxicity 122.5
 hypersensitivity reactions 8.54
 ant bites 34.16
 antibiotics 19.42
 azathioprine hypersensitivity
 syndrome 19.9
 bee stings 34.16
 CCR3 role 8.39
 dapsona hypersensitivity
 syndrome 19.15
 drug-induced
 IgE-mediated 12.1–2
 T-cell-mediated 12.2–4
 IgE-mediated 109.15
 immune reactants 8.54, 8.55
 molybdenum toxicity 122.9
 mosquito bites 25.33
 solar urticaria 127.21
 tattoo inks 123.21
 type(s) 8.54, 8.55, 12.1
 type I early-phase response 8.57–8
 type II 8.59
 type III 8.59
 type IV 8.60
 wasp stings 34.16
 hypersensitivity syndrome (HSS) *see* drug
 reaction with eosinophilia and
 systemic symptoms (DRESS)
 hypertension
 ciclosporin-induced 19.11, 19.12
 psoriasis association 35.21
 hyperthermia, wart treatment 25.53
 hyperthyroidism 88.19, 145.20–1, 149.13
 systemic lupus erythematosus 51.29
 hypertrichosis 89.61–4
 acquired
 localized 89.63
 malignant generalized 89.62
 non-malignant generalized 89.62–3
 acquired lanuginosa 89.62
 paraneoplastic 147.17
 chemotherapy-induced 120.6
 congenital 113.4
 generalized 89.61
 lanuginosa 89.61
 localized 68.11–12, 89.61–2
 universalis Ambras type **68.2**, 68.11
 cubiti 68.11
 drug-induced 89.62, **89.63**
 topical medications 89.63
 endocrine disorder skin signs **149.10**
 eyelashes in HIV infection 89.47
 inherited 68.1, **68.2–3**, 68.11
 generalized 68.1, 68.11
 lanuginosa
 acquired 89.62, 147.17
 congenital 89.61
 lumbosacral 89.62
 malignant acquired generalized 89.62
 naevoid 89.61–2
 non-malignant acquired
 generalized 89.62–3
 paradoxical 23.16
 paraneoplastic 120.6
 acquired lanuginosa 147.17
 pinna 108.6
 posterior and anterior cervical 68.11
 terminalis, generalized **68.2**, 68.11
 universalis congenita, Ambras type **68.2**,
 68.11
 hypertriglyceridaemia 62.8–10
 acquired generalized
 lipodystrophy 100.1, 100.2
 eruptive xanthomas 62.3
 HIV-associated lipodystrophy
 association 100.7
 hypertrophic osteoarthropathy 147.17
 hypertrophic scars 10.9, 96.45–9
 clinical features 96.48
 definition 96.45
 epidemiology 96.46
 investigations 96.48
 laser treatment 23.10, 96.49
 management 23.10, 96.48–9
 pathophysiology 96.46–7
 pseudofolliculitis complication 93.2
 hypervitaminosis A 63.8–9
Hyphomycetes 32.5
 hypnotherapy 86.40
 hypoadrenocorticalism, chronic
 mucocutaneous candidosis 32.68
 hypoalbuminaemia 105.21
 hypoandrogenism 145.19
 hypocalcaemia, vitamin D deficiency 63.10
 hypochondriasis, monosymptomatic
 delusional 86.4
 hypoglossal palsy 110.7
 hypohidrosis 94.10–12
 congenital disorders of glycosylation 81.10
 congenital ichthyoses 65.39
 Fabry disease 81.8
 neurological causes **94.11**
 syringomyelia association 85.8
 hypokeratosis, palmoplantar
 circumscribed 65.70–1
 hypomelanosis 88.8
 acquired 88.34–47
 syndromic 88.43–7
 differential diagnosis 88.34
 idiopathic guttate 88.46–7, 155.3
 inherited, vitiligo differential
 diagnosis 88.38
 post-infectious 88.38
 post-inflammatory 88.38, 88.43–5
 clinical features 88.44–5
 epidemiology 88.44
 post-traumatic 88.38
 progressive macular 88.38, 88.45
see also vitiligo
 hypomelanosis of Ito 70.10
 chromosomal mosaicism 76.5
 vitiligo differential diagnosis 88.38
 hyponychium 2.11
 hypo-oestrogenism 145.19
 hypoparathyroidism 145.21–2
 chronic mucocutaneous
 candidosis 32.58, 32.68
 hypopigmentation
 ageing of skin 155.1, 155.3
 allergic contact dermatitis 128.60–1
 atopic eczema 41.16, 41.17
 Chediak–Higashi syndrome 82.14
 chemotherapy-induced 120.9–10
 disorders 70.1, **70.2**, 70.3–10
 electron microscopy 3.27
 genital 111.34
 Griselli syndrome 82.14
 HIV infection 31.12–13
 onchocerciasis 33.3, 33.4–5
 paraneoplastic **147.18**
 patch test complication 128.71
 phenylketonuria 81.12
 pityriasis alba 39.25–6
 postinflammatory
 with chemical peels 159.12
 chemotherapy-induced
 hypopigmentation differential
 diagnosis 120.10
 primary immunodeficiency 82.3
 psoriasis 35.9
 sarcoidosis 98.13
 tattoo removal complication 160.4–5
 hypopituitarism 149.16
 hypoplasminogenaemia, aphthous
 ulceration 110.41
 hyposalivation, angular cheilitis 110.80
 hypospadias 111.7
 hypothalamopituitary axes 149.2, 149.4
 hypothalar hammer syndrome 123.12–13
 hypothyroidism 145.20–1, 149.13
 benign symmetrical lipomatosis
 association 100.14
 chronic mucocutaneous candidosis
 association 32.58, 32.68
 hypertrichosis 89.62
 iatrogenic 145.21
 systemic lupus erythematosus 51.29
 yellow nails 95.15
 hypotrichoses **68.4–10**, 68.15–18
 autosomal dominant
 non-syndromic 68.15–16
 syndromic 68.16–17
 autosomal recessive 2.19
 localized **68.5**, 68.15
 non-syndromic **68.5**, 68.16
 syndromic 68.17–18
 Bazex syndrome 141.21
 with juvenile macular dystrophy **68.6**,
 68.17, 68.18
 neonatal ichthyosis–sclerosing
 cholangitis 65.36
 non-syndromic
 autosomal dominant 68.15–16
 autosomal recessive **68.5**, 68.16
 simplex of the scalp **68.4**, 68.15
 syndromic
 autosomal dominant 68.16–17
 autosomal recessive 68.17–18
 types 4 and 5 **68.4–5**, 68.12
 types 7 and 8 **68.5**, 68.16
 hypotrichosis–lymphoedema–
 telangiectasia syndrome 73.19
 hypoxanthine-guanine
 phosphoribosyltransferase (HPRT)
 deficiency 81.16–17
 hystrix-like ichthyosis and deafness
 syndrome 65.30–2
 clinical features 65.31
 management 65.31–2
 pathophysiology 65.31
I
 iatrogenic conditions, oral lesions 110.55
 ichthammol 39.7
 ichthyin 65.10
 ichthyoses 3.39
 acquired 65.40–2, 87.1–2, 147.17
 associated disorders **87.1**
 clinical features 65.40–1, 87.2
 definition 87.1
 epidemiology 87.1
 Hodgkin disease 140.49
 HTLV-1 association 140.36
 investigations 87.2
 management 87.2
 pathophysiology 65.40, 87.1–2
 annular epidermolytic 65.15
 bathing 65.38
 bathing suit 65.7–9
 collodion baby 65.7, 65.9, 65.11
 management 65.37–8
 coloboma heart defect–ichthyosiform
 dermatosis–mental retardation–ear
 anomalies syndrome 65.34
 Comèl–Netherton syndrome 65.24–5
 confetti 65.16
 congenital 65.2–36
 common 65.2–20
 management 65.36–40
 patient organizations/
 resources 65.39–40
 syndromic 65.20–36
 congenital disorders of
 glycosylation 81.10
 Curth–Macklin **65.14**, 65.17
 definition 65.2
 exfoliative 65.20
 harlequin 65.7, 65.8, 65.9
 collodion baby differential
 diagnosis 116.19
 prenatal diagnosis 7.9
 HIV infection 31.12
 with hypotrichosis **65.35**, 65.36
 hystrix-like ichthyosis and deafness
 syndrome 65.30–2
 keratitis–ichthyosis–deafness
 syndrome 65.30–2
 lamellar 65.9–13
 clinical features 65.11–12
 definition 65.9–10
 investigations 65.12–13
 pathophysiology 65.10
 mutilating keratoderma 65.49
 neonatal ichthyosis–sclerosing
 cholangitis **65.35**, 65.36
 neuro-ichthyotic syndromes 65.27–34
 palmoplantar keratodermas with
 neurological manifestations 65.64
 neutral lipid storage disease with
 ichthyosis 65.32–3
 non-syndromic 65.2, **65.3**, 65.6–20
 palmoplantar phenotype 65.42, **65.43**
 paraneoplastic 147.17
 peeling skin syndromes 65.26–7
 pityriasis rotunda 65.41–2
 primary immunodeficiency 82.3
 recessive X-linked 65.2, 65.4–6
 clinical features 65.5–6
 definition 65.4
 investigations 65.6
 management 65.6
 pathophysiology 65.4–5
 Refsum disease 65.27–9
 self-improving congenital 65.7, 65.11
 superficial epidermolytic **65.14**, 65.15,
 65.17
 syndromic 65.2, **65.3**, 65.20–36
 xerosis cutis differential
 diagnosis 87.26–7
see also autosomal recessive
 congenital ichthyosis (ARCI);
 autosomal recessive ichthyosis
 with hypotrichosis; congenital
 ichthyosiform erythroderma;
 epidermolytic ichthyosis;
 keratinopathic ichthyosis (KPI)
 ichthyosiform atrophy, Hodgkin
 disease 140.49
 ichthyosiform erythroderma 116.19

- see also* congenital ichthyosiform erythroderma
 ichthyosiform sarcoidosis 98.13
 ichthyosis follicularis with atrichia and photophobia (IFAP) syndrome 65.23, 68.4, 68.15
 ichthyosis linearis circumflexa 89.53
 ichthyosis prematurity syndrome 65.7, 65.34–5, 65.36
 ichthyosis vulgaris 2.7, 3.39, 65.2–4
 clinical features 65.4
 definition 65.2
 investigations 65.4
 keratosis pilaris association 87.9
 management 65.4
 pathophysiology 65.3–4
 icterus 88.49–50
IDH1 and *IDH2* gene mutations 73.15
 idiopathic facial aseptic granuloma (IFAG) 91.15
 idiopathic guttate hypomelanosis 88.46–7, 155.3
 idiopathic inflammatory myopathies (IIM) 53.1, 53.2
 idiopathic lenticular pigmentation 110.12
 idiopathic thrombocytopenic purpura
 IgA vasculitis differential diagnosis 102.15
 urticarial vasculitis association 44.2
 idoxuridine 18.13
 IFN-inducible protein 10 (CXCL10) 8.39
 IgA antineutrophil cytoplasmic antibodies (ANCA) 102.10
 IgA myeloma, urticarial vasculitis association 44.2
 IgA nephropathy, IgA vasculitis differential diagnosis 102.15
 IgA pemphigus 110.47–8
 intercellular
 clinical features 50.2
 subcorneal pustular dermatosis differential diagnosis 49.15
 subcorneal pustular dermatosis differential diagnosis 49.15
 IgA vasculitis 102.13–16
 classification criteria 102.13
 clinical features 102.15–16
 definition 102.13
 epidemiology 102.13–14
 investigations 102.16
 management 102.16
 nomenclature 102.13
 pathophysiology 102.14–15
 relapse 102.16
 IgG gammopathy 147.23
 IgG4-related disease 148.14
 Iggo discs *see* touch spots
IKBK gene mutations 70.11
 IκB (IKK) complex 70.11, 82.16
IL36RN gene mutations 119.2
 ileostomy *see* stomas
 ilioinguinal lymph nodes, abdominal wall lymphoedema 105.21
 iloprost
 frostbite management 125.3
 Raynaud phenomenon treatment 125.10
 imatinib, hair pigmentary changes 89.71
 imidazoles 19.43, 19.44
 topical 18.12
 imidazolidinyl urea 128.34–5
 imiquimod
 actinic keratosis treatment 142.8, 142.9, 142.10, 146.15
 anal intraepithelial neoplasia 113.17
 basal cell carcinoma treatment 141.13–14, 141.15
 Bowen disease treatment 142.21, 142.22, 142.22
 HPV infection treatment 18.13
 human papillomavirus treatment 31.24
 keratoacanthoma treatment 142.36
 perianal contact dermatitis induction 113.8, 113.9
 port-wine stains 23.9
 topical 18.27
 wart treatment 18.27, 25.53
 immediate pigment darkening (IPD) 88.9
 immediate-weal tests 4.24
 immersion foot 125.3–4
 immigrant patients, yaws diagnosis 29.14–15
 immobility
 chronically swollen leg 105.8
 lymphoedema 105.50–1
 immune defence system 2.12
 immune deficiency
 angular cheilitis 110.80
 aphthous stomatitis differential diagnosis 110.29
 mouth ulcers 110.17
 oral lesions 110.54
 primary and HPV infection 25.61
 immune dysregulation, atopic eczema 41.9–10
 immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome 41.10
 immune function
 obesity 100.25–6
 peripheral and ageing 2.46
 immune reactions
 adverse to drugs 12.1–6
 types 12.1
 immune reconstitution associated disease (IRAD) 31.7–8, 31.35, 31.36
 cytomegalovirus treatment 31.24
 herpes simplex virus treatment 31.22
 Kaposi sarcoma 31.30
 leishmaniasis 31.28
 pityriasis versicolor in HIV 31.28
 immune reconstitution inflammatory syndrome (IRIS) 31.7–8, 31.35, 31.36
 crusted scabies 34.45
 cytomegalovirus treatment 31.24
 herpes simplex virus treatment 31.22
 Kaposi sarcoma 31.30
 leishmaniasis 31.28
 pityriasis versicolor in HIV 31.28
 immune response
 acne vulgaris 90.35
 cell-mediated 25.4
 wart rejection 25.46
 cytokines role 8.32
 filler adverse reaction 157.9, 157.10
 HSV infection 25.16
 neuroendocrine role 149.7
 wound healing 10.1, 10.2–3, 10.4
 immune restoration disease (IRD) 31.7–8, 31.35, 31.36
 cytomegalovirus treatment 31.24, 31.36
 herpes simplex virus treatment 31.22, 31.36
 Kaposi sarcoma 31.30
 leishmaniasis 31.28
 pityriasis versicolor in HIV 31.28
 varicella-zoster virus reactivation 31.23
 immune surveillance 2.15
 immune system
 adipocyte interactions 99.7
 antimicrobial peptide role 8.14
 pregnancy 115.3
 see also adaptive immune system; innate immunity
 immune tolerance 8.30
 immune trafficking, lymphatic vessels 105.11
 immunoabsorption, pemphigus treatment 50.9
 immunoblotting 3.11
 immunobullous disease 109.25
 cicatrical conjunctivitis associated with 109.25–7, 109.28–9, 109.29–34, 109.35, 109.36
 delusional infestation differential diagnosis 86.6
 mast cell role 2.17
 mixed 50.36
 orf complication 25.10
 subepidermal 50.9–49
 autoantibody specificity 50.10
 clinical signs 50.10
 vulval 112.19–20
 see also dermatitis herpetiformis; pemphigoid
 immunobullous diseases, digestive system 152.6
 immunocompromised patients, skin cancer 146.1–18
 clinopathological features 146.9–12
 epidemiology 146.1–5
 management 146.12–18
 organizations for patients/health care professionals 146.18
 pathophysiology 146.5–9
 prevention 146.15–17
 revision of immunosuppression 146.16
 screening/surveillance 146.17–18
 see also immunosuppression
 immunocytes, recruitment 8.7
 immunocytochemistry panels of cell markers 3.11
 immunocytoplast 140.39
 immunodeficiency
 acquired 148.16, 148.17
 immunosuppressive antibodies 148.18
 skin cancers 146.2–5
 antibodies against cytokines 148.15, 148.17
 inherited 82.1–3
 definition 82.1
 diagnosis 82.1–3
 lymphoedema 105.52
 mutations in cytokines/signalling proteins 148.18
 oral manifestations 110.90
 secondary 82.1
 see also combined immunodeficiencies; HIV infection; primary immunodeficiency
 immunodeficiency and neoplasia syndromes 147.13–14
 immunodeficiency, centromeric instability-facial anomalies (ICF) syndrome 82.11
 immunodysregulation polyendocrinopathy enteropathy X-linked syndrome 82.14
 immunoediting, skin cancer 146.5–6
 immunoelectron microscopy 3.11
 immunoenzyme methods 3.14–16
 avidin-biotin coupling of antibody and enzyme 3.16
 chemical conjugation of peroxidase to antibody 3.14
 conjugates 3.14–15
 avidin-biotin coupling 3.16
 controls 3.16
 fixed frozen sections 3.15–16
 paraffin sections 3.16
 peroxidase reaction detection 3.16
 technical limitations 3.14
 immunofluorescence technique 3.10–14
 blood specimens 3.13
 direct 3.11, 3.12, 3.13
 double staining 3.12
 indirect 3.11, 3.12, 3.13
 calcium enhancement 3.14
 complement binding 3.14
 split skin 3.13–14
 methods 3.12–14
 immunogenotyping 3.27
 immunoglobulin A (IgA), salivary 110.4
 immunoglobulin A (IgA) deficiency 82.3
 childhood linear 82.14, 82.15
 oral infections 110.4
 see also linear IgA disease
 immunoglobulin A (IgA) vasculitis 45.6
 immunoglobulin deposition disorders 148.5–6
 immunoglobulin E (IgE)
 allergen-specific 8.58
 amplification mechanisms 8.57
 atopic eczema 41.11–12, 41.14
 biology 8.56–7
 early-phase allergic response 8.57, 8.58
 immunoglobulin switching process 8.56
 production 8.55
 protease role 8.56
 protective immunity 8.54–5
 receptors 8.57
 Staphylococcus aureus antigens 41.12
 structure 8.56
 immunoglobulin E (IgE) mediated hypersensitivity reactions 109.15
 drug-induced 12.1–2
 immunoglobulin G (IgG) 136.2
 hypersensitivity reactions 8.59
 maternal autoantibodies 116.12
 urticaria 42.3–4
 immunoglobulin G-κ (IgG-κ) 136.22
 immunoglobulin M (IgM), paraprotein deposition 148.5
 immunoglobulin superfamily, cell adhesion molecules 8.11–12
 immunohistochemistry
 microorganism detection 3.10
 viral disease techniques 3.27
 immunological contact urticaria *see* allergic contact urticaria
 immunological tolerance 128.9–10
 immunomodulation, UVR-induced 9.8–9
 immunomodulatory therapy 1.8, 19.3–41
 adverse effects 19.3
 azathioprine 19.7–10, 129.8
 counselling 19.3
 fumaric acid esters 19.15–17, 35.26, 35.28
 glucocorticoids 2.31, 19.17–21
 mycophenolate mofetil 19.25–7, 38.6
 potassium iodide 19.27–8
 pre-treatment checklist 19.3
 retinoids, systemic 19.37–40, 65.6
 see also antihistamines; antimalarials; biological therapies; ciclosporin; colchicine; dapsone; hydroxycarbamide; intravenous immunoglobulin (IVIg); methotrexate; thalidomide
 immunopathology techniques 3.10–16
 applications 3.16–25
 immunoreconstitution phenomena
 candidosis 31.26
 histoplasmosis 31.27
 molluscum contagiosum 31.25
 penicilliosis 31.27
 see also immune reconstitution associated disease (IRAD); immune reconstitution inflammatory syndrome (IRIS); immune restoration disease (IRD)
 immunosuppression
 apoptotic pathway induction 8.54
 bacillary angiomatosis association 26.61
 basal cell carcinoma incidence 141.3
 chemical peel contraindication 159.6
 children 31.34–5
 cytomegalovirus 25.36
 Demodex lesions 34.53–4
 disseminated superficial porokeratosis 65.67
 haemophagocytic lymphohistiocytosis 25.32
 herpes simplex virus infection 25.16
 HIV infection 31.5
 human herpesvirus reactivation 25.35–6
 human papillomavirus infection 25.61–3, 112.28
 iatrogenic causes 25.63
 infection reactivation 19.3
 infectious panniculitis 99.44
 investigations 25.30
 management 25.30
 Merkel cell carcinoma 145.2
 molluscum contagiosum 25.12
 penile cancer complication 111.30
 renal transplantation 153.5–6
 revision 146.16
 sebaceous carcinoma 138.18–19
 squamous cell carcinoma

- immunosuppression (*continued*)
 development risk 142.5, 142.27, 146.9
 secondary prevention 142.32–3
 systemic lupus erythematosus
 treatment 51.36
 systemic sclerosis management 56.19
 trichodysplasia spinulosa 25.42–3, 87.14
 varicella infection 25.26
 zoster infection 25.27, 25.30
see also immunomodulatory therapy
- immunosuppressive drugs
 acne association 90.11
 skin cancer 146.3–4
- immunotherapy
 contact in alopecia areata
 treatment 89.34
 intralesional in wart treatment 25.53
 melanoma treatment 143.30–1
 mycosis fungoides 140.24
 Sézary syndrome 140.24
 topical in wart treatment 25.53
- Impact of Psoriasis Questionnaire (IPSO) 16.6
- imperforate anus 113.4
- impetigo 26.12, 26.13–16, 34.44, 110.50
 antibiotic resistance 26.16
 clinical features 26.14–15
 definition 26.13
 diphtheria differential diagnosis 26.38
 endemic 26.16
 epidemiology 26.13–14
 eyelids 109.41
 herpeticiformis 35.35
 immunodeficiency association 148.15
 infants 117.7
 infective cheilitis 110.87
 investigations 26.15
 Kaposi varicelliform eruption
 mimicking 41.22
 management 26.15–16
 neonates 26.15
 non-bullous 26.13, 26.14–15, 117.7
 pathophysiology 26.14
 pemphigus foliaceus differential
 diagnosis 50.7
 post-streptococcal
 glomerulonephritis 153.6
 recurrent toxin-mediated perineal
 erythema association 26.32
 subcorneal pustular dermatosis
 differential diagnosis 49.15
 tinea capitis differential diagnosis 32.40
 tinea corporis differential
 diagnosis 32.37
see also bullous impetigo
- implants, metal, allergic reactions 128.59
- in situ* hybridization 3.10
- incidence 5.13
- incisional hernia, risk with
 obesity 100.26
- inclusion body fibromatosis 137.10–11
- inclusion body myositis 53.1
 subacute cutaneous lupus
 erythematosus association 51.12
- incontinentia pigmenti 70.2, 70.11, 70.12,
 70.13
 epidermolysis bullosa differential
 diagnosis 71.23
 Klinefelter syndrome 76.4
 MIDAS syndrome differential
 diagnosis 67.25
 NFκB pathway-related
 immunodeficiency 82.16
- indinavir, retinoid-like effects 31.20
- indocyanine green-augmented diode
 laser, leg veins 23.10
- indirect immunofluorescence (IIF)
 technique 3.11, 3.12, 3.13
 calcium enhancement 3.14
 complement binding 3.14
 split skin 3.13–14
- indometacin 18.36
- induced illness 86.30
- inducible lymphoid cells, IL-4 in
 production 8.57
- industrial skin diseases 1.8
see also occupational disorders
- infant(s)
 acne 117.5
 acne conglobata 90.62
 acrodermatitis enteropathica 63.26
 acute haemorrhagic oedema 117.9–10
 age effects on drug therapeutic
 outcomes 14.7
 annular erythema of infancy 47.6–8
 arteriovenous malformation 103.21
 atopic eczema 41.16
 beriberi 63.14
 blistering treatment 71.24–5
 bullous diseases 117.7–8
 chronic mucocutaneous
 candidosis 32.69
 cold panniculitis 99.33–4, 116.14
 congenital candidosis 32.67
 congenital syphilis 116.26
 constricting bands of the
 extremities 96.43
 cryopyrin-associated periodic
 syndrome 45.4
 cutaneous mucinosis of infancy 59.7
 dermatitis gangrenosa infantum 26.83–4
 dermatoses 117.1–16
 epidermolysis bullosa treatment 71.24–5
 fibrous hamartoma of infancy 137.6–7
 generalized pustular psoriasis 35.35–6
 genetic conditions 117.12–13
 haemangiomas 117.17–23
 hair loss 117.14
 hair shedding 116.3
 herpes zoster 116.22
 ichthyosiform erythroderma 39.33
 inclusion body fibromatosis 137.10–11
 infective conditions 117.6–9
 inflammatory conditions 117.1–6
 iron deficiency 63.24
 Kawasaki disease 102.32
 koilonychia 95.7
 lipoblastoma 137.59–60
 lipid proteinosis 72.32
 low birthweight 116.26
 Michelin tyre baby 72.15
 raised linear bands of infancy
 differential diagnosis 116.18
 smooth muscle hamartoma 75.20
 multiple sulphatase deficiency 65.29
 nodular/granulomatous candidosis of
 the napkin area 32.66
 noma neonatorum 116.26
 paronychia of great toe 95.36
 perineal candidosis 32.65–6
 pigmented neuroectodermal
 tumour 137.53–4
 prepubertal acne 90.59–64
Pseudomonas aeruginosa infection 26.52
 raised linear bands of infancy 116.18
 reactive conditions 117.9–12
 small-for-gestational age 116.4
 neonatal cold injury 116.14
 viral exanthems 117.6–7
 vitamin D deficiency
 management 63.11
 vitamin K deficiency bleeding 63.12–13
see also circumcision; developmental
 abnormalities; *named infantile
 conditions*; neonates; preterm infants
- infantile acropustulosis 116.7–8, 117.4–5
- infantile eosinophilic pustular folliculitis
 differential diagnosis 93.10
- infantile digital fibromatosis 137.10
- infantile eosinophilic pustular
 folliculitis 93.9–10
- infantile fibromatosis
 plantar fascial fibromatosis differential
 diagnosis 96.33
 variant 137.14
- infantile gluteal granuloma 117.4
 corticosteroid treatment
 association 18.17
- infantile haemangiomas 117.16–23,
 117.20–3
- associated anomalies 117.17
- cherry angioma differential
 diagnosis 103.12
- classification 117.17
- clinical features 117.18–22, 117.20–2
 complications/co-morbidities 117.21–2
- definition 117.16
- disease course 117.22
- epidemiology 117.17
- eyelid 109.48, 109.48
- hepatic 117.21
- investigations 117.22
- laser therapy 23.6
- management 117.22–3, 117.24
- multifocal cutaneous with/
 without extracutaneous
 involvement 117.20–1
- nomenclature 117.17
- oral 110.72
- pathophysiology 117.17–18
- perianal skin 113.4
- periocular 117.22
- prognosis 117.22
- segmental 117.20
- variants 117.20–1
- vascular malformation differential
 diagnosis 117.17
- infantile haemangiopericytoma 137.42
- infantile hyaline fibromatosis 72.17–18
- stiff skin syndrome differential
 diagnosis 72.18
- infantile myofibromatosis 96.38–9, 137.42
- infantile Refsum disease 65.28
- infantile seborrhoeic dermatitis 40.2–3,
 41.23, 107.1, 107.2, 117.2
- atopic eczema differential
 diagnosis 41.21
 differential diagnosis 40.4
- infantile stiff skin syndromes 72.17–20
- infantile systemic hyalinosis 96.40
- infections 111.21
 acne fulminans 90.51
 acquired ichthyoses 65.41
 alcohol abuse co-morbidity 86.32
 allergic eczema relationship 41.13–14
 alopecia areata 89.30
 angular cheilitis 110.80
 ano-rectal necrotizing soft tissue 113.11
- aphthous stomatitis 110.48–54
- atopic eczema 41.13, 41.30
- azathioprine-associated 19.9
- breast lymphoedema 105.24
- burns
 central line-associated 126.8
 control 126.7–9
 inhalation injuries 126.5
 systemic 126.8
 topical 126.8
 cardiac involvement 150.5
 cat bites 131.5–6
 cheilitis 110.87
 chemical peels 159.10–11
 childhood and atopic eczema
 protection 41.9
 complement diseases 82.17–18
 corticosteroid-induced
 exacerbations 18.17
 delayed-type hypersensitivity 8.60
 dermatitis 39.22–4
 HTLV-1-associated of children 39.24
- diabetes 64.3
- DOCK8 deficiency 82.9–10
- dog bites 131.5–6
- Down syndrome 76.2
- DRESS differential diagnosis 119.10
- external ear 108.11, 108.15–22
- eyes 109.36–8, 109.39–40, 109.40–3
- genital lymphoedema 105.18
- glucocorticoid effects 19.19, 19.20
- granuloma annulare 97.2
- hair loss 89.47
- hidradenitis suppurativa differential
 diagnosis 92.7
- historical aspects 1.7–8
- IgA vasculitis 102.15
- immunosuppression
 reactivation in 19.3
 for renal transplantation 153.5–6
- injecting drug abuse 121.3–4
- IVIG adverse reaction 19.36
- lymphatic malformations 105.37
- lymphoedema 105.52
 with amniotic band
 constriction 105.38
 complication 105.13
 management 105.56
 massive localized 105.25
 prevention 105.56
- malakoplakia 136.21
- male genital dermatoses 111.21–4
- mevalonate kinase deficiency
 complication 45.6–7
- malaria 94.13
- mycophenolate mofetil-associated 19.26
- nail cosmetics risks 95.64
- nail fold 95.35–8
- nail plate subungual abscess 95.37–8
- neonatal 116.21–7
- neutrophilic eccrine hidradenitis 94.14
- nummular dermatitis 39.8
- obesity 100.25
- opportunistic
 AIDS-defining 31.5
 in lymphoedema 105.52
 systemic sclerosis 56.11
- oral cavity 110.91–2
 oral mucosa disorders 110.7, 110.8
 ulceration 110.48–54
- perineum/perianal region 113.9–17
- phobias 86.20
- pinna 108.11, 108.15
- pregnancy 115.3–5
- pressure ulcers 124.2, 124.3, 124.5,
 124.6–7, 124.7–8
- prevention in lymphoedema
 management 105.56
- psoriasis association 35.4, 35.20
- purpura 101.15
- radiodermatitis 120.13
- rat bites 26.71–2, 131.5–6
- reactivation in immunosuppression 19.3
- recurrent in primary
 immunodeficiency 82.2
- renal involvement 153.6
- respiratory disorder association 151.1–2,
 151.4
- scalp disorders 107.10
- secondary in eczema 39.4, 39.6
 lower leg eczema complication 39.20
- Sjögren syndrome 55.6
- skin resurfacing complication 160.10
- Stevens-Johnson syndrome 119.21
- stomas 114.3–4
- subungual abscess 95.37–8
- superinfections and congenital
 ichthyoses 65.39
- surgical 20.10, 20.11
- Sweet syndrome 49.9
- systemic lupus erythematosus 51.32
 association 51.18–19
 systemic sclerosis 56.11
- tattoo complications 123.21
- TNF-α role 8.35
- toxic epidermal necrolysis 119.21
- urticaria 42.6, 42.8, 47.3, 47.8
- vulva 112.23–9
see also bacterial infections; cellulitis;
 fungal infections; parasitic diseases;
 sexually transmitted infections;
 viral infections; wound infections
- infectious mononucleosis 25.31–3
 clinical features 25.31–2
 investigations 25.32–3
 management 25.33
 oral lesions 110.51
 urticarial vasculitis association 44.2
- infective agents 5.10
- infective arthropathies 154.2–5
- infective eczematoid dermatitis,
 pinna 108.11

- infective endocarditis 101.16, 101.17
cardiac involvement 150.5
- inferior vena cava obstruction, abdominal
wall lymphoedema differential
diagnosis 105.21
- infestations
alcohol abuse co-morbidity 86.32
delusional infestation differential
diagnosis 86.6
microscopy in diagnosis 4.22
urticaria 42.6, 47.3
- infestations, delusional 86.4–7, 86.8
clinical features 86.6–7
complications/co-morbidities 86.6
disease course 86.6
epidemiology 86.5
investigations 86.7
management 86.7, 86.8
pathophysiology 86.5–6
prognosis 86.6
specimen sign 86.7
- infiltrating lipomatosis of the face
(IL-F) 100.17–18
- inflammation
acne vulgaris 90.18–19
acute phase 8.2
antimicrobial peptide role 8.14
apoptosis 8.53–4
atrophic scars 96.11–12
cell–cell adhesion in epidermis/
dermis 8.9–13
cell–cell communication 8.7–9
cellular components 8.2, 8.4–13
chronic 8.2
chronic paronychia 95.36–7
clinical characteristics 8.1–2
cytokines 8.33–4
 role 8.32
dysaesthesia 8.1–2
early 8.2
endothelial cells 8.7
fibroblast role 8.6
free radical activity 8.45
heat 8.1
hyperalgesia 8.1–2
keratinocytes 8.2, 8.4–6
Langerhans cell role 8.29
lips 110.82–8
lymphatics 105.51
lysosome role 8.44
major histocompatibility complex 8.26–8
male genital dermatoses 111.9–21
mucous membrane pemphigoid 109.27
 suppression 109.33
neurogenic 8.50, 85.2–3
nitric oxide role 8.44
pain 8.1–2
perianal region 113.6–8
perineum 113.6–8
phases 8.2
post-inflammatory hypopigmentation,
 occupational dyspigmentation
 differential diagnosis 130.12
pruritus 8.1–2
reactive oxygen species role 8.44
redness 8.1
scleroderma 8.6
sports injuries 123.16
subtype histology 8.3
swelling 8.2
TLR activity 8.14–15
TNF- α role 8.35
vulval conditions 112.6–17
wound healing 10.1, 10.2–3, 10.4
- inflammatory arthropathies 154.5–8
- inflammatory bowel disease 152.1–3
aseptic abscess syndrome 49.17
bowel-associated dermatosis–arthritis
 syndrome 49.12
erythema nodosum 99.21
psoriasis association 35.20, 114.4–5,
 152.3
pyoderma gangrenosum
 association 49.1–2, 49.3, 49.4
 reactive lesions 152.2–3
- seronegative arthritis/spondylitis 154.5
skin cancer association 146.5
subcorneal pustular dermatosis
 association 49.14
 see also Crohn disease; ulcerative colitis
- inflammatory chondropathies 154.11–13
- inflammatory dendritic epidermal
 cells 8.29
- inflammatory dermatoses
cardiac involvement 150.4–5
cutaneous vasculitis differential
 diagnosis 102.4
cytokine signalling in macrophages 8.23
HIV infection 31.13–17
male genital 111.9–21
MMP activity 8.43
post-inflammatory
 hypermelanosis 88.31–2
 reactive erythemas 47.1–15, 47.16
 respiratory disorder association 151.1
- inflammatory diseases
assessment tools 16.2
ear lymphoedematous
 enlargement 105.15
high-power microscopy 3.30–3
historical aspects 1.8
immune-mediated 146.5
immunomodulatory treatments 1.8
integrins 8.9–10
neutrophil role 8.18
pregnancy 115.8–9, 115.10
subcutaneous fat 99.6–8
- inflammatory linear verrucous epidermal
 naevus (ILVEN) 75.4
 ano-genital 113.4
 clinical features 75.4–8
 lichen striatus differential
 diagnosis 37.20
 management 75.8
 psoriasis overlap 75.5
- inflammatory mediators 8.2, 8.31–2,
 8.33–4, 8.34–6, 8.37, 8.38–54
acute-phase proteins 8.31–2
chemokine receptors 8.38, 8.39–40
cytokine inhibitors 8.35–6
leukotrienes 8.49
lysosomal mediators 8.43–4
neuromediators 8.49–53
nitric oxide 8.44, 8.45–6
platelet activating factor 8.47
platelets 8.24–5
prostaglandins 8.48–9
proteases 8.40–2
 itching in skin disease 83.7
radical oxygen species 8.44–5
thromboxanes 8.48–9
wound healing 10.2
see also chemokines; cytokines;
 histamine; matrix
 metalloproteinase(s) (MMPs);
 tumour necrosis factor (TNF);
 individual interleukins
- inflammatory myopathy 140.35–6
- inflammatory peeling skin
 disease 65.26–7
- inflammatory response, microbiological
 agents 8.5
- inflammatory skin reactions, IRIS/IRD/
 IRAD 31.36
- infliximab
acne conglobata treatment 90.56
adverse effects 19.30
dosage 19.30
psoriasis therapy 19.29, 31.16
psoriatic arthritis treatment 35.45–6
pyoderma gangrenosum
 treatment 49.5–6
 sarcoidosis treatment 98.16–17
 TNF- α neutralization 8.35
information websites 15.3–4
informed consent, biopsy 3.2
infragluteal folds 113.3
- infrared radiation
diseases caused by 125.12–13
physiological reactions 125.11
- infundibulofolliculitis, disseminate and
 recurrent 93.6–7
- ingenol mebutate, actinic keratosis
 treatment 18.27, 142.8, 142.9, 146.15
- inguinal folds 113.3
- inguinal hernia 105.18
- inguinal lymph nodes 113.3
- inhalants 121.2
- inhalation injury, burns 126.1, 126.4–5
diagnosis 126.4–5
treatment 126.5
- inherited disorders 7.2, 7.2–3
analysis 7.8–9
cardiac 150.1, 150.2, 150.3–4
linkage studies 7.8
prenatal diagnosis 7.9–10
renal involvement 153.1–2
respiratory disorder association 151.2,
 151.4–5
- INI 1 tumour-suppressor gene 3.23
- injecting drug abuse 121.3–4
HIV infection 31.35
infections 121.3–4
panniculitis 99.47
phlebotymphoedema 105.8
- injecting drug use, lymphoedema 105.50
- injections, self-inflicted 99.46–7
- injury, skin 123.1–26
determinants of response 123.1–2
foreign-body reactions 123.16–18,
 123.19, 123.20–3
friction 123.5–13
see also Koebner phenomenon; trauma
- innate immune cells, atopic eczema 41.11,
 41.13
- innate immunity 2.12, 8.13–26, 8.54
acne vulgaris 90.35
activation 12.4
antimicrobial peptides 8.13–14
atopic eczema 41.11, 41.13
cells regulating 8.15–26
defence mechanisms 8.13–15
hidradenitis suppurativa 92.2–3
mast cell roles 2.17
NK cells 8.16–17
rosacea 91.4
UVR exposure 9.13
- innate lymphoid cells (ILCs) 8.26, 8.27
- inner root sheath (IRS) 2.9
- inoculation herpes simplex
 infection 25.23
- insect bite-like reaction 148.8
malignancy association 147.23
- insect bites
actinic prurigo differential
 diagnosis 127.11
cutaneous vasculitis differential
 diagnosis 102.4
exaggerated reaction 148.8
hypersensitivity reaction 117.11
pityriasis lichenoides differential
 diagnosis 135.5
venom immunotherapy 46.9
- insect repellants 34.5
- insect venom allergies, IgE 8.56
- insect-borne viral infections 25.74–8
- insecticide resistance 18.13
- insulin
allergic reactions 64.4
burns treatment 126.11
fat hypertrophy association 100.13
lipodystrophy 64.4
localized lipotrophy induction 100.9–
 10
PCOS 89.65, 89.68
sensitivity 99.5
- insulin resistance
acanthosis nigricans 87.3, 87.4, 112.21
acne association 90.3
acquired generalized
 lipodystrophy 100.1, 100.2
dyslipidaemia 62.11
- insulin resistance syndrome, type B 87.4
- insulin-induced localized fat
 hypertrophy 100.12–13
- insulin-like growth factor 1 (IGF-1)
acanthosis nigricans 87.3
burns treatment 126.10
raised prolactin levels 149.17
- integrase inhibitors 31.9
- integrated clinical management 11.7–8
- integrin(s) 2.2, 8.7, 8.9–11
inflammatory skin diseases 8.9–10
laminin cell binding 2.23, 2.25
leukocyte trafficking 8.10–11
ligation 8.9
mechanical function 123.5
wound healing 10.4–5
- $\alpha\beta 4$ integrin 71.4
 $\alpha 3$ integrin subunit 71.4
 $\beta 1$ -integrins 8.9
 $\beta 2$ -integrins 8.10
- intellectual disability, Down
 syndrome 76.2
- intense pulsed light (IPL) systems 160.2–3
- intensity modulated radiotherapy
(IMRT) 24.3, 24.4
- intention to treat (ITT) analysis 17.13
- intercellular adhesion molecule 1
(ICAM-1) 8.9, 8.11–12
 expression on keratinocytes 8.12
- intercellular adhesion molecule 2
(ICAM-2) 8.11, 8.12
- intercellular IgA pemphigus
clinical features 50.2
subcorneal pustular dermatosis
 differential diagnosis 49.15
- interdigital sinus 123.22
- interferon 8.32, 8.34–5
drug eruptions 31.18
macrophage secretion 8.21–2
receptors 8.34
wart treatment 25.53
- interferon (IFN- α) 8.32, 8.34
melanoma treatment 143.28–9
sarcoidosis 98.3–4
systemic lupus erythematosus 51.18–19
- interferon α -2b (IFN- α -2b), basal cell
 carcinoma treatment 141.15
- interferon β (IFN- β) 8.32, 8.34
- interferon γ (IFN- γ) 8.32, 8.34
- interferon γ release assays (IGRA) 27.4–5
- interferon-producing plasmacytoid
 predendritic cells, type I 2.15
- interleukin(s) 8.32, 8.33–4
- interleukin 1 (IL-1)
cell communication 8.32
keratinocyte-derived 8.4
- interleukin 1 (IL-1) antagonists 19.32
- interleukin 1 (IL-1) converting
 enzyme 8.41
- interleukin 1 receptor A (IL-1RA) 8.36
- interleukin 1 receptor antagonist
 deficiency 45.7
- interleukin 2 (IL-2)
itching in skin disease 83.7
melanoma treatment 143.31
- interleukin 4 (IL-4)
early-phase allergic response 8.58
immunoglobulin switching 8.56
inducible lymphoid cell production 8.57
- interleukin 5 (IL-5), atopic eczema 41.10
- interleukin 6 (IL-6), wound healing 10.3
- interleukin 8 (IL-8) 8.39, 8.40
chemokine receptors 8.39
- interleukin 10 (IL-10) 8.36
- interleukin 12/interleukin 23 p40
inhibitors, plaque psoriasis
 treatment 35.30–1
- interleukin 13 (IL-13)
Dercum disease 100.16
early-phase allergic response 8.58
- interleukin 17 (IL-17), atopic eczema 41.10
- interleukin 17 (IL-17) inhibitors 19.31–2
- plaque psoriasis treatment 35.31
psoriatic arthritis treatment 35.46
- interleukin 18 (IL-18) 8.4
- interleukin 18 receptor A (IL-18RA) 8.36
- interleukin 23 (IL-23) antagonists 19.31–2

- interleukin 25 (IL-25) 8.58
interleukin 31 (IL-31) 8.2
 atopic eczema 41.15
 itching in skin disease 83.7
interleukin 33 (IL-33) 8.4, 8.58
interleukin 36 receptor antagonist (IL-36RA) deficiency 45.8, 45.11
internal consistency 16.2
International Conference on Harmonisation Good Clinical Practice (ICH-GCP) Guideline 14.12
internet use in diagnosis 4.26
interpersonal counselling 86.39
interpersonal psychotherapy 86.39
interquartile range 17.18
interstitial granulomatous dermatitis, rheumatoid arthritis association 55.2–3, 154.14
interstitial lung disease (ILD), dermatomyositis 53.8–9, 53.11
intertrigo
 Candida 32.63–4
 candidosis 32.69
 groin 123.16
 male genital **111.3**
 psoriasis differential diagnosis 112.16
 symmetrical drug-related intertriginous and flexural exanthem differential diagnosis 118.6
 tinea cruris differential diagnosis 32.47
intertrigous eruption associated with chemotherapy 120.1, 120.2
intestinal disorders 152.1–4
intestinal polyposis 67.5, 152.4
intracellular enzymes **14.4**, 14.5
intra-dermal injection
 diagnostic 4.23
 long-delayed 4.25
intra-dermal tests, delayed sensitivity 4.24–5
intraepithelial carcinoma 142.17
 anal 142.25
intraepithelial neoplasia, ano-genital 25.57
intrahepatic cholestasis of pregnancy 83.11, 83.12, 115.10–11
intralymphatic histiocytosis 154.14
intraoral examination 110.6–7
intraoral hairy flaps, laser-assisted hair removal 23.15
intravascular large B-cell lymphoma 140.43–4, 140.43–5
intravascular papillary endothelial hyperplasia 110.72, 137.23–4
intravascular pressure, raised in purpura 101.4–5
intravenous drug use *see* injecting drug abuse
intravenous immunoglobulin (IVIg) 19.35–6
 adverse effects 19.35–6
 Comèl–Netherton syndrome treatment 65.25
 contraindications 19.36
 dermatological uses 19.35
 dermatomyositis 53.12
 discoid lupus erythematosus treatment 51.11
 dose 19.36
 DRESS treatment 119.11
 drug–drug interactions 19.36
 epidermolysis bullosa acquisita treatment 50.46
 Kawasaki disease treatment 102.33
 monitoring 19.36
 pemphigus treatment 50.9
 pharmacological properties 19.35
 pre-treatment screening 19.36
 regimens 19.36
 scleredema treatment 59.11
 Stevens–Johnson syndrome/toxic epidermal necrolysis 119.21–2
 systemic lupus erythematosus treatment 51.36
 intrinsic factor 63.20
 involucrin 2.7, 8.4
 iodides, acne association 90.12
 iodine
 exposure and dermatitis herpetiformis 50.53
 topical therapy 18.10
 ion channels **14.4**, 14.5
 ionizing radiation
 exposure and occupational skin cancers **130.14**
 skin cancer treatment 24.1–2
 iontophoresis, hyperhidrosis treatment 94.8–9
 iridium wire implants, radioactive 24.7
 IRIS/IRD/IRAD *see* immune reconstitution associated disease (IRAD); immune reconstitution inflammatory syndrome (IRIS); immune restoration disease (IRD)
 iron deficiency 63.23–5
 anaemia 148.16
 aphthous ulceration 110.39
 clinical features 63.24
 deficiency glossitis 110.64
 dysphagia and oesophageal web 152.1
 investigations 63.24
 management 63.24–5
 pruritus 83.11
 telogen effluvium 89.25
 iron salts, tattoos 88.53
 irritancy potential of substances **129.1**
 irritant contact dermatitis 107.4, 129.1–8
 acrodermatitis enteropathica differential diagnosis 63.26
 allergic contact dermatitis differential diagnosis 128.62
 ano-genital 111.10, 111.11
 apron pattern 129.4
 cheilitis 129.5
 chemical burns differential diagnosis 129.12
 clinical features 129.3–6
 cosmetics 129.4–5
 definition 129.1
 differential diagnosis 129.4, 129.5–6
 drug-induced eczema differential diagnosis 118.5
 epidemiology 129.1–2
 erythema 129.6
 faecal 114.10–13
 haemodialysis complication 153.4
 hand 129.2, 129.4
 advice to patients **129.7**
 histology of reactions 129.3–4
 hydration 129.6
 investigations 129.6
 management 129.6–8
 musical instruments 123.11
 napkin (diaper) 129.5
 occupational **129.2**, 130.1–5
 skin protection programme **129.8**
 occupational allergic contact dermatitis differential diagnosis 130.6
 occupational irritant contact dermatitis differential diagnosis 130.3
 pathophysiology 129.2–3
 perianal 129.5
 perineum/perianal region 113.7
 peristomal 129.5
 reaction types 129.1
 severity classification 129.6
 skin thickness 129.6
 stoma complications 114.10–13
 transepidermal water loss 129.6
 transient acantholytic dermatosis association 87.22
 urinary 114.10–13
 volatile/airborne 129.5
 irritants **129.2**
 dissociation constant 129.3
 hand eczema 39.17
 hydrophobicity 129.3
 mechanism of action 129.3
 plant **129.2**
 volatile/airborne 129.5
 ischaemic fasciitis 137.6
 ischio-anal fossa 113.2
 Islamic medicine, early 1.3
 isoflavones, anti-ageing products 156.9
 isomorphic phenomenon *see* Koebner phenomenon
 isoniazid 27.9–10
 acne association 90.11
 drug eruption 31.17
 N-isopropyl-*N'*-phenyl-*p*-phenylenediamine (IPPD) 128.14
 isothiazolinones 18.8, 128.35–7
 isotretinoin 19.37
 acanthosis nigricans treatment **87.5**
 acne conglobata treatment 90.56
 acne fulminans treatment 90.53
 acne treatment 11.4
 acne vulgaris treatment 18.22
 acute acne flare 90.47, 90.51
 alcohol effects 90.47–8
 confluent and reticulated papillomatosis treatment 87.7
 congenital ichthyoses 65.38–9
 depression association 86.34–5
 distribution control 90.45–6
 dosage 90.45–6
 education 90.45
 hidradenitis suppurativa management 92.10
 keloid induction 96.46
 keratosis pilaris treatment 87.11
 loricrin keratoderma treatment 65.49
 mood disorder association 86.34–5
 papulopustular acne treatment 90.44
 pregnancy testing 90.45
 prepubertal acne 90.63, 90.64, **90.64**
 prescribing 90.44–5, 90.46
 rosacea treatment 91.13, 91.14
 sacroiliitis precipitation 154.10
 sebaceous gland hyperplasia treatment 93.13
 severe acne treatment 90.44–8
 side effects 90.46–8
 mood changes 90.46–7
 mucocutaneous 90.46
 teratogenicity 90.45
 topical 18.22–3
 isotretinoin efficacy, drug interactions 90.48
 Italian Renaissance 1.3
 Itch Severity Scale 16.3
 itching
 acne vulgaris 90.22
 atopic 83.9
 atopic eczema 41.14–15
 central transmission 83.5
 cutaneous induction 83.4–5
 diagnosis 4.2
 histamine mediation 8.46
 infantile acropustulosis 116.7–8
 lichen simplex chronicus 83.20, 107.4
 mediators 83.6–7
 paraneoplastic 148.10
 perianal 83.14, 113.4–6
 pregnancy 115.10–11
 primary biliary cirrhosis 152.5
 psychogenic 86.21–2
 scabies 34.40
 scalp 107.12–13
 sweating relationship 41.15
 systemic disease 83.10–14
 vulval 83.14
 water-induced 83.11
 see also pruritus; scratching
 itching purpura 101.8, **101.9**, 101.10
 ITPKC gene mutations, Kawasaki disease 102.32
 itraconazole 19.44
 blastomycosis treatment 32.87
 coccidioidomycosis treatment 32.89
 dermatophytosis treatment 32.33–4
 treatment failure 32.35
 paracoccidioidomycosis treatment 32.90
 sporotrichosis treatment 32.73
 Talaromyces marneffei treatment 32.91
 tinea capitis treatment 32.40
 ivermectin 18.13
 cutaneous larva migrans treatment **33.19**
 head louse treatment 18.13
 loiasis treatment 33.11
 lymphatic filariasis treatment 33.9, 105.45
 myiasis treatment 34.12
 onchocerciasis treatment 33.6
 rosacea treatment 91.13
 scabies treatment 18.13, 34.43–4
 streptocerciasis treatment 33.6, **33.7**
 strongyloidosis treatment 33.17
 ixekizumab, plaque psoriasis treatment 35.31
 Ixodidae 34.35–6
J
 Jaccoud arthropathy 51.27–8
 Jackson–Lawler syndrome *see* pachyonychia congenita
 Jacob disease 110.25
 Jadassohn, Josef 128.1
 Jadassohn naevus phakomatosis 73.17
 Jadassohn–Lewandowsky syndrome *see* pachyonychia congenita
 JAK2V617F gene mutation 101.11, 101.12
 Jak-Stat-Socs pathway 8.23, 8.32
 Jamaican children, infective dermatitis associated with HTLV-1 39.24
 Jaquet dermatitis 117.4
 Jarisch–Herxheimer reaction 29.26
 jaundice 88.49–50
 acute pancreatitis 152.6
 hepatitis A virus 25.83
 liver cirrhosis 152.5
 neonatal 88.49, 88.50, 116.10
 neonatal ichthyosis–sclerosing cholangitis 65.36
 jaws, examination 110.5
 jeep driver's disease *see* pilonidal sinus
 jellyfish stings 131.1–2
 Jessner's lymphocytic infiltrate 135.10–11
 discoid lupus erythematosus differential diagnosis 51.9
 lymphocytoma cutis differential diagnosis 135.9
 papulopustular rosacea differential diagnosis 91.11
 polymorphic light eruption differential diagnosis 127.4
 Jessner's solution chemical peel 159.3, 159.4, 159.5, 159.6
 skin of colour 159.13
 systemic toxicity 159.12
 trichloroacetic acid combination 159.9, 159.10
 jewellery
 allergic contact dermatitis 128.13, 128.16
 ear piercing complications 108.7
 earring argyria 122.7
 jiggers 34.13
 Job syndrome *see* hyper-IgE syndrome
 Jod–Basedow phenomenon, potassium iodide-induced 19.28
 jogger's nipples 123.16
 jogger's toe 123.15–16
 joints
 effusions in fibroblastic rheumatism 55.4
 elbow in nail–patella syndrome 69.16
 stiff in diabetes 64.6
 see also knees
 Jordan anomaly 65.32
 judo jogger's itch 123.16
 junctional adhesion molecules (JAMs) 2.20
 juvenile aponeurotic fibroma 96.32
 juvenile dermatomyositis 53.2, 53.9
 acquired generalized lipodystrophy association 100.3
 juvenile elastoma 72.30
 juvenile fibromatoses 96.38–40
 variant 137.14
 juvenile hyaline fibromatosis 72.17–18, 96.39–40

- juvenile idiopathic arthritis
atrophoderma of Pasini and Pierini
differential diagnosis overlap 96.16
pachydermodactyly differential
diagnosis 96.36
systemic-onset 45.11
Kawasaki disease differential
diagnosis 102.33
- juvenile myeloid leukaemia
association with NF1/juvenile
xanthogranuloma 80.5
chronic 148.12
- juvenile plantar dermatosis 39.21–2
juvenile polyposis coli 80.14
juvenile rheumatoid arthritis 45.11, 55.4–5
infantile urticaria 117.6
Kawasaki disease differential
diagnosis 102.33
rheumatoid nodule differential
diagnosis 55.2
- juvenile spring eruption 127.8–9
pinna 18.13, 108.14
- juvenile xanthogranuloma 136.12–14
association with NF1/juvenile myeloid
leukaemia 80.5
clinical features 136.12–13
deep 136.13
definition 136.12
epidemiology 136.12
Erdheim–Chester disease differential
diagnosis 136.20
eyelid 109.47
infants 117.14–15
investigations 136.13
leukaemia association 148.12
management 136.13–14
necrobiotic xanthogranuloma
differential diagnosis 99.17
nomenclature 136.12
ocular 136.13, 136.14
pathophysiology 136.12
variants 136.13
- K**
- Kabuki syndrome/Kabuki make-up
syndrome 111.7
macrothia 108.5
- Kairo cancer 125.12
kala-azar *see* leishmaniasis, visceral
kallikreins 8.42
Kamino bodies 3.37
Kang cancer 125.12
Kangri cancer 125.12
- Kanzaki disease, α -N-acetyl-
galactosaminidase deficiency 81.5
- Kaposi sarcoma 25.37, 31.6, 31.29–30,
139.1–6
acquired ichthyoses 65.40
African endemic 139.4
AIDS-associated 139.4, 139.6
ano-genital psoriasis differential
diagnosis 111.9
bacillary angiomatosis differential
diagnosis 26.62
causative organisms 139.1, 139.2–3
children 31.35, 139.4
classic 139.4
clinical features 139.4–6
immunocompromised patients 146.11
complications/co-morbidities 139.5
conjunctival 109.51
cutaneous 31.29
definition 139.1
diagnosis 31.30
differential diagnosis 31.29, 111.24, 139.4
disease course 139.5–6
disseminated 31.29, 139.6
environmental factors 139.3
epidemiology 139.2
eyelid 109.51
eyelid oedema 105.15
facial lymphoedema 105.16
genital 111.33
granuloma annulare differential
diagnosis 31.17
- haemorrhoids differential
diagnosis 113.31
high-power microscopy 3.33
immunocompromised patients 146.11
incidence 31.5
investigations 139.6
management 139.6
nodular 139.1, 139.4
nomenclature 139.1
oncogenic viral infection 146.7
oral 31.29, 31.34
oral hyperpigmentation 110.67
pathophysiology 139.1–3, 139.4
penile 111.33
podoconiosis differential diagnosis 105.47
prevalence 31.29
prognosis 139.5–6
radiotherapy 24.13
severity classification 139.5
staging 139.5
treatment 31.30
variants 139.4
- Kaposi varicelliform eruption 41.13
mimicking impetigo 41.22
- kaposiform
haemangioendothelioma 137.33
- kaposiform lymphangiomatosis 105.39,
105.40
- Kaposi–Stemmer sign 105.3, 105.6
karyorrhexis 3.37
- Kasabach–Merritt phenomenon,
kaposiform
haemangioendothelioma
association 137.33
- Kashin–Beck disease 63.29
- Katayama fever 33.25
- Kawasaki disease 26.84–5, 102.32–3, 117.10
cardiac involvement 150.5
clinical features 26.84, 102.32–3, 154.4
coronary artery disease 150.5
drug-induced serum sickness-like
reaction differential diagnosis 118.9
epidemiology 26.84, 102.32
erythema multiforme differential
diagnosis 47.6
infantile seborrhoeic dermatitis
differential diagnosis 117.2
infantile urticaria 117.6
infective cheilitis 110.87
investigations 26.85, 102.33
management 26.85, 102.33
measles differential diagnosis 25.85
oral lesions 110.56
pathophysiology 26.84, 102.32
perineum/perianal region 113.11
severity classification 102.33
toxic shock syndrome differential
diagnosis 26.30–1
- Kayanur Forest disease 25.72
- keloid 96.45–9
chemical peel contraindication 159.6
clinical features 96.48
carbon dioxide laser incisional
surgery 23.17–18
definition 96.45
dermatofibrosarcoma protuberans
differential diagnosis 137.15
ear piercing complications 108.7–8
epidemiology 96.46–7
genital 111.26–7
hair pulling 86.18
healing 10.9
hyaluronic acid synthesis 2.40
investigations 96.48
linear 96.47
management 96.48–9
pathophysiology 96.47–8
plantar fascial fibromatosis differential
diagnosis 96.33
pseudofolliculitis complication 93.2
radiotherapy 24.7
tattoo reaction 88.55
- keloid-associated lymphoid tissue 10.9
- Kennedy disease, alopecia risk
reduction 89.16
- Kennedy terminal ulcer 124.8
- kenogen 89.7
androgenetic alopecia 89.18
- keratin(s) 2.1
gene mutations 65.44, 65.45
genetic disorder association 2.8
hair 2.9
immunopathology 3.18–19
nail structure 95.4
trichocyte 95.4
- keratin 1 71.6
mutations 65.13, 65.16, 65.17
- keratin 5 71.3, 71.10–11
- keratin 10 71.6
mutations 65.13, 65.15
- keratin 14 71.3, 71.10–11
- keratin 17 mutations, steatocystoma
multiplex 134.4
- keratin filaments 2.6
keratin genes 2.7–8
mutations 65.2, 65.13, 65.17, 69.1
- α -keratin intermediate filaments
(α -KIF) 89.6
- keratinization disorders 65.2
miscellaneous 65.66–71
see also ichthyoses; keratoderma;
palmoplantar keratodermas (PPKs)
- keratinocyte(s) 2.1, 2.5, 2.7–8
accelerated cell death 8.54
actinic keratosis 142.2
activated 8.12
activation by IFN- γ 8.34
acute phase inflammation 8.2
adhesion 2.18–19
antimicrobial peptides
effects 2.12
production 26.5
cell adhesion 8.5–6
chromosomal mosaicism 76.5
cultured for skin grafting 10.12
differentiation 2.7–8
early-phase allergic response 8.58
enzymes in inflammation 8.40–1
epidermal barrier formation 8.4
function 13.1
genetic changes 8.5
growth factor roles 8.5
ICAM-1 expression 8.12
IL-1 communication role 8.32
inflammation role 8.2, 8.4–6, 8.40–1
injury response 8.2, 8.4
keloid 10.9
lichen planus 37.2
lichen striatus 37.18
lipid production 8.4
mechanical stretching 123.1
melanosomes 88.3
transfer 88.4
microbiological agents 8.5
migrating 10.4, 10.5
nail matrix 2.11
necrotic
erythema annulare
centrifugum 47.9
erythema multiforme 47.4
pigmentation role 70.1
proliferation 10.5
proliferative properties 2.45
revertant 7.8
Stevens–Johnson syndrome 119.13
UV radiation 8.5
wound healing 10.3, 10.4, 10.5, 10.8–9
skin grafting 10.12
- keratinocyte growth factor (KGF) 132.6
- keratinocyte intraepithelial neoplasia
(KIN) 142.2, 142.4
- keratinocyte skin cancer (KC) *see* non-
melanoma skin cancer (NMSC)
- keratinocytic acanthomas 133.1–8
clear cell acanthoma 133.5–6
pseudoeplitheliomatous
hyperplasia 133.7–8
stucco keratosis 133.3, 133.4
wart-like dyskeratoma 110.19, 133.5
- see also* dermatosis papulosa
nigricans; keratosis follicularis,
inverted; seborrhoeic keratosis;
skin tags
- keratinopathic ichthyosis (KPI) 65.13–17
definition 65.13
management 65.38–9
pathophysiology 65.13
- keratinopathies 65.2
- keratitis
dendritic 109.38, 109.39
herpetic 109.37–8, 109.39
interstitial 29.31
sclerosing 109.42
stromal 109.40
- keratitis–ichthyosis–deafness
syndrome 65.30–2, 68.17, 90.31,
110.19
clinical features 65.31
management 65.31–2
pathophysiology 65.31
- keratoacanthoma 142.33–6
actinic keratosis differential
diagnosis 142.5
basal cell carcinoma differential
diagnosis 141.10
bony destruction 95.48
clinical features 142.35
definition 142.33
diagnosis 142.33
differential diagnosis 142.35
epidemiology 142.33
eyelid 109.49
generalized eruptive 142.35, 142.37–8
multiple self-healing squamous
epithelioma differential
diagnosis 142.37
genetics 142.34–5
intralesional therapy 20.44
investigations 142.35
lips 110.82
management 142.35–6
molluscum contagiosum differential
diagnosis 25.13
Muir–Torre syndrome differential
diagnosis 110.24
pathophysiology 142.33–5
radiography 95.48
radiotherapy 24.6
squamous cell carcinoma
association 142.27
differential diagnosis 108.25, 142.28
subungual 95.27–8
surgery 20.46, 142.35–6
variants 142.35
- keratoconjunctivitis
sicca
primary biliary cirrhosis 152.5
Sjögren syndrome 55.6
see also atopic keratoconjunctivitis;
vernal keratoconjunctivitis
- keratoconus 109.20–1, 109.22
atopic eczema 41.22
- keratocystic odontogenic tumours
(KCOT) 110.25
- keratoderma 71.24
acquired 65.42, 65.64–6
connexin gene abnormalities 2.19
Greither 65.46–7
loricrin 65.2, 65.49
mutilating 65.58
with ichthyosis 65.49
plantar 69.1, 69.11
punctate of genetic origin 147.17
plantar wart differential
diagnosis 25.50
transient aquagenic 65.54–5
see also palmoplantar keratoderms
(PPKs)
- keratoderma blenorrhagica 30.13, 30.14
reactive arthritis 154.2
- keratoelastoidosis marginalis 65.53
- keratohyalin 2.6
- keratohyalin granule
disorder 65.19–20

- keratolysis
 exfoliativa 39.15, 87.24–5
 acral peeling skin syndrome
 differential diagnosis 65.27
 ringed 39.15
see also pitted keratolysis
- keratolytic winter erythema 65.66–7
- keratosis
 acquired seed-like of palms and soles 147.17
 circumscripta 87.12, 87.13 (*see also* pityriasis rubra pilaris)
 frictional 110.74
 lichenoides chronica 37.11, 37.18, 95.45
 linearis-ichthyosis congenita-sclerosing keratoderma 65.19–20
 lorincrin keratoderma differential diagnosis 65.49
 mosaic acral 65.53
 multiple minute digitate 87.17–18
 obturans
 cholesteatoma differential diagnosis 108.28
 external auditory canal 108.28
 oral 110.75
 perforating disorders 65.68–9
 punctate of palmar creases 65.53
 PUVA side effect 21.13
 spinulosa (*see* lichen spinulosus)
 stucco 133.3, 133.4
 Flegel disease differential diagnosis 87.17
 universalis multiformis (*see* pityriasis rubra pilaris)
 waxy of childhood 65.71
see also actinic keratoses; arsenic keratosis; seborrhoeic keratosis
- keratosis follicularis 87.8–11, 96.14
 inverted 138.2–3
 Langerhans cell histiocytosis differential diagnosis 136.6
 monilethrix association 89.51
 spinulosa decalvans 68.15, 87.9
 trichodysplasia spinulosa differential diagnosis 87.15
 variants 87.9–10
- keratosis ichthyosis deafness syndrome, hidradenitis suppurativa association 92.2
- keratosis pilaris 87.8–11, 90.28
 atrophicans 87.9–10, 87.10
 clinical features 87.9–10
 definition 87.8
 differential diagnosis 87.10
 disease course 87.10
 epidemiology 87.8–9
 erythromelanosis follicularis of the face and neck 88.14
 faciei 87.9, 87.10
 investigations 87.10
 management 87.10–11
 pathophysiology 87.9
 phrynoderma differential diagnosis 87.14
 prognosis 87.10
 spinulosa
 acquired cicatricial alopecia 89.36
 Graham-Little syndrome 89.39–40
- keratotic plaques, perianal 113.4
- kerion 32.39
 dermatophytide reaction 32.51
 dissecting cellulitis of scalp differential diagnosis 107.8
 management 32.40
- Keshan disease 63.29
- ketoconazole 19.44
 dermatophytosis treatment 32.34
 seborrhoeic dermatitis treatment 40.5, 40.6
 subcorneal pustular dermatosis 49.15
 tinea capitis treatment 32.40
- ketoprofen 128.78
- ketotifen 127.23
- khat, oral cancer risk 110.34
- kidney disease *see* renal diseases
- KIF11* gene mutations 105.29
- Kikuchi histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease) 25.32, 148.12, 148.13
 subacute cutaneous lupus erythematosus association 51.12
 systemic lupus erythematosus association 51.31
 differential diagnosis 51.27
- Kimura disease 148.13–14
- epithelioid haemangioma differential diagnosis 137.28
- kinase inhibitors, melanoma treatment 143.30–2
- Kindler syndrome 71.2, 71.18–19
 acquired poikiloderma 96.10
 molecular pathology 8.5, 71.19
 oral lesions 110.25
 poikiloderma differential diagnosis 71.19
 revertant mosaicism 7.8
 Rothmund-Thomson syndrome differential diagnosis 77.6
 transmission electron microscopy 71.20
- kindlin-1 71.4, 71.19
- kinesiotaping, lymphoedema 105.57
- kinky hair 68.23
- kissing bugs 34.27–8
- Kit (CD117) 2.16
- KIT* gene mutations 46.1, 46.2, 70.3
KIT mutated melanoma 143.33–4
Klebsiella granulomatis, perineum/perianal region 113.12
Klebsiella pneumoniae rhinoscleromatis 26.54–6
- Klein-Waardenburg syndrome 70.5
- Klinefelter syndrome 76.4
 systemic lupus erythematosus association 51.19
- Klippel-Trenaunay syndrome 103.24, 103.26, 105.27, 105.28–9
 capillary malformations 73.5–6, 103.24, 103.25, 103.26
 clinical features 103.26
 definition 103.24
 epidemiology 103.24
 investigations 103.25
 lymphatic malformations 73.16, 105.35
 management 103.25, 103.26
 oral mucosa haemangiomas 110.15
 Parkes Weber syndrome differential diagnosis 103.25, 103.27
 pathophysiology 103.24–5
 purpura 101.5
 spindle cell haemangioma association 137.32
 tongue haemangiomas 110.15
 varicose veins association 103.24, 103.34
 venous malformations 103.24, 103.25, 103.26
- knees
 maculopapular sarcoidosis 98.7, 98.8, 98.15
 nail-patella syndrome 69.16
 scar sarcoidosis 98.9
- Knemidokoptidae 34.47
- knuckle pads 96.34–5
 clinical features 96.35
 epidemiology 96.34
 management 96.35
 pachydermodactyly differential diagnosis 96.35, 96.36
 pathophysiology 96.35
- Knudson 'two-hit' hypothesis 80.2
- Koch phenomenon 27.3
- Koebner phenomenon 4.9, 123.2–3
 dermatitis beryllium 122.8
 erythema ab igne 125.12
 erythema multiforme 47.5
 lichen planus 123.2
 male genital lichen planus 111.16
 nail biting 95.17
 psoriasis association 35.5, 123.2, 129.4
 psoriatic arthritis 35.44
 radiotherapy sites 120.13
- stoma complication 114.4–5
 tattoos 123.21
 vitiligo 88.36, 123.2
- Koenen tumours 95.26, 95.27
 tuberous sclerosis complex 80.11
- kohl pencils 122.4–5
- Kohlmeier-Degos disease 101.23–4
- koilonychia 95.7
 infants 117.13
- kojic acid 156.9, 156.11
- Kokoj spongiform pustule 3.38
- Koplik spots 110.75–8, 117.7
- koro syndrome 111.36
- Korsakoff syndrome 63.14
- Kramer syndrome 70.9
- krokodil 121.3
- KRT1* gene mutations 65.43, 65.44
KRT6A/KRT16 gene mutations 65.44, 65.45
KRT6B/KRT17 gene mutations 65.44, 65.45
KRT9 gene mutations 65.43, 65.44
KRT14 gene mutations 70.13
- KTP lasers 23.6, 160.2
 complications 23.11
 telangiectases 23.9
- Kveim test 4.25
- kwashiorkor 63.1–6
 acrodermatitis enteropathica differential diagnosis 63.26
 hair colour changes 89.71
 marasmic 63.1, 63.2, 63.4
- Kyrie disease 65.69, 96.49, 153.3
 Flegel disease differential diagnosis 87.17
- L**
- L1 cell adhesion molecule 8.12
- La antibodies 116.12
- labia majora 112.2
 angiokeratomas 112.3
 Fordyce spots 112.3
 melanoma 112.38
 variations 112.3
- labia minora 112.2–3
 Fordyce spots 112.3
 variations 112.3
- labial veins, varicosities 112.4
- laboratory methods for skin 3.5–10
 histochemistry 3.10
 routine tissue processing 3.7
 specimen preparation 3.5–6, 3.7
 staining techniques 3.7–10
- Lacazia loboi* 32.79
- lactate, sweat composition 94.4
- lactation
 antihistamine caution 19.4
 antimalarials caution 19.7
 azathioprine caution 19.9
 biological therapy caution 19.31
 chemical peel contraindication 159.6
 effects on drug therapeutic outcome 14.8
 hydroxycarbamide caution 19.22
 methotrexate contraindication 19.24
 thalidomide contraindication 19.41
- lactic acid
 acquired ichthyoses treatment 87.2
 chemical peel in skin of colour 159.13
- lactrodectism 34.32, 34.33
- Lactrodectus* 34.32–3
- lagophthalmos 28.13
- LAMB (lentiginos, atrial and mucocutaneous myxomas and multiple blue naevi) syndrome 101.17, 147.11
- oral mucosa 110.12
- lamellar desquamation/exfoliation of the newborn *see* collodion baby
- laminin(s) 2.23–5, 10.6
 cell binding 2.23, 2.25
 structure 2.23, 2.24
 wound healing 10.6
- laminin 322 2.21, 2.24, 2.26, 2.45
 epidermolysis bullosa 71.5, 71.14
 mucous membrane pemphigoid 50.32
 laminin A 72.24
- laminin γ 1 50.38
- laminin-nidogen complex 2.25
- lamivudine, drug eruptions 31.18
- lamotrigine 86.38
- lanatoprost 89.63
- Langer-Giedion syndrome 67.20, 68.16
- Langerhans cell(s) 2.1, 2.5, 2.13–15, 136.1, 136.2–3
 acute phase inflammation 8.2
 antigen processing/presentation 2.14, 8.29
 dendricity loss 9.7
 functions 2.14–15, 2.43
 immunological tolerance 128.10
 inflammation 8.29
 keratinocyte interactions 8.4
 lymphocyte interactions 2.14
 markers 3.23, 3.24
 migration 8.29
 motion 2.14
 origins 136.3
 phagocytosis 2.14
 psoriasis 8.29
 sensitization 128.7
 skin ageing 2.46
 skin pathology association 2.14
 structure 2.15
 subsets 2.15
- Langerhans cell histiocytosis 2.15, 117.15, 136.1, 136.2–8
 cells 136.3
 classification 117.15
 clinical features 136.4–6
 definition 136.2
 differential diagnosis 136.6
 disease course 136.6
 disseminated disease 136.5–6
 epidemiology 136.2
 Erdheim-Chester disease differential diagnosis 136.20
 genetics 136.3
 hidradenitis suppurativa differential diagnosis 92.7
 infantile eosinophilic pustular folliculitis differential diagnosis 93.10
 investigations 136.6, 136.7
 juvenile xanthogranuloma association 136.12
 management 136.7–8
 adults 136.8
 children 136.7
 mechlorethamine therapy 18.27
 multisystem (MS) disease 136.4, 136.6, 136.7, 136.8
 low risk 136.5
 nomenclature 136.2
 pathophysiology 136.2–4
 penile 111.34
 perianal 113.20
 presentation 136.4
 prognosis 136.6
 single system (SS) disease 136.4, 136.6
 skin 13.7–8, 136.4–5, 136.7, 136.8, 147.2
 skin-only 136.5, 136.7, 136.8
 treatment ladder 136.7–8
 variants 136.4–6
 vulval lesions 112.38–9
- langerin 3.23, 8.29, 31.5, 136.3
- Langer's lines 20.15
- lanolin 128.40
 topical medication 18.6–7
- lanugo hair 116.4
- Launois-Bensaude adenolipomatosis 100.13
- large cell anaplastic lymphoma 136.27
- larva currens 33.16, 33.17
 cutaneous larva migrans differential diagnosis 33.19
- larva migrans *see* cutaneous larva migrans; visceral larva migrans
- laryngeal papilloma 25.55
- lasers 23.1–20
 acne treatment 90.49–50
 active medium 23.2
 alexandrite 23.6

- basal cell carcinoma treatment 141.16–17
Bowen disease treatment 142.22
characteristics 23.2
clinical applications 23.5–20
complications 23.11
delivery systems 23.2
energy supply 23.2
flushing management 106.9
fractional modalities 23.19–20
hidradenitis suppurativa management 92.11
indocyanine green-augmented diode 23.10
low-level therapy for lymphoedema 105.57
low-power 23.20
non-ablative techniques 23.19–20, 96.4
optical cavity 23.2
output coupler 23.2
pigmentary disorder treatment 88.34
pigmented lesion treatment 160.4–6
pulse characteristics of beam 23.2–3
pulse duration 23.4
pulsed dye 23.6, 160.1
Q-switching 23.3, 23.12, 88.34
rosacea treatment 91.13, 91.14
skin resurfacing 160.6–10
solar lentigines 132.7
superpulsing 23.3
tattoo removal 88.5
tissue optics 23.3–4
treatments 160.1–10
vascular 23.6–11
 devices 23.6
 indications 23.7
vascular lesion treatment 160.1–4
wart treatment 25.52–3
see also carbon dioxide laser; Er:YAG laser; flashlamps; KTP lasers; Nd:YAG laser; pulsed dye lasers (PDL); Q-switched lasers
Lassa fever 25.70
La/SS-B antibodies 51.37, 51.39
Lassueur–Graham–Little syndrome 89.39–40
latanoprost, hair pigmentary changes 89.71
latent class analysis 5.4
latent TGF- β binding family of proteins (LTBP) 2.36
late-onset focal dermal elastosis 96.30
lateral pterygoid muscle 110.5
latex allergy 112.15
 allergic contact urticaria 128.83
 regulatory measures 128.76
 spina bifida 85.9–10
Laugier–Hunziker syndrome 110.12, 110.13
Lawrence syndrome *see* acquired generalized lipodystrophy (AGL)
lax skin *see* skin laxity
lead, reactions to 122.4–5
learning difficulties, tuberous sclerosis complex 80.11
Ledderhose disease 137.13
Leeds Acne Grading System 16.3
leftunomide 35.45
leg(s)
 allergic contact dermatitis 128.17
 armchair 105.8, 105.50
 chronically swollen 105.5–6
 lymphoedema 105.51–2
 diffuse large B-cell lymphoma 140.42, 140.43
 lower and eczema 39.18–21
 restless legs syndrome 85.16–17
 telangiectasia 160.3–4
 trench foot 125.3–4
 veins
 laser treatment 23.10, 160.3–4
 sclerotherapy 23.10
 venulectasias 160.3–4
 see also digit(s); foot; toe(s)
leg ulceration
 arterial 104.1, 104.8–10
 classification 104.1
 diabetes 64.1
 Feltz syndrome 55.3
 hypertensive ischaemic 104.1, 104.10–13
 clinical features 104.12–13
 definition 104.10
 epidemiology 104.11
 investigations 104.13
 management 104.13
 pathophysiology 104.11–12
 Klinefelter syndrome 76.4
 livedoid vasculopathy 101.22
 mixed venous and arterial 104.1, 104.5, 104.7–8
 prolidase deficiency 72.8, 72.9, 81.14
 rheumatoid arthritis association 55.3, 154.7
 trench foot differential diagnosis 125.3
 vasculitic
 mixed leg ulcer differential diagnosis 104.7
 venous leg ulcer differential diagnosis 104.3
 see also venous leg ulcers
Legionella pneumophila 26.72
legionellosis 26.72
Legius syndrome 74.8, 80.8, 80.9, 148.13
leiomyoma 137.55–6
 genital 137.55, 137.56
 oral 110.60
 pilar 137.55, 137.56
 vulval 112.30
leiomyosarcoma 137.57
Leishmania 33.41
Leishmania aethiops 33.41, 33.45, 33.46, 33.46–7
Leishmania brasiliensis complex 33.41, 33.43, 33.47
 ocular disease 109.43
Leishmania donovani donovani 33.48, 33.49, 33.51
 lymphocytoma cutis 135.9
 ocular disease 109.43
Leishmania donovani infantum 33.41, 33.46, 33.48, 33.49, 33.51, 33.51
Leishmania major 33.41, 33.43, 33.44–5
Leishmania mexicana complex 33.41, 33.47
Leishmania tropica 33.41, 33.45
 ocular disease 109.43
leishmaniasis 33.33, 33.40–51
 chronic 33.46
 cutaneous 33.40–8
 American 33.41, 33.42, 33.43–4, 33.47–8
 anthroponotic 33.45
 chronic blepharitis 109.12
 classification 33.40–1
 clinical features 33.44–8
 clinical variants 33.44–7
 definition 33.40
 diffuse 33.46–7
 disseminated 33.46–7
 dry 33.45
 epidemiology 33.41, 33.43
 eyelid 109.12
 genital 111.24
 geographical distribution 33.42
 investigations 33.47–8
 leprosy differential diagnosis 28.11
 management 33.44, 33.48
 Old World 33.41–2, 33.43, 33.44–7, 33.48
 pathophysiology 33.41–2
 returned traveller 33.48
 rural 33.44–5
 tropical ulcer differential diagnosis 26.66
 urban 33.45
 wet 33.44–5
 zoonotic 33.44–5
 epidermoid cyst differential diagnosis 134.2
 HIV infection 31.28
 Kaposi sarcoma differential diagnosis 31.29
 lupoid 33.46
 mucocutaneous 33.41, 33.42, 33.43–4, 33.47–8
 ocular 109.12, 109.43
 oral lesions 110.54
 post-kala-azar dermal 33.50, 33.51, 154.5
 recidivans 33.46
 sarcoidosis differential diagnosis 98.2, 98.8
 sporotrichosis differential diagnosis 32.72
 visceral 33.48–51
 clinical features 33.50–1
 clinical variants 33.50
 complications/co-morbidities 33.50–1
 epidemiology 33.49
 HIV infection 33.50–1
 investigations 33.51
 life cycle of parasite 33.49
 management 33.51
 pathophysiology 33.49
 leishmanoid, dermal *see* leishmaniasis, post-kalar-azar dermal
 leisure factors, diagnosis 4.4
 LEKTI serine protease inhibitor 8.41, 8.56, 65.24, 65.25
LEMD3 gene mutations 75.18
lentigines 132.2, 132.3–8
 Carney complex 132.5, 147.17
 definition 132.3
 differential diagnosis 132.4–5
 epidemiology 132.4
 familial syndromes 132.3
 genetics 132.4
 ink-spot 132.8–9
 investigations 132.5
 LAMB syndrome 101.17
 laser treatment 160.5
 management 132.6
 mucosal melanotic lesions 132.9–12
 NAME syndrome 101.17
 nomenclature 132.4
 pathophysiology 132.4
 Peutz–Jeghers–Touraine syndrome 70.14, 70.15
 psoriatic plaque 35.9
 PUVA side effect 21.13
lentigines, atrial and mucocutaneous myxomas and multiple blue naevi (LAMB) syndrome 101.17, 147.11
 oral mucosa 110.12
lentiginosis 88.16–17, 132.3
 agminated 132.4
 eruptive 88.16–17
 familial syndromes 132.3
 generalized 88.16
 inherited patterned in black people 88.16, 110.12
 oral mucosa 110.11–12
 penile 132.11
 profusa 132.3–4
 PUVA 88.17
 segmental 132.4
 speckled lentiginous naevi differential diagnosis 132.17
 unilateral 88.16
 zosteriform 88.16
lentigo
 actinic 132.6–7
 photochemotherapy 132.7–8
 solar 132.6–7
 management 132.6–7
lentigo maligna 24.13, 132.5, 132.6, 143.6, 144.5
 clinical features 143.12
 dermoscopy 144.8
 ink-spot lentigo differential diagnosis 132.9
 laser treatment contraindication 23.14
 management 18.29, 132.11, 143.24–5
 mixed desmoplastic melanoma association 144.12
 presentation 143.9–10, 143.11–12, 143.12
 radiotherapy 24.13
 seborrhoeic keratosis differential diagnosis 133.3
 in situ 143.24–5
lentigo simplex 132.4–6
 benign lichenoid keratosis differential diagnosis 133.7
Lenz–Majewski syndrome 72.12
LEOPARD syndrome 80.8, 132.3, 150.3, 150.4
Lepidoptera 34.30–2
leprechaunism 72.15
leprosy 28.1–17
 anaesthetic foot 28.13, 28.17
 borderline 28.3, 28.5, 28.12, 28.15
 clinical features 28.10, 28.11
 polyarthritides 154.4
 causative organism 28.6–7
 characteristics 28.7
 chemotherapy 28.14–15
 classification 28.3–5
 clinical features 28.7–13
 clinical variants 28.7–11
 co-morbidities 28.12–13
 complications 28.12–13
 control 28.17
 definition 28.1
 diagnosis 28.14
 differential diagnosis 28.11–12
 epidemiology 28.1–2
 erythema nodosum
 leprosum 99.24–6
 histopathology 99.25–6
 eye infections 109.42
 eye involvement 28.13
 granuloma multiforme differential diagnosis 28.11, 96.27
 hair loss 89.47
 histology 28.3
 historical aspects 1.7–8
 HIV infection 31.22
 immunology 28.6
 indeterminate 28.5
 infective cheilitis 110.87
 investigations 28.14
 lepromatous 28.4, 28.6
 clinical features 28.8–10
 Lucio 28.12, 28.13
 lupus vulgaris differential diagnosis 27.23–4
 management 28.14–17
 first line treatment 28.14–15
 second line 28.16
 treatment complications 28.16
 nerve damage 28.12–13, 28.16
 complications 28.17
 nomenclature 28.1
 onchocerciasis differential diagnosis 33.5
 oro-facial lesions 110.53
 paralysis 28.17
 pathogenesis 28.2–3
 pathology 28.2–7
 pathophysiology 28.2
 patient education 28.16–17
 plantar ulceration 28.17
 pregnancy 28.14, 115.5
 presentation 28.7
 prevention 28.17
 pure neuritic 28.11
 reactions 28.16
 rehabilitation 28.17
 relapse 28.15–16
 sarcoidosis differential diagnosis 98.2, 98.8
 serology 28.6
 severity classification 28.12
 tuberculoïd 27.8, 28.3–4, 28.6
 clinical features 28.7, 28.8
 pinta differential diagnosis 26.68
 type 1 reactions 28.3, 28.5, 28.6, 28.12, 28.13
 type 2 reactions 28.3, 28.5, 28.6, 28.12, 28.13
 vaccines 28.17
 vulval lesions 112.24
 weakness 28.17
leptin 2.43, 99.5, 149.2
leptomeningeal disease, congenital melanocytic naevi 75.14–15

- Leptospira* 26.71
Leptospira interrogans complex 26.71
 leptospirosis 26.71
 Lesch–Nyhan syndrome 81.16–17
 nail biting 95.17
 lethal midline granuloma, aphthous ulceration 110.40
 Letterer–Siwe disease 136.5–6
 leucomelanoderma 127.28
 leukaemia
 aphthous ulceration 110.40
 erythroderma 39.32–3
 erythromelalgia 84.10
 hairy cell 147.24
 skin involvement 147.2
 transplacental transfer of maternal disease 116.14
see also named leukaemias and leukaemia conditions
 leukaemia cutis 140.48–9, 147.2, 148.2–4
 clinical features 148.3
 definition 148.2
 epidemiology 148.2, **148.3**
 management 148.4
 pathology 148.4
 pathophysiology 148.3
 prognosis 148.4
 leukocyte(s)
 adherence 8.35
 migration and endothelial adhesion molecules 8.9
 platelet activating factor role 8.47
 trafficking and integrins 8.10–11
 leukocyte adhesion deficiency (LAD) 8.10, 8.18
 primary immunodeficiency 82.2
 leukocyte function-associated antigen 1 (LFA-1) 8.7, 8.10–11
 leukocytoclastic vasculitis 102.5, 102.6
 inflammatory bowel disease association 152.3
 papulonecrotic tuberculid differential diagnosis 27.29
Rickettsia conorii association 26.78
 leukoderma 88.8
 acquisitum centrifugum 88.40
 disseminate lenticular 88.46
 halo naevi-associated 88.37
 occupational 130.12–13
 causative chemicals **130.12**
 punctate 88.47
 leukoedema 110.19, 116.4
 leukonychia 95.13–14
 apparent 95.14
 punctate 95.14
 selenium toxicity 122.6
 subtotal 95.13–14
 total 95.13
 transverse 95.14
 leukopenia, aphthous ulceration 110.39
 leukoplakia 110.9
 clinical features 110.76–7
 definition 110.75
 dyskeratosis congenita 69.14, 77.3, 77.4
 epidemiology 110.75
 heterotopic sebaceous glands differential diagnosis 93.12
 investigations 110.77
 male genital 111.7
 malignant potential 110.77
 management 110.77–8
 oral submucous fibrosis predisposition 110.57
 pathophysiology 110.76
 proliferative verrucous 110.38, 110.77
 syphilis 110.53
see also hairy leukoplakia
 leukotrienes 8.49
 levator ani muscle 113.3
 levator ani syndrome 113.32
 levodopa, restless legs syndrome management 85.17
 levofloxacin, phototoxicity 127.28
 Lewar disease 110.61–2
 L'Hôpital St Louis (Paris) 1.4–5
 Libman–Sacks disease 101.17
 antiphospholipid syndrome association 52.2
 systemic lupus erythematosus 51.15, 51.16
 lice 34.16–18
 body 34.21–2, 88.24
 clothing 34.21–2
 crab 34.17, 34.22–3
 head 34.18–21
 management 18.13
 pubic, perineum/perianal region 113.13
see also Pediculus spp.; Phthirus pubis
 lichen 128.53, 128.55
 lichen amyloidosis 58.13
 lichen planus 37.13
 lichenification differential diagnosis 39.30
 pretibial myxoedema differential diagnosis 105.49
 lichen aureus 101.8, **101.9**, 101.10
 lichen myxoedematosus 59.2–8
 classification 59.2, **59.3**
 definition 59.2
 discrete papular 59.6–7
 generalized 59.2–6
 localized 59.6–8
 nodular 59.7
 proteoglycans 2.40
 lichen nitidus 37.10, 37.11, 37.18
 keratosis pilaris differential diagnosis 87.10
 nails 95.45
 penile 111.16
 phrynoderma differential diagnosis 87.14
 trichodysplasia spinulosa differential diagnosis 87.15
 lichen pilaris 87.8–11
 lichen planopilaris 37.4, 37.6–7, 89.37–9
 acquired cicatricial alopecia 89.35–6, 89.36
 clinical features 89.38–9
 complications 37.11–12
 dermatitis herpetiformis association 37.12
 management 37.17, 89.39
 pathophysiology 89.37–8
 scarring 89.38
 vulval 112.10
 lichen planus 37.1–18
 acquired cicatricial alopecia 89.36
 actinic 37.7–8, 37.18
 actinic keratosis differential diagnosis 142.4
 acute with confluence of lesions 37.9
 allergic contact dermatitis 128.60
 differential diagnosis 128.62
 annular 37.8–9
 ano-genital 37.6, 37.17
 genital wart differential diagnosis 111.25
 male 111.16
 nail involvement 112.12
 oral involvement 112.12
 vulval 112.9–12, 112.42
 ano-genital psoriasis differential diagnosis 111.9
 associated conditions 37.13
 atrophic 37.14
 bullous 37.9–10, 37.14, 37.18
 pemphigoides **50.10**
 causative organisms 37.2
 classic 112.10
 clinical features 37.3–5, 112.10–12
 complications 37.11–13, 111.16
 conjunctival, mucous membrane pemphigoid differential diagnosis 50.29
 corticosteroid therapy 37.15, 37.16, 37.17, 37.18
 dermatophyte-induced onychomycosis differential diagnosis 32.49
 dermoscopy 37.13–14
 differential diagnosis 111.16, 112.11
 discoid lupus erythematosus differential diagnosis 89.41
 disease course 37.13
 dyskeratosis congenita differential diagnosis 69.15
 environmental factors 37.3
 epidemiology 37.2, 112.9
 epidermodysplasia verruciformis differential diagnosis 25.60
 erosive 37.18
 vulval 112.10–11
 erythema multiforme differential diagnosis 47.5
 erythroderma 39.33
 follicular 37.6–7, 37.12, 89.37–40
 genetics 37.2–3
 genital lesions (*see* lichen planus, ano-genital)
 gold reactions 122.4
 guttate 37.9
 hand eczema differential diagnosis 39.16
 hypertrophic 37.7, 37.14
 pretibial myxoedema differential diagnosis 59.12
 vulval 112.10
 immunopathology 37.2
 immunostaining **110.46**
 investigations 37.13–15, 112.12
 Koebner phenomenon 123.2
 lichen sclerosus differential diagnosis 111.14, 112.7–8, 112.11
 lichen sclerosus overlap syndrome 110.45
 lichen striatus differential diagnosis 37.20
 lichenification differential diagnosis 39.30
 lichenoid drug eruptions 118.9, 118.10–11
 linear 37.4
 liver disease 152.9
 longitudinal erythronychia 95.15
 lower leg eczema differential diagnosis 39.20
 malignancy association 147.23
 management 37.15–18, 111.16, 112.12
 mild 110.45
 mixed discoid lupus erythematosus pattern 37.9, 37.18
 moderate 110.45
 mucous membrane lesions 37.4–5, 37.5–6, 37.12–13, 37.14
 nail involvement 37.12, 37.17, 95.44–6
 genital lichen planus 112.12
 management 95.45–6
 shedding 95.8
 variants 95.45
 non-reticular 110.45
 oral 37.5–6, 37.13, 37.14, 110.43–5
 aetiology 110.43
 clinical features 110.43–4
 diagnosis 110.44
 genital lichen planus 112.12
 management 37.16–17, 110.44–5
 mucous membrane pemphigoid differential diagnosis 50.29
 pathology 110.43
 prognosis 110.44
 soreness 110.63
 palms 37.7
 papular 112.10
 pathophysiology 37.2–3, 112.9–10
 pemphigoides 37.9–10, 37.18, 50.49
 oral lesions 110.45
 penile cancer risk 111.30
 perineum/perianal region 113.7, 113.8
 pigmentosus 37.8
 ashy dermatosis differential diagnosis 88.33
 pinta differential diagnosis 26.68
 pityriasis lichenoides differential diagnosis 135.5
 plantar wart differential diagnosis 25.50
 prognosis 37.13
 psoriasis differential diagnosis 95.41
 severe 110.45
 skin picking disorder differential diagnosis 86.15
 soles 37.7
 subacute cutaneous lupus erythematosus association 51.12
 subacute with confluence of lesions 37.9
 subtropical 37.7–8
 tattoo-association 123.21
 variants 37.5–11, 112.10–11
 vulval 112.9–12
 graft-versus-host disease differential diagnosis 112.42
 Wickham's striae 37.13–14
 lichen ruber acuminatus *see* pityriasis rubra pilaris
 lichen ruber moniliformis 37.11
 lichen sclerosus
 anetoderma differential diagnosis 96.22
 ano-genital 111.13–16
 clinical features 111.13–14
 complications 111.15
 epidemiology 111.13
 management 111.14–15
 pathophysiology 111.13
 prepuce 111.7
 vulval 112.6–9
Borrelia burgdorferi 26.70
 clinical features 112.6–9
 ano-genital 111.13–14
 definition 112.6
 differential diagnosis 112.7–8
 epidemiology 112.6
 ano-genital 111.13
 hormonal factors 5.9
 investigations 112.9
 lichen planus association 37.13
 differential diagnosis 112.7–8, 112.11
 malignant atrophic papulosis differential diagnosis 101.24
 management 112.9
 ano-genital 111.14–15
 morphea overlap 57.5–6
 nails 95.45
 oral 110.45
 pathophysiology 112.6
 ano-genital 111.13
 penile cancer association 111.30, 111.31
 perineum/perianal region 113.7, 113.8
 persistent disease 111.15
 prepuce 111.7
 stoma complication 114.5, 114.6, 114.7
 UVA-1 phototherapy 21.6
 verrucous carcinoma association 112.35, 112.37
 vitiligo differential diagnosis 112.20
 vulval 112.6–9
 lichen scrofulosorum 27.25–8, 151.4
 clinical features 27.26–7
 clinical variants 27.26, 27.27
 differential diagnosis 27.27
 epidemiology 27.26
 investigations 27.28
 lichen nitidus differential diagnosis 37.10
 management 27.28
 pathophysiology 27.26
 lichen simplex 39.28–30
 ano-genital 111.10, 111.11
 chronic otitis externa 108.18
 clinical features 39.29–30
 definition 39.28
 epidemiology 39.28
 nape of neck 39.29
 pathophysiology 39.28–9
 perineum/perianal region 113.7
 pretibial myxoedema differential diagnosis 59.12
 psoriasis differential diagnosis **35.18**, 35.19
 tinea corporis differential diagnosis 32.37
 variants 39.29
 vulval 112.15–16

- lichen simplex chronicus 83.20, 86.13, 86.14
- lupus vulgaris differential diagnosis 27.24
- musical instruments 123.11
- scalp 107.4
- seborrhoeic dermatitis differential diagnosis 107.1, 107.2
- lichen spinulosus 87.11–12
- keratosis circumscripta differential diagnosis 87.12
- phrynoderma differential diagnosis 87.14
- lichen striatus 37.18–20
- clinical features 37.19–20
- definition 37.18
- differential diagnosis 37.20
- disease course 37.20
- environmental factors 37.19
- epidemiology 37.18
- genetics 37.19
- hypopigmentation 88.44
- management 37.20
- nails 95.45
- nomenclature 37.18
- pathophysiology 37.18–19
- prognosis 37.20
- variants 37.19–20
- lichen verrucosus et reticularis 37.11
- lichenification 39.28–30
- Down syndrome 76.2
- pebbly 39.29
- secondary 39.30
- lichenified onchodermatitis (LOD) 33.2, 33.3, 33.4
- lichenoid dermatitis 37.14–15
- gold-induced 122.3
- lichenoid drug eruptions 118.9–11
- causes 118.9–10
- clinical features 118.10–11
- investigations 118.11
- lichen planus differential diagnosis 112.11
- management 118.11
- pathophysiology 118.10
- lichenoid keratoses, benign 37.15, 133.6–7
- lichenoid reactions 3.37
- allergic contact dermatitis 128.60
- lichenoid sarcoidosis 98.13
- lidocaine 20.11
- dosage 20.11–12
- with epinephrine 20.11–12
- life course impairment 16.7–8
- lifestyle behaviours, psoriasis 11.6
- Li–Fraumeni syndrome, radiotherapy-induced 24.19
- ligase 4 syndrome 82.11
- light 23.1
- light therapy, melasma treatment 88.34
- light-cured gels 95.62–3
- lightening agents 156.3
- light–tissue interaction 23.4, 23.6
- hair reduction 23.15
- photothermal ablation 23.16–17
- skin pigmentation 23.11–12
- likelihood ratio 17.15–16
- Liliaceae* 128.53
- limb(s)
- constricting bands of the extremities 96.43–5
- surgery 20.5
- see also arm, swollen; leg entries; lower limb
- limb ischaemia, acute 103.4
- limb–mammary syndrome 67.9
- lincosamides 19.43
- lindane 18.13
- linea alba, neonates 116.4
- linear atrophoderma 96.15
- of Moulin 57.19–20, 75.19
- linear bands, raised of infancy 116.17–18
- linear focal elastosis 96.29–30
- linear furrows 96.2
- linear IgA bullous dermatitis antigen (LABD) 97 50.34
- linear IgA disease 50.18, 50.33–7, 50.38
- anti-p200 pemphigoid differential diagnosis 50.39
- autoantibody specificity 50.10
- bullous pemphigoid differential diagnosis 50.21
- bullous systemic lupus erythematosus differential diagnosis 50.48
- childhood 50.33, 50.35, 82.14, 82.15 (see also immunobullous disease)
- clinical features 50.35–7
- clinical signs 50.10
- definition 50.33
- dermatitis herpetiformis differential diagnosis 50.53
- diagnosis 50.37
- differential diagnosis 50.36
- disease course 50.37
- epidemiology 50.33–4
- epidermolysis bullosa acquisita differential diagnosis 50.43, 50.45
- genetics 50.35
- genital 111.19
- immunostaining 110.46
- investigations 50.37
- malignancy association 147.22
- management 50.37, 50.38
- mucous membrane pemphigoid 109.27
- diagnostic overlap 50.36
- differential diagnosis 50.24
- nomenclature 50.33
- oral ulceration 110.42
- pathophysiology 50.34–5
- pemphigus vulgaris differential diagnosis 50.7
- predisposing factors 50.34–5
- prognosis 50.37
- severity classification 50.37
- vancomycin-induced, erythema multiforme differential diagnosis 47.6
- variants 50.36
- vulval, clinical features 112.19
- linear IgA/IgG bullous dermatosis 50.36
- linear morphoea 117.12–13
- linear naevus syndrome 110.19
- linear sebaceous naevus syndrome 73.17
- lines of Blaschko see Blaschko's lines
- linezolid 19.43
- lingual thyroid 110.11
- lingual tonsil 110.7, 110.10–11
- lingual veins 110.6
- linkage disequilibrium 7.8
- lip fillers, foreign-body cheilitis 110.85
- lip-lick cheilitis 41.24, 41.29
- lip(s)/lip disorders 110.3, 110.7–9
- acquired lesions 110.78–88
- allergic contact dermatitis 128.15–16
- blisters 110.80–1
- calibre-persistent artery 110.88
- cancer 110.34–5, 110.81–2
- chapping 110.82
- Crohn disease 97.12
- dimples 110.25
- double lip 110.24
- examination 110.6
- factitious cheilitis 86.25, 110.84
- fissures 110.88
- haemangiomas 110.15
- hereditary haemorrhagic telangiectasia 110.14–15
- inflammation 110.82–8
- lobular capillary haemangioma 110.72
- lupus erythematosus 110.88
- melanotic macules 110.13
- muscle 110.3
- myxoid cyst 110.60–1
- oedema 105.15, 105.16
- Peutz–Jeghers syndrome 110.13
- pits 110.25, 110.26
- radiotherapy for skin cancer 24.11–12
- sinuses 110.25
- squamous cell carcinoma 110.32–8
- Stevens–Johnson syndrome 119.16, 119.17
- toxic epidermal necrolysis 119.16, 119.17
- van der Woude syndrome 110.26
- vermilion zone 110.3
- wedge excision 20.33
- xeroderma pigmentosum 110.26
- see also lipsticks/lipsalves; venous lakes; vermilion border
- lipid(s)
- atopic eczema 41.6
- epidermal 129.3
- synthesis and skin ageing 2.47
- topical drug delivery 18.5–7
- lipid metabolism 62.1
- epidermal barrier 8.4
- see also dyslipidaemias
- lipid redistribution syndrome 31.10
- lipid storage diseases, neutral lipid storage disease with ichthyosis 65.32–3
- lipoatrophy 31.20
- localized 100.8–12
- corticosteroid-induced 100.10–11
- injected drugs 100.9–11
- insulin-induced 100.9–10
- semicircular 100.8–9, 123.14
- lipoblastoma 137.59–60
- lipoblastomatosis 137.59–60
- lipodermatosclerosis 99.28–9, 99.30, 99.31, 105.6, 105.9–10
- acute 105.9, 105.10
- chronic 105.9, 105.10
- chronic venous insufficiency 103.38, 103.39
- clinical features 105.9–10
- definition 105.9
- epidemiology 105.9
- investigations 105.10
- lower leg eczema complication 39.20
- management 105.10
- nomenclature 105.9
- pathophysiology 105.9
- recurrent cellulitis differential diagnosis 105.12
- lipodystrophy
- antiretroviral therapy effect 31.10, 31.19–20
- centrifugal 100.11–12
- congenital 74.1–3
- acquired 100.3
- generalized 74.1, 74.2
- familial partial 74.1–3
- gynoid 100.23
- insulin-induced 64.4
- localized secondary to panniculitis 100.11
- mandibulo-acral dysplasia with type A and type B 79.2, 79.5
- treatment 31.20
- see also acquired generalized lipodystrophy (AGL); acquired lipodystrophy; acquired partial lipodystrophy (APL)
- lipoedema 100.19–23, 105.30–3
- clinical features 100.20, 105.31–2
- complications/co-morbidities 105.32
- definition 105.30
- Dercum disease differential diagnosis 100.17
- diagnostic criteria 105.31
- differential diagnosis 100.20, 100.21, 105.31–2
- epidemiology 105.31
- familial 74.10
- inheritance 105.31
- investigations 105.32–3
- lipo-lymphoedema 100.21–2
- lower limbs 100.19–21
- management 105.33
- pathophysiology 105.31
- phenotype 105.31
- progression 105.32
- prevention 105.33
- scalp 100.22–3
- severity classification 105.32
- stages 105.32
- lipoedematous alopecia 107.9
- lipofibromatosis 137.14
- lipogenesis 99.4
- lipogranuloma, penile 111.8, 111.35
- lipohypertrophy 31.20
- lipoedema differential diagnosis 100.20
- swollen arm differential diagnosis 105.13
- α-lipoic acid (ALA) 156.1–2, 156.10
- lipoid proteinosis 72.32–3
- diabetes associations 64.4
- hyaline fibromatosis syndrome differential diagnosis 72.18
- lipolymphoedema 100.21–2, 105.32
- lipolysis 99.4
- laser-assisted 23.20
- lipomas 137.58–9
- atypical 137.60–1
- congenital 75.18
- epidermoid cyst differential diagnosis 134.2
- mitochondrial disorders 81.9–10
- oral 110.60
- pleomorphic 137.60
- spindle cell 137.60
- surgery 20.46
- vulval 112.30
- lipomatosis, hereditary 74.6, 74.8, 74.9
- multiple
- familial 74.8, 74.9
- symmetrical 74.8
- lipomatosis, subcutaneous 100.13–19
- benign symmetrical 100.13–15
- infiltrating of face 100.17–18
- see also Dercum disease; encephalocraniocutaneous lipomatosis
- lipomeningomyelocele 74.8
- lipoprotein glomerulopathy, hyperlipoproteinaemia type III 62.8
- lipoprotein lipase (LPL) deficiency 62.8, 62.9
- liposarcoma 137.61
- liposclerosis, nodular 100.23
- liposomes 18.3, 18.8
- liposuction 99.3, 160.11
- lipoedema management 105.33
- lymphoedema management 105.58–9
- lipoxins 8.49
- 5-lipoxygenase (5-LO) 8.49
- 5-lipoxygenase (5-LO) inhibitors 8.49
- lipoxygenase 12B 65.10, 65.11
- lipoxygenase E3 65.10, 65.11
- Lipschütz ulcers 25.32, 25.36, 112.18–19
- lipsticks/lipsalves
- cheilitis 110.82, 110.83, 128.32
- dermatitis 128.15
- liquefactive fat necrosis 99.8
- liquid nitrogen cryotherapy 20.43
- liquiritin 18.29
- Lisch nodules 80.3
- NF1 80.1, 80.2, 80.4
- Listeria monocytogenes* 26.45–6, 116.25–6
- listeriosis 26.45–6
- neonatal 116.25–6
- Listrophoridae 34.47
- lithium
- acne association 90.11
- hidradenitis suppurativa induction 92.3
- lithium gluconate, seborrhoeic dermatitis treatment 40.5
- livedo
- annularis 125.6
- sarcoidosis association 98.13
- livedo racemosa 125.6, 125.7
- Sneddon syndrome 101.21
- livedo reticularis 125.6–8
- acquired idiopathic 125.7–8
- cholesterol emboli 101.16
- classification 125.7
- clinical features 125.6–7
- congenital 125.7
- definition 125.6
- erythrocytosis differential diagnosis 125.6
- investigations 125.8

- livedo reticularis (*continued*)
 management 125.8
 pancreatitis 152.6
 pathophysiology 125.6
 physiological 125.7
 polyarteritis nodosa differential
 diagnosis 102.30
 proximal nail fold capillaroscopy 95.52
 rheumatic fever 55.8
 rheumatoid arthritis 55.4
 Sneddon syndrome 101.21
 systemic lupus erythematosus 51.24
 variants 125.7–8
- livedoid vasculopathy 101.22–3
- liver disease 152.4–5
 cirrhosis 152.5
 DRESS syndrome 119.8
 drug reactions **152.9**
 erythropoietic protoporphyria 60.16
 hair changes 152.9
 nail changes 152.9
 neonatal lupus erythematosus 51.38
 oral manifestations **110.89**
 oro-facial-digital syndrome type 1 153.2
 porphyria cutanea tarda 60.13, 152.7,
 152.9
 pruritus association 152.8
 psoriasis association 35.21
 retinoid-induced 19.39
 sarcoidosis 98.5
 skin pigment changes 152.8
 systemic diseases 152.7
 systemic lupus erythematosus 51.29
 vascular changes 152.8–9
- liver X receptors (LXRs) 8.4
 liverworts 128.53, 128.55
 LL-37 8.14
 LMNA gene mutations 72.20, 72.24, 72.25
Loa loa infection 33.10–11
 onchocerciasis differential
 diagnosis 33.5
- lobomycosis 32.79
- local anaesthesia
 biopsy 3.2–3
 conjunctival 20.12
 discomfort minimization 20.12
 epinephrine-containing 20.11–12, 20.121
 ester-type 20.11
 methods 20.12
 surgery 20.11–12
 toxic reactions 20.11–12
 types 20.11
- localized intravascular coagulopathy
 (LIC), venous malformation 73.11
- locusts 34.30
- Loeffler syndrome 33.15
- Loeys–Dietz syndrome
 Ehlers–Danlos syndrome differential
 diagnosis 72.7
 Marfan syndrome differential
 diagnosis 72.17
- Löfgren syndrome 98.6, 98.15
 synovitis 154.8
- loiasis *see Loa loa* infection
- lonafarnib 72.22
- lonomism 34.31, 34.32
- loose anagen syndrome 68.23, 89.11,
 89.58–9
 infants 117.14
 uncumbable hair 89.57
- lopinavir, drug eruptions 31.18
- Lopitamide, familial
 hypercholesterolaemia
 management 62.7
- loricrin 8.4
- loricrin keratoderma 65.2, 65.49
 collodion baby 116.19
- lotions 18.2
- Louis-Bar syndrome *see* ataxia
 telangiectasia
- Lovibond's angle 95.6
- low-density lipoprotein (LDL)
 diabetes 62.11
 familial hypercholesterolaemia 62.6
 hyperlipoproteinaemia
- type III 62.8
 type IV 62.10
- lower limb
 lipoedema 100.19–21
 surgery 20.5
 venous malformation 73.10
- low-grade fibromyxoid sarcoma 137.18–19
- low-level laser therapy,
 lymphoedema 105.57
- loxoscelism 34.32, 34.33–4
- L-selectin 8.8–9, 8.9
- neutrophils location 8.18
- lubricating oils, occupational skin
 cancers 130.14
- Lucio reaction 28.12, 28.13, 99.25–6
- Lujo virus haemorrhagic fever 25.70–1
- lumpy scalp syndrome 107.9
- lungs, systemic lupus
 erythematosus 51.28–9
- lupoid sycosis 26.26–7
- lupus anticoagulant
 antiphospholipid syndrome 52.2
 Sneddon syndrome 101.21
- lupus anticoagulant syndrome 101.19–20
- lupus band test 3.17, 51.16
- lupus erythematosus 51.1–39
 allergic contact dermatitis differential
 diagnosis 128.61
 atrophic scars 96.11
 bullous
 hydroa vacciniforme differential
 diagnosis 127.24
 juvenile spring eruption differential
 diagnosis 127.9
 chemical-induced photosensitivity
 differential diagnosis 127.29
 chilblain 51.7, 51.22, 125.4
 classification 51.1–2
 cutaneous
 acute 51.21
 chilblain 51.7, 125.4
 chronic 51.21, 89.40–1
 pinna **108.13, 108.14**
 cutaneous lupus mucinosis 59.13–14
 drug-induced 118.9–10, 118.11
 drug-induced photosensitivity
 differential diagnosis 127.29
 erythema multiforme differential
 diagnosis 47.6
 with erythema multiforme-like
 lesions 47.6
 erythematotelangiectatic rosacea
 differential diagnosis 91.9
 gyrateum repens 147.21
 hyperpigmentation 88.21
 immunofluorescence studies 3.17
 Jessner's lymphocytic infiltrate
 differential diagnosis 135.9
 lichenoid drug eruptions 118.9
 macrophage inhibitory factor role 8.22
 malignancy association 147.20–1
 MMP expression 8.43
 pemphigus foliaceus differential
 diagnosis 50.7
 photosensitivity disease differential
 diagnosis 127.35
 polymorphic light eruption
 association 127.2
 differential diagnosis 127.4
 profundus 51.7–9, 99.35
 proximal nail fold capillaroscopy 95.52
 skin picking disorder differential
 diagnosis 86.15
 subcutaneous 99.35
 tumidus 59.9
see also discoid lupus erythematosus
 (DLE); neonatal lupus
 erythematosus; subacute cutaneous
 lupus erythematosus (SCLE);
 systemic lupus erythematosus (SLE)
- lupus hair 51.23
- lupus miliaris disseminatus faciei 27.31,
 27.32, 90.28
- lupus mucinosis, cutaneous 59.13–14
- lupus nephritis 51.17
- lupus panniculitis 51.21, 99.35–8
 clinical features 99.36–7
 definition 99.35
 differential diagnosis 99.36–7
 dystrophic calcinosis association 51.25–6
 hemifacial 96.18
 investigations 99.37–8
 sclerosing postirradiation panniculitis
 differential diagnosis 99.60
 subacute cutaneous lupus
 erythematosus association 51.12
 subcutaneous panniculitis-like
 T-cell lymphoma differential
 diagnosis 140.32
- lupus pernio
 phymatous rosacea differential
 diagnosis 91.11
 sarcoidosis 98.8–9, 98.11, 98.17
- lupus vulgaris 27.7, 27.8, 27.21–5
 atrophic scars 96.11
 clinical features 27.21–4
 clinical variants 27.23
 co-morbidities 27.24
 complications 27.24
 definition 27.21
 differential diagnosis 27.23–4
 discoid lupus erythematosus differential
 diagnosis 51.9
 disease course 27.25
 epidemiology 27.21
 investigations 27.25
 management 27.25
 mucosal involvement 27.23
 mutilating form 27.22, 27.23
 nodular form 27.23
 papular form 27.23
 pathophysiology 27.21
 patterns 27.22–3
 plaque form 27.22
 primary inoculation
 tuberculosis 27.13
 prognosis 27.25
 sarcoidosis differential diagnosis 98.2,
 98.8
 tumour-like form 27.23
 ulcerating form 27.22, 27.23
 vegetating form 27.23
- lycopene, antioxidant use 156.8, **156.11**
- Lycosidae 34.34
- Lyell syndrome *see* toxic epidermal
 necrolysis (TEN)
- Lyme disease 26.69–71, 34.38
 acrodermatitis chronica
 atrophicans 96.13–14, 140.38
 clinical features 26.69–70
 cutaneous B-cell lymphoma
 association 140.38
 definition 26.69
 dissemination 26.70, 26.71
 epidemiology 26.69
 investigations 26.70
 management 26.71
 ocular manifestations 109.42
 pathophysiology 26.69
 tick vector 34.35
 urticarial vasculitis association 44.2
 variants 26.70
- lymph fistula 105.42
- lymph nodes
 fine-needle aspiration 4.22
 head and neck 110.4–5
 histological classification 140.7–8
 transfer surgery 105.58
see also sentinel lymph node biopsy
- lymphadenitis, HIV infection 31.20
- lymphadenopathies
 idiopathic 148.12–14
 sarcoidosis 98.5
- lymphadenosis benigna cutis 26.70
see also lymphocytoma cutis
- lymphangiectasia 105.40–2, 105.52
 clinical features 105.41–2
 intestinal 105.41–2
 management 105.42
 pathophysiology 105.41
- lymphangiectatic oedema, Turner
 syndrome 76.3
- lymphoendothelioma, benign 105.39
- lymphangiography **105.53, 105.54**
- lymphangioleiomyomatosis 105.39–40,
 105.40
- lymphangioma 105.39
 acquired progressive 137.39–40
 circumscriptum 105.34–7
 presentation 105.36
 head and neck 105.15
 Kaposi sarcoma differential
 diagnosis 31.29
 neonatal alveolar ridge 110.10
 oral lesions 110.10
- lymphangiomatosis 105.34, 105.39–40
 chronically swollen leg **105.5**
 diffuse 137.41
 kaposiform 105.39, 105.40
 lymphangiosarcoma 105.53, 137.36
 lymphangiothrombosis 105.50
- lymphangitis 105.51
- lymphatic(s)
 chronically swollen leg 105.5–6
 dysfunction 105.1–3, 105.4, 105.5–53
 facial 20.3
 histopathological investigations
 105.55
 imaging 105.53–5
 immune trafficking 105.11
 inflammation 105.51
 limb surgery 20.5
 lymph fistula 105.42
 lymphocele 105.42
 obstruction 105.52
 malignancy association 147.26
- oedema 105.1–3, 105.4, 105.5
 causes **105.2**
 clinical features 105.3
 definition 105.1–2
 epidemiology 105.2
 erysipelas 105.10–12
 investigations 105.3, 105.4, 105.5
 management 105.5
 mixed lymphovenous
 disease 105.6–9
 nomenclature 105.1–2
 pathophysiology 105.2–3
 phleboedema 105.6–9
 recurrent cellulitis 105.10–12
 podoconiosis 105.45–7
 lymphatic filariasis differential
 diagnosis 105.44
 seroma 105.42
 skin 2.43
 swollen arm 105.12–14
 swollen breast 105.23–4
 swollen face, head and neck 105.14–17
 swollen genitalia 105.17–19
 swollen mons pubis 105.17–19
 trauma 105.49–50
 tumour spread 147.4
see also lipoedema; lymphoedema;
 pretibial myxoedema; yellow-nail
 syndrome
- lymphatic anomalies 73.15–21
 generalized 105.39
 hereditary lymphoedema type
 1A 73.17–18
 hypotrichosis–lymphoedema–
 telangiectasia syndrome 73.19
see also lymphatic malformations
- lymphatic filariasis 33.7–9, 105.42–5
 causative organisms 33.7
 clinical features 33.8–9, 105.44
 complications/co-morbidities 33.8–9
 definition 33.7, 105.42
 epidemiology 33.7, 105.43
 investigations 33.9, 105.45
 lymphangitis 105.51
 management 33.9, 105.45
 morbidity control 33.9
 nomenclature 33.7
 onchocerciasis differential
 diagnosis 33.5

- pathophysiology 33.7–8, 105.44
podoconiosis differential
 diagnosis 105.44, 105.47
lymphatic malformations 73.15–17,
 105.34–7
 chronically swollen leg **105.5**
 clinical features 105.35–7
 complications 105.37
 definition 105.34
 differential diagnosis 105.37
 epidemiology 105.35
 head and neck 105.15
 investigations 105.37
 macrocystic 73.15, 73.16, 105.35
 management 105.37
 microcystic 73.15–16, 73.17, 105.35
 pathophysiology 105.35
 swollen face, head and neck **105.15**
 vascular component 105.36
 venous lesion association 73.16
lymphatic microangiopathy 56.10
lymphatic tumours 137.39–41
 non-malignant 105.39–40
lymphatico-lymphatic anastomosis
 surgery 105.58
lymphatico-venous anastomosis
 surgery 105.58
lymphadenoma, cutaneous 138.12–13
lymphocele 105.42
lymphocytes
 high-power microscopy 3.31
 Langerhans cells interactions 2.14
 wound healing 10.2
 see also B cell(s); T cells
lymphocytic vasculitis 25.36
lymphocytoma cutis 135.8–10
 definition 135.8
 Jessen's lymphocytic infiltrate
 differential diagnosis 135.9
 phymatous rosacea differential
 diagnosis 91.11
 see also pseudolymphoma
lymphocytoma, solitary 26.70
lymphoedema 105.1–3, 105.4, 105.5
 abdominal wall 105.20–1
 amniotic band constriction 105.37–9
 clinical features 105.38
 epidemiology 105.38
 investigations 105.39
 management 105.39
 pathophysiology 105.38
 ano-genital 111.35
 breast 105.23–4
 breast reconstruction 105.49
 cancer treatment-associated 105.16
 cellulitis association 105.11–12
 choanal atresia 73.20
 chronic venous insufficiency **103.38**,
 105.7
 chronically swollen leg 105.5–6
 complications 105.51–3
 congenital multisegmental 105.27,
 105.29
 cutaneous/vascular anomalies 105.26,
 105.27, 105.28–9
 disturbed growth 105.26, 105.27,
 105.28–9
 erythema ab igne 125.12
 facial 105.14–17
 phymatous rosacea differential
 diagnosis 91.11
 solid 90.35–6, 91.11, 91.16
 factitious 105.50
 fat deposition 105.19
 generalized lymphatic dysplasia 105.27,
 105.28
 swollen face, head and neck **105.15**
 genetic mutations 105.13
 genetics 105.8
 genital 105.17–19, 111.35
 clinical features 105.18–19
 complications 105.18–19
 definition 105.17
 genetics 105.17, 105.18
 investigations 105.19
 management 105.19
 pathophysiology 105.18
 head and neck 105.14–15
 Hennekam lymphangiectasia–
 lymphoedema syndrome 73.19
 hypotrichosis–lymphoedema–
 telangiectasia syndrome 73.19
 immobility associated 105.50–1
 intravenous drug use 105.50
 investigations 105.3, 105.4, 105.5, 105.14
 Kaposi–Stemmer sign 105.3, 105.6
 late-onset four-limb 105.27, 105.30
 leprotic, podoconiosis differential
 diagnosis 105.47
 lipodema differential diagnosis 100.20,
 100.21, 105.31
 localized myxoedema 59.12, 59.13
 lymphatic filariasis 105.44, 105.45
 differential diagnosis 105.44
 lymphatic malformations 105.35, 105.53
 malignancy association 105.53
 management 105.5, 105.14, 105.55–9
 compression 105.56
 intensive therapy 105.57
 maintenance treatment 105.57
 massage 105.56–7
 physical therapies 105.55–8
 skin care 105.56
 surgical 105.58–9
 massive localized 105.24–5
 mechanical properties of skin 123.5
 medical assessment 105.55
 melanoma-related 105.22
 Milroy-like 105.27, 105.29
 multisegmental lymphatic dysplasia
 with systemic involvement 105.26,
 105.27, 105.28
 Noonan syndrome 73.21
 obesity association 100.25
 obesity-related 105.19–20
 penile 111.20
 podoconiosis 105.45–7
 postmastectomy 105.12–14
 praecox 73.18
 pretibial myxoedema differential
 diagnosis 105.49
 primary 73.18, 105.25–6, 105.27,
 105.28–30
 classification 105.26, 105.27
 clinical features 105.26, 105.28–30
 congenital-onset 105.26, 105.27, 105.29
 definition 105.25
 differential diagnosis 105.30
 epidemiology 105.26
 genetic factors 105.25
 late-onset 105.26, 105.27, 105.29–30
 with myelodysplasia 73.20
 nomenclature 105.25
 severity classification 105.30
 variants 105.26
 prolidase deficiency 81.14
 psychosocial issues 105.52–3
 rosaceous 105.16
 saphenous vein graft harvesting 105.49
 sarcoma-related 105.22
 secondary 100.21–2
 self-inflicted 105.50
 spindle cell haemangioma
 association 137.32
 squamous cell carcinoma
 association 142.27
 syndromic 105.26, 105.27
 systemic/visceral involvement 105.26,
 105.27, 105.28
 trauma-induced 105.49–50
 Turner syndrome 73.21
 upper limb 105.12–14
 urogenital cancers 105.22
 urticaria differential diagnosis 42.14
 varicose vein treatment 105.49
 yellow nail syndrome 95.15
 see also breast cancer-related
 lymphoedema; cancer-
 related lymphoedema;
 phlebolymphoedema
- lymphoedema–distichiasis syndrome
 73.18–19, 105.25, 105.27, 105.29–30,
 150.3
lymphoedema–intestinal
 lymphangiectasia–intellectual
 disability syndrome 73.19
lymphoedema–lymphangiectasia–mental
 retardation syndrome 73.19
lymphoedematous mucinosis 59.12, 105.49
lymphoepithelial Kazal-type related
 inhibitor (LEKTI) 65.24, 65.25
lymphoepithelioma-like
 carcinoma 138.43–4
lymphogranuloma venereum 30.15–20
 clinical features 30.17–19
 complications/co-morbidities 30.19
 definition 30.15–16
 differential diagnosis 30.19
 epidemiology 30.16, 30.17
 genital wart differential diagnosis 25.57
 hidradenitis suppurativa differential
 diagnosis 92.7, 113.21
 investigations 30.19
 management 30.20
 nomenclature 30.15–16
 pathophysiology 30.16–17
 perineum/perianal region 113.12
 stages 30.17–18
 treatment ladder **30.20**
 vulval sarcoidosis differential
 diagnosis 98.14
lymphography **105.53**, 105.54
lymphoid enhancer-binding factor 1
 (LEF1) 2.4
lymphoid markers 3.23–5
lymphoid reactions, ear piercing
 complications 108.7
lymphoma
 angiotropic 140.43–4
 aphthous ulceration 110.40
 atopic eczema association 41.23
 chronic superficial scaly dermatitis
 distinction 39.26
 clinical features 146.12
 Crosti 140.40–1
 cutaneous 140.1–2
 bacillary angiomatosis differential
 diagnosis 26.62
 classification 140.1, **140.2**
 peripheral T-cell 140.32–8
 phymatous rosacea differential
 diagnosis 91.11
 pseudolymphoma differential
 diagnosis 135.2
 radiotherapy 24.14
 DRESS differential diagnosis 119.10
 Epstein–Barr virus-associated 25.34
 erythroderma 39.31, 39.32–3
 external ear 108.24
 extranodal NK/T-cell 140.36–7
 follicle centre cell 140.37, 140.40–1
 follicular mucinosis association 107.7
 genital 111.34
 granulomatous slack skin 96.19
 HIV infection 31.31–2
 hyperhidrosis 94.5
 immunocompromised patients 146.12
 leukaemia cutis 140.48–9, **148.3**
 lymphoepithelioma-like carcinoma
 differential diagnosis 138.44
 marginal zone 140.37, 140.38–40
 lymphocytoma cutis differential
 diagnosis 135.9
 natural killer cell 116.14
 natural killer/T-cell 25.33
 pigmentation 88.19–20
 primary effusion 139.5
 primary effusion, Kaposi sarcoma
 association 139.5
 PUVA side effect 21.13–14
 skin involvement 147.2
 subcorneal pustular dermatosis
 association 49.14
 see also cutaneous anaplastic large-
 cell lymphoma; cutaneous B-cell
 lymphoma; cutaneous CD30+
 lymphoproliferative disorders;
 cutaneous peripheral T-cell
 lymphoma; cutaneous T-cell
 lymphoma (CTCL); diffuse large
 B-cell lymphoma; Hodgkin
 disease; non-Hodgkin lymphoma;
 primary cutaneous marginal zone
 lymphoma; primary cutaneous
 peripheral T-cell lymphoma;
 subcutaneous panniculitis-like
 T-cell lymphoma
lymphomatoid eruptions, allergic contact
 dermatitis 128.60
lymphomatoid granulomatosis 140.44–5
 aphthous ulceration 110.40
 clinical features 140.44–5
 definition 140.44
 management 140.45
 pathophysiology 140.44
 respiratory disorder association 151.6
lymphomatoid papulosis 140.28–9
 acquired ichthyoses 65.40
 adalimumab-induced 154.15
 clinical features 140.29
 definition 140.28
 disease course 140.29
 management 140.29
 treatment algorithm **140.28**
 pathophysiology 140.28
 pityriasis lichenoides differential
 diagnosis 135.5
 prognosis 140.29
 subgroups 140.29
lymphomatous skin infiltrates 148.4
lymphoproliferative disease
 B-cell and Schnitzler syndrome
 association 45.10
 cryoglobulinaemia-associated 101.13
 Epstein–Barr virus-associated 25.34,
 140.47
 linear IgA disease association 50.34
 malignancies 148.1
 post-transplant 140.47–8
 lymphorrhoea 105.52
lymphoscintigraphy 105.3, 105.4, 105.6,
 105.53, 105.54
 phlebolymphoedema investigation 105.9
Lynch syndrome *see* hereditary non-
 polyposis colon cancer (HNPCC)
Lyonzation 7.7–8
lysine-threonine-threonine-lysine-serine
 (KTTKS) 156.4
lysosomal degradation by
 macrophages 8.23
lysosomal mediators 8.43–4
lysosomal storage disorders 81.1–9
 angiokeratoma corporis diffusum 81.8
 angiokeratomas **81.8**
 Farber disease 81.7
 galactosidosis 81.6
 glycoprotein degradation
 disorders 81.4–5
 GM1 gangliosidosis 81.6
 mucopolidoses 81.5–6
 mucopolysaccharidoses 81.1–4
 Niemann–Pick disease 81.6, 81.9
 sphingolipidoses 81.6–9
 see also Gaucher disease
lysosomes 8.43–4
 epidermal cell phagocytic function 8.44
lysyl oxidase-like (LOXL) genes 2.32
lysyl oxidases 2.36, 2.37
- M**
M protein, streptococcal infections 26.11,
 26.12, 26.35
macrocephaly, alopecia, cutis laxa and
 scoliosis (MACS) syndrome **72.12**,
 79.7
macrocheilia 110.86, **110.87**
macrocomedone removal 90.48, 90.49
macroglubulinaemia cutis 148.5
macroglossia 110.60
macrogols, topical drug delivery 18.7

- macrolide antibiotics 19.42
 Macroonyssidae 34.52
 macrophage(s) 2.15, 136.1–2
 complement system 8.22
 cytokine signalling in inflammatory dermatoses 8.23
 early-phase allergic response 8.57–8
 high-power microscopy 3.31
 immune function 8.21–3, 8.24
 keloid 10.9
 in Langerhans cell histiocytosis 136.3
 lysosomal degradation 8.23
 pathogen killing 8.23
 receptors 8.23
 secretions 99.6
 wound healing 10.2, 10.3
 diabetic wounds 10.9
 macrophage activation syndrome 45.11
 macrophage inflammatory protein 1 β ,
 Dercum disease 100.16
 macrophage inhibitory factor (MIF) 8.5,
 8.22–3
 macrophage inhibitory protein 1a
 (CCL3) 8.38
 macrophage inhibitory protein 1b
 (CCL4) 8.38
 macrophage-activating syndrome 45.7
 macrophage–monocyte pathway 8.21,
 136.2
 macrotia 108.4–5
 macular atrophy 96.20, 96.22
 macular syphilide 29.10, 29.11
 maculopapular cutaneous mastocytosis
 (MPCM) 46.1
 Madelung disease 74.8, 100.13–15
 swollen arm differential
 diagnosis 105.13, 105.14
Madurella grisea 32.74
Madurella mycetomatis 32.73, 32.75
 Maffucci syndrome 73.14–15, 105.39–40
 facial haemangiomas 110.15
 spindle cell haemangioma
 association 137.32
 magenta 18.33
 maggots
 wound debridement 34.10
 see also myiasis
 MAGIC (mouth and genital ulcers
 with inflamed cartilage)
 syndrome 154.13
 genital ulceration 111.18
 magnetic resonance imaging (MRI)
 diagnostic 4.22
 nails 95.50, 95.51
 magnetic resonance
 lymphangiography 105.53, 105.54–5
 Majeed syndrome 45.8
 Majewski osteodysplastic primordial
 dwarfism type II 74.5
 Majocchi disease 101.8, 101.9
 Majocchi granuloma 31.26
 major basic protein (MBP) 8.19
 major depressive disorder 86.33
 major histocompatibility complex
 (MHC) 7.6, 136.2
 antigen presentation 8.28
 class I 8.27
 induction by interferons 8.34
 inhibitory receptors for 8.16
 class II 128.7
 antigens 8.28
 induction by interferons 8.34
 drugs as haptens 12.4
 ethnic differences in gene
 expression 56.7
 inflammation 8.26–8
 pemphigus susceptibility 50.4
 mal de Meleda 65.46, 65.47–9
 clinical features 65.48
 differential diagnosis 65.48
 investigations 65.49
 management 65.49
 pathophysiology 65.48
 malabsorption 152.7
 hyperpigmentation 88.23–5
 malakoplakia 136.21
 HIV infection 31.29
 vulval lesions 112.24–5
 malaria 33.33–4
 hyperhidrosis 94.5
Malassezia 26.3
 annular erythema of infancy 47.6
 ano-genital 111.12, 111.24
 confluent and reticulated papillomatosis
 association 87.6
 diagnosis 32.9–10
 folliculitis 31.28, 32.13–14, 76.2, 90.30
 hypomelanosis 88.44
 neonatal cephalic pustulosis 90.61
 pustulosis 116.27
 scalp pruritus 107.13
 seborrhoeic dermatitis association 32.14,
 40.1, 40.2
 HIV infection 31.14
 treatment 40.5, 40.6
 skin diseases 32.10–14
 see also pityriasis versicolor
 malathion 18.13
 maldistribution syndrome see HIV-
 associated lipodystrophy
 malignancy
 acanthosis nigricans association 87.3,
 87.4
 acquired ichthyoses 65.40
 acrocyanosis 125.5
 anal 113.17–20
 anal abscess differential
 diagnosis 113.26
 asteatotic eczema association 39.11
 Bloom syndrome 79.4
 ciclosporin association 19.11
 coloboma heart defect–ichthyosiform
 dermatosis–mental retardation–ear
 anomalies syndrome 65.34
 cutaneous markers 147.1–26
 dermatomyositis association 53.2, 53.11
 dermatoses associated with internal
 malignancy 147.18–24
 DOCK8 deficiency 82.10
 dyskeratosis congenita 77.4
 erythema gyratum repens
 association 47.11
 erythema nodosum 99.20
 erythroderma 39.32–3
 external ear 108.23–7
 focal keratoderma 65.52
 genodermatoses associated with internal
 malignancy 147.7–13
 glucocorticoid-associated 19.18
 haemorrhoids differential
 diagnosis 113.31
 Howel–Evans syndrome 65.59
 HPV-associated intraepithelial/invasive
 neoplasias 25.58–9
 human papillomavirus 25.45, 31.24
 hypermelanosis 88.19–20
 hypertrichosis differential
 diagnosis 68.12
 infiltrating lipomatosis of the face
 differential diagnosis 100.18
 linear IgA disease association 50.34
 lymphoedema association 105.53
 mal de Meleda 65.49
 malakoplakia differential
 diagnosis 112.25
 male genital dermatoses 111.29–34
 methotrexate association 19.24
 multicentric reticulohistiocytosis
 association 136.24
 multiple minute digitate keratoses
 association 87.17
 mycophenolate mofetil-
 associated 19.26–7
 mycosis fungoides 140.14
 NF1-associated 80.3–4
 nodular fasciitis 137.5
 oculocutaneous albinism
 association 70.7
 oral 110.32–9
 oral leukoplakia 110.77
 palmoplantar keratoderma 65.58–60
 paraneoplastic skin conditions 147.14–
 18, 148.6–10
 pathological criteria for
 melanoma 143.17
 perianal 113.17–20
 pityriasis rotunda association 87.7
 pruritus 83.12, 83.15
 psoriasis association 35.20
 radiotherapy 140.7–9
 soft-tissue tumours 137.2
 solid tumours 88.19, 88.20
 Sweet syndrome association 49.6, 49.7,
 49.10
 systemic lupus erythematosus
 association 51.31, 51.32
 systemic sclerosis association 56.8–9
 telogen effluvium 89.26
 TNF antagonists 19.30
 toxic shock syndrome association 26.30
 transient acantholytic dermatosis
 association 87.22
 transplacental transfer of maternal
 disease 116.14
 urticaria association 42.3–4
 vascular tumours, intermediate 137.33–6
 vulval 112.34–9
 warts 25.51, 25.58–9
 xeroderma pigmentosum 78.4
 see also named conditions and cancers
 malignant acrospiroma 138.36
 malignant
 angioendotheliomatosis 140.43–4
 malignant atrophic papulosis 101.23–4
 malignant hidradenoma 138.36
 malignant histiocytosis 136.26–9
 clinical features 136.27
 epidemiology 136.26
 pathophysiology 136.26–7
 malignant melanoma see melanoma
 malignant peripheral nerve sheath
 tumour 137.54
 NF1-associated 80.4
 malignant spiradenoma 138.36–7
 malignant syringoma 138.37–8
 malingering 86.23, 86.29
 malnutrition 63.1–6
 classification 63.2
 clinical features 63.3–6
 complications/co-morbidities 63.6
 copper deficiency 63.27
 epidemiology 63.2
 furuncles 26.23
 hair colour changes 89.71
 investigations 63.6
 management 63.6
 pathophysiology 63.2–3
 phrynoderma 87.13, 87.14
 predisposing factors 63.3
 severe 63.2
 severity classification 63.4–6
 skin signs 63.3–63.4, 63.5
 telogen effluvium 89.26
 see also protein–energy malnutrition
 Malnutrition Universal Screening Tool
 (MUST) 63.5–6
 mammary-like gland adenoma of the
 vulva 138.21–2
 mandibular deformities 110.5
 mandibuloacral dysplasia (MAD) 74.1
 acquired generalized lipodystrophy
 differential diagnosis 100.3
 familial 72.24–5
 progeria differential diagnosis 72.22
 mandibulo-acral dysplasia with type
 A (MADA) and type B (MADB)
 lipodystrophy 79.2, 79.5
 manganese
 deficiency 63.30–1
 excess 63.30–1
 mange 34.47
 mannan-binding lectin 8.31
 mannose receptor 8.15
 α -mannosidosis 81.5
 β -mannosidosis 81.5
Mansonella streptocerca 33.6
 manual lymphatic drainage, lymphoedema
 management 105.56–7
 marantic endocarditis 101.16, 101.17
 marasmic kwashiorkor 63.1, 63.2, 63.4
 marasmus 63.1–6
 telogen effluvium 89.26
 maraviroc 31.10
 Marburg haemorrhagic fever 25.72–3
 Marfan syndrome 2.36, 72.15–17
 clinical features 72.16–17
 definition 72.15
 differential diagnosis 72.16–17
 Ehlers–Danlos syndrome
 association 72.1, 72.16
 differential diagnosis 72.7
 epidemiology 72.16
 investigations 72.17
 management 72.17
 pathophysiology 72.16
 progeria differential diagnosis 72.22
 striae 96.9, 96.10
 variants 72.16–17
 marfanoid habitus 72.16
 marginal papular keratoderma 65.53–4
 marginal zone lymphoma (MZL) 140.37,
 140.38–40
 lymphocytoma cutis differential
 diagnosis 135.9
 Marie Unna hereditary hypotrichosis 68.4–
 5, 68.12, 68.14
 Marjolin ulcer, pressure ulcer
 association 124.5
 Maroteaux–Lamy syndrome 81.2, 81.4
 Marshall syndrome 96.20
 Mas-related G protein-coupled
 receptor agonists, itching in skin
 disease 83.7
 masseter muscle 110.5
 Masson ammoniacal silver nitrate
 technique 3.8, 3.9
 Masson haemangioma 110.72
 Masson pseudoangiosarcoma 137.24
 mast cell(s) 2.16–17, 8.19–21
 activation 2.16, 8.21, 8.57
 acute phase inflammation 8.2
 chymase release 8.41
 cytokines 8.21
 degranulation 117.16
 growth/differentiation 2.16
 high-power microscopy 3.32
 histamine release 107.13
 keloid 10.9
 mastocytosis 46.3
 mediators 8.20–1
 nerve interactions 2.17
 neurofibromas 80.2
 products 2.17
 pro-inflammatory activity 149.8
 proteases 8.21
 receptors 8.20
 roles 2.17
 skin pathology 2.17
 stabilization 46.9
 staining 3.9, 3.10
 tryptase release 8.41
 wound healing 10.2
 mast cell disorders
 activation syndrome 46.7
 histological sections 3.40
 monoclonal mast cell activation
 syndrome 46.7
 urticaria 42.3–4
 see also mastocytoma; mastocytosis
 mast cell mediator-induced angio-
 oedema 43.1, 43.2
 clinical features 43.4–5
 epidemiology 43.2
 management 43.5, 43.6
 pathophysiology 43.3–4
 mastication muscles 110.5

- mastitis 116.24
 tuberculous 27.32
 mastocytoma 46.5–6
 prognosis 46.10
 mastocytosis 46.1–10, 154.13
 aetiopathogenesis 46.2
 clinical features 46.3–7
 cutaneous 46.2, 46.3–6, 46.7, 46.8–9
 diffuse 46.6
 maculopapular 46.3–5
 prognosis 46.10
 definition 46.1
 disease course 46.10
 epidemiology 46.2–3
 flushing 106.6, 106.8, 147.24, 147.25
 infantile urticaria 117.6
 infants 117.15–16
 investigations 46.7, 46.8
 Langerhans cell histiocytosis differential diagnosis 136.6
 management 46.8–10
 mast cell activation syndrome 46.7
 monoclonal mast cell activation syndrome 46.7
 nomenclatures 46.1
 non-mast cell haematological disorders 46.2, 46.3
 pathophysiology 46.3
 prognosis 46.10
 systemic 46.2, 46.6, 46.7
 WHO classification 46.1, 46.2, 46.6
 maternal autoantibodies, transplacental transfer 116.11–14
 matriptase 8.41–2
 matrix metalloproteinase(s) (MMPs) 2.32–3, 8.42–3, 103.1
 activation 8.57
 ageing of skin 155.6, 155.8
 collagen degradation 9.10–11
 early-phase allergic response 8.58
 inflammation 8.22
 metastatic spread role 147.5
 rosacea association 91.4
 UV induced 2.47
 wound healing 10.2, 10.4, 10.5, 10.8, 10.9
 diabetic wounds 10.9
 matrix metalloproteinase 1 (MMP-1) 8.43
 retinoid effects 96.4
 matrix metalloproteinase 2 (MMP-2) 8.43
 matrix metalloproteinase 8 (MMP-8) 10.2
 matrix metalloproteinase 9 (MMP-9) 8.43
 matrix metalloproteinase 14 (MMP14) gene mutations 72.19
 matrix metalloproteinase 19 (MMP-19) 8.43
 matrix metalloproteinase 26 (MMP-26) 10.2
 mattresses, pressure ulcers
 prevention 124.5
 treatment 124.6
 maxacalcitol 18.26
 maxillary air sinuses 110.5
 maxillary deformities 110.5
 Mayaro virus infection 25.77–8
 MBTPS2 gene mutations 65.62
 MC1R gene mutations 75.9, 141.3, 143.4, 155.4
 McCune–Albright syndrome 74.4
 café-au-lait macules 80.4, 80.5
 heterotrimeric G-protein mosaic disorders 75.21
 McDuffie syndrome *see* urticarial vasculitis
 MCLID (microcephaly with/without chorioretinopathy, lymphoedema or intellectual disability) syndrome 105.27, 105.29
 MDMA 121.2
 measles 25.84–6, 117.7
 clinical features 25.85
 epidemiology 25.84
 investigations 25.85
 management 25.86
 mortality 5.8
 pathophysiology 25.84–5
 measurement 16.1–8
 assessment tools 16.2–3
 patient-specific 16.6
 skin disease impact 16.4–8
 skin properties 16.3–4
 utility 16.6
 validation of methods 16.2
 mebendazole
 ancylostomiasis treatment 33.15
 enterobiasis treatment 33.14
 visceral larva migrans treatment 33.20
 mechanical injury 123.1–26
 athletes
 acne mechanica 123.15
 black heel/palm 123.10
 friction blisters 123.9, 123.10
 hypothenar hammer syndrome 123.12
 foreign-body reactions 123.16–18, 123.19, 123.20–3
 friction 123.5–13
 sports injuries 123.15–16
 hypothenar hammer syndrome 123.12
 see also hand–arm vibration syndrome; Koebner phenomenon; trauma
 mechanical properties of skin 123.4–5
 biomechanical 123.3–5
 determinants 123.4–5
 pathological variation 123.5
 physiological variation 123.5
 mechanical stimuli 123.2–3
 resistance 123.3–4
 mechanical strength 123.4
 mechanic's hands 53.7, 53.8, 53.11
 mechanoreceptors in skin 2.11
 mechlorethamine 18.27–8
 see also nitrogen mustard, topical
 Meckel–Gruber syndrome, spinal dysraphism association 85.9
 medallion-like dermal dendrocyte hamartoma 116.10–11
 medial pterygoid muscle 110.5
 median canaliform dystrophy of Heller 95.10–11, 95.17
 median raphe cysts 111.26
 median rhomboid glossitis, candidosis 32.63, 110.71
 medical genetics 7.2, 7.2–3, 7.4
 medical writing, ancient 1.1–2
 medications *see* drug(s)
 Mediterranean spotted fever 34.38
 medium-chain triglycerides (MCTs) 105.42
 Medline 17.6, 17.7
 limitations 17.7
 MEDNIK (mental retardation–enteropathy–deafness–neuropathy–ichthyosis–keratoderma) 65.27, 65.28
 medullary sponge kidney, Ehlers–Danlos syndrome association 72.1
 medullary thyroid carcinoma 147.25
 MEN type 2 association 147.10
 Mee's lines, nails 122.2, 122.8
 megavoltage X-ray therapy technique 24.3
 megencephaly–capillary malformation–polymicrogyria (MCAP) syndrome, capillary malformations 73.5–6
 meibomian gland dysfunction 109.8, 109.9, 109.10
 associated factors 109.9
 clinical features 109.13
 environmental factors 109.13
 investigations 109.14
 management 109.16
 natural history 109.13
 pathology 109.10
 rosacea association 91.4
 Meige lymphoedema 105.25, 105.27, 105.30
 meiosis 7.2
 Meirowsky phenomenon 88.9
 Meissner corpuscles 2.46
 MEK inhibitors
 melanoma treatment 143.32–3
 nail changes 120.7
 papulopustular eruptions 120.3
 Mel-5 3.21
 melan-A (MART-1) 3.21
 melanin 2.17, 2.43, 70.1, 88.1
 biological significance 88.8
 blue naevus 88.2
 deficiency in oculocutaneous albinism 70.6
 hair 89.68
 Hodgkin disease pigmentation 140.49
 light absorption 23.3, 23.5, 23.11–12
 nail plate pigmentation 95.13
 photoprotective role 88.9
 pigmentation 88.1–2
 precursors 70.1
 production 88.3
 by *Candida albicans* 32.58
 selective photothermolysis 23.4, 23.5
 vitamin D synthesis 9.9
 melanoacanthoma, eyelid 109.48
 melanoblasts 2.17
 differentiation/migration 88.3–4
 melanoacanthoma, oral 110.67–8
 melanocortin 1 receptor (MC1R) 2.18, 88.7
 melanoma risk 149.9–10
 melanocortin 1 receptor (MC1R)
 gene 143.4, 155.4
 mutations 75.9, 141.3
 melanocortin(s), Addison disease 88.7
 melanocytes 2.1, 2.5, 2.17–18, 70.1, 88.1, 88.2–5
 alopecia areata 89.30
 antibodies 88.36
 culture 88.4–5
 development 2.3, 2.5, 2.17
 distribution 88.3
 embryology 88.3–4
 epidermal melanin unit 88.2–3
 filopodia 88.4
 hair 89.68–9
 hair bulb 89.69
 lineage segregation 88.4
 mitogens 88.4–5
 nail 2.11
 nests 132.2
 oestrogen receptors 88.7
 regulation 88.5
 autocrine factors 88.7–8
 endocrine factors 88.7
 paracrine factors 88.7–8
 self-destruction theory 88.36
 signalling pathways 2.18
 stem cells 2.17
 α-melanocyte-stimulating hormone (α-MSH) 8.52, 9.8, 70.1, 74.4, 88.4
 adverse cutaneous effects 149.15
 functions 149.9
 immune privilege guardian role 149.10
 renal failure 88.22
 melanocytic lesions, dermal 132.12–15
 melanocytic markers 3.20–1
 melanocytic matricoma 138.14
 melanocytic proliferations/neoplasms,
 benign cutaneous 132.1–49
 congenital melanocytic naevi 132.15, 132.16–17, 132.17–18
 definitions 132.2
 dermal melanocytic lesions 132.12–15
 mucosal melanotic lesions 132.9–12
 terminology 132.2
 see also ephelides; lentiginos; naevi
 melanogenesis 88.6
 biochemistry 88.5
 regulation 8.50
 sunbed use 9.13
 tanning 9.7–8
 melanoma 143.2–35
 ABCD algorithm 143.7, 143.16, 144.1
 acral 144.5, 144.8
 acral lentiginous 95.33, 143.7, 143.10, 143.12, 144.5
 amelanotic 143.15
 actinic keratosis association 142.2
 algorithms 143.7–8
 amelanotic 143.14–15, 144.10–11
 metastases 143.30
 nodular 144.11, 144.12
 squamous cell carcinoma differential diagnosis 108.25
 angiokeratoma circumscriptum differential diagnosis 103.14
 animal-type 143.19
 ano-genital 111.33, 113.20
 atypical junctional/intraepithelial pattern presentation 143.18
 atypical naevi differential diagnosis 132.44
 basal cell carcinoma differential diagnosis 141.11
 benign lichenoid keratosis differential diagnosis 133.7
 biopsy 143.23
 black heel/palm differential diagnosis 123.10
 blue naevus differential diagnosis 132.39
 BRAF mutated 143.31–3, 143.34
 Breslow thickness 143.16, 143.19–20
 chemotherapy 143.34–5
 classification 143.6–7
 molecular 143.7
 clinical features 143.7–10, 143.11–12, 143.12, 143.13–16
 immunocompromised patients 146.11
 clinicopathology 143.11–12, 143.13–16
 comparative genomic hybridization 143.19
 completion lymph node dissection 143.24, 143.25, 143.26
 congenital melanocytic naevi association 75.10, 75.11, 75.13, 75.15
 conjunctival 109.50, 143.14
 definition 143.2
 dermal proliferation presentation 143.17
 dermoscopy 144.1, 144.2, 144.5, 144.6–7, 144.7, 144.8, 144.9, 144.10–12
 desmoplastic 143.18–19, 144.11, 144.12
 diagnosis 143.2, 143.8
 difficulties 143.17
 histopathological 143.16–19
 novel techniques 143.19
 pathological patterns 143.17–18, 143.19
 diagnostic tools 143.8
 dual pathway hypothesis 143.7
 dynamic analysis 143.8
 early detection 143.16
 economic burden 6.5–6
 elective lymph node dissection 143.24
 environmental factors 143.5–6
 epidemic 5.9
 epidemiology 143.2
 external ear 108.23
 eyelid 109.49, 109.50, 109.51
 familial 143.3
 fluorescent *in situ* hybridization 143.19
 follow-up 143.21, 143.22
 freckles 88.16
 genes predisposing for 5.9, 143.4–5
 genetic counselling 143.6
 genetics 143.4–5
 genital 111.33
 GNAQ mutated 143.33–4
 halo naevi association 88.41
 HIV infection 31.30–1
 hypomelanotic halo 88.41
 IL-8 role 8.40
 immunocompromised patients 146.11
 management 146.13–14
 immunohistochemistry 143.19
 immunopathology diagnosis 3.21
 incidence 143.2
 intraindividual comparative analysis 143.8
 investigations 143.16–20
 keratoderma association 65.59
 KIT mutated 143.33–4
 lymph node dissection 143.26
 lymphoedema association 105.22
 major susceptibility genes 143.4–5
 malignancy pathological criteria 143.17

- melanoma (*continued*)
- malignant blue naevus 132.41, 143.15, 143.19, 143.19
 - management 143.20–35, 146.14
 - surgical treatment 143.23–7
 - systemic treatment 143.28–35
 - topical treatment 18.29
 - melanocyte proliferation
 - with lentiginous pattern presentation 143.17–18
 - melanoma-specific structures 144.5, 144.6–7, 147
 - metastases 143.19, 143.25, 143.26
 - lymph node dissection 143.27
 - management 143.28–35
 - pigmented 143.29
 - micro-Hutchinson sign 144.8, 144.9, 144.10
 - mortality 5.8, 143.2
 - mucosal 143.14, 144.9, 144.10
 - nail apparatus 95.33–4, 95.35, 144.8, 144.9, 144.10
 - nail unit 144.8, 144.9, 144.10
 - nodular 143.7, 144.11–12
 - presentation 143.8–9, 143.10
 - NRAS mutated 143.31–3
 - ocular 143.14
 - oral 110.67
 - pathology 143.7
 - pathophysiology 143.2–7
 - pattern recognition 143.8
 - penile 111.33
 - phakomatosis pigmentovascularis 75.23
 - phenotypic traits 143.3
 - photocarcinogenesis 127.29
 - pigmented 143.29
 - pigmented naevi distinction 110.13
 - precursors 143.2
 - predisposing factors 143.2–3
 - pregnancy 115.7
 - presentation 143.9–10, 143.11–12, 143.12–15
 - prevention 143.6
 - prognostic markers 143.19–20
 - public health education 143.16
 - PUVA side effect 21.13
 - radiotherapy 24.13
 - regressive 143.15, 143.19
 - ridge pattern 144.5, 144.8, 144.9
 - risk
 - with multiple acquired melanocytic naevi 132.18
 - Turner syndrome 76.3
 - screening 143.16
 - seborrhoeic keratosis differential diagnosis 133.3
 - sentinel lymph node
 - biopsy 143.23, 143.25–7
 - status 143.20
 - signalling pathways 143.30
 - sinonasal 143.15
 - in situ* 112.21, 143.24–5
 - actinic keratosis association 142.2
 - ink-spot lentigo differential diagnosis 132.9
 - of soft parts 137.66
 - spitzoid 143.19
 - staging 143.20–1, 143.21
 - structures on sun-damaged skin 144.5, 144.8
 - subungual 143.13
 - sun exposure 143.5–6
 - sunscreen protection 9.12
 - superficial spreading subtype 143.7, 144.5
 - presentation 143.8, 143.9
 - surgery 143.23–7
 - wide local excision 143.23–7
 - survival rates 143.21
 - systemic adjuvant therapy 143.28–9
 - transplacental transfer of maternal disease 116.14
 - treatment 31.31
 - tumour kinetics/aggressiveness 143.7
 - ultraviolet light exposure 143.5–6
 - UVR role 9.9–10
 - vaginal 144.9
 - vitiligo association 88.35
 - vulval 112.38
 - wide local excision 143.23–7
 - xeroderma pigmentosum 78.3–4
 - see also* lentigo maligna
 - melanoma–astrocytoma syndrome 147.7
 - melanonychia
 - confocal microscopy 95.49, 95.50
 - lichen planus of nail bed 37.12
 - longitudinal 95.34
 - melanophages, amyloidosis 88.23
 - melanosis
 - facial 88.9–15
 - ochronosis differential diagnosis 88.51
 - genital 132.11
 - penile 111.34
 - photocontact facial melanosis 88.12–13
 - transient pustular 116.7
 - vulval 112.20, 112.21
 - melanosomes 2.17, 70.1, 88.3
 - defects 70.2
 - racial skin groups 88.9
 - transfer to keratinocytes 88.4
 - transport 88.4
 - melanotic lesions
 - mucosal 132.9–12
 - neuroectodermal tumour 137.53
 - prognoma 137.53
 - melanotic macules
 - labial 132.11–12
 - lips 110.13
 - oral mucosa 110.12–13
 - hyperpigmentation 110.68
 - pigmented 132.9–11
 - clinical features 132.10–11
 - definition 132.9
 - epidemiology 132.9
 - investigations 132.11
 - management 132.11
 - nomenclature 132.9
 - pathophysiology 132.10
 - melanotrichoblastoma, giant 138.11
 - melasma 88.10–12
 - chemical peel 159.5, 159.6, 159.8, 159.13
 - clinical features 88.10
 - depigmenting agents 18.28
 - endocrine disorder skin signs 149.10, 149.12
 - epidemiology 88.10
 - laser treatment 23.14, 160.5–6
 - management 88.11–12, 88.34
 - pathophysiology 88.10–11
 - pregnancy 88.12, 115.1
 - melatonin receptors 2.18
 - meloidosis 26.52–3
 - glanders differential diagnosis 26.54
 - Melkersson–Rosenthal syndrome
 - fissured tongue 110.21
 - granulomatous cheilitis 110.85–7
 - penile lymphoedema 111.20
 - solid facial oedema 90.35–6
 - Meloidae 34.29
 - melphalan, melanoma treatment 143.29
 - membrane-bound transporters 14.5
 - men who have sex with men (MSM), genital warts 31.24
 - MEND syndrome 65.21
 - Mendelian disorders of cornification 65.2
 - Mendes da Costa syndrome, acquired poikiloderma 96.10
 - meningiomas 147.8
 - cutaneous 137.52
 - meningitis
 - Acinetobacter* 26.50
 - cryptococcal 31.27
 - IVIG adverse reaction 19.36
 - listeriosis 26.45, 26.46
 - recurrent lymphocytic 25.19
 - meningococcaemia 26.49
 - meningococcal infection 26.48–9, 26.50
 - clinical features 26.49
 - epidemiology 26.49
 - investigations 26.49
 - management 26.49, 26.50
 - pathophysiology 26.49
 - meningococcal septicaemia
 - epidemic typhus differential diagnosis 26.77
 - Rocky Mountain spotted fever differential diagnosis 26.78
 - tick typhus differential diagnosis 26.78
 - meningothelial heterotopias 137.52
 - Menkes disease 63.27, 68.6, 68.21, 79.7, 81.18–19
 - copper deficiency 2.36
 - hair colour changes 89.71
 - pili torti 68.10, 89.51, 89.52
 - differential diagnosis 68.20
 - trichothiodystrophy differential diagnosis 78.11
 - menopause
 - ageing of skin 155.4
 - flushing 106.4
 - hypo-oestrogenism 145.19
 - menstrual cycle
 - acne vulgaris 90.16
 - urticaria 42.8, 47.8
 - mental neuropathy, malignancy association 147.23
 - mental retardation, obesity, mandibular prognathism, eye and skin anomalies (MOMES) syndrome 74.5
 - mental retardation *see also* enteropathy–deafness–neuropathy–ichthyosis–keratoderma (MEDNIK) 65.27
 - mentalis muscle, botulinum toxin A injection 158.6, 158.7
 - menthol 18.34
 - mentophyma 91.8
 - mepacrine 19.5
 - discoid lupus erythematosus treatment 51.11
 - nail colouration 95.14
 - subacute cutaneous lupus erythematosus 51.14
 - mepyramine maleate 18.33
 - mequinol 18.29
 - mercaptans, substituted 18.29
 - Mercurialis (Italian physician) 1.3
 - mercurials, organic 128.39
 - mercury toxicity 122.5–6
 - allergic contact dermatitis 128.24
 - amalgam fillings 128.18
 - hyperpigmentation 88.53
 - oro-facial granulomatosis 128.61
 - protein–energy malnutrition differential diagnosis 63.4
 - Meretoja syndrome 58.12
 - MERRF (myoclonus epilepsy and myopathy with ragged red fibres) syndrome 81.9
 - Dercum disease differential diagnosis 100.17
 - subcutaneous lipomatosis association 100.14
 - Merkel cell(s) 2.1, 2.5, 2.11–12, 145.1
 - autoantibodies 2.12
 - function 85.1
 - origins 2.12
 - trichoblastoma 138.12
 - Merkel cell carcinoma 2.12, 145.1–4, 145.5, 145.6–9
 - chemotherapy 145.8–9
 - clinical features 145.3, 145.5, 145.6–7
 - immunocompromised patients 146.11–12
 - definition 145.1
 - diagnosis 3.19, 145.6
 - disease course 145.6
 - epidemiology 145.1–2
 - experimental treatments 145.9
 - eyelid 109.51
 - follow-up care 145.9
 - immunocompromised patients 146.11–12
 - management 146.13–14
 - immunohistochemistry 145.3, 145.4
 - immunotherapy 145.8–9
 - investigations 145.7
 - management 145.7–9
 - metastases 145.6
 - distant 145.8–9
 - locoregional 145.7–8
 - neurofilament expression 3.20
 - nomenclature 145.1
 - oncogenic viral infection 146.7
 - pathophysiology 145.2–3, 145.5
 - plaque-like variants 145.5, 145.6
 - polyomavirus infection 25.42
 - primary tumours 145.7–8
 - prognosis 145.6
 - radiotherapy 24.13, 145.8
 - sentinel lymph node biopsy 145.8
 - squamous cell carcinoma 125.13
 - differential diagnosis 108.25
 - staging 145.6–7
 - Merkel cell hyperplasia 2.12
 - Merkel cell polyomavirus 2.12, 25.41–2, 145.2, 146.7
 - Merkel cell–neurite complex 2.11
 - mesangiocapillary
 - glomerulonephritis 100.4
 - mesenchymal cells 2.4
 - mesenchymal markers 3.21–3
 - mesoderm 2.3, 2.4
 - Mesopotamia 1.2
 - messenger RNA (mRNA) 7.6
 - meta-analysis 17.5
 - confidence intervals 17.10
 - data statistical heterogeneity 17.11
 - point estimates 17.10
 - sensitivity analysis 17.11
 - metabolic diseases 81.1–20
 - acquired ichthyoses 65.40–1
 - amino acid disorders 81.11–16
 - cholesterol synthesis disorders 81.2, 81.16
 - congenital disorders of glycosylation 81.2, 81.10–11
 - with eccrine gland inclusions 94.14, 94.15
 - lysosomal storage disorders 81.1–9
 - mitochondrial disorders 81.2, 81.9–10
 - oral manifestations 110.91
 - telogen effluvium 89.26
 - metabolic disorders
 - kidney disease 153.2–3
 - musculoskeletal 154.9–10
 - metabolic syndrome
 - psoriasis association 35.21
 - psoriatic arthritis association 35.43
 - metal(s)
 - allergic contact dermatitis 128.19–24, 128.67
 - systemically reactivated 128.59
 - implant cutaneous reactions 128.59
 - pigmentation 88.52–3
 - metal halide lamps, UVR source 9.3
 - metal poisoning 122.1–9
 - antimony 122.1–2
 - arsenic 122.2–3
 - keratosis 65.52
 - beryllium, reactions to 122.8
 - lead 122.4–5
 - molybdenum, reactions to 122.9
 - platinum 122.9
 - thallium, reactions to 122.8
 - see also other named metals*
 - metaplasia 3.37
 - metastases 147.2–7
 - basal cell carcinoma 141.10
 - breast cancer 147.2, 147.3
 - calcification 61.6, 153.2
 - differential diagnosis from calciphylaxis 99.33
 - malignancy association 147.22
 - cutaneous 147.3–6
 - appearance 147.4
 - distribution 147.4–6
 - histopathology 147.6
 - mechanisms 147.4–6
 - prognosis 147.6

- cutaneous tumours 3.23
epidermoid cyst differential diagnosis 134.2
epithelioid sarcoma 137.66
melanoma 143.19, 143.25, 143.26
 lymph node dissection 143.27
 management 143.29–35
Merkel cell carcinoma 145.6
 distant 145.8–9
 locoregional 145.7–8
necrolytic migratory erythema 47.15
oral neoplasms 110.39
penile 111.34
perianal 113.31
radiotherapy 24.14
scalp 107.10
 acquired cicatricial alopecia 89.36
 skin cancer 146.14
 soft-tissue tumours 137.2
 squamous cell carcinoma 142.31
 tumour-to-tumour 147.5
 see also carcinoma erysipeloides
metformin, hirsutism treatment 89.68
meth mites 121.2
meth mouth 121.2
methaemoglobinaemia, dapsone-induced 19.14
methamphetamine 121.2
methanol 129.3
methanethline, hyperhidrosis treatment 94.9
methotrexate 19.22–5
 adverse effects 19.23–4
 atopic eczema treatment 41.33
 bullous systemic lupus erythematosus treatment 50.48, 50.49
 cautions 19.25
 contraindications 19.24–5
 dermatological uses 19.22
 discoid lupus erythematosus treatment 51.11
 dose 19.25
 gastrointestinal toxicity 19.24
 hepatotoxicity 19.24, 19.25
 HIV infection complications 31.16
 intralesional therapy 20.44
 malignancy association 19.24
 monitoring 19.25
 morphoea treatment 57.27–8
 mucous membrane pemphigoid 109.33
 myelotoxicity 19.23–4
 pemphigus treatment 50.9
 pharmacological properties 19.22–3
 pityriasis rubra pilaris treatment 36.5, 36.6–7
 plaque psoriasis treatment 35.26–7
 pre-treatment screening 19.25
 psoriasis treatment 19.22
 psoriatic arthritis treatment 35.45
 pulmonary toxicity 19.24
 regimens 19.25
 reproductive toxicity 19.24
 sarcoidosis treatment 98.16
 systemic lupus erythematosus treatment 51.36
 systemic-onset juvenile idiopathic arthritis treatment 45.11
 topical 18.28
 toxicity 14.10
5-methoxypsoralen (5-MOP) 21.8
8-methoxypsoralen (8-MOP) 21.8–9
methyl aminolevulinate (MAL) 22.2, 22.3
 application 22.9–10
methylchloroisoethiazolinone 128.36
methylidibromo glutaronitrile 128.37–8
methylisothiazolinone 128.36
meticillin-resistant *Staphylococcus aureus* (MRSA) 26.6, 26.8
 burns 126.8
 community-acquired 26.6, 26.8
 folliculitis 26.22, 26.23
 furuncle 26.23, 26.24, 26.25
 staphylococcal scalded skin syndrome 26.28
 folliculitis 113.9
 HIV infection 31.20
 sexual transmission 111.24
meticillin-sensitive *Staphylococcus aureus* (MSSA) 26.6
 furuncle 26.24, 26.25
metronidazole 18.11
 amoebiasis treatment 33.35
 rosacea treatment 91.13, 91.14
 trichomoniasis treatment 33.36
mevalonate kinase deficiency 45.2, 45.3, 81.16
 with recurrent fever and hyper-IgD syndrome 45.6–7
mevalonic aciduria 45.7
Meyerson naevus 39.27–8, 132.29–30
 halo naevi association 132.30
Michaelis–Gutmann bodies 136.21
Michelin tyre baby 72.15
 raised linear bands of infancy differential diagnosis 116.18
 smooth muscle hamartoma 75.20
miconazole, candidosis treatment 32.61
microbicides, HIV prevention 31.9
microcephaly with/without chorioretinopathy, lymphoedema or intellectual disability (MCLID) syndrome 73.19–20, 105.27, 105.29
microcephaly–capillary malformation syndrome 73.6–7
Micrococcus 26.3
 age effects 26.4
 microcystic adnexal carcinoma 138.37–8
 microdialysis 13.7
 microfibril-associated glycoproteins (MAGPs) 2.37
 micro-Hutchinson sign, melanoma 144.8, 144.9, 144.10
microorganisms
 high-power microscopy 3.33
 staining 3.10
microphthalmia-associated transcription factor (MiTF) 132.6
micro-RNAs (miRNAs) 2.41
 morphoea 57.10
 wound healing 10.2
microscopic examination of tissue sections 3.29–33
 high-power 3.30–3
 low power histological pattern diagnosis 3.30
microscopic polyangiitis 102.20–3
 clinical features 102.21–2
 definition 102.20
 epidemiology 102.21
 granulomatosis with polyangiitis differential diagnosis 102.25
 investigations 102.22
 management 102.22–3
 pathophysiology 102.21
 relapse 102.22
 respiratory disorder association 151.4
 severity classification 102.22
microscopic treatment zone (MTZ) 160.7
microscopy, simple diagnostic procedures 4.22
microsponges 18.2
microsporidiosis, HIV infection 31.28
Microsporium 32.18, 32.19, 32.20
 identification 32.23, 32.25–7
 Wood's light examination 32.6–7
Microsporium audouinii 32.23, 32.25
Microsporium canis 32.25–6
 tinea corporis 32.36, 117.9
Microsporium equinum 32.26
Microsporium ferrugineum 32.26
Microsporium fulvum 32.26
Microsporium gypsum 32.26
Microsporium nanum 32.26
Microsporium persicolor 32.26–7
microstomia, recessive generalized severe dystrophic epidermolysis bullosa 71.17
microtia 108.4, 108.5
microvascular filtration rate 105.2–3
microvenular haemangioma 137.31
MIDAS syndrome 67.24–5
 focal dermal hypoplasia differential diagnosis 67.24
mid-dermal elastolysis 96.23
midges 34.7, 34.8
midline destructive disease, idiopathic 110.40
Miescher cheilitis 110.85–7
Miescher granuloma 97.9–10
 radial in erythema nodosum 99.22–3
 sarcoidosis differential diagnosis 98.2
MIFT-1 3.21
migraine, rosacea association 91.12
migratory erythema 147.19
migratory thrombophlebitis 147.25, 152.6
Mikulicz ulcers 110.28, 110.29, 110.40
milia 134.4–5
 acne vulgaris differential diagnosis 90.24, 90.25
 chemical peels 159.12
 clinical features 134.5
 closed comedone differential diagnosis 90.24, 90.25
 epidemiology 134.5
 eyelid 109.47
 infants 117.13
 management 134.5
 neonates 116.3–4
 pathophysiology 134.5
 surgery 20.47
miliaria 94.12–13, 116.5–7
 actinic folliculitis differential diagnosis 93.6
 apocrine 94.17–18
 clinical features 116.6–7
 crystallina 94.12, 116.5, 116.6–7
 differential diagnosis 116.6–7
 epidemiology 116.6
 infantile acropustulosis differential diagnosis 116.8
 investigations 116.7
 management 116.7
 pathophysiology 116.6
 profunda 94.12–13, 116.5, 116.6
 pustulosa 116.6, 116.7
 folliculitis differential diagnosis 26.22
 perioritis staphylogenes differential diagnosis 116.24
 rubra 94.12, 116.5, 116.6, 116.7
 miliary calcinosis cutis 61.4, 61.5, 61.6
 miliary granulomas, listeriosis 116.25
 military personnel, friction blisters 123.9
milk, maternal, toxic substance transfer 116.14
milker's nodules 25.11–12
 cowpox differential diagnosis 25.9
 milker's sinus 123.22
millipedes 34.54–5
Milroy disease 105.25, 105.27, 105.29
 miltefosine, visceral leishmaniasis treatment 33.51
mineral deficiencies 63.23–31, 152.1
 copper deficiency 2.36, 63.27–8
 iron deficiency 63.23–5
 manganese deficiency 63.30–1
 selenium deficiency 63.28–30
 zinc deficiency 63.6, 63.25–7
 biotin deficiency differential diagnosis 63.23
mineral oils
 occupational disorders 130.14
 topical medications 18.6
mineralization abnormalities 72.26–32
minimal erythema dose (MED) 9.2, 21.7, 21.10
minimal phototoxic dose (MPD) 21.9
minocycline
 α_1 -antitrypsin deficiency panniculitis treatment 99.43
 hyperpigmentation 88.27
 laser treatment 23.14
 oral 110.66
 polyarteritis nodosa induction 102.30
minoxidil
 female pattern hair loss management 89.23
 hair lotion 128.16
 hair regrowth acceleration 18.36, 120.6
 hypertrichosis 89.62, 89.63
 male pattern baldness management 89.22
 topical therapy 18.36
minute pirate bugs 34.28
miosin, Horner syndrome 85.15
mipomersin 62.7
mirtazapine 86.36
Mitchell disease see erythromelalgia
mites 34.48–54
 bird 34.52
 Cheyletiella 34.50–1
 follicle 34.52–4
 harvest 34.51–2
 house-dust 34.48
 parasitic 34.49, 34.50–1, 34.52
 plant 34.50
 Pyometes 34.49
 reptile 34.52
 rodent 34.52
 spider 34.50
 stored products 34.48
 see also scabies
MITF gene mutations 143.5
mitochondrial damage 9.10
mitochondrial disorders 7.5, 81.2, 81.9–10
 dermatological features 81.9–10
mitochondrial DNA (mtDNA) 7.5
 mutation frequency 9.11
mitochondrial oxidative stress 8.44
mitogen-activated protein kinase (MAPK) activation by TLRs 8.14
 ageing of skin 155.6
 pathway in melanoma 143.31
mitogen-activated protein kinase (MAPK) inhibitors, papulopustular eruptions 120.3
Mitsuda test 4.25
mixed connective tissue disease 53.9, 54.1–3
 cardiac involvement 150.4
 clinical features 54.2
 complications/comorbidities 54.2
 definition 54.1
 epidemiology 54.1
 investigations 54.2
 management 54.3
 nomenclature 54.1
 pathophysiology 54.2
 respiratory disease association 151.2
 severity classification 54.2
 systemic lupus erythematosus differential diagnosis 51.27
 systemic sclerosis overlap 56.7, 56.8
 variants 54.2
mixed cryoglobulinaemia 125.10
 management 125.11
mixed immunobullous disease 50.36
mixed lymphovenous disease 105.6–9
mixed tumour of the skin 138.32–3
MLH1 gene mutations 142.39, 142.40
MMR vaccination 117.7
mobile phone-based interventions 4.25, 4.26
mogul skier's palm 123.16
Mohr orofaciocutaneous syndrome 108.4
Mohs micrographic surgery 20.8, 20.35, 20.36, 20.37–40
 costs 20.38
 criteria for high-risk lesions 20.39
 definition 20.35
 flaps for repair 20.25, 20.27–8
 historical aspects 20.35
 indications 20.38–9
 procedure 20.37–8
 reflectance confocal microscopy 4.21–2
 results 20.38
 skin cancer treatment 20.35, 20.36, 20.37
 squamous cell carcinoma 142.30–2
 high-risk 142.30–2
 training 20.40
 wound repair 20.38

- moisturizers
keratolysis exfoliativa treatment 87.25
recessive X-linked ichthyosis 65.6
rosacea 91.12
xerosis cutis treatment 87.27
- mole phobias 86.20
- molecular genetics 1.8
see also genetics/genetic factors
- molluscipoxvirus 31.25
- molluscs, stings 131.3–4
- molluscum
HIV infection 31.25
sebaceum 142.33
surgery 20.47
- molluscum contagiosum 25.12–14
basal cell carcinoma differential diagnosis 141.10
clinical features 25.13–14
epidemiology 25.12
eyelids 109.36, 109.38
genital 111.25, 112.27
genital wart differential diagnosis 111.25
granuloma annulare differential diagnosis 97.7
infants 117.9
investigations 25.14
keratoacanthoma differential diagnosis 142.35
lymphangiectasia differential diagnosis 105.41
lymphocytoma cutis 135.9
management 25.14
pathophysiology 25.12–13
perforating dermatosis differential diagnosis 96.51
primary immunodeficiency 82.2
treatment ladder 25.14
vulval 112.27
- molybdenum, reactions to 122.9
- MOMES (mental retardation, obesity, mandibular prognathism, eye and skin anomalies) syndrome 74.5
- Mondor disease 103.33–4
after breast surgery 103.33, 103.34
chest wall-type 103.33, 103.34
involving other venous territories 103.33, 103.34
lymphangitis 105.51
malignancy association 147.26
penile-type 103.33
- Mongolian spot 3.39, 88.2, 88.8, 116.4, 132.12–13
- monilethrix 68.5, 68.19, 89.11, 89.50–1
follicular keratosis association 89.51
trichotillomania differential diagnosis 89.47
- monkey bites, herpes B virus infection 25.38
- monkeypox 25.7–8
- monoamine oxidase inhibitors (MAOIs) 86.37
- monoarthritis 154.2
- monochromator phototesting 127.33–4
- monoclonal antibodies, mycosis fungoides/Sézary syndrome treatment 140.27
- monoclonal gammopathy 147.23
necrobiotic xanthogranuloma association 136.22, 148.9
normolipaemic xanthoma association 148.9
subcorneal pustular dermatosis association 49.14
TEMPI syndrome association 148.12
of undetermined significance 148.4
circulating abnormal immunoglobulins 148.5–6
pyoderma gangrenosum association 148.7
scleromyxoedema association 148.8, 148.9
- monoclonal IgA gammopathy, IgA pemphigus association 50.7
- monoclonal mast cell activation syndrome 46.7
- monoclonal plasmacytic ulcerative stomatitis 110.56
- monocyte(s) 8.21–3
high-power microscopy 3.31
histamine activity 8.47
wound healing 10.2, 10.3
- monocyte chemotactic proteins (MCPs) 8.38
- monocyte-derived receptors 8.23
- monogenic autoinflammatory syndromes 45.1–2, 45.3, 45.4–8
autoinflammatory granulomatosis of childhood 45.7
autoinflammation with pustulosis 45.7–8
definition 45.1–2
epidemiology 45.2, 45.3
hereditary periodic fevers 45.4–7
pathophysiology 45.4
- mononuclear phagocyte system (MPS) 136.1
- monounsaturated fatty acids (MUFA) 90.20
- mons pubis 112.2
swollen 105.17–19
- montelukast, solar urticaria 127.23
- mood disorders
assessment 86.33
isotretinoin association 86.34–5
see also anxiety; depression
- mood stabilizers 86.38
- moon facies, endocrine disorder skin signs 149.10
- Mooren-type corneal ulceration, hidradenitis suppurativa association 92.2
- Moraxella* 26.50
- Morbihan disease 91.11
- morbiliform eruptions, primary immunodeficiency 82.3
- morbillivirus 25.84, 25.85
- Morgellons syndrome 86.9–10
- MORM syndrome 111.7
- morphine
pruritus induction 83.12
topical 18.36
- morphoea 57.1–29
anticentromere antibodies 57.7
antinuclear antibodies 57.1, 57.6–7
associated diseases 57.5–6, 57.22
atrophic variant 96.15–16, 96.18
autoimmunity 57.6–7
Borrelia burgdorferi 26.70
causative organisms 57.9
chemokines 57.7–8
classification 57.2–4
clinical features 57.11–12, 57.13, 57.14, 57.15, 57.16–20, 57.21, 57.22–3
complications/co-morbidities 57.22–3
deep 57.14, 99.12–13
sclerosing postirradiation panniculitis differential diagnosis 99.60
differential diagnosis 57.20, 57.22
disease course 57.23–4
disease damage assessment 57.26
drug-induced 96.43
en coup de sabre 57.18, 57.19
environmental factors 57.10–11
epidemiology 57.4–6
ethnicity 57.4
extracutaneous manifestations 57.22–3
fibrosis 57.8
generalized 57.14, 57.23
genetics 57.9–10
guttate 57.11
head/neck variants 57.17–18
histopathology 57.8–9
history 57.11
hyperpigmentation 88.20–1
immunopathology 57.7–8
incidence 57.4
investigations 57.24–6
keloidal 57.13–14
lichen planus association 37.13
differential diagnosis 112.11
- lichen sclerosus differential diagnosis 112.7–8
limited type 57.11–12, 57.13, 57.14
linear 57.17–20, 57.19, 57.21, 117.12–13
deep atrophic 57.20
lupus panniculitis differential diagnosis 99.36
management 57.26–8, 57.29
mixed type 57.20
nodular 57.13–14
outcome measures 57.24–6
pansclerotic 57.14, 57.16–17
of children 99.13
pathophysiology 57.6–11
patient assessment 57.24
plaque 57.5
disseminated 57.14, 57.15
limited 57.11, 57.13
post-irradiation 120.14, 147.2, 147.21
predisposing factors 57.6
presentation 57.11
prevalence 57.4
profunda 99.13
dermatofibrosarcoma protuberans differential diagnosis 137.15
prognosis 57.23–4
psychological manifestations 57.23
sarcoidosis 98.13
differential diagnosis 98.8
scalp 107.5, 107.6
sclerosing panniculitis differential diagnosis 99.29
severity classification 57.20, 57.22
squamous cell carcinoma association 142.27
subacute cutaneous lupus erythematosus association 51.12
subcutaneous 57.17
systemic sclerosis differential diagnosis 56.15, 56.16
relationship 57.23
terminology 57.1–2
trunk/limb variant 57.19
UVA-1 phototherapy 21.6
variants 57.14, 57.15, 57.16–20, 57.21
- morpholines 18.12
- Morquio disease 81.2, 81.3
morsicatio buccarum 110.74
- Morton neuroma 137.45–6
- Morvan disease 85.7–8
mosaic acral keratosis 65.53
- mosaicism 7.4, 7.7–8
pigmentary 76.5, 117.12, 117.13
revertant 7.8
- mosquito bites 34.7–8
hypersensitivity 25.33
- mosquitoes 34.6
- moths 34.30–2
clinical features of reactions 34.31–2
epidemiology of reactions 34.30–1
pathophysiology of reactions 34.31
- moulds 32.2, 32.3, 32.3
isolate identification 32.10
saprophytic 32.18
- moulting, seasonal 89.8
- mouth
anatomical variants 110.7
biology 110.3–4
burning mouth syndrome 84.1–3
Candida albicans carriage 32.56–7
eczema 41.24
examination 110.4–7
floor examination 110.6
lip-lick cheilitis 41.24, 41.29
peribuccal pigmentation of Brocq 88.15
see also MAGIC (mouth and genital ulcers with inflamed cartilage) syndrome; oral cavity; oral mucosa; oral ulcers; teeth; tongue
- mouthwashes, cheilitis 110.82–3
M-plasty 20.33, 20.34
MSH2 gene mutations 142.39, 142.40
mTOR inhibitors 146.16
see also rapamycin; sirolimus
- Mucha–Habermann disease
febrile ulceronecrotic 135.4
see also pityriasis lichenoides
- mucin 59.1
- mucinoses, cutaneous 59.1–18
classification 59.1, 59.2
dermal 59.2–15
focal 59.14–15
oral lesions 110.24
follicular 59.15–17, 107.7
of infancy 59.7
lupus 59.13–14
papular 59.2–6
papular and nodular 59.13–14
primary 59.1, 59.2–17
secondary 59.1, 59.2, 59.18
self-healing 59.14
systemic lupus erythematosus 51.25
systemic manifestations 59.1–2
see also scleromyxoedema
- mucinous carcinoma 138.38–9
- mucinous cysts, vulval 112.29
- Muckle–Wells syndrome 19.32, 42.11, 45.3, 45.4, 47.11, 58.11, 58.12, 58.13
amyloid A amyloidosis 153.2
cryopyrin-associated periodic syndrome association 45.4
familial cold autoinflammatory syndrome association 47.11
IL-1 antagonist therapy 19.32
infantile urticaria 117.6
urticarial vasculitis association 44.2
- mucocele
oral 110.60–1
superficial immunostaining 110.46
oral lesions 110.56
- mucoctaneous lymph node syndrome *see* Kawasaki disease
- mucocutaneous pain syndromes 84.1–10
burning mouth syndrome 84.1–3
chronic scalp pain 84.9
erythromelalgia 84.10
trigeminal neuropathic pain syndromes 84.5–6
trigeminal trophic syndrome 84.6–7
see also post-herpetic neuralgia
- mucocutaneous venous malformation 73.11–12
- mucoepithelial dysplasia *see* hereditary mucoepithelial dysplasia (HMD)
- mucoïd cysts 111.26
- mucoïlipidoses 81.4, 81.5–6
mucoïpolysaccharides *see* glycosaminoglycans (GAGs)
- mucoïpolysaccharidoses 81.1–4
hypertrichosis 89.61
- mucormycete infections, necrotizing subcutaneous infection differential diagnosis 26.74
- mucormycosis 32.94
panniculitis 99.58
rhinocerebral 110.54
- mucosal melanotic lesions 132.9–12
- mucosal ulceration, folate deficiency association 63.19
- mucositis
oral lesions 110.55
oral mucosa 110.8–9
radiodermatitis 24.17
- mucous membrane lesions
Stevens–Johnson syndrome 119.15–16
surgery 20.46
systemic lupus erythematosus 51.26–7
toxic epidermal necrolysis 119.15–16
- mucous membrane pemphigoid 50.18, 50.23–32, 50.33, 112.19
antilaminin-332 109.27
autoantibodies 50.25
serum 50.25–6
specificity 50.10
tissue-bound 50.25
cicatricial conjunctivitis 109.25–7, 109.28–9, 109.29–34, 109.35, 109.36
cicatricial pemphigoid diagnosis 50.49

- clinical features 50.26–30, 109.27, 109.28–9, 109.29–30
- clinical signs **50.10**
- complications/co-morbidities 50.30
- definition 50.23
- diagnosis 50.31, 109.30
- diagnostic criteria 109.31
- differential diagnosis 50.24, 50.29, 109.29–30
- direct immunofluorescence methods 109.30
- disease course 50.30
- epidemiology 50.23–5, 109.26
- epidermolysis bullosa acquisita differential diagnosis 50.43, 50.45
- fibrosis 109.27
- management 109.34
- genetics 50.25–6
- genital lesions 50.27
- immunostaining **110.46**
- inflammation 109.27
- suppression 109.33
- investigations 50.31–2, 109.30–1
- lichen planus differential diagnosis 112.11
- lichen sclerosus differential diagnosis 111.14, 112.7
- linear IgA disease
- diagnostic overlap 50.36
- differential diagnosis 50.36
- management 50.32, **50.33**, 109.31–4
- nomenclatures 50.23
- ocular lesions 50.27–8, 50.29, 50.30
- classification **50.30**
- oral lesions 50.26–7, 110.45–6
- pathophysiology 50.25, 109.26–7
- prognosis 50.30
- secondary infections 109.32
- severity classification 50.29–30, 109.30
- skin lesions 50.28
- treatment guidelines 50.32
- treatment ladder 109.33, 109.33
- variants 50.28, 109.27
- see also* immunobullous disease
- mucous membranes
- dyskeratosis congenita 77.3
- iron deficiency 63.24
- lichen nitidus 37.10
- lichen planus lesions 37.12–13
- sample collection for fungal infections 32.8
- mucous retention cyst 110.60–1
- Muehrcke's bands 152.9
- paired white 95.14
- Muir–Torre syndrome 142.38–40, 147.11–12
- basal cell carcinoma **141.5**
- clinical features 142.39–40
- definition 142.38
- differential diagnosis 142.39
- epidemiology 142.39
- generalized eruptive keratoacanthoma differential diagnosis 142.38
- inheritance 147.11–12
- investigations 142.40
- keratoacanthoma differential diagnosis 142.35
- malignancy association 147.12
- management 142.40
- multiple self-healing squamous epithelioma differential diagnosis 142.37
- pathophysiology 142.39
- sebaceous carcinoma 138.18
- sebaceous tumours 90.27, 138.16
- multicarboxylase deficiency testing 63.23
- multicentric Castleman disease 25.37
- glomeruloid haemangioma 137.25
- IgG4-related disease differential diagnosis 148.14
- Kaposi sarcoma association 139.5
- lichen planus 37.13
- paraneoplastic pemphigus association 148.8
- multicentric osteolysis, nodulosis and arthropathy (MONA) 72.19
- multicentric reticulohistiocytosis 136.22–4, 154.13
- aphthous ulceration 110.41
- malignancy association 147.23–4
- respiratory disorder association 151.6
- multiple endocrine neoplasia (MEN) 145.20, 147.25
- type 1 **74.8**, 147.10
- benign symmetrical lipomatosis differential diagnosis 100.15
- Dercum disease differential diagnosis 100.17
- metastases 147.10
- type 2a 147.10
- type 2b 72.16, 110.11, 147.10
- infiltrating lipomatosis of the face differential diagnosis 100.18
- malignancy association 147.10
- multiple haemorrhagic sarcoma *see* Kaposi sarcoma
- multiple hamartoma and neoplasia syndrome 153.2
- storiform collagenoma association 137.3
- multiple lentiginoses syndrome 150.3
- Mulvihill–Smith syndrome differential diagnosis 72.26
- see also* LEOPARD syndrome
- multiple minute digitate keratosis 87.17–18
- multiple mucosal neuromas 137.45
- multiple myeloma
- acquired ichthyoses 65.40
- circulating abnormal immunoglobulins 148.5–6
- cryoglobulins 101.13
- HIV infection 31.31
- intraoral mass 110.61
- malignant infiltration of skin 148.4–5
- scleromyxoedema association 148.8, 148.9
- subcorneal pustular dermatosis association 49.14
- multiple neurofibromas 137.48
- multiple organ failure, hyperpigmentation 88.21
- multiple pigment sarcoma *see* Kaposi sarcoma
- multiple pterygium syndrome 72.33
- multiple self-healing squamous epithelioma (MSSE) 142.36–7
- generalized eruptive keratoacanthoma differential diagnosis 142.38
- keratoacanthoma differential diagnosis 142.35
- multiple sulphatase deficiency (MSD) 65.29
- multiple symmetrical lipomatosis 100.13
- Dercum disease differential diagnosis 100.17
- multipotent stem cells 2.43
- multisegmental lymphatic dysplasia with systemic involvement 105.26, 105.27, 105.28
- multisystem tumours 147.2
- Mulvihill–Smith syndrome 72.25–6
- progeria differential diagnosis 72.22
- MUM-1 3.25
- MUM1 gene expression 140.28
- Münchhausen syndrome 86.23, 86.29–30
- by proxy 86.22, 86.23, 86.30
- Munro microabscesses 3.38
- mupirocin 18.11
- murine typhus 26.77
- Murray Williams' warts 39.28
- Muscidae 34.7, 34.8
- myiasis 34.9
- muscle strength, dermatomyositis 53.8
- muscle tumours 137.55–8
- skeletal muscle 137.57–8
- musculoskeletal disease 154.2–15
- autoinflammatory disorders 154.10–11
- cutaneous adverse reactions to antirheumatic therapies 154.14–15
- generalized severe recessive dystrophic epidermolysis bullosa 71.26
- infective arthropathies 154.2–5
- inflammatory arthropathies 154.5–8
- inflammatory chondropathies 154.11–13
- metabolic disorders 154.9–10
- osteoarthritis 154.8
- retinoid-induced 19.38
- sarcoidosis 98.6
- scurvy 63.21–2
- systemic lupus erythematosus 51.28
- systemic sclerosis 56.15, 56.18
- see also* arthritis; rheumatoid arthritis
- musculoskeletal system examination 154.1–2
- history taking 154.1
- musical instruments, skin reactions 90.24, 123.11–12
- mustine 18.27–8
- MVK gene mutations 65.67, 142.15
- myasthenia gravis, pemphigus erythematosus association 50.6
- mycetoma 32.73–6
- bone destruction 154.5
- botryomycosis differential diagnosis 26.73
- definition 32.73
- epidemiology 32.73
- investigations 32.75
- management 32.76
- pathophysiology 32.73–4
- treatment ladder **32.76**
- mycobacteria, staining 3.10
- mycobacterial infections 27.1–5
- atypical in HIV infection 31.22
- biology 27.3–4
- cat scratch disease differential diagnosis 26.61
- classification 27.2
- diagnosis 27.4–5
- epidemiology 27.2–3
- eyes 109.41–2
- fast-growing 27.42–5
- classification 27.42–3
- clinical features 27.43–4
- epidemiology 27.43
- investigations 27.44
- management 27.45
- pathophysiology 27.43
- HIV infection 31.22
- impaired cellular immunity 148.15
- infectious panniculitis 99.44
- IRIS/IRD/IRAD **31.36**
- joint disease 154.4
- non-tuberculous 27.3, 27.32–45
- classification **27.2**, 27.32
- oral ulcers 110.53
- pinna 108.11
- sporotrichosis differential diagnosis 32.73
- vulval 112.24
- see also* leprosy; tuberculosis
- Mycobacterium abscessus* 27.32
- antimicrobials with high activity **27.45**
- fast-growing mycobacteria 27.43, 27.44
- Mycobacterium avium*
- classification 27.2
- lichen scrofulosorum 27.26
- Mycobacterium avium*–*intracellulare* complex 27.3, 27.32, 27.39–40
- HIV infection 31.22
- oral ulcers 110.53
- Mycobacterium bovis*
- BCG infection of glans penis 27.11–12
- classification 27.2
- erythema induratum of Bazin 27.30
- lichen scrofulosorum 27.26
- lupus vulgaris 27.21
- primary inoculation tuberculosis 27.12, 27.13
- Mycobacterium chelonae* 27.32
- antimicrobials with high activity **27.45**
- erythema induratum of Bazin 27.30
- fast-growing mycobacteria 27.43, 27.44
- Mycobacterium fortuitum* 27.32
- antimicrobials with high activity **27.45**
- fast-growing mycobacteria 27.43
- Mycobacterium goodii* 27.3
- Mycobacterium haemophilum* 27.32, 27.40–1
- Mycobacterium intracellulare* 27.39–40
- Mycobacterium kansasii* 27.3, 27.35–6
- Mycobacterium leprae* 28.1, 28.2, 28.3, 28.6–7
- classification 27.2
- Mycobacterium mageritense* 27.32
- Mycobacterium marinum* 27.32
- classification 27.2
- clinical features 27.34
- epidemiology 27.33
- granuloma annulare differential diagnosis 97.7
- infection 27.33–5
- investigations 27.34
- management 27.34–5
- pathophysiology 27.34
- warty tuberculosis differential diagnosis 27.21
- Mycobacterium mucogenicum* 27.32
- fast-growing mycobacteria 27.43
- Mycobacterium peregrinum* 27.32
- Mycobacterium scrofulaceum* 27.32, 27.41–2
- Mycobacterium smegmatis* 27.32
- antimicrobials with high activity **27.45**
- fast-growing mycobacteria 27.43, 27.44
- Mycobacterium szulgai* 27.32, 27.42
- lichen scrofulosorum 27.26
- Mycobacterium tuberculosis* 27.1
- classification 27.2
- epidemiology 27.2–3
- erythema induratum of Bazin association 27.30, 99.26, 99.27
- histopathology 27.7
- HIV co-infection 27.3, 31.21–2
- immunopathology 27.4
- lichen scrofulosorum 27.26
- lupus vulgaris 27.21
- metastatic tuberculous abscesses 27.18
- miliary tuberculosis 27.17
- nucleic acid amplification tests 27.8–9
- papulonecrotic tuberculid 27.28
- primary inoculation tuberculosis 27.13
- protective immunity 27.3–4
- sarcoidosis 98.4
- scrofuloderma 27.15
- warty tuberculosis 27.19
- Mycobacterium ulcerans* 27.32, 27.36–9
- clinical features 27.38
- epidemiology 27.37
- giant water bug carrier 34.28
- investigations 27.38
- management 27.39
- pathophysiology 27.37–8
- mycophenolate mofetil 19.25–7
- acute graft-versus-host disease 38.6
- adverse effects 19.26–7
- atopic eczema treatment 41.33
- contraindications 19.27
- dermatological uses 19.25
- discoid lupus erythematosus treatment 51.11
- dose 19.27
- drug–drug interactions **19.27**
- epidermolysis bullosa acquisita treatment 50.46
- monitoring 19.27
- morphoea treatment 57.28
- pemphigus treatment 50.8
- pemphigus/pemphigoid treatment 19.25
- pharmacological properties 19.25–6
- pre-treatment screening 19.27
- regimens 19.27
- skin cancer association 146.6
- systemic lupus erythematosus treatment 51.36
- Mycoplasma* 26.75
- Stevens–Johnson syndrome 119.17
- vulval infection 112.25
- Mycoplasma fermentans*, Behçet disease association 48.2

- Mycoplasma pneumoniae*-associated mucositis (MPAM) 119.17
Mycoplasma pneumoniae 12.2, 26.75
 mycoses *see* fungal infections
 mycosis fungoides 140.1, 140.2, 140.4–15, 140.24–7
 annular erythema of infancy differential diagnosis 47.7
 aphthous ulceration 110.40
 atypical cutaneous lymphoproliferative disorder 31.32
 cell of origin 140.2, 140.3
 chromosomal abnormalities 140.20–1
 chronic superficial scaly dermatitis differential diagnosis 39.27
 clinical features 140.9–14
 definition 140.4
 diagnostic criteria 140.7
 differential diagnosis 140.12
 pathological 140.7
 disease course 140.12–14
 epidemiology 140.4
 epidermotropic 140.17
 erythrodermic 140.19–20
 extracutaneous disease pathology 140.7–8
 follicular mucinosis association 107.7
 folliculotropic 140.10, 140.11
 gene abnormalities 140.21–2
 genital 111.34
 HTLV-1 140.4
 hypopigmented 140.10, 140.11–12
 ichthyosiform variants 140.10–11
 immunopathology 140.6–7
 investigations 140.14–15
 management 140.22–7
 combination therapies 140.24–5
 electron beam radiotherapy 24.14–16
 radiotherapy 24.14–16, 140.24
 skin-directed therapy 140.23–4
 systemic therapy 140.24–7
 toxin therapies 140.26
 molecular pathogenesis 140.20–2
 pathophysiology 140.4–9
 peripheral lymphadenopathy 140.10
 pilotropic 140.10, 140.11
 pityriasis alba differential diagnosis 39.25
 pityriasis lichenoides association 135.3
 plaques 140.9–10
 poikiloderma atrophicum vasculare 96.10
 poikilodermatous 96.10, 96.11, 140.10, 140.11–12
 presentation 140.9–10
 prognosis 140.12–14, 140.15
 pruritus 83.8–9
 psoriasis differential diagnosis 31.15, 35.18, 35.19
 second malignancies 140.14
 severity classification 140.12
 solitary 140.10, 140.12
 staging system 140.3, 140.4, 140.7–8, 140.12
 T-cell clones 140.9
 T-cell receptor gene analysis 140.8–9
 TCR genes 140.9
 tinea cruris differential diagnosis 32.47
 variants 140.10–12
 see also cutaneous T-cell lymphoma (CTCL); follicular mucinosis
 myelodysplastic syndrome
 aphthous ulceration 110.40
 copper deficiency differential diagnosis 63.28
 perniosis 125.4
 pyoderma gangrenosum association 148.7
 myeloid leukaemia, pyoderma gangrenosum association 148.7
 myeloma, necrobiotic xanthogranuloma association 136.22
 myelomeningocele 85.8
 myeloperoxidase 8.17–18
 myeloproliferative disorders
 purpura 101.11–12
 transient, neonatal pustulosis 116.8
 MYH-associated polyposis, pilomatricoma association 138.13
 myiasis 34.8–12
 cavitary 34.11
 classification 34.8, 34.9–11
 clinical features 34.11
 cutaneous 34.11
 Dipteran larvae 34.8
 furuncular 34.11–12
 investigations 34.11
 management 34.11–12
 migratory 34.11, 34.12
 wound 34.11, 34.12
 myocardial infarction (MI), complex regional pain syndrome association 85.13
 myoclonus epilepsy and myopathy with ragged red fibres (MERFF) syndrome 81.9
 Dercum disease differential diagnosis 100.17
 subcutaneous lipomatosis association 100.14
 myoepithelioma, cutaneous 138.33–4
 myofibroblast(s)
 high-power microscopy 3.32
 keloid 10.9
 wound healing 10.7–8
 myofibroblastic tumours 137.2–19
 myofibromatosis
 adult 137.42
 infantile 96.38–9, 137.42
 myopericytoma 137.42–3
 myositis
 inflammatory 53.2
 systemic sclerosis association 56.7
 overlap 56.8
 myositis-associated antibodies (MAAs) 53.2, 53.10–11
 myositis-specific antibodies (MSAs) 53.2, 53.11
 myotonic dystrophy, pilomatricoma association 138.13
 myxoedema
 endocrine disorder skin signs 149.10
 localized 59.11–13
 systemic sclerosis differential diagnosis 56.15
 in thyroid disease 59.11–13
 variants 59.11–12
 see also pretibial myxoedema
 myxofibrosarcoma 137.17–18
 myxoid cyst
 cutaneous 137.62
 of lip 110.60–1
 myxoid degeneration 3.35
 myxoinflammatory fibroblastic sarcoma 137.16–17
 myxoma
 mucocutaneous 150.4
 oral cavity 110.61
 myxoma syndrome *see* Carney complex
 myxovirus infections 25.84–6
 N
 N-acetylcysteine (NAC), trichotillomania treatment 89.47
 NADPH oxidase 8.44, 8.45
 Naegeli–Franceschetti–Jadassohn ectodermal dysplasia 70.3, 70.13–14, 71.8
 Cole disease differential diagnosis 65.54
 naevi
 acneform 90.25
 acquired melanocytic 132.18–22
 agminated 132.21
 clinical features 132.20–1
 definition 132.18
 epidemiology 132.18
 eruptive 132.21
 investigations 132.22
 malignant transformation 132.21
 management 132.22
 multiple 132.18
 nomenclature 132.18
 pathophysiology 132.18–20
 penile 111.6
 acral 132.23–4
 agminated naevomelanocytic 132.17
 anaemicus 88.37
 angora hair 75.19
 apocrine 75.5–6
 atypical 132.42–4, 132.45–6, 132.46–7
 clinical features 132.44, 132.45–6, 132.46
 definition 132.42, 132.44
 diagnostic criteria 132.44
 differential diagnosis 132.44
 disease course 132.44, 132.46
 epidemiology 132.42
 genetics 132.43–4
 genital 112.32
 investigations 132.46
 laser treatment contraindication 23.14
 management 132.46–7
 melanoma predisposition 143.3
 nomenclature 132.42
 pathophysiology 132.42–4
 prognosis 132.44, 132.46
 severity classification 132.44
 superficial spreading melanoma 143.8, 143.9
 balloon cell 132.19
 bathing trunk 111.6
 Becker 75.19
 laser treatment 23.13–14
 speckled lentiginous naevi differential diagnosis 132.17
 biopsy 3.2
 blue 132.38–40, 132.41
 clinical features 132.40
 congenital 75.16
 congenital melanocytic naevi differential diagnosis 75.12
 definition 132.39
 differential diagnosis 132.40
 epidemiology 132.38
 genetics 132.39–40
 histological sections 3.39–40
 investigations 132.40, 132.41
 malignant 132.41–2, 143.15
 malignant blue naevus differential diagnosis 132.41
 management 132.40
 nomenclature 132.38
 pathophysiology 132.38–40
 penile 111.6
 pigmentation 88.2
 variants 132.40
 blue rubber bleb naevus syndrome 73.12–13
 capillary 125.8
 CHILD syndrome 65.21–3, 75.3–4, 75.7
 CLOVES syndrome 75.7
 Cockade 132.31
 comedo 138.4–5
 comedonicus 75.7
 common acquired 132.18–22
 melanoma predisposition 143.3
 compound 132.2, 132.18, 132.21, 132.22
 congenital 75.1–18
 classification 75.2, 75.24
 clinical phenotypic classification 75.2
 connective tissue 75.17–18
 fat 75.17–18
 genetic classification 75.2
 histological classification 75.2
 melanoma arising in 143.13–14
 melanoma predisposition 143.2
 nomenclature 75.2–3
 penile 111.6
 phenotypes 75.1
 pigment 75.9–16
 pillar and smooth muscle 137.55
 congenital epidermal 75.2–9
 clinical features 75.5–8
 definition 75.2
 epidemiology 75.3
 management 75.8–9
 pathophysiology 75.3–4
 variants 75.6–8
 congenital melanocytic 75.9–15, 132.15, 132.16–17, 132.18
 clinical features 75.11–14
 complications/comorbidities 75.13–14
 definition 75.9
 epidemiology 75.9
 facial features 75.14
 genetics 75.11
 giant 85.9
 hydrocephalus 75.14
 hypertrichosis 89.62
 investigations 75.14
 leptomeningeal disease 75.15
 management 75.14–15
 melanoma association 75.10, 75.11, 75.13–14, 75.15
 melanoma predisposition 143.2
 melanosis 75.13
 neuroid proliferations 75.12
 neurological abnormalities 75.13, 75.15
 nodules 75.10, 75.12, 75.15
 pathophysiology 75.9–11
 severity 75.12–13
 speckled lentiginous naevi differential diagnosis 132.17
 spilus-type 75.12, 75.16–17
 variants 75.12
 conjunctival 132.24
 connective tissue 75.2–3
 papular elastorrhexis 96.30
 depigmentosus
 pityriasis alba differential diagnosis 39.25
 vitiligo differential diagnosis 88.37
 dermal 132.2, 132.21
 dermoscopy 144.1–2
 dysplastic 132.42, 132.47
 melanoma predisposition 143.3
 eccrine 75.5–6
 angiomatous 138.24
 epidemiology 75.9
 epidermal 75.2
 confluent and reticulated papillomatosis differential diagnosis 87.7
 epidermolytic epidermal 65.13, 65.15, 75.8
 faun tail 138.7
 FGFR3 epidermal naevus syndrome 75.7
 follicular 75.3, 75.5
 follicular naevus/naevus comedonicus syndrome 75.7
 functional sweat gland 94.7
 genetics 75.3–4
 keratinocytic 75.3
 giant congenital, melanoma arising in 143.13–14
 hair follicle 138.7
 halo 88.40–3, 132.28–9
 clinical features 88.41–2, 132.29
 differential diagnosis 88.42
 disease course 88.42
 epidemiology 88.40–1, 132.28
 investigations 88.43, 132.29
 management 88.43, 132.29
 Meyerson naevi association 132.30
 pathophysiology 88.41, 132.28–9
 variants 88.41
 vitiligo association 88.35, 88.37, 88.41
 vitiligo differential diagnosis 88.37, 88.42
 Happle–Tinschert syndrome 75.7
 hypertrichosis 89.61–2
 inflammatory linear verrucous epidermal 75.4
 clinical features 75.5
 lichen striatus differential diagnosis 37.20
 management 75.8–9
 psoriasis overlap 75.5

- intra-dermal 132.2, 132.18–19, 132.21
 junctional 132.2, 132.18, 132.20, 132.22
 Kaposi sarcoma differential
 diagnosis 31.29
 keratinocytic 75.3, 75.5, 75.8
 lentiginous 23.14
 malignant blue 132.41, 143.15, 143.19,
 143.19
 melanocytic 144.1
 acral 13.25, 132.24
 basal cell carcinoma differential
 diagnosis 141.10
 combined 132.26–7
 genital area 132.23
 growth in GH therapy 149.17
 halo 132.28–9
 halo dermatitis 39.27, 39.28
 laser treatment 23.14
 naevoid basal cell carcinoma
 syndrome differential
 diagnosis 141.19
 penile 111.6
 pregnancy 115.1, 115.7
 recurrent 132.27–8
 seborrhoeic keratosis differential
 diagnosis 133.3
 shave biopsy artefacts 3.28
 surgery 20.46
 Turner syndrome 76.3
 melanoma progression 143.7–8
 Meyerson 39.27–8, 132.29–30
 halo naevi association 132.30
 mucinosis 75.18
 nail matrix/nail bed 132.24–5
 organoid 89.49
 patterns 144.1–2, 144.3–4
 PENS syndrome 75.7
 phakomatosis
 pigmentokeratotic 75.7
 phenotype and melanoma risk 143.3
 pigment cell 75.2
 pigmented
 eyelid 109.48
 oral mucosa 110.13
 pigmented spindle cell of Reed 132.34
 porokeratotic eccrine 75.3
 ostial duct 65.30, 65.32
 Proteus syndrome 75.7
 psiloliparus 75.18
 Reed 132.36
 ridge pattern 144.5
 Schimmelpenning–Feuerstein–Mims
 syndrome 73.17, 75.7
 sebaceous 75.3, 75.5
 acne vulgaris differential
 diagnosis 90.25–6
 scalp 107.10
 shave excision 20.14
 speckled
 laser treatment 23.14
 lentiginous 75.16–17, 132.15,
 132.17–18
 spider 103.8, 103.10–12
 Spitz 132.32–8
 atypical 132.37
 clear cell sarcoma differential
 diagnosis 137.66
 clinical features 132.35–7
 congenital 75.15
 definition 132.32
 differential diagnosis 132.36
 epidemiology 132.33
 genetics 132.34–5
 investigations 132.37
 Kamino bodies 3.37
 management 132.37–8
 nomenclature 132.32
 pathophysiology 132.33–5
 pigmented 132.37
 prognosis 132.36–7
 variants 132.36
 surgical excision 20.46
 targetoid haemosiderotic 132.31–2
 unusual morphology 132.25–32
 unusual sites 132.22–5
 vascular 103.9, 103.10
 eyelid 109.48
 white sponge 31.33, 110.19–20
 woolly hair 89.57
 naevi, atrial myxoma, myxoid
 neurofibromas and epheles
 (NAME) syndrome 101.17,
 147.10–11
 oral mucosa 110.12
 naevoid basal cell carcinoma (BCC)
 syndrome 67.7, 110.25, 141.3, 141.4,
 141.18–21, 147.7
 aggressive tumours 141.19
 clinical features 141.18–20
 complications/co-morbidities 141.19–20
 definition 141.18
 differential diagnosis 141.19
 epidemiology 141.18
 epidermoid cysts 134.1
 investigations 141.20
 management 141.20–1
 nomenclature 141.18
 pathophysiology 141.18
 patient assessment 141.20
 photodynamic therapy 22.2, 22.7
 naevoid hypermelanosis, linear and
 whorled 70.2, 70.10, 70.11–12
 naevoid lesions 75.19
 linear on penis 111.6
 nomenclature 75.3
 naevoid melanoma-like melanocytic
 proliferations 132.35
 naevus comedonicus syndrome 111.26,
 138.4
 naevus flammeus 103.9, 103.10
 naevus lipomatosus superficialis of
 scalp 100.23
 naevus of Ito 88.8, 132.14–15
 naevus of Ota 88.2, 88.8, 132.13–14, 132.15
 clinical features 132.13–14
 epidemiology 132.13
 eyelid 109.48
 laser treatment 23.14, 132.14
 management 132.14
 naevus of Ito differential
 diagnosis 132.15
 pathophysiology 132.13
 naevus sebaceous of Jadassohn 90.25–6,
 110.19
 apocrine tubular adenoma 138.22
 naevus spilus 132.17
 naevus syringocystadenomatosus
 papilliferus 138.20–1
 naftifine 18.11
 Nager syndrome 108.3
 nail(s) 2.9–2.11
 acquired ungual fibrokeratoma 95.26–7
 acrodermatitis continua of
 Hallopeau 35.41
 allergens 95.43–4
 alopecia areata 89.32
 attachment abnormalities 95.8–10
 beading 95.12
 Beau's lines 95.11
 biting 95.17–18
 blood supply 95.4
 buffing 95.64
 candidosis 32.66–7, 32.69
 chemotherapy-induced changes 120.6–8
 children 95.46
 colour changes 95.12–16
 psoriasis 95.40
 cuticle 2.11
 Darier disease 95.43
 dermatitis differential diagnosis 95.44
 dermatoses affecting 95.38–46
 development 2.4, 2.5, 2.9–10
 digital myxoid pseudocyst 95.24–5,
 95.26
 dominant generalized dystrophic
 epidermolysis bullosa 71.14, 71.15
 dyskeratosis congenita 69.12–15
 dystrophy 95.7–8
 lamellar 95.12
 eczema 95.43–4
 fibromas in tuberous sclerosis
 complex 80.11
 function 2.43
 gel 95.62–3
 genetic defects 69.1, 69.11–16
 genetics 95.3–4
 glomus tumour 95.22–3
 grooves
 longitudinal 95.10–11
 transverse 95.11, 95.17
 growth 95.4–5
 linear 95.5
 habit tic 95.17, 95.18
 Hailey–Hailey disease 95.43
 half-and-half 95.14
 hereditary onychia 69.16
 hidrotic ectodermal dysplasia 67.21, 67.22
 HIV infection 31.32–3
 hypertrophy 95.18–19
 hypohidrotic ectodermal
 dysplasias 67.13
 idiopathic atrophy 95.45
 imaging 95.46–53
 ingrowing toenails 95.19–21
 chemical cautery 95.58–60
 iron deficiency 63.24
 junctional epidermolysis bullosa 71.12,
 71.13
 lichen nitidus 37.10, 95.45
 lichen planus 37.12, 37.17, 95.44–6
 genital 112.12
 liver disease 152.9
 mal de Meleda 65.48
 manicure instrument trauma 95.18
 median canaliform dystrophy of
 Heller 95.10–11, 95.17
 Mee's lines 122.2, 122.8
 morphology 95.5
 nail–patella syndrome 69.15–16
 Neoscytalidium infection 32.52
 older people 95.46
 pachyonychia congenita 65.44–5, 69.1,
 69.11–12
 painful dorsolateral fissure of
 fingertip 95.38
 perionychial disorders 95.35–8
 periunguim
 biting 95.17
 trauma 95.38
 pigmentation with cytotoxic
 agents 88.26
 pincer 95.7–8
 pitting 95.11, 95.39
 prefomed plastic 95.63
 pregnancy changes 115.1, 115.2
 Pseudomonas aeruginosa infection 26.52
 psoriasis 35.12–14, 35.15, 95.38–43
 clinical features 95.39–42
 differential diagnosis 95.41–2, 95.44
 management 95.42–3
 pathophysiology 95.39
 red lunulae 95.15
 ridging 95.12
 transverse 95.17
 ringworm 32.47–9
 sample collection in fungal
 infection 32.7–8
 sarcoidosis 98.14
 sculptured 95.62
 selenium toxicity 63.29, 63.30, 122.6
 shape abnormalities 95.6–8
 shedding 95.8
 signs 95.5–16
 silicone rubber prosthesis 95.63
 split nail deformity 95.17
 subungual keratoacanthoma 95.27–8
 superficial acral fibromyxoma 95.30
 surface changes 95.10–12
 surgery 95.53–4, 95.55–7, 95.57–60
 anaesthesia 95.53
 avulsion 95.57–8
 diagnostic 95.54, 95.55–7, 95.57
 excisional 95.57–60
 instrumentation 95.54
 postoperative care 95.60
 systemic lupus erythematosus 51.22–3
 thickening 95.19
 trauma 95.16–21
 acute 95.16–17
 chronic repetitive 95.17–21
 delayed 95.17
 plantar keratoderma differential
 diagnosis 69.12
 tricho-rhino-phalangeal syndrome 67.20
 trichothiodystrophy 68.21
 tumours under/adjacent 95.21–34,
 95.35
 benign 95.21–31
 malignant 95.31–4, 95.35
 whiteners 95.64
 Wilson disease 81.19
 X-ray examination 95.46–8
 yellow nail syndrome 95.14–15
 see also clubbing; *onycho-* entries;
 paronychia; splinter haemorrhages;
 subungual entries
 nail apparatus
 basal cell carcinoma 95.33
 biopsy 95.54, 95.57
 lobular capillary haemangioma 95.21–2
 melanoma 95.33–4, 95.35
 squamous cell carcinoma 95.31–2, 95.43
 verrucous carcinoma 95.32
 Nail Assessment in Psoriasis and Psoriatic
 Arthritis (NAPPA) 16.3
 nail bed 2.11, 95.3
 apparent leukonychia 95.14
 biopsy 95.54
 biting 95.17
 blood supply 95.4
 colour changes 95.13
 dermal layer 2.11
 keratins 95.4
 laceration 95.17
 salmon patches 95.39, 95.40
 nail cosmetics 95.60–4
 allergic reactions 95.62
 buffing 95.64
 coatings that polymerize 95.62–3
 removal 95.63
 cuticle removers 95.63
 gel nails 95.62–3
 gel polish 95.63
 hardeners 95.63
 infection risks 95.64
 irritant reactions 95.62
 light-cured gels 95.62–3
 nail cream 95.64
 nail-mending kits 95.63
 prefomed plastic nails 95.63
 silicone rubber prosthesis 95.63
 whiteners 95.64
 see also nail varnish
 nail cream 95.64
 nail disease, factitious 86.26
 nail dystrophy
 Darier disease 66.3, 66.6
 Olmsted syndrome 65.62
 pachyonychia congenita 69.1, 69.11
 nail fold 2.10–11, 95.3
 biopsy 95.54
 biting 95.18
 capillary abnormalities 54.2
 chemotherapy effects 120.7
 dermatomyositis 53.5–6
 Hutchinson sign 95.34
 hypertrophy of lateral 95.38
 infections 95.35–8
 proximal nail fold
 capillaroscopy 95.50–3
 nail fold capillaroscopy, Raynaud
 phenomenon 56.13–14
 nail hardeners 95.63
 nail matrix 2.10, 95.2, 95.3
 biopsy 95.54, 95.55–6
 blood supply 95.4
 keratinocyte layers 2.11
 kinetics 95.4–5
 scarring 95.8
 nail matrix/nail bed naevi 132.24–5

- nail plate 2.11, 95.3
biting 95.17
darkening in paronychia 95.37
growth 2.10
infections 95.37
lichen planus 95.44
lucency loss 95.13
older people 95.46
pigmentation 95.12–13
psoriatic abnormalities 95.40
staining from nail varnish 95.61
structure 95.5
subungual abscess 95.37–8
- nail polish *see* nail varnish
- Nail Psoriasis Severity Index (ANPSO) 16.3
- nail unit 2.10–11
anatomy 95.2–3
biology 95.3–5
melanoma 95.33–4, **95.35**, 144.8, 144.9, 144.10
structure 95.2–3
- nail varnish 95.60–2, 128.15
allergy 128.31, 128.32
cheilitis 128.16
patch testing 95.61
removers 95.62
- nail-mending kits 95.63
- nail-patella syndrome 69.15–16
hyperhidrosis 94.5
renal involvement 153.1
- Nakajo–Nishimura syndrome *see* chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome
- Na-K-ATPase 94.2
- NALP-3 inflammasome 8.2
- NAME (naevi, atrial myxoma, myxoid neurofibromas and ephelides) syndrome 101.17, 147.10–11
oral mucosa 110.12
- NAP-2 (CXCL7) 8.39
- napkin dermatitis 117.3
infantile seborrhoeic dermatitis differential diagnosis 117.2
persistent 117.4
psoriasiform 40.3
- narrow-band UVB, plaque psoriasis 35.25
- nasal cavity, extranodal NK/T-cell lymphoma 140.36–7
- nasal glioma 137.52
- nasal inflammation/mucosal necrosis 121.3
- nasal inverting papillomas 25.57
- nasal mucosa
allergens 128.18
radiodermatitis 24.17
- nasal vestibule, bacterial flora 26.5
- naso-labial fold, radiotherapy for skin cancer 24.10–11
- naso-palpebral lipoma–coloboma syndrome **74.8**
- nasopharyngeal carcinoma, Epstein–Barr virus-associated 25.34
- nasopharyngitis, congenital syphilis 29.28, **29.29**
- nasopharynx, extranodal NK/T-cell lymphoma 140.36–7
- natal cleft 113.3
- National Guideline Clearinghouse 17.7
- National Institute for Health and Care Excellence (NICE) 17.7
- natural gene therapy 7.8
- natural killer (NK) cell(s) 8.15–16, 8.31
atopic eczema 41.11
chemokine expression 8.16
cytokine secretion 8.16
IFN role 8.34
inhibitory receptors for MHC class I proteins 8.16
innate immunity 8.16–17
- natural killer (NK) cell lymphoma, transplacental transfer of maternal disease 116.14
- natural killer (NK) cell receptors 8.16–17
- natural killer/T-cell lymphoma, Epstein–Barr virus 25.33
- nausea, PUVA side effect 21.12
- Naxos disease **65.50**, 65.55–6
woolly hair 65.56, **68.6**, 68.20, 89.57
- NBCCS gene mutations 141.18
- Nd:YAG laser 23.6, 160.2
frequency-doubled 23.6
hair removal 23.15, 160.6
leg veins 23.10
melasma treatment 160.5–6
tattoo treatment 23.12
- Neapolitan nails 95.14
- near infrared lymphangiography **105.53**, 105.54
- Necator americanus* 33.15
- neck
ageing of skin 155.3
allergic contact dermatitis 128.16
botulinum toxin A injection 158.7
fiddler's 90.24, 123.11
folliculitis keloidalis 93.3–4
white fibrous papulosis 96.36–7
see also head and neck *entries*
- neck, head and face, swollen 105.14–17
- neurobiosis 3.37
atypical of the face and scalp margins 97.9–10
rheumatoid arthritis 154.6
scalp disorders **107.5**, 107.6
- neurobiosis lipoidica 97.8–11, 99.11–12
annular elastolytic giant cell granuloma differential diagnosis 96.27
clinical features 97.9–10
definition 97.8, 99.11–12
diabetes association 64.5, 97.8
differential diagnosis 97.9–10
discoid lupus erythematosus differential diagnosis 51.9
endocrine disorder skin signs **149.10**
epidemiology 97.8–9
investigations 97.10
management 97.10–11
neurobiotic xanthogranuloma differential diagnosis 99.17
pathophysiology 97.9, 99.12
rheumatoid nodule differential diagnosis 99.15, 99.16
sarcoidosis differential diagnosis 93.10, 98.8, 98.10, 98.13
scalp **107.5**, 107.6
subcutaneous granuloma annulare differential diagnosis 99.14
ulceration 97.10, 97.11
- neurobiotic granuloma
granuloma annulare 97.2, 97.9
palisading 97.2, 97.3
rheumatoid nodule differential diagnosis 99.16
- neurobiotic xanthogranuloma 97.10, 99.17–18, 136.21–2, 148.9–10
clinical features 99.17
differential diagnosis 99.17
investigations 99.17–18
malignancy association **147.22**
pathophysiology 99.17
plane xanthoma differential diagnosis 62.5
- necrolysis 3.37
- necrolytic acral erythema, HCV association 25.65, 152.5
- necrolytic migratory erythema 47.13–15, 47.16, 147.19
clinical features 47.14–15
definition 47.13
differential diagnosis 47.14
endocrine disorder skin signs **149.10**, 149.13
epidemiology 47.13
erythema multiforme differential diagnosis 47.5
genital 111.19
glucagonoma 145.19–20
glucagonoma syndrome 152.6
investigations 47.15
- metastatic disease 47.15
- nomenclature 47.13
- octreotide therapy **47.15**, 47.16
- pathophysiology 47.13–14
severity 47.15
treatment ladder **47.15**
variants 47.14
vulval lesions 112.42–3
- necrosis 3.37
injecting drug abuse 121.3
ischaemic following radiotherapy 24.19
- necrotizing cellulitis 26.74
- necrotizing fasciitis 26.13, 26.74, 116.25
Aeromonas 26.63
cellulitis differential diagnosis 26.20
erysipelas differential diagnosis 26.20
eyelids 109.41
gas gangrene differential diagnosis 26.48
human bites 131.6
injecting drug abuse 121.4
perineum/perianal region 113.11
pressure ulcer-induced 124.3
recurrent cellulitis differential diagnosis 105.12
toxic shock syndrome association 26.30
umbilical infection 116.25
vulval lesions 112.24
- necrotizing infundibular crystalline folliculitis 65.69
- necrotizing lymphocytic folliculitis of the scalp margin 93.4–5
- necrotizing sarcoïd
granulomatosis 151.5–6
- necrotizing sialometaplasia, oral ulceration 110.56
- necrotizing subcutaneous infections 26.73–5
clinical features 26.74
definition 26.73
differential diagnosis 26.74
epidemiology 26.73–4
investigations 26.74
management 26.74–5
pathophysiology 26.74
variants 26.74
- nectinopathies 2.19
- nectins 2.19
- needlestick injuries, surgical 20.8
- negative-pressure wound therapy (NPWT), pressure ulcers 124.8
- Neisseria gonorrhoeae* 30.3
inflammatory arthritis 154.4
- Neisseria meningitidis* 26.48–9, **26.50**
inflammatory arthritis 154.4
serotypes 26.49
- Nékan disease 37.11, 37.18
- nelfinavir, drug eruptions 31.18
- Nelson syndrome 88.18, 88.19
oral hyperpigmentation 110.66
- nematocysts 131.1, 131.2
- nematode infections 33.1–23, 33.24
human nematodes 33.1–17
nematodes of other animals 33.17–23, 33.24
see also named nematode species and conditions
- neoangiogenesis 103.1
- neomycin, topical 18.11, 128.29
- neonatal cephalic pustulosis 90.61, 116.27
differential diagnosis 90.62
- neonatal ichthyosis–sclerosing cholangitis (NISCH) **65.35**, 65.36
- neonatal lupus erythematosus 51.37–9, 115.5, **115.6**, 116.12–13
annular erythema of infancy differential diagnosis 47.7
cardiac involvement 150.4
clinical features 51.37–8
complications/co-morbidities 51.38
definition 51.37
differential diagnosis 51.38
disease course 51.38
epidemiology 51.37
investigations 51.38
- management 51.38–9
pathophysiology 51.37
pregnancy 51.39
prognosis 51.38
- neonatal necrotizing enterocolitis 8.47
- neonatal onset multisystem inflammatory disease (NOMID) *see* CINCA (chronic infantile neurological, cutaneous and articular) syndrome
- neonatal pemphigus 50.5
- neonatal progeroid syndrome 72.26
- neonates 116.1–27
acne 90.59, 90.61
adnexal polyp 116.18
alveolar ridge lymphangioma 110.10
ankyloblepharon–ectodermal defect–cleft lip/palate syndrome 67.17
atrophic lesions 116.10–11
bacterial infections 116.23–7
barrier function of skin 116.1–2
failure in colodion baby 116.20
blistering disorder treatment 71.24–5
blueberry muffin baby 116.20, 148.5
bronze baby syndrome 88.49–50
bullous impetigo 116.23
candidiasis 116.27
congenital 116.27
cellulitis 116.25
circumcision 111.6–7
cold injury 116.14
subcutaneous fat necrosis of the newborn 116.15
cold panniculitis 99.33–4, 116.14
congenital candidosis 32.67
congenital erosive and vesicular dermatosis healing with reticulated supple scarring 116.8–9
congenital syphilis 116.26
evaluation 29.33–4
congenital tuberculosis 116.26–7
cryopyrin-associated periodic syndrome 45.4
dominant/recessive dystrophic bullous dermolysis **71.14**, 71.15–16
eccrine sweating 116.2
ecthyma gangrenosum 116.26
epidermal barrier 41.25
epidermolysis bullosa treatment 71.24–5
fetal varicella syndrome 116.22
fungal infections 116.27
gonococcal ophthalmia 30.3, 30.4
harlequin ichthyoses 65.7, 65.8
herpes simplex virus 25.22–3, 116.21–2
epidermolysis bullosa differential diagnosis 71.23
HIV infection 116.23
hypohidrotic ectodermal dysplasia 67.13
impetigo 26.15
infections 116.21–7
jaundice 116.10
keratitis–ichthyosis–deafness syndrome 65.31
listeriosis 26.45, 116.25–6
lupus erythematosus 115.5, **115.6**, 116.12–13
Malassezia pustulosis 116.27
Marfan syndrome 72.16
medallion-like dermal dendrocyte hamartoma 116.10–11
medical procedure complications 116.10
medical trauma hair loss 89.45
necrotizing fasciitis 116.25
Neu–Laxova syndrome 65.34
noma neonatorum 116.26
nomenclature 116.1
omphalitis 116.25
oral cavity 116.4
orbital cellulitis 116.25
pemphigus vulgaris 116.11
percutaneous absorption 116.2
postmature 116.4
prematurity complications 116.9
preorbital cellulitis 116.25

- primary herpetic gingivostomatitis 25.16
 progeria **79.2**
 purpura fulminans 116.21, 116.26
 pustular eruptions **116.7**
 pustulosis of transient myeloproliferative disorder 116.8
 raised linear bands of infancy 116.18
 rashes **116.10**
 scleredema neonatorum 99.57
 sebaceous glands 116.2–3
 Sjögren–Larsson syndrome 65.29–30
 skin appearance 116.3–4
 skin cleansers 116.2
 skin disorders 116.4–27
 skin function 116.1–3
 staphylococcal cold abscesses of the large folds 116.24–5
 staphylococcal scalded skin syndrome 26.28
 subcutaneous fat disorders 116.14–17
 toxic erythema of the newborn 116.4–5, 116.8
 toxic substance transfer in maternal milk 116.14
 transepidermal water loss 116.2
 transient pustular melanosis 116.7
 transplacental transfer of maternal autoantibodies 116.11–14
 of maternal malignant disease 116.14
 trichothiodystrophy 65.33
 umbilical bacterial flora 26.5
 viral infections 116.21–3
 vitamin K deficiency bleeding 63.12–13
see also collodion baby; preterm infants; sclerema neonatorum; staphylococcal scalded skin syndrome; subcutaneous fat necrosis of the newborn
- Neoscytalidium* 32.51–3
 diagnosis 32.9
Neoscytalidium dimidiatum 32.52–3
Neoscytalidium hyalinum 32.52, 32.53
 nephrogenic fibrosing dermatopathy diabetes association 64.7
 gadolinium radiocontrast agent association 153.5
 UVA-1 phototherapy 21.6
 nephrogenic systemic fibrosis 96.40–2, 153.4–5
 clinical features 96.41–2
 definition 96.40
 epidemiology 96.40–1
 investigations 96.42
 management 96.42
 pathophysiology 96.41
 systemic sclerosis differential diagnosis 56.15, **56.16**
- nephrotic syndrome secondary dyslipidaemia 62.11
 zinc deficiency 63.26
 nerve blocks 20.12
 facial 20.3–4
 nerve damage, surgical 20.2
 nervous system, systemic lupus erythematosus 51.29
 Néstor–Guillermo progeria, mandibuloacral dysplasia differential diagnosis 72.25
 Netherton syndrome 8.5, **68.6**, 68.21
 bamboo hair 89.53–4
 collodion baby 116.19
 epidemiology 146.2
 ichthyosis linearis circumflexa 89.53
 kallikrein role 8.42
 peeling skin syndrome differential diagnosis 65.27
 pili torti **68.6**
 differential diagnosis 68.20
 SPINK5 polymorphisms 8.21, 8.56
 trichorrhexis invaginata 89.53
 trichorrhexis nodosa 89.53
 trichothiodystrophy differential diagnosis 78.11
- Neu–Laxova syndrome 65.34
 collodion baby differential diagnosis 116.20
 restrictive dermatopathy differential diagnosis 72.20
 neural tube defects, folate deficiency 85.9
 neurilemmoma 137.46–8
 neurodegeneration, xeroderma pigmentosum 78.5–6
 neurodermatitis 86.13
 circumscribed 39.28–30
 neurodevelopmental disorders, self-injury 8.53
 neuroectoderm 2.3
 neuroendocrine markers 3.20
 neuroendocrine signalling 149.9
 complexity 149.7–8
 neuroendocrine stimuli 149.6–7
 neuroendocrine stress response systems 149.8
 neurofibromas 80.1
 cutaneous 80.3, 80.4
 diffuse 137.49
 hypertrichosis 89.62
 mast cells 80.2
 multiple 137.48
 NF1 80.1, 80.2, 80.3
 oral 110.26
 plexiform 80.3, 137.48–9
 sarcomatous change 80.4
 solitary 137.48
 vulval **112.30**
- neurofibromatosis 80.1–5, 80.6–7, 80.7–9
 carbon dioxide laser incisional surgery 23.18
 cutis laxa differential diagnosis 96.20
 freckles 88.16
 mechanical properties of skin 123.5
 segmental 80.5
 type 147.8
 neurofibromatosis type 1 (NF1) **74.8**, 80.1–5, 80.6–7, **80.9**, 147.8, 150.3
 clinical features 80.1, 80.2–4
 Dercum disease differential diagnosis 100.17
 diagnosis 80.4
 diagnostic criteria **80.3**
 diffuse neurofibroma 137.49
 disease course 80.4
 gene 80.1–2
 genetic counselling 80.5
 inheritance 147.8
 investigations 80.4
 with juvenile xanthogranuloma/juvenile chronic myeloid leukaemia 80.5
 Legius syndrome 80.8
 leukaemia association 148.12
 malignancy association 147.8
 malignant peripheral nerve sheath tumour 137.54
 management 80.4–5
 Manchester checklist 80.4–5, 80.6–7
 meningothehal heterotopias 137.52
 multiple neurofibromas 137.48
 naevoid basal cell carcinoma syndrome differential diagnosis 141.19
 oral lesions 110.26
 pathophysiology 80.2
 plexiform neurofibroma 137.48
 prognosis 80.4
 renal involvement 153.1
 respiratory disorder association 151.5
 uncombable hair syndrome 89.57
- neurofibromatosis type 2 (NF2) 80.1, 147.8
 meningiomas 147.8
 neurofibromatosis–Noonan syndrome 80.7–8
 neurofibromin 80.2
 metabolic bone defect in NF1 80.3
 neurofibrosarcoma 137.54
 neuro-ichthyotic syndromes 65.27–34
 palmoplantar keratodermas with neurological manifestations 65.64
 neurokinin 1 receptor (NK1R) 83.6
 cutaneous vasodilatation 106.1
- neurokinin A 85.2, 85.3
 neurolabyrinthitis, late congenital syphilis 29.32
 neuroleptics, hyperprolactinaemia induction 149.15
 neurological disease 85.1–4
 Adamantiades–Behçet disease 48.6, **48.10**
 bullous pemphigoid association 50.11
 burning feet syndrome 85.16–17
 complex regional pain syndrome 85.12–14
 DRESS syndrome association 119.6
 gustatory hyperhidrosis 85.15–16, 94.7–8
 hereditary sensory and autonomic neuropathies 85.10–12
 Horner syndrome 85.14–15
 oral manifestations **110.92**
 pigmentation 88.21
 pruritus 83.13
 restless leg syndrome 85.16–17
 retinoid-induced 19.39
 spinal cord injury-associated dermatoses 85.10
 spinal dysraphism 85.8–10, 113.4
 sympathetic nerve injury 85.12
 syringomyelia 85.7–8
 vitamin E deficiency 63.11
 xeroderma pigmentosum 78.5–6
- neuromas amputation stump 137.45
 epithelial sheath 137.53
 MEN type 2b 147.10
 Morton 137.45–6
 multiple mucosal 137.45
 solitary circumscribed 137.46
 neuromediators 8.49–53, 149.6
 neuromuscular blockers, anaphylactic reactions 118.7
 neuromuscular hamartoma 137.45
 neuromuscular tissues, glucocorticoid adverse effects **19.19**
 neuron-specific enolase 3.20
 neuropathic pain 8.50
 management 84.5
 neuropathic ulcer 85.4–7
 clinical features 85.5
 definition 85.4
 epidemiology 85.4
 healing 10.2
 investigations 85.5, 85.6
 management 85.6–7
 pathophysiology 85.4
 severity classification 85.5
- neuropeptide(s) 8.2, 85.2
 receptors 90.19
 stress role 8.50
 neuropeptide Y 85.3
 neurosarcoidosis 98.6
 neurosyphilis 29.17, 29.18
 asymptomatic 29.18
 gummatous 29.19
 late congenital syphilis 29.32
 meningeal 29.18–19
 tabetic 29.17, 29.19, 29.20
 neurothecoma 137.50
 cellular 137.50–1
 oral cavity 110.61
 neurotic excoriations, linear IgA disease differential diagnosis 50.36
 neurotransmitter-affecting peptides 156.4–5, **156.10**
- neutrophins, itching in skin disease 83.7
 neurovascular disorders 103.6–8
 neutral lipid storage disease with ichthyosis 65.32–3
 clinical features 65.32–3
 collodion baby 116.19
 management 65.33
 neutropenia periungual toe infections 95.37
 retinoid-induced 19.39
 neutrophil(s) 8.17–19
 activation by TNF 8.35
- adhesion 8.18
 defects 82.16
 chemotaxis defects 8.18
 deficiencies 8.18
 differentiation defects 82.15–16
 functional defects 8.18–19, 82.15
 high-power microscopy 3.31
 inflammatory disease role 8.18
 mediators 8.17–18
 pyoderma gangrenosum 49.2
 Sweet syndrome 49.8
 tissue damage 8.18
 wound healing 10.2, 10.3
 neutrophil lysosomal granules 8.17
 neutrophilia, glucocorticoid therapy effects 19.21
 neutrophilic dermatoses 49.1–17
 acute febrile 49.6
 inflammatory bowel disease association 152.2
 CCR1 role 8.39
 cutaneous vasculitis differential diagnosis 102.4
 of dorsal hands 49.9, 49.11, 148.6
 eccrine hidradenitis 120.1, 120.2
 malignancy association 147.23
 pathology 49.8, 49.13
 respiratory disorder association 151.5
 rheumatoid 154.7–8
see also bowel-associated dermatosis–arthritis syndrome; pyoderma gangrenosum; subcorneal pustular dermatosis; Sweet syndrome
- neutrophilic eccrine hidradenitis 94.13–14, 148.7
 drug-induced 148.7
 neutrophilic lobular panniculitis 99.48–50
 definition 99.48
 neutrophilic urticarial dermatosis 44.2, 45.4
 neutrophil–macrophage colony-forming unit (NM-CFU) 136.1
 neutrophil-specific granule deficiency 82.2
 nevirapine 31.11
 drug eruptions 31.18
 NF1 gene mutations 80.1–2, 80.4, 80.7, 80.8
 somatic mosaicism 80.5
 niacin deficiency 63.15–17, 88.24
 iron deficiency differential diagnosis 63.24
 niacinamide antioxidant activity 156.2
 erythema elevatum diutinum treatment 102.10
 nickel allergy 128.14, 128.19–21
 avoidance 128.20–1
 cheilitis 128.16
 chemistry 128.19
 clinical features 128.20
 clioquinol combination with topical corticosteroids 18.18
 contact dermatitis 128.63
 decline 128.2
 delayed-type hypersensitivity 8.60
 dietary intake 128.20
 ear piercing complications 108.7
 hand eczema 128.8, 128.20
 incidence 128.19
 occurrence 128.19
 patch tests 128.21, 128.67–8
 prevalence 128.19
 prognosis 128.21
 regulatory measures 128.76
 risk 128.11
 sensitivity 128.5
 capacity 128.10
 hand eczema predisposition 128.8
 systemically reactivated allergic contact dermatitis 128.59
 therapies 18.18, 128.21
 urticaria 42.8, 47.8
 nicorandil perianal ulceration 113.8, 113.9, 114.5
 ulceration around stomas 114.5–6, 114.7

- nicotinamide 18.36
acne therapy 90.48–9
- nicotinic acid 5.2
acquired ichthyoses 65.41
topical 18.36
- nicotinic acid esters 129.8
- nicotinic stomatitis 110.17
- nidogen 2.24–5
- Niemann–Pick cells, sphingolipidoses 81.7
- Niemann–Pick disease 81.6–7
- nifedipine
hand–arm vibration syndrome
treatment 123.25
Raynaud phenomenon treatment 125.9–10
- nifurtimox, trypanosomiasis
treatment 33.40
- night blindness 87.14
- Nijmegen breakage syndrome 82.11, 148.13
- Nikolsky sign 50.18, 119.15, 123.2, 123.3
pemphigus vulgaris 50.4–5
- nipple
eczema 138.42
erosive adenomatosis 138.22
hyperkeratosis 65.71
Paget disease 138.40–2
- nitric oxide (NO) 8.44, 8.45–6
complex formation 8.46
pathophysiology in skin 8.45
production regulation 8.45
topical therapy 18.36–7
- nitric oxide (NO) derivatives 8.2
- nitric oxide synthase (NOS) 8.44, 8.46
inducible 8.46
- nitrite 18.37
- nitritoid reaction, gold 122.4
- nitrofurantoin 31.34
- nitrogen mustard, topical 18.27–8, 140.23, 140.29
- nitrogen oxide, inhalation injury with
burns 126.4
- nivolumab 143.30
- Nocardia* 26.81–2, 32.73
- nocardiosis 26.81–2
- NOD (nucleotide-binding oligomerization-domain protein)-like receptors 8.2
- NOD (nucleotide-binding oligomerization-domain protein) proteins 8.15
- NOD2 gene mutations 45.7
- nodular fasciitis 96.40, 110.61, 137.4–5
- nodular fibrosis, subepidermal 137.19
- nodular granulomatous phlebitis 99.9
- nodular lymphangitis 105.51
- nodular vasculitis, tuberculous 27.31
- Noggin 2.4
- noma neonatorum 116.26
- NOMID (neonatal onset multisystem inflammatory disease) *see* CINCA (chronic infantile neurological, cutaneous and articular) syndrome
- non-ablative fractional resurfacing (NAFR) 160.8
- non-accidental injury 117.13, 117.14
chemical burns differential diagnosis 129.12
irritant contact dermatitis differential diagnosis 129.6
- non-adherence to treatment 11.6–7
psychological factors 11.4
- non-bullous ichthyosiform erythroderma 116.19
- non-dendritic cell disorders 136.1, 136.2, 136.9–11
- non-epidermolytic palmoplantar keratoderma 65.46–9
transient aquagenic keratoderma differential diagnosis 65.55
types 65.46
- non-esterified fatty acids (NEFA) 99.4
- non-Hodgkin lymphoma
acquired ichthyoses 65.40
cutaneous T-cell lymphoma association 140.5
erythroderma 39.32
- granulomatous slack skin disease association 140.18
- Kaposi sarcoma association 139.5
- necrobiotic xanthogranuloma association 136.22
- paraneoplastic pemphigus association 50.6
- pigmentation 88.20
skin cancer 146.3
skin involvement 148.4
systemic lupus erythematosus association 147.21
- Wiskott–Aldrich syndrome 147.13
- non-immune contact urticaria 129.8–9
- non-Langerhans cell histiocytoses 136.11–26
dendritic cell origin 136.12–20
non-dendritic cell origin 136.20–6
- non-mast cell haematological disorder, mastocytosis association 46.2, 46.3, 46.6, 46.10
- non-melanoma skin cancer (NMSC) 142.1
Bowen disease differential diagnosis 142.19
drug induced 154.15
economic burden 6.5–6
HIV infection 31.30–1
immunosuppressive drug-induced 146.3–4
inflammatory bowel disease 146.5
malignancy association 147.23
mortality 5.8
PUVA
lentiginos association 132.8
patient follow-up 21.15
side effect 21.13
treatment 31.31
UVB, patient follow-up 21.15–16
xeroderma pigmentosum 78.3
see also basal cell carcinoma (BCC); squamous cell carcinoma (SCC)
- non-nucleoside reverse transcriptase inhibitors (non-NRTIs) 31.9, 31.10
side effects 31.10
- nonsense read-through drugs, epidermolysis bullosa 71.30
- non-steroidal anti-inflammatory drugs (NSAIDs)
actinic keratosis treatment 142.8, 142.9
adverse drug reactions 154.14
eosinophilic pustular folliculitis treatment 93.8
exanthem induction 118.1, 118.2
fixed drug eruption 118.12
frostbite management 125.3
hypersensitivity reactions 12.2
photoallergic contact dermatitis 128.78
phototoxicity 127.28, 129.10
pseudoporphyria induction 60.19
psoriatic arthritis treatment 35.45
skin cancer protection 146.7
stabilization 46.9
Sweet syndrome treatment 49.12
urticarial eruptions 42.14, 42.16, 47.7, 118.7
urticarial vasculitis treatment 44.5
- non-syndromic autosomal dominant hypotrichoses 68.15–16
- non-syndromic autosomal recessive hypotrichoses 68.5, 68.16
- non-syphilitic spirochaetal ulcerative balanoposthitis 111.23
- non-tuberculous mycobacteria *see* mycobacterial infections, non-tuberculous
- Noonan syndrome 80.8, 80.9, 132.3, 150.3
chylous reflux 105.41
intestinal lymphangiectasia 105.42
lymphoedema 73.21
with multiple lentiginos 80.8, 80.9
with neurofibromatosis 80.7–8
oral lesions 110.25
swollen face, head and neck 105.15
woolly hair 68.20
see also LEOPARD syndrome
- Noonan with multiple lentiginos syndrome *see* LEOPARD syndrome
- noradrenergic and specific serotonergic antidepressants (NaSSAs) 86.36, 86.37
- norepinephrine 8.52
- normolipaemic xanthoma 148.9–10
- normophosphaemic familial tumoral calcinosis 81.19–20
- North American blastomycosis, anthrax differential diagnosis 26.44
- Norton scale for pressure ulcers 124.5
- nose, radiotherapy for skin cancer 24.10–11
- notalgia paraesthetica 88.31
pruritus 83.8, 83.13
- Notch signalling 2.45
melanocytes 2.18
- NOTCH1 and NOTCH2 mutations 142.26
- Nottingham Eczema Severity Score (NESS) 16.3
- NRAS gene mutations 75.2, 75.11
NRAS mutated melanoma 143.31–3
nuchal fibroma 137.12
- nuclear factor- κ B (NF κ B) 8.10
activation
by α -MSH 8.52
by TLRs 8.14
ectodermal dysplasias 67.7–8
- nuclear factor- κ B (NF κ B) essential modulator (NEMO) 67.7, 67.10, 70.11, 82.16
- nuclear factor- κ B (NF κ B) pathway-related primary immunodeficiencies 82.16
- nuclear hormone receptors 14.4, 14.5
- nucleic acid amplification tests, cutaneous tuberculosis 27.8–9
- nucleoside reverse transcriptase inhibitors (NRTIs) 31.9, 31.10
lipodystrophy 31.19–20
side effects 31.10
- nucleotide binding site and leucine-rich repeat (NBS-LRR) proteins 8.15
- nucleotide excision repair (NER) 9.5–6
Cockayne syndrome 78.7
xeroderma pigmentosum 78.2, 78.3, 78.4, 78.5, 78.6
- null hypothesis 17.20
- numb chin syndrome, malignancy association 147.23
- number needed to treat (NNT) 17.10–11, 17.14–15
- nutrition/nutritional deficiencies
angular cheilitis 110.80
burns and hypermetabolic response management 126.10
generalized severe recessive dystrophic epidermolysis bullosa 71.25–6
hair colour changes 89.71
hyperpigmentation 88.23–5
mineral deficiencies 63.23–31
pressure ulcers
prevention 124.5–6
treatment 124.6
see also malnutrition; protein–energy malnutrition; *vitamin entries*
- nympho-hymenal tears 112.40–1
- nystatin 18.12
candidosis treatment 18.12, 32.61
- O**
- oak moss 128.53
- obesity 100.25–6
abdominal wall lymphoedema 105.21
acanthosis nigricans association 87.3, 87.4
atopic eczema association 41.7
benign symmetrical lipomatosis differential diagnosis 100.15
chronically swollen leg 105.6, 105.8
cold panniculitis 99.34
Dercum disease 100.15, 100.26
endocrine disorder skin signs 149.13
endocrine dysregulation 100.25–6
epidemic 99.1, 99.3
genetic disorders 100.26
- hereditary 74.3–5, 74.6, 74.7, 74.8
- hidradenitis suppurativa association 92.2
- hyperlipidaemia-related skin disease 64.3
- immunological dysregulation 100.25–6
- Klinefelter syndrome 76.4
- lipoedema differential diagnosis 100.20, 100.21
- lymphoedema 105.19–20
massive localized 105.24
risk factor 105.19
- mechanical problems 100.25
- monogenic
with cutaneous features 74.3–6, 74.7
without cutaneous features 74.3–4
- physiological consequences 100.25
- Prader–Willi syndrome 74.6
- psoriasis association 35.21
- pyoderma gangrenosum association 49.2
- skin tags 111.5
striae 96.10
swollen breast 105.23, 105.24
vanishing penis syndrome 111.7
- Objective Severity Assessment of Atopic Dermatitis (OSAAD) score 16.3
- obsessive–compulsive disorder 86.10–20
acné excoriée 86.15–16
body dysmorphic disorder 86.10–13
health anxieties 86.20
lichen simplex chronicus 86.13, 86.14
nodular prurigo 86.13, 86.14
olfactory reference syndrome 86.8
onychophagia 86.19
onychotillomania 86.19
skin picking disorder 86.14–15
trichotillomania features 89.45–6
see also trichotillomania; trichotillois
- OCA2 gene mutations 70.6
- occipital horn syndrome 72.6, 72.12, 72.13, 79.7, 81.18–19
copper deficiency 2.36
- occludins 2.20, 8.56
- occupational disorders 1.8, 5.10, 130.1–15
acne 90.56–9
of chemical origin 130.10–12
acroosteolysis 95.47
acrylate allergy 128.50
actinic keratosis 142.2
alkali tests 130.5
allergens 128.5, 130.6, 130.7–10
allergic contact dermatitis 128.12, 128.76, 130.5–10
clinical features 130.6
definition 130.5
epidemiology 130.5
investigations 130.6–7
management 130.7–10
occupational irritant contact dermatitis differential diagnosis 130.3, 130.6
pathophysiology 130.5
arsenic toxicity 122.2
chemical burns 129.12
chemical depigmentation 88.45
chloracne 90.12
collier's stripes 88.53
contact dermatitis with arsenic toxicity 122.2
dermatitis potential measurement 130.5
dermatitis studies 128.5
diagnosis 4.4
dyspigmentation 130.12–13
causative chemicals 130.12
epidemiology 128.3
epoxy resin allergy 128.48–9
exposure period 130.3
fragrances 128.26
hairdressers 128.31
hand eczema 39.13, 130.2
hypothenar hammer syndrome 123.12
irritant contact dermatitis 129.2, 130.1–5
clinical features 130.3
definition 130.1
epidemiology 130.2

- investigations 130.3–4
 management 130.4–5
 occupational allergic contact dermatitis differential diagnosis 130.3, 130.6
 pathophysiology 130.2–3
 skin protection programme **129.8**
 leukoderma 130.12–13
 causative chemicals **130.12**
 mouth cancer 110.35
Mycobacterium kansasii infection 27.35
Mycobacterium marinum infection 27.34
 nickel allergy 128.20
 occupation types 130.2–3
 onycholysis 95.9
 palmar fascial fibromatosis 96.32
 patch tests 130.6–7
 perforating dermatosis 96.51
 prevention 130.3–4
 psoriasis 130.1, 130.2
 saltpetre disease 96.28
 scrotal carcinoma 111.31–2
 skin cancers 130.13–14
 skin prick test 130.6–7
 surveillance 128.5
 systemic lupus erythematosus 51.19
 systemic sclerosis 56.13, 96.42, 96.43
 transepidermal water loss measurement 130.5
 UVR exposure 9.13
 warts 25.46, 25.50
 wood allergy 128.54–5, **128.56–7**, 128.58
 workplace visits 130.3–4
see also hand–arm vibration syndrome
- ochronosis 88.51–2
 endogenous 88.51–2
 exogenous 88.51–2
 treatment 18.28, 88.52
 octopus stings 131.4
 octreotide therapy, necrolytic migratory erythema **47.15**, **47.16**
 2-*n*-octyl-4-isothiazolin-3-one 128.37
 ocular medications, causing dermatitis 128.15
 ocular rosacea 109.10, **109.11**
 oculocerebral syndrome with hypopigmentation 70.9
 oculocerebrocutaneous syndrome encephalocraniocutaneous lipomatosis differential diagnosis 100.19
 MIDAS syndrome differential diagnosis 67.25
 oculocutaneous albinism 70.6–8
 basal cell carcinoma **141.5**
 classification **70.2**, 70.6
 clinical features 70.6–7
 genetics 70.6
 Hermansky–Pudlak syndrome 82.14
 investigations 70.7–8
 management 70.8
 pathophysiology 70.6
 prenatal diagnosis 7.9
 variants 70.7
 oculocutaneous tyrosinaemia 65.63–4
 oculodentodigital dysplasia syndrome **68.7**, 68.17
 oculoectodermal syndrome 100.19
 oculomucocutaneous syndromes **110.31**
 odds ratio 5.13, 17.10, 17.17
 Odland bodies 2.6
 odonto-onychodermal dysplasia **65.58**, 65.61, 67.7
 oedema
 acute haemorrhagic in infancy 117.9–10
 ano-genital 111.35
 eyelids 105.15, 105.16
 head and neck in DRESS syndrome 119.8
 laryngeal 151.2
 lips 105.15, 105.16
 pharyngeal 151.2
 pregnancy 115.2
 swollen face, head and neck 105.14–17
 venous insufficiency 105.7
see also lymphatic(s), oedema
- oedematofibrosclerotic panniculopathy 100.23
 Oedemeridae 34.29
 oesophageal cancer, tylosis 65.59, 110.19, 147.7
 oesophageal dysmotility 51.29
 oesophageal sphincter, dermatomyositis 53.9, 53.10
 oesophagus disorders 152.1–4
 generalized severe recessive dystrophic epidermolysis bullosa 71.17, 71.25–6
 squamous cell carcinoma 152.1
 17-oestradiol 145.19
 Oestridae 34.10–11
 oestrogen
 ingestion and porphyria cutanea tarda risk 60.13
 menopausal ageing of skin 155.4
 papulopustular acne treatment 90.43
 pigmentation effects 88.7
 oestrogen-producing tumours 145.19
 oil beetles 34.29
 oil folliculitis 130.14
 oil hyperkeratosis 130.14
 oil in water systems 18.7
 oil shale, occupational skin cancers 130.14
 oil syndrome 90.58
 ointments 18.2, 18.9
 older people
 actinic keratoses 142.2
 adverse drug reactions 14.7
 age effects on drug therapeutic outcomes 14.7
 angiomas of the face/scalp 137.36
 asteatotic eczema 39.10
 atypical fibroxanthoma 137.22
 botulinum toxin A injection 158.8
 erosive pustular dermatitis of scalp 107.11
 lentigo maligna melanoma presentation 143.9–10, **143.11**
 Merkel cell carcinoma 145.2
 nails 95.46
 onychomycosis 95.46
 polypharmacy 14.7
 pruritus of senescence 83.13
 psoriasis 35.18
 skin disease prevalence 6.1
 systemic lupus erythematosus 51.30
 wound healing 10.2, 10.10
 olfactory reference syndrome 86.8–9
 olive oil 18.6
 Ollier disease 73.15
 Olmsted syndrome 65.61–3, 110.19
 perianal keratotic plaques 113.4
 omalizumab 19.34, **109.18–19**, 109.19, **109.23**
 atopic eczema treatment 41.12, 41.33
 recurrent angio-oedema without weals 43.5
 urticaria treatment 19.34, 42.18
 omega 3 fatty acids 156.4
 polymorphic light eruption management 127.8
 omega 6 fatty acids 156.4
 Omenn syndrome 82.7–8, **148.17**
 candidosis association 148.15
 eczematous lesions 41.9
 omphalitis 116.25
Onchocerca volvulus 33.1, 33.2, 61.1
 blindness 109.42
 life cycle 33.3
 onchocerciasis 33.1–6, 109.43
 atrophic scars 96.11
 causative organism 33.2, 109.43
 clinical features 33.2–5
 complications/co-morbidities 33.5
 definition 33.1
 differential diagnosis 33.5
 epidemiology 33.2
 genital 111.24
 HIV infection 31.28
 investigations 33.5–6
- leprosy differential diagnosis 28.12
 management 33.6, 109.43
 microfilariae 33.2
 nomenclature 33.1
 pathophysiology 33.2
 presentation 33.2–5
 prognosis 33.5
 treatment ladder **33.6**
 variants 33.5
 oncostatin M receptor (OSMR) gene 58.8
Onychocola canadensis 32.55
 onychocryptosis 95.19–21
 onychocytes 2.11
 onychodermal band 2.11
 onychodystrophy, chemotherapy-induced 120.7
 onychogryphosis 95.18–19, 95.20
 onycholysis 95.9–10
 allergic contact dermatitis 128.61
 chemotherapy-induced 120.7
 dermatophyte-induced onychomycosis differential diagnosis 32.49
 idiopathic 95.9
 lichen planus of nail bed 37.12
 psoriatic 95.9, 95.39–40
 secondary 95.9–10
 onychomadesis 95.8, 95.11
 onychomatricoma 95.28–30
 onychomycosis
 Candida 31.32, 32.61
 candidosis 32.67
 confocal microscopy 95.49
 dermatophyte-induced 32.47–9
 causative organisms 32.48
 clinical features 32.48–9
 differential diagnosis 32.49
 distal and lateral subungual 32.48
 endonyx 32.49
 epidemiology 32.48
 management 32.49
 mixed 32.49
 pathophysiology 32.48
 patterns **32.47**
 proximal subungual 32.49
 superficial 32.48
 totally dystrophic 32.49
 treatment ladder **32.49**
 differential diagnosis **95.44**
 Down syndrome 76.2
 HIV infection 31.26, 31.32
 non-dermatophyte moulds 32.53–6
 identification 32.53
 Onychocola canadensis 32.55
 superficial 32.55
 older people 95.46
 sample collection 32.7–8
 Scopulariopsis brevicaulis 32.54–5
 Trichophyton rubrum 31.32
 yellow-nail syndrome differential diagnosis 105.34
 onychopapilloma 95.16, 95.31
 onychophagia 86.19, 95.17–18
 onychoptosis defluvium 95.8
 onychoschizia 95.12
 onychotillomania 86.19, 95.17–18, 95.38
 O'Nyong–Nyong fever 25.76
 ophthalmia neonatorum 30.3, 30.4
 ophthalmic zoster 25.28–9
 HIV infection 31.23
 ophthalmoganglionic complex 33.39
 ophthalmomyiasis 34.12
 opioid(s)
 drug eruptions 118.3
 restless legs syndrome management 85.17
 opioid peptides, itching in skin disease 83.6
 optic nerve glioma, NF1-associated 80.3
 optic neuropathy, Menkes disease 63.27
 optical coherence tomography 95.48–9
 oral administration of drugs 14.2
 oral allergy syndrome 42.13, 110.61
 oral cavity 110.2
 allergic reactions 128.18
 anatomical variants 110.7
- biology 110.3–4
 cancer 110.32–9
 causative organisms 110.34
 erythroplasia 110.72
 investigations 110.37
 malignant transformation risk **110.35**, 110.36
 management 110.37–8
 oral submucous fibrosis predisposition 110.57
 risk factors **110.33**
 second cancer risk 110.34
 severity classification 110.36–7
 sites 110.36
 Compositae allergy 128.52
 erosions in reactive arthritis 154.2
 examination 110.4–7
 immunity 110.4
 infections **110.91–2**
 lumps 110.58–63
 neonates 116.4
 pigmented lesions 110.64–8, 143.13, 143.14
 red lesions 110.68–73
 Sjögren syndrome 55.7
 soreness without ulceration 110.63–4
 Stevens–Johnson syndrome 119.16, 119.17, 119.18
 management 119.20
 swellings 110.58–63
 systemic disease manifestations **110.89–92**
 tissue elasticity loss 110.56–8
 toxic epidermal necrolysis 119.16, 119.18
 management 119.20
 vascular proliferative lesions 110.72
 white lesions 110.73–8
 see also lips; mouth; teeth; tongue
- oral commissures 110.3
 oral contraceptives
 acne association 90.11
 antibiotics interactions 90.42
 hyperoestrogenism 145.19
 melasma 88.10
 papulopustular acne treatment 90.43
 systemic lupus erythematosus 51.30
 oral disease
 generalized severe recessive dystrophic epidermolysis bullosa 71.25
 scurvy 63.21
 oral dysaesthesia *see* burning mouth syndrome
 oral epithelium 110.3
 oral hair 110.21
 oral hairy leukoplakia 25.33
 oral hyperkeratosis syndrome 110.18
 oral hyperpigmentation, HIV infection 31.33
 oral hypoglycaemic drugs, allergic reactions 64.4
 oral leukokeratoses, plantar keratoderma 69.12
 oral mucosa
 biology 110.3
 junction with teeth 110.4
 oral mucosa disorders 110.7–9
 acquired 110.26–56
 Darier disease 66.3, 66.7
 eosinophilic ulcer 110.27
 genetic 110.9–26
 lumps 110.7–8, 110.9–11
 NF1 80.3
 orocutaneous syndromes 110.21–6
 pigmented lesions 110.8, 110.11–13
 psoriasis 35.14, 35.15, 110.78
 red lesions 110.8–9, 110.13–16
 swellings 110.7–8, 110.9–11
 vesiculoerosive 110.16–17
 viral infections 110.7, **110.8**
 white lesions 110.9, 110.17–20
see also aphthous stomatitis; oral ulcers
- oral submucous fibrosis 110.56–7
 oral ulcers 110.26–56
 aphthous in Behçet disease **48.7**
 deficiency glossitis 110.64

- oral ulcers (*continued*)
 eosinophilic ulcer of oral mucosa 110.27
 Felty syndrome 110.16
 gold therapy 122.3–4
 granulomatosis with polyangiitis 102.25
 herpetiform in arsenic toxicity 122.2
 HIV infection 31.33
 immune deficiency 110.17
 local aetiology 110.27–30
 management 110.27
 prognosis 110.27
 recurrent 110.27
 systemic disease association 110.39–56
see also aphthous stomatitis
- orbicularis muscle 110.3
 orbicularis oris muscle, botulinum toxin A injection 158.6, 158.7
 orbital cellulitis 116.25
 orf 25.9–11
 brucellosis differential diagnosis 26.59
 cowpox differential diagnosis 25.9
 external ear 108.15
 giant 25.10
 milker's nodule differential diagnosis 25.11
 monkeypox differential diagnosis 25.8
 paronychia 95.36
 vulval lesions 112.27
- organ transplantation
 actinic keratosis prevalence 142.2
 children 146.4
 ciclosporin use 19.11, 19.12
 HPV infection/warts in recipients 25.63
 Merkel cell carcinoma 145.2
 penile cancer complication 111.30
 post-transplant lymphoproliferative disorder 140.47–8
 radiotherapy for skin cancers 24.14
 skin cancer
 immunosuppressive drug therapy-induced 146.3–4, 146.9
 management 146.13
 pre-transplant 146.14–15
 screening/surveillance 146.17–18
 trichodysplasia spinulosa 87.14, 87.15
- organic mercurials 128.39
 organic solvents 96.42
Orientia tsutsugamushi 26.79
Ornithonyssus 34.52
 orocutaneous syndromes 110.21–6
 oro-facial and cutaneous herpes, recurrent 25.18–20
 oro-facial gangrene 116.26
 oro-facial granulomatosis 97.11, 97.12, 105.16, 105.17, 128.18
 aphthous ulceration 110.41–2
 dental material allergy 128.61
 granulomatous cheilitis differential diagnosis 110.86
 sarcoidosis differential diagnosis 98.2
 oro-facial-digital syndrome
 type 1 153.2
 orokeratosis striata lichenoides 37.11
 oro-pharyngeal cancer 110.32
 oro-pharynx
 dermatomyositis 53.9, 53.10
 HIV infection 31.29, 31.33–4
 Oropouche virus 25.72
 Oroya fever 26.62–3
 orthopaedic implants, metal 128.59
 Orthoptera 34.30
 osmidrosis 94.15–16
 osseous choristoma 110.61
 osseous neoplasms, radiography 95.48
 osteoarthritis 154.8
 psoriatic arthritis differential diagnosis 35.44
 osteoarthropathy, secondary
 hypertrophic 95.7, 147.17
 osteochondritis, congenital syphilis 29.30, 29.31
 osteogenesis imperfecta 72.9–11
 Ehlers–Danlos syndrome
 association 72.1
- Menkes disease differential diagnosis 63.28
 variants 72.10
 osteoid osteoma, radiography 95.48
 osteolyses, inherited 72.19
 osteoma cutis 90.36
 osteoma mucosae 110.61
 osteomalacia
 RAS gene mosaicism 75.7–8
 vitamin D deficiency differential diagnosis 63.10
 osteomyelitis
Acinetobacter 26.50
 chronic recurrent multifocal 45.8
 mycetoma differential diagnosis 32.75
 pressure ulcer-induced 124.3
 scarlet fever association 26.35
 syphilitic 29.30, 29.31
 osteopenia, vitamin D deficiency
 differential diagnosis 63.10
 osteoporosis
 generalized severe recessive
 dystrophic epidermolysis
 bullosa 71.26
 mastocytosis association 46.3, 46.10
 systemic lupus erythematosus 51.28
 vitamin D deficiency differential diagnosis 63.10
 otitis externa 108.15–19, 128.16
 acute 108.17
 diffuse 108.15, 108.19
 localized 108.15, 108.19
 bullous 108.18
 causative organisms 108.17
 chronic 108.16, 108.17–18, 108.19
 clinical features 108.17–19
 definition 108.15
 epidemiology 108.16–17
 granular 108.18
 hypertrophic 108.18
 investigations 108.19
 management 108.19
 necrotizing 108.16, 108.17, 108.19–21
 causative organisms 108.20
 chronic otitis externa differential diagnosis 108.18, 108.20
 clinical features 108.20–1
 definition 108.19
 differential diagnosis 108.18, 108.20
 epidemiology 108.20
 investigations 108.21
 management 108.21
 pathophysiology 108.20
 pathophysiology 108.17
 severity classification 108.18
 variants 108.18
 otomandibular syndrome 108.28
 otomycosis 32.17–18, 108.16, 108.21–2
 clinical features 108.22
 definition 108.21
 epidemiology 108.21–2
 management 108.22
 otophyma 91.8
 Oudtschoorn disease 65.66–7
 outer root sheath (ORS) 2.9
 ovarian tumours, hirsutism 89.65
 ovariectomy, hypo-oestrogenism 145.19
 overgrowth syndromes
 lymphatic malformations 105.35
see also CLOVES (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal/spinal anomalies) syndrome; Klippel–Trenaunay syndrome; Proteus syndrome
- overlap syndrome *see* mixed connective tissue disease
 oxalate embolus 101.16–17
 oxandrolone, burns treatment 126.10–11
 oxazolindiones 19.43
 oxidative stress 8.44, 9.5
 irradiated cells 120.14
 vitiligo 88.36
 oxybutynin, hyperhidrosis
 treatment 94.9
- oxyhaemoglobin 23.6
 oxymetazoline 91.13
- P**
P value 5.13
 P13 κ d deficiency 82.13
 p53 gene family 67.8
 DNA damage 9.8
 melanocytes 88.7
 sunburn cell formation regulation 9.6
 p63 transcription factor 2.3, 2.45
 ectodermal dysplasias 67.8–9
 pachydermatoglyphy 147.15–16
 pachydermia oralis *see* white sponge naevus
 pachydermodactyly 96.36
 knuckle pads differential diagnosis 96.35, 96.36
 pachydermoperiostosis 154.13–14
 cutis verticis gyrata differential diagnosis 107.9
 keloid association 96.47
 primary hypertrophic osteoarthropathy 72.31–2
 pachyonychia congenita 65.44–6, 67.3, 67.3, 69.1, 69.11–12
 blistering 71.24, 123.9
 classification 69.1
 clinical features 65.45, 69.1, 69.11–12, 110.19
 definition 65.44, 69.1
 and epidermolytic ichthyosis 71.23
 hidradenitis suppurativa
 association 92.2
 investigations 65.45
 keratin location 95.4
 management 65.45
 nomenclature 65.44
 oral lesions 110.19
 pathophysiology 65.44–5, 69.1
 resources 65.45–6
 steatocystoma multiplex association 134.4
 type 2 90.27
Paederus 34.29
 paediatric dermatology
 historical aspects 1.8
see also children
 Paget disease 147.6–7
 diagnosis 3.19–20
 extramammary 138.42–3, 147.6–7
 ano-genital 111.32–3
 ano-genital psoriasis differential diagnosis 111.9
 clinical features 138.42–3
 definition 138.42
 epidemiology 138.42
 management 138.43
 pathophysiology 138.42
 perianal 113.20
 photodynamic therapy 22.7
 vulval 112.36–7
 Langerhans cell histiocytosis differential diagnosis 136.6
 of the nipple 138.40–2, 147.6
 clinical features 138.41–2
 definition 138.40
 differential diagnosis 147.6
 epidemiology 138.40
 histopathological markers 147.6
 management 138.42
 pathophysiology 138.40–1
 pagetoid reticulosis 140.16–17
 Paget–Schrötter syndrome 105.13
 pain
 complex regional pain syndrome 85.12–14
 cryosurgery 20.43
 diagnosis 4.2–3
 erythromelalgia 103.7
 genital 111.35
 chronic pain syndrome 111.36
 high-intensity focused ultrasound 160.12
 inflammation 8.1–2
 necrotizing otitis externa 108.20
- perineal/perianal 113.32
 photodynamic therapy 22.13–14
 pressure ulcers 124.3
 PUVA side effect 21.12
 referred in external ear 108.28
 rest 103.4
 restless legs syndrome 85.17
 scalp dysaesthesia 107.14
 Stevens–Johnson syndrome 119.21
 sympathetically maintained 85.14
 toxic epidermal necrolysis 119.21
 varicella-zoster virus 31.23
 vulval 112.39–40
see also mucocutaneous pain syndromes; neuropathic pain
- painful hereditary callosities (PHC) 65.46
 painter's colic 122.4–5
 paints 18.2
 palate examination 110.7
 palisaded neutrophilic and granulomatous dermatitis (PNGD) 51.30
 palladium 128.16, 128.23
 palliative care, pressure ulcers 124.8
 Pallister–Killian syndrome 75.14
 palmar erythema 147.24, 152.9
 endocrine disorder skin signs 149.10
 palmar fascial fibromatosis
 camptodactyly differential diagnosis 96.38
 investigations 96.32
 keloid association 96.47
 management 96.32, 96.33
 palmar fibromatosis 137.13
 fascial 96.31–3
 epidemiology 96.31–2
 pathophysiology 96.32
 palmoplantar erythrodysesthesia 120.1, 120.2
 palmoplantar hyperkeratosis
 autosomal dominant 110.19
 focal 110.18
 palmoplantar hypokeratosis, circumscribed 65.70–1
 palmoplantar keratodermas (PPKs) 65.2, 65.20, 65.42–64, 71.24
 acquired 65.42, 65.64–6
 cancer 65.58–60
 and cardiomyopathy 65.55–6
 clinical pattern 65.42–3
 Cole disease 65.54
 definition 65.42–3
 diagnosis 65.43
 in ectodermal dysplasia 65.61–3
 epidermolytic 65.43–4, 96.34
 focal 65.49–51, 147.7
 hearing impairment 65.56–8
 hyperhidrosis 94.5
 Mal de Meleda 65.46, 65.47–9
 management 65.51
 marginal papular keratoderma 65.53–4
 mitochondrial with hearing impairment 65.57–8
 morphology 65.43
 mtDNA mutation 81.10
 neurological manifestations 65.64
 non-epidermolytic 65.46–9
 transient aquagenic keratoderma differential diagnosis 65.55
 types 65.46
 non-syndromic 65.42, 65.43–55
 ophthalmic manifestations 65.63–4
 painful hereditary callosities 65.46
 plantar 69.1, 69.11
 punctate 65.51–2
 with/without ectopic calcification 65.54
 sex reversal and cancer 65.59–60
 spiny keratoderma 65.52–3
 spiny palmoplantar keratosis 65.70
 striate 65.49–51
 clinical features 65.50–1
 definition 65.50
 investigations 65.51
 pathophysiology 65.50
 syndromic 65.42, 65.55–64

- transient aquagenic keratoderma 65.54–5
- woolly hair association 65.55–6
see also pachyonychia congenita
- palmoplantar psoriasis, smoking association 5.2–3
- palmoplantar pustulosis 35.37–40
- acrodermatitis continua of Hallopeau association 35.41
- clinical features 35.38–40
- definition 35.37
- differential diagnosis 35.39
- disease course 35.40
- epidemiology 35.37–8
- investigations 35.40
- management 35.40
- pathophysiology 35.38
- prognosis 35.40
- reactive arthritis 154.2
- severity classification 35.39
- variants 35.38–9
- palmoplantar venous malformation 73.13
- pamidronate 99.55
- panatrophy of skin 96.7, 96.17
- pancreatic disease 152.5–6
- adenocarcinoma 152.6
- DRESS involvement 119.9
- pancreatic neuroendocrine tumours
- MEN1 association 147.10
- necrolytic migratory erythema 47.13
- TNM staging classification 47.15
- pancreatic panniculitis 99.8, 99.38–41
- associated disorders 99.40
- clinical features 99.39–40
- differential diagnosis 99.40
- epidemiology 99.38
- investigations 99.40–1
- management 99.41
- pathophysiology 99.39
- pancreatitis
- acute 152.6
- systemic lupus erythematosus 51.29
- pangeria *see* Werner syndrome
- pannexins 2.19
- panniculitis 51.9, 99.6–8
- α_1 -antitrypsin deficiency 99.8
- biopsy 3.2
- calcification of muscle/deep tissue 99.38
- chemotherapy-induced 99.46
- classification 99.7–8
- cold 99.33–5, 116.14, 125.4
- cosmetic fillers 99.48
- cytophagic histiocytic 99.58–9
- definition 99.6
- Dercum disease differential diagnosis 100.17
- dermatomyositis-associated 53.8, 99.36, 99.38
- factitious 99.45–8
- causative organisms 99.46
- clinical features 99.46–7
- definition 99.45–6
- investigations 99.47–8
- management 99.48
- pathophysiology 99.46
- fungal 99.58
- gouty 99.57–8
- hereditary 74.9
- HIV infection 31.20
- infectious 99.43–5
- causative organisms 99.43–4
- investigations 99.44–5
- pancreatic panniculitis differential diagnosis 99.40
- pathophysiology 99.43–4
- injecting drug abuse 99.47
- leukaemia cutis differential diagnosis 140.49
- lipotrophic of the ankles in childhood 99.52–3
- lobular 99.6, 99.7, 99.33
- pancreatic panniculitis differential diagnosis 99.40
- localized lipodystrophy secondary to 100.11
- lupus 99.35–8, 140.31
- calcifying 51.12
- hemifacial 96.18
- sclerosing post-irradiation panniculitis differential diagnosis 99.60
- subacute cutaneous lupus erythematosus association 51.12
- malignancy association 147.21
- neutrophilic lobular 99.48–50
- pancreatic 99.8, 99.38–41
- pancreatic disease association 152.6
- pentazocine 99.47
- post-irradiation 120.14
- poststeroid 99.35, 99.55–6
- clinical features 99.55
- investigations 99.55–6
- management 99.56
- povidone 99.47
- sclerosing postirradiation 99.59–61
- septal 99.6, 99.7
- suppurative 99.46–7
- traumatic 99.51–2
- variants 99.8
- see also* α_1 -antitrypsin deficiency
- panniculitis; erythema nodosum; lupus erythematosus, profundus; *named disorders and conditions*; sclerosing panniculitis; subcutaneous panniculitis-like T-cell lymphoma
- panniculopathy, oedematofibrosclerotic 100.23
- panthenol 156.2
- Panton–Valentine leukocidin (PVL) 26.8, 26.9
- ano-genital *Staphylococcus aureus* infection 112.23
- folliculitis 113.9
- necrotic skin lesions 26.6
- furuncle 26.24, 26.25
- PAPA (pyogenic sterile arthritis, pyoderma gangrenosum and acne) syndrome 90.9
- acne conglobata association 90.54
- acne fulminans association 90.50–1
- papillary haemangioma 137.26
- papillary hidradenoma 112.31, 138.21–2
- papillary hyperplasia 110.61
- papillary intralymphatic angioendothelioma 137.34–5
- papillary tip microabscesses 3.38
- papilloma 3.37
- oral 110.61
- papillomatosis 3.37
- florid cutaneous 147.16
- florid oral 110.38
- vestibular 112.3–4
- see also* confluent and reticulated papillomatosis
- papillomatous dermatitis, chronic 114.13, 114.112
- management 114.113
- Papillon–Léfevre syndrome 65.58, 65.61, 65.62
- neutrophil differentiation defects 82.16
- papular and nodular mucinosis in connective tissue diseases 59.13–14
- papular elastorrhesis 96.30
- pseudoxanthoma elasticum differential diagnosis 72.30
- papular epidermal naevus with ‘skyline’ basal cell layer (PENS) syndrome 75.4–5
- naevi 75.7
- papular facial rashes 90.31–2
- papular mucinosis 59.2–6
- of infancy 59.7
- malignancy association 147.22
- see also* lichen myxoedematosus
- papular pruritic eruption of HIV 116.23
- papular syphilide 29.10, 29.11, 29.12–13
- papular xanthoma 136.15–16
- papular-pruritic gloves and socks syndrome 25.37, 25.66, 25.87
- parvovirus infection 25.87, 31.25
- papules, orf 25.10
- papuloerythema of Ofuji, erythroderma 39.33–4
- papulopustular reactions, chemotherapy-induced 120.3–4
- parabens 18.8, 128.37
- contact allergy 118.4
- Paracoccidioides brasiliensis* 32.89, 32.90
- paracoccidioidomycosis 32.89–90
- clinical features 32.89–90
- genital 111.24
- investigations 32.90
- management 32.90
- pathophysiology 32.89
- paradise nuts 122.6
- paraffinoma 99.47, 123.20
- paragonimiasis 33.24, 33.28, 33.29
- Paragonimus* 33.28
- parakeratosis 3.38
- actinic keratosis 142.2, 142.3
- Bowen disease 142.17
- parakeratosis pustulosa 117.4
- acrodermatitis continua of Hallopeau differential diagnosis 35.42
- psoriasis 95.41
- paraneoplastic hypertrichosis lanuginosa acquisita 147.17
- paraneoplastic pemphigus 2.19
- lichen planus association 37.13
- oral lesions 110.47
- respiratory disorder association 151.6–7
- paraneoplastic skin conditions 147.14–18, 148.6–10
- paraphenylenediamine (PPD) 89.73
- paraphimosis 111.3
- incomplete 111.14
- paraproteinaemia 110.61
- parapsoriasis 135.6–8
- chronic superficial scaly dermatitis 39.26–7
- large plaque 135.6, 135.7–8
- pityriasis lichenoides association 135.3
- small plaque 135.6–7
- parasitic diseases
- cestodes 33.29–33
- IgE in protective immunity 8.54–5
- nematodes 33.1–23, 33.24
- ocular 109.42–3
- protozoa 33.33–52
- topical therapy 18.13
- trematodes 33.24–8, 33.29
- parasitophobia 86.4, 95.18
- parathyroid hormone (PTH) 145.21–2
- paratoluenediamine (PTD) 89.73
- parechovirus 25.79, 25.80, 25.83
- parenteral administration of drugs 14.2
- Parents’ Index of Quality of Life in Atopic Dermatitis (PIQoL-AD) 16.6
- Parkes Weber syndrome 73.3, 73.4, 103.20, 103.25–7
- capillary malformations 73.5–6
- clinical features 103.27
- definition 103.25–7
- epidemiology 103.26
- investigations 103.27
- Klippel–Trenaunay syndrome differential diagnosis 103.25, 103.27
- management 103.27
- pathophysiology 103.26–7
- Proteus syndrome differential diagnosis 103.27
- Parkinson disease
- hyperhidrosis 94.5
- seborrhoeic dermatitis 107.1
- paronychia
- acute 95.35
- psoriasis 95.41
- surgery 95.58
- candidosis 32.66–7, 32.69
- chronic 95.36–7
- differential diagnosis 95.44
- surgery 95.58, 95.59
- dermatophyte-induced onychomycosis differential diagnosis 32.49
- drug-induced 95.36, 95.38
- erythema multiforme 95.36
- great toe of infants 95.36
- herpetic 95.35–6
- orf 95.36
- selenium toxicity 122.6
- subacute, psoriasis 95.41
- syphilitic 29.10, 29.13, 29.28
- see also* herpetic whitlow
- parotid duct 110.6
- parotid glands 110.6
- injury and gustatory sweating 94.7, 94.8
- sarcoidosis 98.6
- paroxysmal finger haematoma 96.16–17, 101.6
- Parry–Romberg syndrome 57.18, 96.17–18
- partners, skin disease impact measurement 16.7
- parvovirus infection 25.66–7
- arthritis 154.2
- fifth disease 117.6
- HIV infection 31.25
- papular-pruritic gloves and socks syndrome 25.87, 31.25
- systemic sclerosis 56.11
- PASH (pyoderma gangrenosum, acne conglobata and suppurative hidradenitis) syndrome 90.54
- Pasint syndrome 96.40
- PASS (pyoderma gangrenosum, acne conglobata, suppurative hidradenitis and seronegative spondyloarthritis) syndrome 90.54
- pastes 18.2
- Pasteurella multocida* 26.57, 131.5
- patatin-like phospholipase 65.10
- patch testing 4.23, 128.1, 128.64–73
- active sensitization 128.72
- allergen storage 128.66
- aluminium 128.24
- baseline series 128.69–70
- children 128.6
- chromium 128.23
- cobalt allergy 128.22
- complications 128.71–2
- compound allergy 128.69
- concentration 128.65–6, 128.71
- cosmetics 128.32
- cross-reactions 128.73
- diagnosis 128.2
- dose 128.66
- eczema 39.5–6
- exposure time 128.66
- false negative reactions 128.68–9
- false positive reactions 128.67–8
- fragrances 128.26–7
- gold 128.24
- hair dyes 128.42
- hand eczema 39.17
- indications 128.64
- interpretation 128.67–8
- marking of test site 128.66
- mercury 128.24
- methods 128.64–6
- multiple positive reactions 128.72–3
- multiple primary hypersensitivities 128.72–3
- nail varnish 95.61
- nickel allergy 128.21
- non-invasive measurement techniques 128.68
- non-specific hyperreactivity 128.72
- occupational disorders 130.6–7
- photoallergic contact dermatitis 128.79–80
- photosensitivity diseases 127.34–5
- plant allergens 128.53–4
- population studies 128.4
- quenching 128.69
- readings 128.67–8
- recording 128.67
- relevance 128.68
- sensitivity 128.72
- sources of error 128.68–9
- test materials 128.64–5
- test site 128.66
- test substance selection 128.69–71
- topic medicaments 128.29, 128.31
- vehicles 128.65, 128.71

- patched* gene (*PTCH*) mutations 67.7
 Paterson–Brown–Kelly syndrome 152.1
 pathology 123.2
 bowel-associated dermatitis–arthritis syndrome 49.13
 Sweet syndrome 49.8
 pathogen-associated molecular patterns (PAMPs) 8.2
 pathogenesis-related protein 10 (PR10) 42.13
 pathogens
 innate lymphoid cell role in response 8.26
 macrophage role in killing 8.23
 patient(s)
 beliefs about skin conditions 11.7, 11.7
 education 15.3
 empowerment 15.3–4
 Patient Benefit Index (PBI) 16.3
 patient education, systemic therapy 19.2
 Patient Generated Index 16.6
 Patient-Oriented Eczema Measure (POEM) 16.3
 Pautrier microabscesses 3.38
 P-cadherin 2.4
 mutations 2.19
 PECAM-1 8.12
 PEComa 137.63–4
 pedal papules of infancy 117.14
 pediculosis pubis 26.41
Pediculus capitis 34.18–20
Pediculus corporis 34.21
Pediculus humanus 34.16–17, 88.24
 peeling skin syndromes 65.26–7
 acral 65.27
 type A 65.26
 type B 65.26–7
 pellagra 63.16–17, 88.24
 acanthosis nigricans differential diagnosis 87.5
 epidemiology 5.2
 pelvic inflammatory disease (PID)
 Chlamydia infection 30.11–12, 30.15
 gonococcal 30.4, 30.7, 30.7
 PELVIS syndrome 111.7
 pembrolizumab 143.30, 143.31
 pemphigoid
 anti-105 kDa antigen 50.52
 anti-type IV collagen 50.51
 dermatitis herpetiformis differential diagnosis 50.53
 erythema multiforme differential diagnosis 47.6
 HSV infection 25.16
 mycophenolate mofetil therapy 19.25
 ocular 50.28
 oral 50.28, 110.7, 110.8, 110.45
 pemphigus vulgaris differential diagnosis 50.7
 stoma complication 114.6
 very rare disorders 50.49–52
 vulvar 50.28
 see also anti-p200 pemphigoid;
 Brunsting–Perry pemphigoid;
 bullous pemphigoid; bullous systemic lupus erythematosus;
 cicatricial pemphigoid;
 epidermolysis bullosa, acquisita;
 lichen planus, pemphigoides; linear IgA disease; mucous membrane pemphigoid
 pemphigoid gestationis 115.13–14
 autoantibody specificity 50.10
 clinical features 115.13–14
 clinical signs 50.10
 epidermolysis bullosa differential diagnosis 71.23
 immunopathology 3.18
 investigations 115.14–15
 management 115.15
 pathophysiology 115.13
 pruritus 83.12
 treatment ladder 115.15
 pemphigoid vegetans 110.46
 pemphigus 50.1–9, 110.31
 acantholysis 50.3
 acetylcholine receptor antibodies 50.3
 antibodies 50.3
 apoptolysis 50.3
 bullous pemphigoid differential diagnosis 50.21
 clinical features 50.2, 50.4–7
 cytodiagnosis 3.25–6
 desmoglein compensation hypothesis 50.2
 diagnosis 123.3
 differential diagnosis 50.7
 disease course 50.7
 drug-induced 50.4
 environmental factors 50.4
 epidemiology 50.1
 epidermolysis bullosa differential diagnosis 71.23
 familial benign chronic 24.6
 genetics 50.3–4
 genital 111.19
 HSV infection 25.16
 IgA 50.7, 110.47–8
 pemphigus vulgaris differential diagnosis 50.7
 subcorneal pustular dermatitis differential diagnosis 49.15
 immunofluorescence studies 3.18
 immunostaining 110.46
 investigations 50.7–8
 lichen planus association 37.13
 malignancy association 147.22
 management 50.8–9
 mycophenolate mofetil therapy 19.25
 radiotherapy 24.6
 neonatal 50.5
 oral mucosa 110.7, 110.8, 110.46–8
 paraneoplastic 2.19, 50.3, 50.6, 147.21, 148.8
 clinical features 50.2
 differential diagnosis 50.7
 immunopathology/immunogenetics 50.2
 lichen planus association 37.13
 mucous membrane pemphigoid differential diagnosis 50.29
 oral lesions 110.47
 pemphigus vulgaris differential diagnosis 50.7
 respiratory disorder association 151.6–7
 pathophysiology 50.2–4
 prognosis 50.7
 radiotherapy 24.6
 severity classification 50.7
 skin picking disorder differential diagnosis 86.15
 subtypes 5.4
 target antigens 50.2
 variants 50.6–7
 pemphigus erythematosus 50.6, 50.7, 51.26
 seborrhoeic dermatitis differential diagnosis 40.4
 pemphigus foliaceus 50.5–6
 clinical features 50.2
 differential diagnosis 50.7
 endemic
 clinical features 50.2
 immunopathology/immunogenetics 50.2
 erythroderma 39.33
 immunopathology/immunogenetics 50.2
 pregnancy 115.5–6
 seborrhoeic dermatitis differential diagnosis 40.4
 subcorneal pustular dermatitis differential diagnosis 49.15
 vegetative 113.6
 pemphigus gestationis, transplacental 116.11
 pemphigus herpetiformis 50.6
 pemphigus syphiliticus 29.28, 29.30
 pemphigus vegetans 50.6
 clinical features 50.2
 Hallopeau type 50.6
 heroin abuse 121.3
 immunopathology/immunogenetics 50.2
 Neumann type 50.6
 oral lesions 110.47
 pemphigus vulgaris differential diagnosis 50.7
 pemphigus vulgaris 50.4–5
 clinical features 50.2
 differential diagnosis 50.7
 fixed drug eruption differential diagnosis 118.12
 immunopathology/immunogenetics 50.2
 mucous membrane pemphigoid differential diagnosis 50.29
 neonatal 116.11
 oral lesions 110.46–7
 pregnancy 115.5–6
 vulval, clinical features 112.19
 penciclovir 18.13
 penetration enhancers
 agents 18.3
 topical drug delivery 18.6, 18.7–8
 penicillamine
 cutaneous sclerosis induction 96.43
 pemphigus association 50.4
 penicillin 19.42
 drug-induced serum sickness-like reaction 118.8, 118.9
 eczema induction 118.4
 exanthem induction 118.1
 reactions to 29.26
 recurrent cellulitis management 105.12
 syphilis treatment 29.25
 congenital disease 29.34, 29.35
 penicilliosis 31.27, 31.28
Penicillium marneffeii see *Talaromyces marneffeii*
 penile carcinoma 111.29–31
 classification 111.30
 clinical features 111.30, 111.31
 epidemiology 111.29
 investigations 111.31
 management 111.31
 pathology 111.30
 pathophysiology 111.29–30
 prognosis 111.31
 risk factors 111.29, 111.30
 verrucous 111.32
 penile fibromatosis 96.33–4, 137.13–14
 penile haematoma 111.7
 penile horn 111.29
 penile intraepithelial neoplasia (PIN) 111.28, 142.25
 penile lymphoedema 111.20
 chronic 111.21–2
 penile melanoma 111.33
 penile necrosis 111.4, 111.18, 111.19
 penile pearly papules 111.5
 genital wart differential diagnosis 111.25
 penile thrombophlebitis 111.8
 penile ulceration
 herpes genitalis 25.20, 25.21
 pyoderma gangrenosum differential diagnosis 111.8
 tuberculosis 111.23
 penis 111.4, 111.5
 acne 111.19
 amyloidosis 111.20
 aphthous ulcers 111.17
 benign tumours 111.26–7
 biopsy 111.4
 bite injuries 111.9, 111.26
 Bowen disease 111.27–8
 bowenoid papulosis 111.27–8
 carcinoma *in situ* 111.27–8
 chronic oedema 111.21–2
 colloid degeneration 111.27
 drug eruptions 111.19
 embryology 111.5
 foreign bodies 111.8
 giant condyloma 111.32
 hair sinus 123.23
 heterotopic sebaceous glands 93.11, 111.5
 hypoplasia 111.7
 Kaposi sarcoma 111.33
 lichen nitidus 111.16
 lichen sclerosis 111.13
 lipogranuloma 111.8
 lymphoedema 105.17–19
 melanosis 111.34
 metastases 111.34
 mutilation 111.8
 pilonidal sinus 111.19
 plastic surgery complications 111.35
 psoriasis 35.12
 Raynaud phenomenon 111.19
 rupture 111.7
 sclerosing lymphangitis 105.51, 111.8
 squamous cell carcinoma 111.29–31
 lichen sclerosis complication 111.15
 strangulation 111.8
 tinea 111.23–4
 trauma 111.7–9
 tuberculosis 111.23
 variants 111.5–6
 penodynia 84.8–9
 peno-scrotal swelling 111.21–2
 PENS (papular epidermal naevus with ‘skyline’ basal cell layer) syndrome 75.4–5
 naevi 75.7
 pentamidine
 drug eruptions 31.17, 31.18
 trypanosomiasis treatment 33.40
 Pentatomidae 34.28
 pentazocine 96.43
 panniculitis 99.47
 ulcers 123.20
 pentoxifylline 127.13
 peptide histidine methionine (PHM) 85.3
 peptide hormones 149.2, 149.4
 peptides 156.10
 antiageing products 156.4–5
 peptidoglycans 26.5
 perchlorethylene 96.42
 perennial allergic conjunctivitis 109.15, 109.16, 109.17, 109.19, 109.23
 perforating dermatoses 96.49–53
 acquired 96.49–51
 definition 96.49
 epidemiology 96.50
 pathophysiology 96.50–1
 clinical features 96.50–1
 definition 96.49
 exogenous agent-induced 96.51
 management 96.51
 variants 96.50–1
 perforating disorders, renal failure 153.3–4
 perforating folliculitis 96.49
 perforating vein insufficiency 103.36
 perforin 3.24, 8.31, 136.10
 perfumes 128.25–7
 avoidance 128.26
 oak moss ingredients 128.53
 photoallergic contact dermatitis 128.78
 perianal abscess 113.25–6
 fistula formation 113.26
 pilonidal sinus differential diagnosis 113.24
 perianal candidosis 32.65
 perianal cellulitis, anal abscess differential diagnosis 113.26
 perianal dermatitis, infants 117.8
 perianal disease
 herpes simplex virus in HIV 31.22
 irritant contact dermatitis 129.5
 perianal fistula 113.26–8
 Crohn disease 113.25
 pilonidal sinus differential diagnosis 113.24
 perianal haematoma 113.31
 perianal itching 83.14, 113.4–6
 perianal keratotic plaques 113.4
 perianal metastases, haemorrhoids differential diagnosis 113.31

- perianal region
 bacterial infections 113.9–11
 drug reactions 113.8, 113.9
 extramammary Paget disease 147.7
 infections 113.9–17
 inflammatory dermatoses 113.6–8
 malignancy 113.17–20
 sexually transmitted diseases 113.12–17
- perianal skin tags 113.30–1
- perianal streptococcal cellulitis 26.33–4
- perianal ulceration 113.8, 113.9
 Crohn disease differential diagnosis 113.25
- periarteritis nodosa, oral lesions 110.55
- periauricular cysts/sinuses 117.12
- periauricular pits/sinuses/tags 108.5
- peribuccal pigmentation of Brocq 88.15
- pericytes, high-power microscopy 3.32
- periderm 2.3
- perifollicular fibroma 138.15–16
- perifolliculitis, dermatophytosis 32.22
- perineal candidosis of infancy 32.66
- perineal fistulae 113.4
- perineal groove 113.4
- perineum 113.8, 113.9
 anatomy 113.2
 bacterial flora 26.5
 bacterial infections 113.9–11
 drug reactions 113.8, 113.9
 examination 113.1
 history taking 113.1
 infections 113.9–17
 necrotizing soft tissue 113.11
 inflammatory dermatoses 113.6–8
 investigations 113.1
 recurrent toxin-mediated erythema 26.32
 sexually transmitted diseases 113.12–17
- perineuroma 137.49–50
- periocular dermatitis 18.17
- periodic acid–Schiff (PAS) stain 3.7–8, 3.10
- periodontal disease, HIV infection 31.33
- perionychial disorders 95.35–8
- perioral dermatitis 90.29, 91.17–18
 corticosteroid-induced development/exacerbation 18.17
- papulopustular rosacea differential diagnosis 91.11
- perioral region
 allergic contact dermatitis 128.15–16
 examination 110.4–7
- perioral ulceration, herpes simplex virus 31.22
- periorbital dermatitis 41.29
- periorbital oedema, eyelids 109.5–6
- periorbital syringomas, carbon dioxide laser ablation 23.18
- periostin, wound healing 10.6
- periostritis, congenital syphilis 29.31–2, 29.33
- peripheral artery disease 103.2, 103.3, 103.4
 arterial leg ulceration 104.8, 104.9, 104.10
 hyperlipoproteinaemia type III 62.8
 mixed leg ulcers 104.5, 104.7–8
- peripheral ischaemic disorders 103.2, 103.3, 103.4
- peripheral nerve sheath tumour, malignant 137.54
- peripheral neuroectodermal tumours 137.45–55
- peripheral neuropathies
 benign symmetrical lipomatosis association 100.14
 burning feet syndrome differential diagnosis 85.17
 dapsone-induced 19.14–15
 hyperhidrosis 94.5
 neuropathic ulcer 85.4
 restless legs syndrome differential diagnosis 85.17
 thalidomide-induced 19.40
 thallium poisoning 122.8
- peripheral primitive neuroectodermal tumour 137.54–5
- peripheral ulcerative keratitis 92.2
- peripheral vascular disease 103.2
 clinical features 103.2
 hand–arm vibration syndrome differential diagnosis 123.24
 investigations 103.3
 management 103.4
 neuropathic ulcer 85.4
 periosis differential diagnosis 125.5
 pyoderma gangrenosum association 49.2
- perioritis staphylogenes and sweat gland abscesses 116.24
- periunguim
 biting 95.17
 trauma 95.38
- periuethral abscess, gonococcal 30.4, 30.5
- perivascular cell tumours 137.42–5
- epithelioid 137.63–4
- periventricular nodular heterotopia, Ehlers–Danlos syndrome 72.7
- perleche *see* angular cheilitis
- Perls Prussian blue reaction 3.8, 3.9
- permethrin
 louse infestation treatment 18.13
 rosacea treatment 91.14
 scabies treatment 18.13, 34.43, 34.44
- pernicious anaemia, acquired
 systemic lupus erythematosus association 51.31
 vitamin B₁₂ deficiency association 63.19
- perniosis 125.4–5
- peroneal muscular atrophy, leprosy differential diagnosis 28.12
- peroxidase 3.14, 3.15
- peroxidase–antiperoxidase (PAP) complexes 3.14, 3.15
- peroxisome proliferator-activated receptor(s) (PPARs) 8.4, 8.23
- peroxisome proliferator-activated receptor- γ (PPAR- γ)
 lichen planopilaris 89.37
 signalling 149.9
- peroxisome proliferator-activated receptor- γ (PPAR- γ) agonists, burns treatment 126.11
- persistent light reaction 127.13, 127.28
- persistent pigment darkening (PPD) 88.9
- personalized medicines 14.10
- perspiration, insensible 2.8
- pet animals
 arthropod skin disease 34.4–5
 atopic eczema 41.28
 protection 41.8
 flea bites 34.12, 34.13
- petechiae
 primary immunodeficiency 82.3
 rheumatic fever 55.8
- petrolatum-based emollients 116.2
- Peutz–Jeghers syndrome
 Cowden syndrome differential diagnosis 80.14
 lentigenes 132.3
 laser treatment 23.13
 lips 110.13
 oral mucosa 110.12, 110.13
- Peutz–Jeghers–Touraine syndrome 70.3, 70.14–15
- Peyronie disease 96.33, 111.7, 111.19, 137.13–14
- P-glycoprotein system
 ciclosporin drug interactions 19.11
 colchicine drug interactions 19.13
- PHACES (posterior fossa malformations, haemangiomas, arterial anomalies, cardiac anomalies, eye abnormalities and sternal pit/supraumbilical raphe) syndrome 117.20
- phaeochromocytoma 88.19, 145.19
 flushing 106.6–7, 147.24, 147.25
- MEN type 2 association 147.10
 pigmentation 88.20
- phaeohyphomycosis 32.78–9
 genital 111.24
- phaemelanin 88.5, 89.69
- phagocytes 136.1–2
 congenital defects in function, differentiation and adhesion 82.15–16
- phagocytosis 136.1–2
 Langerhans cells 2.14
 lysosome role 8.44
- phakomatosis pigmentokeratolica 132.15
see also Schimmelpenning–Feuerstein–Mims syndrome
 congenital epidermal 75.3
 naevi 75.7
- phakomatosis pigmentovascularis 75.22–3, 132.1, 132.15
 heterotrimeric G-protein mosaic disorders 75.21
 subclassifications 75.23
- phalangeal microgeodic syndrome 95.47
- phantosmia 86.8
- pharmacodynamics 14.3–6
 age effects 14.7
 clinical factors affecting 14.7–8
- pharmacogenetics 14.10–11
- pharmacokinetics 14.1–3
 age effects 14.7
 clinical factors affecting 14.7–8
- pharmacological interaction with immune receptors (p-i) concept 12.5
- pharmacology 14.1–12
 factors affecting therapeutic outcome 14.6–11
 pharmacodynamics 14.3–6
 clinical factors affecting 14.7–8
 pharmacokinetics 14.1–3
 clinical factors affecting 14.7–8
 terminology 14.1, 14.2
- pharmacovigilance registries 14.6
- pharyngitis, streptococcal 26.10
- phenol
 chemical peel 159.3, 159.4
 depigmentation 88.45
 systemic toxicity 159.12
- phenol esters 129.3
- phenol formaldehyde resin
 allergy 128.50–1
- phenol-soluble modulin 26.9
- phenothiazines
 eczema induction 118.4
 photoallergic contact dermatitis 128.78
 phototoxicity 129.10
- phenothrin 18.13
- phenotype 7.2, 7.4
- phenylketonuria 5.10, 81.11, 81.12
- phenytoin
 cutaneous sclerosis induction 96.43
 hyperpigmentation 88.26–7
 hypertrichosis 89.62
 polyfibromatosis syndrome impact 96.31–2
- phenytoin hypersensitivity syndrome 31.17
- phaemelanin 155.4
- Phialophora verrucosa* 32.77
- philtrum 110.3
- phimosi 111.3
 lichen sclerosis 111.14, 111.15
 management 111.15
 penile cancer risk 111.30
- phlebolympoedema 105.6–9
 clinical features 105.8
 complications 105.8
 definition 105.6
 epidemiology 105.7
 investigations 105.8–9
 management 105.9
 pathophysiology 105.7–8
- phobias, cutaneous 86.20
- phosphatidylcholine 99.47
- phosphodiesterase, atopic eczema 41.14
- phosphoglycerate dehydrogenase deficiency 65.34
- phosphomannomutase 2 deficiency 81.10–11
- photoactivation 128.78
- photoageing 2.47, 2.48, 155.8
 atrophic 155.1–2
 collagen degradation 9.10–11
 histological features 9.10
 hypertrophic 155.2
 neck skin 155.3
 PUVA side effect 21.12–13
 quantification 155.4–5
 skin cancer relationship 9.11
 sunscreens protection 9.12
 UV radiation-induced 9.10–11
 UVA radiation 9.11
 UVB phototherapy side effect 21.11
 UVB radiation 9.11
- photoaggravated dermatoses 127.1, 127.31
- photoallergic contact dermatitis 128.77–80, 128.81
 clinical features 128.78–9
 complications/co-morbidities 128.79
 cross reactions 128.78
 definition 128.77
 differential diagnosis 128.79
 environmental factors 128.78
 epidemiology 128.77
 investigations 128.79–80
 management 128.80, 128.81
 nomenclature 128.77
 pathophysiology 128.77–8
- photobiology 9.1–13
 principles 9.1–5
see also photoprotection; ultraviolet radiation (UVR)
- photobleaching 3.11
- photocarcinogenesis 127.29
- photochemical change, tissue optics 23.4
- photochemotherapy (PUVA) 21.1–2
 acute phototoxicity 21.12
 administration 21.8–9
 alopecia areata treatment 89.34
 chronic actinic dermatitis management 127.20
 chronic graft-versus-host disease treatment 38.9
- ciclosporin-induced malignancy 19.11
 combination therapy 21.9–10
 contraindications 21.5, 21.6
 delivery methods 21.9
 eczema treatment 39.7
 equipment 21.3
 eye protection 21.9
 granuloma annulare treatment 97.7
 historical aspects 1.8
 history 21.2
 indications 21.4–5
 lentiginosis complication 88.17
 mastocytosis 46.9
 melanoma risk 143.6
 minimal phototoxic dose 21.9
 morphea treatment 57.26, 57.28
 mycosis fungoides 140.23–4
 combination therapy 140.24–5
 nail psoriasis 95.42
 necrobiosis lipoidica treatment 97.11
 palmoplantar pustulosis 35.40
 patient follow-up 21.15–16
 patient records 21.16
 patient safety 21.15
 penile cancer risk 111.30
 perioral acne complication 130.11
 photosensitivity diseases 127.35
 pityriasis lichenoides management 135.6
 plaque psoriasis 35.25–6
 polymorphic light eruption 127.7
 psoralen use 21.8–9
 psoriasis 21.4, 31.15
 regimen variables 21.9
 scleredema treatment 59.10
 Sézary syndrome 140.23–4
 combination therapy 140.24–5

- photochemotherapy (*continued*)
 side effects 21.12–14
 counselling 21.15
 solar urticaria 127.23
 subacute cutaneous lupus erythematosus 51.13
 subcorneal pustular dermatosis 49.15
 systemic agent combination 21.10
 topical agent combination 21.9
 versus UVB phototherapy 21.5, **21.6**
 UVR source 9.3
 vitiligo treatment 88.39
 see also extracorporeal photochemotherapy (photopheresis) (ECP)
- photochemotherapy (PUVA)
 lentigo 132.7–8
- photocontact allergy 128.18
 chronic actinic dermatitis association 127.13
- photocontact facial melanosis 88.12–13
- photodamage
 chemical peels 159.5, 159.8, 159.9
 collagenous and elastotic marginal plaques of hands 96.4–5
 colloid degeneration 96.5–6
 colloid milium 96.5–6
 dermal connective tissue changes 96.1–6
 erythematotelangiectatic rosacea differential diagnosis 91.9
 see also solar elastosis; wrinkles
- photodermatitis
 actinic prurigo 110.79
 chemical peel contraindication 159.6
 erythema multiforme differential diagnosis 47.5
 North American Indians 127.9
- photodermatoses, idiopathic 127.2–26
- photodynamic reactions 88.29–30
- photodynamic therapy (PDT) 22.1–15
 acne treatment 22.7, 90.49–50
 actinic cheilitis 22.5
 actinic keratosis treatment 22.3, 22.4–5, 22.8, 142.10, 146.15–16
 daylight regimen 22.11
 pain 22.14
 adverse effects 22.12–14
 aftercare 22.12
 allergy 22.13
 ambulatory 22.10–11
 5-aminolaevulinic acid 22.2, 22.3, 22.4–5
 basal cell carcinoma treatment 22.5, 22.6, 22.7, 141.15
 Gorlin naevoid syndrome 22.2, 22.7
 Bowen disease treatment 22.5, 22.6, 22.8, 22.9, 142.21, 142.22, **142.22**
 clinical governance 22.14
 conditions used for **22.8**
 contraindications 22.7
 cutaneous T-cell and B-cell lymphoma treatment 22.7
 daylight 22.11–12
 dermatitis 22.13
 diagnosis 22.7–9
 extramammary Paget disease treatment 22.7
 follow-up 22.12
 fractionation of light delivery 22.4
 historical aspects 22.1–2
 HPV-related neoplasia treatment 22.7
 indications 22.4–5, 22.6, 22.7
 innovations 22.14–15
 irradiance level 22.4, 22.11–12
 irradiation 22.10
 keratoacanthoma treatment 142.36
 LED sources 22.4, 22.10
 lesion preparation 22.9
 light sources 22.3–4, 22.10
 limitations on use 22.2
 methodology 22.7–12
 methyl aminolevulinic acid 22.2, 22.3
 pain 22.13–14
 patient selection 22.7–9
 photochemical change 23.4
 photorejuvenation 22.7
- photosensitizers 22.2–3
- polychromatic light sources 22.4
- porphyrin 22.2
- port-wine stains treatment 23.9
- pro-drug application 22.9–10
- scarring 22.14
- sebaceous gland hyperplasia treatment 93.13
- service 22.14
- squamous cell carcinoma treatment 22.5, 142.32
- treatment schedules 22.12
- wart treatment 22.7, 25.53
- photography, skin disease extent measurement 16.4
- photoirritation 129.9–10
- photons 9.1–2
 absorption 9.4
- photo-onycholysis 95.9–10
- photo-oxidative stress 141.3
- photopatch testing 127.34–5, 128.79–80, **128.81**
- photopheresis *see* extracorporeal photochemotherapy (photopheresis) (ECP)
- photoprotection 9.11–12
 actinic prurigo 127.13
 active 9.12
 caffeine 156.10
 clothing 9.12
 hydroa vacciniforme 127.25, 127.26
 hypermelanosis treatment 88.33
 juvenile spring eruption **127.9**
 oculocutaneous albinism 70.8
 passive 9.12
 photosensitivity diseases 127.35
 polymorphic light eruption 127.7
 pomegranate extract 156.8
 rosacea 91.12, 91.13
 shade 9.12
 solar lentiginos 132.7
 solar urticaria management 127.23
 see also sun protection; sunscreens
- photorejuvenation 22.7
- photosensitivity 127.1, 128.77–8
 abnormal 127.1
 allergic contact dermatitis differential diagnosis 128.61, 128.62
 atopic eczema 41.19
 clinical assessment 127.31–5
 photosensitivity diseases 127.1–35
 assessment 127.31–5
 chemical-induced 127.1, 127.26–30
 clinical features 127.27–9
 definition 127.26
 differential diagnosis 127.29
 epidemiology 127.26–7
 exogenous 127.26–30
 investigations 127.29–30
 management 127.30
 pathophysiology 127.27
 chemotherapy-induced 120.10–11
 dermatitis 127.13
 drug-induced 127.1, 127.26–30
 chronic actinic dermatitis differential diagnosis 127.16
 clinical features 127.27–9
 definition 127.26
 differential diagnosis 127.29
 epidemiology 127.26–7
 exogenous 127.26–30
 investigations 127.29–30
 management 127.30
 pathophysiology 127.27
 genophotodermatoses 127.1
 idiopathic photodermatoses 127.2–26
 investigations 127.33–5
 management 127.35
 photoaggravated 127.1
 photo-exposed sites 127.32
 symptoms 127.31–2
 tattoo-associated 123.22
- photosensitizers, exogenous **127.27**
- photostimulation, tissue optics 23.4
- phototherapy 21.1–17
- acne treatment 90.49
- actinic keratosis incidence 142.3
- actinic prurigo management 127.13
- adverse effects 21.11–14
 counselling 21.15
 adverse incident recording 21.16
- atopic eczema 41.32
- audit 21.16
- chronic actinic dermatitis management 127.20
- clinical governance 21.16
- developments 21.17
- documentation 21.16
- dosimetry 21.16
- eczema treatment 39.7
- eosinophilic folliculitis 31.16
- equipment 21.3
 maintenance 21.16
- historical aspects 1.8
- hydroa vacciniforme 127.26
- indications 21.4–5
- intermittent 1.8
- irritant contact dermatitis 129.8
- juvenile spring eruption **127.9**
- mastocytosis 46.9
- minimal erythema dose 21.7
- modality choice 21.5
- morphoea treatment 57.26–7, **57.28**
- mycosis fungoides 140.23–4
- neonatal jaundice 88.49, 88.50, 116.10
- patient education 21.15
- patient follow-up 21.15–16
- patient records 21.16
- patient safety 21.15
- patient selection/assessment 21.14–15
- performance indicators 21.16
- pityriasis lichenoides management 135.6
- pityriasis rubra pilaris treatment 36.5, 36.7
- plaque psoriasis 35.25–6
- polymorphic light eruption 127.7
- pruritic papular eruption 31.17
- pruritus in atopic eczema 83.9
- psoriasis 31.15, 31.16
- risk management 21.16
- scleredema treatment 59.10
- setting up of unit 21.16
- Sézary syndrome 140.23–4
- solar urticaria 127.23
- staff safety 21.15
- UV calibration/dosimetry 21.3
- photothermal ablation 23.16–19
 anaesthesia 23.17
 complications 23.19
 indications 23.17–18
 see also carbon dioxide laser
- photothermal non-ablative techniques 23.19–20
- photothermolysis
 fractional 160.7
 ablative 160.7–8
 non-ablative 160.8
 selective 23.4–23.5
- phototoxic contact dermatitis 129.9–10
- phototoxicity
 acute with PUVA 21.12
 drug reactions 120.10–11
 hyperpigmentation 88.29–30
 porphyrins 60.1–2, 129.10
- phrynoderma 87.13–14
 clinical features 87.13–14
 definition 87.13
 epidemiology 87.13
 investigations 87.14
 management 87.14
 multiple minute digitate keratoses differential diagnosis 87.18
 pathophysiology 87.13
 scurvy 63.21
 vitamin A deficiency 63.7, 63.8
- Phthiraptera 34.16–18
- phthiriasis
 genital 111.25
 ocular 109.42
- Phthirus pubis*
- chronic blepharitis 109.12
- eyelashes 109.42
- perineum/perianal region 113.13
- PHYH* gene mutations 65.28
- Physician's Global Assessment (PGA) 16.2
- physiotherapy, congenital ichthyoses 65.39
- phytanic acid 65.28
- phytochemicals
 antiageing products 156.7–9
 anti-inflammatory 156.9–10
 antioxidants 156.6–8, 156.10, **156.11**
 cosmeceutical use 156.5–10, **156.11**
- phyto-oestrogens,
 hyperoestrogenism 145.19
- phytophotodermatitis 88.29, 88.30, 127.28, 129.10
- piano paronychia 123.12
- Piccardi-Lassueur-Little syndrome 89.39–40
- picker's acne 86.15
- picker's nodules 86.13
- picornavirus infections 25.79–84
 enterovirus infection 25.80–1
 foot and mouth disease 25.79–80
 hand, foot and mouth disease 25.81–2
 hepatitis A virus 25.79, 25.83–4
 hepatovirus **25.80**, 25.83
 herpangina 25.82–3
 parechovirus 25.79, **25.80**, 25.83
- picosecond lasers 160.4
- PICOT acronym 17.3
- piebaldism 2.17, **70.2**, 70.3–4
 clinical features 70.3–4
 pathophysiology 70.3
 vitiligo differential diagnosis 88.38
- piedra
 black 32.15–16
 white 32.16–17
- Piedraia hortae* 32.15, 32.16
- piercing, oral injuries 110.65
- piezogenic pedal papules 123.25–6
- PiGL* gene mutations 65.34
- pigmentary demarcation lines **88.2**
- pigmentary disorders
 allergic contact dermatitis 128.60–1
 arsenic toxicity 122.2–3
 chemical peels 159.5
 chromosomal mosaicism 76.5
 classification 88.8
 discoid lupus erythematosus 51.5, 51.7
 dyskeratosis congenita 77.3
 electron microscopy 3.27
 genetic 70.1, **70.2–3**, 70.3–16
 histological sections 3.39
 HIV infection 31.12–13
 Hodgkin disease 140.49
 liver disease 152.8
 mosaicism 117.12, 117.13
 occupational dyspigmentation 130.12–13
 Stevens-Johnson syndrome/toxic epidermal necrolysis 119.18
 systemic lupus erythematosus 51.26
 vulval 112.20–2
 xeroderma pigmentosum 78.3
 see also facial melanoses; hypermelanosis
- pigmentary incontinence 3.38
- oral hyperpigmentation 110.68
- pigmentation 88.1–5, 88.6, 88.7–9
 addisonian 149.18
 constitutive 70.1, 88.8–9
 facultative 70.1
 gene regulation 70.1
 haemosiderin 88.48–9
 hair 89.68–71
 accidental discoloration 89.71
 acquired defects 89.71
 biology 89.68–9
 colour variation 89.69
 loss 89.69–70
 nutritional deficiencies 89.71
 physical phenomena 89.71
 heat load 88.8
 idiopathic lenticular 110.12
 lysosome role 8.44

- measurement 16.4
 melanoma risk 143.4
 nail plate 95.12–13
 non-melanin 88.8, 88.47–55
 endogenous 88.47–52
 exogenous 88.52–5
 oral mucosa 110.8
 paraneoplastic 147.17, **147.18**
 pregnancy 115.1, **115.2**
 skin colour 4.13–14, **4.15**
 vitamin D synthesis restriction 88.8
see also dyspigmentation
- pigmented lesions
 laser treatment 23.11–14, 160.4–6
 complications 23.14–15
 SIAoscopy 4.21
 surgery 20.46–7
- pigmented neuroectodermal tumour of
 infancy 137.53–4
- pigmented purpuric dermatoses 101.8–10
- pigmented purpuric lichenoid dermatosis
 of Gougerot and Blum 101.8, **101.9**,
 101.10
- PIK3CA* gene mutations 105.13
PIK3CA mosaicism, facial features 75.14
PIK3CA-related overgrowth spectrum 75.7
- pilar cyst *see* trichilemmal cysts
- pilar sheath acanthoma 138.4
- piles *see* haemorrhoids
- pili annulati 68.23, 89.56
 hair colouration 89.71
- pili incarnati *see* pseudo-folliculitis
- pili multigemini 89.59
- pili pseudoannulati 68.23
- pili torti 68.20–1, 89.51–2
 Björnstad syndrome **68.9**, **89.52**
 differential diagnosis 68.20
 Menkes disease 81.18, 89.51, 89.52
 monilethrix differential
 diagnosis 68.19
- pili triangulati et canaliculi 68.22, 68.23
- pilocarpine 2.8
- pilomatricarcinoma 138.14–15
- pilomatricoma 138.13–14
- pilonidal sinus 113.23–4
 ano-genital 123.22–3
 clinical features 113.23–4
 definition 113.23
 dissecting cellulitis of scalp
 association 107.8
 epidemiology 113.23
 folliculitis differential diagnosis 113.10
 hidradenitis suppurativa
 association 92.2
 investigations 113.24
 laser-assisted hair removal 23.15
 management 113.24
 obesity aggravation 100.26
 pathophysiology 113.23
 penile 111.19
- pilosebaceous cysts, plantar
 keratoderma 69.11, 69.12
- pilosebaceous follicles 2.1–2
 trichofolliculoma 138.8
- pilosebaceous naevoid disorders 90.25–6
- pilosebaceous unit 2.9, 2.10, 138.1–2
 acquired disorders 93.1–13
 actinic folliculitis 93.6
 disseminate and recurrent
 infundibulofolliculitis 93.6–7
 eosinophilic pustular folliculitis 93.7–
 8, **93.9**, 117.11–12
 folliculitis keloidalis 93.3–4
 heterotopic sebaceous glands 93.10–
 12, 111.5–6
 infantile eosinophilic pustular
 folliculitis 93.9–10
 necrotizing lymphocytic folliculitis of
 the scalp margin 93.4–5
 pseudofolliculitis 93.1–2, 112.24
 scalp folliculitis 93.5–6
 sebaceous gland hyperplasia 93.12–13
 endocrinological activity 149.8–9
 stress mediators 8.50
 tumours 107.10
- see also* apocrine glands; eccrine glands;
 hair follicles; sebaceous glands
- pimecrolimus
 atopic eczema treatment 41.31
 chronic actinic dermatitis
 management 127.20
 eczema treatment 39.6, 39.7
 eosinophilic pustular folliculitis
 treatment **93.9**
 granuloma annulare treatment 97.7
 pityriasis alba treatment 39.26
 structure 18.19
 systemic lupus erythematosus 51.35
 topical 18.19, 18.20–1
- pincer nail 95.7–8
- Pinkus follicular mucinosis 59.15–16, 59.17
- pinna
 hypertrichosis 108.6
 infections 108.11, 108.15
 shape variation 108.5–6
- pinta 26.66, 26.68
 ashy dermatosis differential
 diagnosis 88.33
 pityriasis versicolor differential
 diagnosis 32.12
- pinworm 33.13–14
- pitch (coal-tar) 130.11
 actinic keratosis 142.2
 occupational skin cancers 130.13
- pitted keratolysis **26.37**, 26.42–3
 hyperhidrosis 94.6
- pituitary adenylate cyclase activating
 peptide (PACAP) 85.3
 cutaneous vasodilatation 8.51, 106.1
- pityriasis alba 39.25–6, 88.44
 children 117.5
 leprosy differential diagnosis 28.11
 pinta differential diagnosis 26.68
 pityriasis rosea differential
 diagnosis 25.92
- pityriasis amiantacea 107.3–4
- pityriasis circinata et marginata of
 Vidal 25.91
- pityriasis folliculorum 91.10–11
- pityriasis lichenoides 110.56, 135.3–6
 causative organisms 135.4
 chronica 135.3–6
 psoriasis differential diagnosis 35.19
 clinical features 135.4–5
 definition 135.3
 differential diagnosis 135.5
 epidemiology 135.3
 et varioliformis acuta 135.3–6
 investigations 135.5
 management 135.5–6
 papulonecrotic tuberculid differential
 diagnosis 27.29
 pathophysiology 135.3–4
 pityriasis rosea differential
 diagnosis 25.92
- pityriasis rosea 5.10, 25.89–92
 clinical features 25.90–2
 complications/co-morbidities 25.92
 definition 25.89
 differential diagnosis 25.91–2
 drug eruptions **25.90**, 118.14–15
 eczema differential diagnosis 39.4
 epidemiology 25.89–90
 genital 111.24
 herald patch 25.90, 25.91, 25.92
 HHV-8 association 25.37
 investigations 25.92
 management 25.92
 nomenclature 25.89
 nummular dermatitis differential
 diagnosis 39.9
 pathophysiology 25.90
 pityriasis versicolor differential
 diagnosis 32.12
 pregnancy 115.9
 seborrhoeic dermatitis differential
 diagnosis 40.4
 tinea corporis differential
 diagnosis 32.37
 variants 25.91
- pityriasis rotunda 65.41–2, 87.7–8, 147.17
- pityriasis rubra pilaris 36.1–2, 36.3, 36.4–7
 adult-onset
 atypical (type II) 36.4, 36.5
 classical (type I) 36.2, 36.3, 36.4–5,
 36.6
 clinical features 36.2, 36.3, 36.4–5
 complications/co-morbidities 36.4
 definition 36.1
 differential diagnosis 36.4
 disease course 36.4–5
 epidemiology 36.1–2
 erythroderma 39.33
 familial 36.2, 36.4
 genetics 36.2
 HIV-related (type VI) 36.1, 36.2, 36.4
 investigations 36.5
 juvenile-onset
 atypical (type II) 36.5
 atypical (type V) 36.4
 circumscribed (type IV) 36.3, 36.4,
 36.5, 87.12
 classical (type III) 36.3, 36.4, 36.5
 keratosis pilaris differential
 diagnosis 87.10
 management 36.5–7
 nomenclature 36.1
 pathophysiology 36.2
 phrynoderma differential
 diagnosis 87.14
 prognosis 36.4–5
 psoriasis differential diagnosis **35.18**,
 35.19
 variants 36.2, 36.3, 36.4
- pityriasis versicolor 32.10–13
 causative organisms 32.10–11, 32.12
 clinical features 32.12
 confluent and reticulated papillomatosis
 differential diagnosis 87.7
 epidemiology 32.11
 erythrasma differential diagnosis 26.39
 HIV infection 31.28
 hyper-/hypopigmentation 88.44
 hypomelanosis 88.44
 investigations 32.12, 32.13
 leprosy differential diagnosis 28.11
 management 32.13
 pathophysiology 32.11–12
 pityriasis rotunda differential
 diagnosis 87.8
 reticular erythematous mucinosis
 differential diagnosis 59.9
 tinea cruris differential
 diagnosis 32.46–7
 treatment ladder **32.13**
- Pityrosporum* folliculitis, acneiform
 drug eruption differential
 diagnosis 118.17
- pizzicato paronychia 123.11
- placebo effect 15.2
- placental sulphatase deficiency 65.5
- plague 26.57–8, 34.12
 bubonic 34.12
- plakins 2.18
- plakoglobin 2.19, 71.3, 71.10, 71.24
- plakophilin 2.18
- plakophilin-1 71.3, 71.9–10, 71.24
- plane xanthoma
 malignancy association **147.22**
 solar elastosis differential diagnosis 96.4
- plant allergens 128.11, 128.14, 128.15,
 128.17, 128.51–4
 airborne 128.18
 clinical features 128.52–3
 cosmetics 128.31
 epidemiology 128.51–2
 investigations 128.53–4
 management 128.54
- plant sap, phototoxic 127.28, 129.10
- plantar dermatosis, juvenile 39.21–2
- plantar fascial fibromatosis 96.33
- plantar fibromatosis 137.13
- fascial 96.33
- plantar hyperkeratosis 100.25
- plantar keratoderma 69.1, 69.11
- investigations 69.12
 management 69.12
 postmenopausal 100.25
- plaque-like CD34-positive dermal
 fibroma 137.8–9
- plasma cell cheilitis 110.87–8
- plasma cell disorders
 malignant infiltration of skin 148.4–5
see also monoclonal gammopathy;
 multiple myeloma; Waldenström
 macroglobulinaemia
- plasma cell(s), high-power
 microscopy 3.31
- plasma cell vulvitis 112.12–13
- plasma-acanthoma 110.88
- plasmacytoma 110.61, 148.4–5
 scleromyxoedema association 148.8,
 148.9
- plasmapheresis
 pemphigus treatment 50.9
 solar urticaria management 127.23
 systemic lupus erythematosus
 treatment 51.36
- plasminogen activation 8.41
- plasminogen-activator inhibitors
 (PAIs) 8.41
 wound healing 10.4, 10.5
- Plasmodium* 33.33
- plastics allergy 128.48–51
- platelet(s)
 growth factors 8.24–5
 immune response role 8.25–6
 inflammation role 8.23–6
 inflammatory mediators 8.24–5
 leukocyte association 8.24, 8.25
 receptors 8.25
 thrombi 103.2, 103.3
 wound healing 10.2
- platelet activating factor (PAF) 8.47
- platelet disorders **101.2**
 function abnormalities 101.3, **101.4**
 plugging 101.10–12
 purpura 101.3, **101.4**
- platelet-derived growth factor (PDGF) 8.6
 wound healing 10.6, 10.11
- platinum, reactions to 122.9
- plectin 71.4, 71.9
- pleomorphic fibroma 137.3–4
- pleomorphic lipoma 137.60
- pleomorphism 3.38
- plexiform fibrohistiocytic tumour 137.22
- plexiform neurofibroma 137.48–9
- plumbism 122.4–5
- Plummer–Vinson syndrome 63.24, 152.1
- PMM2* gene mutations 81.10–11
- Pneumocystis jiroveci*, cutaneous
 infection 32.95
- Pneumocystis jiroveci* pneumonia
 (PCP) **31.6**, 31.28
 drug eruptions from treatment 31.17
 incidence 31.5
 prophylaxis 31.8
- Pneumocystis*, Kaposi sarcoma differential
 diagnosis 31.29
- pneumonia, aspiration in
 dermatomyositis 53.10
- pneumonitis, interstitial 53.9
- podoconiosis 105.45–7
 definition 105.45–6
 lymphatic filariasis differential
 diagnosis 105.44, 105.47
- podophyllin 18.13
 wart treatment 18.13, 25.53
- podophyllotoxin 18.13
 wart treatment 18.13, 25.53
- POEMS (polyneuropathy, organomegaly,
 endocrinopathy, monoclonal
 gammopathy and skin changes)
 syndrome 25.37, 148.11
 acquired partial lipodystrophy
 association 100.4
 glomeruloid haemangioma 137.25
 hyperpigmentation 88.25
 malignancy association 147.22
- POFUT1* gene mutations 70.14

- poikiloderma 77.1–7
 acquired 96.10, 96.11
 acrokeratotic of Weary 77.7
 atrophicans vasculare 96.10
 chronic superficial scaly dermatitis
 differential diagnosis 39.27
 clinical features 77.2
 hereditary fibrosing with tendon
 contractures, myopathy and
 pulmonary fibrosis 77.7
 Kindler syndrome differential
 diagnosis 71.19
 mycosis fungoides 140.10, 140.11–12
 with neutropenia, Clericuzio type 77.7
see also dyskeratosis congenita;
 Rothmund–Thomson syndrome
 poikiloderma of Civatte 88.13–14, 155.3
 laser therapy 160.2–3
 poldine methylsulphate 18.33
 poliomyelitis 25.79
 poliosis 89.70
 pollution *see* environmental pollution
 polyacrylamide fillers 157.7
 polyalkylamide fillers 157.7
 polyarteritis nodosa 102.29–32
 clinical features 102.30, 102.31
 cutaneous 99.10–11, 102.29–32
 inflammatory bowel disease
 association 152.3
 definition 102.29
 epidemiology 102.30
 genital 111.21
 HCV association 25.65
 investigations 102.30–1
 management 102.31–2
 microscopic polyangiitis differential
 diagnosis 102.22
 oral lesions 110.55
 pathophysiology 102.30
 superficial thrombophlebitis differential
 diagnosis 99.9
 polybrominated biphenyls 130.11
 polychlorinated biphenyls (PCBs) 90.57,
 90.58, 130.11
 polycyclic hydrocarbons, occupational
 skin cancers 130.13–14
 polycystic ovarian syndrome 145.18,
 149.18
 acne association 90.3, 90.5, 90.7
 hirsutism 89.64, 89.65
 treatment 89.68
 weight loss 89.68
 polycythaemia rubra vera 147.24
 polycythaemia vera
 erythromelalgia 84.10
 flushing 106.8
 pruritus 83.11
 purpura 101.11–12
 polyendocrine disease 145.20
 polyene antifungals 19.43, 19.44
 topical 18.12
 polyethylene glycol (PEG) 18.7
 polyfibromatosis syndrome 96.31
 polyhydroxy acids, antiageing
 products 156.3–4
 poly-L-lactic acid (PLLA) 157.2, 157.3–4
 polymerase chain reaction (PCR)
 microorganism detection 3.10
 nucleic acid amplification tests for
 tuberculosis 27.8–9
 viral infections 25.5
 techniques 3.27
 polymethylmethacrylate and collagen
 fillers 99.47, 157.7
 polymorphic light eruption 127.1, 127.2–8
 actinic folliculitis differential
 diagnosis 93.6
 associated diseases 127.2
 clinical features 127.3–4
 complications/co-morbidities 127.4
 definition 127.2
 differential diagnosis 127.4
 discoid lupus erythematosus
 differential diagnosis 51.10
 relationship 51.4
 disease course/prognosis 127.4
 environmental factors 127.3
 epidemiology 127.2
 flare with UVB phototherapy 21.11, 21.12
 genetics 127.3
 investigations 127.4–6, 127.7
 Jessner's lymphocytic infiltrate
 differential diagnosis 135.9
 juvenile spring eruption
 association 127.9
 lymphocytoma cutis differential
 diagnosis 135.9
 management 127.6–8
 pathophysiology 127.2–3
 of pregnancy 83.12, 115.11–13
 psoriasis association 35.5
 PUVA 21.4
 side effect 21.12
 recurrent cutaneous necrotizing
 eosinophilic vasculitis differential
 diagnosis 102.11
 severity classification 127.4
 sunscreen use 18.32
 tinea faciei differential diagnosis 32.42
 UVB phototherapy 21.4
 side effect 21.11, 21.12
 variants 127.4, 127.5
 polymorphism 3.38
 polymorphonuclear granulocytes 8.17–19
 polymyalgia rheumatica, giant cell arteritis
 association 102.34
 polymyositis 53.1
 classification 53.1
 pathophysiology 53.2
see also mixed connective tissue disease
 polymyxin B 18.11
 polyneuropathy, benign symmetrical
 lipomatosis association 100.14
 polyneuropathy, organomegaly,
 endocrinopathy, monoclonal
 gammopathy and skin changes
 (POEMS) syndrome *see* POEMS
 (polyneuropathy, organomegaly,
 endocrinopathy, monoclonal
 gammopathy and skin changes)
 syndrome
 polyomavirus 25.41–3
 disease domain 25.41
 Merkel cell carcinoma 145.2
 Merkel cell infection 25.41–2
 trichodysplasia spinulosa 25.42–3, 89.47
 polypharmacy, older people 14.7
 polyps, hypergranulating 114.11
 n-3 polyunsaturated fatty acids
 (PUFAs) 41.7
 polyunsaturated fatty acids (PUFAs),
 antiageing products 156.4, 156.10
 pomade acne 90.17
 pomades 89.75
 pomegranate, antioxidant use 156.8,
 156.11
 pompholyx eczema
 blistering distal dactylitis differential
 diagnosis 26.34
 hand 39.11, 39.13, 39.14, 39.17
 hand eczema differential
 diagnosis 39.16
 keratolysis exfoliativa differential
 diagnosis 87.24
 recurrent focal palmar peeling 39.15
 ponesimod, plaque psoriasis 35.29
 Pontiac fever 26.72
 popliteal pterygium syndrome 72.33
 populations
 determination of skin disease
 frequency 5.8–10
 disease severity 5.2
 epidemiology 5.2–4
 skin diseases as entities 5.2
 study 5.3
 porcine collagen fillers 157.6
 porcine dermal matrices 126.7
 porokeratosis 3.39, 65.67–8, 87.18–22
 autosomal dominant punctate 65.52
 classification 87.19
 clinical features 87.20–2, 146.11
 complications/co-morbidities 87.21–2
 definition 65.67, 87.18
 differential diagnosis 87.21
 disseminated palmoplantar 87.19, 87.21
 disseminated superficial 87.21
 of childhood 65.67–8
 of immunosuppression 65.67
 eccrine naevi 75.5, 75.7
 Flegel disease differential
 diagnosis 87.17
 genital 87.19, 87.20, 87.21, 111.29
 giant 65.68
 investigations 65.68, 87.22
 lichen striatus differential
 diagnosis 37.20
 linear 65.68, 87.19, 87.20
 systemized 87.21
 malignancy association 65.58
 management 87.22
 of Mibelli 65.68, 87.18, 87.19, 87.20
 elastosis perforans serpiginosa
 differential diagnosis 96.53
 genital 111.29
 palmoplantar of Mantoux 65.68
 pathophysiology 65.67, 87.19–20
 perianal 87.20, 87.21
 ptychotropica 65.68
 punctate palmoplantar 87.19, 87.20
 treatment 65.68
 variants 65.67–8
see also disseminated superficial actinic
 porokeratosis (DSAP)
 porokeratotic eccrine ostial duct naevus
 (PEN) 65.30, 65.32
 porphyria(s) 60.1–19
 acute attacks 60.6–7
 bullous 60.4
 classification 60.2, 60.4
 clinical features 60.2, 60.4–9
 diagnosis of acute attack 60.6–7
 enzyme deficiencies 60.2
 faecal analysis 60.8–9
 histopathology of skin 60.5
 hypertrichosis 89.63
 laboratory testing 60.7–9
 management, acute attacks 60.7
 pathogenesis of skin disease 60.4–5
 plasma spectrofluorimetry 60.8
 screening of relatives 60.9
 skin manifestations 60.4–6
 subepidermal bullae 60.4, 60.5
 urinary analysis 60.8
 whole blood/red cell analysis 60.8
see also named individual diseases
 porphyria cutanea tarda 60.4, 60.7,
 60.11–14
 alcohol-induced 96.43
 allergic contact dermatitis differential
 diagnosis 128.62
 biochemical findings 60.12
 chemical-induced photosensitivity
 differential diagnosis 127.29
 clinical features 60.11–12
 definition 60.11
 differential diagnosis 60.12
 drug-induced photosensitivity
 differential diagnosis 127.29
 epidermolysis bullosa acquisita
 differential diagnosis 50.43, 50.45
 genetic counselling 60.14
 HCV association 25.65
 histopathology 60.12
 HIV infection 31.17
 hypertrichosis 89.63
 investigations 60.12–13
 irritant contact dermatitis differential
 diagnosis 129.4, 129.5
 liver disease 60.13, 152.7, 152.8
 malignancy association 147.22
 management 60.13–14
 photoprotection 60.13
 pinna 108.13, 108.15
 pseudoporphyria differential
 diagnosis 60.19
 renal failure 153.4
 risk factors 60.12–13
 scarring 90.32
 solar elastosis association 96.3
 solar urticaria differential
 diagnosis 127.22
 subacute cutaneous lupus
 erythematosus association 51.12
 variants 60.12
 porphyrins 22.2
 chemistry 60.1–2
 phototoxicity 60.1–2, 129.10
 Porphyromonas 26.64–5
 port-wine stains
 eyelid 109.48–9
 Klippel–Trenaunay syndrome 103.24,
 103.26
 laser therapy 23.7–9, 23.11
 recurrent 23.9
 Sturge–Weber syndrome 23.7, 75.22
 positron emission tomography (PET) 4.22
 postcoital fissures 112.40–1
 post-herpetic neuralgia 25.29, 25.30,
 84.3–5, 109.40
 clinical features 84.4
 definition 84.3
 epidemiology 84.3
 investigations 84.4
 management 25.30, 84.4–5, 86.38, 109.40
 mood stabilizers 86.38
 pathophysiology 84.3–4
 prevention 84.5
 posthitis 111.3, 111.4
 xerotic obliterans 111.14
 post-ionizing radiation keratosis 142.14
 post-irradiation angiosarcoma 137.36,
 137.37
 post-kala-azar dermal leishmaniasis 33.50,
 33.51, 154.5
 post-menopausal syndrome,
 pruritus 83.13
 post-streptococcal
 glomerulonephritis 26.10
 impetigo 153.6
 scarlet fever association 26.35
 post-surgical artefact 86.27
 post-thrombotic syndrome 104.5
 post-transfusion purpura 148.19
 post-transplant lymphoproliferative
 disorder 140.47–8
 postural exercises, lymphoedema 105.57
 potassium iodide 19.27–8
 erythema nodosum treatment 99.24
 Sweet syndrome treatment 49.12
 potassium permanganate soaks 18.9
 infective eczema 39.24
 potassium-titanyl-phosphate lasers *see*
 KTP lasers
 Pott disease 154.4
 povidone storage disease 99.47
 powders 18.2
 topical drug delivery 18.8
 power (statistical) 17.23
 poxvirus infections 25.5–15
 biology 25.6
 brucellosis differential diagnosis 26.59
 vulval 112.27
 poxvirus officinalis 25.7
 p-phenylenediamine (PPD) 128.2, 128.6,
 128.11, 128.41–2
 active sensitization 128.72
 regulatory measures 128.76
 Prader–Willi syndrome 74.4, 74.6
 prayer nodules 123.8
 prayer sign, diabetes association 64.6
 praziquantel
 cysticercosis treatment 33.31
 paragonimiasis treatment 33.28, 33.29
 schistosomiasis treatment 33.27
 prebullous eruptions, urticaria differential
 diagnosis 42.14
 prebullous pemphigoid 102.19
 predictive value 5.13
 pregabalin 86.38
 scalp dysaesthesia treatment 107.14

- pregnancy 115.1–17
 acne vulgaris 90.17, 115.8–9
 acute generalized pustular psoriasis 35.35
 antihistamines 42.17
 contraindication 19.4
 antimalarials contraindications 19.7
 antiphospholipid syndrome 52.2, 52.3
 apocrine glands 115.2
 atopic eczema 41.15
 atopic eruption 83.12, 115.15, 115.16
 autoimmune diseases 115.5–6
 azathioprine caution 19.9
 biological therapy caution 19.31
 chemical peel contraindication 159.6
 ciclosporin cautions 19.11
 dapsone cautions 19.15
 dermatoses 115.1–15, 115.16
 eccrine glands 115.2
 effects on drug therapeutic outcome 14.7–8
 Ehlers–Danlos syndrome 72.8, 115.6
 folate deficiency 63.18, 63.19
 glucocorticoid adverse effects 19.20
 gonococcal complications 30.4
 granuloma gravidarum 137.26
 hair changes 115.1–2, 115.2
 HIV infection 31.34
 hydroxycarbamide caution 19.22
 immune system changes 115.3
 infections 115.3–5
 inflammatory skin diseases 115.8–9, 115.10
 intrahepatic cholestasis 83.11, 83.12, 115.10–11
 iron deficiency 63.24
 itching 115.10–11
 leprosy 28.14, 115.5
 Lyme disease 26.70
 melasma 88.10–11, 88.12
 methotrexate contraindication 19.24
 nail changes 115.1–2, 115.2
 neonatal lupus erythematosus 51.39
 NF1 symptoms 80.4
 nitrofurantoin associated Stevens–Johnson syndrome 31.34
 pemphigoid gestationis 115.13–15
 pemphigus 50.5
 physiological skin changes 115.1–3
 pigmentation 115.1, 115.2
 pityriasis lichenoides et varioliformis acuta 135.4
 polymorphic eruption 83.12, 115.11–13
 potassium iodide
 contraindication 19.28
 pruritus 83.12–13
 pseudoxanthoma elasticum 72.29, 115.6
 psoriasis 115.8
 impact 35.21
 retinoid contraindications 19.39, 19.40
 rubella infection 25.78–9
 safe treatments 115.17
 scabies management 34.44
 sebaceous glands 115.2
 skin tumours 115.7
 spider telangiectases 103.11
 striae distensae 115.3
 syphilis 29.26
 systemic lupus erythematosus 51.30
 thalidomide contraindication 19.41
 urticaria 42.8, 47.8
 varicella infection 25.25
 vascular changes 115.2–3
 vulval changes 112.4
 see also polymorphic light eruption
 prehaptens 128.8
 preimplantation genetic diagnosis (PGD) 7.10
 preimplantation genetic haplotyping (PGH) 7.10
 premature ageing syndromes 72.20–6, 79.1, 79.2, 79.3–7
 clinical features 72.21
 see also Bloom syndrome; Werner syndrome
- prematurity
 anetoderma of 116.9
 see also preterm infants
 prenatal diagnosis 7.9–10
 preorbital cellulitis 116.25
 prepuce
 circumcision 111.6–7
 dorsal perforation 111.4
 function 111.4, 111.5
 non-specific balanoposthitis 111.17
 restoration 111.7
 structure 111.4, 111.5
 variants 111.6
 prescribing errors 14.9–10
 preservatives
 allergic contact dermatitis 128.32–40
 chlorocresol 128.39
 chloroxylenol 128.38–9
 formaldehyde-releasing 128.34–5
 methylidibromo glutaronitrile 128.37–8
 parabens 128.37
 topical drug delivery 18.6, 18.8
 pressure erythema, chronic venous insufficiency 103.38
 pressure ischaemia, medical trauma hair loss 89.45
 pressure ulcers 113.31–2, 124.1–3, 124.4, 124.5–8
 adjunctive therapies 124.8
 amyloidosis association 124.5
 anatomical locations 124.1
 assessment scales 124.5
 classification 124.2, 124.3
 clinical features 124.3
 complications 124.3, 124.5
 debridement 124.7
 definition 124.1
 epidemiology 124.2
 friction 124.2, 124.3
 healability determination 124.6
 healing 10.2
 histopathology 124.3
 infections 124.2, 124.3, 124.5, 124.6–7, 124.7–8
 investigations 124.3
 management 124.3, 124.5–6
 Marjolin ulcer association 124.5
 negative-pressure wound therapy 124.8
 nutrition
 in prevention 124.5–6
 treatment 124.6
 palliative care 124.8
 pathophysiology 124.2–3
 patient repositioning 124.5
 pressure 124.2
 prevention 124.5
 risk assessment 124.5
 risk factors 124.2–3
 shear 124.2–3
 skin microclimate 124.3
 skincare 124.6
 staging system 124.3, 124.4
 support surfaces 124.5
 surgical management 124.8
 treatment 124.6–8
 unavailability 124.8
 wound care 124.6–8
 wound dressings 124.7
 wound swabs 124.7–8
 preterm infants
 anetoderma of prematurity 116.9
 barrier function of skin 116.2
 HSV infection 116.22
 noma neonatorum 116.26
 raised linear bands of infancy 116.18
 skin appearance 116.4
 zinc deficiency 63.25
 pretibial myxoedema 59.11–13, 105.47–9
 clinical features 105.48–9
 definition 105.47
 diabetes associations 64.4
 elephantiasis 59.12, 59.13
 epidemiology 105.47
 investigations 59.12, 105.49
 management 59.12–13, 105.49
- pathophysiology 59.11–12, 105.48
 systemic sclerosis differential diagnosis 56.15
 treatment ladder 59.13
 prevalence 5.13
Prevotella 26.64
 priapism 111.35
 prick tests 4.23–4
 modified 4.24
 prickly heat 94.12–13, 116.5, 116.6
 primary biliary cirrhosis 152.5, 152.9
 hyperpigmentation 88.22
 systemic lupus erythematosus association 51.31
 systemic sclerosis association 56.7, 56.18
 primary care 5.11
 primary cutaneous marginal zone lymphoma 140.37, 140.38–40, 140.39–40
 clinical features 140.39–40
 immunophenotype 140.39
 investigations 140.40
 management 140.40
 treatment algorithm 140.38
 pathophysiology 140.38–9
 primary cutaneous peripheral T-cell lymphoma 140.32–8
 aggressive epidermotropic CD8+ 140.32–3
 CD4+ small/medium-sized pleomorphic 140.34
 extranodal NK/T-cell lymphoma 140.36–7
 $\gamma\delta$ T-cell 140.33–4
 see also adult T-cell leukaemia–lymphoma (ATLL)
 primary effusion lymphoma, Kaposi sarcoma association 139.5
 primary herpetic gingivostomatitis 25.16–17, 25.18
 primary hypertrophic osteoarthropathy 72.31–2
 see also pachydermoperiostosis
 primary immunodeficiency (PID) 148.14–16, 148.17
 antibody deficiencies 82.12–13
 autoimmune lymphoproliferative syndrome 82.14–15
 clinical features 82.1–2
 combined 82.7–12
 complement diseases 82.17–18
 definition 82.1
 diagnosis 82.1–3
 epidemiology 146.1–2
 GARFIELD acronym 82.2
 granulomatous lesions 82.8
 immune dysregulation diseases 82.13–15
 immunodysregulation
 polyendocrinopathy enteropathy X-linked syndrome 82.14
 innate immunity defects 82.16–17
 management 82.3
 NF κ B pathway-related 82.16
 phagocyte function, differentiation and adhesion congenital defects 82.15–16
 skin cancer 146.1–2
 skin manifestations 82.3–4, 82.4–6
 warning signs 148.14
 primary localized cutaneous amyloidosis (PLCA) 58.2, 58.2.58.3, 58.4–8, 58.5–8
 primary lymphoedema with myelodysplasia 73.20
 primary neuroendocrine carcinoma of the skin see Merkel cell carcinoma
 primin 128.51, 128.53
 primitive polypoid granular cell tumour 137.62–3
Primulaceae 128.52–3
 exposure time 128.66
 prioritization (economic) 6.5
 pristinamycin 119.2, 119.4
 PRKARIA gene mutations 150.4
- proanthocyanidin 156.7
 probability (P) 17.20
 probability of disease 5.9
 probenecid, hypersensitivity reaction 31.17
 proctalgia, chronic 113.32
 proctalgia fugax 113.32
 profilins 42.13
 progeria 72.20–2
 adult 147.13
 Cockayne syndrome differential diagnosis 78.9
 coronary artery disease 150.5
 freckles 88.16
 mandibuloacral dysplasia differential diagnosis 72.25
 neonatal 72.26, 79.2
 premature hair greying 89.70
 Werner syndrome differential diagnosis 72.23
 see also Hutchinson–Gilford progeria syndrome
 progerin 79.5
 progesterone, urticaria 47.8
 progestins
 acne association 90.11
 papulopustular acne treatment 90.43
 programming of adult disease 5.9
 progressive bacterial synergistic gangrene 26.74
 progressive capillary haemangioma 137.25
 progressive cephalothoracic lipodystrophy see acquired partial lipodystrophy (APL)
 progressive hemifacial atrophy 57.18–19, 57.20
 progressive nodular histiocytosis 136.16
 prohormone convertase 1 deficiency 74.4
 prohormone convertase 2 deficiency 74.6
 prolactin 149.2, 149.17
 functions 149.9
 systemic lupus erythematosus association 51.19
 prolidase deficiency 72.8–9, 81.11, 81.14
 proliferative verrucous leukoplakia 110.77
 verrucous carcinoma 110.38
 promethazine 18.33
Pronematus davisi 34.49
 pro-opiomelanocortin (POMC) 8.52
 congenital defects of synthesis 149.16
 deficiency 74.4, 74.5, 74.7
 propantheline, hyperhidrosis treatment 94.9
 propionibacteria 26.43
Propionibacterium 26.3, 26.4
 age effects 26.4
Propionibacterium acnes 26.4, 26.43, 90.19–20
 acne fulminans 90.51, 90.52
 antibiotic-resistant 18.10
 folliculitis of the scalp 93.5–6
 prepubertal acne 90.61
 SAPHO syndrome 90.8
 sarcoidosis 98.4
 strains 90.20
Propionibacterium avidum 26.43
Propionibacterium granulosum 26.43
 propolis 128.55
 propanolol
 burns treatment 126.11
 infantile haemangioma treatment 117.22, 117.24
 propylene glycol (PG)
 as co-solvent 13.7–8, 13.9
 penetration enhancer 18.7
 preservative 18.8
 prosector's warts see tuberculosis, cutaneous, warty
 prostacyclin 8.48
 prostaglandin(s) 8.48–9
 receptors 8.49
 prostaglandin E₂ 8.48
 prostanoids 8.2
 prostatitis, gonococcal 30.4
 protamine, anaphylactic reactions 118.7

- protease activated receptors (PARs) 8.41
 protease inhibitor-associated
 lipodystrophy syndrome *see* HIV-associated lipodystrophy
 protease inhibitors 8.41, 31.9, 31.10, **31.11**
 cytochrome P450 system effects 31.11
 drug eruptions 31.18
 lipodystrophy 31.19–20
 retinoid-like effects 31.20
 side effects **31.11**
 proteases 8.40–2
 IgE production 8.56
 itching in skin disease 83.7
 lysosomal 8.44
 protective clothing, surgical 20.7
 protective immunity 8.54–5
 protein C deficiency 101.17–19
 clinical features 101.18
 epidemiology 101.17
 investigations 101.18
 management 101.18–19
 pathophysiology 101.18
 protein contact dermatitis 128.83–4
 protein malnutrition, hair colour changes 89.71
 protein S deficiency 101.17–19
 clinical features 101.18
 epidemiology 101.17
 investigations 101.18
 management 101.18–19
 pathophysiology 101.18
 protein therapeutics *see* biological therapies
 protein tyrosine kinases (PTKs), ageing of skin 155.6
 protein tyrosine phosphatases (PTPs), ageing of skin 155.6
 proteinase-activated receptor (PAR) 8.21, 8.25
 activation 8.53
 proteinase-activated receptor (PAR) 2 83.7, 85.2
 atopic eczema 41.14
 proteinase-activated receptor (PAR) 4 83.7
 protein-based therapies 14.1
 protein–calorie restriction, telogen effluvium 89.26
 protein–energy malnutrition 63.1–6
 clinical features 63.3–6
 complications/co-morbidities 63.6
 management 63.6
 predisposing factors 63.3
 riboflavin deficiency 63.15
 severity classification 63.4–6
 proteins induced by vitamin K absence (PIVKA) 63.13
 proteoglycans 2.37, **2.38**, 2.39, 2.40
 cell surface 2.37
 core proteins 2.37
 functions 2.40
 molecular characteristics **2.39**
 pathological processes 2.40
 synthesis by fibroblasts 2.40–1
 Proteus syndrome **74.8**, 74.9, 105.27, 105.29
 capillary malformations 73.5–6, 105.36
 collagenoma 75.18
 congenital collagenoma 75.18
 congenital epidermal naevi 75.3
 encephalocraniocutaneous lipomatosis
 differential diagnosis 100.19
 infiltrating lipomatosis of the face
 differential diagnosis 100.18
 lymphatic malformations 105.35
 naevi 75.6–7
 PTEN-related 80.13
 Proteus-like syndrome 80.13
 protoporphyrin 60.16
 protoporphyrin IX (PpIX) 22.3
Prototheca algal infection 32.95–6
 protothecosis 32.95–6
 protozoal infections 33.33–52
 erythema nodosum **99.19**
 HIV infection 31.28
 infective cheilitis 110.87
 ocular disease 109.43
 oral lesions 110.54
 provisional matrix, wound healing 10.3
 provocation testing 127.34
 proximal myopathies,
 dermatomyositis 53.8
 proximal nail fold capillaroscopy 95.50–3
 prurialgia 83.13
 prurigo
 Hodgkin disease 140.49
 linear IgA disease differential
 diagnosis 50.36
 sarcoidosis association 98.14
 see also actinic prurigo
 prurigo nodularis 83.15–20, 86.13, 86.14
 chronic actinic dermatitis 127.15,
 127.17
 clinical features 83.17–18
 clinical variants 83.18, **83.19**
 cytomegalovirus in HIV 31.23, 31.24
 definition 83.15, 83.16
 diagnosis 83.19
 epidemiology 83.16
 investigations 83.18–19
 management 83.19–20
 nerve fibres 83.16–17
 pathophysiology 83.16–17
 underlying diseases 83.18, **83.19**
 pruritic papular eruption (PPE) of
 HIV 31.16–17
 children 31.35
 pruritus 83.3–15
 acquired ichthyosis 87.2
 ancyllostomiasis 33.15
 ani 113.4–6, 128.17
 clinical features 113.5–6
 Crohn disease differential
 diagnosis 113.25
 pathophysiology 113.4–5
 aquagenic 83.11
 atopic eczema 41.14–15
 atopic eruption of pregnancy 115.15
 brachioradial 83.13
 bullous pemphigoid 50.17
 central sensitization 83.5–6
 cholestatic 83.11
 chronic 83.3–12
 prurigo nodularis 83.16
 chronic renal disease 83.10–11
 classification 83.3
 clinical features 83.7–14
 clinical variants 83.8–9
 definition 83.3
 delusional infestation differential
 diagnosis 86.6
 dermatoses 83.8–9
 diabetes association 64.7
 diabetogenic 83.12
 diagnosis 83.14–15
 diseases inducing 83.3, **83.4**
 drug-induced 83.12, 118.3–4
 elderly people 83.13
 enterobiasis 33.13
 epidemiology 83.3–4
 generalized 147.26
 gold therapy 122.4
 gravidarum 115.10
 hepatobiliary disease 83.11
 histamine role 41.14
 HIV infection 31.12
 Hodgkin disease 140.49
 inflammation 8.1–2
 investigations 83.14–15
 iron deficiency 83.11
 lichen planus 37.5
 liver disease association 152.8
 localized 147.26
 male genital **111.2**
 malignancy association 147.26
 management 83.15
 measurement 83.14
 medicament 128.28
 nephrogenic 83.10–11
 neuropathic 83.13
 NF1-associated 80.4
 nocturnal 83.14
 notalgia paraesthetica 83.13
 paraneoplastic 83.12, 83.15, 147.26,
 148.10
 pathophysiology 83.4–7
 peripheral sensitization 83.5–6
 polycythaemia vera 83.11
 pregnancy 83.12–13
 premonitory 83.12, 83.15
 psoriasis 83.8, 83.9–10
 psychogenic 83.13–14, 86.21–2
 PUVA side effect 21.12
 quality of life 83.3
 recessive generalized severe dystrophic
 epidermolysis bullosa 71.16
 renal failure 153.3
 scalp 107.12–14
 clinical features 107.13
 epidemiology 107.12
 investigations 107.14
 management 107.14
 pathophysiology 107.12–13
 presentation 107.13–14
 scratching 83.5
 seborrhoeic dermatitis association 40.2
 senescence 83.13
 severity classification 83.14
 Sézary syndrome 83.6
 skin barrier function effects 155.9
 skin picking disorder differential
 diagnosis 86.15
 symptomatic treatment 83.15
 systemic disease 83.10–14
 systemic sclerosis 56.4, 56.15
 thyrotoxicosis 83.12
 UVB phototherapy side effect 21.11
 vulvae 128.17
 see also itching
 P-selectin 8.7, 8.18
 pseudo familial hypercholesterolaemia
 62.6, 93.1–2
 pseudoacanthosis nigricans 111.27
 pseudo-ainhum 65.48, 96.43, 96.44–5
 acquired 96.45
 congenital 96.44–5, 116.18
 pseudoallergy 118.6
 pseudoangiosarcoma 110.72
 pseudochancre redux 111.24–5
 pseudochromohidrosis 94.17
 pseudoclubbing 95.6
 pseudo-Cushing syndrome *see* HIV-associated lipodystrophy
 pseudocyst of ear 108.10–11
 pseudoepitheliomatous
 hyperplasia 133.7–8
 pseudoepitheliomatous micaceous and
 keratotic balanitis (PEMKB) 111.29
 pseudofolliculitis 93.1–2
 vulval staphylococcal infection
 differential diagnosis 112.24
 pseudofolliculitis barbae 123.23
 laser-assisted hair removal 23.15, 23.16
 sycosis differential diagnosis 26.27
 pseudofolliculitis vibrissae 123.23
 pseudo-Hutchinson sign 144.8, 144.10
 pseudo-Kaposi sarcoma, haemodialysis
 complication 153.4
 pseudo-knuckle pads 96.34, 96.35
 knuckle pads differential
 diagnosis 96.35
 pseudologica fantastica 86.29–30
 pseudolymphoma 135.1–3
 aphthous ulceration 110.41
 clinical features 135.2
 cutaneous 31.32
 definition 135.1
 epidemiology 135.1–2
 investigations 135.2
 management 135.3
 tattoo-associated 123.22
 pseudomembranous disease,
 candidosis 31.26
Pseudomonas
 botryomycosis 26.72
 chronic paronychia 95.37
 diabetic infections 64.3
 HIV infection 31.20
 nail plate pigmentation 95.12, 95.13
 yellow nail syndrome 95.14
 see also *Stenotrophomonas maltophilia*
Pseudomonas aeruginosa 26.4, 26.50–2
 cellulitis 26.18–19
 clinical features 26.51–2
 ecthyma 26.17
 gangrenous 116.26
 erysipelas 26.18–19
 HIV infection 31.20
 infection in Langerhans cell
 histiocytosis 136.4
 investigations 26.52
 management 26.52
 noma neonatorum 116.26
 otitis externa 108.17
 necrotizing 108.20
 pathophysiology 26.50–1
 septicaemia 26.52
 variants 26.52–3
 pseudomonilethrix 68.19
 pseudomyogenic
 haemangioendothelioma 137.35–6
 pseudopelade of Brocq 89.41–2
 pseudophotodermatitis 128.53
 Compositae allergy 128.52
 pseudoporphyria 60.18–19, 127.28
 renal failure 153.4
 pseudoscars
 diabetes 96.12
 stellate 96.11
 pseudosyndactyly
 Kindler syndrome 71.19
 recessive generalized severe dystrophic
 epidermolysis bullosa 71.17
 pseudoanthoma elasticum 72.26–31
 acquired 96.28
 calcification 61.4
 cardiovascular changes 72.28–9, 72.30
 clinical features 72.27–30
 coronary artery disease 150.5
 cutis laxa differential diagnosis 96.20
 definition 72.26
 diagnostic criteria **72.28**
 differential diagnosis 72.30, 96.4, 96.20
 Ehlers–Danlos syndrome
 association 72.1
 epidemiology 72.27
 gastrointestinal changes 72.29, 72.30
 iatrogenic 96.28
 investigations 72.30
 management 72.30
 mechanical properties of skin 123.5
 obstetric risk 72.29
 ocular changes 72.29, 72.30
 pathophysiology 72.27
 perforating 96.28
 pregnancy 115.6
 proteoglycans 2.40
 resources 72.31
 skin changes 72.27–8
 solar elastosis differential diagnosis 96.4
 toxic 96.28
 variants 72.29–30
 psittacosis 26.76
 erythema marginatum association 47.12
 psoralen
 hypertrichosis **89.63**
 ocular side effects 109.46
 phototoxicity 129.10
 see also photochemotherapy (PUVA)
 psoralen photoadducts 21.1, 21.8–9
 eye effects 21.14
 psoriasisiform hyperkeratosis *see*
 keratoderma blenorrhagica
 psoriasisiform napkin dermatitis 35.11, 40.3
 psoriasisiform sarcoidosis 98.13
 psoriasis 35.1–42
 acrodermatitis continua of
 Hallopeau 95.41
 acrodermatitis enteropathica differential
 diagnosis 63.26
 acropustulosis 95.41
 alcohol abuse co-morbidity 86.32
 alcohol misuse 35.4

- allergic contact dermatitis differential diagnosis 128.61, 128.62
- alopecia areata association 89.29
- ano-genital 111.9–10, 112.16–17
- assessment tools 16.2–3
- disease-specific quality of life measures 16.5–6
- atypical 35.17
- basal cell carcinoma differential diagnosis 141.11
- cancer association 35.20
- cardiovascular disease association 35.21
- chemokine role 8.40
- chemotherapy-induced nail change differential diagnosis 120.7
- Chikungunya fever association 25.76
- children 35.17–18
- chronic obstructive pulmonary disease association 35.21
- classification 35.2
- clinical features 31.15, 107.2–3
- co-morbidities 11.6
- cost-of-illness 6.7–9
- Crohn disease association 35.20
- defensin activity 8.14
- diabetes association 64.7
- differential diagnosis 31.15, 95.44
- discoid lupus erythematosus differential diagnosis 51.9
- disease association 5.10
- disease-specific quality of life measures 16.5–6
- distress 11.6
- DRESS differential diagnosis 119.10
- drug combinations 18.25
- drug-induced 35.4
- economic burden 6.7–9
- elephantine 35.17
- epidemiology 107.2
- erythrodermic 35.16–17, 39.32, 107.3
- exacerbated 35.18
- by antimetabolites 19.6
- exanthemic pustular 119.1–4
- extramammary Paget disease differential diagnosis 112.37
- eyelids 35.14, 109.5
- flexural 35.11
- erythrasma differential diagnosis 26.40
- gel nail contraindication 95.62
- genetics 35.2–4
- geographic tongue 35.14, 35.15
- hand eczema differential diagnosis 39.16
- histopathology 35.6–7
- HIV infection 31.15–16, 35.18
- ichthyosis linearis circumflexa 89.53
- immune activation 35.6
- infantile 35.11, 117.4
- infection association 35.4, 35.20
- inflammatory bowel disease association 35.20, 114.4–5, 152.3
- inflammatory linear verrucous epidermal naevus overlap 75.5
- integrated management 11.8
- integrins 8.9–10
- irritant contact dermatitis differential diagnosis 129.4, 129.5
- keratolysis exfoliativa differential diagnosis 87.24
- keratosis circumscripta differential diagnosis 87.12
- Koebner phenomenon 35.5, 123.2, 129.4
- Langerhans cell role 8.29
- laser treatment 23.11
- lichen striatus differential diagnosis 37.20
- lichenification differential diagnosis 39.30
- lifestyle behaviours 11.6
- linear 35.17, 35.18
- liver disease association 35.21
- lower leg eczema differential diagnosis 39.20
- lupus vulgaris differential diagnosis 27.24
- macrophage inhibitory factor role 8.22
- male genital 111.9–10
- management 19.10, 19.16, 31.15, 107.3
- biological therapies 19.29, 19.31, 31.16
- calcipotriol 18.25
- coal tar use 18.32
- mechlorethamine therapy 18.27–8
- methotrexate 19.22
- psychological distress 11.4
- topical tacrolimus 18.20
- vitamin D analogues 18.24
- metabolic syndrome association 35.21
- MHC role 8.27
- MMP activity 8.43
- mucosal lesions 35.14, 35.15
- nail plate abnormalities 95.40
- nails 35.12–14, 35.15, 95.38–43
- differential diagnosis 95.44
- discoloration 95.40
- onycholysis 95.9, 95.39–40
- proximal nail fold capillaroscopy 95.53
- non-pustular palmoplantar 35.12, 35.13
- nummular dermatitis differential diagnosis 39.9
- occupational 130.1, 130.2
- ocular lesions 35.14
- older people 35.18
- onycholysis 95.9, 95.39–40
- onychomycosis differential diagnosis 31.26
- oral mucosa 110.78
- ostraceous 35.17
- parakeratosis pustulosa association 95.41, 117.4
- paronychia
- acute 95.41
 - subacute 95.41
- pathogenesis 8.7
- HIV infection 31.15
 - plaque-type 35.6
- pathophysiology 107.2
- plaque-type 35.2–7
- patient education 15.3
- perineum/perianal region 113.7
- photoaggravated guttate 127.32
- photosensitive and polymorphic light eruption association 127.2
- phototherapy 31.15, 31.16
- physical trauma association 35.5–6
- pityriasis rotunda differential diagnosis 87.8
- pityriasis rubra pilaris differential diagnosis 36.4
- platelet role 8.26
- porokeratosis differential diagnosis 87.21
- pregnancy 115.8
- outcomes 35.21
- pro-/anti-inflammatory prostanoid receptor targeting 8.49
- proximal nail fold capillaroscopy 95.53
- pruritus 83.8, 83.9–10
- psychological distress 11.3, 11.4, 15.2, 35.4–5, 35.20, 86.2–3
- psychological impact 11.2–4
- PUVA 21.4, 31.15
- radiodermatitis differential diagnosis 120.13
- rupioid 35.17
- scale removal 35.9, 107.2–3
- scalp 35.10–11, 107.2–3
- seborrhoeic dermatitis differential diagnosis 31.15, 35.19, 39.4, 107.1, 107.3
- segmental 35.17
- seronegative arthritis/spondylitis 154.5
- skin cancer association 35.20, 146.5
- social stigma 11.5, 16.6
- static 35.15–16
- stoma complication 114.4–5, 114.6, 152.7
- subacute cutaneous lupus erythematosus association 51.12
- subungual hyperkeratosis 95.40
- sunlight association 35.5
- symmetrical drug-related intertriginous and flexural exanthem differential diagnosis 118.6
- systemic lupus erythematosus association 51.31
- tattoo association 123.21
- tinea corporis differential diagnosis 32.37
- tinea cruris differential diagnosis 32.47
- TNF antagonist-induced 19.30
- TNF- α treatment 8.35
- tonsillitis association 35.4
- topical corticosteroid formulations 18.18–19
- topical tacrolimus therapy 18.20
- transient acantholytic dermatosis association 87.22
- treatment options 17.6
- Turner syndrome 76.3
- unstable 35.16
- UVB phototherapy 21.4, 21.7–8
- uveitis 35.14
- variants 35.15–18
- vulval 112.16–17
- warts 25.50
- Psoriasis Area and Severity Index (PASI) 16.2
- Psoriasis Disability Index (PDI) 16.5
- Psoriasis Family Impact questionnaire 16.7
- psoriasis, guttate 35.15–16, 127.32
- children 35.18
- differential diagnosis 35.18–19
- perianal streptococcal cellulitis association 26.33
- pityriasis lichenoides differential diagnosis 135.5
- pityriasis rosea differential diagnosis 25.92
- streptococcal infections 26.10
- Psoriasis Life Stress Inventory (PLSI) 16.6
- psoriasis, plaque 19.16, 35.1–31, 35.2–7, 142.20
- biological therapy 35.29–31
 - blistering with UVB phototherapy 21.11
 - cigarette smoking 35.4
 - clinical features 35.7–22
 - complications/co-morbidities 35.20
 - disease course 35.21–2
 - environmental factors 35.4–6
 - epidemiology 35.1–2
 - flexural 35.11
 - follicular 35.11
 - genetics 35.2–4
 - genital 35.11–12
 - histopathology 35.6–7
 - history taking 35.7
 - HIV infection 35.18
 - immune-mediated inflammatory diseases 35.20
 - investigations 35.22
 - management 35.22–31
 - pathophysiology 35.2–7
 - phototherapy 35.25–6
 - presentation 35.8–10
 - prognosis 35.21–2
 - scaling 35.9–10
 - scalp 35.10–11
 - seborrhoeic 35.11
 - severity classification 35.19–20
 - systemic therapy 35.26–9
 - thickness measurement 16.3
 - topical therapies 35.22–5
 - treatment 19.16, 35.26, 35.28
 - treatment ladder 35.31
- psoriasis, pustular 35.32–42, 119.4
- acrodermatitis continua of Hallopeau 35.40–2
- amicrobial pustulosis of the skin folds differential diagnosis 49.17
- CARD14-mediated 45.11
- generalized 35.32–7
- acute 35.34
 - acute of pregnancy 35.35
 - complications/co-morbidities 35.36
 - definition 35.32–3
 - differential diagnosis 35.36
 - disease course 35.36
 - epidemiology 35.33
 - infantile/juvenile 35.35–6
 - investigations 35.36
 - management 35.36–7
 - pathophysiology 35.33–4
 - pregnancy 115.8
 - prognosis 35.36
 - severity classification 35.36
 - subacute annular 35.34–5
 - variants 35.34–6
- nail shedding 95.8
- palmoplantar pustulosis 35.37–40
- subcorneal pustular dermatosis differential diagnosis 49.15
- Psoriasis Symptom Inventory (PSI) 16.3
- psoriatic arthritis 35.20, 35.42–6
- causes 35.44
 - classification 35.43
 - clinical features 35.44
 - definition 35.42–3
 - diagnosis 35.44
 - differential diagnosis 35.44
 - epidemiology 35.43–4
 - genetics 35.43
 - investigations 35.44
 - management 19.29, 19.31, 35.45, 35.46
 - MMP-9 expression 8.43
 - nail psoriasis 35.13
 - pathophysiology 35.44
 - presentation 154.2
 - severity classification 35.44
 - treatment 35.44–6
 - uveitis association 35.14
- PSORIQoL 16.6
- Psoroptidae 34.47
- PSTPIP1 gene mutations 45.8
- PSTPIP1/CD2BPI gene mutations 49.3
- psychiatric disorders
- alcohol abuse co-morbidity 86.32
 - bullous pemphigoid association 50.11
 - Dercum disease differential diagnosis 100.17
 - genital chronic pain syndromes 111.36
 - glucocorticoid adverse effects 19.19, 19.20
 - oral manifestations 110.89
 - pruritus 83.13–14
 - retinoid-induced 19.38
 - seborrhoeic dermatitis association 40.4
 - systemic lupus erythematosus 51.29
 - xeroderma pigmentosum 78.6
- psychoanalysis 86.39–40
- psychodermatology 1.8, 86.1–4
- alcohol misuse 86.32
 - assessment 86.4
 - coping strategies 86.3–4
 - deliberate self-harm 86.30–1
 - delusional beliefs 86.4–10
 - depression 86.32–3
 - disability 86.4
 - disease classification 86.2
 - drug treatments 86.35–8
 - eating disorders 86.20–1, 89.63
 - factitious skin disease 86.22–32
 - golden rules 86.2–3
 - multidisciplinary teams 86.2
 - organizations 86.2
 - psychiatric treatments 86.35
 - psychogenic itch 86.21–2
 - quality of life 86.4
 - service provision models 86.2
 - stigmatization 86.3–4
 - suicide 86.33–5
 - visible differences 86.3–4
 - see also obsessive-compulsive disorder
- Psychodidae 34.6
- psychogenic itch 86.21–2
- psychological distress
- atopic eczema association 41.15, 41.28
 - copied 11.4
 - embarrassment 11.4
 - psoriasis 11.3, 11.4, 15.2, 35.5, 35.20, 86.2–3

- psychological factors 11.1–8, 15.2
 acne vulgaris 90.23, 90.34–5
 alopecia areata 86.3
 atopic eczema 41.15, 86.2
 blushing 106.3
 chronic skin disease 86.2–3
 chronic spontaneous urticaria 86.3
 impact of dermatological conditions 11.2–4
 integrated clinical management impact 11.7–8
 non-adherence to treatment 11.4
 treatment challenges 11.6–7
 psychological therapies 86.38–40
 cognitive behavioural therapy, body dysmorphic disorder 86.12–13, 86.39
 therapeutic relationship 86.39
 wart treatment 25.54
 psychoneuroimmunology 11.3
 Psychosomatic Scale for Atopic Dermatitis (PSS-AD) 16.6
 psychotherapy
 dynamic 86.39–40
 interpersonal 86.39
 psychotropic drugs 88.27
 acne association 90.11
PTCH1 mutations 141.3, 141.15, 141.18
PTEN gene mutations 73.9, 80.13, 110.24
PTEN hamartoma of soft tissue 147.11
PTEN hamartomatous tumour syndrome 73.9, **74.8**, 80.13–15, 132.3, 147.11
 arteriovenous malformations 73.7
 basal cell carcinoma **141.5**
 benign symmetrical lipomatosis differential diagnosis 100.15
 clinical features 80.14
 congenital epidermal naevi 75.3–4
 diagnosis 80.14
 genetics 80.13, **80.14**
 infiltrating lipomatosis of the face differential diagnosis 100.18
 malignancy association 147.11
 management 80.15
 mucocutaneous lesions 80.14
 oral lesions 110.24
 pathophysiology 80.14
 punctate keratoderma 147.17
 storiform collagenoma association 137.3
p-tertiary-butylphenol formaldehyde resin 128.14
 pterygium syndromes 72.33, 95.10
 pterygoid muscles 110.5
Phthirus pubis 34.17, 34.22–3
 ptosis 109.5
 blepharochalasis differential diagnosis 96.25
 Horner syndrome 85.15
PTPN11 gene mutations 80.8
PTPN14 gene mutations 73.20
 puberty
 age effects on drug therapeutic outcomes 14.7
 androgen effects on hair growth 89.8–9
 hair growth 89.9
 miniature 116.4
 pubic hair 111.5
 hair pulling 86.17, 86.18
 pubic lice, perineum/perianal region 113.13
 public health 5.4–8
 PubMed Clinical Queries 17.7
Pulex irritans 34.12
 Pulicidae 34.12
 pulmonary arterial hypertension in systemic sclerosis 56.11, 56.15, 56.18, 56.21
 pulmonary stenosis with café-au-lait macules 80.5, 80.7
 pulmonary thromboembolism, venous malformation association 73.11
 pulse granuloma 110.61–2
 pulsed dye lasers (PDL) 23.6
 complications 23.11
 granuloma faciale 23.11
 hidradenitis suppurativa management 92.11
 hypertrophic scars 23.10
 infantile haemangioma treatment 117.22
 keratosis pilaris treatment 87.11
 leg veins 23.10
 port-wine stains 23.7–9
 psoriasis 23.11
 telangiectases 23.9–10
 viral warts 23.10, 23.11
 punctate keratoderma of genetic origin palmoplantar 65.51–2, 65.54
 plantar wart differential diagnosis 25.50
 punctate keratosis of palmar creases 65.53
 purpura 101.1–25
 acroangiodermatitis 101.5
 actinic 101.5
 allergic contact dermatitis 128.60
 allergic genital anaphylactoid 111.20
 amyloid 58.10
 annular in sports enthusiasts 123.15
 annularis telangiectodes 101.8, **101.9**
 antiphospholipid syndrome 101.17, 101.19–20
 artefact 86.27
 artefactual bleeding 101.6–7
 atrophie blanche 101.22–3
 Bateman 101.5, 155.3–4
 benign hypergammaglobulinaemic 101.7–8
 calcific uraemic arteriopathy 101.24–5
 cardiac embolus 101.16–17
 causes **101.2**
 non-thrombocytopenic **101.6**
 cholesterol emboli 101.15–16
 classification 101.2, **101.3**
 colour change 101.1–2
 contact dermatitis **101.9**
 corticosteroid 101.5–6
 cryogelling/cryoagglutination disorders 101.12–15
 cultural remedies 101.6
 Cushing syndrome 101.5–6
 cutaneous microvascular occlusion disorders 101.10–15
 cutaneous vasculitis differential diagnosis 102.4
 definition 101.1
 differential diagnosis 101.1
 dysproteinaemic 101.7–8
 emboli 101.15–20
 exercise-induced 101.5, **101.9**
 external causes **101.2**
 Fabry disease differential diagnosis 81.8
 Favre–Chaix 101.8
 fulminans, neonatal 116.21, 116.26
 granulomatosis with polyangiitis 102.25
 gravitational 101.4–5
 heparin necrosis 101.10–11
 infections in vessels 101.15
 with inflammation **101.2**
 intravascular bleeding 101.2
 itching 101.8, **101.9**, 101.10
 lichen aureus 101.8, **101.9**, 101.10
 livedoid vasculopathy 101.22–3
 localized oral 110.68
 lupus anticoagulant syndrome 101.19–20
 malignant atrophic papulosis 101.23–4
 management 101.1
 mechanical vascular causes **101.2**
 myeloproliferative disorders 101.11–12
 oral hyperpigmentation 110.68
 oxalate embolus 101.16–17
 paroxysmal finger haematoma 101.6
 physical bleeding 101.6–7
 pigmented purpuric dermatoses 88.49, 101.8–10
 platelet disorders **101.4**
 platelet plugging 101.10–12
 progressiva pigmentosa 101.8
 protein C/protein S deficiency 101.17–19
 raised intravascular pressure 101.4–5
 scurvy 101.6
 senile 155.3–4
 Sjögren syndrome 55.6
 Sneddon syndrome 101.21–2
 solar 101.5
 systemic coagulopathies 101.17–20
 thrombocytopenia 101.3, **101.4**
 thrombocytosis 101.11–12
 transfusion association 148.19
 vascular coagulopathies 101.21–5
 Waldenström
 hypergammaglobulinaemic 101.7–8
 pustular bacterid 35.38–9
 pustular miliaria, folliculitis differential diagnosis 26.22
 pustular ulcerative syphilide 29.13
 pustules 3.38
 bowel-associated dermatosis–arthritis syndrome 49.13
 iatrogenic of scalp 107.12
 monkeypox 25.8
 vaccinia virus 25.7
 pustulosis
 amicrobial of the skin folds 49.16–17
 autoinflammatory syndromes with 45.7–8
Malassezia 116.27
 neonatal cephalic 116.27
 see also acute generalized exanthematous pustulosis (AGEP); palmoplantar pustulosis
 PUVA see photochemotherapy (PUVA)
 pyknosis 3.38
 pyoderma
 chancriform 26.82–3
 cicatricial pemphigoid differential diagnosis 50.51
 faciale 90.29, 91.15–16
 fistulous signfica 92.1
 mycosis-like 49.16
 vegetans 26.83, 49.16
 pyoderma gangrenosum 49.1–6, 148.7
 acne conglobata association 90.54
 associated diseases 49.1–2
 atypical 49.1
 bullous variant 49.4, 148.7
 classical ulcerative 49.1, 49.3
 clinical features 49.3–5
 cocaine use 121.3
 complications/co-morbidities 49.5
 definition 49.1
 differential diagnosis 49.4
 disease course 49.5
 dissecting cellulitis of scalp differential diagnosis 107.8
 ecthyma differential diagnosis 26.17
 epidemiology 49.1–2
 extracutaneous 49.4
 genetics 49.3
 genital ulceration 111.18
 glanders differential diagnosis 26.54
 granulomatous superficial 49.4
 hepatitis association 152.9
 hidradenitis suppurativa association 92.2
 hypertensive ischaemic leg ulcer differential diagnosis 104.13
 infantile 26.84
 inflammatory bowel disease association 152.2
 investigations 49.5
 malignancy association 147.23
 management 49.5–6
 necrotizing subcutaneous infection differential diagnosis 26.74
 neutrophil role 49.2
 neutrophilic dermatosis of dorsal hands differential diagnosis 49.10
 nomenclature 49.1
 parastomal 49.3–4
 pathophysiology 49.2–3
 penile ulceration differential diagnosis 111.8
 pityriasis lichenoides differential diagnosis 135.5
 prognosis 49.5
 pustular 49.4
 pyogenic sterile arthritis, pyoderma gangrenosum and acne syndrome **45.3**, 45.8
 respiratory disorder association 151.5
 rheumatoid arthritis association 154.6–7
 rheumatoid neutrophilic dermatosis 55.3
 sarcoidosis association 98.14
 severity classification 49.4–5
 stoma complication 114.7–8, 114.9, 114.10, 152.7
 subcorneal pustular dermatosis association 49.14
 Sweet syndrome coexistence 148.7
 systemic lupus erythematosus association 51.30
 ulcerative colitis association 154.5
 variants 49.1, 49.3–4
 pyoderma gangrenosum, acne conglobata and suppurative hidradenitis (PASH) syndrome 49.2, 49.3, 49.6, 90.54
 after bowel bypass surgery 49.12
 pyoderma gangrenosum, acne conglobata, suppurative hidradenitis and seronegative spondyloarthritis (PASS) syndrome 90.54
 pyodermatitis–pyostomatitis vegetans 49.16
 inflammatory bowel disease association 152.2–3
 pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome 49.2, 49.3, 49.6
 acne association 154.10
 pyogenic granuloma 137.26–8
 acne 90.36
 bacillary angiomatosis differential diagnosis 26.62
 clinical features 137.27
 definition 137.26
 epidemiology 137.26
 granuloma gravidarum 137.26
 hidradenitis suppurativa 92.5
 Kaposi sarcoma differential diagnosis 31.29
 laser therapy 23.10
 management 137.27–8
 molluscum contagiosum differential diagnosis 25.13
 nail apparatus 95.21–2
 orf differential diagnosis 25.10
 pathophysiology 137.26–7
 pregnancy 115.2
 pyogenic sterile arthritis, pyoderma gangrenosum and acne (PAPA) syndrome **45.3**, 45.8, 90.9
 acne conglobata association 90.54
 acne fulminans association 90.50–1
Pyrometes mites 34.49
 pyostomatitis vegetans
 oral lesions 110.42
 pyoderma gangrenosum differential diagnosis 49.4
 pyrantel pamoate
 ancylostomiasis **33.15**
 enterobiasis treatment 33.14
 pyrazinamide 27.9, 27.10
 pyrethroids 18.13
 pyridoxine deficiency 63.17–18
 niacin deficiency differential diagnosis 63.17
 pyrimethamine, toxoplasmosis treatment 33.52
 pyruvic acid, chemical peel 159.4
Pythium insidiosum 32.95
Q
 Q fever, infectious panniculitis 99.44
 Q-switched lasers 23.3, 23.12
 actinic lentigines 23.12–13
 ephelides 23.12
 genital melanosis treatment 23.13
 lentigines 160.5
 lentiginous naevi 23.14

- melanocytic naevi 23.14
 melasma treatment 160.5–6
 naevus of Ota 23.14
 pigmented lesion treatment 160.4–6
 speckled naevi 23.14
 tattoo treatment 23.12
 quality of life 4.5, 86.4
 acne measures 16.6
 acne vulgaris impact 90.33, 90.34, 90.34
 assessment 16.4
 atopic eczema 41.21
 measures 16.6
 dermatology-specific measures 16.4–5
 disease-specific measures 16.5–6
 general health measures 16.4
 health economics 6.3, 6.4–5, 6.9
 hidradenitis suppurativa 92.9
 measures 16.4–7
 clinical use 16.8
 minimal clinically important difference (MCID) of score 16.4
 morphea 57.23
 pruritus 83.3
 psoriasis measures 16.5–6
 seborrheic dermatitis 40.4–5
 quality-adjusted life year (QALY) 6.3, 6.4, 16.6
 quantitative risk assessment (QRA)
 procedure 128.2
 quaternium-15 128.34
 Questionnaire on Experience with Skin Complaints (QES) 16.6
 Quincke's oedema *see* angio-oedema
 quinines
 photoallergic contact dermatitis 128.78
 phototoxicity 127.28
 quinolones 119.2, 119.4
- R**
- racial factors
 actinic keratoses 142.2
 allergic contact dermatitis 128.6
 multiple self-healing squamous epithelioma 142.36
 sarcoïdosis 98.2, 98.13
 skin colour 88.2
 variation 88.9
 squamous cell carcinoma 142.26
 radiation
 acute reaction 24.16–18
 epilation 24.6
 late reaction 24.18–19
 occupational actinic keratosis 142.2
 post-ionizing radiation keratosis 142.14
 squamous cell carcinoma
 complication 142.27
 visible 9.1
 radiation carcinogenesis 24.6, 24.7
 risk 24.3
 radiation recall, chemotherapy-induced 120.11–12
 radical oxygen species 8.44–5
 radiodermatitis 107.4, 107.5, 120.12–14
 acute 24.16–18, 120.13
 ano-genital 111.11
 chronic 24.18–19, 120.13
 clinical features 120.12–13
 epidemiology 120.12
 grades 120.13
 infections 120.13
 investigations 120.13
 management 24.17–18, 120.13
 pathophysiology 120.12
 perineum/perianal region 113.8
 radiation recall differential diagnosis 120.12
 radiofrequency devices, skin tightening 160.10–11
 radioisotope scans 4.22
 radiosensitivity 24.3
 radiotherapy 24.1–19
 abdominal wall lymphoedema cause 105.21
 actinic keratosis incidence 142.3
 adjuvant
 skin cancer 140.9
 squamous cell carcinoma treatment 142.32
 angiosarcoma induction 120.13, 137.36, 137.37
 applicators 24.2
 atypical fibroxanthoma 24.19, 137.22
 atypical vascular proliferation after 137.40, 137.41
 basal cell carcinoma 140.7–12
 adjuvant 140.9
 recurrence 24.19
 treatment 141.16
 bathing cap distribution 24.3, 24.4
 benign conditions 24.3, 24.6–7
 Bowen disease 24.13
 treatment 142.23
 cutaneous B-cell lymphoma 24.16
 cutaneous lymphoma 24.14
 cutaneous T-cell lymphoma 24.16
 dermatofibrosarcoma
 protruberans 24.14
 dosage 24.3
 dose fractionation 24.9
 hidradenitis suppurativa management 92.11
 HIV infection 31.34
 implants 24.2, 24.7
 indications for 24.3, 24.6–9
 intensity modulated 24.3
 Kaposi sarcoma 24.13
 keloid 24.7
 keratoacanthoma 24.6, 142.36
 lentigo maligna 24.13
 lentigo maligna melanoma 24.13
 malignant conditions 140.7–9
 megavoltage X-ray therapy technique 24.3
 melanoma 24.13
 Merkel cell carcinoma 145.8
 metastases 24.14
 morphea association 57.10–11
 morphea induction 120.14
 moulds 24.2
 mycosis fungoides management 24.14–16, 140.24
 panniculitis induction 120.14
 post-ionizing radiation keratosis 142.14
 post-irradiation angiosarcoma 120.13, 137.36, 137.37
 sarcoma development 24.19
 sclerosing postirradiation
 panniculitis 99.59–61
 Sézary syndrome 140.24
 skin cancer 24.1–16, 146.9, 146.14
 adjuvant 140.9
 recurrence 24.19
 skin side effects 120.12–14
 squamous cell carcinoma 140.7–13
 adjuvant 140.9
 recurrence 24.19
 treatment 142.32
 stocking distribution 24.3, 24.5–6
 superficial treatment technique 24.2, 24.3
 Sweet syndrome association 148.6
 swollen breast 105.23
 TomoTherapy 24.3, 24.5–6
 treatment regimens 24.9
 tumours induced by/recurrence 24.19
 ulceration 120.13
 vascular neoplasms 120.13
 X-ray photon beams 24.1
 see also electron beam radiotherapy
 raised linear bands of infancy 116.17–18
 raltegravir 31.10
 Ramsay Hunt syndrome 84.3
 external ear 108.15
 random-effects models 17.9–10
 randomized controlled trials (RCT)
 evidence-based medicine 17.2–3
 negative results 17.3
 question type 17.5
 systematic reviews 17.8
 range (data) 17.18
 RANTES 2.12, 8.38
 ranula 110.60–1
 rapamycin
 hidradenitis suppurativa induction 92.3
 port-wine stains 23.9
 Rapp-Hodgkin syndrome 67.16
 Rapunzel syndrome 86.19
 RAS gene mosaicism 75.6
 RASA1 gene mutations 73.3, 103.20, 103.25, 103.27
 rash
 acrodermatitis enteropathica 81.17
 adult-onset Still disease 45.10
 ancylotomiasis 33.15
 antimony reactions 122.2
 autoinflammatory granulomatosis of childhood 45.7
 complement deficiency 82.18
 dermatomyositis 53.4, 53.5, 53.6, 53.11
 ehrlichiosis 26.63
 enterovirus infection 25.80, 25.81
 gold therapy 122.3–4
 meningococcal disease 26.49
 neonatal 116.10
 papular facial 90.31–2
 rubella infection 25.78, 25.79
 severe combined immunodeficiency 82.7
 syphilis
 congenital disease 29.28, 29.30
 secondary disease 29.10, 29.11, 29.12
 Ras/MAPK pathway 80.8, 80.9
 RASopathies 75.6, 75.14, 80.8–9, 150.3–4
 see also neurofibromatosis type 1 (NF1)
 rat-bite fever 26.71–2, 131.4–5
 streptobacillary 26.72
 rational medicine 1.2–3
 rationalization (economic) 6.5
 Raynaud disease 125.8
 hand-arm vibration syndrome
 differential diagnosis 123.24
 primary biliary cirrhosis 152.5
 Raynaud phenomenon 125.8–10
 acrocyanosis differential diagnosis 125.5
 acroosteolysis 95.47
 aetiology 125.8
 clinical features 125.9
 definition 125.8
 diagnosis 56.18, 56.19
 diagnostic criteria 125.8
 digital nerves 85.3
 epidemiology 125.9
 fibroblastic rheumatism 55.4, 154.8
 hyperhidrosis 94.5
 investigations 125.9
 malignancy association 147.24
 management 125.9–10
 mechanical properties of skin 123.5
 nail fold capillaroscopy 56.13–14
 pathophysiology 125.9
 penile 111.19
 primary 125.8, 125.9
 proximal nail fold capillaroscopy 95.51–2
 rheumatoid arthritis 55.3
 secondary 125.8, 125.9
 Sneddon syndrome 101.21
 systemic lupus erythematosus 51.24
 systemic sclerosis 56.4, 56.13–14
 differential diagnosis 56.15
 vibration white finger 123.23, 130.14–15
 see also mixed connective tissue disease
 reactive angioendotheliomatosis 137.24–5
 malignant form 137.24
 reactive arthritis 110.31, 154.2
 Chlamydia infection 30.12, 30.13, 30.15
 vulval 112.17
 reactive cutaneous lymphoid hyperplasia
 see lymphocytoma cutis
 reactive dermopathy 72.18
 reactive inflammatory erythemas 47.1–15, 47.16
 reactive oxygen species (ROS) 9.4, 9.5
 ageing of skin 8.44, 155.4, 155.6, 155.7–8, 155.9
 DNA damage in basal cell carcinoma 141.3
 5-LO in induction of production 8.49
 matrix metalloproteinase induction 9.11
 signal transduction pathway stimulation 8.45
 skin ageing 155.4, 155.6, 155.7–8, 155.9
 reactive perforating collagenosis 153.3
 rebound phenomenon, topical corticosteroids 18.18
 recall reaction, chemotherapy-induced 120.11–12
 receptor tyrosine kinases (RTKs) 14.4, 14.5
 receptor-effector system 14.4
 recombinant DNA technology 19.28
 recombinant human growth hormone (rhGH)
 burn treatment 126.10
 therapy 149.17
 RECQL2 gene 72.22
 recurrent aphthous stomatitis, Adamantiades-Behçet disease association 48.2
 recurrent cutaneous necrotizing eosinophilic vasculitis 102.10–11
 recurrent focal palmar peeling 39.15
 recurrent oro-facial and cutaneous herpes 25.18–20
 recurrent toxin-mediated perineal erythema 26.32
 red burning scrotum syndrome 111.36
 Reduviidae 34.27–8
 re-epithelialization, wound healing 10.1, 10.4–6, 10.10
 refeeding syndrome 63.6
 reflectance confocal microscopy 4.21–2, 95.49, 95.50
 skin ageing measurement 155.5
 reflex neurovascular dystrophy 85.13
 reflex sympathetic dystrophy 85.13
 hyperhidrosis 94.5
 see also complex regional pain syndrome (CRPS)
 Refsum disease 65.27–9
 clinical features 65.28–9
 definition 65.27
 genetics 65.28
 infantile 65.28
 management 65.29
 pathophysiology 65.28
 regulatory T cells (T_{reg}) 8.29, 8.30
 allergic contact dermatitis 128.7
 atopic eczema 41.10–11
 dendritic cell actions 8.35
 mycosis fungoides 140.6–7
 regulome 7.1
 relapsing fever 26.68–9, 34.21
 epidemic 26.68–9
 louse-borne 26.68–9
 tick-borne 26.69, 34.35, 34.38
 relapsing polychondritis 154.11–13
 associated conditions 154.11
 clinical features 154.11–13
 definition 154.11
 diagnosis 154.13
 disease course 154.12
 ear piercing complications 108.8
 genital ulceration 111.18
 nomenclature 154.11
 pathology 154.11
 respiratory disease association 151.2
 treatment 154.13
 relative risk 17.16–17
 relaxed skin tension lines (RSTLs) 20.2, 20.15
 relaxin 2.33
 relaxin family peptide receptor 1 (RFPRI) 2.33
 renal angiomyolipoma 45.7
 renal anomalies, external ear anomaly association 108.3, 108.4
 renal diseases
 acquired disorders 153.6
 dialysis 153.3–5
 DRESS syndrome 119.8

- renal diseases (*continued*)
 inherited disorders 153.1–2
 metabolic disorders 153.2–3
 oral manifestations **110.90**
 renal transplantation 153.5–6
 systemic diseases 153.2–3
 systemic lupus erythematosus 51.17, 51.29, 51.32
 tuberous sclerosis complex 80.12
 renal failure 153.3–5
 hyperpigmentation 88.22
 renal osteodystrophy, bone resorption 95.48
 renal transplantation 153.5–6
 renal tubular acidosis, Ehlers–Danlos syndrome association 72.1
 repeatability 5.13
 repifermin 10.11
 resins, allergy 128.5, 128.48–51
 resorcinol, hair pigmentary changes 89.71
 resorcinol
 chemical peel 159.4
 dandruff treatment 18.12
 hidradenitis suppurativa management 92.9
 systemic toxicity 159.12
 respiratory papillomatosis 25.57
 respiratory syncytial virus 25.86
 respiratory system disorders 151.1–7
 allergy 151.1–2
 autoimmune disorder association 151.2–3
 congenital disorder association 151.4–5
 dermatomyositis 53.8–9, 53.11
 DRESS association 119.9
 genetic syndromes 151.4–5
 infection association **151.1–2**, 151.4
 inherited disorder association **151.2**, 151.4–5
 interstitial lung disease 53.8–9
 Stevens–Johnson syndrome 119.17, 119.18
 systemic disease association 151.5–7
 systemic lupus erythematosus 51.28–9
 toxic epidermal necrolysis 119.17, 119.18
 vasculitis association 151.3–4
 respiratory tract nodules, granulomatosis with polyangiitis 102.25, 102.26
 restless legs syndrome 85.16–17
 restriction fragment length polymorphisms (RFLPs) 7.8
 restrictive dermopathy 72.20, **79.2**
 collodion baby differential diagnosis 116.19
 Neu–Laxova syndrome differential diagnosis 65.34
 resuscitation, burns 126.1, 126.2–4
 resuscitation formula
 burns 126.3–4
 colloid 126.4
 crystalloid 126.4
 RET gene mutations 147.10
 retapamulin 18.11
 reticular degeneration 3.35
 reticular erythematous mucinosis 59.8–9
 reticulate acropigmentation of Kitamura **70.3**, 70.14, 70.15
 reticuloendothelial system, sarcoidosis 98.5
 reticulohistiocytoma 136.20, 136.23
 reticulohistiocytosis *see* multicentric reticulohistiocytosis
 retiform haemangioendothelioma 137.34
 retinaldehyde, antiageing products 156.5
 retinitis pigmentosa, Refsum disease 65.28–9
 retinoic acid
 acne vulgaris treatment 18.22
 antiageing products 156.5
 chemical peel 159.2, 159.13
 dyslipidaemia induction 62.11
 topical 18.22
 wart treatment 25.52
 retinoic acid nuclear receptors 2.31
 retinoic acid receptors (RAR) 18.21–2
- retinoid(s)
 acanthosis nigricans treatment **87.5**
 acquired ichthyoses treatment 87.2
 cheilitis 110.84
 congenital ichthyoses treatment 65.38–9
 dermatitis side effect 18.29
 endogenous 18.22
 Fliegel disease treatment 87.17
 hand eczema treatment 39.17–18
 harlequin ichthyosis treatment 65.8
 hidradenitis suppurativa management 92.10
 HPV infection treatment 18.13
 keratitis–ichthyosis–deafness syndrome 65.30, 65.32
 keratosis pilaris treatment 87.11
 melasma treatment 88.12
 multiple minute digitate keratoses treatment 87.18
 mycosis fungoides treatment 140.24
 nail psoriasis treatment 95.42
 neutral lipid storage disease with ichthyosis 65.33
 papulopustular acne treatment 90.40
 porokeratosis management 87.22
 prepubertal acne treatment 90.63
 Sézary syndrome treatment 140.24
 Sjögren–Larsson syndrome treatment 65.30
 skin cancer treatment in immunocompromised patients 146.16
 wart treatment 25.54
see also acitretin; etretinate; isotretinoin; vitamin A
- retinoid(s), oral
 Bowen disease treatment 142.23
 Darier disease treatment 66.9
 mal de Meleda treatment 65.49
 ocular side effects 109.43
 palmoplantar pustulosis treatment 35.40
 squamous cell carcinoma secondary prevention 142.32
- retinoid(s), systemic 18.22, 19.37–40
 adverse effects 19.38
 cautions 19.39
 contraindications 19.39
 dermatological uses 19.37
 drug–drug interactions **19.39**
 keratoacanthoma treatment 142.36
 monitoring 19.40
 pharmacological properties 19.37–8
 pre-treatment screening 19.39
 recessive X-linked ichthyosis treatment 65.6
- retinoid(s), topical 2.31, 18.21–3
 actinic keratosis treatment 142.11
 ageing of skin 155.9
 comedonal acne treatment 90.39
 cutaneous amyloidosis treatment 58.13
 Darier disease treatment 66.9
 plaque psoriasis treatment 35.25
 retinoid cheilitis 90.46, 90.48
 retinoid dermatitis 90.46, 90.48
 retinoid X receptors (RXR) 18.21–2
 retinol 18.22
 antiageing products 156.5, **156.10**
 topical 18.22
- retinopathy, antimetabolic-induced 19.6–7
 retinyl esters **156.10–11**
 antiageing products 156.5
 reverse transcriptase inhibitors 31.9
 Revesz syndrome 77.3–4
 rexinoids, mycosis fungoides/Sézary syndrome treatment 140.23, 140.24
 rhabdomyocytes, high-power microscopy 3.32
 rhabdomyolysis, varicella infection 25.26
 rhabdomyoma 137.58
 oral 110.62
 rhabdomyosarcoma
 cutaneous 137.58
 oral 110.62
 rhabdomyosarcomatous congenital hamartoma 137.57–8
- rhabdovirus infections 25.84
 Rhagionidae 34.7
 Rhazes (Persian physician) 1.3
 rheumatic endocarditis 101.17
 rheumatic fever 55.8, 154.4
 cardiac involvement 150.5
 Duckett Jones criteria for diagnosis **47.12**
 erythema marginatum
 association 47.12–13
 nodules 55.2, 55.8
 rheumatoid nodule differential diagnosis 55.2
 scarlet fever association 26.35
 rheumatism, fibroblastic 154.8
 rheumatoid arthritis 55.1–4, 154.5–8
 arteritis 55.3
 atrophic skin 154.6
 callosities 123.7
 cryoglobulins 101.13
 epidemiology 55.1
 gangrene 55.3
 gold therapy 122.3–4
 hyperpigmentation 88.20
 interstitial granulomatous dermatosis association 55.2–3, 154.14
 leg ulcers 55.3
 linear subcutaneous bands 55.2–3
 livedo reticularis 55.4
 management 19.5
 neutrophilic dermatosis 55.3
 proximal nail fold capillaroscopy 95.52
 psoriatic arthritis differential diagnosis 35.44
 pyoderma gangrenosum
 association 49.2
 rheumatoid nodules 55.2
 skin cancer 154.15
 association 146.5
 subacute cutaneous lupus erythematosus association 51.12
 subcorneal pustular dermatosis
 association 49.14
 systemic lupus erythematosus association 51.27–8, 51.30
 differential diagnosis 51.27
 systemic sclerosis
 association 56.7
 overlap 56.8
 vascular lesions 55.3
 rheumatoid disease 55.1–8
 rheumatoid factor, Sjögren syndrome 55.7
 rheumatoid neutrophilic dermatosis 55.3, 154.7–8
 rheumatoid nodules 55.2, 99.15–16, 154.6, 154.7
 definition 99.15
 differential diagnosis 99.15–16
 investigations 99.16
 knuckle pads differential diagnosis 96.35
 palisading necrobiotic granuloma 99.16
 pathophysiology 99.15
 subcutaneous granuloma annulare differential diagnosis 99.14
 variants 99.15
 rheumatological disease
 DRESS syndrome association 119.6
 malignancy association 147.19–21
 rhinoconjunctivitis
 allergic 151.1–2
 platinum toxicity 122.9
 rhinotomophthoromycosis 32.80–1
 rhinophyma
 carbon dioxide laser ablation 23.18, 23.19
 electrosurgery 20.41, 20.42
 rosacea-associated 91.7–8, 91.11, 91.12
 rhinoscleroma 26.54–6
 clinical features 26.54–5
 differential diagnosis 26.55
 epidemiology 26.54
 infective cheilitis 110.87
 investigations 26.55
- management 26.55–6
 pathophysiology 26.54
 rhinosporidiosis 32.79–80
Rhinosporidium seeberi 32.79
 rhinovirus **25.80**
 riboflavin deficiency 63.14–15
 iron deficiency differential diagnosis 63.24
 Richter–Hanhart syndrome *see* tyrosinaemia type 2
 rickets
 congenital ichthyoses 65.39
 hypophosphataemic 75.7–8
 vitamin D-deficient 63.9, 63.10
 vitamin D-resistant, atrichia with papular lesions differential diagnosis **68.4**, 68.13–14, 68.14
Rickettsia akari 26.78
Rickettsia australiensis 26.78
Rickettsia conorii 26.78
Rickettsia felis 34.12
Rickettsia mooseri 26.77
Rickettsia prowazekii 26.76, 34.12, 34.21
Rickettsia rickettsii 26.77
Rickettsia tsutsugamushi 26.79
Rickettsia typhi 34.12
 rickettsial infections 26.76–9
 management **26.76**
 rickettsialpox 26.78–9
 rifabutin 19.43
 rifampicin 19.43, 27.9, 27.10
 drug eruptions 31.17
 hidradenitis suppurativa management 92.9
 leprosy treatment 28.15
 rifamycin 19.43
 Rift Valley fever 25.72
 Riley–Day syndrome, hyperhidrosis 94.5
 riloncept 19.32
 ringworm
 annular 32.22
 beard/moustache area 32.41
 foot 32.42–5
 glabrous skin 32.35–7, 32.41–2
 hand 32.45–6
 infants 117.9
 nails 32.47–9
 pityriasis rosea differential diagnosis 25.92
 scalp 32.38–41
 steroid-modified 32.50
 syndromes 32.35–51
 trichotillomania differential diagnosis 89.46
 X-ray therapy 107.4
 ritonavir
 drug eruptions 31.18
 psoriasis therapy 31.16
 Ritter disease 26.27
 rituximab 19.32, 19.33–4
 atopic eczema treatment 41.33–4
 bullous systemic lupus erythematosus treatment 50.48, **50.49**
 dermatomyositis treatment 53.12
 discoid lupus erythematosus treatment 51.11
 epidermolysis bullosa acquisita treatment 50.46
 pemphigus treatment 50.9
 rheumatoid nodule treatment 154.6
 systemic lupus erythematosus treatment 51.36
 river blindness *see* onchocerciasis
 RNA, splicing 7.6
 RNA viruses **25.3**, 25.4
 RNase 2,3,7 2.12
 Ro antibodies 116.12
Rochalimea henselae see Bartonella henselae
 Rocky Mountain spotted fever 26.77–8, 34.38
 ehrlichiosis differential diagnosis 26.63
 rodent bites 131.4–5
 rodent ulcer *see* basal cell carcinoma (BCC)
 Roman Empire 1.3
 Romaña's sign 33.39

- Rombo syndrome
 basal cell carcinoma **141.4**
 milia association 134.5
- rosacea 91.1–19
 acne differential diagnosis 90.28–9
 antimicrobial peptides 2.12
 associated dermatoses 91.4, 91.15–19
 atypical distribution 91.8–9
 causative organisms 91.4, 91.5
 chalazion association 109.48
 classification 91.1, **91.2**
 clinical features 91.6–12
 complications/co-morbidities 91.11–12
 conglobata 91.15–16
 corticosteroid-induced development/
 exacerbation 18.17
 definition 91.1
Demodex role 34.53
 differential diagnosis 91.9–11
 disease course 91.12
 environmental factors 91.6
 epidemiology 91.3–4
 erythematotelangiectatic 91.1, **91.2**, 91.3
 clinical features 91.6
 differential diagnosis 91.9, **91.10**
 disease course 91.12
 management 91.13, 91.14
 flushing **106.4–5**
 fulminans 90.29, 91.15–16
 pregnancy 115.9
 genetics 91.5–6
 granulomatous 91.8–9
 periorificial dermatitis differential
 diagnosis **91.18**
 incidence 91.3
 investigations 91.12
 lymphocytoma cutis differential
 diagnosis 135.9
 lymphoedematous 91.11
 management 91.12–14, **91.15**
 mucous membrane pemphigoid
 differential diagnosis 50.29
 ocular 91.1, **91.2**, 91.3, 91.4
 clinical features 91.8
 differential diagnosis 91.11
 disease course 91.12
 management 91.13, 91.14, **91.14–15**
 pathophysiology 91.4–6
 periorificial dermatitis differential
 diagnosis 91.11, **91.18**
 phymatous 91.1, **91.2**, 91.3
 atypical distribution 91.8
 clinical features 91.7–8
 differential diagnosis 91.11
 management 91.13, 91.14, **91.15**
 pregnancy 115.8–9
 prevalence 91.3
 prognosis 91.12
 sarcoidosis differential diagnosis 98.2
 severity grading 91.1, **91.2**
 solid facial oedema 90.35–6
 variants 91.8–9
- rosacea-like dermatoses, papulopustular
 rosacea differential diagnosis 91.10
- Rosai–Dorfman disease 136.24–6, 136.25,
 148.14
- IgG4-related disease differential
 diagnosis 148.14
- S-100 protein stain 3.20
- roseola infantum 25.34–5, 117.6
- Ross River virus 25.76–7
- Ross syndrome 94.11–12
- Ro/SS-A antibody 51.12
 neonatal lupus erythematosus 51.37, 51.39
- Rothmann–Makai disease 99.8
- Rothmund–Thomson syndrome 77.5–7
 acquired poikiloderma 96.10
- basal cell carcinoma **141.5**
 clinical features 77.5–6
 Cockayne syndrome differential
 diagnosis 78.9
- congenital erosive and vesicular
 dermatosis with reticulated scarring
 differential diagnosis 96.12
- definition 77.5
- differential diagnosis 77.6
- dyskeratosis congenita differential
 diagnosis 69.15
- Kindler syndrome differential
 diagnosis 71.19
- malignancy association 147.12
 management 77.7
- neonatal lupus erythematosus
 differential diagnosis 51.38, 116.13
- pathophysiology 77.5
- premature hair greying 89.70
- Werner syndrome differential
 diagnosis 72.23
- xeroderma pigmentosum differential
 diagnosis 78.6
- rough endoplasmic reticulum (RER),
 collagen biosynthesis 2.30
- rove beetles 34.29
- Rowell syndrome 47.6
- R-spondin 4 2.10
- R-spondin transcription factors 2.5
- rubber allergy 128.5, 128.43–5
 ano-genital eczema 111.11
 shoes 128.47
- rubella infection 25.78–9
 arthritis 154.2
 congenital 25.79, 116.22–3
 neonatal lupus erythematosus
 differential diagnosis 116.13
 scarlet fever differential diagnosis 26.36
 vaccination 25.79
- rubeosis 64.2
- Rubinstein–Taybi syndrome
 keloid association 96.47
 pilomatricoma association 138.13
- rule of hand 18.4
- S**
- S-100 protein 3.20–1, 3.23
- S100A7 2.12
- sacral dimple 85.9
- sacroiliitis 154.8
 acne conglobata association 154.10
- saddle-nose deformity, congenital
 syphilis 29.17, 29.29
- SAHA (seborrhoea, acne, hirsutism
 and androgenetic alopecia)
 syndrome 89.65, 149.17
- acne 90.9
- sailor's lip 110.78–9
- salbutamol 18.37
- salicylic acid
 acanthosis nigricans treatment **87.5**
 acne therapy 90.49
 acquired ichthyoses treatment 87.2
 antiageing products 156.3
 chemical peel 88.34, 159.1, 159.3, 159.4,
 159.9
 skin of colour 159.13
 keratosis pilaris treatment 87.11
 multiple minute digitate keratoses
 treatment 87.18
 penetration enhancer 18.7
 systemic toxicity 159.12
 topical corticosteroid
 formulations 18.18–19
 wart treatment 25.51
 Whitfield's ointment 18.12
- salivary glands, examination 110.6
- saltpetre disease 96.28
- sampling error 5.13
- sandflies 34.7
 bites 26.62
- Sanfilippo syndrome **81.2**, 81.3, 81.4
- saphenofemoral junction 103.28
- saphenous vein(s) 103.27
- saphenous vein graft
 harvesting 105.49
 post-traumatic eczema 39.25
- SAPHO (synovitis, acne, pustulosis,
 hyperostosis and osteitis)
 syndrome 45.11
 acne association 90.6, 90.8, 154.10
 acne conglobata association 90.54
 acne fulminans association 90.50, 90.52
 hidradenitis suppurativa
 association 92.2
 IL-1 antagonist therapy 19.32
 palmoplantar pustulosis
 association 35.38
 prepubertal acne association 90.60
- saponification 99.40
- saquinavir, drug eruptions 31.18
- sarcoid
 cutaneous reaction 98.17
 facial and laser treatment 23.18
 genital lesions 111.20
 granulomatous rosacea differential
 diagnosis 91.9
 idiopathic reactions 98.17
- sarcoid dactylitis 98.12
 chronic 154.8
- sarcoid granuloma 98.2, 98.3, 98.4
 calcification 99.51
 cutaneous 98.17
 environmental factors 98.4–5
 subcutaneous sarcoidosis 98.10
- sarcoidosis 98.1–17, **107.5**, 107.6–7, 154.8
 angioliipoid 98.12
 annular elastolytic giant cell granuloma
 differential diagnosis 96.27
 associated diseases 98.2
 cardiac involvement 150.4
 causative organisms 98.4
 clinical features 98.5–6
 cutaneous 98.6–10, 98.11, 98.12–17
 variant 99.50
 CXCR3 expression 8.39
 definition 98.1
 diagnostic criteria 98.15, **98.16**
 differential diagnosis 98.2
 environmental factors 98.4–5
 epidemiology 98.1–2
 erythema nodosum 98.1, 98.6, 98.14,
 98.15, 99.20–1
 differential diagnosis 98.2, 98.12
- erythrodermic 98.13
- extrapulmonary 98.5–6
- genetics 98.4
- genital 98.14
- granuloma annulare differential
 diagnosis 97.7
- granulomatous cheilitis differential
 diagnosis 110.86
- hypopigmented 98.13
 with hypopituitarism 149.16
- ichthyosiform 98.13
- immunopathogenesis 98.2–4
 investigations 98.14–15
- leprosy differential diagnosis 28.11
- lesion location 98.14
- leukaemia cutis differential
 diagnosis 140.49
- lichenoid 98.13
- lip lesions 110.88
- livedo association 98.13
- lupus pernio 98.8–9, 98.11, 98.17
- lupus vulgaris differential
 diagnosis 27.23–4
- lymphocytoma cutis differential
 diagnosis 135.9
- maculopapular 98.6–7, 98.8, 98.15
 management 98.15–17
- morphoea-like 98.13
- nail 98.14
- necrobiosis lipoidica 93.10, 98.8, 98.10
 association 97.9
- necrobiosis lipoidica-like lesions 97.13
- nephrolithiasis/nephrocalcinosis 153.6
- nodular 98.8, 98.9
- oral/perioral lesions 110.62
- papular 98.15
- pathophysiology 98.2–5
- patient assessment **98.16**
- plaque 98.8, 98.9, 98.10
- psoriasisiform 98.13
- pulmonary 98.5
- renal involvement 153.6
- respiratory disorder association 151.5
- sarcoid granuloma 98.2, 98.3, 98.4
 subcutaneous sarcoidosis 98.10
- scar 98.9, 98.12
- scarring alopecia 98.14
- sclerosing panniculitis differential
 diagnosis 99.29
- subcutaneous 98.10, 98.12, 99.50–1
 definition 99.50
 epidemiology 99.50
 investigations 99.50–1
- systemic lupus erythematosus
 association 51.31
- systemic manifestations 98.5–6
- testicular 98.14
- TNF antagonist-induced 19.30
- ulcerative 98.13
- verrucous 98.13
- vulval 98.14
- sarcoma
 clear cell 137.66
 epithelial membrane antigen
 expression 3.19–20
- epithelioid 137.65–6
- lymphoedema association 105.22
- post-irradiation 24.19
- radiation-induced 24.19
- skin 146.12
- Sarcophagidae 34.10
- Sarcoptes scabiei* 115.4
 perineum/perianal region 113.12
- Sarcoptidae 34.39–40, 34.41–2, **34.42**,
 34.43–5, 34.46, 34.47
- Sarcocladum strictum* 32.55
- Satchmo syndrome 123.12
- saturated fatty acids 32.21
- saturnism 122.4–5
- saw-toothing 3.38
- scabies 27.5, 34.39–40, 34.41–2, **34.42**,
 34.43–5, 34.46, 34.47
 allergic contact dermatitis differential
 diagnosis 128.62
- animal 34.47
- atopic eczema differential
 diagnosis 41.21
- atypical forms 34.40, **43.42**
- bedbug bite differential diagnosis 34.25
- clinical features 34.40, 34.41–2, 34.43
- animal scabies 34.47
 crusted 34.45, 34.46, 34.47
- complications 34.40, 34.43
- corticosteroid therapy 18.17
- crusted 34.45, 34.46, 34.47
 clinical features 34.45, 34.46, 34.47
 management 34.47
 pathophysiology 34.45
- definition 34.39
- dermatitis herpetiformis differential
 diagnosis 50.53
- ecthyma association 26.17
- epidemic (Panama) 5.2
- epidemiology 34.39–40
- follow-up 34.45
- genital 111.25–6
- HIV infection 31.28
- identification of mites 4.22
- incognito 34.43
- infantile acropustulosis differential
 diagnosis 116.8, 117.5
- infants 117.9
- institutional outbreaks 34.44–5
- investigations 34.43
- irritant contact dermatitis differential
 diagnosis 129.4, 129.5
- Langerhans cell histiocytosis differential
 diagnosis 136.6
- management 18.13, 34.43–5, 34.47
- Norwegian 34.45, 34.46, 34.47
 erythroderma 39.33

- scabies (*continued*)
 onchocerciasis differential
 diagnosis 33.5
 pathophysiology 34.40
 crusted 34.45
 perineum/perianal region 113.12
 pregnancy 115.4
 secondary infection 34.43
 sexually transmission 34.44
 streptococcal infections 26.10
 transient acantholytic dermatosis
 differential diagnosis 87.23
 variants 34.40, **43.42**
 scalded skin syndrome 2.19, 26.28
see also staphylococcal scalded skin
 syndrome; toxic epidermal
 necrolysis (TEN)
 scaling (dermatological)
 generalized exfoliative
 dermatitis 119.11–12
 harlequin ichthyoses 65.7, 65.8
 keratinization disorders 65.2
 recessive X-linked ichthyosis 65.5–6
 scaling (economic) 6.5
 scalp/scalp disorders 107.1–14
 allergic contact dermatitis 128.16
 alopecia areata 89.31
 angiosarcoma 137.36
 apocrine tubular adenoma 138.22
 biopsy 89.11, 89.13–14
 orientation 89.13, 89.14
 pattern hair loss 89.21
 site 89.14
 cicatricial pemphigoid 107.7–8
 contact dermatitis 107.4
 cooling in chemotherapy 89.49, 120.5–6
 cutis verticis gyrata 107.9
 cylindroma 138.30–1
 dissecting cellulitis 90.31, 92.2, 107.8–9
 dysaesthesia 107.14
 erosive pustular dermatitis 107.11–12
 dissecting cellulitis of scalp
 differential diagnosis 107.8
 follicular mucinosis 107.7
 folliculitis 90.30, 93.5–6
 hair growth 89.8
 hair pulling 86.17, 86.18
 histological sections 3.40
 HIV infection 107.10
 iatrogenic pustulation 107.12
 infections 107.10
 inflammation 89.10
 itch 107.12–13
 lichen simplex chronicus 107.4
 lipoedema 100.22–3
 lipoedematous alopecia 107.9
 metastases 107.10, 147.6
 acquired cicatricial alopecia 89.36
 morphea **107.5**, 107.6
 naevus lipomatosus superficialis 100.23
 necrobiotic **107.5**, 107.6
 pain
 androgenetic alopecia 89.15
 chronic 84.9
 chronic telogen effluvium 89.27
 pilosebaceous unit tumours 107.10
 pityriasis amiantacea 107.3–4
 pruritus 107.12–14
 psoriasis 107.2–3
 pustular conditions 107.11–12
 radiodermatitis 107.4, **107.5**
 sarcoidosis **107.5**, 107.6–7
 scaling disorders 107.1–5
 scleroderma **107.5**, 107.6
 sebaceous naevi 107.10
 seborrhoeic dermatitis 107.1–2
 secondary cicatricial alopecia 107.5–9
 sun exposure 107.9
 surgery and medical trauma hair
 loss 89.45
 syphilis 107.10
 syringocystadenoma
 papilliferum 107.10
 thickened scalp 107.9
 trichoepitheliomas 107.10
 tumours 107.9–10
see also alopecia; erosive pustular
 dermatitis of scalp; folliculitis, scalp
 scar metastases 147.4–5
 SCARF syndrome **72.12**
 scarlatina, staphylococcal 26.31
 scarlatiniform erythema 26.36
 scarlet fever 26.34–6
 clinical features 26.35–6
 definition 26.34
 differential diagnosis 26.36
 epidemiology 26.35
 investigations 26.36
 Kawasaki disease differential
 diagnosis 102.33
 management 26.36
 nomenclature 26.34
 pathophysiology 26.35
 scarlet fever toxin A, *Streptococcus*
pyogenes 26.30
 scarring
 acne vulgaris 90.22, 90.23, 90.24, 90.35
 mimics 90.32
 atrophic 96.11–12
 anetoderma differential
 diagnosis 96.22
 spontaneous of cheeks 96.12
 chemical peels 159.5
 complication 159.12–13
 discoid lupus erythematosus 51.5–6,
 51.7
 hidradenitis suppurativa 92.4–5
 hydroa vacciniforme 90.32
 injecting drug abuse 121.3
 photodynamic therapy 22.14
 prepubertal acne 90.63
 severity 10.8
 skin resurfacing complication 160.10
 wound healing *10.7*, 10.8
 age-related changes 10.10
see also hypertrophic scars; keloid
 scars
 orientation of surgical 20.2
 sarcoidosis 98.9, 98.12
 unsatisfactory 20.11
 SCART1 8.15
 SCART2 8.15
 scavenger receptors 8.15
Scedosporium apiospermum 32.75
 Schamberg disease 101.8, **101.9**, 101.10
 capillaritis 88.49
 Schamroth's window 95.6
 Scheie syndrome 81.1, **81.2**
 Schimmelpennning–Feuerstein–Mims
 syndrome 73.17
 congenital epidermal naevi 75.3
 naevi 75.6
 Schindler disease, a-N-acetyl-
 galactosaminidase deficiency 81.5
Schistosoma 33.25, 33.26, 33.27
 schistosomiasis **33.24**, 33.25–7
 clinical features 33.25–6
 definition 33.25
 ectopic cutaneous 33.25–6
 epidemiology 33.25
 investigations 33.26–7
 management 33.27
 nomenclature 33.25
 pathophysiology 33.25
 perineum/perianal region 113.12
 Schnitzler syndrome 45.1, 45.9–10, 148.10,
 148.11
 clinical features 45.9–10
 differential diagnosis 45.10
 drug-induced serum sickness-like
 reaction differential
 diagnosis 118.9
 IgG variant 45.9
 pathophysiology 45.9
 Schöpf–Schulz–Passarge syndrome 65.61
 apocrine hydrocystoma 138.20
 basal cell carcinoma **141.5**
 nail lichen planus differential
 diagnosis 95.45
 Schulman syndrome 57.17
 Schwann cells, high-power
 microscopy 3.32
 schwannoma 137.46–8
 clinical features 137.47–8
 definition 137.46
 epidemiology 137.46
 malignant 137.54
 NF1-associated 80.3
 pathophysiology 137.47
 variants 137.47
 schwannomatosis 80.1
 SCINEXA score 155.5
 scleredema 59.9–11, 148.9
 of Buschke 72.19
 endocrine disorder skin signs **149.10**
 neonatorum 99.57
 systemic sclerosis differential
 diagnosis 56.15, **56.16**
 sclerema neonatorum 99.35, 99.56–7,
 116.16–17
 clinical features 99.56–7, 116.16–17
 definition 99.56, 116.16
 differential diagnosis 99.56–7
 epidemiology 116.16
 investigations 99.57, 116.17
 management 99.57, 116.17
 pathophysiology 116.16
 progeria differential diagnosis 72.22
 restrictive dermopathy differential
 diagnosis 72.20
 sclerodactyly
 fibroblastic rheumatism 55.4
 mal de Meleda 65.48
 systemic sclerosis 56.4
 scleroderma
 acroosteolysis 95.47
 chemical exposure 56.13–14, 95.47
 drug-induced 96.42, 96.43
 environmental triggers 96.42–3
 histological sections 3.39
 inflammation 8.6
 localized 57.1–2
 malignancy association 147.21
 mast cell role 2.17
 mechanical properties of skin 123.5
 renal crisis 56.11, 56.15
 scalp **107.5**, 107.6
 sclerosing panniculitis differential
 diagnosis 99.29
 stiff skin syndrome differential
 diagnosis 72.18
 Werner syndrome differential
 diagnosis 72.23
see also systemic sclerosis
 scleroderma diabeticorum 64.6
Scleroderma domesticum 34.15
 scleromyxoedema 59.2–6, 148.8–9
 clinical features 59.4, 59.5
 definition 59.2
 differential diagnosis **59.5**
 epidemiology 59.2
 investigations 59.5
 malignancy association **147.22**
 management 59.5–6
 nephrogenic systemic fibrosis
 differential diagnosis 96.42
 nomenclature 59.2
 pathophysiology 59.2–4
 of renal disease (*see* nephrogenic
 systemic fibrosis)
 respiratory disorder association 151.6
 systemic implications **59.5**
 systemic sclerosis differential
 diagnosis 56.15, **56.16**
 treatment ladder **59.6**
 sclerosing angioma 137.19
 sclerosing cholangitis 65.36
 sclerosing epithelial hamartoma 138.10
 sclerosing lipogranuloma 99.47
 sclerosing lymphangitis, penile 105.51,
 111.8
 sclerosing panniculitis 99.28–9, 99.30,
 99.31
 clinical features 99.29
 definition 99.28
 differential diagnosis 99.29
 histopathology 99.29, 99.30
 investigations 99.29, 99.31
 pathophysiology 99.29, 99.31
 post-irradiation 99.59–61
 clinical features 99.60
 definition 99.59–60
 investigations 99.60–1
 management 99.61
see also lipodermatosclerosis
 sclerosing sweat duct carcinoma 138.37–8
 sclerosis
 lymphatic malformations 73.16–17
 skin 56.14–15
 sclerosteosis 67.7
 sclerotherapy
 hypertrichosis 89.63
 leg veins 23.10
 lymphatic malformations 105.37
 SCN9A gene mutations 103.7
 scoliosis, syringomyelia association 85.8
 Scoloidea 34.15
 scombroid fish, urticaria 42.5
Scopulariopsis brevicaulis
 diagnosis 32.9
 onychomycosis 32.54–5
 SCORing Atopic Dermatitis
 (SCORAD) 16.3
 Scorpiones (scorpions) 34.34–5
 scratch test 4.24
 scratching 83.5
 lichen simplex chronicus 83.20
see also itching
 screwworms 34.9
 scrofuloderma 27.5, 27.6, 27.7, 27.8,
 27.13–16
 children with HIV 31.35
 clinical features 27.15–16
 differential diagnosis 27.15
 epidemiology 27.15
 investigations 27.16
 management 27.16
 pathogenesis 27.14–15
 pathophysiology 27.15
 scrotal calcinosis 61.4, 61.5, 111.26
 scrotal candidosis 32.65
 scrotal carcinoma 111.31–2
 prognosis 111.31
 scrotodynia 84.8–9
 scrotum 111.4
 acute 111.20
 aphthous ulcers 111.17
 cribriform atrophy 111.7
 hyperpigmentation in neonates 116.4
 lymphoedema 105.17–19
 psoriasis 35.12
 squamous cell carcinoma 111.20
 tinea 111.23–4
 ulceration 111.17–18
 variants 111.5–6
 scrub typhus 26.79
 scurvy 5.1–2, 63.20–2
 purpura 101.6
 Scyphozoa 131.1
 sea anemone stings 131.1–2
 sea chervil 131.3
 sea mat stings 131.3
 sea urchins, envenomation 131.3
 seabather's eruption 131.2
 seasonal allergic conjunctivitis 109.15,
 109.16, 109.17, **109.23**
 sebaceoma 138.16–18
 sebaceous adenoma 110.19, 138.16–18
 acne vulgaris differential
 diagnosis 90.26–7
 sebaceous carcinoma 138.18–19
 acne vulgaris differential
 diagnosis 90.26, 90.27
 eyelid 109.50–1, 138.18, 138.19
 chronic blepharitis *109.12*
 sebaceous cysts 90.27, 134.1
 sebaceous glands 2.44
 breast areola 93.12
 development 2.4
 ectopic (*see* Fordyce spots)

- heterotopic 93.10–12, 111.5–6
hyperplasia 93.12–13
 acne vulgaris differential diagnosis 90.26
 basal cell carcinoma differential diagnosis 141.10
 carbon dioxide laser ablation 23.18
 hypertrophy 116.3–4
 immune defence function 90.20
 neonates 116.2–3
 neuropeptide receptors 90.19
 pregnancy 115.2
 tumours 90.26, 138.16–19
- sebaceous keratoacanthoma, Muir–Torre syndrome 138.17
sebaceous tumours, keratoacanthomas and visceral malignancy *see* Muir–Torre syndrome
sebocystomatosis *see* steatocystoma multiplex
sebopsoriasis 32.14, 40.4
seborrhoea
 acne 90.36
 hyperandrogenism 145.18
seborrhoea, acne, hirsutism and
 androgenetic alopecia (SAHA) syndrome 89.65, 149.17
 acne 90.9
seborrhoeic dermatitis 40.1–5, 40.6
 acquired 140.36
 acrodermatitis enteropathica differential diagnosis 63.26
 alcohol abuse co-morbidity 86.32
 ano-genital 111.11
 chalazion 109.48
 chronic mucocutaneous candidosis 32.69
 clinical features 31.14, 40.2–5, 107.1–2
 clinical variants 40.2–40.3
 complications/co-morbidities 40.4
 differential diagnosis 31.14, 40.4, 107.1–2
 epidemiology 40.1, 107.1
 erythematotelangiectatic rosacea differential diagnosis 91.9
 folate deficiency association 63.19
 gold reactions 122.4
 HIV infection 31.14, 107.1
 infantile 40.2–3, 107.1, 107.2, 117.2
 atopic eczema differential diagnosis 41.21
 inflammatory 107.1
 investigations 40.5
 Langerhans cell histiocytosis differential diagnosis 136.6
 Malassezia association 32.14, 40.1, 40.2
 HIV infection 31.14
 treatment 40.5, 40.6
 management 31.14, 40.5, 40.6, 107.2
 Parkinson disease 107.1
 pathophysiology 40.1–2
 pemphigus foliaceus differential diagnosis 50.7
 perineum/perianal region 113.7
 periostomal dermatitis differential diagnosis 91.18
 photoaggravated 127.18
 pityriasis rosea differential diagnosis 25.92
 pityriasis versicolor differential diagnosis 32.12
 presentation 40.2, 40.3
 protein–energy malnutrition differential diagnosis 63.4
 psoriasis differential diagnosis 31.15, 35.19, 39.4, 107.1, 107.3
 pyridoxine deficiency 63.18
 quality of life 40.4–5
 reticular erythematous mucinosis differential diagnosis 59.9
 riboflavin deficiency differential diagnosis 63.15
 rosacea association 91.4, 91.12
 scalp 107.1–2
 severity 40.4
 spinal cord injury 85.10
 tinea capitis differential diagnosis 32.40
 tinea corporis differential diagnosis 32.37
seborrhoeic eczema
 allergic contact dermatitis differential diagnosis 128.61, 128.62
 discoid lupus erythematosus differential diagnosis 51.9
 photoaggravated, chronic actinic dermatitis differential diagnosis 127.16
 vulval 112.13
 psoriasis differential diagnosis 112.16
seborrhoeic keratosis 133.1–3, 133.4
 actinic keratosis differential diagnosis 142.4
 benign lichenoid keratosis differential diagnosis 133.7
 clinical features 133.2–3
 confluent and reticulated papillomatosis differential diagnosis 87.7
 definition 133.1
 dermoscopic features 133.3
 differential diagnosis 133.3
 eyelid 109.46
 genital wart differential diagnosis 25.57
 investigations 133.3
 laser treatment 23.14
 pathophysiology 133.1–2
 solar lentigo progression 132.6
 surgery 20.46
 treatment ladder 133.4
 variants 133.3, 133.4, 133.5
second messengers 14.4
secondary care 5.11–12
secondary hypertrophic osteoarthropathy 95.7
secondary localized cutaneous amyloidosis (SLCA) 58.2, 58.2, 58.4, 58.5
secosteroids 18.23–6, 149.9
 therapeutic actions 18.23–4
Secretan syndrome 86.27, 99.46
sectioning, artefacts 3.28
secukinumab, plaque psoriasis treatment 35.31
selectins 8.7–9
selective serotonin reuptake inhibitors (SSRIs) 86.36
 body dysmorphic disorder 86.12
 phobia treatment 86.20
 trichotillomania treatment 89.47
selenium
 deficiency 63.28–30, 122.6
 excess 63.30
 reactions to 122.6–7
 supplementation 122.6
 toxicity 63.30
 protein–energy malnutrition differential diagnosis 63.4
selenium sulphide, tinea capitis treatment 32.40
self-esteem 11.1, 11.2, 11.4
 low 11.4
self-healing mucinosis 59.14
self-help 5.11
self-help groups 15.3
self-image, poor 11.4
self-injury, neurodevelopmental disorders 8.53
self-mutilation 86.30–1
selumetinib 143.33
semen allergy 112.15
semicircular lipotrophy 100.8–9, 123.14
senile purpura 155.3–4
sensitive skin 129.10–11
sensitization 8.55–6
 active 128.72
 allergic contact dermatitis 128.6–7
 ear piercing complications 108.7
 potential 128.9
 risk 128.9
 susceptibility 128.10
sensitizing agents, topical therapy 18.30
sensorineural hearing loss 51.29
sensory innervation 85.1–3
sentinel lymph node biopsy
 melanoma 143.23, 143.25–7
 Merkel cell carcinoma 145.8
sepsis
 abdominal wall lymphoedema complication 105.21
 burns 126.9
 macrophage inhibitory factor role 8.23
 pressure ulcer-induced 124.3
septic shock
 IgA vasculitis differential diagnosis 102.15
 toxic shock syndrome differential diagnosis 26.30
septicaemia
 Acinetobacter 26.50
 melioidosis 26.53
 Pasteurella multocida 26.57
 Pseudomonas aeruginosa 26.52
 Stevens–Johnson syndrome/toxic epidermal necrolysis 119.18
serine protease inhibitors 8.41
seroma 105.42
serotonin noradrenergic reuptake inhibitors (SNRIs) 86.36
sertaconazole, seborrhoeic dermatitis treatment 40.5
serum sickness, urticarial vasculitis association 44.2
serum sickness-like reactions, drug-induced 118.8–9
sesquiterpene lactone mix 128.51, 128.52, 128.53, 128.54
severe combined immunodeficiency (SCID) 82.2, 82.7–8
 BCG infection 82.8
 candidosis association 148.15
 epidemiology 146.2
 genotypes 82.8
 with microcephaly, growth retardation and sensitivity to ionizing radiation 82.11
severe cutaneous adverse reaction (SCAR) syndromes 119.1
 acute generalized exanthematous pustulosis 119.1
 DRESS syndrome 119.4, 119.9–10
 severe dermatitis–multiple allergies–metabolic wasting (SAM) syndrome 65.25–6
sex chromosome defects 76.3–5
sex-linked characters 7.4
sexual abuse
 children 117.13
 lichen sclerosus differential diagnosis 112.8
 see also child abuse; non-accidental injury
sexual development disorders 112.4
sexually acquired reactive arthritis (SARA) 30.12, 30.13, 30.15
sexually transmitted infections
 anal fissure differential diagnosis 113.29
 chancroid 30.20–3
 genital *Chlamydia* 30.8–13, 30.14, 30.15
 gonorrhoea 30.1–4, 30.5, 30.6–8
 granuloma inguinale 30.23–5, 30.25
 Langerhans cell histiocytosis differential diagnosis 136.6
 lymphogranuloma venereum 30.16–20
 male genital dermatoses 111.24–6
 meticillin-resistant *Staphylococcus aureus* 111.24
 perineum/perianal region 113.12–17
 scabies 34.44
 see also syphilis
Sézary cells 140.18
 count 140.20
Sézary syndrome 140.18–20, 140.19–20
 atypical cutaneous lymphoproliferative disorder 31.32
 cell of origin 140.2, 140.3
 chromosomal abnormalities 140.20–1
 definition 140.18
 differential diagnosis 140.19–20
disease course 140.20
epidemiology 140.18
erythroderma 39.32–3
gene abnormalities 140.21–2
investigations 140.15
leukaemia cutis differential diagnosis 140.49
management 140.22–7
 combination therapies 140.24–5
 skin-directed therapy 140.23–4
 systemic therapy 140.24–7
 toxin therapies 140.26
molecular pathogenesis 140.20–2
pathophysiology 140.18–19
pityriasis rubra pilaris differential diagnosis 36.4
prognosis 140.14, 140.15, 140.20
pruritus 83.6, 83.8
staging system 140.3, 140.4
shade, photoprotection 9.12
shagreen patch 80.11
Shah–Waardenburg syndrome 70.5
shaken baby syndrome 117.13
shale tar 18.32
shampoos 89.72, 128.16
 medicated 107.2, 128.16
Sharp syndrome *see* mixed connective tissue disease
SHARPIN adapter protein 8.10, 8.11
sharps injuries, surgical 20.8
shawl sign 53.5
shea butter 18.6
shear-stress, papillary capillary rupture 123.10
Sheehan syndrome 149.16
sheep nostril fly 34.10
shingles *see* zoster infection
shock, burn-induced 126.2–3
shoe allergy 128.47–8
shoe dermatitis 128.43, 128.48
short anagen syndrome 89.11, 89.24
 loose anagen syndrome differential diagnosis 68.23
short-term digital dermoscopic monitoring (STM) 144.5
shoulder surgery 20.46
shoulder–hand syndrome 85.13
shrinking lungs syndrome 51.29
 respiratory disease association 151.2
Shulman syndrome *see* eosinophilic fasciitis
sialidosis 81.5
Siberian tick typhus 34.38
Sicariidae 34.33–4
sickle cell anaemia 148.16
 pseudoxanthoma elasticum-like lesions 96.28
sign of Leser–Trelat 133.1, 147.16
signal peptides 156.4, 156.10
signal transduction pathway 14.4
signalling lymphocytic activating molecule (SLAM) family receptors 8.17
signalling proteins, mutations 148.18
sildenafil
 lymphatic malformation treatment 105.37
 morphoea treatment 57.28
 Raynaud phenomenon treatment 125.10
silica
 systemic lupus erythematosus 51.19
 systemic sclerosis trigger 56.12–13, 96.42
silicone
 dressings 18.37
 fillers 157.6–7
 gels 18.37
 reactions to 123.20–1
silicone gel sheeting, keloid treatment 96.49
Silk Road 1.2
silver nitrate 18.9, 20.43
silver, reactions to 122.7–8
 ear piercing complications 108.7
 photosensitive 122.7, 122.8
silver sulfadiazine 18.11
Simplified Psoriasis Index (SPI) 16.2, 16.6

- Simuliidae 34.6–7, 34.8
 Sindbis virus infection 25.75
 single nucleotide polymorphisms (SNPs) 14.10
 sinus histiocytosis with massive lymphadenopathy 148.14
see also Rosai–Dorfman disease
 sinus tracts, hidradenitis suppurativa 92.4, 92.5
 Siphonaptera 34.12–14
 classification 34.12
see also flea bites
 Sipple syndrome 137.45, 147.10
 sirolimus
 acne association 90.11
 Cowden syndrome treatment 80.15
 lymphatic malformations 105.37
 skin cancer treatment in immunocompromised patients 146.16
 squamous cell carcinoma secondary prevention 142.33
 Sister Mary Joseph nodules 147.4, 152.1
 sitosterolemia 62.10
 tendon xanthomas 62.3
 Six Area Six Sign Atopic Dermatitis (SASSAD) severity score 16.3
 Sjögren syndrome, respiratory disease association 151.3
 Sjögren–Larsson syndrome 65.29–30
 collodion baby 116.19
 Sjögren syndrome 55.5–8
 angular cheilitis 110.80
 classification criteria 55.5
 clinical features 55.6–7
 clinical types 55.6
 complications/co-morbidities 55.7
 connective tissue disease 55.6, 55.7
 cryoglobulins 101.13
 definition 55.5
 differential diagnosis 55.7
 digestive system disorders 152.6
 disease course 55.7
 epidemiology 55.5
 genetics 55.6
 hypohidrotic ectodermal dysplasia differential diagnosis 67.14
 investigations 55.7
 mouth 55.7
 mucous membrane pemphigoid differential diagnosis 50.29
 mucous membranes 55.7
 multicentric reticulohistiocytosis association 136.24
 nomenclature 55.5
 pathophysiology 55.5–6
 prognosis 55.7
 severity classification 55.7
 subacute cutaneous lupus erythematosus association 51.12, 51.13
 systemic sclerosis association 56.7
 overlap 56.8
 treatment 55.8
 urticarial vasculitis association 44.2
 skeletal abnormalities, NF1 80.3
 skeletal muscle tumours 137.57–8
 skin
 barrier function 13.1–10, 129.2–3
 ageing effects 155.8–9
 atopic eczema 41.5
 disruption 129.3
 mechanical 2.43
 repair 129.7
 blood flow 125.1
 blood vessels 2.41–3
 components 2.1–2
 development 2.3–5
 diagnostic testing techniques 4.23–5
 fragility 71.5–6
 functions 11.1
 glabrous 2.43–4
 hair-bearing 2.43, 2.44
 homeostasis 2.44–5
 innervation 2.2, 85.1–3
 neurophysiological testing 85.4
 lymphatics 2.43
 microbiome 2.13
 atopic eczema relationship 41.9
 neural network 2.11
 neuro-endocrine organ role 149.4, 149.4–5, 149.6–7
 percutaneous absorption mechanisms 13.2–3
 physiological functions 2.43–4
 property measurement 16.3–4
 sample collection in fungal infection 32.7
 surface electrical properties 16.3
 tensile strength 96.19
 tension lines surgical considerations 20.2
 tightening 160.10–11
 skin age score (SAS) 155.5
 skin appendage tumours 146.12
 skin cancer
 chronic lymphocytic leukaemia 146.3
 cost-of-illness 6.5–6, 6.7
 Crohn disease 146.5, 146.10
 donor-derived cells 146.9
 economic burden 6.5–6, 6.7, 6.9
 end-stage organ failure 146.4
 graft-versus-host disease 146.9
 haemopoietic cell transplantation 146.4
 high-risk 146.13–14
 HIV infection 146.3
 host genetic predisposition 146.8–9
 immunocompromised patient 146.1–18
 clinopathological features 146.9–12
 epidemiology 146.1–5
 locally advanced disease 146.14
 management 146.12–18
 metastatic disease 146.14
 organizations for patients/health care professionals 146.18
 pathophysiology 146.5–9
 prevention 146.15–17
 revision of immunosuppression 146.16
 risk factors 146.9
 screening/surveillance 146.17–18
 immunosuppressive drugs 146.3, 146.6–7
 inflammatory bowel disease 146.5
 intralesional therapy 20.44
 ionizing radiation in treatment 24.1–2
 lupus vulgaris co-morbidity 27.24
 metastatic disease 146.14
 mycosis fungoides 140.14
 non-Hodgkin lymphoma 146.3
 occupational 130.13–14
 oncogenic viral infections 146.7–8
 organ transplantation
 immunosuppressive drug therapy-induced 146.3–4
 management 146.13
 pre-transplant 146.14–15
 screening/surveillance 146.17–18
 photoageing 9.11
 phototherapy
 patient follow-up 21.15–16
 side effect 21.13
 post-organ transplantation 24.14
 prevalence 6.1
 psoriasis 146.5
 association 35.20
 PUVA
 patient follow-up 21.15
 side effect 21.13
 radiation-induced 24.19
 radiotherapy 24.1–16, 146.9, 146.14
 adjuvant 140.9
 recurrence 24.19
 recessive dystrophic epidermolysis bullosa 71.17, 71.27
 reduced tumour immune surveillance 146.5–6
 rheumatoid arthritis 146.5
 risk factors 146.9
 sports injuries 123.15
 staging 146.13–14
 sunbed use 9.13
 surgery 146.12–13, 146.14
 surveillance after phototherapy 21.15–16
 systemic lupus erythematosus 146.5
 ulcerative colitis 146.5
 UVB phototherapy, patient follow-up 21.15–16
 UVR role 9.9–10
 xeroderma pigmentosum 78.3–4, 78.6
see also basal cell carcinoma (BCC); melanoma; non-melanoma skin cancer (NMSC); squamous cell carcinoma (SCC)
 skin cleansers, neonates 116.2
 skin colour 70.1
 constitutive 88.1–2, 88.9
 facultative 88.2
 measurement 16.3–4
 racial factors 88.2
 variation between racial groups 88.9
 skin conditions
 co-morbidities 11.6
 emotional reactions 11.3
 patient beliefs 11.7, 11.7
 treatment challenges 11.6–7
 skin disease
 assessment tools 16.2–3
 association measures 5.13
 chronicity 5.9
 co-occurrence 5.10
 definition 4.1–2
 endocrinological considerations in therapy 149.15
 extent measurement 16.4
 frequency measures 5.13
 historical classification 1.4–5, 1.6
 historical definition 1.4
 impact measurement 16.4–8
 adolescents 16.7
 children 16.6–7
 family 16.7
 partners 16.7
 incidence 5.9, 11.2
 life course impairment assessment 16.7–8
 pathogenesis 149.9–10
 psychological comorbidities 86.2–3
 severity measurement 16.1–3
 symptom measurement 16.3
 therapy benefit measurement 16.3
 validation of measurement 16.2
 skin grafts/grafting 20.31, 20.32, 20.33
 burns 10.12
 combined epidermal/dermal substitutes 10.12, 10.13
 composite 20.31
 dermal substitutes 10.12, 10.13
 epidermal substitutes 10.12
 full-thickness 20.31, 20.31–2
 meshing 20.33
 split-thickness 20.31, 20.33
 vitiligo treatment 88.39–40
 wound healing 10.12–13
 skin laxity 96.19
 ageing 155.9
 Ehlers–Danlos syndrome 72.5–6, 72.7
 occipital horn syndrome 72.13, 81.19
 Williams–Beuren syndrome 72.14, 72.15
see also anetoderma; cutis laxa
 skin lesions
 additional clinical examination 4.19–26
 simple 4.18–19
 annular 4.16
 arrangement 4.6–8
 body sites 4.16, 4.17, 4.18
 borders 4.14
 colour 4.13–14, 4.15
 description 4.5–10
 distribution 4.6, 4.16–17, 4.19
 linear 4.15
 nomenclature 4.10–17
 palpation 4.17–18, 4.19
 pattern 4.6–10
 shape 4.8–10, 4.11, 4.12, 4.14–16
 surface features 4.13
 skin of colour
 black skin biological significance 88.8
 chemical peels 159.13
 skin picking disorder 86.14–15
 skin prick test, occupational disorders 130.6–7
 skin rejuvenation, chemical peels 159.4–5, 159.8, 159.9
 skin resurfacing, laser treatment 160.6–10
 ablative devices 160.6–8
 anaesthesia 160.8–9
 complications 160.10
 fractionated ablative 160.8, 160.9, 160.10
 devices 160.7–8
 non-ablative devices 160.8
 fractionated 160.7
 preoperative management 160.8–9
 skin tags
 acanthosis nigricans 87.4
 benign 133.7
 diabetes 64.3
 male ano-genital 111.5
 naevoid basal cell carcinoma syndrome differential diagnosis 141.19
 perianal 113.30–1
 snip excision 20.45
 skin thickness
 irritant contact dermatitis 129.6
 thickening and diabetes association 64.6
 thinning as corticosteroid therapy side effect 18.16
 skin tumours
 Mohs micrographic surgery 20.38
 pregnancy 115.7
 renal transplantation 153.6
 retinoic acid therapy 18.22
 shave biopsy 20.14
 skin types
 Fitzpatrick classification 9.8
 sun-reactive 88.9
 Skindex 6.4, 16.5
 skin-window technique 4.24
 SLAM-associated protein (SAP) 8.17
 SLC6A19 gene mutations 81.15
 SLC24A5 gene mutations 70.6
 SLC45A2 gene mutations 70.6
 sleep deprivation, acne vulgaris 90.16–17
 sleeping sickness *see* trypanosomiasis
 slime, bacterial 26.5
 Smad signalling mediators 2.4
 small molecule therapies, epidermolysis bullosa 71.30
 smallpox 25.6
 scarlet fever differential diagnosis 26.36
 vaccination 25.7
 smart phone technology 4.26
 Smith–Lemli–Opitz syndrome 81.16
 smoking
 acne vulgaris 90.16
 actinic cheilitis predisposition 110.78
 ageing of skin 155.2–3, 155.9
 α_1 -antitrypsin deficiency
 panniculitis 99.43
 atopic eczema association 41.7–8
 benign symmetrical lipomatosis association 100.14
 dermal connective tissue changes 96.1
 dermatitis herpetiformis 50.53
 flap necrosis risk 20.31
 hidradenitis suppurativa association 92.2
 keratosis 110.75
 nail plate pigmentation 95.12
 oral cancer risk 110.33, 110.34
 oral hyperpigmentation 110.66
 palmoplantar psoriasis association 5.2–3
 pemphigus protection 50.4
 penile cancer risk 111.30
 plaque psoriasis 35.4
 probability of disease 5.9
 psoriatic arthritis 35.44
 skin ageing 2.47

- thromboangiitis obliterans 103.4–5, 103.6
- venous lake association 103.14
- vulval intraepithelial neoplasia risk 112.32
- smooth muscle cells, high-power microscopy 3.32
- smooth muscle hamartoma 75.20, 75.21, 137.55
- snake bites 131.5
- cutaneous vasculitis differential diagnosis 102.4
- lymphangitis 105.51
- Sneddon syndrome 101.21–2
- Sneddon–Wilkinson disease 49.14
- acute generalized exanthematous pustulosis differential diagnosis 119.4
- see also subcorneal pustular dermatosis
- snip excision 20.45
- snuff, keratosis 110.75
- soap substitutes 18.9
- social avoidance 11.2, 11.5
- social factors 11.1–8
- appearance role 11.1–2
- impact of dermatology conditions 11.5–6
- impacts over lifespan 11.5–6
- integrated clinical management impact 11.7–8
- social isolation 11.2
- social medicine 1.8
- social stigma 11.5
- socioeconomic factors 5.9–10
- SOCS proteins 8.5
- sodium
- concentration in sweat 94.3
- sweat composition 94.3
- sodium hypochlorite 18.10
- sodium pump 94.2
- sodium sulfacetamide 91.13
- sodium valproate 89.57
- sudoku 26.71–2
- soft-tissue lesions, radiography 95.48
- soft-tissue tumours 137.2
- classification 137.2
- fat cells 137.58–61
- fibrohistiocytic 137.19–23
- fibrous 137.2–19
- lymphatic 137.39–41
- muscle 137.55–8
- myofibroblastic 137.2–19
- radiography 95.48
- vascular 137.23–39
- solar cheilosis 110.78–9
- solar elastosis 96.2–4
- acquired elastic haemangioma 137.30
- actinic comedonal plaque 96.3
- actinic keratosis 142.2, 142.3
- elastic nodules of the ear 96.3–4
- investigations 96.4
- management 96.4
- variant 96.5
- solar keratoses see actinic keratoses
- solar lentigines see actinic lentigines
- solar purpura 101.5
- solar urticaria 127.20–3
- chemical-induced photosensitivity differential diagnosis 127.29
- chronic actinic dermatitis association 127.14
- clinical features 127.21–2
- definition 127.20
- differential diagnosis 127.22
- drug-induced photosensitivity differential diagnosis 127.29
- epidemiology 127.21
- investigations 127.22, 127.23
- management 127.23
- pathophysiology 127.21
- polymorphic light eruption differential diagnosis 127.4
- variants 127.21–2
- solid facial oedema 90.35–6, 91.11, 91.16
- solitary circumscribed neuroma 137.46
- solitary giant trichoepithelioma 138.11
- solitary lymphocytoma 26.70
- solitary neurofibroma 137.48
- soluble oil dermatitis 130.1, 130.2
- solvents
- systemic lupus erythematosus 51.19
- topical drug delivery 18.6
- somatic mutations 7.5
- somatostatin 8.50, 8.51–2
- sonic hedgehog (SHH) 2.4
- basal cell carcinoma genetics 141.3
- ectodermal dysplasias 67.7
- pathway mutations in syndromic cleft lip/palate 110.23
- see also hedgehog pathway inhibitors
- soot, occupational skin cancers 130.13
- sorbic acid 18.8, 129.8, 129.9
- SOX-10 transcription factor 3.21
- SOX18 gene mutations 73.19
- soya, antiageing products 156.9, 156.11
- sparganosis 33.31–3
- application 33.32
- proliferum 33.33
- specific granule deficiency 8.19
- speckled lentiginous naevus syndrome 132.18
- spectacle frames
- acanthoma 123.13–14
- dermatitis 128.16
- spectrophotometric image analysis (SIAoscopy) 4.21
- spermatogenesis, drug effects 14.8
- sphingolipidoses 81.4, 81.6–9
- spices 128.25–7
- spider(s) 34.32–4
- brown recluse 34.33–4
- fiddleback 34.33–4
- funnel web 34.33
- violin 34.33–4
- widow 34.32–3
- wolf 34.34
- spider angioma 103.8, 103.10–12
- spider mites 34.50
- spider telangiectases 103.10–12
- clinical features 103.11
- definition 103.10
- epidemiology 103.10–11
- investigations 103.11, 103.12
- liver disease 152.8–9
- management 103.12
- pathophysiology 103.11
- Spiegler–Fendt sarcoma see lymphocytoma cutis
- Spiegler’s tumour see eccrine glands, cylindroma
- spiky hair 68.23
- spina bifida 85.8, 85.9, 113.4
- anaphylaxis risk 85.10
- investigations 85.10
- latex allergy 85.9–10
- spinal cord compression, hand–arm vibration syndrome differential diagnosis 123.24
- spinal cord cyst 85.7–8
- spinal cord injury, dermatoses 85.10
- spinal dysraphism 85.8–10, 113.4
- clinical features 85.9–10
- definition 85.8
- epidemiology 85.8–9
- investigations 85.10
- management 85.10
- occult 85.9
- pathophysiology 85.9
- spindle cell haemangioma 73.14, 73.15, 137.32
- spindle cell lipoma 137.60
- SPINK5 gene mutation 65.24, 146.2
- spiny keratoderma 65.52–3
- spiny palmoplantar keratosis 65.70
- spiradenocarcinoma 138.36–7
- spiradenoma 138.31–2
- malignant 138.36–7
- Spirillum minor* 26.71–2
- spirochaetes 26.66–8
- Spirometra* 33.31–2
- spironolactone
- female pattern hair loss management 89.23
- hirsutism treatment 89.68
- papulopustular acne treatment 90.43
- splenomegaly, neonatal lupus erythematosus 51.38
- splinter haemorrhages 95.13, 95.16, 123.15–16
- psoriasis 95.40
- split-hand–split-foot malformation (SHFM) 67.9
- spondylitis 154.5
- psoriatic arthritis 35.43
- spondyloarthritis 154.5, 154.8
- sponges, dermatitis 131.2–3
- spongiosis 3.38
- Sporothrix schenckii* 32.71–3
- colony 32.73
- sporotrichosis 32.71–3
- anthrax differential diagnosis 26.44
- atrophic scars 96.11
- cat scratch disease differential diagnosis 26.61
- clinical features 32.71–2
- disseminated cutaneous 32.73
- epidemiology 32.71
- glanders differential diagnosis 26.54
- hidradenitis suppurativa differential diagnosis 92.7
- investigations 32.73
- lymphangitis 105.51
- management 32.73
- pathophysiology 32.71
- sports injuries 123.15–16
- abrasions 123.16
- acne mechanica 123.15
- athlete’s nodule 123.16
- black heel/palm 123.10, 123.15
- clinical features 123.15–16
- corns/calluses 123.16
- definition 123.15
- friction blisters 123.9
- haemorrhagic 123.15–16
- hyperpigmentation 123.16
- hypothenar hammer syndrome 123.12
- inflammation 123.16
- spotted fevers 26.77–9
- Rocky Mountain spotted fever 26.77–8
- ehrlichiosis differential diagnosis 26.63
- SPRED1 gene mutations 80.8
- spun-glass hair 89.57
- squamous cell carcinoma (SCC) 142.1, 142.25–33
- acrodermatitis chronica atrophicans complication 96.14
- actinic keratosis association 142.2
- differential diagnosis 142.4–5
- risk of development 142.5, 146.9
- anal 113.17–20
- clinical features 113.18–20
- epidemiology 113.18
- investigations 113.20
- management 113.20
- pathophysiology 113.18
- staging 113.19
- variants 113.19
- anal fistula complication 113.27
- antirheumatic drug-induced 154.15
- associated diseases 142.26
- basal cell carcinoma differential diagnosis 141.10
- Bowen disease differential diagnosis 142.19, 142.20
- cervical lymph node involvement 24.12
- chondrodermatitis nodularis differential diagnosis 108.9
- cicatrical pemphigoid differential diagnosis 50.51
- clinical features 142.28–30, 146.9–10
- complications/co-morbidities 142.29
- Crohn disease association 112.23
- cutaneous 142.25–33
- definition 142.25
- differential diagnosis 142.28
- disease course 142.30
- dyskeratosis congenita 69.14
- epidemiology 142.25–6
- epidermodysplasia verruciformis 146.1
- epithelioma cuniculatum 142.29
- external auditory canal 108.26–7
- staging 108.27
- external ear 108.23–7
- eyelid 109.49, 109.50
- genital HPV association 25.59
- Hailey–Hailey disease 66.13
- heat-associated 125.12–13
- high-risk 142.29, 142.31–2
- HIV infection 31.30
- HPV role in pathogenesis 146.7–8
- immunocompromised patients, management 146.13–14
- investigations 142.30
- keratoacanthoma differential diagnosis 142.35
- lichen planus 37.12–13
- association 112.12
- lichen sclerosus association 112.8–9
- lip 110.26, 110.81
- low-risk 142.32
- lupus vulgaris co-morbidity 27.24
- male genital 111.20, 111.29–34
- management 142.30–3, 142.31–3
- with Merkel cell carcinoma 125.13
- metastases risk 142.29, 142.31
- Mohs micrographic surgery 20.38, 20.39
- molluscum contagiosum differential diagnosis 25.13
- nail apparatus 95.31–2, 95.43
- oesophagus 152.1
- oral 110.32–8
- causes 110.34–5
- disease course 110.37
- epidemiology 110.33
- genetics 110.34
- history 110.35
- investigations 110.37
- malignant transformation 110.36
- management 110.37–8
- predisposing factors 110.33–4
- presentation 110.35–6
- prognosis 110.37
- risk reduction 110.35
- severity classification 110.36–7
- sites 110.36
- parotid lymph node involvement 24.12
- pathophysiology 142.26–8
- penile 111.29–31
- lichen sclerosus complication 111.15
- perianal 113.17–20
- photocarcinogenesis 127.29
- photodynamic therapy 22.5
- phymatous rosacea differential diagnosis 91.11
- pilonidal sinus complication 123.23
- pinna 108.24–6
- poorly differentiated 142.31
- post-organ transplantation 24.14
- precursors 146.15
- presentation 142.28
- prognosis 142.30
- progression prevention 146.15
- pseudoepitheliomatous hyperplasia differential diagnosis 133.7, 133.8
- radiation-induced 24.19
- radiotherapy 140.7–13, 146.14
- adjuvant 140.9
- recurrence 24.19
- recessive dystrophic epidermolysis bullosa 71.17, 71.27
- recurrence risk 142.29, 142.31
- scrotal 111.20
- secondary prevention 142.32–3
- severity classification 142.29

- squamous cell carcinoma (*continued*)
 signalling pathways 142.26
in situ 142.2, 142.17
 sunscreen protection 9.12
 surgery 140.7, 140.8, **140.9**, 142.30–1
 transplant recipients 25.63
 treatment 31.31
 modality 140.7
 trichilemmal carcinoma 138.6–7
 UVR role 9.9–10
 variants 142.27, 142.28
 vulval 112.34–5
 well-differentiated 142.30, 142.33
 xeroderma pigmentosum 78.4–5
- squamous hyperplasia, genital 111.28
- squamous intraepithelial lesions (SIL) 142.25
 genital 111.28
- squaric acid dibutylester, sensitizing agent
 use 18.30
- SSTRs 8.51–2
- ST14* gene mutations 65.36
- stable flies 34.7, 34.8
- staining
 artefacts 3.28
 techniques 3.7–10
- stainless steel implants 128.59
- STAMBP* gene mutations 73.6
- standard deviation 17.18
- standard error 17.18
- standard erythema dose (SED) 9.2
 sun exposure 9.12
- Staphylinidae 34.29
- staphylococcal enterotoxin B 8.28, 26.30
- staphylococcal folliculitis 31.20
 stoma infection 114.3
 vulval 112.24
- staphylococcal infections
 acrodermatitis continua of Hallopeau
 differential diagnosis 35.42
 atopic eczema 2.13
 coagulase-negative 26.9
 folliculitis 26.22
 eye infections 109.41
 genital 111.21
 immunodeficiency association 148.14
 infective eczema 39.24
 vulval 112.23–4
- staphylococcal scalded skin
 syndrome 8.28, 26.6, 26.14, 26.27–9,
 116.24
 bullous impetigo epidemics 116.23
 clinical features 26.28–9
 epidemiology 26.27
 epidermolysis bullosa differential
 diagnosis 71.23
 HIV infection 31.20, 31.21
 infants 117.7–8
 investigations 26.29
 management 26.29
 neonates 26.28
 pathophysiology 26.27–8
 vulval lesions 112.23
- staphylococcal superantigen 18.15
- Staphylococcus* 26.3
 classification 26.8
- Staphylococcus aureus* 26.3, 26.6–9
 adherence 26.7
 allergic eczema relationship 41.13
 anthrax differential diagnosis 26.44
 antibiotic resistance 26.8
 antigens in atopic eczema 41.12, 41.13
 associated diseases 26.7
 atopic eczema 26.13, 41.30
 bacterial interference 26.6
 biofilms 26.5
 blepharitis 109.10
 blistering distal dactylitis 117.8
 botryomycosis 26.72, 26.73
 carbuncle 26.25–6
 carriage 26.7
 suppression 26.7–8
 cellulitis 105.11
 chancriform pyoderma 26.83
 children with HIV infection 31.35
 clinical history 26.12
 colonization 26.9
 definition 26.6
 dermatitis vegetans 26.83
 dracunculiasis secondary infection 33.12
 ecthyma 26.17
 environmental factors 26.9
 epidemiology 26.6–7
 erysipelas 26.18, 26.21
 ethnic differences 26.4
 exfoliative toxins 26.14, 26.27–8
 exotoxins 26.13
 folliculitis 26.22, 90.30, 113.9
 folliculitis decalvans 89.43, 89.44
 furuncle 26.23, 26.24
 genetics 26.8–9
 glanders differential diagnosis 26.54
 HIV infection 31.20
 children 31.35
 impetigo 26.13–16, 117.7
 bullous 116.23
 involvement in cutaneous disease **26.6**
 Kawasaki disease 26.84
 necrotizing lymphocytic folliculitis of
 the scalp margin 93.4, 93.5
 otitis externa 108.17
 pathology 26.8
 pathophysiology 26.7–9
 perioritis staphylogenes and sweat
 gland abscesses 116.24
 pinna infection 108.11
 recurrent toxin-mediated perineal
 erythema 26.32
 scalp pruritus 107.13
 septic arthritis 154.3–4
 sex differences 26.4
 superantigen production 26.13, 26.32
 sycosis 26.26–7
 toxic shock syndrome 26.29–32
 vulval infection 112.23–4
see also staphylococcal scalded skin
 syndrome
- Staphylococcus epidermidis* 26.3, 26.9
 blepharitis 109.10
 rosacea association 91.5
- Staphylococcus hominis* 26.3
- Staphylococcus lugdunensis* 26.9
- starch 18.8
- starvation, telogen effluvium 89.26
- stasis dermatitis 105.49
- statins, familial hypercholesterolaemia
 management 62.7
- status protusus cutis 100.23
- stavudine, drug eruptions 31.18
- steatocystoma multiplex 90.27–8, 134.4
 hidradenitis suppurativa
 association 92.2
 differential diagnosis 92.7
- stellate pseudoscars 96.11
- stem cell(s) 2.44–5
 activation regulation 2.45
 burns management 126.7
 epidermal proliferation unit
 concept 2.44–5
 transplantation erythematous
 reactions 47.6
- stem cell factor (SCF) 2.16
- stem cell factor receptor (KIT) 46.2
- stem cell therapy
 systemic sclerosis management 56.19
 wound healing 10.11
- Stemmer's sign 100.20
- Stenotrophomonas maltophilia* 26.54
- HIV infection 31.20
- Stensen's duct 110.6
- sternum, surgery 20.46
- steroid hormones 149.2, 149.4
- steroid sulphatase (*STS*) gene
 mutations 65.4, 65.6
- steroid withdrawal syndrome 19.18–19
- Stevens–Johnson syndrome 12.2–3,
 119.12–22
 antiretroviral therapy effect 31.10
 classification 47.2
 clinical features 110.48, 119.14–19
 complications 119.17–18
 culprit drug removal 119.19–20
 definition 119.13
 diagnosis 110.48
 differential diagnosis **119.17**
 disease course 119.18–19
 drug eruptions 31.17, 31.18, 154.10,
 154.14
 drug-induced 47.3
 drugs predisposing to 119.2, **119.13**
 epidemiology 119.13
 erythema multiforme relationship 47.1
 fixed drug eruption differential
 diagnosis 118.13
 fluid replacement 119.20–1
 folate synthesis inhibitor-induced 19.43
 genetics 119.14
 genital ulceration 111.18
 haemorrhagic crusting of lips 110.83,
 110.84
 hand, foot and mouth disease
 differential diagnosis 25.82
 infections 119.21
 investigations 119.19
 management 110.48, 119.19–22
 mucous membrane pemphigoid
 differential diagnosis 50.29
 nail lichen planus differential
 diagnosis 95.45
 nitrofurantoin in pregnancy 31.34
 nutrition 119.21
 ocular complications 109.34, 109.35,
 109.36
 ocular effects 109.27
 ocular mucous membrane
 pemphigoid 109.29
 oral lesions 110.48
 pathology 47.4
 pathophysiology 119.13–14
 perineum/perianal region 113.8
 prognosis 119.18–19
 severity classification 119.17
 variants 119.17
 varicella infection 25.26
see also toxic epidermal necrolysis (TEN)
- Stewart–Treves syndrome 105.53, 137.36,
 137.37
- stiff skin syndrome 72.18–19
 hyaline fibromatosis syndrome
 differential diagnosis 72.18
 systemic sclerosis differential
 diagnosis 56.15–16
see also Winchester syndrome
- stigmatization 86.3–4
- Still disease
 hyperpigmentation 88.20
see also adult-onset Still disease; juvenile
 rheumatoid arthritis
- sting(s) 131.1–4
- stinging, delayed-type/immediate-
 type 129.10–11
- stingrays 131.4
- stink bugs 34.28
- STK11* gene mutations 70.14
- stomach disorders 152.1–4
- stomas
 acanthotic papules 114.112
 allergic contact dermatitis 114.1–3
 appliances 114.1, **114.2**
 bladder carcinoma **114.2**
 complications 114.1–7
 Crohn disease association 114.7–8,
 114.9, 114.10
 irritant skin reactions 114.10–13
 pyoderma gangrenosum
 association 114.7–8, **114.9**, 114.10
 cutaneous Crohn disease 97.12
 dermatological assessment **114.3**
 granulomas 114.11
 hypergranulating polyps 114.11
 hyperkeratotic papules 114.112
 infections 114.3–4
 inflammatory dermatosis
 treatment 114.1
 irritant contact dermatitis 129.6
 irritant skin reactions 114.10–13
 papular reactions 114.10–12
 patch testing 114.3
 patient assessment 114.1, **114.2**, **114.3**
 psoriasis association 114.4–5, 114.6, 152.7
 pyoderma gangrenosum
 association 114.7–8, **114.9**, 114.10,
 152.7
 skin complications 152.7
 types 114.1, **114.2**
 ulceration 114.7–8, **114.9**, 114.10
 underlying bowel disease 114.7–8, **114.9**,
 114.10
- stomatitis
 denture-related 110.69–70
 angular cheilitis association 110.80
 monoclonal plasmacytic
 ulcerative 110.56
 riboflavin deficiency differential
 diagnosis 63.15
 ulcerative 110.42
see also aphthous stomatitis
- stonefish stings 131.4
- stop codon 7.5
- storiform collagenoma 137.3
- storiform patterning 3.38
- Stormorken syndrome 65.27
- stratum basale 2.5
- stratum corneum 2.1, 2.2, 2.5, 2.6–7, 13.1
 barrier function 13.2
 epidermal barrier 8.4, 129.2–3
 factors determining permeation 13.3–4
 intercellular lipid domains 13.2–3
 mechanical function 123.4
 penetration pathways 13.2–3
- stratum granulosum 2.5, 2.6
- stratum lucidum 2.7
- stratum spinosum 2.5, 2.6
- straw itch 34.49
- strawberry naevus *see* infantile
 haemangiomas
- strawberry tongue 110.72
- streptodactyly 96.38
- streptobacillary rat-bite fever 26.72
- Streptobacillus moniliformis* 26.72
- streptocerciasis 33.6, **33.7**
- streptococcal infections 26.9–12
 ano-genital dermatitis 112.24
 associated diseases 26.10–11
 atopic eczema 26.13
 carriage 26.11–12
 causative organisms 26.11–12
 cellulitis 26.20–1, 105.11
 perianal 26.33–4, 111.21, 113.10
 classification 26.12
 clinical history 26.13
 cutaneous **26.10**
 definition 26.9
 dermatitis/perianal cellulitis 26.33–4,
 111.21, 113.10
emm genes 26.11, 26.12, 26.35
 environmental factors 26.12
 epidemiology 26.10–11
 erysipelas 26.18, 26.20–1
 erythema annulare centrifugum 47.9
 erythema marginatum association 47.12
 eyes 109.41
 genital 26.33–4, 111.21, 113.10
 impetigo 26.13–16
 infective eczema 39.24
 investigations 26.12
 Lancefield group antigens 26.11
 M protein 26.11, 26.12, 26.35
 pathophysiology 26.11–12
 perianal cellulitis 26.33–4, 111.21, 113.10
 perianal dermatitis 113.10
 post-streptococcal glomerulonephritis
 with impetigo 153.6
 recurrent toxin-mediated perineal
 erythema 26.32
 rheumatic fever 150.5
 superantigen toxins 26.32
 throat and recurrent toxin-mediated
 perineal erythema association 26.32
 toxic shock-like syndrome 26.36–7

- toxin-mediated 26.34–7
 vulval 112.24
 vulvovaginitis 26.33
 streptococcal pyrogenic exotoxins (SPE) 26.11
 streptococcal toxic shock syndrome 26.6, 26.10, 26.11
Streptococcus faecalis, vulval infection 112.24
Streptococcus group A 26.9–12, 26.11, 26.13
 blistering distal dactylitis 26.34
 dermatitis vegetans 26.83
 ecthyma 26.16–17
 erysipelas 26.18
 HIV infection 31.20
 β -haemolytic 154.4
 erythema nodosum 99.18
 perianal dermatitis 117.8
 toxic shock-like syndrome 26.36–7
 vulvovaginitis 26.33
Streptococcus pyogenes 26.4, 26.10–12
 carriage 26.11–12
 ecthyma 26.17
 genetics 26.12
 HIV infection 31.20
 impetigo 26.13–16, 117.7
 isolates 26.12
 Kawasaki disease 26.84
 pathophysiology 26.11
 recurrent toxin-mediated perineal erythema 26.32
 scarlet fever 26.35
 toxins 26.30, 26.35
 toxic shock syndrome 26.29–32
 vulval infection 112.24
Streptococcus sanguinis, Behçet disease association 48.2
Streptomyces, pitted keratolysis 26.42
Streptomyces somaliensis 32.73
 stress, mechanical 123.3
 stress, psychological 11.3
 acne vulgaris 90.16–17
 neurogenic inflammation 8.50
 systemic lupus erythematosus association 51.18–19
 urticaria 42.8, 47.8
 stress response systems, neuroendocrine 149.8
 stretch marks 96.9–10, 100.25
 endocrine disorder skin signs **149.10**
 striae
 atrophicans 96.9–10
 distensae 96.9–10
 elastotic 96.29–30
 gravidarum 96.9, 96.10, 115.3
 striated muscle hamartoma 75.20
 string-of-pearls sign 50.35–6, 50.37
 stroke
 antiphospholipid syndrome association 52.1, 52.2
 complex regional pain syndrome association 85.13
 stromelysins 2.33
Strongyloides stercoralis 33.15, 33.16–17
 perineum/perianal region 113.11–12
 urticaria weals 42.6
 strongyloidosis 33.15–17
 HIV infection 31.29
 stucco keratosis 133.3, 133.4
 Flegel disease differential diagnosis **87.17**
 stump acne 123.15
 Sturge–Weber syndrome 73.2–3, 75.21–2
 facial haemangiomas 110.15
 genetics 75.22
 heterotrimeric G-protein mosaic disorders 75.21
 port-wine stains 23.7, 75.22
 stye 109.41
 subacute cutaneous lupus erythematosus (SCLE) 51.1, 51.11–14, 51.21
 associated diseases 51.12
 clinical features 51.13–14
 complications/co-morbidities 51.13
 definition 51.11
 differential diagnosis **51.14**
 epidemiology 51.11–12
 investigations 51.14
 malignancy association 147.20–1
 management 51.14
 pathophysiology 51.12–13
 subclavian vein thrombosis 105.13
 subcorneal pustular dermatosis 49.14–15
 acute generalized exanthematous pustulosis differential diagnosis 119.4
 amicrobial pustulosis of the skin folds differential diagnosis 49.17
 clinical features 49.14–15
 differential diagnosis 49.15
 epidemiology 49.14
 IgA pemphigus association 50.7
 investigations 49.15
 management 49.15
 pathophysiology 49.14
 pyoderma gangrenosum differential diagnosis 49.4
 subcorneal pustules 3.38
 subcutaneous fat necrosis of the newborn 99.35, 99.53–5, 116.14–16
 clinical features 99.54, 116.15–16
 complications/co-morbidities 99.54
 definition 116.14
 epidemiology 116.15
 investigations 99.54–5
 management 99.55
 pathophysiology 99.53–4, 116.15
 sclerema neonatorum differential diagnosis 99.56, 116.17
 subcutaneous fat necrosis, pancreatic disease association 152.6
 subcutaneous lipomatosis 100.13–19
 subcutaneous panniculitis-like T-cell lymphoma 99.58–9, 140.31–2
 clinical features 140.32
 definition 140.31
 lupus panniculitis differential diagnosis 99.36–7
 management 140.31
 pathophysiology 140.31–2
 subcutaneous tissue
 anatomy 99.3
 cellular composition 99.2, 99.3
 subepidermal nodular fibrosis 137.19
 subjective sensory irritation 129.10–11
 submandibular glands 110.6
 substance P 2.12, 85.2, 85.3
 cutaneous vasodilatation 106.1
 itching in skin disease 83.6
 sebaceous gland cells 90.19
 self-injury 8.53
 stress role 8.50
 subungual abscess 95.37–8
 subungual disturbances 95.13
 subungual exostosis 95.23–4, 95.25
 subungual haematoma 95.16–17, 123.15
 subungual haemorrhage 95.13
 subungual hyperkeratosis
 lichen planus of nail bed 37.12
 psoriasis 95.40
 subungual keratoacanthoma 95.27–8
 succulent gums 116.4
 sucking blisters 116.3
 suckling pads 116.4
 Sudeck atrophy 85.13, 154.2
 Sugio–Kajii syndrome 67.20–1
 suicidal ideation 86.33–4
 deliberate self-harm 86.31
 suicide
 acne vulgaris 90.34–5
 attempts by acne patients 11.4
 dermatological patients 86.33–5
 risk assessment 86.34
 sulphamethoxypyridazine
 dermatitis herpetiformis 50.54, **50.55**
 linear IgA disease treatment 50.37, **50.38**
 sulphapyridine
 dermatitis herpetiformis 50.54, **50.55**
 linear IgA disease treatment 50.37, **50.38**
 mucous membrane pemphigoid 109.33
 sulphasalazine
 adverse reactions 154.15
 dermatitis herpetiformis treatment 50.54, **50.55**
 psoriatic arthritis treatment 35.45
 sulphatases, multiple sulphatase deficiency 65.29
 sulphonamides 19.43
 acute generalized exanthematous pustulosis predisposition 119.2, **119.4**
 exanthem induction 118.1
 photoallergic contact dermatitis 128.78
 toxoplasmosis treatment 33.52
 sulphonylureas, eczema induction 118.4
 sulphur, acne therapy 90.49
 sulphur amino acids, trichothiodystrophy 89.55
 sun exposure
 acquired elastotic haemangioma 137.30
 actinic lichen planus 37.7–8
 allergic contact dermatitis 128.11
 atypical naevi 132.44
 Bloom syndrome 79.4
 children 143.5–6
 dermatoporosis 155.9
 Flegel disease 87.16
 granuloma annulare 97.2
 lentigo maligna 144.5
 lip cancer 110.34–5
 mechanical properties of skin 123.5
 melanoma 143.5–6
 structures 144.5, **144.8**
 Merkel cell carcinoma 145.2
 Meyerson naevi 132.30
 occupational skin cancers 130.13
 ochronosis 88.51
 pigmentation response 88.8–9
 psoriasis 35.5
 radiotherapy protection 120.13
 scalp 107.9
 seborrhoeic keratosis 133.1, 133.2
 simple lentigo 132.4
 sports injuries 123.15
 squamous cell carcinoma association 142.28
 systemic lupus erythematosus 51.19, 51.21–2
 UVR 9.12
 venous lake association 103.14
 xeroderma pigmentosum 78.3, 78.4, 78.5
 see also actinic entries; photodamage; solar entries
 sun protection see photoprotection
 sun protection factor (SPF) 9.11
 sunbeds
 actinic keratosis incidence 142.3
 melanoma risk 143.6
 pseudoporphyria induction 60.19
 squamous cell carcinoma association 142.28
 UVR exposure 9.13
 sunburn
 severe reactions in xeroderma pigmentosum 78.3, 78.4, 78.5
 sports injuries 123.15
 sunburn cells (SBC) 9.6
 sun-reactive skin types **88.9**
 sunscreens 9.11–12, 18.30–2
 actinic prurigo 127.13
 active photoprotection 9.12
 allergy 127.10
 Bowen disease management 142.21
 chronic actinic dermatitis 127.20
 erythropoietic protoporphyria 60.15
 hydroa vacciniforme 127.25
 juvenile spring eruption **127.9**
 non-erythema endpoints 9.11–12
 passive photoprotection 9.12
 photodamage protection 96.4
 photosensitivity diseases 127.35
 phototoxic 127.28
 polymorphic light eruption 127.7
 porphyria management 60.6, 60.10
 porphyria cutanea tarda 60.13
 rosacea 91.13
 management 91.12
 solar lentiginos 132.7
 subacute cutaneous lupus erythematosus treatment 51.14
 usage 9.11
 UV light blocking 18.30
 superantigens 8.28
 superficial acral fibromyxoma 95.30
 superficial angiomyxoma 137.62
 superficial epithelioma with sebaceous differentiation 138.18
 superficial vein insufficiency 103.36
 superficial venous thrombosis 103.30–1, **103.32**
 clinical features **103.31**
 definition 103.30
 epidemiology 103.30–1
 investigations 103.31, **103.32**
 pathophysiology 103.31
 thrombophlebitis migrans 103.31–2
 treatment **103.32**
 superinfections, congenital
 ichthyoses 65.39
 superoxide 8.44
 production regulation 8.45
 support organizations 15.4
 support surfaces, pressure ulcers prevention 124.5
 treatment 124.6
 suppressors of cytokine signalling (SOCS) 8.5
 suramin
 onchocerciasis treatment 33.6
 trypanosomiasis treatment **33.40**
 surgery
 anatomy 20.2–5
 aseptic technique 20.8
 basal cell carcinoma 140.7, 140.8, **140.9**
 benign naevi 20.46
 bleeding complications 20.8, 20.10–11
 complications 20.8, **20.9**, 20.10, 20.10–11
 consent 20.14
 cryosurgery 20.43
 curettage 20.44–5, 20.45
 dog-ear repair 20.34–5
 dressings 20.22–3
 electrocautery 20.40
 electrosurgery 20.40–3
 elliptical excision 20.15–16
 epidermoid cysts 20.45
 equipment 20.5–8
 eyelids 20.5
 facial
 blood vessels 20.2–3
 cosmetic units 20.2
 free margins 20.2
 lymphatic supply 20.3
 nerve blocks 20.3–4
 sensory nerves 20.3–4
 flaps 20.25–7, 20.28, **20.29–30**, 20.30
 granulating wounds 20.23, 20.24
 haemostasis for open wounds 20.45
 hand hygiene 20.6–7
 head and neck 20.2–5
 hidradenitis suppurativa management 92.10–11
 history taking 20.8
 incomplete excision 20.11
 infections 20.6, 20.10, 20.11
 keratoacanthoma 20.46
 knots 20.16–17
 limbs 20.5
 lipomas 20.46
 local anaesthesia 20.11–12
 male genital lichen sclerosis management 111.15
 M-plasty 20.33, 20.34
 mucous membrane lesions 20.46
 nerve damage 20.2
 NF1 treatment 80.4
 patient preparation 20.14
 pigmented lesions 20.46
 postoperative care 20.22–3, 20.24
 postsurgical artefact 86.27

- surgery (*continued*)
 preoperative preparation 20.14–15
 pressure dressings 20.23
 protective clothing 20.7
 relaxing incisions 20.35
 safety 20.8
 scars
 orientation 20.2
 unsatisfactory 20.11
 secondary intention healing 10.10, 20.23
 shoulder 20.46
 skin cancer 146.12–13, 146.14
 skin grafts 20.31, 20.31–2, 20.33
 skin surface cleansing 20.15
 skin tension lines 20.2
 snip excision 20.45
 spina bifida 85.10
 squamous cell carcinoma 140.7, 140.8, 140.9, 142.31–2
 standing cutaneous deformity
 repair 20.34–5
 sterilization 20.7–8
 sternum 20.46
 surgical needles 20.16
 Sweet syndrome association 148.6
 syringomyelia treatment 85.8
 techniques
 historical aspects 1.8
 wart treatment 25.53
 tricone repair 20.34–5
 undermining levels 20.2
 upper back 20.46
 vermilion border 20.5, 20.6
 wedge excision 20.33
 wound closure 20.25–7, 20.28, 20.29–30, 20.30–5
 wound dressings 20.11
 wound healing 20.23, 20.24
 obesity 100.26
 wound infections 20.6, 20.10, 20.11
 Z-plasty 20.33, 20.34
see also biopsy of skin; Mohs micrographic surgery; sutures
 Sutton ulcers 110.29
 sutures
 buried dermal 20.19–20
 horizontal mattress 20.20–1
 knots 20.16–17, 20.18, 20.19
 materials 20.16
 pulley 20.21, 20.22
 purse string 20.22
 removal 20.23
 running intradermal 20.22
 simple interrupted 20.18–19
 subcuticular 20.22
 technique 20.17–22
 vertical mattress 20.20, 20.21
 wound healing 10.10
 sweat
 abnormal odour 94.15–16
 composition 94.3–4
 rate of production 2.9
 sweat chloride test 94.4
 sweat duct 94.3
 sweat glands 2.1, 2.2, 2.8–9
 abscesses 116.24
 carcinomas 138.34–40
 endocrine mucin-producing 138.39
 sclerosing 138.37–8
 development 2.4
 disorders 94.1, 94.4–18
 endocrine mucin-producing carcinoma 138.39
 hypohidrotic ectodermal dysplasias 67.13
 male ano-genital region 111.5
 precursor fluid 2.8–9
 secretory nerve fibres 2.8
 sympathetic nerve terminals 2.8
see also apocrine glands; eccrine glands
 sweating
 active 2.8
 atopic eczema 41.15
 cold-induced syndrome 94.7
 eccrine in spinal cord injury 85.10
 emotional 2.8
 flushing association 106.3, 106.4–7
 gustatory 85.15–16, 94.7–8
 submental 94.7
 treatment 18.33
 itching relationship 41.15
 mental 2.8, 94.3
 night sweats 94.5
 osmotic factors 94.3
 submental gustatory 94.7
 thermal 2.8
 thermoregulatory 94.3, 94.4–5
 transient acantholytic dermatosis association 87.22, 87.23
 urticaria 42.9
 sweating sickness 94.4
 Sweet syndrome 49.6, 49.7, 49.8–12, 110.31
 aphthous ulcers 110.32
 associated diseases 49.6, 49.7, 49.8
 classical 49.6, 49.7
 clinical features 49.9–11, 148.6
 definition 49.6
 diagnostic criteria 49.10, 49.11
 differential diagnosis 49.10–11
 disease course 49.11
 drug-induced 49.6, 49.7, 49.9, 148.6
 environmental factors 49.9
 epidemiology 49.6, 49.7, 49.8
 erythema elevatum diutinum differential diagnosis 102.9–10
 erythema nodosum association 99.18
 histiocytoid 49.10
 hypocomplementaemic urticarial vasculitis differential diagnosis 102.19
 infections 49.9
 investigations 49.11–12
 leukaemia cutis differential diagnosis 140.49
 Majeed syndrome association 45.8
 malignancy-associated 49.6, 49.7, 49.9, 147.23
 management 49.12
 nomenclature 49.6
 paraneoplastic 148.6
 pathergy 49.8
 pathophysiology 49.8
 prognosis 49.11
 pyoderma gangrenosum coexistence 148.7
 respiratory disorder association 151.5
 rheumatoid neutrophilic dermatosis 55.3
 sarcoidosis association 98.14
 severity classification 49.11
 subacute cutaneous lupus erythematosus association 51.12
 subcutaneous 49.10, 99.48–9
 systemic lupus erythematosus association 51.30
 variants 49.9
 swimmer's itch 131.2
 swimmer's shoulder 123.16
 swimming, otitis externa 108.17
 sycosis 26.26–7
 clinical features 26.26–7
 herpes simplex virus 31.22
 investigations 26.27
 lupoid 26.26–7
 management 26.27
 pathophysiology 26.26
 pseudofolliculitis differential diagnosis 93.2
 symmetrical drug-related intertriginous and flexural exanthem (SDRIFE) 118.4, 118.5–6
 symmetrical dyschromatosis of the extremities 70.15–16
 sympathetomy, hyperhidrosis treatment 94.9–10
 sympathetic nerve injury 85.12
 sympathetic skin response 85.4
 symplastic haemangioma 137.32–3
 symptoms, measurement 16.3
 synaptophysin 3.20
 syndecans 2.37
 wound healing 10.7
 syndromic hypotrichoses
 autosomal dominant 68.16–17
 autosomal recessive 68.17–18
 synovitis, *Acinetobacter* 26.50
 synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome
 see SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome
 syphilides
 corymbose 29.13
 lichenoid 29.13
 macular 29.10, 29.11
 nodular 29.15, 29.16
 papular 29.10, 29.11, 29.12–13
 serpiginous nodulosquamous 107.10
 tubercular 29.15
 syphilis 29.3–27, 111.24–5
 age groups 29.5
 congenital disease 29.27
 anal fissure differential diagnosis 113.29
 anal lesions 29.9
 antimicrobial resistance 29.5
 associated diseases 29.6
 biological false positive reactions 29.24
 cardiovascular 29.6–7, 29.17–18, 29.19
 cerebrospinal fluid examination 29.24–5
 HIV-seropositive individuals 29.26
 chancre 29.8–9, 111.24
 extragenital 29.10
 classification 29.3
 clinical features 29.8–10, 29.11, 29.12–14, 29.15, 29.16–22
 congenital disease 29.28, 29.29, 29.30–3
 clinical variants 29.19
 congenital disease 29.28, 29.30, 29.31
 congenital 29.27–8, 29.29, 29.30–5
 classification 29.27
 clinical features 29.28, 29.29, 29.30–3
 clinical variants 29.28, 29.30, 29.31
 definition 29.27
 epidemiology 29.27, 29.28
 investigations 29.33–5
 late 29.31–2
 management 29.34–5
 neonatal lupus erythematosus differential diagnosis 116.13
 neonates 29.33–4, 116.26
 pathophysiology 29.28
 presentation 29.28, 29.29
 saddle-nose deformity 29.17, 29.29
 stigmata 29.32–3
 course of untreated 29.8
 definition 29.3
 differential diagnosis 29.19–22
 endemic 26.66–7
 epidemiology 29.3, 29.4, 29.5–6
 congenital disease 29.27, 29.28
 follow-up 29.26–7
 gummata 29.6, 29.16, 29.16–17, 29.18, 111.24–5
 hair loss 89.47
 histopathology 29.6–7
 historical aspects 1.7
 HIV infection 31.21
 incidence 29.3, 29.4, 29.5
 incubation period 29.8
 infective cheilitis 110.87
 investigations 29.22–5
 latent 29.3, 29.5, 29.13–14
 diagnosis 29.25
 follow-up 29.26–7
 leukoplakia 110.53
 management 29.5, 29.25–7
 congenital disease 29.34–5
 treatment failure 29.26
 treatment ladder 29.25
 meningovascular 29.6–7, 29.19
 nomenclature 29.3
 ocular 109.42
 onchocerciasis differential diagnosis 33.5
 oral ulceration 110.53
 other STI screening 29.25
 parenchymatous 29.19
 pathophysiology 29.6–8
 congenital disease 29.28
 penicillin treatment 29.25
 perineum/perianal region 113.12
 pinna 108.11
 pregnant women 29.26
 presentation 29.8–10, 29.11, 29.12–14, 29.15, 29.16–19
 congenital disease 29.28, 29.29
 prevalence 29.3, 29.4, 29.5
 primary 29.3, 29.5
 differential diagnosis 29.19–21
 fingers 95.38
 presentation 29.8–10
 prognosis 29.22
 rapid point-of-care tests 29.24
 response to treatment 29.26
 scalp 107.10
 secondary 29.3, 29.5
 differential diagnosis 29.21
 erythema multiforme 31.21
 nephrotic syndrome 153.6
 pathophysiology 29.6
 pityriasis rosea differential diagnosis 25.92
 pityriasis versicolor differential diagnosis 32.12
 presentation 29.10, 29.11, 29.12–13, 29.14, 29.15
 psoriasis differential diagnosis 35.19
 telogen effluvium 89.26
 serological screening 29.24
 sex differences 29.5
 congenital disease 29.27
 sexual contact management 29.27
 stages 29.8
 tertiary 29.15–19, 29.20
 atrophic scars 96.11
 differential diagnosis 29.22
 mucous membrane lesions 29.16–17, 29.18
 necrotizing lymphocytic folliculitis of the scalp margin differential diagnosis 93.5
 tongue lesions 110.53
 treatment failure 29.26
 treatment ladder 29.25
 vulval sarcoidosis differential diagnosis 98.14
 yaws 29.14
 differential diagnosis 26.68
 syphilitic alopecia 29.13, 29.15
 syringocystadenoma papilliferum 138.20–1
 scalp 107.10
 syringoid eccrine carcinoma 138.38
 syringoma
 acne vulgaris differential diagnosis 90.25
 eyelid 109.47
 malignant 138.37–8
 malignant chondroid 138.32, 138.33
 penile 111.27
 vulval 112.30
 syringomyelia 85.7–8
 hand–arm vibration syndrome differential diagnosis 123.24
 post-traumatic 85.10
 systematic reviews 17.5
 application to specific patient 17.11–12
 critical appraisal 17.8
 fixed-effects models 17.9–10
 importance of results 17.9–11
 language bias 17.8
 publication bias 17.8, 17.11
 random-effects models 17.9–10
 randomized controlled trials 17.8
 summary value 17.10
 validity 17.8–9
 systemic amyloidosis 147.22
 systemic capillary leak syndrome 43.4
 systemic diseases

- Compositae allergy 128.52
digestive system disorder
 association 152.6–9
eye involvement 109.36, **109.37**
hoarseness sign 151.7
itching 83.10–14
kidney disease 153.2–3
liver disease association 152.7
mouth ulcer association 110.39–56
oral manifestations **110.89–92**
respiratory disease association 151.5–7
with skin features and cardiac involvement 150.4–6
systemic fibrosis *see* nephrogenic systemic fibrosis
systemic lupus erythematosus (SLE) 51.1–2, 51.14–37
 alopecia areata association 89.29
 ANA-negative 51.34
 antinuclear antibodies 51.27
 antiphospholipid syndrome
 association 52.1, 52.2
 autoantibodies 51.18
 bullae 51.26
 cardiac involvement 150.4
 children 51.30
 classification 51.1–2, 51.14, **51.15**
 clinical features 51.14, 51.19–32
 complement deficiency 82.18
 complications/co-morbidities 51.27–31
 cryoglobulins 101.13
 differential diagnosis 51.27
 discoid lupus erythematosus differential diagnosis 51.9
 disease activity assessment 51.34–5
 disease course 51.31–2
 DRESS association 119.10
 environmental factors 51.18–19
 epidemiology 51.14–15
 genetic factors 51.17–18
 hair changes 51.23
 hypocomplementaemic urticarial vasculitis differential diagnosis 102.19
 IgA vasculitis differential diagnosis 102.15
 immunohistology 51.16–17
 infantile urticaria 117.6
 inheritance 51.17
 investigations 51.32–5
 Klinefelter syndrome 76.4
 lichen planus association 37.13
 lip manifestations 110.88
 lupus-specific changes 51.21–2
 malignancy association 147.20–1
 management 19.5, 51.35–7
 mucinosis 51.26
 mucous membrane lesions 51.26–7
 multicentric reticulohistiocytosis association 136.24
 nail changes 51.22–3
 older people 51.30
 oral contraceptives 51.30
 oral lesions 110.45
 pathophysiology 51.15–19
 pigmentary changes 51.26
 pinna **108.13**, **108.14**
 pregnancy 51.30, 115.5
 primary immunodeficiency 82.3
 prognosis 51.31–2
 prolidase deficiency differential diagnosis 72.9
 respiratory disease association 151.2
 Schnitzler syndrome differential diagnosis 45.10
 serum factor defects 8.32
 skin cancer association 146.5
 subcorneal pustular dermatosis association 49.14
 systemic sclerosis, overlap 56.8
 telogen effluvium 89.26
 urticaria 51.26
 urticarial vasculitis association 44.2
 UVA-1 phototherapy 21.6
 variants 51.20–7
 vascular reactions 51.23–5
 vasculopathy 51.23–5
 warts 25.62
see also bullous systemic lupus erythematosus; mixed connective tissue disease
systemic sclerosis 56.1–21, **56.22**, 57.1
 antibodies 57.7
 associated diseases 56.7–9
 autoantibodies 56.2, 56.8
 autoantibody patterns 56.2, **56.2–3**
 bromodomains 56.12
 cardiac involvement 150.4
 cardiopulmonary manifestations 56.11, 56.13
 causative organisms 56.11
 classification 56.1–2, **56.2–3**, 56.4, 56.16
 clinical features 56.13–18
 complications/co-morbidities 56.16–17, **56.20**
 cryoglobulins 101.13
 cutaneous features 56.4, 56.4–6, 56.14–15
 definition 56.1
 diagnosis 56.18, 56.19
 differential diagnosis 56.16–17
 diffuse 56.1, 56.2, 56.6, 56.15
 digestive system disorders 152.6
 digital nerves 85.3
 disease course 56.17
 environmental factors 56.12–13
 epidemiology 56.6–9
 erectile dysfunction 56.21
 ethnicity 56.7
 extracellular matrix deposition 56.10
 gastrointestinal manifestations 56.4, 56.13, 56.15
 genetics 56.11–12
 history taking 56.13
 HLA region role 56.11
 hyperpigmentation 88.20–1
 incidence 56.6–7
 innate immune components 56.12
 investigations 56.18, 56.19
 limited 56.1, 56.2, 56.15
 lung involvement 56.11, 56.15, 56.18, 56.21
 macrophage inhibitory factor role 8.23
 malignancy association 56.8–9, 147.21
 management 56.19, 56.21, **56.22**
 microvascular injury 56.9
 morphoea relationship 57.23–4
 musculoskeletal manifestations 56.15, 56.18
 nomenclature 56.1
 occupational disorders 56.13, 96.42, 96.43
 oral features 110.57–8
 organ-based disease assessment 56.18, **56.20**, **56.21**, **56.22**
 overlap 56.1, 56.7–8, 56.16–17
 pathophysiology 56.9–13
 pityriasis rubra pilaris association 36.1
 predisposing factors 56.9
 presentation 56.13–15
 prevalence 56.6–7
 primary biliary cirrhosis 152.5
 prognosis 56.17
 proteoglycans 2.40
 proximal nail fold capillaroscopy 95.53
 pulmonary arterial hypertension 56.11, 56.15, 56.18
 radiography 95.47
 Raynaud phenomenon 56.4, 56.13–14
 renal manifestations 56.11, 56.15
 respiratory disease association 151.2
 scleredema differential diagnosis 59.10
 severity classification 56.16
 subsets 56.1, 56.2
 UVA-1 phototherapy 21.6
 variants 56.15–16
 Werner syndrome differential diagnosis 72.23
see also mixed connective tissue disease
systemic therapy 19.1–3
 drug interactions 19.2
 monitoring 19.2
 patient education 19.2
 patient selection 19.2
 pharmacology 19.3
 pre-treatment screening 19.2, **19.3**
 record keeping 19.2–3
 risk reduction 19.1–2
 standards of care 19.2
see also immunomodulatory therapy
systemic-onset juvenile idiopathic arthritis
 see juvenile rheumatoid arthritis
T
T cells 8.30
 activation by APCs 8.28
 atopic eczema lesions 41.9–10
 histamine regulation of function 8.47
 immunity against ringworm 32.21–2
 immunogenotyping 3.27
 macrophage interactions 8.23
 sensitization process 8.55
 sensitized 128.7
 skin disease pathogenesis 8.30
 skin-resident 2.15
 subcutaneous fat 99.7
 see also cytotoxic T lymphocytes (CTLs); natural killer (NK) cell(s); regulatory T cells (T-regs); T-cell clones; T-cell receptor(s) (TCR)
 $\gamma\delta$ T cells 8.30
 atopic eczema 41.11
 epithelial 8.4
 wound healing 10.3
T helper cells 8.30
 histamine regulation of response 8.47
 T helper type 1 (Th1) cells 8.30, 8.59
 immune response 8.59
 T helper type 2 (Th2) cells 8.30, 8.59
 allergy 8.56–7
 atopic eczema 41.10, 41.14
 IgE production 41.11
 immune response 8.58, 8.59
 T helper type 2 (Th2) pathway, immunity against ringworm 32.22
 T helper type 17 (Th17) cells 8.59, 148.15
 acne vulgaris 90.18
 morphoea 57.8
 T helper type 17/interleukin 22 (Th17/IL-22) cells 8.30
 T helper type 22 (Th22) cells 8.59
 T4 endonuclease V 18.28
 skin cancer treatment in immunocompromised patients 146.16
 Tabanidae 34.7, 34.8
 tabes dorsalis 29.17, 29.19, 29.20
 tacalcitol 18.24–5
 plaque psoriasis treatment 35.23
 structure 18.24
 tachykinin substance P 8.51
 tachykinins, itching in skin disease 83.6
 tachyphylaxis, topical corticosteroids 18.18
 tacrolimus
 acne association 90.11
 atopic eczema treatment 41.31
 chronic actinic dermatitis management 127.20
 eczema treatment 39.6, 39.7
 eosinophilic pustular folliculitis treatment **93.9**
 granuloma annulare treatment 97.7
 Hailey–Hailey disease treatment 66.13
 hypertrichosis treatment 89.63
 lower leg eczema treatment 39.21
 morphoea treatment 57.26, **57.28**
 necrobiosis lipoidica treatment 97.11
 pityriasis alba treatment 39.26
 pityriasis lichenoides management 135.5
 structure 18.19
 systemic lupus erythematosus treatment 51.35
 topical 18.19–20
 wound healing 10.11
 Taenia solium 33.30, 61.1
 taeniasis 33.30–1
 Takayasu arteritis 102.35–6
 Talaromyces marneffei 32.90–1
 HIV infection-associated 32.90–1
 talc 18.8
 talon noir 101.6–7
 tamoxifen
 alopecia 89.49
 palmar fascial fibromatosis management **96.32**, **96.33**
 tampons, super-absorbent 26.30, 26.31
 tanapox virus infection 25.15
 tanning 88.5
 ability of skin 143.4
 delayed 9.7–8, 88.9
 devices 9.13
 immediate pigment darkening 9.7
 melanogenesis 9.7–8
 persistent pigment darkening 9.7
 response to UV radiation 88.9
 UVR-induced 9.7–8
 tanning industry 9.3
 tapeworms *see* cestode infections
 tar
 carcinogenicity 18.33
 occupational skin cancers 130.13, 130.14
 topical corticosteroid formulations 18.18–19
 topical therapies 18.32–3
 tar derivatives, photocontact facial melanosis 88.12
 tar warts 130.14
 taste sensation 110.7
 TAT gene mutations 65.63, 81.12
 tattoos 88.53–5
 accidental 88.53, 88.54
 black henna 88.54
 complications 88.54–5, 123.21–2
 decorative 88.53–5
 functions 88.54
 granulomas, carbon dioxide laser ablation 23.18, 23.19
 granulomatous reactions 128.61
 Koebner phenomenon 123.21
 laser treatment 23.11–12, 23.13, 160.4–5
 lichen planus 37.13
 mercury toxicity 128.24
 oral 110.65
 paradoxical darkening 160.5
 pigments 88.54
 removal 88.5
 traumatic 123.22
 taxanes, alopecia induction 120.5
 permanent 89.49
 Tay syndrome 65.33
 tazarotene 18.23
 T-cell clones 140.2–3
 mycosis fungoides 140.9
 T-cell deficiency disorders 148.15
 T-cell mediated cytotoxicity 8.31
 T-cell receptor(s) (TCR) 8.30
 T-cell receptor (TCR) genes, mycosis fungoides 140.9
 T-cell-mediated drug hypersensitivity 12.2–4
 tea tree oil 128.52
 teeth
 biology 110.3–4
 congenital syphilis 29.32–3
 development 110.3
 ectrodactyly–ectodermal dysplasia–cleft lip/palate (EEC) syndrome 67.18
 epidermolysis bullosa 110.16
 generalized severe recessive dystrophic epidermolysis bullosa 71.25
 hypohidrotic ectodermal dysplasias 67.13
 junctional epidermolysis bullosa 71.12, 71.13
 nail–patella syndrome 69.16
 oral mucosa junction 110.4
 recessive generalized severe dystrophic epidermolysis bullosa 71.17
 structure 110.3
 teicoplanin 19.42–3
 TEK gene mutations 73.11, 73.12, 103.22

- telangiectasia 101.2, 103.8–12
 ageing of skin 155.9
 Bloom syndrome 79.3
 causes **103.9**
 chronic venous insufficiency 103.39
 cutis marmorata congenita 116.3
 discoid lupus erythematosus 51.6
 generalized essential **103.9**, 103.9,
 103.16–18
 clinical features 103.17
 definition 103.16
 epidemiology 103.16–17
 management 103.17–18
 pathophysiology 103.17
 hereditary haemorrhagic **103.9**
 hypotrichosis–lymphoedema–
 telangiectasia syndrome 73.19
 laser treatment 23.9–10, 23.11, 160.2
 legs 160.3–4
 macularis eruptiva perstans **103.9**
 mastocytosis 46.1, 46.3, 46.5
 oral mucosa 110.9, 110.72
 pathophysiology 103.9
 primary 103.15–16
 systemic sclerosis 56.4, 56.13
 unilateral naevoid telangiectasia
 syndrome 103.18–19
 varicose veins 103.35
see also ataxia telangiectasia; hereditary
 haemorrhagic telangiectasia (HHT);
 spider telangiectases
- telangiectatic metastatic carcinoma 147.2
 teledermatology 4.25–6
 adherence to treatment 11.7
- telogen 89.7
 gravidarum 89.25
 prolongation 89.18
 release, delayed/immediate 89.24
 telogen effluvium 89.10, 89.24–8
 abrupt-onset 89.25
 acute 89.24–5
 chronic 89.25–7
 investigations 89.27–8
 primary 89.27–8
 monitoring 89.24
 drug-induced 89.27
 female pattern hair loss differential
 diagnosis 89.21
 histological sections 3.40
 HIV infection association 89.47, 107.10
 hyperandrogenism 145.18
 infants 117.14
 pathogenesis 89.24
 systemic lupus erythematosus 51.23
- telomere shortening, dyskeratosis
 congenita 69.13, 77.3
- temozolomide, melanoma
 treatment 143.35
- TEMPI syndrome 148.12
- temporal arteritis *see* giant cell arteritis
- temporal artery 20.2–3
- temporal lobe epilepsy 86.9
- temporalis muscle 110.5
- temporomandibular joint (TMJ),
 examination 110.5
- tenascin-X deficiency 72.7
- tendon sheath
 fibroma 137.11–12
 giant cell tumour 137.19
- Tenebrionidae 34.29
- tennis toe 123.16
- tenofovir 31.9
- tensile strength of skin 96.19
- teratogenicity
 methotrexate 19.24
 mycophenolate mofetil 19.27
 potassium iodide 19.28
 retinoids 19.38
 thalidomide 19.40
- terbinafine 18.11, 19.44
 acute generalized exanthematous
 pustulosis predisposition 119.2,
119.4
 dermatophytosis 32.33
 treatment failure 32.35
- seborrhoeic dermatitis treatment 40.5,
40.6
- sporotrichosis treatment 32.73
- tinea capitis treatment 32.40
 treatment ladder **32.73**
- Terry's nails 95.14, 152.9
- p*-tertiary-butylphenol 88.45, 88.46
- testes 111.4
- testosterone, male balding 89.17
- test–retest reliability 16.2
- tetanus
 dracunculiasis secondary infection 33.12
 immunization 131.6
 injecting drug abuse 121.4
 umbilical infection 116.25
- tetracyclines 18.11, 19.42
 acne conglobata treatment 90.56
 anti-inflammatory effects 19.43
 hyperpigmentation 88.27, 88.28
 nail colouration 95.14
 phototoxicity 129.10
 sarcoidosis treatment 98.16
- Texier disease 99.47
- TGFBRI* gene mutations 142.36, 142.37
- TGF- β type II receptor (TRII) 155.6,
 155.7–8
- TGMI* gene mutations 65.7–8
- thalassaemias 148.16
 pseudoxanthoma elasticum-like
 lesions 96.28
- thalidomide 19.40–1
 actinic prurigo management 127.13
 adverse effects 19.40–1
 cautions 19.41
 contraindications 19.41
 discoid lupus erythematosus
 treatment 51.11
 dose 19.41
 drug–drug interactions 19.41
 embryopathy 108.4
 erythema multiforme 47.6
 erythema nodosum leprosum
 treatment 28.16
 microtia 108.4
 monitoring 19.41
 oral aphthous ulceration in HIV 31.33
 pharmacological properties 19.40
 pre-treatment screening 19.41
 recurrent aphthous stomatitis 110.30
 regimens 19.41
- thallium, reactions to 122.8
- theque 3.38–9
- therapeutic relationship 86.39
- Theridiidae 34.32–3
- thermal damage time (TDT), selective
 thermolysis 23.5
- thermal injury
 acronecrosis 95.47
 chemical burns differential
 diagnosis 129.12
 irritant contact dermatitis differential
 diagnosis 129.6
- thermal relaxation time (TRT), selective
 thermolysis 23.5
- thermokinetic selectivity 23.5
- thermoregulation 2.43, 125.1
 disturbance in malaria 94.13
- thiamine 63.13–14
- thiazides, phototoxicity 127.28
- thimerosal 18.8
- thioacetazone, drug eruptions 31.17
- thioalcohols 18.29
- thioglycollates 18.29
- thiomersal 18.8
- thiopurine methyltransferase
 (TPMT) 14.10
 azathioprine metabolism 19.8, 19.9
- thoracic outlet obstruction 105.13, 105.14
- thoracic outlet syndrome and cervical rib
 hand–arm vibration syndrome
 differential diagnosis 123.24
 Raynaud phenomenon differential
 diagnosis 125.9
- Thost–Unna keratoderma 65.46
- threadworm 33.13–14
- anal abscess differential
 diagnosis 113.26
- thrips 34.28
- thrombasthenia 101.3
- thrombin receptor 8.41
- thromboangiitis obliterans 103.4–6, 121.2
 acute scrotum 111.20
 arterial occlusion 103.5, 103.6
 clinical features **103.5**
 corkscrew collaterals 103.5, 103.6
 epidemiology 103.5
 investigations 103.5, 103.6
 management 103.6
 pathophysiology 103.5
 Raynaud phenomenon differential
 diagnosis 125.9
- thrombophlebitis migrans
 association 103.32
- thrombocytopenia 101.1
 heparin-induced 101.10–11
 antiphospholipid syndrome
 differential diagnosis 52.2
 neonatal lupus erythematosus 51.38
 subcutaneous fat necrosis of the
 newborn 116.15
- thrombocytopenic purpura 101.3, **101.4**
 Epstein–Barr virus 25.32
 HIV infection 31.13
 varicella infection 25.26
- thrombotic thrombocytopenic
 syndrome 101.3–4
 erythromelalgia 84.10
 purpura **101.4**, 101.11–12
- thromboembolism prophylaxis 103.30
- thrombo-occlusive disease 102.4
- thrombopathia 101.3
- thrombophlebitis
 krokodil abuse 121.3
 migrans 103.31–2
 definition 103.31
 penile 111.8
 superficial migratory 99.8–9, 99.10
- thrombosis
 cancer-associated 147.25–6
 inflammatory bowel disease
 association 152.3
 IVIG adverse reaction 19.36
 thrombospondin 1 (TSP-1) 8.25
- thrombotic thrombocytopenic
 purpura 110.62
 antiphospholipid syndrome differential
 diagnosis 52.2
 HIV infection 31.13
- thromboxanes 8.48–9
- thrush *see* candidosis
- thymic stromal lymphopoietin
 (TSLP) 41.10, 41.14
- thymol 18.34
- thymoma 148.16, **148.18**
 paraneoplastic pemphigus
 association 50.6, 148.8
 pemphigus erythematosus
 association 50.6
- thyroid dermopathy *see* pretibial
 myxoedema
- thyroid disease
 Cowden syndrome association 80.14,
 80.15
 DRESS involvement 119.9
 myxoedema in 59.11–13
 periorcular oedema 105.16
 systemic lupus erythematosus 51.29
 telogen effluvium 89.25, 89.26
 vitiligo association 88.35
- thyroid hormones 149.9
 receptors 145.20
- thyroid tissue, ectopic 110.11
- thyroid transcription factor 1
 (TTF-1) 3.23
- thyroiditis
 alopecia areata association 89.29
 postpartum 145.20
- thyroid-stimulating hormone (TSH),
 function 149.9
- thyroid-stimulating hormone receptor
 (TSHR) 105.48, 145.20
- thyroid-stimulating hormone (TSH)
 receptors 149.20
- thyrotoxicosis, pruritus 83.12
- thyrotrophin-releasing hormone (TRH),
 function 149.9
- Thysanoptera 34.28
- TIA-1 3.24
- Tichner–Hanhart syndrome 65.63–4
- tick(s) 34.35–9
 classification 34.35–6
 hard 34.35–6, 34.36
 mouthparts 34.36
 soft 34.35–6, 34.36, 34.38
- tick bites/tick-borne diseases 34.37–9
 acrodermatitis chronica
 atrophicans 96.13
 clinical features 34.38
 ecthyma differential diagnosis 26.17
 ehrlichiosis 26.63
 IgE induction 12.2
 Lyme disease 26.69, 96.13
 lymphadenopathy 34.38
 management 34.39
 pathophysiology 34.38
 prevention 34.39
 reactions 34.38
 relapsing fever 26.69, 34.35, 34.38
 Rocky Mountain spotted fever 26.77
 secondary infections 34.38
 tick paralysis 34.38
 tick typhus 26.78
 tularaemia 26.56–7
- TIE2* gene mutations 103.22
- tight junctions 2.19–20, 129.3
- time trade-off (TTO) 16.6
- tinea
 acrodermatitis continua of Hallopeau
 differential diagnosis 35.42
 amiantacea 32.40
 barbae 32.41
 sycosis differential diagnosis 26.27
 chemotherapy-induced nail change
 differential diagnosis 120.7
 circinata 32.36
 faciei 32.41–2
 papulopustular rosacea differential
 diagnosis 91.11
 genital 111.23–4
 granuloma annulare differential
 diagnosis 97.6
 hand eczema 39.17
 imbricata 32.37
 incognita 18.17
 nigra 32.14–15
 nummular dermatitis differential
 diagnosis 39.8–9
 steroid-modified 32.50
- tinea capitis 32.38–41, 117.9
 alopecia areata differential
 diagnosis 89.32
 causative organisms 32.38
 clinical features 32.38–40
 differential diagnosis 32.40
 ectothrix type 32.38, 32.39
 endothrix type 32.38, 32.39
 epidemiology 32.38
 favus type 32.38, 32.40
 infection control 32.40–1
 kerion 32.39
 management 32.40–1
 pathophysiology 32.38
 prevention 32.33
 seborrhoeic dermatitis differential
 diagnosis 107.1, 107.2
 treatment ladder **32.40**
- tinea corporis 32.35–7
 annular erythema of infancy differential
 diagnosis 47.7
 clinical features 32.36–7
 definition 32.35
 differential diagnosis 32.37
 infants 117.8–9
 leprosy differential diagnosis 28.11
 management 32.37
 pathophysiology 32.35–6

- pityriasis rotunda differential diagnosis 87.8
- pityriasis versicolor differential diagnosis 32.12
- treatment ladder 32.37
- tinea cruris 32.46–7
- psoriasis differential diagnosis 35.19
- symmetrical drug-related intertriginous and flexural exanthem differential diagnosis 118.6
- vulval 112.26–7
- tinea manuum 32.45–6
- allergic contact dermatitis differential diagnosis 128.62
- hand eczema differential diagnosis 39.16
- keratolysis exfoliativa differential diagnosis 87.24
- tinea pedis 32.32–3, 32.42–5
- causative organisms 32.43
- clinical features 32.43–5
- differential diagnosis 32.44–5
- epidemiology 32.43
- erythrasma differential diagnosis 26.40
- infection control 32.45
- management 32.45
- pathophysiology 32.43
- pitted keratolysis differential diagnosis 26.42
- treatment ladder 32.45
- tinidazole, trichomoniasis treatment 33.36
- tin-tack sign 51.4
- tissue cooling 23.5
- tissue hypoxia, subcutaneous fat necrosis of the newborn 116.15
- tissue inhibitor of metalloproteinase (TIMP) 8.43
- wound healing 10.2, 10.5, 10.7
- diabetic wounds 10.9
- tissue inhibitor of metalloproteinase 1 (TIMP-1) 8.43
- tissue inhibitor of metalloproteinase 2 (TIMP-2) 8.43, 10.2, 10.5
- tissue optics 23.3–4
- absorption 23.3–4
- photochemical change 23.4
- photomechanical reactions 23.4
- photostimulation 23.4
- photothermal reactions 23.4
- reflection 23.3
- scattering 23.4
- transmission 23.4
- tissue plasminogen activator (t-PA), frostbite management 125.3
- tissue sections, microscopic examination 3.29–33
- titanium dioxide 18.8
- UV light blocking 18.30–1
- Tityus* 34.34–5
- TNF-receptor associated periodic syndrome (TRAPS) 8.35
- TNFRSF1A* gene mutations 45.5
- tobacco chewing
- erythroplasia 110.72
- keratosis 110.75
- toe(s)
- acquired digital fibrokeratoma 137.4
- deformities 123.7
- distal phalangeal erosive lesions 95.47
- fibro-osseous pseudotumour of the digits 137.5–6
- fused
- in Kindler syndrome 71.19
- in recessive generalized severe dystrophic epidermolysis bullosa 71.17
- inclusion body fibromatosis 137.10–11
- paronychia of great toe of infants 95.36
- periungual infections 95.38
- sports injuries 123.15–16
- toe clefts, bacterial flora 26.5
- toe webs, *Pseudomonas aeruginosa* infection 26.52
- toenails
- footwear-induced trauma 95.18–21
- ingrowing 95.19–21
- chemical cautery 95.58–60
- tofacitinib
- plaque psoriasis 35.29
- psoriatic arthritis treatment 35.45
- togavirus infections 25.74–8
- tolbutamine, eczema induction 118.4
- Toll-like receptor(s) (TLRs) 8.2, 8.14–15
- signalling 26.6
- Toll-like receptor 2 (TLR2), rosacea 91.4, 91.5
- tolnaftate 18.12
- toluene-2,5-diamine (PTD) 128.41–2
- TomoTherapy 24.3, 24.5–6
- tongue
- argyria 122.7
- brown/black hairy 110.65–6
- cellulitis 26.18
- central papillary atrophy 32.63
- circumvallate papillae 110.7
- coated 110.65–6
- dorsum 110.6–7
- erythema migrans 110.13–14
- filiform papillae 110.7
- fissured 110.14, 110.20–1
- foliate papillitis 110.60
- furred 110.65–6
- haemangiomas in Klippel–Trenaunay syndrome 110.15
- lymphangioma 110.10
- macroglossia 110.60
- median rhomboid glossitis 32.63, 110.71
- movement 110.7
- oral hairy leukoplakia 25.32–3
- plicated 110.20–1
- psoriasis 35.14, 35.15
- scrotal 110.20–1
- strawberry 110.72
- venous malformation 73.10
- ventrum 110.6
- see also geographic tongue
- tongue-tie see ankyloglossia
- tonsillitis, psoriasis association 35.4
- toothpaste allergy 128.15
- topical drug delivery 13.1, 14.2, 18.1–8
- absorption 18.5
- active pharmaceutical ingredient 13.6
- adherence 11.6
- advice to patients 18.4
- alcohols 18.7, 18.9
- antibiotics 18.10–11
- antifungal agents 18.11–12
- antihistamines 18.33
- antiparasitic agents 18.13
- antiseptics 18.9–10
- antiviral agents 18.12–13
- application frequency 18.3
- concentration of drug 18.1–2
- co-solvent use 13.7–8, 13.9
- depigmenting agents 18.28–9
- dermato-pharmacokinetic method 13.7
- emulsifiers 13.9, 18.6, 18.7
- erythema multiforme 47.4
- factors determining permeation 13.3–4
- fatty acids 18.7
- flux across skin 13.7–10
- formulations 13.4–5, 18.5–8
- greases 18.6
- hazards 18.5
- humectants 18.6, 18.7
- lanolin 18.6–7
- lipids 18.5–7
- macrogols 18.7
- microdialysis 13.7
- mineral oils 18.6
- occlusion 18.5
- topical corticosteroids 18.19
- optimization 13.7–10
- penetration enhancers 18.3, 18.6, 18.7–8
- percutaneous absorption
- mechanisms 13.2–3, 13.6
- powders 18.8
- preservatives 18.6, 18.8
- propylene glycol as co-solvent 13.7–8, 13.9
- quantity for application 18.3–4
- side effects 18.5
- solvents 18.6
- surfactants 13.9
- uptake by skin microcirculation 13.6
- vehicles 18.5–8
- choice of 18.2–3
- metamorphosis 13.9–10
- volatile solvent use 13.8–9
- waxes 18.7
- see also calcineurin inhibitors, topical; corticosteroids, topical; retinoid(s); vitamin D analogues
- topical therapy 18.1–37
- anti-infective agents 18.9–11
- antiperspirants 18.33
- astringents 18.9
- depigmenting agents 18.28–9
- depilatories 18.29
- sensitizing agents 18.30
- sunscreens 18.30–2
- traditional remedies 18.33–4
- see also emollients
- TORCH syndrome 25.87, 148.5
- Torulopsis*, vulvo-vaginitis 112.26
- torus mandibularis 110.6
- touch corpuscles 2.12
- touch domes 2.12
- touch pads, development 2.4
- touch sensation, Merkel cell–neurite complex 2.11
- touch spots 2.12
- Touraine centrofacial lentiginosis 110.12
- Touraine–Solente–Gole syndrome
- see primary hypertrophic osteoarthropathy
- Townes–Brocks syndrome 108.3
- toxic epidermal necrolysis (TEN) 12.2–3, 119.12–22
- classification 47.2
- clinical features 110.48, 119.14–19
- complications 119.17–18
- culprit drug removal 119.19–20
- definition 119.13
- diagnosis 110.48
- differential diagnosis 119.17
- disease course 119.18–19
- drug eruptions 31.17, 31.18, 154.10, 154.14
- drugs predisposing to 119.2, 119.13
- epidemiology 119.13
- erythema multiforme relationship 47.1
- fluid replacement 119.21
- generalized bullous fixed drug eruption
- differential diagnosis 118.12, 118.13
- genetics 119.14
- Hailey–Hailey disease differential diagnosis 66.12
- infections 119.21
- investigations 119.19
- management 110.48, 119.19–22
- mucous membrane pemphigoid
- differential diagnosis 50.29
- nail shedding 95.8
- nutrition 119.21
- ocular complications 109.34, 109.36
- ocular effects 109.29
- oral lesions 110.48
- pathology 47.4
- pathophysiology 119.13–14
- prognosis 119.18–19
- renal failure 153.6
- severity classification 119.17
- staphylococcal scalded skin syndrome
- differential diagnosis 26.28, 116.24
- subacute cutaneous lupus
- erythematosus association 51.12
- systemic lupus erythematosus
- association 51.21
- variants 119.17
- vulval adenosis 112.42
- see also Stevens–Johnson syndrome
- toxic erythema of chemotherapy 120.1–3
- agents 120.1
- clinical features 120.2–3
- definition 120.1
- epidemiology 120.1
- investigations 120.3
- management 120.3
- pathophysiology 120.1–2
- symmetrical drug-related intertriginous and flexural exanthem differential diagnosis 118.6
- variants 120.2
- toxic erythema of the newborn 116.4–5
- infantile acropustulosis differential diagnosis 116.8
- toxic oil syndrome 96.43
- toxic products of combustion, inhalation
- injury with burns 126.4
- toxic pustuloderma 119.1–4
- toxic shock syndrome 8.28, 26.29–32
- clinical features 26.30–1
- complications/co-morbidities 26.31
- definition 26.29
- epidemiology 26.30
- investigations 26.31
- management 26.31–2
- measles differential diagnosis 25.85
- pathophysiology 26.30
- streptococcal toxic shock-like syndrome
- differential diagnosis 26.37
- toxin 1 26.30
- vulval lesions 112.23
- see also streptococcal toxic shock syndrome
- Toxicodendron* spp. 128.52, 128.54
- desensitization 128.59
- toxin-mediated perineal erythema, recurrent 26.32
- Toxocara canis* 33.19
- chronic urticaria 42.6
- Toxocara cati* 33.19
- Toxocara malayensis* 33.19
- Toxoplasma gondii* 33.51–2
- toxoplasmosis 33.33, 33.51–2
- oral lesions 110.51
- TP53 gene mutations 142.2, 142.26
- TP63 gene 67.8
- TP73 gene 67.8
- trabecular carcinoma of the skin see Merkel cell carcinoma
- trachoma, leprosy differential diagnosis 28.12
- trachyonychia 95.11–12
- traditional remedies
- topical therapy 18.33–4
- see also complementary therapies; herbal products/medications
- TRAF1* gene expression 140.28
- transaldolase deficiency 72.12
- transcription coupled repair (TCR) 9.6
- transcription/DNA repair factor IIIH (TFIIH) 65.33
- transepidermal elimination (TEE) 96.49–50, 96.51
- transepidermal water loss (TEWL) 13.1–2
- irritant contact dermatitis 129.6
- measurement 16.3
- measurement in occupational disorders 130.5
- neonates 116.2
- xerosis cutis 87.25
- transfersomes 18.8
- transferrin, unsaturated 32.21
- transforming growth factor α (TGF- α), keratinocyte-generated 8.5
- transforming growth factor β (TGF- β) 2.36, 8.36
- ageing of skin 155.6
- collagen gene expression
- modulation 2.31
- collagen production regulation 155.6
- hair growth inhibition 89.10
- keratinocyte-generated 8.5
- scarring 10.8
- wound healing 10.6, 10.7, 10.8, 10.11
- transforming growth factor β 1 (TGF- β 1), wound healing 10.3, 10.5

- transfusion reactions 148.16, **148.18**, 148.19
 allergic 148.16, 148.19
 skin involvement **148.18**
 transglutaminase 1 (TG1) 65.10
 deficiency 65.10, 65.12
 transglutaminase 5 71.4
 transient acantholytic dermatosis 87.22–4
 clinical features 87.23
 definition 87.22
 epidemiology 87.22
 investigations 87.23
 malignancy association 147.17
 management 87.24
 pathophysiology 87.22–3
 pemphigus vulgaris differential
 diagnosis 50.7
 transient aquagenic keratoderma 65.54–5
 transient pustular melanosis 116.7
 neonatal **93.10**
 transient receptor potential vanilloid 3
 gene (*TRPV3*) gene 65.62
 transient receptor potential vanilloid
 receptor 1 (*TRPV1*) 85.2
 transmembrane receptors
 linked to intracellular enzymes **14.4**,
 14.5
 without enzyme-linked activity **14.4**,
 14.5
 transplacental transfer
 of maternal autoantibodies 116.11–14
 of maternal malignant disease 116.14
 TRAPS *see* tumour necrosis factor receptor-
 associated periodic syndrome
 (TRAPS)
 trauma
 anal 113.31–2
 anal fissure differential diagnosis 113.29
 atrophic scars 96.11–12
 burns 126.1
 chemotherapy-induced nail change
 differential diagnosis 120.7
 complex regional pain syndrome 85.13
 cutaneous vasculitis differential
 diagnosis 102.4
 ear piercing complications 108.7
 eczema 39.24–5
 excessive response to injury 96.45–9
 external ear 108.6–7
 factitious panniculitis 99.48
 fibro-osseous pseudotumour of the
 digits 137.6
 footwear 95.18–21
 friction blisters 123.9
 gas gangrene 26.47
 granuloma annulare 97.2
 hair shaft 89.60
 HSV transfer 25.16
 infiltrating lipomatosis of the face
 differential diagnosis 100.18
 lymphoedema 105.49–50
 male genital dermatoses 111.7–9
 manicure instruments 95.18
 medical trauma hair loss 89.45
 morphea association 57.10
 mucous membrane pemphigoid
 differential diagnosis 50.29
 nails 95.16–21
 acute 95.16–17
 chronic repetitive 95.17–21
 delayed 95.17
 footwear-induced 95.18–21
 plantar keratoderma differential
 diagnosis 69.12
 shedding 95.8
 neuromas 137.45
 obstetric 113.32
 onycholysis 95.9
 panniculitis 99.51–2
 penile 111.7–9
 perianal/perineal 113.31–2
 periungual tissues 95.38
 pseudo-knuckle pads 96.34, 96.35
 psoriasis association 35.5–6
 spinal cord injury 85.10
 Sweet syndrome association 148.19
 sympathetic nerve injury 85.12
 tattoos 123.22
 trichothiodystrophy association 89.55
 vulval 112.40–1
see also athletes; injury, skin; mechanical
 injury; sports injuries
 traumatic alopecia 32.40
 travel, diagnosis of skin disease 4.4
 Treacher–Collins syndrome
 microtia 108.4, 108.5
 peri-auricular anomalies 108.5
 trematode infections 33.24–8, **33.29**
 trench fever 26.60, 34.21
 trench foot 125.3–4
Treponema pallidum 26.66
Treponema pallidum subsp. *carateum* 26.68
Treponema pallidum subsp. *endemicum* 26.66
Treponema pallidum subsp. *pallidum* 29.3, 29.7
 congenital disease 29.28
 dark-field microscopy 29.22
 differential diagnosis 29.7
 fetal infection 29.27
 immunoevasiveness 29.6
 microbiology 29.7–8
 molecular amplification tests 29.22
 morphology 29.7
 non-treponemal tests 29.23
 serological tests 29.23
 treponemal antigen tests 29.23–4
 Western blot assay 29.24
Treponema pallidum subsp. *pertenue* 26.67,
 26.68
 treponemal infections
 eyes 109.42
 tropical ulcer 26.65
see also syphilides; syphilis
 treponematoses, non-venereal 26.66–8
 tretinoin
 solar elastosis management 96.4
 striae management 96.10
see also isotretinoin; retinoic acid
TREX1 gene mutations 51.17, 51.22
 triamcinolone acetonide 20.44
 intralesional 18.19
 skin atrophy 96.7
 localized lipoatrophy from
 injection 100.10
 prepubertal acne 90.63
 Triatominae 34.27–8
 triazoles 19.43, 19.44
Tribolium castaneum 34.29
 trichiasis 120.6
 trichilemmal carcinoma 138.6–7
 trichilemmal cysts 107.10, 134.1, 134.2,
 134.3–4
 proliferating tumours 138.5
 trichilemmal tumour, proliferating 138.5–6
 trichilemmoma 138.6
Trichinella spiralis 33.22–3, 33.24
 trichloroacetic acid 20.43–4
 chemical peel 159.2, 159.4, 159.9
 actinic keratosis treatment 142.11
 trichloroethylene 96.42
 trichoadenoma 138.4
 trichobezoar 86.18–19, 89.46
 trichoblastoma 138.11–12
 cutaneous lymphoadenoma 138.12–13
 solitary giant trichoepithelioma 138.11
 tricho-dento-osseous syndrome 67.9–10,
 67.19
 kinky hair 67.19, 68.23
 trichodiscoma 138.15
 trichodynia
 androgenetic alopecia 89.15
 chronic telogen effluvium 89.27
 trichodysplasia spinulosa 25.42–3,
 87.14–15, **87.16**, 89.47, 89.48
 clinical features 87.15
 definition 87.14
 epidemiology 87.14
 investigations 87.15
 management 87.15, **87.16**
 multiple minute digitate keratoses
 differential diagnosis 87.18
 pathophysiology 87.14–15
 trichodysplasia spinulosa polyoma virus
 (TSPyV) 87.14, 87.15
 trichoepitheliomas 107.10, 138.9–10
 desmoplastic 138.10–11
 eyelid 109.47
 familial 23.18
 multiple 138.9, 139.10
 solitary giant 138.11
 trichofolliculoma 138.8–9
 trichogram 89.11
 trichohepato-enteric syndrome,
 trichorhexis nodosa 89.54
 tricholemmomas, eyelid 109.47
 trichome stains **3.8**, 3.9
 trichomegaly
 eyelashes in HIV 31.32
 trichiasis 120.6
Trichomonas 33.36
 vulvo-vaginal candidosis differential
 diagnosis 32.64
 trichomoniasis **33.33**, 33.35–6
 trichomycosis
 axillaris **26.37**, 26.41–2
 pubis 111.22–3
 trichonosis 33.22–3, 33.24
 trichophagia 86.18, 89.46
 trichophytin test 4.24
Trichophyton 32.18, 32.19, 32.20
 hand eczema differential
 diagnosis 39.16
 identification 32.27–8, 32.29–30, 32.30–2
Trichophyton concentricum 32.27, 32.37
Trichophyton equinum 32.27
Trichophyton erinacei 32.27
Trichophyton gourvillii 32.27
Trichophyton interdigitale 32.28, 32.32
 tinea cruris 32.46
 tinea pedis 32.43, 32.44
Trichophyton megninii 32.27
Trichophyton mentagrophytes 32.2, 32.27
Trichophyton mentagrophytes var.
quinckeianum 32.27–8
Trichophyton rubrum 32.28, 32.29, 32.30
 HIV infection 31.26, 31.32
 onychomycosis 31.32
 perineum/perianal region 113.11
 tinea corporis 32.35, 32.36
 tinea cruris 32.46
 tinea manuum 32.45, 32.46
 tinea pedis 32.43, 32.44
Trichophyton schoenleinii 32.28, 32.30
Trichophyton simii 32.30
Trichophyton soudanense 32.30
Trichophyton tonsurans 32.30, 32.31, 117.9
Trichophyton verrucosum 32.31
Trichophyton violaceum 32.31–2
 erythroderma 39.33
Trichophyton yaoundei 32.32
 trichoptilosis 89.60
 tricho-rhino-phalangeal syndrome 67.9–
 10, 67.20–1, 68.16
 trichorhizophagia 86.18
 trichorhexis invaginata 68.21
 Netherton syndrome 89.53
 trichorhexis nodosa 68.21, 89.54–5
 argininosuccinic aciduria 81.15, 89.54
 biotinidase deficiency 89.54
 distal 89.54–5
 hair colouration 89.71
 localized 89.55
 Menkes disease 81.18
 Netherton syndrome 89.53
 proximal 89.55
 trichohepato-enteric syndrome 89.54
 weathering 89.60
 trichoscopy 89.11, 89.12
Trichosporon 32.16, 32.17
 systemic mycosis 32.94–5
 trichostasis spinulosa 89.59
 trichoteiromania 89.45
 trichotemnomania 89.45
 trichothiodystrophy 65.33, **68.10**, 68.21–2,
 78.9–11, 89.55–6
 autism association 89.55
 clinical features 78.10–11
 epidemiology 78.9
 investigations 78.11
 management 78.11
 pathophysiology 78.9–10
 photosensitive 65.33
 premature ageing **79.2**
 skin ageing 2.47
 trauma association 89.55
 variants 68.21, **68.22**, 78.9, 78.11
 xeroderma pigmentosum/
 trichothiodystrophy syndrome 78.6,
 78.11
 trichotillomania 86.17–19, 89.45–7
 alopecia areata differential
 diagnosis 89.32
 clinical features 86.17–18, 89.45–7
 DSM-IV criteria **89.45**
 epidemiology 86.17, 89.45–6
 investigations 86.19
 management 86.19, 89.47
 pathophysiology 89.46
 psychopathology 89.45–6
 trichotillosis 86.17–19
 trichromes 88.5, 88.6
 triclocarban 18.10
 triclosan 18.10
 tricyclic antidepressants 86.36–7
 trigeminal nerve zoster 25.28–9
 trigeminal neuropathic pain
 syndromes 84.5–6
 clinical features 84.6
 definition 84.5
 epidemiology 84.5–6
 investigations 84.6
 management 84.6
 nomenclature 84.5
 pathophysiology 84.6
 trigeminal trophic syndrome 84.6–7
 acné excoriée differential
 diagnosis 86.16
 atypical 84.7–8
 triggering receptors expressed by myeloid
 cells (TREM2) 8.23
 triglycerides 99.4
 trimethylaminuria 94.16–17
 olfactory reference syndrome differential
 diagnosis 86.9
 triparanol, acquired ichthyoses 65.41
 tripe palms 147.15–16
 triple response of Lewis 85.4
 trisomy 13 76.2
 spinal dysraphism association 85.8
 trisomy 18 76.2
 spinal dysraphism association 85.8
 trisomy 21 76.1–2
 neonatal pustulosis of transient
 myeloproliferative disorder 116.8
see also Down syndrome
 triton tumour 137.45
 Trombiculidae 34.51–2
Tropheryma whipplei 152.4, 154.4
 trophoblastic tumours, pemphigoid
 gestationis 115.13
 tropical immersion foot 26.52
 tropical pulmonary eosinophilia
 syndrome 105.44
 tropical sprue 88.24
 tropical ulcer 26.65–6
 yaws differential diagnosis 26.68
 tropoelastin 2.34–5
 Trousseau sign 147.25
 Trousseau syndrome, thrombophlebitis
 migrans association 103.32
 TRPV superfamily 8.53
 TRPV3 gene mutations 65.62
 true histiocytic lymphoma 136.27–8
Trueperella pyogenes 26.43
 trunk, allergic contact dermatitis 128.16–
 17
Trypanosoma 33.36, 33.37–8, 33.39
 trypanosomiasis **33.33**, 33.36–40
 African 33.36, 33.37–8, 33.39, 33.40
 American 33.36–7, 33.38, 33.39–40
 causative organisms 33.37–8
 clinical features 33.39–40

- definition 33.36
epidemiology 33.36–7
HIV infection 31.28
 association 31.28
investigations 33.40
nomenclature 33.36
pathophysiology 33.37–8
treatment ladder 33.40
tryptase 2.17, 8.21, 8.41
ectopic eczema 41.14
mastocytosis 46.6, 46.7, 46.8
urticaria 42.4
L-tryptophan 96.43
TSC1 and TSC2 genes 80.10, 147.8
tsetse flies 34.7
t-test 17.20–1
tuberculid erythema induratum 27.6
tuberculids 27.25–32
 atrophic scars 96.11
 classification 27.25
 nodular 27.25, 27.29–32
 papulonecrotic 27.28–9, 151.4
 granuloma annulare differential diagnosis 97.7
 necrotizing lymphocytic folliculitis of the scalp margin differential diagnosis 93.5
 see also erythema induratum of Bazin; lichen scrofulosorum
tuberculin reaction 8.60
tuberculin skin test 4.24, 27.4
tuberculosis
 complex regional pain syndrome association 85.13
 congenital 116.26–7
 cutaneous 27.5–12
 anti-TNF- treatment 27.12
 BCG vaccination 27.11–12
 classification 27.5–6
 clinical spectrum 27.5–6
 description 27.6
 diagnostic tests 27.8–9
 differential diagnosis 27.7–8
 disease-specific changes 27.7
 drug dosing schedule 27.9–10
 granuloma development 27.7
 gummata 27.18–19
 haematogenous spread 27.5, 27.6, 27.18
 leprosy differential diagnosis 28.11
 metastatic abscesses 27.5, 27.18–19
 miliary 27.12, 27.17–18
 nucleic acid amplification tests 27.8–9
 pathogenesis 27.6–7
 prevention 27.11
 prognosis 27.10
 transmission 27.6
 treatment 27.9–10, 27.11–12
 wartly 27.8, 27.19–21
 diagnostic tests 27.4–5
 erythema nodosum 99.18
 extensively drug resistant 27.1, 27.2, 27.10
 eye infections 109.41–2
 genital 112.24
 glanders differential diagnosis 26.54
 granulomatous cheilitis differential diagnosis 110.86
 hidradenitis suppurativa differential diagnosis 92.7
 HIV co-infection 27.1, 27.3, 27.10, 31.21–2
 hyperhidrosis 94.5
 immunology 27.3
 immunopathology 27.4
 infective cheilitis 110.87
 latent 27.4–5
 miliary 27.12, 27.17–18
 multidrug resistant 27.1–2, 27.10
 oral lesions 110.53
 orificial 27.16–17
 penile 111.23
 perianal 113.10
 anal abscess differential diagnosis 113.26
 anal fissure differential diagnosis 113.29
 anal fistula differential diagnosis 113.27
 peripheral arthritis 154.4
 primary inoculation 27.12–13
 protective immunity 27.3–4
 skin reactions 151.4
 spine 154.4
 verrucosa cutis 27.6
 amoebiasis differential diagnosis 33.35
 vulval sarcoidosis differential diagnosis 98.14
 see also lupus vulgaris; scrofuloderma
tuberculous chancre 27.12–13
tuberculous lymphadenitis, HIV infection 31.22
tuberculous mastitis 27.32
tuberin 80.10
tuberous sclerosis complex 80.9–12
 cardiac disorders 150.3
 clinical features 80.10–12
 diagnostic criteria 80.11
 disease course 80.12
 fibrous connective tissue naevi 75.18
 genetic counselling 80.12
 inheritance 80.10
 investigations 80.12
 malignancy association 147.8
 management 80.12
 oral lesions 110.26
 pathophysiology 80.10
 prevalence 80.10
 prognosis 80.12
 radiological findings 80.12
 renal involvement 153.2
 respiratory disorder association 151.5
 vitiligo differential diagnosis 88.38
tufted angioma 137.25–6
tularaemia 26.56–7, 34.38
tumbu fly 34.9
tumoral calcinosis 61.4
 familial 81.19–20
tumour immune surveillance, reduced and skin cancer 146.5–6
tumour necrosis factor (TNF) 8.35
 biological properties 8.35
 endothelial cell actions 8.35
 IFN role 8.34
 receptors 8.35
tumour necrosis factor (TNF)
 antagonists 19.29–31
 dermatological uses 19.29–30
 pityriasis rubra pilaris treatment 36.5
 early-phase allergic response 8.57
tumour necrosis factor α (TNF- α) 8.35
 hidradenitis suppurativa management 92.10
 keratinocyte function 8.5
 melanoma treatment 143.29
 sarcoidosis 98.3
 Stevens–Johnson syndrome/toxic epidermal necrolysis 119.21
 toxic epidermal necrolysis association 12.3
tumour necrosis factor α (TNF- α)
 antagonists, sarcoidosis treatment 98.16–17
tumour necrosis factor α (TNF- α) inhibitors
 adverse reactions 154.15
 plaque psoriasis treatment 35.29–30
tumour necrosis factor α (TNF- α) receptor, pegylated recombinant human 8.35
tumour necrosis factor receptor-associated periodic syndrome (TRAPS) 45.2, 45.3, 45.5, 58.11, 58.12
 amyloid A amyloidosis 153.2
tumour suppressor genes 7.2
tumours
 benign 137.2
 male genital 111.26–7
 nail 95.21–31
 vulval 112.29, 112.30, 112.31–2
 fat cells 137.58–61
 haematopoietic 147.2
 malignant nail 95.31–4, 95.35
 multisystem 147.2
 nail 95.21–34, 95.35
 oestrogen-producing 145.19
 peripheral neuroectodermal 137.45–55
 perivascular cells 137.42–5
 pityriasis rubra pilaris association 36.1
 precancerous male genital 111.27–9
 of skin appendages 138.1–2
 spillage 147.3, 147.5
 spread from adjacent/distant tissues 147.2–7
 uncertain histogenesis 137.61–6
 see also malignancy; metastases; soft-tissue tumours
tumour-to-tumour metastasis 147.5
 Tunga penetrans 34.13, 34.14
 tungiasis 34.13–14
 Tungidae 34.12
 turban tumour 107.10, 138.30–1
 Turcot syndrome 80.13
 Muir–Torre syndrome association 142.39
turf cancer 125.12
turf toe 123.16
Turner syndrome 76.3–4, 105.35
 halo naevi association 88.41
 intestinal lymphangiectasia 105.42
 lymphatic malformations 105.35
 lymphoedema 73.21
 macrota 108.4–5
 pilomatricoma association 138.13
 sclerema neonatorum differential diagnosis 116.17
 swollen face, head and neck 105.15
 venous malformations 103.22
turpentine
 allergy 128.54–5, 128.58
 substitutes 128.58
twenty-nail dystrophy 95.45
Tydeidae 34.49
tylosis 110.19
 oesophageal cancer 65.59, 65.60, 110.19, 147.7
typhus
 epidemic 26.76–7, 34.12, 34.21
 murine 26.77, 34.12
 scrub 26.79
 sporadic 26.77
 tick 26.78
TYR gene mutations 70.6
tyrosinaemia type 1 81.13
tyrosinaemia type 2 65.63–4, 81.11, 81.12–13
tyrosinaemia type 3 81.13
tyrosinase
 delayed tanning 9.8
 hair pigmentation loss 89.69–70
 tyrosine 70.1
 tyrosine deficiency, phenylketonuria 81.12
tyrosine kinase (TK) inhibitors
 hair depigmentation 120.6
 papulopustular eruptions 120.3, 120.4
TYRP1 gene mutations 70.6
Tyson glands 93.11, 111.5
Tzanck smear 3.25
- U**
ubiquinone 156.2
ulceration
 ano-genital in HIV infection 113.13
 basal cell carcinoma 141.10
 calibre-persistent artery of lip 110.88
 conjunctival 87.14
 cytomegalovirus in HIV 31.23, 31.24
 diabetic foot 64.2
 diabetic of leg 64.1
 genital
 HIV infection 113.13
 primary herpes genitalis 25.20–2
 granulomatosis with polyangiitis 102.25, 102.26
 haemodialysis complication 153.4
 infantile haemangiomas 117.21
 infective eczema in lower leg 39.20
 injecting drug abuse 121.3
 leukaemia cutis differential diagnosis 140.49
 Lipschutz 112.18–19
 livedoid vasculopathy 101.22
 male genital 111.4, 111.17–19
 HIV infection 111.25
 necrobiosis lipoidica 97.10, 97.11
 neuropathic ulcer 85.4–7
 oral mucosa 110.7, 110.8
 pentazocine ulcers 123.20
 perianal 113.8, 113.9
 Crohn disease differential diagnosis 113.25
 perioral in herpes simplex virus 31.22
 pressure points 103.3
 pressure sores 113.32
 prevention in foot 85.6
 primary immunodeficiency 82.2
 proliferase deficiency 81.14
 radiotherapy-induced 120.13
 rheumatoid 154.6–7
 sickle cell anaemia 148.16
 squamous cell carcinoma complication 142.27
 stoma complication 114.7
 systemic sclerosis 56.4, 56.13, 56.18
 thalassaemias 148.16
 trigeminal trophic syndrome 84.7
 atypical 84.8
 tropical ulcer 26.65–6
 vasculopathic in dermatomyositis 53.6, 53.7
 Vibrio vulnificus infection 26.64
 vulval 112.18–20
 causes 112.18
 see also aphthous stomatitis; aphthous ulcers; leg ulceration; oral ulcers; venous leg ulcers; venous ulcers
ulcerative colitis 152.1–3
 hair colour changes 89.71
 lichen planus association 37.13
 linear IgA disease association 50.34
 necrobiosis lipoidica association 97.8
 pyoderma gangrenosum association 154.5
 reactive lesions 152.2–3
 skin cancer association 146.5
ulcerative sarcoidosis 98.13
ulcerative stomatitis 110.42
ulerythema ophryogenes
 erythematotelangiectatic rosacea differential diagnosis 91.9
 scarring 90.32
Ullrich–Turner syndrome see Noonan syndrome
ulnar artery 123.12
ulnar–mammary syndrome 74.5
ultrasonography 95.48, 95.49
 diagnostic 4.22
 psoriatic plaque thickness 16.3
 three-dimensional 7.10
ultraviolet (UV) exposure 2.47
 acne vulgaris 90.17
 actinic prurigo 127.10
 allergic contact dermatitis 128.11
 damage 88.8
 dermal connective tissue changes 96.1–6
 melanocyte response 88.5, 88.7
 melanoma 143.5–6
 Merkel cell carcinoma 145.2
 mixed connective tissue disease 54.2
 polymorphic light eruption 127.3
 porokeratosis association 87.20
 premature ageing of skin 153.4
 reactive oxygen species production 8.44
 rosacea association 91.4
 subacute cutaneous lupus erythematosus 51.13
 systemic lupus erythematosus 51.18, 51.21–2
 tanning 88.9
 transient acantholytic dermatosis association 87.22, 87.23
 see also sun exposure

- ultraviolet (UV) filters 128.43
 photoallergic contact dermatitis 128.78
 ultraviolet index (UVI) 9.12–13
 ultraviolet protection factor (UPF) 9.12
 ultraviolet radiation (UVR) 21.1–3
 absorption spectrum 9.5
 action spectroscopy 9.4–5
 acute effects 9.7–9
 ageing of skin 155.9
 ambient erythema 9.12–13
 artificial sources 9.3, 21.2–3
 population exposure 9.13
 basal cell carcinoma risk factor 141.2–3
 biological dosimetry 9.2
 calibration/dosimetry 21.3
 carcinogenesis 9.9–10
 cardiovascular disease role 9.9
 cellular effects on skin 9.6–7
 chromophore changes 9.4
 chronic effects 9.9–11
 clinical effects 9.7–11
 DNA damage repair 9.5–6
 erythema 9.7
 exposure risks 9.13
 fluorescent tube source 9.3
 gene upregulation 9.6
 genetic changes 146.5
 immunomodulation 9.8–9
 innate immunity enhancement 9.13
 keratinocyte function 8.5
 measurement 9.2
 molecular effects on skin 9.5–6
 normal effects on skin 9.5–11
 occupational skin cancers 130.14
 photoageing 9.10–11
 physical dosimetry 9.2
 population exposure 9.12–13
 production 9.1–2
 sclerodema treatment 59.10
 seborrhoeic keratosis 133.2
 skin cancer 9.9–10, 146.5
 occupational 130.14
 skin damage 155.6
 skin interactions 9.3–4
 solar 9.1, 9.2–3
 sources 9.1–2
 subcategories 9.2
 tanning induction 9.7–8
 terrestrial 9.2–3
 therapeutic and melanoma risk 143.6
 transmission through skin 9.4
 vitamin D role 9.9
see also phototherapy; UVA radiation;
 UVA-1 phototherapy; UVB
 phototherapy; UVB radiation
- ultraviolet (UV)-sensitive
 syndrome 78.8–9
 Cockayne syndrome differential
 diagnosis 78.9
 xeroderma pigmentosum differential
 diagnosis 78.6
- umbilicus
 bacterial flora 26.5
 bacterial infections 116.25
Pseudomonas aeruginosa infection 26.52
 skin metastases 147.4
- uncombable hair syndrome 89.57, 89.58
 uncomfortable hair syndrome 68.22, 68.22
 undecylenic acid 18.12
Urticaria stenocephala 33.18
 unilateral naevoid telangiectasia
 syndrome 103.18, 103.19
- Unna–Thost disease 65.43–4
 upper limb
 surgery 20.5
see also arm, swollen
- Urbach–Wiether disease *see* lipid
 proteinosis
- urea, penetration enhancer 18.7
 urethral caruncle 112.30
 urethritis, gonorrhoea 30.3
 urogenital cancers, lymphoedema 105.22
 urokinase receptor (uPAR) 8.41
 uroporphyrinogen decarboxylase
 (UROD) 60.4
- deficiency 60.11
 gene mutation 60.11, 60.12
- urothelial carcinoma of bladder/urethra,
 extramammary Paget disease
 association 112.37
- ursodeoxycholic acid (UDCA),
 intrahepatic cholestasis of
 pregnancy treatment 115.10–11
- urticaria 42.1–18
 acute spontaneous 42.5
 investigations 42.14
 aetiology 42.4–6
 aggravating factors 47.7–8
 alcohol-induced 42.5
 allergic 41.24, 42.5, 47.8
 angio-oedema 42.14, 151.2, 151.3
 annular erythema of infancy differential
 diagnosis 47.7
 aquagenic 42.12–13, 42.13
 autoimmune 42.6, 47.8
 progesterone 42.8
 caterpillar reactions 34.31
 challenge procedures 42.9, 47.9
 children 42.14
 cholinergic 42.9, 42.11–12, 42.14, 47.8,
 47.11–12, 106.8, 117.5–6
 cold urticaria association 42.11
 chronic spontaneous 42.5–6, 42.14
 investigations 42.14–15
 psychological factors 86.3
 classification 42.3
 clinical features 47.7–15
 cold contact 42.9, 42.10–12, 42.14, 45.5,
 47.11
 complications/co-morbidities 42.14
 contact 42.13–14
 allergic 42.13–14
 chemical burns differential
 diagnosis 129.12
 irritant contact dermatitis differential
 diagnosis 129.6
 non-allergic 42.14
 non-immune 129.8–9
 definition 42.1
 delayed pressure 42.10, 42.14, 47.6, 47.10
 dermographism 42.14, 47.9–10, 47.11
 diagnosis 4.3, 123.3
 differential diagnosis 42.3, 42.14
 disease course 42.14
 drug eruptions 42.5, 42.14, 42.16, 47.7,
 118.6–8
 environmental factors 42.7, 47.6
 eosinophil granule proteins 8.19
 epidemiology 42.3–4
 erythema marginatum differential
 diagnosis 47.12
 factitious 42.8–10
 foods 47.7–8
 genetics 42.7, 47.6
 heat contact 42.10, 47.10
 heroin abuse 121.3
 histamine liberators 42.5, 42.13
 histological sections 3.40
 idiopathic 42.5
 immunomodulatory therapy 42.18
 inducible 42.8, 42.9, 47.8–13
 classification 47.8
 weals 47.9
 infants 117.5–6
 infection-induced 42.5–6, 47.8
 infections 42.8, 47.3
 infestations 42.6
 investigations 42.14–16
 locusts 34.30
 malignancy association 147.23
 management 19.34, 42.16–18
 mechanical 42.9, 47.8, 47.9–10
 mechanical forces 42.8–10
 menstrual cycle 42.8
 association 47.8
 molybdenum toxicity 122.9
 neutrophilic urticarial dermatosis 44.2,
 45.4
 nickel allergy 42.8, 47.8
 nomenclature 42.1
- non-allergic 42.5
 non-immune contact 129.8–9
 papular 42.14, 117.11
 arthropod bites/stings 34.3–4
 caterpillar reactions 34.31
 perforating dermatosis differential
 diagnosis 96.51
 toxic erythema of the newborn 116.5
 transient acantholytic dermatosis
 differential diagnosis 87.23
 patch test complication 128.72
 pathophysiology 42.4–7
 physical 42.8–10, 47.9–10
 pigmentosa 3.40
 mastocytosis 46.1, 46.3–5, 46.10
 platelet role 8.26
 platinum toxicity 122.9
 pregnancy 42.8, 47.8, 115.9, 115.10
 presentation 42.14
 pressure 47.7
 progesterone 47.8
 prognosis 42.14
 pseudoallergic reactions 42.5, 42.6, 42.6,
 47.7–8, 118.6
 psychological factors 47.8
 rheumatic fever 55.8
 schistosomiasis 33.25
 Schnitzler syndrome 45.9
 severity classification 42.14
 solar 42.12
 spontaneous 47.7–8
 stress 42.8
 sweating 42.9
 systemic lupus erythematosus 51.26
 targeted therapy 42.18
 temperature-dependent 42.10–12, 47.8,
 47.10–12
 urticarial vasculitis differential
 diagnosis 44.3–4
 vibration 47.10
see also allergic contact urticaria
- urticarial vasculitis 42.6, 42.14, 47.6
 associated diseases 44.2
 clinical features 44.3–4
 complications/co-morbidities 44.4
 definition 44.1
 differential diagnosis 44.3–4
 disease course 44.4
 epidemiology 44.1–2
 erythema multiforme differential
 diagnosis 47.6
 hypocomplementaemic disease 44.3
 Schnitzler syndrome differential
 diagnosis 45.10
 investigations 44.4, 44.5
 management 44.4–5
 nomenclature 44.1
 pathophysiology 44.2–3
 prognosis 44.4
 severity classification 44.4
 variants 44.3
- urticaria-like follicular mucinosis 59.16–17
 ustekinumab 19.31–2
 palmoplantar pustulosis treatment 35.40
 pityriasis rubra pilaris treatment 36.6–7
 plaque psoriasis treatment 35.30–1
 psoriasis treatment 19.31
 psoriatic arthritis treatment 19.31, 35.45,
 35.46
 pyoderma gangrenosum treatment 49.6
- UVA radiation 9.2, 21.1, 21.2
 action spectroscopy 9.4–5
 matrix metalloproteinase induction 9.10
 photoageing 9.11
 sunscreen protection 9.11
- UVA-1 phototherapy 21.1–2, 21.5–6
 administration 21.10
 delivery methods 21.10
 minimal erythema dose 21.10
 side effects 21.14
 systemic sclerosis 56.19
see also photochemotherapy (PUVA)
- UVB phototherapy 21.1–2
 administration 21.7–8
 adverse effects 21.11–12
- carcinogenic risk 21.12
 combination therapy 21.9–10
 contraindications 21.5, 21.6
 delivery methods 21.8
 home treatment 21.8
 indications 21.4–5
 minimal erythema dose 21.7
 narrow-band for plaque psoriasis 35.25
 versus PUVA 21.5, 21.6
 regimen variables 21.7–8
 staff safety 21.15
 subcorneal pustular dermatosis 49.15
 systemic agent combination 21.10
 topical agent combination 21.9
- UVB radiation 9.2, 21.1, 21.2
 action spectroscopy 9.4–5
 matrix metalloproteinase induction 9.10
 photoageing 9.11
 sunscreen protection 9.11
- UVC radiation 9.2
- uveitis
 autoimmune inflammatory granulomatosis of
 childhood 45.7
 herpes zoster 109.40
 psoriasis association 35.14
 psoriatic arthritis association 35.43
 vitiligo association 88.35
- V**
- vaccinations
 atopic eczema 41.9, 41.29
 morphea association 57.10, 57.14
 vaccinia virus infection 25.7
 anthrax differential diagnosis 26.44
 monkeypox differential diagnosis 25.8
 vacuum-assisted closure, neuropathic
 ulcers 85.6
- vagabonds' disease 88.24, 88.25
 vaginal adenocarcinoma, vulval
 adenosis 112.42
 vaginal candidosis 31.26
 vaginal discharge 112.23
 vaginitis, desquamative 112.9–12
 valaciclovir 19.44
 post-herpetic neuralgia 84.5
- validation, measurement tools 16.2
 validity 5.13, 17.7–9
 clinical trials 17.12–13
 strengthening 17.13–14
- valproate 86.38
 cutaneous sclerosis induction 96.43
- valvular heart disease, antiphospholipid
 syndrome association 52.2
- Van Buchem disease 67.7
- van der Woude syndrome
 ectrodactyly–ectodermal dysplasia–cleft
 lip/palate syndrome differential
 diagnosis 67.18
 oral lesions 110.26
 syndromic cleft lip/palate 110.23
- Van Maldergem syndrome 73.19
- vancomycin 19.42–3
 vancomycin-induced linear IgA disease 47.6
- vanishing bone syndromes 72.19
 lymphatic malformations 73.16
see also Gorham–Stout syndrome
- vanishing penis syndrome 111.7
- varicella gangrenosa 25.26
 varicella infection 25.23, 25.24–6
 atypical, rickettsialpox differential
 diagnosis 26.79
 children with HIV 31.35
 chronic 25.26
 clinical features 25.25–6
 complications/co-morbidities 25.25–6
 fetal 116.22
 haemorrhagic 25.25
 infants 117.7
 investigations 25.26
 management 19.44, 25.26–7
 maternal 116.22
 monkeypox differential diagnosis 25.8
 mouth ulcers 110.51
 oral mucosa 110.7, 110.8
 orf differential diagnosis 25.10

- pathophysiology 25.24–5
 pityriasis lichenoides differential
 diagnosis 135.5
 pregnancy 25.25
 prophylaxis 25.26–7
 toxic shock syndrome association 26.30
 variants 25.25
- varicella-zoster immune globulin
 (VZig) 116.22
- varicella-zoster virus (VZV) 25.15,
 25.23–31
 aphthous ulceration 110.40
 biology 25.24
 chronic verrucous 31.23
 cytodiagnosis 3.26
 disseminated 31.23
 HIV infection 31.23
 infective cheilitis 110.87
 lichen planus 37.2
 pain management 31.23
 pregnancy 115.3–4
 reactivation in immune restoration
 disease 31.23
 transmission 25.24
 treatment 31.23
 varicella 25.24–6
 vulval lesions 112.28
- varicose eczema 39.18
 allergic contact dermatitis differential
 diagnosis 128.62
- varicose veins 103.34–5, **103.36**
 chronic venous insufficiency **103.38**
 Klippel–Trenaunay syndrome 103.24,
 103.34
 stripping causing
 phlebolympoedema 105.8
 surgery-induced lymphoedema 105.49
 telangiectases 103.35
- varicosities
 labial veins 112.4
 oral cavity 110.72
- variegate porphyria 60.4, 60.6, 60.7
 acute attacks 60.17
 chemical-induced photosensitivity
 differential diagnosis 127.29
 clinical features 60.17–18
 definition 60.17
 differential diagnosis 60.18
 drug-induced photosensitivity
 differential diagnosis 127.29
 genetic counselling 60.18
 investigations 60.18
 malignancy association 147.22
 management 60.18
 skin lesion pathogenesis 60.17
 variants 60.17–18
- vascular coagulopathies 101.21–5
- vascular disorders
 arteriovenous 73.7–9
 capillary 73.1–7
 erythrocytosis differential
 diagnosis 125.6
 internal malignancy
 association 147.24–6
 lymphatic anomalies 73.15–21
 systemic lupus erythematosus 51.23–5
 venous 73.9–15
- vascular disruption theory 105.38
- vascular endothelial cells 103.1
- vascular endothelial growth factor
 (VEGF) 8.5, 103.1
 Bartonella stimulation 26.60
 wound healing 10.2, 10.6
- vascular lesions
 Adamantiades–Behçet disease 48.6,
 48.10
 atypical 105.39, 105.40
 flashlamp treatment 23.6
 laser therapy 23.6–11, 160.1–4
 vascular malformations 105.34
 infantile haemangioma differential
 diagnosis **117.17**
 swollen face, head and neck **105.15**
- vascular neoplasms, radiotherapy-
 induced 120.13
- vascular proliferative lesions, oral 110.72
- vascular tumours 137.23–39
 benign 137.25–33
 malignant 137.36–9
 intermediate 137.33–6
 reactive vascular lesions 137.23–5
 see also haemangiomas
- vasculitides
 cardiac involvement 150.4
 oral lesions 110.54–5
 respiratory disorder association 151.3–4
- vasculitis, cutaneous 102.1–36
 allergic genital 111.20
 ANCA-associated
 giant cell arteritis differential
 diagnosis 102.34
 polyarteritis nodosa differential
 diagnosis 102.30
 anti-GBM 102.19–20
 chemotherapy-induced nail change
 differential diagnosis 120.7
 classification **102.2**
 clinical features 102.1–4
 cocaine use 121.3
 cryoglobulinaemic 102.16–17, **102.18**,
 125.11, 152.5
 clinical features 102.17
 definition 102.16
 epidemiology 102.16
 investigations 102.17, **102.18**
 management 102.17
 pathophysiology 102.16–17
- definition 102.1
 diagnosis 123.3
 erythema elevatum diutinum 102.8–10
 erythema induratum of Bazin 99.27–8
 erythema multiforme differential
 diagnosis 47.5
 erythema nodosum 99.24
 familial Mediterranean fever 45.6
 history taking 102.1–2
 hypocomplementaemic
 urticarial 102.18–19
 IgA 102.13–16
 investigations 102.4
 large-vessel 102.33–6
 leg ulceration
 mixed leg ulcer differential
 diagnosis 104.7
 venous leg ulcer differential
 diagnosis 104.3
 leukocytoclastic 102.5, **102.6**
 inflammatory bowel disease
 association 152.3
 papulonecrotic tuberculid differential
 diagnosis 27.29
Rickettsia conorii association 26.78
 livedo pattern 102.3–4
 lymphocytic 25.36
 malignancy association 147.24
 management 102.4
 medium-vessel 102.29–33
 meningococcal disease differential
 diagnosis 26.49
 microscopic polyangiitis 102.20–3
 nodular 99.8, 99.26–8
 tuberculous 27.31
 periosis differential diagnosis 125.5
 pityriasis lichenoides differential
 diagnosis 135.5
 presentation 102.2–3
 primary immunodeficiency 82.3
 recurrent necrotizing
 eosinophilic 102.10–11
 renal involvement 153.6
 rheumatoid 154.6–7
 single-organ small-vessel 102.5–13
 small-vessel ANCA-associated 102.20–5,
 102.26, 102.27–9
 respiratory disorder
 association 151.3–4
 small-vessel immune complex-
 associated 102.13–20
 respiratory disorder association 151.4
 systemic disease indications **102.2**
- systemic lupus erythematosus 51.24
 systemically reactivated allergic contact
 dermatitis 128.58
 Takayasu arteritis 102.35–6
 urticarial 118.9
 variable-vessel 151.4
 variants 102.3–4
 vessel size 102.2–3
 X-linked lymphoproliferative
 diseases 82.10–11
 see also cutaneous small-vessel vasculitis;
 eosinophilic granulomatosis with
 polyangiitis; giant cell arteritis;
 granuloma faciale; granulomatosis,
 with polyangiitis; Kawasaki disease;
 urticarial vasculitis
- vasculogenesis 103.1
- vasculopathy, systemic lupus
 erythematosus 51.24–5
- vasoactive intestinal peptide (VIP) 2.8,
 85.3
 cutaneous vasodilatation 106.1
 vasoconstriction, cold-induced 125.1, 125.4
 VCAM-1 8.12
- vegetable oils 18.5–6
- vegetating cicatricial pemphigoid, oral
 lesions 110.46
- VEGFC protein, lymphoedema
 therapy 105.58
- VEGFR3 gene mutations 105.25, 105.29
- veil cells 2.42
- veins
 anatomy 103.27
 deep 103.27, 103.28
 macrocirculation 103.27–8
 perforating 103.27
 physiology 103.27–8
 superficial 103.27
- vellus hair
 eruptive cyst 138.7–8
 growth 89.8
- Velpeau disease see hidradenitis
 suppurativa
- vemurafenib 143.32, 143.34
- Venezuelan haemorrhagic fever 25.71
- venlafaxine phototoxicity 127.28
- venom
 Hymenoptera stings/bites 34.15
 immunotherapy 34.16
- veno-occlusive priapism 111.35
- venous angioma 73.9–11, 103.21–3
- venous disorders 73.9–15, 103.27–37,
103.38, 103.39, 103.40
 chronic venous insufficiency 103.36–7,
 103.38, 103.39, 103.40
 lymphatic malformation
 association 73.16
 venous thrombosis 103.28–34
- venous eczema, chronic venous
 insufficiency **103.38**
- venous hypertension, femoral veins 39.19
- venous insufficiency 103.36
 oedema 105.7
 see also chronic venous insufficiency
- venous lakes 103.14–15, 110.72–3
 laser therapy 23.10
- venous leg ulcers 104.1–5
 associated disorders **104.2**
 classification 104.1, 104.3
 clinical features 104.2–3
 definition 104.1
 differential diagnosis 104.3
 epidemiology 104.1–2
 investigations 104.3–4
 management 104.4, **104.5**, **104.6**
 pathophysiology 104.2
 treatment algorithm **104.6**
 variants 104.3
 see also leg ulceration
- venous malformations 73.9–11, 103.21–7
 associated disorders 103.24–7
 blue rubber bleb naevus
 syndrome 73.12–13
 clinical features **103.22**
 definition 103.21
- epidemiology 103.22
 gastrointestinal 73.13
 glomuvenous 73.13–14
 investigations **103.23**
 Maffucci syndrome 73.14–15
 management 103.22–3
 mucocutaneous 73.11–12, 110.16
 palmoplantar 73.13
 pathophysiology 103.22
 solitary 103.21–3
- venous obstruction 147.26
- venous occlusion, acrocyanosis differential
 diagnosis 125.5
- venous outflow obstruction 103.37
 swollen arm differential
 diagnosis 105.13
- venous reflux 103.37
- venous system, macrocirculation 103.27–8
- venous thromboembolism,
 antiphospholipid syndrome
 association 52.1, 52.2
- venous thrombosis 103.28–34
 HIV infection 31.13
 Mondor disease 103.33–4
 superficial venous
 thrombosis 103.30–1
 thrombophlebitis migrans 103.31–2
 varicose veins 103.34–5, **103.36**
 Klippel–Trenaunay syndrome 103.24
 see also deep vein thrombosis (DVT)
- venous ulcers
 chronic venous insufficiency 103.36,
 103.38, 103.39
 healing 10.2, 10.10
 lower leg eczema complication 39.20
 tropical ulcer differential
 diagnosis 26.66
- ventilator-associated pneumonia,
 burns 126.8
- venulectasias, legs 160.3–4
- venules 2.42
- vermillion border 110.3
 surgical incisions 20.5, 20.6
- vermillionectomy 20.33
- vernal keratoconjunctivitis 109.15, 109.16–17
 clinical characteristics 109.18–19, 109.19,
 109.23
 management 109.22
- Verneuil disease see hidradenitis
 suppurativa
- verruca caseosa 116.3
- verruca necrogenica see tuberculosis,
 cutaneous, warty
- verruca vulgaris
 follicular mucinosis association 107.7
 oral 110.62
- verruciform xanthoma 110.62, **112.30**
 genital 111.26
- verrucous carcinoma 113.19
 foot 142.28
 genital wart differential diagnosis 25.57
 nail apparatus 95.32
 oral 110.38
 vulval 112.35–6, **112.37**
- verrucous haemangioma 103.23–4
- verrucous perforating collagenoma 96.51
- verrucous sarcoidosis 98.13
- verruca peruana 26.62–3
 versican 2.37, 2.39, 2.40
- very low density lipoprotein (VLDL)
 diabetes 62.11
 hyperlipoproteinaemia type III 62.8
 hyperlipoproteinaemia type IV 62.10
 hyperlipoproteinaemia type V 62.9
- Vesalius (Italian physician) 1.3
- vesicles, oral mucosa 110.7, **110.8**
- vesicular stomatitis virus infection 25.84
- Vespoidea 34.15
- vestibular papillomatosis 112.3–4
- vestibule, vulval 112.3
- vestibulodynia 112.39
- vibrating hand tools 123.23
 hypothenar hammer syndrome 123.12
 palmar fascial fibromatosis 96.32
 see also hand–arm vibration syndrome

- vibration white finger *see* hand–arm vibration syndrome
- vibratory angio-oedema 42.9, 42.10, 47.10, 123.25
- Vibrio cholerae* 5.9
- Vibrio vulnificus* 26.64
- vidarabine
- herpes simplex virus treatment 31.23
 - varicella-zoster virus 31.23
- villi 3.39
- vimentin 3.21
- vinegar, cnidarian sting treatment 131.2
- vinorelbine, hyperpigmentation induction 120.8
- vinyl chloride
- occupational acroosteolysis 95.47
 - proximal nail fold capillaroscopy 95.53
 - sclerodactyly 95.53
 - systemic sclerosis trigger 56.13, 96.42, 96.43
- viral antigens, delayed sensitivity testing 4.24–5
- viral arthropathies 154.2–3
- viral haemorrhagic fevers 25.5, 25.69–78
- Argentinian 25.71
 - Bolivian 25.71
 - Brazilian 25.71
 - bunyavirus 25.72
 - epidemic typhus differential diagnosis 26.77
 - filovirus 25.72–3
 - flavivirus infections 25.73–4
 - Lassa fever 25.70
 - Lujo virus 25.70–1
 - meningococcal disease differential diagnosis 26.49
 - Rocky Mountain spotted fever differential diagnosis 26.78
 - tick typhus differential diagnosis 26.78
 - tick-borne 34.38
 - Venezuelan 25.71
- viral infections 25.1–92
- aphthous ulceration 110.40
 - atopic eczema 41.22
 - blood fractions 25.5
 - carcinogenesis 25.4
 - culture specimens 25.5
 - cytodiagnosis 3.26
 - Darier disease complication 66.7
 - diagnosis 3.27
 - drug reaction association 12.3, 12.6
 - drug-induced exanthem differential diagnosis 118.2
 - ear piercing complications 108.7
 - encephalitis 34.38
 - enteroviruses 25.79–84
 - erythema annulare centrifugum 47.9
 - erythema nodosum 99.19
 - exanthems 25.4–5
 - eyes 109.36–8, 109.39–40, 109.40
 - fluorescence microscopy 25.5
 - haemorrhagic fevers 25.5, 25.69–78
 - herpesvirus 25.15–41
 - heterosexual men 31.24, 31.25
 - high-power microscopy 3.33
 - HIV infection 31.22–5
 - human retroviruses 25.67–8, 25.69
 - infants 117.6–7
 - infective cheilitis 110.87
 - insect-borne 25.74–8
 - IRIS/IRD/IRAD 31.36
 - laboratory diagnosis 25.5
 - lichen striatus association 37.19
 - mixed cryoglobulinaemia 125.10
 - mucous membrane pemphigoid differential diagnosis 50.29
 - myxovirus 25.84–6
 - neonatal 116.21–3
 - oncogenic 146.7–8
 - oral cavity 110.92
 - oral mucosa disorders 110.7, 110.8
 - oral ulceration 110.48–52
 - parvovirus 25.66–7
 - pathogenesis 25.2, 25.3–4
 - patterns of cutaneous reaction 25.86–92
 - perineum/perianal region 113.11
 - persistent 25.4
 - picornavirus infections 25.79–84
 - pinna 108.11, 108.15
 - pityriasis lichenoides 135.4
 - polyarteritis nodosa 102.30
 - polymerase chain reaction 25.5
 - polyomavirus 25.41–2
 - poxvirus 25.5–15
 - serological tests 25.5
 - systemic lupus erythematosus association 51.18–19
 - differential diagnosis 51.27
 - systemic sclerosis 56.11
 - tests 25.5
 - togavirus 25.74–8
 - vesicle fluid 25.5
 - viral haemorrhagic fevers 25.69–78
 - vulval 112.27–9
 - see also named viruses and infections*
- virions 25.2
- virus-associated haemophagocytic syndrome 136.27
- viruses
- classification 25.2, 25.2–3
 - latent 25.4
 - reactivation 25.4
 - replication in epidermal cells 25.4
- visceral larva migrans 33.19–20
- vismodegib
- basal cell carcinoma treatment 141.15
 - naevoid basal cell carcinoma syndrome treatment 141.20–1
- visual analogue scale (VAS) 16.3
- vitamin(s)
- deficiencies 5.10, 63.7–23, 152.1
 - excess 63.7–12
- vitamin A 63.7–9
- antiageing products 156.5
 - carotenaemia 63.8–9
 - deficiency 63.7–8, 87.13, 87.14, 88.23, 88.24
 - excess 63.8–9
 - recommended daily intake 63.8
 - skin pathogenesis 149.10
 - toxicity 63.8–9
 - see also retinoid(s); retinol*
- vitamin B, antioxidant activity 156.2
- vitamin B₁ deficiency 63.13–14
- vitamin B₂
- acne association 90.12
 - deficiency 63.14–15
 - iron deficiency differential diagnosis 63.24
- vitamin B₃ deficiency 63.15–17
- iron deficiency differential diagnosis 63.24
- vitamin B₆
- acne association 90.12
 - deficiency 63.17–18
- vitamin B₉ deficiency 63.18–19
- vitamin B₁₂
- acne association 90.12
 - deficiency 63.19–20, 88.24, 145.18
 - aphthous ulceration 110.39
 - deficiency glossitis 110.64
 - folate deficiency differential diagnosis 63.19
 - hyperpigmentation 149.18
 - iron deficiency differential diagnosis 63.24
 - injections and sclerodermiform reactions 123.20
- vitamin C
- antioxidant action 156.2
 - pressure ulcer treatment 124.6
- vitamin C deficiency 63.20–2
- clinical features 63.21–2
 - epidemiology 63.21
 - investigations 63.22
 - management 63.22
 - pathophysiology 63.21
- vitamin D 18.23
- congenital ichthyoses 65.39
 - metabolism 18.24, 63.9
 - skin pathogenesis 149.10
 - synthesis 2.43
 - melanin role 9.9
 - restriction by pigmented skin 88.8
 - sunscreen effects 9.12
 - UVR exposure 9.9, 9.13
- vitamin D analogues
- Flegel disease treatment 87.17
 - nail psoriasis 95.42
 - plaque psoriasis 35.23
 - topical 18.23–6
 - wart treatment 25.52
- vitamin D deficiency 63.9–11
- clinical features 63.10
 - epidemiology 63.10
 - generalized severe recessive dystrophic epidermolysis bullosa 71.26
 - hyperparathyroidism 145.21
 - investigations 63.10
 - management 63.11
 - mixed connective tissue disease 54.2
 - pathophysiology 63.10
 - systemic lupus erythematosus 51.35
- vitamin D receptor 18.23
- vitamin D supplements
- hydroa vacciniforme 127.25
 - photosensitivity diseases 127.35
- vitamin E 63.11
- antioxidant action 156.2–3
 - deficiency 63.11
 - excess 63.11, 63.12
 - recommended daily intake 63.11, 63.12
- vitamin K
- deficiency 63.12–13
 - injections and sclerodermiform reactions 123.20
- vitamin K deficiency bleeding (VKDB) 63.12–13
- vitamin K₁ injections 99.47
- cutaneous sclerosis induction 96.43
- vitiligo 5.4, 88.34–40
- addisonian pigmentation 145.18, 149.18
 - aetiology 88.35–6
 - alopecia areata association 89.29, 89.30
 - autoimmune hypothesis 88.35
 - chemotherapy-induced hypopigmentation differential diagnosis 120.10
 - clinical features 88.36–9
 - definition 88.34–5
 - depigmentation 88.40
 - dermatitis herpetiformis association 50.53
 - differential diagnosis 88.37–8
 - electron microscopy 3.27
 - endocrine disorder skin signs 149.14
 - environmental factors 88.36
 - epidemiology 88.35
 - facial hemiatrophy association 96.18
 - genetics 88.36
 - hair pigmentary defect 89.71
 - halo naevi association 88.35, 88.37, 88.41
 - differential diagnosis 88.37, 88.42
 - HIV infection 31.12, 31.13
 - hypochromic 88.37, 88.38
 - immune responses 88.35–6
 - investigations 88.39
 - Koebner phenomenon 88.36, 123.2
 - leprosy differential diagnosis 28.11
 - lichen planus 37.4 association 37.13
 - lichen sclerosis differential diagnosis 112.7
 - management 88.39–40
 - mixed 88.37
 - occupational dyspigmentation differential diagnosis 130.12
 - pathophysiology 88.35–6
 - piebaldism differential diagnosis 70.4
 - pinta differential diagnosis 26.68
 - pityriasis alba differential diagnosis 39.25
- pityriasis versicolor differential diagnosis 32.12
- psychological impact 11.4
- PUVA 21.4
- radiotherapy-induced 120.14
- repigmentation 88.40
- rheumatoid arthritis 154.5
- segmental 88.37, 88.40
- social stigma 11.5
- trichrome 88.37, 88.38
- universalis 88.37, 88.38
- UVB phototherapy 21.4
- variants 88.37, 88.38
- vulval 112.20
- vitronectin, wound healing 10.4–5
- Voerner disease 65.43–4
- Vogt–Koyanagi–Harada syndrome 88.43
- hair pigmentary defect 88.35, 89.71
 - vitiligo association 88.35
- Vohwinkel syndrome 65.49, 65.56–7
- volatile agents, illicit use 121.2
- volumizing of skin 157.2, 157.3
- vomiting, hyperhidrosis 94.5
- von Hippel–Lindau syndrome 147.8
- renal involvement 153.2
- von Kossa staining 3.9
- von Recklinghausen disease *see* neurofibromatosis type 1
- von Willebrand disease 101.3
- von Willebrand factor, myeloproliferative disorders 101.12
- voriconazole, skin cancer association 146.6
- vulva
- bacterial flora 26.5
 - bacterial infections 112.23–5
 - benign tumours 112.29, 112.30, 112.31–2
 - bullous disorders 112.18–20
 - congenital anomalies 112.4
 - dermatoses 112.1–2
 - examination 112.2
 - extramammary Paget disease 138.43, 147.7
 - female genital mutilation 112.41
 - function 112.2–4
 - fungal infections 112.25–7
 - genodermatoses 112.4–5
 - history taking 112.2
 - infections 112.23–9
 - inflammatory dermatoses 112.6–17
 - investigations 112.2
 - malignancy 112.34–9
 - mammary-like gland adenoma 138.21–2
 - oedema 112.22–3
 - pain 112.39–40
 - pigmentary disorders 112.20–2
 - pigmented lesion 143.13
 - pre-malignant conditions 112.32–4
 - psoriasis 35.12
 - skin flora 112.3
 - structure 112.2–4
 - traumatic lesions 112.40–1
 - ulcerative disorders 112.18–20
 - causes 112.18
 - variants 112.3–4
 - viral infections 112.27–9
- vulval hyperaesthesia, post-inflammatory 112.39
- vulval intraepithelial neoplasia (VIN) 112.32–4, 142.25
- basaloid 112.32
 - extramammary Paget disease differential diagnosis 112.37
 - management 112.34
 - pagetoid 112.32
 - severity classification 112.33–4
 - warty 112.32
- vulval lymphangiectasia/lymphangioma, carbon dioxide laser ablation 23.18
- vulval papillomatosis, genital wart differential diagnosis 25.57
- vulvitis circumscripta 112.12–13
- vulvodysplasia 84.8–9, 112.39–40
- vulvo-vaginal adenosis 112.42
- vulvo-vaginal-gingival syndrome 112.10

- vulvovaginitis
 candidal 32.64–5
 streptococcal 26.33
 VZV immunoglobulin 31.23
- W**
- Waardenburg syndrome 2.17, 70.4–5
 classification 70.2
 piebaldism differential diagnosis 70.4
 spinal dysraphism association 85.9
 variants 70.4–5
 vitiligo differential diagnosis 88.38
- Wade–Fite staining 3.10
- Waldenström hypergammaglobulinaemic purpura 101.7–8
- Waldenström macroglobulinaemia circulating abnormal immunoglobulins 148.5–6
 cryoglobulins 101.13
 malignant infiltration of skin 148.4–5
 oral lesions 110.62
 paraneoplastic pemphigus association 50.6
- Walzel's sign 152.6
- war wounds 26.47
- warble flies 34.10–11
- warfarin
 antiphospholipid syndrome treatment 52.3
 drug eruptions 31.18
 necrosis 101.18
 surgical bleeding complications 20.8
- warming, frostbite management 125.2–3
- Warthin–Starry silver staining 3.10
- warts
 oral 25.55, 110.62
 periungual 25.48, 25.49
 carbon dioxide laser ablation 23.18
see also ano-genital warts
- warts, cutaneous 25.46–54
 basal cell carcinoma differential diagnosis 141.10
 butchers' 25.46, 25.50
 causative organisms 25.47
 clinical features 25.47–51
 common 25.47–8
 definition 25.46
 differential diagnosis 25.48–9
 digitate 25.49
 discoid lupus erythematosus 51.4, 51.5
 epidemiology 25.46
 epidermoid cysts 25.50
 eyelids 109.36, 109.38
 filiform 25.49, 25.50
 growth in primary immunodeficiency 82.2
- hand 25.46
 differential diagnosis 25.50
- HIV infection 25.61–2, 31.24
- Hodgkin disease 25.62
- huge hyperkeratotic 25.50
- human papillomavirus in HIV 31.24
- iatrogenic transmission 25.46
- imiquimod therapy 18.27
- incontinentia pigmenti differential diagnosis 70.11
- infectivity 25.47
- investigations 25.51
- malignant change 25.51, 25.59
- management 18.13, 25.51–4, 25.53
 photodynamic therapy 22.7
 topical bleomycin 18.26
 topical sensitizers 18.30
- multiple minute digitate keratoses differential diagnosis 87.18
- nomenclature 25.46
- pathophysiology 25.46–7
- phobias 86.20
- photodynamic therapy 22.7
- pigmented 25.50
- plane 25.47, 25.48–9
 confluent and reticulated papillomatosis differential diagnosis 87.7
 molluscum contagiosum differential diagnosis 25.13
- plantar 25.47, 25.48, 25.49
 carbon dioxide laser ablation 23.18
 differential diagnosis 25.50
 prognosis 25.50–1
 psoriasis 25.50
 regression 25.50
 systemic lupus erythematosus 25.62
- tar 130.14
- transplant recipients 25.63
- variants 25.49–50
- viral
 black heel/palm differential diagnosis 123.10
 cutaneous horn differential diagnosis 142.12
 Hailey–Hailey disease differential diagnosis 66.12
 laser therapy 23.10, 23.11
 multiple minute digitate keratoses differential diagnosis 87.18
 persistent infections 148.15
 photodynamic therapy 22.7
 porokeratosis differential diagnosis 87.21
see also seborrhoeic keratosis
- warts, hypogammaglobulinaemia, infections and myelokathexis (WHIM) syndrome 82.16, 146.2, 148.17
- warts, immunodeficiency, lymphoedema and ano-genital dysplasia (WILD) syndrome 105.27, 105.29
- warty dyskeratoma 110.19, 133.5
- WAS protein (WASP) 82.9
- wasps 34.14–16, 34.15
 stings
 clinical features 34.15–16
 management 34.16
 pathophysiology 34.15
 venom 34.15
- water
 evaporation from skin 2.8
 light absorption 23.4
- water-in-oil systems 18.7
- Waterlow scale for pressure ulcers 124.5
- Watson syndrome 80.5, 80.7
- wavelength, selective thermolysis 23.4–5
- waxes, topical medication 18.7
- waxy keratoses of childhood 65.71
- weals, urticaria 42.4, 47.7
 allergic 42.12
 cholinergic 47.11–12
 cold urticaria 47.11
 definition 42.1
 histology 42.6–7
 inducible 47.9
 morphology 42.2
- weaning, delayed 41.7
- Weary–Kindler syndrome *see* Kindler syndrome
- weathering nodule of ear 108.13, 108.15
 chondrodermatitis nodularis differential diagnosis 108.9
- Weber–Christian disease 99.8
- Weber–Cockayne disease 123.9
- weeverfish stings 131.4
- Weibel–Palade bodies 2.42
- weight loss
 lymphoedema 105.57
 systemic sclerosis 56.13
- Weil disease 26.71
- Wells syndrome 47.10
 recurrent cutaneous necrotizing eosinophilic vasculitis differential diagnosis 102.11
- Werner syndrome 72.22–3, 79.1, 79.2, 79.3
 basal cell carcinoma 141.5
 calcification 61.4
 clinical features 72.21, 72.23, 79.1, 79.3
 Cockayne syndrome differential diagnosis 78.9
 coronary artery disease 150.5
 definition 72.22
 diabetes associations 64.4
 differential diagnosis 72.23
- epidemiology 72.22
 genetics 72.23
 investigations 72.23
 management 72.23, 79.3
- mandibuloacral dysplasia differential diagnosis 72.25
- neoplasms 147.13
- pathophysiology 72.22–3, 79.1
- premature hair greying 89.70
- Rothmund–Thomson syndrome differential diagnosis 77.6
- skin ageing 2.47
- wet wrap technique
 atopic eczema 41.31
 eczema treatment 39.6
- WHIM (warts, hypogammaglobulinaemia, infections and myelokathexis) syndrome 82.16, 146.2, 148.17
- Whipple disease 152.4, 154.4–5
 pigmentation 88.24
 spondylarthropathy 154.4
- whirlpool footbaths, *Mycobacterium fortuitum* infection 27.43
- white adipose tissue 74.1, 99.4
 adipocytes 99.3
- white dermographism, atopic eczema 41.14
- white fibrous papulosis of the neck 96.36–7
- white piedra 32.16–17
- white sponge naevus 31.33, 110.19–20
- Whitfield's ointment 18.12
- whole exome sequencing 7.8–9
- whole genome sequencing 7.8–9
- Wickham's striae, lichen planus 37.13–14, 112.10
- widow spiders 34.32–3
- Wiedemann–Rautenstrauch syndrome neonatal progeroid syndrome differential diagnosis 72.26
 progeria differential diagnosis 72.22
- WILD (warts, immunodeficiency, lymphoedema and ano-genital dysplasia) syndrome 105.27, 105.29
- Willan, Robert 1.4, 1.5
- Williams–Beuren syndrome 72.14–15
- willingness to pay (WTP) 6.4
- Wilson disease 81.19
- Wimberger's sign 29.30
- Winchester syndrome 72.19
 hyaline fibromatosis syndrome differential diagnosis 72.18
 hypertrichosis 89.61
- window film 127.13, 127.20, 127.23, 127.25
- Wiskott–Aldrich syndrome 82.9, 147.13, 148.17
 bacterial infections 148.15
 eczematous lesions 41.9
 epidemiology 146.2
 oral lesions 110.16
- witchcraft syndrome 86.26
- Witkop–von Sallmann syndrome 67.9, 110.18
 tricho-dento-osseous syndrome differential diagnosis 67.19
- Wnt pathway
 ectodermal dysplasias 67.7
 signalling 2.3, 2.4, 2.19
- WNT10A gene mutation 65.61
- Wnt10b 2.4
- Wnt/ β -catenin pathway, hair follicle stem cell activity regulation 89.8
- Wolbachia endobacteria* 109.42
- Wolff–Chaikoff effect, potassium iodide-induced 19.28
- women
 apocrine miliaria 94.17–18
 hirsutism 89.64–8
 HIV infection 31.34
- wood allergy 128.54–5, 128.56–7, 128.58
 timbers causing 128.56–7
- wood dust 128.18
- Wood's light 4.19–20
 erythrasma diagnosis 26.39, 26.40–1
 fungal infections 32.6–7
- scabies mite identification 4.22
- Woolf syndrome 70.9, 70.10
- woollen garments, sensory irritation 129.10
- woolly hair 68.19–20, 89.57
 Carvajal syndrome 68.20, 89.57
 naevus 89.57
- Naxos disease 65.56, 68.6, 68.20, 89.57
- palmo-plantar keratoderma 65.55–6
- Woringer–Kolopp disease 140.16–17
- wound care
 burns 126.5–7, 126.10
 haemostasis for open wounds 20.44–5
 pressure ulcers 124.6–8
- wound(s), chronic 10.2
 abnormal healing 10.8–9, 10.10
- wound dressings
 burns 126.5–6
 granulating wounds 20.23
 pressure ulcers 124.7
 surgical 20.11, 20.22–3
- wound healing 10.1–13
 abnormal 10.8–9
 accelerated epithelial 10.10
 acute 10.2
 age 10.2
 age-related changes 10.2, 10.9–10
 anchoring fibril function 2.27
 angiogenesis 10.6
 diabetic wounds 10.9
 basement membrane 10.6
 biomaterials 10.12–13
 children 10.2
 chronic wounds 10.10
 corticosteroid-associated impairment 18.17
 diabetic wounds 10.9
 fetal 10.9–10
 fibrin plug 10.2–3
 fibroblast recruitment 10.7–8
 granulating wounds 20.23, 20.24
 granulation phase 10.1, 10.3
 granulation tissue 10.3, 10.7
 growth factor augmentation 10.11
 hyaluronan 2.40, 10.5
 immune response 10.1, 10.2–3, 10.4
 impairment
 corticosteroid-associated 18.17
 by microbial colonization 10.9
 inflammatory exudate 10.10
 inflammatory phase 10.1, 10.2–3, 10.4
 low-power laser therapy 23.20
 macrophage inhibitory factor role 8.22–3
 matrix synthesis 10.8
 microRNA regulation 10.2
 M-plasty 20.33
 novel therapies 10.11–13
 older people 10.2, 10.10
 physiological basis of treatment 10.10
 reactive oxygen species production 8.44
 re-epithelialization 10.1, 10.4–6, 10.10
 remodelling phase 10.1
 retinoic acid therapy 18.22
 scab formation 10.10
 scarring 10.7, 10.8
 by secondary intention 10.10, 20.23
 skin grafts 10.12–13
 stages 10.1
 surgical 20.23, 20.24
 sutures 10.10
see also flaps, surgical; skin grafts
- wound infections
Acinetobacter 26.50
Pseudomonas aeruginosa infection 26.52
 surgical 20.6, 20.11
- wound proteases 10.2
- wound swabs, pressure ulcers 124.7–8
- wrinkles, glyptic 96.2
- wrinkling 96.2, 155.1, 155.2, 155.9
 chemical peels 159.5
 filler use 157.1–2
 pathophysiology 155.5–6
 smoking effects 155.2–3
- WRN gene mutations 72.22, 72.23

- Wucheria bancrofti* 33.7, 105.42, 105.44
life cycle 33.8
- X**
- X chromosome 7.2, 7.4
- xanthelasma 62.4
- cerebrotendinous xanthomatosis 62.10
- chronic cholestasis 62.4, 62.11
- carbon dioxide laser therapy 23.18
- coronary artery disease 150.5
- eyelid 109.47
- xanthogranuloma
- necrobiotic 136.21–2
- plane xanthoma differential diagnosis 62.5
- see also juvenile xanthogranuloma
- xanthoma(s) 62.2–6
- coronary artery disease 150.5
- deep, necrobiotic xanthogranuloma differential diagnosis 99.17
- dyslipidaemic plane 62.4–6
- eruptive 62.3–4
- diabetes 64.3
- hyperlipoproteinaemia type I 62.9
- histiocytic disorders 62.2
- lipid metabolism disorders 62.2
- normolipaemic 148.9
- palmar 62.5–6, 62.8
- primary biliary cirrhosis 152.5
- plane 62.5
- primary biliary cirrhosis 152.5
- tendon 62.2–3, 62.6
- cerebrotendinous xanthomatosis 62.10
- sitosterolaemia 62.10
- tubero-eruptive 62.3
- tuberous 62.3, 62.8
- primary biliary cirrhosis 152.5
- sitosterolaemia 62.10
- xanthoma disseminatum 136.17–18
- cutaneous **136.18**
- malignancy association **147.22**
- systemic **136.18**
- xanthomatosis
- diffuse plane 136.18, 136.19
- plane xanthoma differential diagnosis 62.5
- lipoid proteinosis differential diagnosis 72.33
- xenon (Xe) arc, UVR source 9.3
- Xenopsylla cheopis* 34.12
- xeroderma pigmentosum 78.1–7
- basal cell carcinoma **141.4**
- classification 78.1
- clinical features 78.2–6
- clinical variants 78.6
- Cockayne syndrome differential diagnosis 78.9
- definition 78.1
- DNA repair failure 9.6
- epidemiology 78.2
- freckles 88.16
- inheritance 147.8
- internal malignancy association 147.8
- investigations 78.6–7
- lip lesions 110.26
- management 78.7
- ocular neoplasms 147.8
- pathophysiology 78.2
- Rothmund–Thomson syndrome differential diagnosis 77.6
- trichothiodystrophy differential diagnosis 78.11
- variant XP-V 78.6
- xeroderma pigmentosum/Cockayne syndrome complex 78.6
- xeroderma pigmentosum/trichothiodystrophy (XP/TTD) syndrome 78.6, 78.11
- xerosis
- cutis 87.25–7
- HIV infection 31.12
- HTLV-1 association 140.36
- renal failure 153.3
- skin barrier function effects 155.9
- X-linked agammaglobulinaemia 82.12–13, **148.17**
- X-linked inhibitor of apoptosis protein (XIAP) defects 82.11
- X-linked lymphoproliferative diseases 82.10–11
- X-linked lymphoproliferative syndrome 136.10
- X-linked skin disease, linear manifestations 75.19
- X-ray examination, nails 95.46–8
- XXXXY syndrome 76.4
- XXYY syndrome 76.4
- XY syndrome 76.4
- Y**
- Y chromosome 7.2, 7.4
- yaws 26.66, 26.67–8, 111.23
- onchocerciasis differential diagnosis 33.5
- syphilis 29.14
- tropical ulcer differential diagnosis 26.66
- years lost to disability (YLD) 5.6–7
- yeasts 32.2, **32.3**, 32.3
- isolate identification 32.10
- see also *Candida*; other named organisms
- yellow fever 25.73
- yellow-nail syndrome 31.32–3, 95.14–15, 105.33–4
- clinical features 105.33–4
- definition 105.33
- epidemiology 105.33
- investigations 105.34
- lichen planus differential diagnosis 37.12
- lymphoedema 95.15
- lymphoedema–distichiasis syndrome association 73.18, 73.19
- management 105.34
- onychomycosis differential diagnosis 31.26
- pathophysiology 105.33
- respiratory disorder association 151.6
- Yersinia enterocolitica* 26.57, 26.58
- Yersinia pestis* 26.57–8, 34.12
- Yersinia pseudotuberculosis*, Far East scarlet-like fever 26.36
- young adults, molluscum contagiosum 25.12
- Z**
- zidovudine 31.9
- nail colouration 95.14
- psoriasis therapy 31.16
- Ziehl–Neelsen staining 3.10
- zileuton, Sjögren–Larsson syndrome treatment 65.30
- Zimmermann–Laband syndrome, macrotia 108.5
- zinc deficiency 63.6, 63.25–7
- acquired 63.25, 81.17, 81.18
- telogen effluvium 89.25, 89.26
- acrodermatitis 71.24
- acrodermatitis enteropathica 81.18, 110.16
- angular cheilitis 71.24
- biotin deficiency differential diagnosis 63.23
- clinical features 63.26
- epidemiology 63.25
- genital erythema 111.19
- investigations 63.26
- liver disease association 152.9
- management 63.26–7
- pathophysiology 63.25
- zinc gluconate, hidradenitis suppurativa management 92.10
- zinc oxide 18.8
- UV light blocking 18.30–1
- zinc pyrithione 18.12
- zinc supplementation, pressure ulcer treatment 124.6
- zinc therapy
- oral for papulopustular acne treatment 90.44
- wart treatment 25.54
- Zinsser–Engman–Cole syndrome see dyskeratosis congenita
- Ziprkowski–Margolis syndrome 70.9, 70.10
- ZMPSTE24 gene mutations 72.20, 72.24, 72.25
- Zollinger–Ellison syndrome 147.10
- Zoon balanitis 110.88, 111.7, 111.12–13
- ano-genital psoriasis differential diagnosis 111.9
- lichen sclerosis differential diagnosis 111.14
- Zoon vulvitis 112.12–13
- zoonoses
- brucellosis 26.58–9
- glanders 26.53–4
- Oroya fever 26.62
- plague 26.57–8
- psittacosis 26.76
- zoster immune globulin (ZIG) 25.26
- zoster infection 25.23, 25.27–30, 25.30
- brucellosis differential diagnosis 26.59
- clinical features 25.28–9
- complications/co-morbidities 25.29
- definition 25.27
- epidemiology 25.27
- nomenclature 25.27
- pathophysiology 25.27
- presentation 25.28
- prevention 25.30
- recurrent 25.30
- treatment ladder **25.31**
- variants 25.28–9
- Z-plasty 20.33, 20.34
- zygomatic deformities 110.5
- zygomycosis
- genital 111.24
- panniculitis 99.58
- Zygomycota* see *Glomeromycota*